PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BEER, DJ; MARK, EJ; SHEPARD, JAO; LYNCH, TJ				BEER, DJ; MARK, EJ; SHEPARD, JAO; LYNCH, TJ			A 57-YEAR-OLD MAN WITH A CHRONIC PRODUCTIVE COUGH, DYSPNEA, AND EXTENSIVE BILATERAL AIR-SPACE DISEASE - BRONCHIOLOALVEOLAR CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							PULMONARY ALVEOLAR PROTEINOSIS; BRONCHOCENTRIC GRANULOMATOSIS; CELL-CARCINOMA; EOSINOPHILIC PNEUMONIA; LUNG; DIAGNOSIS; SPECTRUM		TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	BEER, DJ (corresponding author), NEWTON WELLESLEY HOSP, INTENS CARE UNIT, NEWTON, MA 02162 USA.							ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; AXIOTIS CA, 1988, AM J SURG PATHOL, V12, P918, DOI 10.1097/00000478-198812000-00003; BROOKER AS, 1982, BRIT J DIS CHEST, V76, P189, DOI 10.1016/0007-0971(82)90034-1; BURBANK B, 1960, AM J MED, V28, P1002, DOI 10.1016/0002-9343(60)90210-2; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CLAYPOOL WD, 1984, CHEST, V85, P550, DOI 10.1378/chest.85.4.550; CLAYTON F, 1988, PATHOL ANNU, V23, P361; CLEE MD, 1982, THORAX, V37, P947, DOI 10.1136/thx.37.12.947; DENHERTOG RW, 1982, AM REV RESPIR DIS, V126, P344; DEREMEE RA, 1989, SEMIN RESPIR MED, V10, P109, DOI 10.1055/s-2007-1006156; DONOVAN WD, 1993, CHEST, V104, P951, DOI 10.1378/chest.104.3.951; EDGERTON F, 1981, ONCOLOGY, V38, P269, DOI 10.1159/000225568; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; EPSTEIN DM, 1982, AM J ROENTGENOL, V139, P463, DOI 10.2214/ajr.139.3.463; FAUCI AS, 1982, NEW ENGL J MED, V306, P68, DOI 10.1056/NEJM198201143060203; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FRASER RG, 1989, DIAGNOSIS DISEASES C, V2; GLANCY JJ, 1981, THORAX, V36, P345, DOI 10.1136/thx.36.5.345; GRECO RJ, 1986, ANN THORAC SURG, V41, P652, DOI 10.1016/S0003-4975(10)63082-2; HADLOCK FP, 1980, AM J ROENTGENOL, V134, P1015, DOI 10.2214/ajr.134.5.1015; HILL CA, 1984, RADIOLOGY, V150, P15, DOI 10.1148/radiology.150.1.6316417; HOMMA H, 1975, AM REV RESPIR DIS, V111, P857; IMAI S, 1982, ACTA PATHOL JAPON, V32, P677; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; JOHNSON R. SLEIGH, 1960, THORAX, V15, P325, DOI 10.1136/thx.15.4.325; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KATZENSTEIN ALA, 1990, MODERN PROBLEMS PATH, V13; KENNEDY JD, 1981, AM J ROENTGENOL, V136, P1145, DOI 10.2214/ajr.136.6.1145; KODAMA T, 1980, ULTRASTRUCT PATHOL, V1, P177, DOI 10.3109/01913128009141415; KOSS MN, 1981, HUM PATHOL, V12, P632, DOI 10.1016/S0046-8177(81)80047-0; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; LHOSTE RJ, 1984, CANCER, V54, P1397; LIEBOW A A, 1960, Adv Intern Med, V10, P329; LIEBOW AA, 1973, AM REV RESPIR DIS, V108, P1; LUDINGTON LG, 1972, CHEST, V61, P622, DOI 10.1378/chest.61.7.622; MANNING JT, 1984, CANCER-AM CANCER SOC, V54, P525, DOI 10.1002/1097-0142(19840801)54:3<525::AID-CNCR2820540324>3.0.CO;2-X; MARCO M, 1973, AM REV RESPIR DIS, V107, P621, DOI 10.1164/arrd.1973.107.4.621; MARTIN RJ, 1978, AM REV RESPIR DIS, V117, P1059; MILLER WT, 1978, AM J ROENTGENOL, V130, P905, DOI 10.2214/ajr.130.5.905; MYERS JL, 1986, AM J SURG PATHOL, V10, P317, DOI 10.1097/00000478-198605000-00003; PAAKKO P, 1990, AM J SURG PATHOL, V14, P464; RADIN AI, 1990, CANCER-AM CANCER SOC, V65, P550, DOI 10.1002/1097-0142(19900201)65:3<550::AID-CNCR2820650328>3.0.CO;2-W; ROBINSON RG, 1982, AM REV RESPIR DIS, V125, P751; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBLATT MB, 1967, DIS CHEST, V52, P147, DOI 10.1378/chest.52.2.147; SANERKIN NG, 1966, ANN ALLERGY, V24, P586; SARLIN RF, 1980, AM J MED, V68, P618, DOI 10.1016/0002-9343(80)90315-0; SINGH G, 1983, CHEST, V83, P82, DOI 10.1378/chest.83.1.82; SINGH G, 1986, CANCER, V57, P994, DOI 10.1002/1097-0142(19860301)57:5<994::AID-CNCR2820570520>3.0.CO;2-2; THOMPSON GP, 1993, MAYO CLIN PROC, V68, P804, DOI 10.1016/S0025-6196(12)60642-9; TSUMURAYA M, 1981, ACTA CYTOL, V25, P523; VILLINGER U, 1983, PRAX KLIN PNEUMOL, V37, P114; Walker IC, 1920, AM J MED SCI, V159, P825; YOUSEM SA, 1991, HUM PATHOL, V22, P535, DOI 10.1016/0046-8177(91)90229-I	55	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1599	1606						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177251				2022-12-28	WOS:A1994NN21500010
J	GRISSO, JA; KELSEY, JL; STROM, BL; OBRIEN, LA; MAISLIN, G; LAPANN, A; SAMELSON, L; HOFFMAN, S; ANTHONY, J; HIBBERD, A; CLANCY, M; COTLER, J; DELONG, W; ECKER, M; FRIEDENBERG, ZB; GOOD, R; HUMMER, C; JUNKIN, D; MARKMAN, W; MOOAR, P; STEIN, H; WOHL, M; WYNNE, B; ZASLOW, D; ANDREWS, D; PAVILION, A; DICK, H; HABERMANN, E; INSLER, H; MENEZES, P; ROSENTHAL, R; SADLER, A; SHELTON, M; TEICHER, J; ZICKEL, R				GRISSO, JA; KELSEY, JL; STROM, BL; OBRIEN, LA; MAISLIN, G; LAPANN, A; SAMELSON, L; HOFFMAN, S; ANTHONY, J; HIBBERD, A; CLANCY, M; COTLER, J; DELONG, W; ECKER, M; FRIEDENBERG, ZB; GOOD, R; HUMMER, C; JUNKIN, D; MARKMAN, W; MOOAR, P; STEIN, H; WOHL, M; WYNNE, B; ZASLOW, D; ANDREWS, D; PAVILION, A; DICK, H; HABERMANN, E; INSLER, H; MENEZES, P; ROSENTHAL, R; SADLER, A; SHELTON, M; TEICHER, J; ZICKEL, R			RISK-FACTORS FOR HIP FRACTURE IN BLACK-WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THIAZIDE DIURETICS; BONE-DENSITY; WHITE WOMEN; ESTROGEN; THERAPY; SURVIVAL; CALCIUM; RATES; FALLS; RACE	Background. Although more than 1 percent of black women 80 years of age or older have hip fractures each year, little is known about risk factors for hip fracture in these women. Methods. We carried out a case-control study involving 144 black women admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. The controls were 218 black women living in the community who were matched to the case patients according to age and ZIP Code or telephone exchange and 181 hospitalized black women matched according to age and hospital. Information was obtained through personal interviews and was studied by multivariable logistic-regression analysis. Results. When the case patients were compared with the control subjects from the community, the women in the lowest quintile for body-mass index had a markedly increased risk of hip fracture as compared with the women in the highest quintile (odds ratio, 13.5; 95 percent confidence interval, 4.2 to 43.3). Postmenopausal estrogen therapy for one year or more was protective for women under 75 years of age (odds ratio, 0.1; 95 percent confidence interval, < 0.1 to 0.5). Factors associated with an increased risk of hip fracture included a history of stroke (odds ratio, 3.1; 95 percent confidence interval, 1.2 to 8.1), use of aids in walking (odds ratio, 5.6; 95 percent confidence interval, 2.7 to 11.5), and consumption of seven or more alcoholic drinks per week (odds ratio, 4.6; 95 percent confidence interval, 1.5 to 14.1). The results were similar when the case patients were compared with the hospitalized control subjects. Conclusions. Among black women thinness, previous stroke, use of aids in walking, and alcohol consumption are associated with an increased risk of hip fracture. Postmenopausal estrogen therapy protects against hip fracture in women under 75 years of age.	STANFORD UNIV,MED CTR,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY; MERCY CATHOLIC MED CTR,PHILADELPHIA,PA; TEMPLE UNIV,HLTH SCI CTR,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV HOSP,PHILADELPHIA,PA; COOPER HOSP UNIV MED CTR,CAMDEN,NJ; CHESTNUT HILL HOSP,PHILADELPHIA,PA; UNIV PENN,PRESBYTERIAN MED CTR,PHILADELPHIA,PA 19104; BRYN MAWR HOSP,BRYN MAWR,PA; CROZER CHESTER MED CTR,CHESTER,PA; SACRED HEART HOSP,ALLENTOWN,PA; ABINGTON MEM HOSP,ABINGTON,PA; JEANES HOSP,PHILADELPHIA,PA; MED COLL PENN,PHILADELPHIA,PA 19129; FRANKFORD HOSP,PHILADELPHIA,PA; ALBERT EINSTEIN MED CTR,PHILADELPHIA,PA; PHILADELPHIA COLL OSTEOPATH MED,PHILADELPHIA,PA; ST JOSEPHS HOSP,READING,PA; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032; MONTEFIORE MED CTR,NEW YORK,NY; BRONX LEBANON HOSP CTR,BRONX,NY; INTERFAITH MED CTR,BROOKLYN,NY; LONG ISL JEWISH MED CTR,NEW HYDE PK,NY; JACOBI HOSP,BRONX,NY; HARLEM HOSP MED CTR,NEW YORK,NY; BROOKDALE HOSP MED CTR,BROOKLYN,NY; ST LUKES ROOSEVELT HOSP,NEW YORK,NY	Stanford University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Rutgers State University Camden; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; Abington Memorial Hospital; Drexel University; Yeshiva University; Columbia University; NewYork-Presbyterian Hospital; Montefiore Medical Center; BronxCare Health System; Northwell Health; Mount Sinai St. Luke's; Mount Sinai West	GRISSO, JA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DIV GEN INTERNAL MED,317R NURSING EDUC BLDG,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		NIAMS NIH HHS [R01-AR35409] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035409] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL NH, 1993, J BONE MINER RES, V8, P1111; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DAWSONHUGHES B, 1993, J BONE MINER RES, V8, P779; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FURSTENBERG AL, 1987, J CHRON DIS, V40, P931, DOI 10.1016/0021-9681(87)90142-1; GAIL MH, 1981, BIOMETRIKA, V68, P703, DOI 10.1093/biomet/68.3.703; GARROW JS, 1985, INT J OBESITY, V9, P147; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hatten J, 1980, Health Care Financ Rev, V2, P53; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; HOFFMAN S, 1993, OSTEOPOROSIS INT, V3, P171, DOI 10.1007/BF01623672; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAYE JM, 1990, GERONTOLOGIST, V30, P100, DOI 10.1093/geront/30.1.100; KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326; KELSEY JL, 1987, NEW ENGL J MED, V316, P404, DOI 10.1056/NEJM198702123160709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MEIER DE, 1992, J BONE MINER RES, V7, P1181, DOI 10.1002/jbmr.5650071010; NIEVES JW, 1992, OSTEOPOROSIS INT, V2, P122, DOI 10.1007/BF01623818; ORTIZ O, 1992, AM J CLIN NUTR, V55, P8, DOI 10.1093/ajcn/55.1.8; PRUZANSKY ME, 1989, J ORTHOP RES, V7, P192, DOI 10.1002/jor.1100070206; RAY WA, 1989, LANCET, V1, P687; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1990, DHHS HRSA HRSPDV901; 1983, AMA DRUG EVALUATION	34	110	111	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1555	1559		10.1056/NEJM199406023302202	http://dx.doi.org/10.1056/NEJM199406023302202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN215	8177244				2022-12-28	WOS:A1994NN21500002
J	LARSEN, GC; STUPEY, MR; WALANCE, CG; GRIFFITH, KK; CUTLER, JE; KRON, J; MCANULTY, JH				LARSEN, GC; STUPEY, MR; WALANCE, CG; GRIFFITH, KK; CUTLER, JE; KRON, J; MCANULTY, JH			RECURRENT CARDIAC EVENTS IN SURVIVORS OF VENTRICULAR-FIBRILLATION OR TACHYCARDIA - IMPLICATIONS FOR DRIVING RESTRICTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; MORTALITY	Objective-To determine when survivors of ventricular tachycardia (VT) or ventricular fibrillation (VF) might most safely return to driving. Design.-Consecutive case series of 501 VT and VF survivors discharged alive between August 1978 and October 1989 and followed from 0 to 117 months (mean, 26 months). Setting.-Cardiac arrhythmia service of a university hospital. Patients.-The study group comprised 290 consecutive patients with sustained VT and 211 patients with VF who underwent electrophysiological studies and were discharged alive (78% male; mean age, 59 years). The mean ejection fraction (available in 338 patients) was 0.42. Interventions-Antiarrhythmic drug testing for all patients was guided by serial electrophysiological testing. Overall, 227 patients (45%) were discharged on conventional antiarrhythmic agents, 115 (23%) on amiodarone, 39 (8%) received an implantable defibrillator, and 120 (24%) received no specific antiarrhythmic therapy. Main Outcome Measures.-Main outcomes included any event that could hamper a patient's ability to operate a motor vehicle. Specifically, these events included recurrent VF, poorly tolerated, hemodynamically unstable VT, syncope, sudden cardiac death, and implantable defibrillator discharge. Results.-Event risks were assessed during the first year after hospital discharge because that is when most patients decide whether to begin driving again. The 1-year outcome event rate for all 501 patients was 17%. Three distinct periods of risk were identified. The monthly hazard rate was highest in the first month after hospital discharge (4.22% per month), intermediate in months 2 through 7 (1.81% per month), and lowest in months 8 through 12 (0.63% per month). The 191 patients for whom no successful conventional antiarrhythmic drug could be found during electrophysiological testing experienced a persistently high monthly event risk (1.6%) during months 8 through 12. Conclusions.-All survivors of VT or VF should refrain from driving during the first month after hospital discharge when the hazard for events that could impair their ability to drive is greatest. Our data would support restricting driving for most patients until the eighth month after hospital discharge, when risk becomes lowest. Restriction might be lengthened in patients for whom electrophysiological testing finds no satisfactory conventional antiarrhythmic agent because their risk remains higher than average even after 7 months. Individualized recommendations should be allowed because the accident rate for patients who actually suffer sudden death is low.	OREGON HLTH SCI UNIV,DEPT MED,DIV CARDIOL,ARRHYTHMIA SERV,PORTLAND,OR 97201	Oregon Health & Science University	LARSEN, GC (corresponding author), VET AFFAIRS MED CTR,CARDIOL SECT 111B,PORTLAND,OR 97201, USA.							BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; Cox D. R., 1984, ANAL SURVIVAL DATA; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; DICARLO LA, 1992, PACE, V15, P1131, DOI 10.1111/j.1540-8159.1992.tb03115.x; DIXON WJ, 1988, BMDP STATISTICAL SOF; FINCH NJ, 1993, JAMA-J AM MED ASSOC, V270, P1587, DOI 10.1001/jama.270.13.1587; FURUKAWA T, 1989, CIRCULATION, V80, P599, DOI 10.1161/01.CIR.80.3.599; KERWIN AJ, 1984, CAN MED ASSOC J, V131, P312; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; MYERBURG RJ, 1992, CIRCULATION, V85, P2; MYERBURG RJ, 1964, AM HEART J, V68, P586, DOI 10.1016/0002-8703(64)90266-2; OLSSON G, 1985, J AM COLL CARDIOL, V5, P1428, DOI 10.1016/S0735-1097(85)80360-0; STRICKBERGER SA, 1991, ANN INTERN MED, V115, P560, DOI 10.7326/0003-4819-115-7-560; 1989, OREGON DRIVERS 1989; 1982, JAMA-J AM MED ASSOC, V247, P1707; 1981, NEW ENGL J MED, V304, P801	16	49	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1335	1339		10.1001/jama.271.17.1335	http://dx.doi.org/10.1001/jama.271.17.1335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158818				2022-12-28	WOS:A1994NH48700025
J	ARONSON, JK				ARONSON, JK			WHATS IN A BRAND-NAME	BRITISH MEDICAL JOURNAL			English	Article											ARONSON, JK (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							1993, CHEM DRUGGIST, V34	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1140	1141		10.1136/bmj.308.6937.1140	http://dx.doi.org/10.1136/bmj.308.6937.1140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173456	Green Published			2022-12-28	WOS:A1994NK18200020
J	PHILLIMORE, P; BEATTIE, A; TOWNSEND, P				PHILLIMORE, P; BEATTIE, A; TOWNSEND, P			WIDENING INEQUALITY OF HEALTH IN NORTHERN ENGLAND, 1981-91	BRITISH MEDICAL JOURNAL			English	Article							CLASS MORTALITY DIFFERENTIALS; INCOME-DISTRIBUTION; OCCUPATIONAL CLASS; SELECTION; TRENDS; BLACK	Objective-To identify relative and absolute changes in mortality in the Northern region of England between 1981 and 1991. Design-1981 and 1991 census data were used to rank 678 wards on an index of material deprivation composed of four variables (unemployment, car ownership, housing tenure, household overcrowding). Standardised mortality ratios (ah causes) were calculated for various periods between 1981 and 1991 and for different age categories. Setting-Counties of Cleveland, Cumbria, Durham, Northumberland, and Tyne and Wear. Results-During 1981-91 mortality differentials widened between the most affluent and deprived fifths of wards in all age categories under 75 years. The decline in the relative position of the poorest areas was particularly great, and there was no narrowing of inequalities across the remainder of the socioeconomic spectrum. In absolute terms, there were improvements in mortality in all age categories in the most affluent areas. In the poorest areas improvements in the 55-64 age group were balanced by increased mortality among men aged 15-44, a slight rise among women aged 65-74, and static rates among men aged 45-54. Conclusions-These results re-emphasise the case for linking mortality patterns with material conditions rather than individual behaviour.	N TYNESIDE HLTH CARE,N SHIELDS NE29 0LR,ENGLAND; UNIV BRISTOL,DEPT SOCIAL POLICY & PLANNING,BRISTOL BS8 1TN,AVON,ENGLAND	University of Bristol	PHILLIMORE, P (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT SOCIAL POLICY,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.							ATKINSON AB, 1993, WHAT IS HAPPENING DI; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; Blaxter M., 1990, HLTH LIFESTYLES; DUNNELL K, 1991, POPULATION TRENDS, V64, P38; Forwell G, 1993, GLASGOWS HLTH OLD PR; FOX AJ, 1985, J EPIDEMIOL COMMUN H, V39, P1, DOI 10.1136/jech.39.1.1; GOLDBLATT P, 1989, POPULATION TRENDS, V56, P6; GRAHAM H, 1984, WOMEN HLTH FAMILY; Hart N, 1991, OXFORD TXB PUBLIC HL, V1, P151; ILLSLEY R, 1986, Q J SOC AFF, V2, P151; ILLSLEY R, 1987, Q J SOC AFF, V3, P213; MARMOT MG, 1986, LANCET, V2, P274; MORPHET C, 1992, AREA, V24, P63; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; MURRAY CJL, 1993, SOC SCI MED, V36, P143, DOI 10.1016/0277-9536(93)90206-J; OPPENHEIM C, 1992, POVERTY FACTS; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; PHILLIMORE P, 1992, J PUBLIC HEALTH MED, V14, P290; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; STERLING TD, 1978, INT J HEALTH SERV, V8, P437, DOI 10.2190/836R-HD65-G8JC-2CLF; STRONG PM, 1990, J PUBLIC HEALTH MED, V12, P168, DOI 10.1093/oxfordjournals.pubmed.a042542; THUNHURST C, 1985, STATISTICIAN, V34, P93; Townsend P., 1986, INEQUALITIES HLTH NO; Townsend P., 1988, INEQUALITIES HLTH BL; Townsend PP., 1988, HLTH DEPRIVATION INE; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1989, J SOC POLICY, V18, P307, DOI 10.1017/S0047279400017591; WILKINSON RG, 1993, LOCATING HLTH SOCIOL, P7; 1950, STATISTICAL REV EN 1; 1993, REGIONAL TRENDS, V28, P101; 1993, 1991 CENSUS REPORT 2; 1993, 1991 CENSUS REPORT 1; 1993, EC TRENDS, V471, P187; 1990, STATE PUBLIC HLTH; 1993, HOUSEHOLDS AVERAGE I; 1993, POPULATION TRENDS, V71, P22	36	275	275	1	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1125	1128		10.1136/bmj.308.6937.1125	http://dx.doi.org/10.1136/bmj.308.6937.1125			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK182	8173452	Green Published			2022-12-28	WOS:A1994NK18200016
J	GAASCH, WH				GAASCH, WH			DIAGNOSIS AND TREATMENT OF HEART-FAILURE BASED ON LEFT-VENTRICULAR SYSTOLIC OR DIASTOLIC DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ESSENTIAL-HYPERTENSION; MYOCARDIAL-INFARCTION; CLINICAL-CRITERIA; NATURAL-HISTORY; HYPERTROPHY; MORTALITY; EXERCISE; THERAPY; SURVIVAL	Data from large and small clinical trials reflect major differences in the pathophysiology, treatment, and prognosis of left ventricular (LV) systolic and diastolic dysfunction. These studies also indicate that medical therapy can benefit patients with LV dysfunction regardless of whether or not they are symptomatic. Because the descriptive term congestive heart failure does not provide for these important distinctions, a new classification of LV dysfunction has been developed in which patients with LV dysfunction are categorized on the basis of normal or abnormal systolic function. This classification is based on a simple assessment of LV function, it is applicable to patients without symptoms, and it reflects differences in treatment and prognosis. Those with clinically significant LV systolic dysfunction tie, an LV ejection fraction <40%) benefit from therapy whether or not they have symptoms of heart failure. Those with LV dysfunction and a normal LV ejection fraction tie, diastolic dysfunction) also benefit from medical therapy. Annual mortality is higher in those with systolic dysfunction than in those with diastolic dysfunction, but within each of these categories mortality is higher in those with symptoms than in those without. This classification can be useful in the diagnosis and treatment of individual patients as well as in epidemiologic surveys designed to assess medical practice patterns.	UNIV MASSACHUSETTS,SCH MED,DEPT MED,DIV CARDIOL,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester								AMICO AF, 1989, AM HEART J, V118, P1259, DOI 10.1016/0002-8703(89)90018-5; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; BROGAN WC, 1992, AM J MED, V92, P627, DOI 10.1016/0002-9343(92)90781-6; CARLSON KJ, 1985, J CHRON DIS, V38, P733, DOI 10.1016/0021-9681(85)90115-8; CARROLL JD, 1985, CIRCULATION, V72, P119, DOI 10.1161/01.CIR.72.1.119; CHON JN, 1990, CIRCULATION S3, V81, P48; CLYNE CA, 1991, AM J CARDIOL, V68, P1469, DOI 10.1016/0002-9149(91)90281-O; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; CUOCOLO A, 1990, CIRCULATION, V81, P978, DOI 10.1161/01.CIR.81.3.978; CUTLER JA, 1989, HYPERTENSION, V13, P1; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; FORCE TL, 1991, CARDIAC IMAGING; FORMAN DE, 1991, ARCH INTERN MED, V151, P2194, DOI 10.1001/archinte.151.11.2194; FROHLICH ED, 1992, NEW ENGL J MED, V327, P996; Gaasch W, 1994, LEFT VENTRICULAR DIA; GHALI JK, 1991, AM J CARDIOL, V67, P1002, DOI 10.1016/0002-9149(91)90174-J; GIVEN BD, 1985, ARCH INTERN MED, V145, P281, DOI 10.1001/archinte.145.2.281; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HARLAN WR, 1977, ANN INTERN MED, V86, P133, DOI 10.7326/0003-4819-86-2-133; HOIT BD, 1994, LEFT VENTRICULAR DIA; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; JUDGE KW, 1991, J AM COLL CARDIOL, V18, P377, DOI 10.1016/0735-1097(91)90589-2; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEVINE HJ, 1994, LEFT VENTRICULAR DIA; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1988, CIRC RES, V63, P457, DOI 10.1161/01.RES.63.2.457; MARANTZ PR, 1988, CIRCULATION, V77, P607, DOI 10.1161/01.CIR.77.3.607; MASSIE BM, 1987, CIRCULATION, V75, P11; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PARMLEY WW, 1989, J AM COLL CARDIOL, V13, P771, DOI 10.1016/0735-1097(89)90215-5; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SETARO JF, 1992, AM J CARDIOL, V69, P1212, DOI 10.1016/0002-9149(92)90938-U; SHIMIZU G, 1991, CIRCULATION, V83, P1676, DOI 10.1161/01.CIR.83.5.1676; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STAUFFER JC, 1990, PROG CARDIOVASC DIS, V32, P319, DOI 10.1016/0033-0620(90)90019-X; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1729; 1992, NEW ENGL J MED, V327, P685	50	134	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1276	1280						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	8151903				2022-12-28	WOS:A1994NG36200029
J	JARDETZKY, TS; BROWN, JH; GORGA, JC; STERN, LJ; URBAN, RG; CHI, YI; STAUFFACHER, C; STROMINGER, JL; WILEY, DC				JARDETZKY, TS; BROWN, JH; GORGA, JC; STERN, LJ; URBAN, RG; CHI, YI; STAUFFACHER, C; STROMINGER, JL; WILEY, DC			3-DIMENSIONAL STRUCTURE OF A HUMAN CLASS-II HISTOCOMPATIBILITY MOLECULE COMPLEXED WITH SUPERANTIGEN	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; SHOCK SYNDROME TOXIN-1; RECEPTOR BETA-CHAIN; HIGH-AFFINITY BINDING; T-CELL RECOGNITION; HLA-DR; V-BETA; ALPHA; IDENTIFICATION; POLYMORPHISM	The structure of a bacterial superantigen, Staphylococcus aureus enterotoxin B, bound to a human class II histocompatibility complex molecule (HLA-DR1) has been determined by X-ray crystallography. The superantigen binds as an intact protein outside the conventional peptide antigen-binding site of the class II major histocompatibility complex (MHC) molecule. No large conformational changes occur upon complex formation in either the DR1 or the enterotoxin B molecules. The structure of the complex helps explain how different class II molecules and superantigens associate and suggests a model for ternary complex formation with the T-cell antigen receptor (TCR), in which unconventional TCR-MHC contacts are possible.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02154 USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; PURDUE UNIV, DEPT BIOL, W LAFAYETTE, IN 47907 USA	Harvard University; Howard Hughes Medical Institute; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Purdue University System; Purdue University; Purdue University West Lafayette Campus								ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BLACKMAN MA, 1993, J IMMUNOL, V151, P556; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUELOW R, 1992, J IMMUNOL, V148, P1; CAZENAVE PA, 1990, CELL, V63, P717, DOI 10.1016/0092-8674(90)90138-5; CCP4, 1979, CCP4 SUITE PROGRAMS; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; FRASER JD, 1993, RES IMMUNOL, V144, P188, DOI 10.1016/0923-2494(93)80116-G; GASCOIGNE NR, 1993, J SEMIN IMMUN, V5, P13; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GROSSMAN D, 1991, J IMMUNOL, V147, P3274; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HERRMANN T, 1990, J IMMUNOL, V144, P1181; HERRMANN T, 1989, EUR J IMMUNOL, V19, P2171, DOI 10.1002/eji.1830191131; HUDSON KR, 1993, J EXP MED, V177, P175, DOI 10.1084/jem.177.1.175; IRWIN MJ, 1993, IMMUNOL REV, V131, P61, DOI 10.1111/j.1600-065X.1993.tb01530.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; Micusan V V, 1993, Semin Immunol, V5, P3, DOI 10.1006/smim.1993.1002; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MOLLICK JA, 1991, J IMMUNOL, V146, P463; MOLLICK JA, 1993, J EXP MED, V177, P283, DOI 10.1084/jem.177.2.283; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SMITH HP, 1992, J IMMUNOL, V149, P887; SOOS JM, 1993, J IMMUNOL, V150, pA192; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405; WAANDERS GA, 1993, INT IMMUNOL, V5, P55, DOI 10.1093/intimm/5.1.55; WHITE J, 1993, J EXP MED, V177, P119, DOI 10.1084/jem.177.1.119; WOODLAND DL, 1993, J EXP MED, V177, P433, DOI 10.1084/jem.177.2.433; YAGI JJ, 1991, J IMMUNOL, V147, P1398	65	516	542	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					711	718		10.1038/368711a0	http://dx.doi.org/10.1038/368711a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152483				2022-12-28	WOS:A1994NG55300049
J	HENDRIKS, HFJ; VEENSTRA, J; VELTHUISTEWIERIK, EJM; SCHAAFSMA, G; KLUFT, C				HENDRIKS, HFJ; VEENSTRA, J; VELTHUISTEWIERIK, EJM; SCHAAFSMA, G; KLUFT, C			EFFECT OF MODERATE DOSE OF ALCOHOL WITH EVENING MEAL ON FIBRINOLYTIC FACTORS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FAST-ACTING INHIBITOR; PLASMINOGEN-ACTIVATOR; PLATELET-AGGREGATION; CONSUMPTION; BLOOD; RISK	Objectives-To evaluate the effects of moderate consumption of alcoholic beverages on the fibrinolytic system and to assess whether these effects could help explain the relation between moderate alcohol consumption and reduced coronary heart disease. Design-Four treatments were allocated in a randomised controlled order on four days over a period of 11 days. Setting-Metabolic ward of research institute. Subjects-Fight white healthy middle aged men. Interventions-Subjects were provided with food for the 11 days. On the four study days mineral water or 40 g of alcohol in the form of beer, wine, or spirits was consumed at dinner early in the evening. Main outcome measures-Plasminogen activator inhibitor activity, tissue type plasminogen activator antigen, and tissue type plasminogen activator activity one hour before and one, three, five, nine, and 13 hours after dinner with mineral water or alcoholic beverages. Results-After dinner with alcohol plasminogen activator inhibitor activity rose horn 53 (SD 19)% to a maximum of 667 (283%) five hours after dinner (P < 0.001). Tissue type plasminogen activator antigen levels rose from 5.3 (2.2) mu g/l to a maximum of 10.8 (3.8) mu g/l nine hours after dinner with alcohol (P < 0.001). Plasminogen activator activity was reduced in the postprandial period (from 1387 (483) IU/1 to 323 (288) IU/1 five hours after eating; P < 0.001) but was higher than normal early the next morning (1516 (809) IU/1 after alcohol, 779 (516) IU/1 after water; P = 0.04). Conclusion-Moderate alcohol consumption with dinner affects plasminogen activator inhibitor activity, plasminogen activator antigen level, and tissue type plasminogen activator activity temporarily. The effects observed in the early morning are consistent with a decrease in risk of coronary heart disease in moderate drinkers.	TNO,INST AGEING & VASC RES,ORG APPL SCI RES,GAUBIUS LAB,LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	HENDRIKS, HFJ (corresponding author), TNO,INST TOXICOL & NUTR,ORG APPL SCI RES,POB 360,3700 AJ ZEIST,NETHERLANDS.		Hendriks, Henk/AAU-5987-2021					ANDREOTTI F, 1988, Fibrinolysis, V2, P90; ANDREOTTI F, 1991, CHRONOBIOL INT, V8, P336, DOI 10.3109/07420529109059170; BEUTLER HO, 1977, FRESEN Z ANAL CHEM, V284, P113, DOI 10.1007/BF00447345; CEPELAK V, 1979, PROGR CHEM FIBRINOLY, V3, P571; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; FEARNLEY GR, 1957, CLIN SCI, V16, P645; KLUFT C, 1988, THROMB HAEMOSTASIS, V59, P329; KLUFT C, 1988, Fibrinolysis, V2, P93; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MEIJER P, 1992, FIBRINOLYSIS, V6, P97, DOI 10.1016/0268-9499(92)90039-K; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; RANBY M, 1989, THROMB HAEMOSTASIS, V62, P917; ROHAN TE, 1984, AUST NZ J MED, V14, P75, DOI 10.1111/j.1445-5994.1984.tb03596.x; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; Veenstra J, 1991, World Rev Nutr Diet, V65, P38; VEENSTRA J, 1990, ALCOHOL, V7, P547, DOI 10.1016/0741-8329(90)90046-F; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392	20	213	214	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1003	1006		10.1136/bmj.308.6935.1003	http://dx.doi.org/10.1136/bmj.308.6935.1003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167511	Green Published			2022-12-28	WOS:A1994NH08900017
J	DAVIES, J				DAVIES, J			INACTIVATION OF ANTIBIOTICS AND THE DISSEMINATION OF RESISTANCE GENES	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; ESCHERICHIA-COLI; BACTERIAL-RESISTANCE; CHLORAMPHENICOL ACETYLTRANSFERASE; ENTEROCOCCUS-FAECALIS; BETA-LACTAMASES; STREPTOGRAMIN ANTIBIOTICS; PSEUDOMONAS-AERUGINOSA; FOSFOMYCIN RESISTANCE; CONJUGAL TRANSFER	The emergence of multidrug-resistant bacteria is a phenomenon of concern to the clinician and the pharmaceutical industry, as it is the major cause of failure in the treatment of infectious diseases. The most common mechanism of resistance in pathogenic bacteria to antibiotics of the aminoglycoside, beta-lactam (penicillins and cephalosporins), and chloramphenicol types involves the enzymic inactivation of the antibiotic by hydrolysis or by formation of inactive derivatives. Such resistance determinants most probably were acquired by pathogenic bacteria from a pool of resistance genes in other microbial genera, including antibiotic-producing organisms. The resistance gene sequences were subsequently integrated by site-specific recombination into several classes of naturally occurring gene expression cassettes (typically ''integrons'') and disseminated within the microbial population by a variety of gene transfer mechanisms. Although bacterial conjugation once was believed to be restricted in host range, it now appears that this mechanism of transfer permits genetic exchange between many different bacterial genera in nature.			DAVIES, J (corresponding author), UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER V6T 1Z3, BC, CANADA.							Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; Amabile-Cuevas CF, 1993, ORIGIN EVOLUTION SPR; AMABILECUEVAS CF, 1992, CELL, V70, P189, DOI 10.1016/0092-8674(92)90095-T; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; ARCA P, 1990, ANTIMICROB AGENTS CH, V34, P844, DOI 10.1128/AAC.34.5.844; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; ATHER PN, 1992, J BACTERIOL, V174, P3196; BANNAM TL, 1991, ANTIMICROB AGENTS CH, V35, P471, DOI 10.1128/AAC.35.3.471; BENNETT AD, 1983, BIOCHEM J, V215, P29, DOI 10.1042/bj2150029; BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; BERG DE, 1989, GENE TRANSFER ENV, P99; BISSONNETTE L, 1992, J BACTERIOL, V174, P1248, DOI 10.1128/jb.174.4.1248-1257.1992; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BRISSONNOEL A, 1988, J BIOL CHEM, V263, P15880; BRISSONNOEL A, 1988, J BACTERIOL, V170, P1739, DOI 10.1128/jb.170.4.1739-1745.1988; CANNON M, 1990, J ANTIMICROB CHEMOTH, V26, P307, DOI 10.1093/jac/26.3.307; CHEN ST, 1987, J BACTERIOL, V169, P913, DOI 10.1128/jb.169.2.913-916.1987; CLEWELL DB, 1986, ANNU REV MICROBIOL, V40, P635, DOI 10.1146/annurev.mi.40.100186.003223; Clewell DB, 1993, BACTERIAL CONJUGATIO, P369; CLEWELL DB, 1993, BACTERIAL CONJUGATIO; COLLIS CM, 1993, MOL MICROBIOL, V9, P41, DOI 10.1111/j.1365-2958.1993.tb01667.x; COLLIS CM, 1992, J BACTERIOL, V174, P1574, DOI 10.1128/jb.174.5.1574-1585.1992; COUTURE F, 1992, MOL MICROBIOL, V6, P1693, DOI 10.1111/j.1365-2958.1992.tb00894.x; CUNDLIFFE E, 1992, CIBA F SYMP, V171, P199; DAVIES J, 1992, J GEN MICROBIOL, V138, P1553, DOI 10.1099/00221287-138-8-1553; DAY PJ, 1992, J BIOL CHEM, V267, P5122; DOUCETPOPULAIRE F, 1992, ANTIMICROB AGENTS CH, V36, P502, DOI 10.1128/AAC.36.2.502; DOYLE D, 1991, MOL MICROBIOL, V5, P2923, DOI 10.1111/j.1365-2958.1991.tb01852.x; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FRANCIA MV, 1993, MOL MICROBIOL, V10, P823, DOI 10.1111/j.1365-2958.1993.tb00952.x; GEORGOPAPADAKOU NH, 1993, ANTIMICROB AGENTS CH, V37, P2045, DOI 10.1128/AAC.37.10.2045; GORMLEY EP, 1991, J BACTERIOL, V173, P6705, DOI 10.1128/jb.173.21.6705-6708.1991; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; HEINEMANN JA, 1993, MOL MICROBIOL, V10, P57, DOI 10.1111/j.1365-2958.1993.tb00903.x; HEISIG P, 1993, ANTIMICROB AGENTS CH, V37, P696, DOI 10.1128/AAC.37.4.696; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; HONORE N, 1986, EMBO J, V5, P3709, DOI 10.1002/j.1460-2075.1986.tb04704.x; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; Keefer Chester S., 1946, JOUR AMER MED ASSOC, V132, P4; KOCABIYIK S, 1992, FEMS MICROBIOL LETT, V93, P199; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1267, DOI 10.1128/AAC.35.7.1267; LEVESQUE C, IN PRESS GENE; Levy S.B., 1989, GENE TRANSFER ENV; MABILAT C, 1990, PLASMID, V23, P27, DOI 10.1016/0147-619X(90)90041-A; MARTIN P, 1988, MOL MICROBIOL, V2, P615, DOI 10.1111/j.1365-2958.1988.tb00070.x; MARTINEZ E, 1990, EMBO J, V9, P1275, DOI 10.1002/j.1460-2075.1990.tb08236.x; MAZODIER P, 1991, ANNU REV GENET, V25, P147, DOI 10.1146/annurev.ge.25.120191.001051; MERCIER J, 1990, J BACTERIOL, V172, P3745, DOI 10.1128/jb.172.7.3745-3757.1990; NATARAJAN MR, 1992, APPL ENVIRON MICROB, V58, P2701, DOI 10.1128/AEM.58.8.2701-2703.1992; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHARA K, 1989, ANTIMICROB AGENTS CH, V33, P1354, DOI 10.1128/AAC.33.8.1354; PANG Y, IN PRESS ANTIMICROB; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P11538, DOI 10.1073/pnas.90.24.11538; PARENT R, 1992, J BACTERIOL, V174, P2891, DOI 10.1128/JB.174.9.2891-2897.1992; PIDDOCK LJV, 1994, ANTIMICROB AGENTS CH, V38, P163, DOI 10.1128/AAC.38.2.163; Piepesberg W., 1988, ACTINOMYCETOLOGIA, V2, P83, DOI DOI 10.3209/SAJ.2_83; RATHER PN, 1993, J BACTERIOL, V175, P6492, DOI 10.1128/jb.175.20.6492-6498.1993; ROUCH DA, 1987, J GEN MICROBIOL, V133, P3039; Schatz A, 1944, P SOC EXP BIOL MED, V55, P66, DOI 10.3181/00379727-55-14461; SCHUBBERT R, IN PRESS MOL GEN GEN; SCOTT JR, 1992, J BACTERIOL, V174, P6005, DOI 10.1128/JB.174.19.6005-6010.1992; SHAW KJ, 1992, ANTIMICROB AGENTS CH, V36, P1447, DOI 10.1128/AAC.36.7.1447; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; SHAW WV, 1984, BRIT MED BULL, V40, P36, DOI 10.1093/oxfordjournals.bmb.a071945; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; SPEER BS, 1992, CLIN MICROBIOL REV, V5, P387, DOI 10.1128/CMR.5.4.387-399.1992; STEVENS AM, 1993, J BACTERIOL, V175, P6134, DOI 10.1128/JB.175.19.6134-6141.1993; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; SUAREZ JE, 1991, ANTIMICROB AGENTS CH, V35, P791, DOI 10.1128/AAC.35.5.791; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TIMMERMAN KP, 1989, PHYSIOL PLANTARUM, V77, P465, DOI 10.1111/j.1399-3054.1989.tb05668.x; TORRES OR, 1991, MOL GEN GENET, V225, P395, DOI 10.1007/BF00261679; TRIEUCUOT P, 1987, FEMS MICROBIOL LETT, V48, P289, DOI 10.1111/j.1574-6968.1987.tb02558.x; TRIEUCUOT P, 1988, J BACTERIOL, V170, P4388, DOI 10.1128/jb.170.9.4388-4391.1988; UDOU T, 1989, FEMS MICROBIOL LETT, V57, P227; WAKSMAN SA, 1945, P NATL ACAD SCI USA, V31, P157, DOI 10.1073/pnas.31.6.157; WEBB V, 1993, ANTIMICROB AGENTS CH, V37, P2379, DOI 10.1128/AAC.37.11.2379; ZILHAO R, 1990, FEMS MICROBIOL LETT, V68, P267, DOI 10.1111/j.1574-6968.1990.tb13949.x	83	1246	1325	11	460	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	1994	264	5157					375	382		10.1126/science.8153624	http://dx.doi.org/10.1126/science.8153624			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153624				2022-12-28	WOS:A1994NG19400027
J	BEARD, KC; QI, T; DAWSON, MR; WANG, BY; LI, CK				BEARD, KC; QI, T; DAWSON, MR; WANG, BY; LI, CK			A DIVERSE NEW PRIMATE FAUNA FROM MIDDLE EOCENE FISSURE-FILLINGS IN SOUTHEASTERN CHINA	NATURE			English	Article							ADAPIS-PARISIENSIS; EARLY TERTIARY; AFFINITIES; DISCOVERY; DENTITION; AFRICA; TARSIIDAE; PAKISTAN; ALTANIUS; MONGOLIA	We report the discovery of a fauna of primates from Eocene (approximately 45 Myr) deposits in China having a diversity greater than in European and North American localities of similar antiquity. From the many forms that will illuminate questions of primate phylogeny comes evidence for a basal radiation of primitive simians.	ACAD SINICA, INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING 100044, PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	BEARD, KC (corresponding author), CARNEGIE MUSEUM NAT HIST, VERTEBRATE PALEONTOL SECT, 4400 FORBES AVE, PITTSBURGH, PA 15213 USA.		Klein, Richard G/B-5910-2009; Beard, K. Christopher/AAQ-4438-2021	Beard, K. Christopher/0000-0002-6279-9837				BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BEARD KC, 1991, AM J PHYS ANTHROPOL, V85, P159, DOI 10.1002/ajpa.1330850205; CHOW MINCHEN, 1961, VERTEBR PALASIAT, V5, P1; CIOCHON RL, 1985, SCIENCE, V229, P756, DOI 10.1126/science.229.4715.756; COLBERT EDWIN H., 1937, AMER MUS NOVITATES, V951., P1; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; COVERT HH, 1991, J HUM EVOL, V21, P463, DOI 10.1016/0047-2484(91)90096-E; DAGOSTO M, 1983, FOLIA PRIMATOL, V41, P49, DOI 10.1159/000156119; DASHZEVEG D, 1977, Acta Palaeontologica Polonica, V22, P119; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; Delson E., 1980, P445; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; Franzen J.L., 1987, Courier Forschungsinstitut Senckenberg, V91, P151; Franzen J.L., 1986, Modern Geology, V10, P159; Gingerich P.D., 1980, P123; GINGERICH PD, 1981, AM J PHYS ANTHROPOL, V56, P235, DOI 10.1002/ajpa.1330560304; GINGERICH PD, 1991, GEOBIOS-LYON, V24, P637, DOI 10.1016/0016-6995(91)80029-Y; GINGERICH PD, 1984, INT J PRIMATOL, V5, P63, DOI 10.1007/BF02735148; GINSBURG L, 1987, CR ACAD SCI II, V304, P1213; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; GODINOT M, 1984, CR ACAD SCI II, V299, P1291; Godinot M, 1984, ACTES S PALEONTOLOGI, P221; KELLY TS, 1990, NAT HIST MUS LOS ANG, V419, P1; KRISHTALKA L, 1978, Annals of Carnegie Museum, V47, P335; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; Musser G.G., 1987, AM MUS NOVIT, V2867, P1; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; PAN YR, 1988, J HUM EVOL, V17, P359; PILGRIM GUY E., 1927, MEM GEOL SURV INDIA PALAEONT INDICA NEW SERIES, V14, P1; Prothero D.R., 1992, EOCENE OLIGOCENE CLI, P46, DOI DOI 10.1515/9781400862924.46; Qi Tao, 1991, Vertebrata Palasiatica, V29, P59; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P439, DOI 10.1007/BF02196131; RASMUSSEN DT, 1988, FOLIA PRIMATOL, V51, P182; ROSE KD, 1991, P NATL ACAD SCI USA, V88, P98, DOI 10.1073/pnas.88.1.98; ROSE KD, 1984, J MAMMAL, V65, P721, DOI 10.2307/1380867; RUSSELL D E, 1987, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V52, P1; RUSSELL DE, 1980, CR ACAD SCI D NAT, V291, P621; RUSSELL DE, 1987, CR ACAD SCI II, V304, P209; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1988, AM J PRIMATOL, V15, P337, DOI 10.1002/ajp.1350150407; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Wang Banyue, 1990, Vertebrata Palasiatica, V28, P165; WILSON JA, 1976, FOLIA PRIMATOL, V25, P294, DOI 10.1159/000155722; WILSON JA, 1986, U WYOMING CONTRIB GE, V3, P221; Zdansky O., 1930, Palaeontologia Sinica, V6C, P1	50	147	162	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	1994	368	6472					604	609		10.1038/368604a0	http://dx.doi.org/10.1038/368604a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145845				2022-12-28	WOS:A1994NF39200051
J	GERSZTEN, RE; CHEN, J; ISHII, M; ISHII, K; WANG, L; NANEVICZ, T; TURCK, CW; VU, TKH; COUGHLIN, SR				GERSZTEN, RE; CHEN, J; ISHII, M; ISHII, K; WANG, L; NANEVICZ, T; TURCK, CW; VU, TKH; COUGHLIN, SR			SPECIFICITY OF THE THROMBIN RECEPTOR FOR AGONIST PEPTIDE IS DEFINED BY ITS EXTRACELLULAR SURFACE	NATURE			English	Article							NEUROKININ-1 RECEPTOR; ACTIVATION; MECHANISM; BINDING; DOMAINS; CLONING	G-PROTEIN-COUPLED receptors for catecholamines and some other small ligands are activated when agonists bind to the transmembrane region of the receptor1. The docking interactions through which peptide agonists activate their receptors are less well characterized2-7. The thrombin receptor is a specialized peptide receptor. it is activated by binding its tethered ligand domain, which is unmasked upon receptor cleavage by thrombin8,9. Human and Xenopus thrombin receptor homologues are each selectively activated by the agonist peptide representing their respective tethered ligand domains. Here we identify receptor domains that confer this agonist specificity by replacing the Xenopus receptor's amino-terminal exodomain and three extracellular loops with the corresponding human structures. This switches receptor specificity from Xenopus to human. The specificity of these thrombin receptors for their respective peptide agonists is thus determined by their extracellular surfaces. Our results indicate that agonist interaction with extracellular domains is important for thrombin receptor activation.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	19	195	204	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					648	651		10.1038/368648a0	http://dx.doi.org/10.1038/368648a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145852				2022-12-28	WOS:A1994NF39200064
J	BOWLER, C; NEUHAUS, G; YAMAGATA, H; CHUA, NH				BOWLER, C; NEUHAUS, G; YAMAGATA, H; CHUA, NH			CYCLIC-GMP AND CALCIUM MEDIATE PHYTOCHROME PHOTOTRANSDUCTION	CELL			English	Article							A/B-BINDING POLYPEPTIDE; OXYGEN-EVOLVING COMPLEX; MESSENGER-RNA LEVELS; CAB GENE FAMILY; PHOTOSYSTEM-II; CHROMOSOMAL LOCATION; CHALCONE SYNTHASE; KDA POLYPEPTIDE; PROTEIN-KINASE; CDNA CLONE	We have previously used single-cell assays in a phytochrome-deficient tomato mutant to demonstrate that phytochrome signaling involves heterotrimeric G proteins, calcium, and calmodulin. While G protein activation could stimulate full chloroplast development and anthocyanin pigment biosynthesis, calcium and calmodulin could not induce anthocyanins and were only able to stimulate the development of immature chloroplasts tacking cytochrome b(6)f and photosystem I core components. We now report that cyclic GMP is able to trigger the production of anthocyanins, and that a combination of cyclic GMP with calcium can induce the development of fully mature chloroplasts containing all the photosynthetic machinery. Furthermore, using reporter genes for these different pathways (cab-gus, chs-gus and fnr-gus) we demonstrate that cGMP and calcium act primarily by modulating gene expression.	ETH ZENTRUM,INST PFLANZENWISSENSCH,CH-8092 ZURICH,SWITZERLAND; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	Swiss Federal Institutes of Technology Domain; ETH Zurich; Rockefeller University			Bowler, Chris/AAC-6256-2019	Bowler, Chris/0000-0003-3835-6187	PHS HHS [44640] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BUSH DS, 1987, CELL CALCIUM, V8, P455, DOI 10.1016/0143-4160(87)90029-7; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; COTE RH, 1984, J BIOL CHEM, V259, P9635; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; ESTABROOK EM, 1991, PLANT CELL, V3, P299, DOI 10.1105/tpc.3.3.299; FEINBAUM RL, 1991, MOL GEN GENET, V226, P449, DOI 10.1007/BF00260658; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; HOFFMAN NE, 1988, PLANT MOL BIOL, V10, P435, DOI 10.1007/BF00014949; HORN ME, 1983, PLANT PHYSIOL, V72, P426, DOI 10.1104/pp.72.2.426; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JEFFERSON RA, 1987, EMBO J, V6, P3901; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; LAM E, 1989, MOL CELL BIOL, V9, P4819, DOI 10.1128/MCB.9.11.4819; LARSSON KH, 1992, PLANT MOL BIOL, V19, P343, DOI 10.1007/BF00027359; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NEWTON RP, 1991, ANAL CHIM ACTA, V247, P161, DOI 10.1016/S0003-2670(00)83811-8; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; PICHERSKY E, 1988, PLANT MOL BIOL, V11, P69, DOI 10.1007/BF00016015; PICHERSKY E, 1989, PLANT MOL BIOL, V12, P257, DOI 10.1007/BF00043203; PIECHULLA B, 1991, MOL GEN GENET, V230, P413, DOI 10.1007/BF00280298; PUGH EN, 1993, NATURE, V364, P389, DOI 10.1038/364389a0; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; SHARMA R, 1993, PLANT J, V4, P1035, DOI 10.1046/j.1365-313X.1993.04061035.x; SHIRLEY BW, 1990, PLANT MOL BIOL, V14, P909, DOI 10.1007/BF00019389; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STOCKHAUS J, 1989, EMBO J, V8, P2445, DOI 10.1002/j.1460-2075.1989.tb08379.x; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; VONWETTSTEINKNO.P, 1968, HEREDITAS, V60, P318; WALES R, 1989, PLANT MOL BIOL, V12, P439, DOI 10.1007/BF00017583; WALES R, 1989, PLANT MOL BIOL, V13, P573, DOI 10.1007/BF00027317; WALLING L, 1986, P NATL ACAD SCI USA, V83, P2123, DOI 10.1073/pnas.83.7.2123; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	45	429	455	1	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					73	81		10.1016/0092-8674(94)90236-4	http://dx.doi.org/10.1016/0092-8674(94)90236-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156599				2022-12-28	WOS:A1994NF21100011
J	OLSEN, JH; HERTZ, H; BLINKENBERG, K; VERDER, H				OLSEN, JH; HERTZ, H; BLINKENBERG, K; VERDER, H			VITAMIN-K REGIMENS AND INCIDENCE OF CHILDHOOD-CANCER IN DENMARK	BRITISH MEDICAL JOURNAL			English	Article									UNIV COPENHAGEN HOSP,DEPT PAEDIAT,DK-2100 COPENHAGEN,DENMARK; NATL BOARD HLTH,DK-1012 COPENHAGEN,DENMARK; HOLBAEK CENT HOSP,DEPT PAEDIAT,DK-4300 HOLBAEK,DENMARK	University of Copenhagen; Holbaek Hospital	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; DRAPER GJ, 1992, BRIT MED J, V305, P709, DOI 10.1136/bmj.305.6855.709; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301	5	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					895	896		10.1136/bmj.308.6933.895	http://dx.doi.org/10.1136/bmj.308.6933.895			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173370	Green Published			2022-12-28	WOS:A1994NE60000023
J	BEST, G; KNOWLES, D; MATHEW, D				BEST, G; KNOWLES, D; MATHEW, D			MANAGING THE NEW NHS - BREATHING NEW LIFE INTO THE NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article								The essence of the NHS reforms is that they bring market forces to bear on organisations providing public services, while allowing those organisations more freedom to respond in ways that will improve the efficiency, effectiveness, and appropriateness of their services. The new structural changes to the NHS-a leaner management executive and fewer, slimmer regions-could be used either to strengthen these features of the reforms or to frustrate them by allowing ministers and top management to intervene even more at local level and ''overmanage'' the market. To ensure that the aims of the reforms are not frustrated ministers and the management executive must restrict themselves to laying down clear strategies and then allow purchasers and providers to meet those strategies in their own ways. They also need to ensure that the whole NHS can learn and benefit from local experimentation and devise ways of managing the crises that will inevitably arise; otherwise they might be tempted to become involved in managing the market at too local a level, and the NHS will suffer the worst of both worlds: stifling bureaucracy at the top and parochial self interest locally.	KINGS FUND COLL,LONDON W2 4HS,ENGLAND									CARNAGHAN R, 1993, TESTING MARKET COMPE; Osborne D., 1993, REINVENTING GOVT ENT; SCOTT H, 1994, LONDON MONITOR FOCUS; Williamson O.E., 1975, MARKETS HIERARCHIES; 1993, MANGING NEW NHS	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					842	845		10.1136/bmj.308.6932.842	http://dx.doi.org/10.1136/bmj.308.6932.842			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167495	Green Published			2022-12-28	WOS:A1994ND24300030
J	MOHSENIFAR, Z; HAY, A; HAY, J; LEWIS, MI; KOERNER, SK				MOHSENIFAR, Z; HAY, A; HAY, J; LEWIS, MI; KOERNER, SK			GASTRIC INTRAMURAL PH AS A PREDICTOR OF SUCCESS OR FAILURE IN WEANING PATIENTS FROM MECHANICAL VENTILATION	ANNALS OF INTERNAL MEDICINE			English	Article						VENTILATOR WEANING; VENTILATORS, MECHANICAL; HYDROGEN-ION CONCENTRATION; GASTRIC MUCOSA; ISCHEMIA	CRITICALLY ILL PATIENTS; RESPIRATORY MUSCLE; INDICATOR; INDEX; SHOCK; PCO2; OCCLUSION; ISCHEMIA; DISEASE	Objective: To determine whether gastric intramural pH (pHi), an indirect measure of gastric mucosal ischemia, can be used to predict the success of weaning from mechanical ventilation. Gastric mucosal ischemia (and, therefore, acidosis) may develop in patients during unsuccessful attempts to wean them from mechanical ventilation because blood flow from nonvital areas (for example, splanchnic bed) is diverted to meet the increased demands of respiratory muscles. Design: Cohort study. Setting: Intensive care unit. Patients: Twenty-nine patients receiving assisted mechanical ventilation for respiratory failure who were thought by their physicians to be weanable from mechanical ventilation. Measurements: Simultaneous samples of arterial blood and gastric juice were obtained from patients during assisted mechanical ventilation, as well as during weaning trials. The predictor variable, pHi, was calculated using the following equation: 6.1 + log HCO3/(gastric P(CO2) x 0.0307). The outcome was success or failure of weaning, decided by physicians blinded to the study. Results: Patients who could not be weaned from mechanical ventilation had a substantially reduced gastric pHi (7.36 during mechanical ventilation compared with 7.09 during weaning [difference, 0.27; 95% CI, 0.12 to 0.42; P < 0.01]). Patients who were successfully weaned from mechanical ventilation showed no change in pHi (7.45 during mechanical ventilation compared with 7.46 during weaning [difference, 0.01; CI, -0.01 to 0.03; P = 0.291). The sensitivity and specificity of pHi in predicting weaning success or failure were both 100% (CI, 81 to 100 and 72 to 100, respectively). Conclusion: Gastrointestinal acidosis may be an early sign of weaning failure. Measurement of pHi, which is simple and rapid, may be of practical value in predicting the likelihood of weaning success or failure during weaning trials.			MOHSENIFAR, Z (corresponding author), UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DIV PULM, 8700 BEVERLY BLVD, ROOM 6732, LOS ANGELES, CA 90048 USA.							ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; BASS BL, 1985, J SURG RES, V39, P351, DOI 10.1016/0022-4804(85)90114-3; CUNNINGHAM J A, 1987, Current Surgery, V44, P229; DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; FIASTRO JF, 1988, CHEST, V94, P232, DOI 10.1378/chest.94.2.232; FIDDIANGREEN R, 1987, CIRC SHOCK, V21, P326; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; FIELD S, 1982, AM REV RESPIR DIS, V126, P9; FRIESEN B, 1992, American Review of Respiratory Disease, V145, pA791; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HUBMAYR RD, 1988, CHEST, V94, P1148, DOI 10.1378/chest.94.6.1148; HUSSAIN SNA, 1985, J APPL PHYSIOL, V58, P2033, DOI 10.1152/jappl.1985.58.6.2033; HUSSAIN SNA, 1985, J APPL PHYSIOL, V59, P1802, DOI 10.1152/jappl.1985.59.6.1802; KHURI SF, 1979, AM J PHYSIOL, V237, pH253, DOI 10.1152/ajpheart.1979.237.2.H253; MAGDER S, 1986, J APPL PHYSIOL, V60, P1849, DOI 10.1152/jappl.1986.60.6.1849; MARINI J J, 1986, Journal of Critical Care, V1, P32, DOI 10.1016/S0883-9441(86)80114-9; MORGANROTH ML, 1984, ARCH INTERN MED, V144, P1012, DOI 10.1001/archinte.144.5.1012; SAGY M, 1988, J CRIT CARE, V3, P19, DOI 10.1016/0883-9441(88)90005-6; SASSOON CSH, 1987, AM REV RESPIR DIS, V135, P107; SILVERMAN HJ, 1992, CHEST, V102, P184, DOI 10.1378/chest.102.1.184; SUN S, 1991, CLIN RES, V39, pA708; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	24	106	110	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					794	798		10.7326/0003-4819-119-8-199310150-00004	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8166793				2022-12-28	WOS:A1993MB49600004
J	KELLERMANN, AL; CONWAY, C; WOLCOTT, R; HACKMAN, BB; BOGAN, S; BERNSTEIN, E; FISH, S; KERL, T; MITCHELL, T; RAMSEY, C; KELEN, GD; SHAHAN, JB; OSBORN, H; BAZAN, L; HARGARTEN, S; LAURENCE, S; HEDGES, JR; HENKEL, G; WINTER, S; YEKRANG, A; BINDER, L; KEMPTON, B; HARRIMAN, D; WINTEMUTE, G; SMITH, H; HAMILTON, G; MORRIS, L				KELLERMANN, AL; CONWAY, C; WOLCOTT, R; HACKMAN, BB; BOGAN, S; BERNSTEIN, E; FISH, S; KERL, T; MITCHELL, T; RAMSEY, C; KELEN, GD; SHAHAN, JB; OSBORN, H; BAZAN, L; HARGARTEN, S; LAURENCE, S; HEDGES, JR; HENKEL, G; WINTER, S; YEKRANG, A; BINDER, L; KEMPTON, B; HARRIMAN, D; WINTEMUTE, G; SMITH, H; HAMILTON, G; MORRIS, L			ACCESS OF MEDICAID RECIPIENTS TO OUTPATIENT CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; CONSEQUENCES	Background. Visits to the emergency department by Medicaid recipients for nonemergency problems are common and contribute to rising health care costs. However, such patients may have few alternatives. We conducted a telephone survey of 953 ambulatory care sites in 10 cities to determine the availability of appointments for Medicaid recipients with common problems. Methods. Research assistants telephoned all ambulatory care clinics and a stratified sample of private primary care practices in the catchment area served by the hospital emergency department in each city. The assistants identified themselves as Medicaid recipients seeking care for one of three problems (low back pain, dysuria, or sore throat) and asked a standardized series of questions. Data were collected on appointments or walk-in visits authorized at any time, within two days after the call, or after 5 p.m.; copayment requirements; and reasons appointments could not be made. If an appointment was made, it was canceled at the end of each call or shortly thereafter. Several weeks later, private-practice sites in six of the cities were recontacted; the research assistants identified themselves as patients with private insurance and the same problem. Results. An appointment or an authorization for a walk-in visit was obtained from 418 of the 953 practice sites (44 percent); 47 of the sites (5 percent) could not be contacted. Appointment rates for the different types of sites ranged from 72 percent for free-standing urgent care centers to 34 percent for private practices. ''Not accepting Medicaid'' was the most common reason given for not granting an appointment or walk-in visit. Only 72 of the sites (8 percent) offered after-hours care within two working days after the call without a cash copayment. Sixty percent of the 330 private practices that were recontacted agreed to see a patient with private insurance within two working days, but only 26 percent agreed to see a patient with Medicaid within two days (P<0.001). Conclusions. Medicaid recipients in urban areas have limited access to outpatient care apart from that offered by hospital emergency departments.	UNIV TENNESSEE,MEMPHIS,TN; BOSTON UNIV,BOSTON,MA 02215; UNIV S FLORIDA,TAMPA,FL; JOHNS HOPKINS UNIV,BALTIMORE,MD; NEW YORK MED COLL,BRONX,NY; MED COLL WISCONSIN,MILWAUKEE,WI 53226; OREGON HLTH SCI UNIV,PORTLAND,OR 97201; TEXAS TECH UNIV,EL PASO,TX; UNIV CALIF DAVIS,SACRAMENTO,CA; WRIGHT STATE UNIV,DAYTON,OH 45435	University of Tennessee System; University of Tennessee Health Science Center; Boston University; State University System of Florida; University of South Florida; Johns Hopkins University; New York Medical College; Medical College of Wisconsin; Oregon Health & Science University; Texas Tech University System; Texas Tech University; University of California System; University of California Davis; University System of Ohio; Wright State University Dayton			Hedges, Jerris/AAC-1847-2021	Kelen, Gabor/0000-0002-3236-8286				ANDRULIS DP, 1991, ANN EMERG MED, V20, P980, DOI 10.1016/S0196-0644(05)82976-2; ARONOVITZ LG, 1993, GAOHRD PUBLICATION, V9346; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BRELLOCHS C, 1990, BUILDING PRIMARY CAR; CROSS LA, 1992, ANN EMERG MED, V21, P1266, DOI 10.1016/S0196-0644(05)81760-3; DALLEK G, 1992, IMPACT MEDICARE PHYS; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; HILLMAN AL, 1991, ACAD MED, V66, P134, DOI 10.1097/00001888-199103000-00003; KELLERMAN AL, 1991, JAMA-J AM MED ASSOC, V266, P1123, DOI 10.1001/jama.266.8.1123; KUSSEROW RP, 1992, CONTROLLING EMERGENC; KUSSEROW RP, 1992, USE EMERGENCY ROOMS; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; LOWE RA, 1993, ANN EMERG MED, V22, P829, DOI 10.1016/S0196-0644(05)80801-7; LYNN SG, 1991, ANN EMERG MED, V20, P287, DOI 10.1016/S0196-0644(05)80942-4; NADEL V, 1993, GAOHRD PUBLICATION, V934; PANE GA, 1991, ANN EMERG MED, V20, P730, DOI 10.1016/S0196-0644(05)80832-7; SHESSER R, 1991, ANN EMERG MED, V20, P743, DOI 10.1016/S0196-0644(05)80835-2; Siegel S., 1988, NONPARAMETRIC STAT B; 1983, NONURGENT USE HOSPIT; 1993, EC REPORT PRESIDENT, P128	22	161	161	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1426	1430						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159198				2022-12-28	WOS:A1994NK97200007
J	BLENDON, RJ; BRODIE, M; HYAMS, TS; BENSON, JM				BLENDON, RJ; BRODIE, M; HYAMS, TS; BENSON, JM			THE AMERICAN PUBLIC AND THE CRITICAL CHOICES FOR HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM FUTURE HLTH CARE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V270, P2871, DOI 10.1001/jama.270.23.2871; BLENDON RJ, 1991, JAMA-J AM MED ASSOC, V265, P2563, DOI 10.1001/jama.265.19.2563; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; BLENDON RJ, 1993, NEW DEAL AM HLTH CAR	4	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1539	1544		10.1001/jama.271.19.1539	http://dx.doi.org/10.1001/jama.271.19.1539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176837				2022-12-28	WOS:A1994NK71100036
J	KIKUCHI, Y; OKABE, S; TAMURA, G; HIDA, W; HOMMA, M; SHIRATO, K; TAKISHIMA, T				KIKUCHI, Y; OKABE, S; TAMURA, G; HIDA, W; HOMMA, M; SHIRATO, K; TAKISHIMA, T			CHEMOSENSITIVITY AND PERCEPTION OF DYSPNEA IN PATIENTS WITH A HISTORY OF NEAR-FATAL ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENIOGLOSSAL ELECTROMYOGRAM RESPONSES; VENTILATORY RESPONSE; CONSCIOUS MAN; HYPERCAPNIA; HYPOXIA; SENSATION; OCCLUSION; PRESSURE; AIRWAY; HUMANS	Background. Many deaths from attacks of asthma may be preventable. However, the difficulty in preventing fatal attacks is that not all the pathophysiologic risk factors have been identified. Methods. To examine whether dyspnea and chemosensitivity to hypoxia and hypercapnia are factors in fatal asthma attacks, we studied 11 patients with asthma who had had near-fatal attacks, 11 patients with asthma who had not had near-fatal attacks, and 16 normal subjects. Their respiratory responses to hypoxia and hypercapnia, determined by the standard rebreathing technique while the patients were in remission, were assessed in terms of the slopes of ventilation and airway occlusion pressure as a function of the percentage of arterial oxygen saturation and end-tidal carbon dioxide tension, respectively. The perception of dyspnea was scored on the Borg scale during breathing through inspiratory resistances ranging from 0 to 30.9 cm of water per liter per second. Results. The mean (+/-SD) hypoxic ventilatory response (0.14+/-0.12 liter per minute per percent of arterial oxygen saturation) and airway occlusion pressure (0.05+/-0.05 cm of water per percent of arterial oxygen saturation) were significantly lower in the patients with near-fatal asthma than in the normal subjects (0.60+/-0.35, P<0.001, and 0.16+/-0.08, P<0.001, respectively) and the patients with asthma who had not had near-fatal attacks (0.46+/-0.29, P = 0.003, and 0.15+/-0.09, P = 0.004). The Borg score was also significantly lower in the patients with near-fatal asthma than in the normal subjects, and their lower hypoxic response was coupled with a blunted perception of dyspnea. Conclusions. Reduced chemosensitivity to hypoxia and blunted perception of dyspnea may predispose patients to fatal asthma attacks.	TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 1, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Tohoku University				Kikuchi, Yoshihiro/0000-0002-3262-3881				ALTOSE MD, 1976, J APPL PHYSIOL, V40, P338, DOI 10.1152/jappl.1976.40.3.338; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1992, THORAX, V47, P408, DOI 10.1136/thx.47.6.408; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; CHANG KC, 1978, CHEST, V73, P667, DOI 10.1378/chest.73.5.667; CHONAN T, 1990, J APPL PHYSIOL, V69, P1290, DOI 10.1152/jappl.1990.69.4.1290; COLLINS DD, 1978, J CLIN INVEST, V62, P105, DOI 10.1172/JCI109093; DRAZEN JM, 1987, J ALLERGY CLIN IMMUN, V80, P428, DOI 10.1016/0091-6749(87)90069-8; ELMANSHAWI A, 1986, J APPL PHYSIOL, V61, P896, DOI 10.1152/jappl.1986.61.3.896; ES JE, 1979, LUNG FUNCTION ASSESS, P365; HIDA W, 1987, B EUR PHYSIOPATH RES, V23, P227; HUDGEL DW, 1974, ANN INTERN MED, V80, P622, DOI 10.7326/0003-4819-80-5-622; HUDGEL DW, 1975, CHEST, V68, P493, DOI 10.1378/chest.68.4.493; HUDGEL DW, 1985, BRONCHIAL ASTHMA MEC, P193; KAWAKAMI Y, 1982, J APPL PHYSIOL, V52, P537; KELSEN SG, 1979, AM REV RESPIR DIS, V120, P517; LAKSHMINARAYAN S, 1975, AM REV RESPIR DIS, V111, P869; MCFADDEN ER, 1991, NEW ENGL J MED, V324, P409, DOI 10.1056/NEJM199102073240609; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MOORE GC, 1976, NEW ENGL J MED, V295, P861, DOI 10.1056/NEJM197610142951604; NAKAYAMA K, 1963, J INT COLL SURG, V39, P374; OKABE S, 1993, AM REV RESPIR DIS, V147, P190, DOI 10.1164/ajrccm/147.1.190; ONAL E, 1981, AM REV RESPIR DIS, V124, P215; ONAL E, 1981, J APPL PHYSIOL, V50, P1052, DOI 10.1152/jappl.1981.50.5.1052; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; REBUCK AS, 1974, AM REV RESPIR DIS, V109, P345; RUBINFELD AR, 1976, LANCET, V1, P882; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TAGUCHI O, 1991, J APPL PHYSIOL, V71, P2183, DOI 10.1152/jappl.1991.71.6.2183; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; WEST JB, 1985, RESPIRATORY PHYSL ES, P113; WHITELAW WA, 1975, RESP PHYSIOL, V23, P181, DOI 10.1016/0034-5687(75)90059-6; 1991, J ALLERGY CLIN IMM S, V88, P427	36	365	370	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1329	1334		10.1056/NEJM199405123301901	http://dx.doi.org/10.1056/NEJM199405123301901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152444	Bronze			2022-12-28	WOS:A1994NK75300001
J	CROWE, PD; VANARSDALE, TL; WALTER, BN; WARE, CF; HESSION, C; EHRENFELS, B; BROWNING, JL; DIN, WS; GOODWIN, RG; SMITH, CA				CROWE, PD; VANARSDALE, TL; WALTER, BN; WARE, CF; HESSION, C; EHRENFELS, B; BROWNING, JL; DIN, WS; GOODWIN, RG; SMITH, CA			A LYMPHOTOXIN-BETA-SPECIFIC RECEPTOR	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR TNF RECEPTOR; T-CELL HYBRIDOMA; 33-KDA GLYCOPROTEIN; MOLECULAR-CLONING; FACTOR-ALPHA; EXPRESSION; SURFACE; PROTEIN; FORM	Tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses. The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family. Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-LT-beta complex. A receptor specific for human LT-beta was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted LT-alpha.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; BIOGEN INC,CAMBRIDGE,MA 02142; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	University of California System; University of California Riverside; Biogen				Browning, Jeffrey/0000-0001-9168-5233				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BAENS M, 1993, GENOMICS, V16, P214, DOI 10.1006/geno.1993.1161; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GOH CR, 1991, PROTEIN ENG, V4, P385, DOI 10.1093/protein/4.4.385; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; ITOH N, 1993, J BIOL CHEM, V268, P10932; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LIANG CM, 1986, BIOCHEM BIOPH RES CO, V137, P847, DOI 10.1016/0006-291X(86)91157-5; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Marynen P., COMMUNICATION; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moore M., COMMUNICATION; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PENNICA D, 1993, BIOCHEMISTRY-US, V32, P3131, DOI 10.1021/bi00063a027; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P1959; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Ware C. F., UNPUB; WARE CF, 1992, J IMMUNOL, V149, P3881; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	41	361	387	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					707	710		10.1126/science.8171323	http://dx.doi.org/10.1126/science.8171323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171323				2022-12-28	WOS:A1994NH71300033
J	RAFF, MC				RAFF, MC			CELL-DEATH GENES - DROSOPHILA ENTERS THE FIELD	SCIENCE			English	Editorial Material							CAENORHABDITIS-ELEGANS; BCL-2; PREVENTION; SURVIVAL				RAFF, MC (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; MCDONNELL TJ, 1992, CELL, V67, P879; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	23	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					668	669		10.1126/science.8171317	http://dx.doi.org/10.1126/science.8171317			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171317				2022-12-28	WOS:A1994NH71300022
J	BROWN, KE; HIBBS, JR; GALLINELLA, G; ANDERSON, SM; LEHMAN, ED; MCCARTHY, P; YOUNG, NS				BROWN, KE; HIBBS, JR; GALLINELLA, G; ANDERSON, SM; LEHMAN, ED; MCCARTHY, P; YOUNG, NS			RESISTANCE TO PARVOVIRUS B19 INFECTION DUE TO LACK OF VIRUS RECEPTOR (ERYTHROCYTE P-ANTIGEN)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; INVITRO; DISEASE; ANEMIA; CELLS; SERUM; LIVER	Background. The presence of aspecific cellular receptor is thought to be necessary for susceptibility to viral infection. The erythrocyte P antigen is the cellular receptor for parvovirus B19. We hypothesized that the rare persons with the p phenotype, whose erythrocytes do not have this receptor, would be naturally resistant to B19 infection, which causes erythema infectiosum. Methods. Blood samples were collected from two populations in cross-sectional studies. We determined the P antigen phenotype of the red cells and tested plasma for anti-B19-specific antibodies. Bone marrow from donors of known P antigen phenotype was inoculated with parvovirus B19. Infectivity was measured by assays of erythroid progenitor cells, dot blot analysis, and in situ hybridization for B19 DNA, and an immunofluorescence assay for viral-capsid proteins. Results. Of the 17 subjects with the p red-cell phenotype, who did not have P antigen on their erythrocytes, none (0 of 11 and 0 of 6) had serologic evidence of previous parvovirus B19 infection. In contrast, the seropositivity rates in the two control groups were 71 percent (53 of 75, P<0.001) and 47 percent (32 of 68, P = 0.03). In vitro, bone marrow from donors with the p phenotype maintained normal erythropoiesis despite very high concentrations of virus, with no evidence of infection of erythroid progenitor cells by parvovirus B19. Conclusions. People who do not have P antigen, which is the cellular receptor for parvovirus B19, are naturally resistant to infection with this pathogen.	MT EATON CLIN,MT EATON,OH; AMER RED CROSS,CLEVELAND,OH	American Red Cross	BROWN, KE (corresponding author), NHLBI,HEMATOL BRANCH,BLDG 10,RM 7C218,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Gallinella, Giorgio/H-6864-2017	Gallinella, Giorgio/0000-0003-1118-6341; Brown, Kevin/0000-0002-1568-683X				AGRE PC, 1992, PROTEIN BLOOD GROUP, pR11; ANDERSON LJ, 1987, PEDIATR INFECT DIS J, V6, P711, DOI 10.1097/00006454-198708000-00003; ANDERSON MJ, 1983, LANCET, V1, P1378; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BROWN KE, 1989, BRIT J OBSTET GYNAEC, V96, P764, DOI 10.1111/j.1471-0528.1989.tb03313.x; BROWN KE, 1991, J GEN VIROL, V72, P741, DOI 10.1099/0022-1317-72-3-741; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; EDEN CS, 1982, INFECTION, V10, P327, DOI 10.1007/BF01640890; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; GENTILOMI G, 1993, MOL CELL PROBE, V7, P19, DOI 10.1006/mcpr.1993.1003; HADLEY TJ, 1992, PROTEIN BLOOD GROUP, P228; KURTZMAN GJ, 1988, LANCET, V2, P1159; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; LEVINE P, 1951, P SOC EXP BIOL MED, V77, P403; LIU JM, 1992, J VIROL, V66, P4686, DOI 10.1128/JVI.66.8.4686-4692.1992; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MOREY AL, 1992, J CLIN PATHOL, V45, P673, DOI 10.1136/jcp.45.8.673; MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0; OBREGON E, 1980, TRANSFUSION, V20, P621; OZAWA K, 1986, SCIENCE, V233, P883, DOI 10.1126/science.3738514; RACE RR, 1975, BLOOD GROUPS MAN, P139; ROUGER P, 1987, REV FR TRANSFUS IMMU, V30, P699, DOI 10.1016/S0338-4535(87)80138-1; SANGER R, 1955, NATURE, V176, P1163, DOI 10.1038/1761163a0; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; SRIVASTAVA A, 1990, BLOOD, V76, P1997; VONDEMBORNE AEGK, 1986, BRIT J HAEMATOL, V63, P35; WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990; WILLIAMS RK, 1990, ADV EXP MED BIOL, V276, P45; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	29	215	230	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1192	1196		10.1056/NEJM199404283301704	http://dx.doi.org/10.1056/NEJM199404283301704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139629	Bronze			2022-12-28	WOS:A1994NG58600004
J	GAILLARD, C; STRAUSS, F				GAILLARD, C; STRAUSS, F			ASSOCIATION OF POLY(CA)CENTER-DOT-POLY(TG) DNA FRAGMENTS INTO 4-STRANDED COMPLEXES BOUND BY HMG-1 AND HMG-2	SCIENCE			English	Article							HANDED Z-DNA; HOMOLOGOUS RECOMBINATION; EUKARYOTIC GENOMES; CIRCULAR-DICHROISM; HOT SPOT; Z-FORM; PROTEIN; SEQUENCES; GENE; BINDING	The tandemly repeated DNA sequence poly(CA).poly(TG) is found in tracts up to 60 base pairs long, dispersed at thousands of sites throughout the genomes of eukaryotes. Double-stranded DNA fragments containing such sequences associated spontaneously with each other in vitro, in the absence of protein, forming stable four-stranded structures that were detected by gel electrophoresis and electron microscopy. These structures were recognized specifically by the nuclear nonhistone high mobility group (HMG) proteins 1 and 2 as evidenced by gel retardation. Such sequence-specific complexes might be involved in vivo in recombination or other processes requiring specific association of two double-stranded DNA molecules.	INST JACQUES MONOD, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite				Strauss, Francois/0000-0003-4327-6827				ANTAO VP, 1990, NUCLEIC ACIDS RES, V18, P4111, DOI 10.1093/nar/18.14.4111; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; BULLOCK P, 1986, MOL CELL BIOL, V6, P3948, DOI 10.1128/MCB.6.11.3948; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CASTLEMAN H, 1984, J BIOMOL STRUCT DYN, V2, P271, DOI 10.1080/07391102.1984.10507566; DIETRICH W, 1992, GENETICS, V131, P423; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GAILLARD C, UNPUB; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODWIN GH, 1977, METHOD CELL BIOL, V16, pCH15; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HANIFORD DB, 1983, J BIOMOL STRUCT DYN, V1, P593, DOI 10.1080/07391102.1983.10507467; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Johns EW, 1982, HMG CHROMOSOMAL PROT; KASHI Y, 1990, NUCLEIC ACIDS RES, V18, P1129, DOI 10.1093/nar/18.5.1129; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LITT M, 1989, AM J HUM GENET, V44, P397; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MURPHY KE, 1986, NUCLEIC ACIDS RES, V14, P7325, DOI 10.1093/nar/14.18.7325; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; RIAZANCE JH, 1987, NUCLEIC ACIDS RES, V15, P7627, DOI 10.1093/nar/15.18.7627; RIDOUX JP, 1987, NUCLEIC ACIDS RES, V15, P5813, DOI 10.1093/nar/15.14.5813; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STRINGER JR, 1985, MOL CELL BIOL, V5, P1247, DOI 10.1128/MCB.5.6.1247; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; TRECO D, 1985, MOL CELL BIOL, V5, P2029, DOI 10.1128/MCB.5.8.2029; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P1071, DOI 10.1093/nar/10.3.1071; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WOISARD A, 1986, BIOCHEMISTRY-US, V25, P2672, DOI 10.1021/bi00357a057; WRIGHT JM, 1988, BIOCHEMISTRY-US, V27, P576, DOI 10.1021/bi00402a012; ZIMMER C, 1982, NUCLEIC ACIDS RES, V10, P1081, DOI 10.1093/nar/10.3.1081	46	96	97	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	1994	264	5157					433	436		10.1126/science.8153633	http://dx.doi.org/10.1126/science.8153633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153633				2022-12-28	WOS:A1994NG19400043
J	STEPHENS, L; SMRCKA, A; COOKE, FT; JACKSON, TR; STERNWEIS, PC; HAWKINS, PT				STEPHENS, L; SMRCKA, A; COOKE, FT; JACKSON, TR; STERNWEIS, PC; HAWKINS, PT			A NOVEL PHOSPHOINOSITIDE-3 KINASE-ACTIVITY IN MYELOID-DERIVED CELLS IS ACTIVATED BY G-PROTEIN BETA-GAMMA-SUBUNITS	CELL			English	Article							RECEPTOR TYROSINE KINASES; I PHOSPHATIDYLINOSITOL KINASE; BINDING REGULATORY PROTEINS; PHOSPHOLIPASE-C; BOVINE BRAIN; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; CDNA CLONING; 3-KINASE; EXPRESSION	Phosphoinositide 3 kinase (PI3K) is a key signaling enzyme implicated in receptor-stimulated mitogenesis, oxidative bursting in neutrophils, membrane ruffling, and glucose uptake. A PI3K has already been purified, cloned, and shown to be regulated by receptors that act via tyrosine kinase-dependent regulatory mechanisms. We report that an immunologically, pharmacologically, and chromatographically distinct form of PI3K activity present in neutrophils and U937 cells is specifically activated by G protein py subunits. This data suggests PI3Ks conform to the paradigm set by receptor regulation of phosphoinositidase Cs: different receptor transduction systems specifically regulate dedicated isoforms of effector protein.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	STEPHENS, L (corresponding author), AFRC, BABRAHAM INST, BABRAHAM HALL, CAMBRIDGE, ENGLAND.			stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464				ARCARO A, 1994, IN PRESS BIOCH J; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PANG IH, 1990, J BIOL CHEM, V265, P18707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VALIRI C, 1993, J BIOL CHEM, V73, P321; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WENNSTROM S, 1994, IN PRESS ONCOGENE; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	75	553	562	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					83	93		10.1016/0092-8674(94)90237-2	http://dx.doi.org/10.1016/0092-8674(94)90237-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156600				2022-12-28	WOS:A1994NF21100012
J	TJIAN, R; MANIATIS, T				TJIAN, R; MANIATIS, T			TRANSCRIPTIONAL ACTIVATION - A COMPLEX PUZZLE WITH FEW EASY PIECES	CELL			English	Review							DOMAIN; MECHANISM; BINDING; VP16		HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	TJIAN, R (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PTASHNE M, 1992, GENETIC SWITCH GENE; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298	24	992	1014	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					5	8		10.1016/0092-8674(94)90227-5	http://dx.doi.org/10.1016/0092-8674(94)90227-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156597				2022-12-28	WOS:A1994NF21100002
J	SLATTERY, JM				SLATTERY, JM			WHY WE NEED A CLINICAL-TRIAL FOR VITAMIN-K	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; HEMORRHAGIC-DISEASE; NEWBORN	Vitamin K is given to many babies born in the United Kingdom, but we still do not know if it has substantial hazards. Because the population exposed to vitamin K is very large even quite small hazards would involve many adverse events. It is therefore important to be able to put reasonably close bounds on the potential damage that vitamin K prophylaxis could cause. Past research has not allowed us to do this but a large randomised controlled clinical trial of vitamin K against no vitamin K, enrolling only infants at low risk of haemorrhagic disease, would do so. There is no question that vitamin K is a useful treatment in babies at highest risk of haemorrhagic disease: the question is whether the trend towards use of vitamin K in lower risk babies should be encouraged.			SLATTERY, JM (corresponding author), UNIV EDINBURGH, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BHANCHET P, 1977, CLIN PEDIATR, V16, P992, DOI 10.1177/000992287701601106; DAM H, 1952, ADV PEDIATR, V5, P129; DRAPER GJ, 1992, BRIT MED J, V305, P709, DOI 10.1136/bmj.305.6855.709; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; KOH TK, 1969, SINGAP MED J, V10, P43; Lehmann JL, 1944, LANCET, V1, P493; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; MILLER RW, 1992, BMJ-BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016-c; SUTHERLAND JM, 1967, AM J DIS CHILD, V113, P524, DOI 10.1001/archpedi.1967.02090200056003; VIETTI TJ, 1960, J PEDIATR-US, V56, P343, DOI 10.1016/S0022-3476(60)80185-0; 1975, OPCS SERIES MB1, V5; 1968, WORLD HLTH STATISTIC; 1971, OPCS SERIES MB1, V1; 1958, EPIDEMIOLOGICAL VITA	17	7	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	1994	308	6933					908	910		10.1136/bmj.308.6933.908	http://dx.doi.org/10.1136/bmj.308.6933.908			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173376	Green Published			2022-12-28	WOS:A1994NE60000033
J	DAVIES, RJO; JENKINS, NE; STRADLING, JR				DAVIES, RJO; JENKINS, NE; STRADLING, JR			EFFECT OF MEASURING AMBULATORY BLOOD-PRESSURE ON SLEEP AND ON BLOOD-PRESSURE DURING SLEEP	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; FINGER	Objective-To assess whether recording of ambulatory blood pressure at night causes arousal from sleep and a change in the continuous blood pressure recorded simultaneously. Design-Repeated measurement of blood pressure with two ambulatory blood pressure machines (Oxford Medical ABP and A&D TM2420) during continuous measurement of beat to beat blood pressure and continuous electroencephalography. Setting-Sleep reseach laboratory. Subjects-Six normal subjects. Main outcome measures-The duration of electroencephalographic arousal and the beat to beat changes in blood pressure produced by the measurement of ambulatory blood pressure; the size of any changes that this arousal and change in blood pressure produced in the blood pressure recorded by the ambulatory machine. Results-Both ambulatory blood pressure machines caused arousal from sleep: the mean duration of arousal was 16 seconds (95% range 0-202) with the ABP and 8 seconds (0-73) with the TM2420. Both also caused a rise in beat to beat blood pressure. During non-rapid eye movement sleep, this rise led to the ABP machine overestimating the true systolic blood pressure during sleep by a mean of 10 (SD 14.8) mm Hg and the TM2420 by a mean of 6.3 (8.2) mm Hg. On average, diastolic pressure was not changed, but measurements in individual subjects changed by up to 23 mm Hg. These changes varied in size among subjects and stages of sleep and were seen after measurements that did not cause any electroencephalographic arousal. Conclusions-Ambulatory blood pressure machines cause appreciable arousal from sleep and therefore alter the blood pressure that they are trying to record. This effect should be taken into account when recordings of blood pressure at night are interpreted in clinical work and epidemiological research.			DAVIES, RJO (corresponding author), CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND.							BOEHMER RD, 1987, J CLIN MONITOR, V3, P282; BROUGHTON RJ, 1965, ELECTROEN CLIN NEURO, V18, P691, DOI 10.1016/0013-4694(65)90113-6; DAVIES RJO, 1993, J APPL PHYSIOL, V74, P1123, DOI 10.1152/jappl.1993.74.3.1123; JOHNSON LC, 1967, ELECTROEN CLIN NEURO, V22, P11, DOI 10.1016/0013-4694(67)90004-1; MANCIA G, 1983, LANCET, V2, P695; OBRIEN E, 1988, LANCET, V2, P397; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; PARATI G, 1985, J HYPERTENS S2, V3, P107; PENAZ J, 1973, 10TH INT C MED BIOL, P104; PENZEL T, 1991, NONINVASIVE CONTINUO, P95; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; RECHTSCHAFFEN A, 1968, PUBLICATION NAT I HL, V204; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SCHWAN A, 1992, J HYPERTENS, V10, P189; SHIMADA K, 1992, J HYPERTENS, V10, P875; Smith N T, 1985, J Clin Monit, V1, P17, DOI 10.1007/BF02832685; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WILLIAMS HL, 1964, ELECTROEN CLIN NEURO, V16, P269, DOI 10.1016/0013-4694(64)90109-9	18	97	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					820	823		10.1136/bmj.308.6932.820	http://dx.doi.org/10.1136/bmj.308.6932.820			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167489	Green Published			2022-12-28	WOS:A1994ND24300022
J	MILLS, JL				MILLS, JL			DATA TORTURING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											MILLS, JL (corresponding author), NICHHD,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; TUKEY JW, 1980, AM STAT, V34, P23, DOI 10.2307/2682991; WALLIS WA, 1965, NATURE STATISTICS; [No title captured]	5	151	152	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1196	1199		10.1056/NEJM199310143291613	http://dx.doi.org/10.1056/NEJM199310143291613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8166792				2022-12-28	WOS:A1993MA66700013
J	FEANY, MB; BUCKLEY, KM				FEANY, MB; BUCKLEY, KM			THE SYNAPTIC VESICLE PROTEIN SYNAPTOTAGMIN PROMOTES FORMATION OF FILOPODIA IN FIBROBLASTS	NATURE			English	Article							ALPHA-LATROTOXIN RECEPTOR; SYNAPSIN-I; SYNAPTOPHYSIN; EXPRESSION; NEURONS; BINDING; CELLS; IDENTIFICATION; PC12-CELLS; BIOGENESIS	NEURONAL filopodia are actin-rich cytoplasmic extensions that are involved in motility and recognition in growth cones and maturing axonal endings. A detailed understanding of neuronal growth will depend on clarification of the membrane fusion events occurring during filopodial extension. The synaptic vesicle protein synaptotagmin seems to be intimately involved in exocytotic membrane fusion1-3. Here we show that fibroblast cell lines transfected with synaptotagmin form long, highly branched, actin-rich filopodial processes, with the expressed synaptotagmin being incorporated into the plasma membrane. In contrast, cell lines expressing either of two other synaptic vesicle proteins, SV2 or synaptophysin, generate only rudimentary processes, and, like neurons, sort SV2 and synaptophysin to small intracellular vesicles. As presynaptic calcium entry regulates synaptic vesicle fusion, our results indicate that synaptotagmin might link neuronal activity with synaptic growth.			FEANY, MB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.			Feany, Mel/0000-0003-0315-7970; Buckley, Kathleen/0000-0003-0283-4917				BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BEBBINGTON C, 1987, DNA CLONING, V3; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGMANN M, 1991, NEUROSCIENCE, V42, P569, DOI 10.1016/0306-4522(91)90399-9; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHUN JJM, 1988, NEURON, V1, P297; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FOURNIER S, 1988, J NEUROCHEM, V51, P1599, DOI 10.1111/j.1471-4159.1988.tb01130.x; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; INOUE A, 1992, J BIOL CHEM, V267, P10613; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MASON CA, 1986, NEUROSCIENCE, V19, P1319, DOI 10.1016/0306-4522(86)90146-6; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	33	60	60	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					537	540		10.1038/364537a0	http://dx.doi.org/10.1038/364537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8166886				2022-12-28	WOS:A1993LQ66700058
J	NORTON, EC; NEWHOUSE, JP				NORTON, EC; NEWHOUSE, JP			POLICY OPTIONS FOR PUBLIC LONG-TERM-CARE INSURANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	NORTON, EC (corresponding author), RES TRIANGLE INST, 3040 CORNWALLIS RD, HOBBS BLDG, POB 12194, RES TRIANGLE PK, NC 27709 USA.		, Edward/AAQ-1719-2021; Norton, Edward C/B-2211-2009; Newhouse, Joseph/AGJ-5632-2022	, Edward/0000-0003-4555-0631; Norton, Edward C/0000-0003-4555-0631; 				Adams E K, 1986, Health Care Financ Rev, V8, P35; AKERLOF GA, 1970, Q J ECON, V84, P488, DOI 10.2307/1879431; BALLARD CL, 1992, J ECON PERSPECT, V6, P117, DOI 10.1257/jep.6.3.117; CHEN Y, 1993, CARE LONG TERM SEARC, P55; COHENMA, 1992, J HLTH POLIT POLICY, V17, P403; DOTY P, 1988, HLTH CARE FINANCING, P145; DOTY P, 1990, GENERATIONS, V14, P10; HING E, 1991, VITAL HLTH STAT 97, V13; HURD MD, 1990, J ECON LIT, V28, P565; Hurd MD, 1983, DISTRIBUTIONAL IMPAC; KANE RL, 1983, GERONTOLOGIST, V23, P200, DOI 10.1093/geront/23.2.200; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; Levit K R, 1991, Health Care Financ Rev, V13, P29; Newhouse JP, 1993, FREE ALL LESSONS RAN; NORTON EC, 1992, J HEALTH ECON, V11, P105, DOI 10.1016/0167-6296(92)90030-5; PAULY MV, 1990, J POLIT ECON, V98, P153, DOI 10.1086/261673; RIVLIN AM, 1988, CARING DISABLED ELDE; SCANLON WJ, 1992, J ECON PERSPECT, V6, P43, DOI 10.1257/jep.6.3.43; SCHWAB T, 1989, CARING AGING WORLD; SHEINER L, 1991, HOUSING WEALTH AGED; STRUDLER M, 1993, STAT INCOME B, V13, P14; VENTI SF, 1992, TAX POLICY EC, P1; WALLACK SS, 1990, ANAL PUBLIC PROPOSAL; 1991, INCOME SECURITY HLTH; 1990, CALL ACTION FINAL RE; 1991, POLICY CHOICES LONG	26	30	30	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1520	1524		10.1001/jama.271.19.1520	http://dx.doi.org/10.1001/jama.271.19.1520			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176833				2022-12-28	WOS:A1994NK71100032
J	VITATERNA, MH; KING, DP; CHANG, AM; KORNHAUSER, JM; LOWREY, PL; MCDONALD, JD; DOVE, WF; PINTO, LH; TUREK, FW; TAKAHASHI, JS				VITATERNA, MH; KING, DP; CHANG, AM; KORNHAUSER, JM; LOWREY, PL; MCDONALD, JD; DOVE, WF; PINTO, LH; TUREK, FW; TAKAHASHI, JS			MUTAGENESIS AND MAPPING OF A MOUSE GENE CLOCK, ESSENTIAL FOR CIRCADIAN BEHAVIOR	SCIENCE			English	Article							MESSENGER-RNA LEVELS; SUPRACHIASMATIC NUCLEUS; FUNCTIONAL-ANALYSIS; RHYTHMS; DROSOPHILA; PERIOD; LESIONS; MUTATIONS; PACEMAKER; PRODUCT	In a search for genes that regulate circadian rhythms in mammals, the progeny of mice treated with N-ethyl-N-nitrosourea (ENU) were screened for circadian clock mutations. A semidominant mutation, Clock, that lengthens circadian period and abolishes persistence of rhythmicity was identified. Clock segregated as a single gene that mapped to the midportion of mouse chromosome 5, a region syntenic to human chromosome 4. The power of ENU mutagenesis combined with the ability to clone murine genes by map position provides a generally applicable approach to study complex behavior in mammals.	NORTHWESTERN UNIV, NATL SCI FDN, SCI & TECHNOL CTR BIOL TIMING, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Takahashi, Joseph S/E-8482-2012; Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S./0000-0003-0384-8878	NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000015] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P30-CA07175] Funding Source: Medline; NIDCD NIH HHS [T32 DC000015] Funding Source: Medline; NIDDK NIH HHS [R01-DK40493] Funding Source: Medline; NINDS NIH HHS [T32 NS071040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Aschoff J, 1981, HDB BEHAVIORAL NEURO, P3, DOI DOI 10.1007/978-1-4615-6552-9_1; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; Bracewell R. N., 1986, HARTLEY TRANSFORM; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DAVIS FC, 1981, J COMP PHYSIOL, V143, P527, DOI 10.1007/BF00609919; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1993, GENETIC MAPS; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; EBIHARA S, 1978, PHYSIOL BEHAV, V20, P795, DOI 10.1016/0031-9384(78)90308-6; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Enright JT, 1981, HDB BEHAVIORAL NEURO, V4, P11; GAILEY DA, 1991, J COMP PHYSIOL A, V169, P685; GERKEMA MP, 1993, J BIOL RHYTHM, V8, P151, DOI 10.1177/074873049300800205; GERKEMA MP, 1990, J BIOL RHYTHM, V5, P81, DOI 10.1177/074873049000500201; HALL JC, 1990, ANNU REV GENET, V24, P659; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; IBUKA N, 1977, BRAIN RES, V122, P33, DOI 10.1016/0006-8993(77)90660-6; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KOZAK CA, 1993, MAMM GENOME, V4, pS72, DOI 10.1007/BF00360831; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LEHMANN U, 1976, INT J CHRONOBIOL, V4, P223; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; Ott J., 1991, ANAL HUMAN GENETIC L; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; POSSIDENTE B, 1988, BEHAV GENET, V18, P109, DOI 10.1007/BF01067080; POSSIDENTE B, 1982, PHYSIOL BEHAV, V28, P199, DOI 10.1016/0031-9384(82)90126-3; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RINCHIK EM, 1991, TRENDS GENET, V7, P15, DOI 10.1016/0168-9525(91)90016-J; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROSBASH M, 1993, CURR OPIN GENE DEV, V3, P301; RUSAK B, 1977, J COMP PHYSIOL, V118, P145, DOI 10.1007/BF00611819; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SCHEUCH GC, 1982, J COMP PHYSIOL, V149, P333, DOI 10.1007/BF00619149; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; SCHWARTZ WJ, 1991, PHYSIOL BEHAV, V49, P1283, DOI 10.1016/0031-9384(91)90364-T; SHEDLOVSKY A, 1986, GENET RES, V47, P135, DOI 10.1017/S0016672300022977; SILVER J, 1977, J COMP NEUROL, V176, P589, DOI 10.1002/cne.901760409; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; TUREK FW, 1994, RECENT PROG HORM RES, V49, P43; VANDENPOL AN, 1979, BRAIN RES, V160, P307, DOI 10.1016/0006-8993(79)90427-X; YOUNG MW, 1993, MOL GENETICS BIOL RH	53	1217	1262	6	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	1994	264	5159					719	725		10.1126/science.8171325	http://dx.doi.org/10.1126/science.8171325			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171325	Green Accepted			2022-12-28	WOS:A1994NH71300037
J	ALPER, S; DUNCAN, L; LOSICK, R				ALPER, S; DUNCAN, L; LOSICK, R			AN ADENOSINE NUCLEOTIDE SWITCH CONTROLLING THE ACTIVITY OF A CELL-TYPE-SPECIFIC TRANSCRIPTION FACTOR IN BACILLUS-SUBTILIS	CELL			English	Article							POLYMERASE SIGMA-FACTOR; BACILLUS-SUBTILIS; RNA-POLYMERASE; GENE-EXPRESSION; SPORULATION; SPOIIA; LOCUS; TRANSFORMATION; ACTIVATION; PROMOTER	The sigma(F) factor establishes cell type-specific gene transcription during sporulation in B. subtilis. sigma(F) is negatively regulated by SpoIIAB, which forms complexes with of or SpoIIAA. ATP and its nonhydrolyzable analogs stimulate the formation of the SpoIIAB.sigma(F) complex, whereas ADP stimulates the formation of the SpoIIAB.SpoIIAA complex. Which protein SpoIIAB associates with is determined by the concentrations of the two nucleotides, on which basis we propose a partner-switching model for the regulation of sigma(F): [GRAPHICS] Consistent with this model, SpollAA reverses SpoIIAB-mediated inhibition of sigma(F)-directed transcription in a manner that depends on ADP. Cell-specific activation of of could be due to an alteration in adenosine nucleotide levels in one cell of the sporangium.			ALPER, S (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON DE, 1969, ANNU REV MICROBIOL, V23, P47, DOI 10.1146/annurev.mi.23.100169.000403; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BINNIE C, 1986, P NATL ACAD SCI USA, V83, P5943, DOI 10.1073/pnas.83.16.5943; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; BOYLAN SA, 1994, IN PRESS J BACTERIOL; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DELENCASTRE H, 1979, J GEN MICROBIOL, V114, P377, DOI 10.1099/00221287-114-2-377; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN ML, 1987, J BACTERIOL, V169, P771, DOI 10.1128/jb.169.2.771-778.1987; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GUFFANTI AA, 1987, J BACTERIOL, V169, P4469, DOI 10.1128/jb.169.10.4469-4478.1987; HALDENWANG WG, 1980, P NATL ACAD SCI-BIOL, V77, P7000, DOI 10.1073/pnas.77.12.7000; HAROLD FM, 1972, BACTERIOL REV, V36, P172, DOI 10.1128/MMBR.36.2.172-230.1972; HECKER M, 1989, FEMS MICROBIOL LETT, V59, P125; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUTCHISON KW, 1974, J BACTERIOL, V119, P70, DOI 10.1128/JB.119.1.70-75.1974; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; JOLLIFFE LK, 1981, CELL, V25, P753, DOI 10.1016/0092-8674(81)90183-5; KALMAN S, 1990, J BACTERIOL, V172, P5575, DOI 10.1128/jb.172.10.5575-5585.1990; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; KLOFAT W, 1969, J BIOL CHEM, V244, P3270; LIU HM, 1982, J GEN MICROBIOL, V128, P2805; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MARGOLIS P, 1993, THESIS HARVARD U CAM; Miller J.H., 1972, EXPT MOL GENETICS; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHEN LC, 1968, BIOCHEMISTRY-US, V7, P4041, DOI 10.1021/bi00851a035; SINGH RP, 1977, J BACTERIOL, V130, P1130, DOI 10.1128/JB.130.3.1130-1138.1977; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; STADTMAN ER, 1970, ENZYMES, P397; STRAGIER P, 1993, REGULATION BACTERIAL, P139; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VOLKER U, 1994, IN PRESS J GEN MICRO; YI F, 1991, J BIOL CHEM, V266, P3900; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1; YOUSTEN AA, 1972, J BACTERIOL, V109, P886, DOI 10.1128/JB.109.2.886-894.1972; YUDKIN MD, 1985, J GEN MICROBIOL, V131, P959; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P	49	198	200	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					195	205		10.1016/0092-8674(94)90312-3	http://dx.doi.org/10.1016/0092-8674(94)90312-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168129				2022-12-28	WOS:A1994NH63400005
J	GOLUB, TR; BARKER, GF; LOVETT, M; GILLILAND, DG				GOLUB, TR; BARKER, GF; LOVETT, M; GILLILAND, DG			FUSION OF PDGF RECEPTOR-BETA TO A NOVEL ETS-LIKE GENE, TEL, IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH T(512) CHROMOSOMAL TRANSLOCATION	CELL			English	Article							TYROSINE KINASE RECEPTOR; GROWTH-FACTOR RECEPTORS; MYELODYSPLASTIC SYNDROMES; TRANSFORMING GENE; MYELOID-LEUKEMIA; C-FMS; DROSOPHILA; ACTIVATION; BINDING; FAMILY	Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML). CMML thus offers an opportunity to study early genetic events in the transition to AML. A recently recognized subgroup of CMML has a t(5;12)(q33;p13) balanced translocation. We report that the consequence of the t(5;12) translocation is expression of a fusion transcript in which the tyrosine kinase domain of the platelet-derived growth factor receptor beta (PDGFR beta) on chromosome 5 is coupled to a novel ets-like gene, tel, on chromosome 12. The tel-PDGFR beta fusion demonstrates the oncogenic potential of PDGFR beta and may provide a paradigm for early events in the pathogenesis of AML.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GOLUB, TR (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-57261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARKER GF, 1991, MOL CELL BIOL, V11, P60; BARTRAM CR, 1992, MYELODYSPLASTSIC SYN, P557; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERKOWICZ M, 1991, CANCER GENET CYTOGEN, V51, P277, DOI 10.1016/0165-4608(91)90142-H; BIRREN BW, 1989, ANAL BIOCHEM, V177, P282, DOI 10.1016/0003-2697(89)90052-3; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUSQUE L, 1993, BLOOD, V82, P337; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLARK RA, 1991, CURRENT PROTOCOLS IM; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ERICKSON P, 1992, BLOOD, V80, P1825; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GANSER A, 1992, MYLEODYSPLASTIC SYND, P607; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KNAPP RH, 1985, MAYO CLIN PROC, V60, P507, DOI 10.1016/S0025-6196(12)60566-7; KOEFFLER HP, 1992, MYELODYSPLASTIC SYND; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZU T, 1993, BLOOD, V82, P1270; LERZA R, 1992, BRIT J HAEMATOL, V82, P476, DOI 10.1111/j.1365-2141.1992.tb06450.x; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MECUCCI C, 1992, MYELODYSPLASTIC SYND, P523; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NUCIFORA G, 1993, BLOOD, V81, P883; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAO VN, 1993, ONCOGENE, V8, P2167; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROCHFORD R, 1990, MOL CELL BIOL, V10, P4996, DOI 10.1128/MCB.10.9.4996; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROSNET O, 1991, ONCOGENE, V6, P1641; ROWLEY JD, 1981, BLOOD, V58, P759; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SAMBROOK J, 1989, MOL LABORATORY MANUA; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SETH A, 1990, ONCOGENE, V5, P1761; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SRIVASTAVA A, 1988, CANCER GENET CYTOGEN, V35, P61, DOI 10.1016/0165-4608(88)90123-9; THE SM, 1992, ONCOGENE, V7, P2471; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TIGHE JE, 1993, BLOOD, V81, P592; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALIUS B, 1993, CELL, V73, P321; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WESSELS JW, 1993, CANCER GENET CYTOGEN, V65, P7, DOI 10.1016/0165-4608(93)90051-M; YAN XQ, 1994, ONCOGENE, V9, P163; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YUNIS JJ, 1986, BLOOD, V67, P1721	68	1036	1083	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					307	316		10.1016/0092-8674(94)90322-0	http://dx.doi.org/10.1016/0092-8674(94)90322-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168137				2022-12-28	WOS:A1994NH63400015
J	HEMMATIBRIVANLOU, A; KELLY, OG; MELTON, DA				HEMMATIBRIVANLOU, A; KELLY, OG; MELTON, DA			FOLLISTATIN, AN ANTAGONIST OF ACTIVIN, IS EXPRESSED IN THE SPEMANN ORGANIZER AND DISPLAYS DIRECT NEURALIZING ACTIVITY	CELL			English	Article							XENOPUS EMBRYOS; BINDING PROTEIN; AMPHIBIAN DEVELOPMENT; PORCINE FOLLISTATIN; MESODERM INDUCTION; MESSENGER-RNAS; EARLY RESPONSE; LAEVIS; GENE; DIFFERENTIATION	In the accompanying paper, we show that the expression of a dominant negative activin receptor can convert prospective ectoderm into neural tissue, which suggests that activin is an inhibitor of neuralization. Here we report the isolation and characterization of an activin antagonist, follistatin,that can induce neural tissue directly in vivo. Follistatin RNA is localized in the Spemann organizer and notochord, tissues known to be potent neural inducers. We demonstrate that follistatin RNA and protein are able to block the activity of activin in embryonic explants. Furthermore, we show that follistatin RNA directly neuralizes ectodermal explants in the absence of detectable mesoderm. Thus, follistatin is present at the correct time and location to play a role in neural induction in vivo.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; FERREIRO B, 1993, MECH DEVELOP, V40, P25, DOI 10.1016/0925-4773(93)90085-C; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MALACINSKI G, 1975, DEV BIOL, V56, P24; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SAHA MS, 1993, MOL BRAIN RES, V17, P307, DOI 10.1016/0169-328X(93)90016-I; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPERMANN H, 1924, ROUXS ARCH ENTW MECH, V100, P599; Stern C D, 1993, EXS, V65, P369; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	54	570	588	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					283	295		10.1016/0092-8674(94)90320-4	http://dx.doi.org/10.1016/0092-8674(94)90320-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168135				2022-12-28	WOS:A1994NH63400013
J	BROWN, DWG; RAMSAY, MEB; RICHARDS, AF; MILLER, E				BROWN, DWG; RAMSAY, MEB; RICHARDS, AF; MILLER, E			SALIVARY DIAGNOSIS OF MEASLES - A STUDY OF NOTIFIED CASES IN THE UNITED-KINGDOM, 1991-3	BRITISH MEDICAL JOURNAL			English	Article							VACCINE FAILURE; RISK-FACTORS; MUMPS	Objectives-To validate a method for salivary diagnosis of measles and to assess the diagnostic accuracy of notified cases of measles. Design-Blood and saliva samples were collected within 90 days of onset of symptoms from patients clinically diagnosed as having measles and tested for specific IgM by antibody capture radioimmunoassay. Setting-17 districts in England and one in southern Ireland during August 1991 to February 1993. Subjects-236 children and adults with measles notified by a general practitioner. Results-Specific IgM was detected in serum in only 85 (36%) of the 236 cases. In cases associated with outbreaks and tested within six weeks of onset, 53/57 (93%) of samples were IgM positive, thereby confirming the sensitivity of serum IgM detection as a marker of recent infection. The serological confirmation rate was lower in cases with a documented history of vaccination (13/87; 15%) than in those without (70/149; 47%) and varied with age, being lowest in patients under a year, of whom only 4/36 (11%) were confirmed. Measles specific IgM was detected in 71/77 (92%) of adequate saliva samples collected from patients with serum positive for IgM. In cases where measles was not confirmed, 6/101 had rubella specific IgM and 5/132 had human parvovirus B19 specific IgM detected in serum. Conclusions-The existing national surveillance system for measles, which relies on clinically diagnosed cases, lacks the precision required for effective disease control. Saliva is a valid alternative to serum for IgM detection, and salivary diagnosis could play a major role in achieving measles elimination. Rubella and parvovirus B19 seem to be responsible for a minority of incorrectly diagnosed cases of measles in the United Kingdom and other infectious causes of measles-like illness need to be sought.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; CENT PUBL HLTH LAB,PHLS,DIV VIRUS REFERENCE,DIV ENTER & RESP VIRUS,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England			Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; FARACLEGAN H, 1987, J INFECT DIS, V155, P1073; FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742; HINMAN AR, 1983, REV INFECT DIS, V5, P538; HULL HF, 1985, PEDIATRICS, V76, P518; MILLER E, 1992, BMJ-BRIT MED J, V304, P1440, DOI 10.1136/bmj.304.6839.1440-b; MORTIMER PP, 1991, REV MED VIROL, V1, P73; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; REYES MA, 1987, PEDIATR INFECT DIS J, V6, P848, DOI 10.1097/00006454-198709000-00012; ROBERTSON SE, 1992, PUBLIC HEALTH REP, V107, P24; White J M, 1993, Commun Dis Rep CDR Rev, V3, pR71; 1977, LANCET, V2, P571; 1966, SBL607 DEP HLTH STAT; 1990, KC51 DEP HLTH STAT D; 1988, IMMUNISATION INFECTI	16	106	108	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1015	1017		10.1136/bmj.308.6935.1015	http://dx.doi.org/10.1136/bmj.308.6935.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167513	Green Published			2022-12-28	WOS:A1994NH08900020
J	DANTZIG, AH; HOSKINS, J; TABAS, LB; BRIGHT, S; SHEPARD, RL; JENKINS, IL; DUCKWORTH, DC; SPORTSMAN, JR; MACKENSEN, D; ROSTECK, PR; SKATRUD, PL				DANTZIG, AH; HOSKINS, J; TABAS, LB; BRIGHT, S; SHEPARD, RL; JENKINS, IL; DUCKWORTH, DC; SPORTSMAN, JR; MACKENSEN, D; ROSTECK, PR; SKATRUD, PL			ASSOCIATION OF INTESTINAL PEPTIDE-TRANSPORT WITH A PROTEIN RELATED TO THE CADHERIN SUPERFAMILY	SCIENCE			English	Article							BORDER MEMBRANE-VESICLES; BETA-LACTAM ANTIBIOTICS; RABBIT SMALL-INTESTINE; AMINO-ACID-TRANSPORT; CELL-ADHESION; ENTEROCYTIC DIFFERENTIATION; COMPLEMENTARY-DNA; BINDING-PROTEIN; PLASMA-MEMBRANE; CACO-2 CELLS	The first step in oral absorption of many medically important peptide-based drugs is mediated by an intestinal proton-dependent peptide transporter. This transporter facilitates the oral absorption of beta-lactam antibiotics and angiotensin-converting enzyme inhibitors from the intestine into enterocytes lining the luminal wall. A monoclonal antibody that blocked uptake of cephalexin was used to identify and clone a gene that encodes an approximately 92-kilodalton membrane protein that was associated with the acquisition of peptide transport activity by transport-deficient cells. The amino acid sequence deduced from the complementary DNA sequence of the cloned gene indicated that this transport-associated protein shares several conserved structural elements with the cadherin superfamily of calcium-dependent, cell-cell adhesion proteins.	TERRAPIN TECHNOL,SAN FRANCISCO,CA 94080; HYBRITECH INC,SAN DIEGO,CA 92121		DANTZIG, AH (corresponding author), ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BURGETT SG, IN PRESS; DANTZIG AH, 1992, BIOCHIM BIOPHYS ACTA, V1112, P167, DOI 10.1016/0005-2736(92)90388-3; DANTZIG AH, 1994, BBA-BIOMEMBRANES, V1191, P7, DOI 10.1016/0005-2736(94)90226-7; DANTZIG AH, 1990, BIOCHIM BIOPHYS ACTA, V1027, P211, DOI 10.1016/0005-2736(90)90309-C; DANTZIG AH, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRIEDMAN DI, 1989, PHARMACEUT RES, V6, P1043, DOI 10.1023/A:1015978420797; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1991, Current Opinion in Cell Biology, V3, P695, DOI 10.1016/0955-0674(91)90043-X; GANAPATHY V, 1991, INDIAN J BIOCHEM BIO, V28, P317; HAMMOND JR, 1989, CANCER RES, V49, P3867; HOSHI T, 1986, INSERM S, V26, P183; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1030, P50, DOI 10.1016/0005-2736(90)90237-I; KRAMER W, 1993, J BIOL CHEM, V268, P18035; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1028, P174, DOI 10.1016/0005-2736(90)90152-E; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1977, J BIOL CHEM, V252, P1990; MACKENSEN D, UNPUB; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MARDER P, 1990, CYTOMETRY, V11, P498, DOI 10.1002/cyto.990110408; MIYAMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V978, P25, DOI 10.1016/0005-2736(89)90493-8; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PINTO M, 1982, BIOL CELL, V44, P193; RAJENDRAN VM, 1985, GASTROENTEROLOGY, V89, P1298, DOI 10.1016/0016-5085(85)90646-8; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROUSSET M, 1985, J CELL PHYSIOL, V123, P377, DOI 10.1002/jcp.1041230313; SAITO H, 1993, BIOCHEM PHARMACOL, V45, P776; SAITO H, 1993, AM J PHYSIOL, V265, pG289, DOI 10.1152/ajpgi.1993.265.2.G289; Sambrook J, 1989, MOL CLONING LABORATO; SEZAKI H, 1983, TOP PHARM SCI, P133; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2230; TSUJI A, 1986, J ANTIBIOT, V39, P1592, DOI 10.7164/antibiotics.39.1592; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WILSON BS, 1990, CANCER RES, V50, P3124; WILSON D, 1989, BIOCHIM BIOPHYS ACTA, V986, P123, DOI 10.1016/0005-2736(89)90280-0; YOSHIOKA M, 1991, INT J CANCER, V47, P916, DOI 10.1002/ijc.2910470622; [No title captured]	49	167	178	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					430	433		10.1126/science.8153632	http://dx.doi.org/10.1126/science.8153632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153632				2022-12-28	WOS:A1994NG19400042
J	HANNUM, C; CULPEPPER, J; CAMPBELL, D; MCCLANAHAN, T; ZURAWSKI, S; BAZAN, JF; KASTELEIN, R; HUDAK, S; WAGNER, J; MATTSON, J; LUH, J; DUDA, G; MARTINA, N; PETERSON, D; MENON, S; SHANAFELT, A; MUENCH, M; KELNER, G; NAMIKAWA, R; RENNICK, D; RONCAROLO, MG; ZLOTNIK, A; ROSNET, O; DUBREUIL, P; BIRNBAUM, D; LEE, F				HANNUM, C; CULPEPPER, J; CAMPBELL, D; MCCLANAHAN, T; ZURAWSKI, S; BAZAN, JF; KASTELEIN, R; HUDAK, S; WAGNER, J; MATTSON, J; LUH, J; DUDA, G; MARTINA, N; PETERSON, D; MENON, S; SHANAFELT, A; MUENCH, M; KELNER, G; NAMIKAWA, R; RENNICK, D; RONCAROLO, MG; ZLOTNIK, A; ROSNET, O; DUBREUIL, P; BIRNBAUM, D; LEE, F			LIGAND FOR FLT3 FLK2 RECEPTOR TYROSINE KINASE REGULATES GROWTH OF HEMATOPOIETIC STEM-CELLS AND IS ENCODED BY VARIANT RNAS	NATURE			English	Article							COLONY-STIMULATING FACTOR; MOUSE	THE FLT3/FLK2 receptor tyrosine kinase is closely related to two receptors, c-Kit and c-Fms, which function with their respective ligands, Kit ligand and macrophage colony-stimulating factor to control differentiation of haematopoietic and non-haematopoietic cells1-5. FLT3/FLK2 is thought to be present on haematopoietic stem cells and found in brain, placenta and testis3-5. We have purified to homogeneity and partially sequenced a soluble form of the FLT3/FLK2 ligand produced by mouse thymic stromal cells. We isolated several mouse and human complementary DNAs that encode polypeptide with identical N termini and different C termini. Some variants contain hydrophobic transmembrane segments, suggesting that processing may be required to release soluble ligand. The purified ligand enhances the response of mouse stem cells and a primitive human progenitor cell population to other growth factors such as interleukins IL-3 and IL-6 and to granulocyte-macrophage colony-stimulating factor, and also stimulates fetal thymocytes.	INSERM, U119, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	HANNUM, C (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, 901 CALIF AVE, PALO ALTO, CA 94304 USA.		dubreuil, patrice/F-5346-2011; Muench, Marcus O./C-5025-2009; Bazan, J. Fernando/B-4562-2010; Zlotnik, Albert/C-3791-2011; Dubreuil, Patrice/V-4816-2019; Rosnet, Olivier/G-3536-2013	dubreuil, patrice/0000-0003-1155-1150; Muench, Marcus O./0000-0001-8946-6605; Dubreuil, Patrice/0000-0003-1155-1150; RONCAROLO, Maria Grazia/0000-0002-2193-9186; Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X				BARCENA A, IN PRESS BLOOD; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; GALY AHM, 1993, THYMUS, V22, P13; GODFREY DI, 1992, J IMMUNOL, V149, P2281; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHERR CJ, 1990, BLOOD, V75, P1; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	21	407	452	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	1994	368	6472					643	648		10.1038/368643a0	http://dx.doi.org/10.1038/368643a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145851				2022-12-28	WOS:A1994NF39200063
J	SUKI, B; BARABASI, AL; HANTOS, Z; PETAK, F; STANLEY, HE				SUKI, B; BARABASI, AL; HANTOS, Z; PETAK, F; STANLEY, HE			AVALANCHES AND POWER-LAW BEHAVIOR IN LUNG-INFLATION	NATURE			English	Article							AIRWAY-CLOSURE; MODEL	WHEN lungs are emptied during exhalation, peripheral airways close up1. For people with lung disease, they may not reopen for a significant portion of inhalation, impairing gas exchange2,3. A knowledge of the mechanisms that govern reinflation of collapsed regions of lungs is therefore central to the development of ventilation strategies for combating respiratory problems. Here we report measurements of the terminal airway resistance, R(t), during the opening of isolated dog lungs. When inflated by a constant flow, R(t) decreases in discrete jumps. We find that the probability distribution of the sizes of the jumps and of the time intervals between them exhibit power-law behaviour over two decades. We develop a model of the inflation process in which 'avalanches' of airway openings are seen-with power-law distributions of both the size of avalanches and the time intervals between them-which agree quantitatively with those seen experimentally, and are reminiscent of the power-law behaviour observed for self-organized critical systems4. Thus power-law distributions, arising from avalanches associated with threshold phenomena propagating down a branching tree structure, appear to govern the recruitment of terminal airspaces.	BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215; BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; ALBERT SZENT GYORGYI MED UNIV,DEPT MED INFORMAT,SZEGED,HUNGARY; ALBERT SZENT GYORGY MED UNIV,DEPT EXPTL SURG,SZEGED,HUNGARY	Boston University; Boston University; Szeged University; Szeged University	SUKI, B (corresponding author), BOSTON UNIV,DEPT BIOMED ENGN,RESP RES LAB,BOSTON,MA 02215, USA.		Barabasi, Albert-Laszlo/S-6474-2017; Hantos, Zoltan/D-2692-2011	Barabasi, Albert/0000-0002-4028-3522				BAK P, 1989, NATURE, V342, P780, DOI 10.1038/342780a0; BAK P, 1994, FRACTALS SCI; CRAWFORD ABH, 1989, J APPL PHYSIOL, V66, P2511, DOI 10.1152/jappl.1989.66.6.2511; DAVEY BLK, 1993, RESP PHYSIOL, V91, P165, DOI 10.1016/0034-5687(93)90097-T; ENGEL LA, 1975, J APPL PHYSIOL, V38, P1117, DOI 10.1152/jappl.1975.38.6.1117; GAVER DP, 1990, J APPL PHYSIOL, V69, P74, DOI 10.1152/jappl.1990.69.1.74; HORSFIELD K, 1982, J APPL PHYSIOL, V52, P21, DOI 10.1152/jappl.1982.52.1.21; HUGHES JMB, 1970, J APPL PHYSIOL, V29, P340, DOI 10.1152/jappl.1970.29.3.340; LAMBERT RK, 1982, J APPL PHYSIOL, V52, P44, DOI 10.1152/jappl.1982.52.1.44; MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0; PETAK F, 1993, EUR RESPIR J, V6, pS403; SALAZAR E, 1964, J APPL PHYSIOL, V19, P97, DOI 10.1152/jappl.1964.19.1.97; SHLESINGER MF, 1991, PHYS REV LETT, V67, P2106, DOI 10.1103/PhysRevLett.67.2106; Vicsek T, 1992, FRACTAL GROWTH PHENO; West B.J., 1990, FRACTAL PHYSL CHAOS, DOI [10.1142/8577, DOI 10.1142/8577]; WEST BJ, 1990, AM SCI, V78, P40	16	217	221	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					615	618		10.1038/368615a0	http://dx.doi.org/10.1038/368615a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145846				2022-12-28	WOS:A1994NF39200054
J	GOLDSTEIN, LB; MATCHAR, DB				GOLDSTEIN, LB; MATCHAR, DB			CLINICAL-ASSESSMENT OF STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSIENT ISCHEMIC ATTACKS; CEREBRAL INFARCTION; INTEROBSERVER AGREEMENT; INTERRATER RELIABILITY; PROGNOSTIC SCORE; MOOD DISORDERS; DIAGNOSIS; SCALE; RECOVERY; PREVENTION		DEPT VET AFFAIRS MED CTR, DURHAM, NC USA; DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GEN INTERNAL MED, DURHAM, NC 27710 USA	Duke University; Duke University	GOLDSTEIN, LB (corresponding author), DUKE UNIV, MED CTR, CTR HLTH POLICY RES, BOX 3651, DURHAM, NC 27710 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	PHS HHS [282-91-0028] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ADAMS RD, 1985, PRINCIPLES NEUROLOGY; ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; ALLEN CMC, 1983, Q J MED, V52, P515; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; [Anonymous], 1989, STROKE, V20, P1407; ASPLUND K, 1987, STROKE, V18, P528, DOI 10.1161/01.STR.18.2.528; BARER DH, 1989, Q J MED, V70, P27; BARNETT HJM, 1990, STROKE, V21, P40; BOZZAO L, 1989, AM J NEURORADIOL, V10, P1215; BRITTON M, 1984, NEUROLOGY, V34, P1504, DOI 10.1212/WNL.34.11.1504; BRITTON M, 1980, ACTA MED SCAND, V207, P37; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FORD AB, 1966, MEDICINE, V45, P223; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULLERTON KJ, 1988, Q J MED, V66, P147; GARRAWAY WM, 1983, STROKE, V14, P699, DOI 10.1161/01.STR.14.5.699; GELMERS HJ, 1988, STROKE, V19, P709, DOI 10.1161/01.STR.19.6.709; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GLASS TA, 1993, STROKE, V24, P64, DOI 10.1161/01.STR.24.1.64; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GRANGER CV, 1990, STROKE, V21, P66; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; Hachinski V, 1985, ACUTE STROKE; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HENLEY S, 1985, J NEUROL NEUROSUR PS, V48, P1, DOI 10.1136/jnnp.48.1.1; HOWARD G, 1985, JAMA-J AM MED ASSOC, V253, P226, DOI 10.1001/jama.253.2.226; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KINSELLA G, 1980, MED J AUSTRALIA, V2, P663; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; LINCOLN NB, 1989, J NEUROL NEUROSUR PS, V52, P493, DOI 10.1136/jnnp.52.4.493; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; LINDMARK B, 1988, SCAND J REHABIL MED, V20, P103; LOEWEN SC, 1990, STROKE, V21, P78, DOI 10.1161/01.STR.21.1.78; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; NORRIS JW, 1982, LANCET, V1, P328; OLSEN J, 1988, J NEUROL REHABIL, V2, P59; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; PANZER RJ, 1985, ARCH INTERN MED, V145, P1800, DOI 10.1001/archinte.145.10.1800; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1985, J NERV MENT DIS, V173, P221, DOI 10.1097/00005053-198504000-00003; ROSS RT, 1983, ARCH NEUROL-CHICAGO, V40, P633, DOI 10.1001/archneur.1983.04050090069011; ROTHMAN ML, 1989, MED CARE, V27, pS157, DOI 10.1097/00005650-198903001-00013; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHINAR D, 1985, ARCH NEUROL-CHICAGO, V42, P557, DOI 10.1001/archneur.1985.04060060059010; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Sisk C, 1970, STROKE, V1, P14, DOI 10.1161/01.STR.1.1.14; SUZUKI I, 1992, NEUROLOGY, V42, P2207, DOI 10.1212/WNL.42.11.2207; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; TUTHILL JE, 1969, AM HEART J, V78, P53, DOI 10.1016/0002-8703(69)90258-0; VOGEL HP, 1992, NEUROLOGY, V42, P2076, DOI 10.1212/WNL.42.11.2076; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288; VONARBIN M, 1980, J CHRON DIS, V33, P215, DOI 10.1016/0021-9681(80)90066-1; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WERDELIN L, 1988, NEUROLOGY, V38, P677, DOI 10.1212/WNL.38.5.677; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; Ziegler DK, 1973, STROKE, V4, P666, DOI 10.1161/01.STR.4.4.666; 1992, 1993 SROKE FACTS	77	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1114	1120		10.1001/jama.271.14.1114	http://dx.doi.org/10.1001/jama.271.14.1114			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151856				2022-12-28	WOS:A1994NE22800036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FLUOXETINE LABELING REVISED TO IDENTIFY PHENYTOIN INTERACTION AND TO RECOMMEND AGAINST USE IN NURSING MOTHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-28	WOS:A1994NE22800007
J	LIU, F; GREEN, MR				LIU, F; GREEN, MR			PROMOTER TARGETING BY ADENOVIRUS-E1A THROUGH INTERACTION WITH DIFFERENT CELLULAR DNA-BINDING DOMAINS	NATURE			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA GENE-PRODUCT; E1A PROTEINS; MAMMALIAN-CELLS; FACTOR FAMILY; TRANSACTIVATION; ELEMENT; IDENTIFICATION; TRANSFORMATION; EXPRESSION	A puzzling property of the transcriptional activators encoded by several animal viruses is their ability to function promiscuously. The adenovirus E1a protein, for example, stimulates transcription of adenoviral genes as well as a wide variety of other viral and cellular genes. We show that E1a can interact with several classes of cellular DNA-binding domains and thereby be recruited to diverse promoters. Our results explain how a single protein can regulate transcription of multiple genes that lack a common promoter element.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	LIU, F (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DU W, 1993, NATURE, V74, P887; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FLINT KJ, 1991, ONCOGENE, V6, P2019; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1991, ONCOGENE, V6, P627; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHENK T, 1991, ADV CANCER RES, V57, P47; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Tao Jianshi, 1993, V3, P3; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P176, DOI 10.1128/MCB.10.1.176; TENESE N, 1991, GEES DEV, V5, P2212; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZU YL, 1991, J BIOL CHEM, V266, P24134	44	244	253	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					520	525		10.1038/368520a0	http://dx.doi.org/10.1038/368520a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139685				2022-12-28	WOS:A1994NE33500045
J	MEYER, A; MORRISSEY, JM; SCHARTL, M				MEYER, A; MORRISSEY, JM; SCHARTL, M			RECURRENT ORIGIN OF A SEXUALLY SELECTED TRAIT IN XIPHOPHORUS FISHES INFERRED FROM A MOLECULAR PHYLOGENY	NATURE			English	Article							MATING PREFERENCES; FEMALE PREFERENCES; MALE SWORDS; EVOLUTION	DARWIN1 believed that sexual selection accounts for the evolution of exaggerated male ornaments, such as the sword-like caudal fin extensions of male fishes of the genus Xiphophorus, that appear detrimental to survival. Swordtails continue to feature prominently in empirical work and theories of sexual selection; the pre-existing bias hypothesis has been offered as an explanation for the evolution of swords in these fishes2,3. Based upon a largely morphological phylogeny, this hypothesis suggests that female preference to mate with sworded males arose in ancestrally swordless species, thus pre-dating the origin of the sword itself and directly driving its evolution. Here we present a molecular phylogeny (based on mitochondrial and nuclear DNA sequences) of Xiphophorus which differs from the traditional one: it indicates that the sword originated and was lost repeatedly. Our phylogeny suggests that the ancestor of the genus is more likely to have possessed a sword than not, thus questioning the applicability of the pre-existing bias hypothesis as an explanation for the evolution of this sexually selected trait.	SUNY STONY BROOK,PROGRAM GENET,STONY BROOK,NY 11794; UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wurzburg	MEYER, A (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794, USA.		Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193; Schartl, Manfred/0000-0001-9882-5948				ALCOCK J, 1993, ANIMAL BEHAVIOR EVOL; BAKKER TCM, 1993, NATURE, V363, P255, DOI 10.1038/363255a0; BASOLO A L, 1990, Animal Behaviour, V40, P332, DOI 10.1016/S0003-3472(05)80928-5; BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; BASOLO AL, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-b; BRADBURY JW, 1987, SEXUAL SELECTION TES; Darwin C., 1871, P475; DOWLING TE, 1993, NATURE, V362, P444, DOI 10.1038/362444a0; DZWILLO M, 1963, VERH DT ZOOL GES, P152; ENDLER JA, 1992, AM NAT, V139, pS125, DOI 10.1086/285308; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fisher, 1958, GENETICAL THEORY NAT; Gordon M, 1943, AM NAT, V77, P569, DOI 10.1086/281162; HAAS V, 1993, TRENDS ICHTHYOLOGY, P279; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOUDE AE, 1990, SCIENCE, V248, P1405, DOI 10.1126/science.248.4961.1405; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KIRKPATRICK M, 1987, SEXUAL SELECTION TES, P67; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KREBS JR, 1993, INTRO BEHAVIOURAL EC; Kumar S., 1993, MEGA MOL EVOLUTIONAR; MADDISON WP, 1992, MACCLADER VER 3 0 AN; MEYER A, 1993, P ROY SOC B-BIOL SCI, V254, P153, DOI 10.1098/rspb.1993.0140; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MEYER M K, 1980, Senckenbergiana Biologica, V60, P147; Meyer M.K., 1987, Courier Forschungsinstitut Senckenberg, V94, P123; MORIZOT DC, 1982, GENETICS, V102, P539; PARTRIDGE L, 1987, NATURE, V328, P377, DOI 10.1038/328377a0; RAUCHENBERGER M, 1990, AM MUS NOVIT, P1; ROBERTSON SM, 1989, THESIS LUDWIGS MAXIM; Rosen D. E., 1963, Bulletin of the American Museum of Natural History, V126, P1; Rosen D. E., 1969, American Museum Novitates, VNo. 2379, P1; Rosen D. E., 1979, B AM MUS NAT HIST, V162, P268; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; SMITH JM, 1987, SEXUAL SELECTION TES, P9; Swofford D.L., 1993, PHYLOGENETIC ANAL US; WINQUIST ST, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-a; ZANDER C D, 1969, Zeitschrift fuer Wissenschaftliche Zoologie, V178, P276	43	229	234	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					539	542		10.1038/368539a0	http://dx.doi.org/10.1038/368539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139686	Green Published, Green Submitted			2022-12-28	WOS:A1994NE33500052
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			STATISTICS NOTES .1. CORRELATION, REGRESSION, AND REPEATED DATA	BRITISH MEDICAL JOURNAL			English	Note									IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.								0	179	180	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					896	896		10.1136/bmj.308.6933.896	http://dx.doi.org/10.1136/bmj.308.6933.896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173371	Green Published, Bronze			2022-12-28	WOS:A1994NE60000024
J	SULTAN, AH; KAMM, MA; HUDSON, CN; BARTRAM, CI				SULTAN, AH; KAMM, MA; HUDSON, CN; BARTRAM, CI			3RD DEGREE OBSTETRIC ANAL-SPHINCTER TEARS - RISK-FACTORS AND OUTCOME OF PRIMARY REPAIR	BRITISH MEDICAL JOURNAL			English	Article							FECAL INCONTINENCE; VAGINAL DELIVERY; EPISIOTOMY; INJURY; ENDOSONOGRAPHY; LACERATIONS; INSTRUMENT	Objectives-To determine (i) risk factors in the development of third degree obstetric tears and (ii) the success of primary sphincter repair. Design-(i) Retrospective analysis of obstetric variables in 50 women who had sustained a third degree tear, compared with the remaining 8553 vaginal deliveries during the same period. (ii) Women who had sustained a third degree tear and had primary sphincter repair and control subjects were interviewed and investigated with anal endosonography, anal manometry, and pudendal nerve terminal motor latency measurements. Setting-Antenatal clinic in teaching hospital in inner London. Subjects-(i) All women (n = 6603) who delivered vaginally over a 31 month period. (ii) 34 women who sustained a third degree tear and 88 matched controls. Main outcome measures-Obstetric risk factors, defaecatory symptoms, sonographic sphincter defects, and pudendal nerve damage. Results-(i) Factors significantly associated with development of a third degree tear were: forceps delivery (50% v 7% in controls; P = 0.00001), primiparous delivery (85% v 43%; P = 0.00001), birth weight > 4 kg (P = 0.00002), and occipitoposterior position at delivery (P = 0.003). No third degree tear occurred during 351 vacuum extractions. Eleven of 25 (44%) women who were delivered without instruments and had a third degree tear did so despite a posterolateral episiotomy. (ii) Anal incontinence or faecal urgency was present in 16 women with tears and 11 controls (47% v 13%; P = 0.00001). Sonographic sphincter defects were identified in 29 with tears and 29 controls (85% v 33%; P = 0.00001). Every symptomatic patient had persistent combined internal and external sphincter defects, and these were associated with significantly lower anal pressures. Pudendal nerve terminal motor latency measurements were not significantly different. Conclusions-Vacuum extraction is associated with fewer third degree tears than forceps delivery. An episiotomy does not always prevent a third degree tear. Primary repair is inadequate in most women who sustain third degree tears, most having residual sphincter defects and about half experiencing anal incontinence, which is caused by persistent mechanical sphincter disruption rather than pudendal nerve damage. Attention should be directed towards preventive obstetric practice and surgical techniques of repair.	ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; ST BARTHOLOMEWS HOMERTON HOSP,LONDON E9 6SR,ENGLAND	Imperial College London; University of London; Queen Mary University London								BARTER RH, 1960, AM J OBSTET GYNECOL, V80, P654, DOI 10.1016/0002-9378(60)90573-1; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BLAISDELL PC, 1940, SURG GYNECOL OBSTET, V70, P692; BROWNING GGP, 1983, BRIT MED J, V286, P1873, DOI 10.1136/bmj.286.6381.1873; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; CHALMERS JA, 1989, BRIT J OBSTET GYNAEC, V96, P505, DOI 10.1111/j.1471-0528.1989.tb03246.x; COMBS CA, 1990, AM J OBSTET GYNECOL, V163, P100, DOI 10.1016/S0002-9378(11)90678-4; CORMAN ML, 1980, SURG CLIN N AM, V60, P457; Fischer S R, 1979, J Nurse Midwifery, V24, P18, DOI 10.1016/0091-2182(79)90189-7; FLEMING AR, 1960, OBSTET GYNECOL, V16, P172; FRENCKNER B, 1975, GUT, V16, P482, DOI 10.1136/gut.16.6.482; GASS MS, 1986, J REPROD MED, V31, P240; GREEN JR, 1989, OBSTET GYNECOL, V73, P732; HAADEM K, 1991, OBSTET GYNECOL, V78, P823; HENRIKSEN TB, 1992, BRIT J OBSTET GYNAEC, V99, P950, DOI 10.1111/j.1471-0528.1992.tb13695.x; INGRAHAM HA, 1949, AM J OBSTET GYNECOL, V57, P730, DOI 10.1016/0002-9378(49)90713-9; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; LARSSON PG, 1991, GYNECOL OBSTET INVES, V31, P213, DOI 10.1159/000293161; LAW PJ, 1989, GASTROINTEST RADIOL, V14, P349, DOI 10.1007/BF01889235; NEILSON MB, 1992, BRIT J SURG, V79, P104; OLEARY JL, 1965, OBSTET GYNECOL, V25, P235; ORROM WJ, 1990, BRIT J SURG, V77, P876, DOI 10.1002/bjs.1800770810; PEZIM ME, 1987, DIS COLON RECTUM, V30, P521, DOI 10.1007/BF02554781; ROGERS J, 1988, GUT, V29, P1131, DOI 10.1136/gut.29.8.1131; SIEBER EH, 1962, OBSTET GYNECOL, V19, P677; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SORENSEN SM, 1988, ACTA OBSTET GYN SCAN, V67, P315, DOI 10.1111/j.1600-0412.1988.tb07806.x; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1993, BRIT J SURG, V80, P508, DOI 10.1002/bjs.1800800435; Sultan AH, 1994, CONT REV OBSTET GYNA, V6, P18; SULTAN AH, 1993, ATLAS GASTROINTESTIN, P115; SULTAN AH, IN PRESS DIS COLON R; SULTAN AH, IN PRESS BR J SURG; SWSH M, 1992, COLOPROCTOLOGY PELVI, P196; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THORP JM, 1989, AM J OBSTET GYNECOL, V160, P1027, DOI 10.1016/0002-9378(89)90152-X	37	526	537	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					887	891		10.1136/bmj.308.6933.887	http://dx.doi.org/10.1136/bmj.308.6933.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173367	Green Published			2022-12-28	WOS:A1994NE60000020
J	EVANS, PR				EVANS, PR			MEDICINE IN EUROPE - THE CHANGING SCENE IN GENERAL-PRACTICE IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, PR (corresponding author), THE GUILDHALL SURG,BURY ST EDMUNDS IP33 1ET,SUFFOLK,ENGLAND.							[Anonymous], 1986, OFFICIAL J EUROPEAN; BOERMA W, 1993, HLTH CARE GENERAL PR; CROMBIE DE, 1992, 48 ROYAL COLL GEN PR; GROL R, 1992, CONTRIBUTION FAMILY; GROL R, 1992, ROLE GENERAL PRACTIC; GROL R, 1993, QUALITY ASSURANCE GE; HAM C, 1990, HLTH CHECK HLTH CARE, P104; WARDEN J, 1992, BRIT MED J, V304, P1654; 1992, WONCA EUROPEAN WORKI; 1993, CRITERIA GENERAL PRA; 1992, CHOICES HLTH CARE; 1991, ROLE GENERAL PRACTIT; 1992, POLICY STATEMENT; 1992, BRIT MED J, V304, P1457; 1992, RCGP56 ROYAL COLL GE	15	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					645	648		10.1136/bmj.308.6929.645	http://dx.doi.org/10.1136/bmj.308.6929.645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148718	Green Published			2022-12-28	WOS:A1994MZ69800032
J	POZNANSKY, MC; TORKINGTON, J; TURNER, G; BANKES, MJK; PARRY, JV; CONNELL, JA; TOUQUET, R; WEBER, J				POZNANSKY, MC; TORKINGTON, J; TURNER, G; BANKES, MJK; PARRY, JV; CONNELL, JA; TOUQUET, R; WEBER, J			PREVALENCE OF HIV-INFECTION IN PATIENTS ATTENDING AN INNER-CITY ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY		ST MARYS HOSP,DEPT ACCID & EMERGENCY MED,LONDON W2 1NY,ENGLAND; CENT PUBL HLTH LAB,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUNICABLE DIS,LONDON W2 1NY,ENGLAND	Imperial College London; Public Health England; Imperial College London			Poznansky, Mark C/M-4996-2015	Poznansky, Mark C/0000-0003-1344-7103				CONNELL JA, 1990, LANCET, V335, P1366, DOI 10.1016/0140-6736(90)91245-6; CONNELL JA, IN PRESS J MED VIOL; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KELEN GD, 1989, ANN EMERG MED, V18, P378, DOI 10.1016/S0196-0644(89)80574-8; 1993, CDR REV, V3, P1	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					636	636		10.1136/bmj.308.6929.636	http://dx.doi.org/10.1136/bmj.308.6929.636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148714	Green Published			2022-12-28	WOS:A1994MZ69800025
J	COSTE, J; DELECOEUILLERIE, G; DELARA, AC; LEPARC, JM; PAOLAGGI, JB				COSTE, J; DELECOEUILLERIE, G; DELARA, AC; LEPARC, JM; PAOLAGGI, JB			CLINICAL COURSE AND PROGNOSTIC FACTORS IN ACUTE LOW-BACK-PAIN - AN INCEPTION COHORT STUDY IN PRIMARY-CARE PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							LUMBAR SPINE RADIOGRAPHS; DISABILITY; RELIABILITY	Objective-To describe the natural course of recent acute low back pain in terms of both morbidity (pain, disability) and absenteeism from work and to evaluate the prognostic factors for these outcomes. Design-Inception cohort study. Setting-Primary care. Patients-103 patients with acute localised nonspecific back pain lasting less than 72 hours. Main outcome measures-Complete recovery (disappearance of both pain and disability) and return to work. Results-90% of patients recovered within two weeks and only two developed chronic low back pain. Only 49 of 100 patients for whom data were available had bed rest and 40% of 75 employed patients lost no time from work. Proportional hazards regression analysis showed that previous chronic episodes of low back pain, initial disability level, initial pain worse when standing, initial pain worse when lying, and compensation status were significantly associated with delayed episode recovery. These factors were also related to absenteeism from work. Absenteeism from work was also influenced by job satisfaction and gender. Conclusions-The recovery rate from acute low back pain was much higher than reported in other studies. Those studies, however, did not investigate groups of patients enrolled shortly after the onset of symptoms and often mixed acute low back pain patients with patients with exacerbations of chronic pain or sciatica. Several sociodemographic and clinical factors were of prognostic value in acute low back pain. Factors which influenced the outcome in terms of episode recovery (mainly physical severity factors) were only partly predictive of absenteeism from work. Time off work and return to work depended more on sociodemographic and job related influences.	LABS CASSENNE 1,F-92800 PUTEAUX,FRANCE; HOP AMBROISE PARE,SERV RHUMATOL,F-92104 BOULOGNE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	COSTE, J (corresponding author), HOP BICETRE,INSERM,U292,F-94275 LE KREMLIN BICETR,FRANCE.							ANDERSSON GBJ, 1981, SPINE, V6, P53, DOI 10.1097/00007632-198101000-00013; ANDERSSON GBJ, 1983, SPINE, V8, P880, DOI 10.1097/00007632-198311000-00011; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; CATSBARIL WL, 1991, SPINE, V16, P605, DOI 10.1097/00007632-199106000-00001; COSTE J, 1991, SPINE, V16, P426, DOI 10.1097/00007632-199104000-00006; COSTE J, 1991, J CLIN EPIDEMIOL, V44, P1233, DOI 10.1016/0895-4356(91)90156-4; Coste J, 1993, REV RHUM, V60, P295; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1987, ARTHRITIS RHEUM, V30, P1247, DOI 10.1002/art.1780301107; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; DEYO RA, 1988, J RHEUMATOL, V15, P1557; DEYO RA, 1985, ARTHRITIS RHEUM, V28, P1066, DOI 10.1002/art.1780280916; DILLANE JB, 1966, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5505.82; DIXON WJ, 1989, BMDP STATISTICAL SOF; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GOERTZ MN, 1990, SPINE, V15, P1307, DOI 10.1097/00007632-199012000-00013; GUELFI JD, 1989, MANUEL DIAGNOSTIQUE; Hull F M, 1982, J R Coll Gen Pract, V32, P352; LEAVITT F, 1982, SPINE, V7, P398, DOI 10.1097/00007632-198207000-00010; MAGNI G, 1984, ACTA PSYCHIAT SCAND, V70, P614, DOI 10.1111/j.1600-0447.1984.tb01256.x; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; NACHEMSON AL, 1985, CLIN ORTHOPAEDICS, V200, P266; Pedersen P A, 1981, J R Coll Gen Pract, V31, P209; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; WADDELL G, 1982, BMJ-BRIT MED J, V284, P1519, DOI 10.1136/bmj.284.6328.1519; WHITE AWM, 1966, CAN MED ASSOC J, V95, P50; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; 1987, DIAGNOSTIC STATISTIC; 1987, SPINE S, V21, pS17	33	288	294	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					577	580		10.1136/bmj.308.6928.577	http://dx.doi.org/10.1136/bmj.308.6928.577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148683	Green Published			2022-12-28	WOS:A1994MY71400025
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			A MASKED MARAUDER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,MAILSTOP 35K9,BOX 302,BOSTON,MA 02111, USA.							Condon RE, 1991, TXB SURGERY BIOL BAS, P884; COPE CL, 1972, ADRENAL STEROIDS DIS, P247; KASSIRER JP, 1991, LEARNING CLIN REASON, P33; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; PAUKER SG, 1977, COMPUTATIONAL LINGUI, P109; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; SCHROCK TR, 1983, GASTROINTESTINAL DIS, P1268; SILEN W, 1991, COPES EARLY DIAGNOSI, P31; 1993, DRUG FACTS COMP 1993, pB122; 1991, DRUG EVALUATIONS ANN, P1716	10	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1596	1598		10.1056/NEJM199406023302209	http://dx.doi.org/10.1056/NEJM199406023302209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177250				2022-12-28	WOS:A1994NN21500009
J	FEINSTEIN, AR				FEINSTEIN, AR			CLINICAL JUDGMENT REVISITED - THE DISTRACTION OF QUANTITATIVE MODELS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ADDITIONAL BASIC SCIENCE; DIAGNOSTIC-TESTS; MEDICINE; SPECTRUM; TRIALS; SCALES; BIAS	More than 25 years ago, in a book called Clinical Judgment, each act of patient care was described as having an experimental structure. The ''experiments'' needed substantial scientific improvement, however, in quality of basic data, taxonomic classification of phenomena, and specifications of clinical reasoning. During the past 2 decades, these improvements have not occurred as extensively as expected because many investigators working in clinical forms of clinical research have not addressed these basic scientific challenges in data, taxonomy, and reasoning. Instead, the investigators have applied quantitative ''models,'' derived from non-clinical domains, that focus on hard data, randomized trials, Bayes theorem, quantitative decision analysis, and psychometric strategies for clinimetric measurement. Consequently, the main challenges of clinical judgment still remain generally available for basic scientific research by investigative clinicians,			FEINSTEIN, AR (corresponding author), YALE UNIV, SCH MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.							APGAR V, 1953, Curr Res Anesth Analg, V32, P260; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FEINSTEIN AR, 1964, ANN INTERN MED, V61, P944, DOI 10.7326/0003-4819-61-5-944; FEINSTEIN AR, 1964, ANN INTERN MED, V61, P564, DOI 10.7326/0003-4819-61-3-564; FEINSTEIN AR, 1974, YALE J BIOL MED, V47, P5; FEINSTEIN AR, 1987, PERSPECT BIOL MED, V30, P215; FEINSTEIN AR, 1989, J CLIN EPIDEMIOL, V42, P301, DOI 10.1016/0895-4356(89)90034-6; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P705, DOI 10.7326/0003-4819-99-5-705; FEINSTEIN AR, 1964, ANN INTERN MED, V61, P757, DOI 10.7326/0003-4819-61-4-757; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FEINSTEIN AR, 1972, LANCET, V2, P421; FEINSTEIN AR, 1989, J CLIN EPIDEMIOL, V42, P929, DOI 10.1016/0895-4356(89)90157-1; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; FEINSTEIN AR, 1964, ANN INTERN MED, V61, P1162, DOI 10.7326/0003-4819-61-6-1162; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P393, DOI 10.7326/0003-4819-99-3-393; Feinstein AR., 1967, CLIN JUDGMENT; Feinstein AR, 1987, CLINIMETRICS; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; MACKENZIE CR, 1986, BRIT MED J, V292, P40, DOI 10.1136/bmj.292.6512.40; MACKENZIE CR, 1986, ARCH INTERN MED, V146, P1325, DOI 10.1001/archinte.146.7.1325; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; RAIFFA H, 1970, DECISION ANAL; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; WRIGHT JG, 1992, J CLIN EPIDEMIOL, V45, P1201, DOI 10.1016/0895-4356(92)90161-F; YERUSHALMY J, 1947, PUBLIC HEALTH REP, V62, P1432, DOI 10.2307/4586294; 1977, MANUAL STAGING CANCE	30	151	158	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					799	805		10.7326/0003-4819-120-9-199405010-00012	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147553				2022-12-28	WOS:A1994NH25100012
J	HUYCKE, LI; HUYCKE, MM				HUYCKE, LI; HUYCKE, MM			CHARACTERISTICS OF POTENTIAL PLAINTIFFS IN MALPRACTICE LITIGATION	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL MALPRACTICE; ADVERSE EVENTS; CLAIMS; NEGLIGENCE; INJURIES	Objective: To characterize patients calling plaintiff attorneys' offices and claiming to have suffered injury caused by medical negligence. Design: Telephone interviews with an inception cohort of callers to law firms with malpractice complaints before the callers talk to attorneys. Setting: Six law offices in five states. Participants: 502 of 730 callers over 10 randomly selected days in 1991. Measurements: Demographics of potential plaintiffs, types of health care providers named by callers, factors prompting calls, economic and noneconomic motivations for claims, and disposition of claims. Results: An average of 12 calls per office per day were received by law firms concerning malpractice complaints. Many factors affected patients' decisions to call: poor relationships with providers before an injury (53%); television advertising by law firms (73%); explicit recommendations by health care providers to seek legal counsel (27%); impressions of not being kept informed or appropriately referred by providers; and financial concerns (for example, 36% with earned income and outstanding medical bills had bills equaling or exceeding 50% of their annual income, 33% were unemployed, and 31% lacked health insurance). One in 30 calls led to the filing of a lawsuit. Conclusions: Calls to plaintiff law firms by patients are common, are motivated by diverse factors, represent dissatisfaction with modern health care, and infrequently lead to lawsuits.	DEPT VET AFFAIRS MED CTR, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, OKLAHOMA CITY, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center			Huycke, Mark M./AAG-9384-2020					BOVBJERG RR, 1992, ANN INTERN MED, V117, P788, DOI 10.7326/0003-4819-117-9-788; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1985, MED MALPRACTICE THEO; Fleiss JL, 1981, STAT METHODS RATES P; GALANTER M, 1983, UCLA LAW REV, V31, P4; HAIGHT F, 1990, CLIN NEUR, V36, P92; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; JOHNSON WG, 1992, JAMA-J AM MED ASSOC, V267, P2487, DOI 10.1001/jama.267.18.2487; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; Mills DH, 1977, REPORT MED INSURANCE; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; 1987, CHARACTERISTICS CLAI; 1992, AM HOSPITAL ASS HOSP; 1993, COURT STATISTICS PRO; 1992, SOCIOECONOMIC CHARAC	19	70	71	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					792	798		10.7326/0003-4819-120-9-199405010-00011	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147552				2022-12-28	WOS:A1994NH25100011
J	ROWLEY, N; PRIPBUUS, C; WESTERMANN, B; BROWN, C; SCHWARZ, E; BARRELL, B; NEUPERT, W				ROWLEY, N; PRIPBUUS, C; WESTERMANN, B; BROWN, C; SCHWARZ, E; BARRELL, B; NEUPERT, W			MDJ1P, A NOVEL CHAPERONE OF THE DNAJ FAMILY, IS INVOLVED IN MITOCHONDRIAL BIOGENESIS AND PROTEIN-FOLDING	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; ENDOPLASMIC-RETICULUM; INTERMEMBRANE SPACE; INVITRO TRANSCRIPTION; PRECURSOR PROTEINS; TRANSLATION SYSTEM; IMPORT; TRANSLOCATION	Mdj1p, a novel member of the DnaJ family, is a heat shock protein that is associated with the inner membrane of mitochondria of Saccharomyces cerevisiae. Disruption of the MDJ1 gene resulted in a petite phenotype, loss of mitochondrial DNA, and inviability at 37 degrees C. Import of precursor proteins was not affected by a lack of Mdj1p, but folding of newly imported proteins was markedly impaired. The efficiency of refolding of a tester protein, dihydrofolate reductase, was significantly reduced in mitochondria lacking Mdj1p after incubation at elevated temperature. We conclude that Mdj1p is an important mitochondrial chaperone that participates in the folding of newly imported proteins and in the protection of proteins against heat denaturation and aggregation.	INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY		ROWLEY, N (corresponding author), MRC, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Westermann, Benedikt/H-7766-2013; PRIP-BUUS, Carina/P-9084-2017	Westermann, Benedikt/0000-0002-2991-1604; Prip-Buus, Carina/0000-0002-2153-7857				AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Gibson T., 1984, THESIS U CAMBRIDGE C; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RILES L, 1993, GENETICS, V134, P81; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCHWARZ E, IN PRESS GENE; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH V, 1993, METHOD ENZYMOL, V218, P173; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	64	198	201	1	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					249	259		10.1016/0092-8674(94)90317-4	http://dx.doi.org/10.1016/0092-8674(94)90317-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168133	Green Published			2022-12-28	WOS:A1994NH63400010
J	BRUMMEL, CL; LEE, INW; ZHOU, Y; BENKOVIC, SJ; WINOGRAD, N				BRUMMEL, CL; LEE, INW; ZHOU, Y; BENKOVIC, SJ; WINOGRAD, N			A MASS-SPECTROMETRIC SOLUTION TO THE ADDRESS PROBLEM OF COMBINATORIAL LIBRARIES	SCIENCE			English	Article							SIMS	The molecular weights of femtomole quantities of small peptides attached to polystyrene beads have been determined with imaging time-of-flight secondary ion mass spectrometry. The analysis is made possible by the selective clipping of the bond linking the peptide to a bead with trifluoroacetic acid vapor before the secondary ion mass spectrometry assay. The approach can be applied to large numbers of 30- to 60-micrometer polystyrene beads for the direct characterization of massive combinatorial libraries.	PENN STATE UNIV,DEPT CHEM,152 DAVEY LAB,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University			Lee, Irene/C-6104-2011	Winograd, Nicholas/0000-0002-2690-7714				BARANY BG, 1980, PEPTIDES; BEAVIS R, 1983, INT J MASS SPECTROM, V46, P471, DOI 10.1016/0020-7381(83)80154-5; BENNINGHOVEN A, 1978, ANAL CHEM, V50, P1180, DOI 10.1021/ac50030a043; BENNINGHOVEN A, 1993, ANAL CHEM, V65, pA630, DOI 10.1021/ac00062a002; BERNNER S, 1992, P NATL ACAD SCI USA, V89, P5381; BIEMANN K, 1987, MASS SPECTROM REV, V6, P1, DOI 10.1002/mas.1280060102; BRIGGS D, 1982, SURF INTERFACE ANAL, V4, P109, DOI 10.1002/sia.740040306; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1981, INT J MASS SPECTROM, V40, P185, DOI 10.1016/0020-7381(81)80041-1; DAVIES MC, 1988, SURF INTERFACE ANAL, V11, P591, DOI 10.1002/sia.740111202; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GARDELLA JA, 1980, ANAL CHEM, V52, P226, DOI 10.1021/ac50052a003; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KERR JM, 1993, J AM CHEM SOC, V115, P2529, DOI 10.1021/ja00059a070; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEGGETT GJ, 1992, J CHEM SOC FARADAY T, V88, P297, DOI 10.1039/ft9928800297; MANTUS DS, 1993, ANAL CHEM, V65, P1431, DOI 10.1021/ac00058a021; MEGLER M, 1988, TETRAHEDRON LETT, V29, P4009; MEGLER M, 1988, TETRAHEDRON LETT, V29, P4002; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; STEFFENS P, 1985, J VAC SCI TECHNOL A, V3, P1322, DOI 10.1116/1.573058; TAYLOR R, IN PRESS J AM CHEM S; WINOGRAD N, 1993, ANAL CHEM, V65, pA622, DOI 10.1021/ac00062a001; WINOGRAD N, 1992, I PHYS C SER, V128, P259; YOUNGQUIST RS, 1994, RAPID COMMUN MASS SP, V8, P77	27	137	167	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					399	402		10.1126/science.8153627	http://dx.doi.org/10.1126/science.8153627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153627				2022-12-28	WOS:A1994NG19400031
J	MYERBURG, RJ				MYERBURG, RJ			DEPARTMENTS OF MEDICAL SPECIALTIES - SOLUTION FOR THE DIVERGENT MISSIONS OF INTERNAL-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											MYERBURG, RJ (corresponding author), UNIV MIAMI,SCH MED,DEPT MED,DIV CARDIOL D39,POB 016960,MIAMI,FL 33101, USA.							ADKINSON F, IN PRESS AM J MED; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BEESON PB, 1980, ANN INTERN MED, V93, P624, DOI 10.7326/0003-4819-93-4-624; BRAUNWAL.E, 1972, NEW ENGL J MED, V286, P1031, DOI 10.1056/NEJM197205112861905; BRAUNWALD E, 1991, ANN INTERN MED, V114, P76, DOI 10.7326/0003-4819-114-1-76; BRAUNWALD E, 1993, NEW ENGL J MED, V329, P1887, DOI 10.1056/NEJM199312163292513; BRAUNWALD E, 1984, INT J CARDIOL, V5, P223, DOI 10.1016/0167-5273(84)90152-9; BRAUNWALD E, 1972, INT J CARDIOL, V286, P1031; EARLEY LE, 1992, ANN INTERN MED, V116, P1080, DOI 10.7326/0003-4819-116-12-1080; FLETCHER RH, 1991, ANN INTERN MED, V115, P978, DOI 10.7326/0003-4819-115-12-978; GLICKMAN R, 1992, ANN INTERN MED, V117, P259, DOI 10.7326/0003-4819-117-3-259; GLICKMAN RM, 1993, ANN INTERN MED, V118, P903, DOI 10.7326/0003-4819-118-11-199306010-00014; HOOD WB, 1993, ANN INTERN MED, V119, P1225, DOI 10.7326/0003-4819-119-12-199312150-00023; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; Mason D T, 1977, Am J Cardiol, V40, P1013, DOI 10.1016/0002-9149(77)90054-6; NOBLE J, 1992, ANN INTERN MED, V116, P1058, DOI 10.7326/0003-4819-116-12-1058; PETERSDORF RG, 1993, ANN INTERN MED, V119, P1130, DOI 10.7326/0003-4819-119-11-199312010-00011; REITEMEIER RJ, 1991, ANN INTERN MED, V114, P69, DOI 10.7326/0003-4819-114-1-69; RIVO ML, 1993, ANN INTERN MED, V119, P146, DOI 10.7326/0003-4819-119-2-199307150-00009; WARTMAN SA, 1992, ANN INTERN MED, V116, P1071, DOI 10.7326/0003-4819-116-12-1071; ZARET BL, 1993, AM J CARDIOL, V72, P968, DOI 10.1016/0002-9149(93)91116-Y; 1993, ARCH INTERN MED, V153, P2305; 1993, ANN INTERN MED, V119, P1125	23	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1453	1456		10.1056/NEJM199405193302013	http://dx.doi.org/10.1056/NEJM199405193302013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159204				2022-12-28	WOS:A1994NK97200013
J	BREO, DL				BREO, DL			THE CANCER REVOLUTION - FROM BLACK-BOX TO GENETIC-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1452	1454		10.1001/jama.271.18.1452	http://dx.doi.org/10.1001/jama.271.18.1452			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176807				2022-12-28	WOS:A1994NJ69300036
J	PIRISI, M; SOARDO, G				PIRISI, M; SOARDO, G			CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PIRISI, M (corresponding author), UNIV UDINE,CATTEDRA MED INTERNA,I-33100 UDINE,ITALY.		Pirisi, Mario/ABF-2102-2020						0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1279	1279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145783				2022-12-28	WOS:A1994NJ51200006
J	WILLIAMS, HC; STRACHAN, DP; HAY, RJ				WILLIAMS, HC; STRACHAN, DP; HAY, RJ			CHILDHOOD ECZEMA - DISEASE OF THE ADVANTAGED	BRITISH MEDICAL JOURNAL			English	Article							SKIN-TEST REACTIVITY; ENVIRONMENTAL-FACTORS; ALLERGIC DISORDERS; ATOPIC DISEASE; PREVALENCE; POPULATION; SYMPTOMS; INFANCY	Objective-To determine whether the increased prevalence of childhood eczema in advantaged socioeconomic groups is due to increased parental reporting. Design-Comparison of parental reports of eczema with visible eczema recorded by medical officers during a detailed physical examination. Setting-National birth cohort study. Subjects-8279 children from England, Wales, and Scotland born during 3-9 March 1958 and followed up at the ages of 7, 11, and 16. Main outcome measures-Prevalence of eczema according to parental report compared with medical officer's examination at the ages of 7, 11, and 16. Results-Prevalence of both reported and examined eczema increased with rising social class at the ages of 7, 11, and 16 years. The point prevalence of examined eczema at age 7 was 4.8%, 3.6%, 3.6%, 2.4%, 2.2%, and 2.4% in social classes I, II, III nonmanual, III manual, TV, and V respectively (chi(2) value for linear trend 12.6, P < 0.001). This trend persisted after adjustment for potential confounders such as region and family size and was not present for examined psoriasis or acne. Conclusions-Eczema is more prevalent among British schoolchildren in social classes I and II than those in lower classes, Exposures associated with social class are probably at least as important as genetic factors in the expression of childhood eczema.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; St Georges University London				williams, hywel/0000-0002-5646-3093				ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ATKINS E, 1981, EMPIRICAL BASIS PRIM, P25; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BORELLI S, 1965, ENTZUNDLICHE DERMATO, V2, P254; BOWKER NC, 1976, BRIT J DERMATOL, V95, P137, DOI 10.1111/j.1365-2133.1976.tb00816.x; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; COLOFF MJ, 1992, CLIN EXP ALLERGY, V122, P545; DEAN AG, 1990, EPIINFO VERSION 5 2; FORSTER J, 1990, KLIN PADIATR, V202, P136, DOI 10.1055/s-2007-1025506; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; Golding J, 1986, BIRTH 5 STUDY HLTH B; JOHNSON MLT, 1978, VITAL HLTH STAT, V11, P212; LARSSON PA, 1980, ACTA DERM-VENEREOL, V60, P415; LEETE R, 1977, POPULATION TRENDS, V9, P1; MEDING B, 1987, BRIT J DERMATOL, V116, P627, DOI 10.1111/j.1365-2133.1987.tb05895.x; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x; SHEPHERD PM, 1985, NATIONAL CHILD DEV S; SMIT HA, 1993, MONOGR ALLERGY, V31, P29; SMITH JM, 1974, MED CLIN N AM, V58, P3; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WATERS WE, 1971, BRIT MED J, V2, P77, DOI 10.1136/bmj.2.5753.77; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067; 1988, EPIDEMIOLOGICAL GRAP; 1979, MORBIDITY STATISTICS	31	194	195	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1132	1135		10.1136/bmj.308.6937.1132	http://dx.doi.org/10.1136/bmj.308.6937.1132			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173454	Green Published			2022-12-28	WOS:A1994NK18200018
J	LEEFELDSTEIN, A; ANTONCULVER, H; FELDSTEIN, PJ				LEEFELDSTEIN, A; ANTONCULVER, H; FELDSTEIN, PJ			TREATMENT DIFFERENCES AND OTHER PROGNOSTIC FACTORS RELATED TO BREAST-CANCER SURVIVAL - DELIVERY SYSTEMS AND MEDICAL OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING TOTAL MASTECTOMY; HOSPITAL CHARACTERISTICS; GEOGRAPHIC-VARIATION; CONSERVING TREATMENT; DEATH RATES; WOMEN; RECURRENCE; RADIATION; STAGE; CARE	Objective.-To determine differences in and relative importance of treatment modalities by hospital type and their effect on survival of breast cancer patients. Design.-Cohort of population-based cancer registry breast cancer patients diagnosed from 1984 through 1990. The analysis was done within this cohort, stratified by hospital type and treatment modality. Setting.-Orange County, California, residents diagnosed and treated for breast cancer in 126 hospitals (small community, large community, health maintenance organization [HMO], or teaching). Patients.-A total of 5892 non-Hispanic white women with no known prior cancer and with localized or regional, histologically confirmed breast cancer. Main Outcome Measures.-Effects of treatment modality and hospital type on survival. Adjustments for differences in age, tumor size, number of positive lymph nodes, and histology were included in the analysis. Results.-Use of recommended breast-conserving surgery (BCS) was greatest among teaching hospitals, where more than 50% of patients with localized disease received BCS between 1988 and 1990 and 40% to 50% with regional disease received BCS between 1984 and 1990. At nonteaching hospitals, 30% or less of patients received BCS between 1984 and 1989, regardless of stage. Rates of survival after BCS were at least as good as rates of survival after total mastectomy, other factors being equal. Survival rates varied by hospital type for patients with localized disease, with significantly better rates at large community hospitals and significantly worse rates at HMO hospitals in comparison with small hospitals. Patients with regional disease at large hospitals had a significant survival advantage. Conclusions.-Greater use of BCS is strongly urged. Overall, large community hospitals had significantly better survival rates than small community and HMO hospitals. Further follow-up will determine if treatment and survival differences by hospital type persist.	UNIV CALIF IRVINE, COLL MED,DEPT MED,EPIDEMIOL PROGRAM, CANC SURVEILLANCE PROGRAM ORANGE CTY, IRVINE, CA 92717 USA	University of California System; University of California Irvine								AALTOMAA S, 1992, ACTA ONCOL, V31, P635, DOI 10.3109/02841869209083845; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ANTONCULVER H, 1988, CANCER RES, V48, P6580; AYRANIAN JZ, 1993, NEW ENGL J MED, V329, P326; BARTH RJ, 1991, ARCH SURG-CHICAGO, V126, P574; BERGMAN L, 1992, EUR J CANCER, V28A, P1475, DOI 10.1016/0959-8049(92)90547-F; BONETT A, 1991, MED J AUSTRALIA, V154, P695, DOI 10.5694/j.1326-5377.1991.tb121265.x; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CODY HS, 1991, ANN SURG, V213, P297, DOI 10.1097/00000658-199104000-00004; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Fisher B, 1992, J Natl Cancer Inst Monogr, P7; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FOWBLE B, 1992, INT J RADIAT ONCOL, V23, P933, DOI 10.1016/0360-3016(92)90897-Q; GREENWALD HP, 1992, AM J PUBLIC HEALTH, V82, P1099, DOI 10.2105/AJPH.82.8.1099; HAFFTY BG, 1991, J CLIN ONCOL, V9, P997, DOI 10.1200/JCO.1991.9.6.997; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HENSON DE, 1991, CANCER-AM CANCER SOC, V68, P2142, DOI 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D; KARJALAINEN S, 1990, CANCER-AM CANCER SOC, V66, P819, DOI 10.1002/1097-0142(19900815)66:4<819::AID-CNCR2820660437>3.0.CO;2-E; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER RA, 1992, NIH922789 PUBL; MORITZ DJ, 1993, J CLIN EPIDEMIOL, V46, P443, DOI 10.1016/0895-4356(93)90021-R; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Percy C., 1990, INT CLASSIFICATION D; ROBINSON E, 1993, CANCER-AM CANCER SOC, V71, P172, DOI 10.1002/1097-0142(19930101)71:1<172::AID-CNCR2820710127>3.0.CO;2-Y; SAUER R, 1992, INT J RADIAT ONCOL, V23, P907, DOI 10.1016/0360-3016(92)90894-N; SHAMBAUGH EM, 1986, NIH862313 PUBL; SOBIN L, 1978, CODED COMPENDIUM INT; STACEYCLEAR A, 1992, LANCET, V340, P991; TOIKKANEN S, 1990, APMIS, V98, P1005, DOI 10.1111/j.1699-0463.1990.tb05027.x; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; VOOGD AC, 1991, NETH J SURG, V43, P105; 1992, SAS P229 SAS I INC T; 1993, 1993 CALIFORNIA CANC; 1990, SAS STAT USERS GUIDE; 1991, HOSPITAL PEER GROUPI; 1991, 1990 AM HOSPITAL ASS	47	144	144	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1163	1168		10.1001/jama.271.15.1163	http://dx.doi.org/10.1001/jama.271.15.1163			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151873				2022-12-28	WOS:A1994NF20700024
J	SCHUTZE, K; CLEMENTSENGEWALD, A				SCHUTZE, K; CLEMENTSENGEWALD, A			CATCH AND MOVE - CUT OR FUSE	NATURE			English	Article							OPTICAL TWEEZERS; LASER MICROBEAM; MEMBRANE-GLYCOPROTEINS; HUMAN SPERM; CELL; TRAP; MICROMANIPULATION; MANIPULATION; VELOCITY; BIOLOGY		UNIV MUNICH, WOMENS HOSP, DEPT INVITRO FERTILIZAT, D-80337 MUNICH, GERMANY	University of Munich	SCHUTZE, K (corresponding author), MUNICIPAL HOSP HARLACHING, APPLICAT LASER UNIT, SANATORIUMSPL 2, D-81545 MUNICH, GERMANY.							ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; ASHKIN A, 1989, P NATL ACAD SCI USA, V86, P7914, DOI 10.1073/pnas.86.20.7914; BERNS MW, 1981, SCIENCE, V213, P505, DOI 10.1126/science.7017933; BERNS MW, 1991, INT REV CYTOL, V129, P1; BLOCK SM, 1992, NATURE, V360, P493, DOI 10.1038/360493a0; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BULCAN TN, 1987, APPL OPTICS, V26, P5311; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; CLEMENTSENGEWALD A, 1993, P SOC PHOTO-OPT INS, V1876, P187, DOI 10.1117/12.147030; COLON JM, 1992, FERTIL STERIL, V57, P695; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GREULICH KO, 1992, J MICROSC-OXFORD, V167, P127, DOI 10.1111/j.1365-2818.1992.tb03225.x; GREULICH KO, 1989, LABOR 2000, P36; HONG LA, 1991, EXP CELL RES, V197, P21, DOI 10.1016/0014-4827(91)90475-A; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LIANG H, 1993, EXP CELL RES, V204, P110, DOI 10.1006/excr.1993.1015; Liow S. L., 1994, Theriogenology, V41, P239, DOI 10.1016/S0093-691X(05)80149-9; MISAWA H, 1991, J APPL PHYS, V70, P3829, DOI 10.1063/1.350344; MONAJEMBASHI S, 1986, EXP CELL RES, V167, P262, DOI 10.1016/0014-4827(86)90223-5; NEEV J, 1992, J ASSIST REPROD GEN, V9, P513, DOI 10.1007/BF01204247; NG SC, 1993, J ASSIST REPROD GEN, V10, P337, DOI 10.1007/BF01213429; NG SC, 1992, J ASSIST REPROD GEN, V9, P191, DOI 10.1007/BF01203812; SCHUTZE K, 1989, BER BUNSEN PHYS CHEM, V93, P249, DOI 10.1002/bbpc.19890930306; SCHUTZE K, 1994, FERTIL STERIL, V61, P783; SEEGER S, 1991, CYTOMETRY, V12, P497, DOI 10.1002/cyto.990120606; SIMMONS RM, 1993, CURR BIOL, V3, P309, DOI 10.1016/0960-9822(93)90188-T; STEUBING RW, 1991, CYTOMETRY, V12, P505, DOI 10.1002/cyto.990120607; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TADIR Y, 1991, HUM REPROD, V6, P1011, DOI 10.1093/oxfordjournals.humrep.a137451; TADIR Y, 1990, FERTIL STERIL, V53, P944; TADIR Y, 1993, J ASSIST REPROD GEN, V10, P121, DOI 10.1007/BF01207733; Tschachotin S., 1912, MED, V32, P623; WEBER G, 1990, PHYSIOL PLANTARUM, V79, P190, DOI 10.1111/j.1399-3054.1990.tb05885.x; WEBER G, 1992, INT REV CYTOL, V133, P1, DOI 10.1016/S0074-7696(08)61857-4; WIEGAND R, 1987, J CELL SCI, V88, P145	41	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	1994	368	6472					667	669		10.1038/368667a0	http://dx.doi.org/10.1038/368667a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145856				2022-12-28	WOS:A1994NF39200072
J	CHIKASHIGE, Y; DING, DQ; FUNABIKI, H; HARAGUCHI, T; MASHIKO, S; YANAGIDA, M; HIRAOKA, Y				CHIKASHIGE, Y; DING, DQ; FUNABIKI, H; HARAGUCHI, T; MASHIKO, S; YANAGIDA, M; HIRAOKA, Y			TELOMERE-LED PREMEIOTIC CHROMOSOME MOVEMENT IN FISSION YEAST	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; CENTROMERES; MEIOSIS	The movement of chromosomes that precedes meiosis was observed in living cells of fission yeast by fluorescence microscopy. Further analysis by in situ hybridization revealed that the telomeres remain clustered at the leading end of premeiotic chromosome movement, unlike mitotic chromosome movement in which the centromere leads. Once meiotic chromosome segregation starts, however, centromeres resume the leading position in chromosome movement, as they do in mitosis. Although the movement of the telomere first has not been observed before, the clustering of telomeres is reminiscent of the bouquet structure of meiotic-prophase chromosomes observed in higher eukaryotes, which suggests that telomeres perform specific functions required for premeiotic chromosomal events generally in eukaryotes.	KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 606, JAPAN	Kyoto University	CHIKASHIGE, Y (corresponding author), KANSAI ADV RES CTR, COMMUN RES LAB, 588-2 IWAOKA, IWAOKA CHO, NISHI KU, KOBE 65124, JAPAN.		Hiraoka, Yasushi/B-5111-2009	Hiraoka, Yasushi/0000-0001-9407-8228; Funabiki, Hironori/0000-0003-4831-4087; Ding, Da-Qiao/0000-0003-4403-2760				BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; DING DQ, UNPUB; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; FUSSELL C P, 1987, P275; HAGAN I, UNPUB; HAGAN IM, 1988, J CELL SCI, V89, P343; HILLIKER AJ, 1989, EXP CELL RES, V185, P297, DOI 10.1016/0014-4827(89)90301-7; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRATA A, 1982, J GEN APPL MICROBIOL, V28, P263, DOI 10.2323/jgam.28.263; HTERMAN E, 1992, HUMAN CHROMOSOMES, P165; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; John B., 1990, MEIOSIS; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OLSON LW, 1978, HEREDITAS, V89, P189; ROBINOW CF, 1977, GENETICS, V87, P491; UZAWA S, 1992, J CELL SCI, V101, P267	21	397	401	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	1994	264	5156					270	273		10.1126/science.8146661	http://dx.doi.org/10.1126/science.8146661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146661				2022-12-28	WOS:A1994NE41000040
J	SUZUKI, CK; SUDA, K; WANG, N; SCHATZ, G				SUZUKI, CK; SUDA, K; WANG, N; SCHATZ, G			REQUIREMENT FOR THE YEAST GENE LON IN INTRAMITOCHONDRIAL PROTEOLYSIS AND MAINTENANCE OF RESPIRATION	SCIENCE			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; INTERMEMBRANE SPACE; LIVER-MITOCHONDRIA; PROTEINS; MECHANISM; IMPORT; CELLS; ION	The role of protein degradation in mitochondrial homeostasis was explored by cloning of a gene from Saccharomyces cerevisiae that encodes a protein resembling the adenosine triphosphate (ATP)-dependent bacterial protease Lon. The predicted yeast protein has a typical mitochondrial matrix-targeting sequence at its amino terminus. Yeast cells lacking a functional LON gene contained a nonfunctional mitochondrial genome, were respiratory-deficient, and lacked an ATP-dependent proteolytic activity present in the mitochondria of Lon+ cells. Lon- cells were also impaired in their ability to catalyze the energy-dependent degradation of several mitochondrial matrix proteins and they accumulated electron-dense inclusions in their mitochondrial matrix.	NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SUZUKI, CK (corresponding author), UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND.							CHIN DT, 1988, J BIOL CHEM, V263, P11718; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DICE JF, 1975, P NATL ACAD SCI USA, V72, P3893, DOI 10.1073/pnas.72.10.3893; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; FLETCHER MJ, 1961, BIOCHIM BIOPHYS ACTA, V51, P356, DOI 10.1016/0006-3002(61)90177-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ITO K, 1992, J BACTERIOL, V174, P2281, DOI 10.1128/JB.174.7.2281-2287.1992; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; RUSSELL SM, 1980, BIOCHEM J, V256, P8652; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; SUZUKI C, UNPUB; TOJO N, 1993, J BACTERIOL, V175, P2271, DOI 10.1128/JB.175.8.2271-2277.1993; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	22	209	213	3	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					273	276		10.1126/science.8146662	http://dx.doi.org/10.1126/science.8146662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146662				2022-12-28	WOS:A1994NE41000041
J	PETRIE, JC				PETRIE, JC			1ST CONSIDER THE OVERALL PROCESS OF CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					906	906		10.1136/bmj.308.6933.906	http://dx.doi.org/10.1136/bmj.308.6933.906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173375	Green Published			2022-12-28	WOS:A1994NE60000030
J	MACARA, AW				MACARA, AW			REFORMING THE NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article								Rather than improving efficiency, the reforms imposed on the NHS have increased bureaucracy, reduced patient choice, limited the range of core services, and led to inequity of treatment. In this paper I examine how the medical profession might help to solve these problems. Priorities must be set for health care since no government can afford all the possibilities offered by medical science. It is essential to forge a consensus of patients, carers, professionals, the public, and government if a system of priorities is to be equitable and just. We also need to be able to measure quality of outcome in health care. This requires consensus on what is the desired outcome and the development of appropriate guidelines, audit, and performance review. This is primarily a task for the health professions supported by management and by adequate investment. Basically, the government must reinstate the three traditional values of the NHS-equity, consensus, and regard for representative professional advice.			MACARA, AW (corresponding author), BRITISH MED ASSOC,LONDON WC1H 9JP,ENGLAND.							KEDD N, 1992, J MED DEFENCE UNION, V8, P52; KLEIN R, 1994, BRIT MED J, V308, P215, DOI 10.1136/bmj.308.6923.215; MEEK C, 1991, BMA NEWS REV     MAR, P11; Robinson R, 1994, EVALUATING NHS REFOR; 1992, REPORT ACCOUNTS YEAR; 1992, HLTH NATION STRATEGY; 1989, WORKING PATIENTS; 1993, RATIONING ACTION; 1985, TARGETS HLTH ALL; 1994, PROPER CONDUCT PUBLI; 1993, DOH EL93105 DEP HLTH; 1993, DOH EL93103 DEP HLTH; 1992, IMPLEMENTING REFORMS; 1993, ACCESS AVAILABILITY	14	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					848	849		10.1136/bmj.308.6932.848	http://dx.doi.org/10.1136/bmj.308.6932.848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167497	Green Published			2022-12-28	WOS:A1994ND24300033
J	BUYS, H; PEAD, L; HALLETT, R; MASKELL, R				BUYS, H; PEAD, L; HALLETT, R; MASKELL, R			SUPRAPUBIC ASPIRATION UNDER ULTRASOUND GUIDANCE IN CHILDREN WITH FEVER OF UNDIAGNOSED CAUSE	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTIONS	Objectives-To assess the ease of use of suprapubic aspiration of urine under ultrasound guidance in babies with fever of uncertain cause and to assess the importance of bacterial counts and pyuria in relation to abnormalities of the urinary tract and the importance of pyuria in the absence of bacteriuria. Design-Analysis of urine samples obtained by suprapubic aspiration in babies and children from July 1991 to June 1992. The clinical records of the children with bacteriuria and sterile pyuria were examined retrospectively. Setting-Neonatal and paediatric wards of a district general hospital. Subjects-508 babies and children who had fever of uncertain cause or were seriously ill. Results-No difficulties arose in the collection of 545 specimens. Bacteria were isolated from the specimens of 44 children, 24 of whom had abnormalities of the urinary tract. The bacterial count was <10(8)/1 in 18 of the children with bacteriuria, 10 of whom had abnormalities. No white cells were seen in 22 of the 46 bacteriuric specimens; nine of the children with no pyuria had vesicoureteric reflux. 439 of the 499 non-bacteriuric specimens showed no white cells. 60 children had pyuria without bacteriuria. Conclusions-The use of ultrasound guidance simplifies suprapubic aspiration of urine in babies. Low bacterial counts may be associated with abnormalities of the urinary tract. Laboratory techniques capable of detecting such counts reliably should be used. Pyuria is absent in half of babies and very young children with bacteriuria. It rarely occurs without bacteriuria, and if it does an explanation should be sought.	ST MARYS HOSP,DEPT PAEDIATR,PORTSMOUTH PO3 6AD,HANTS,ENGLAND; ST MARYS HOSP,PUBL HLTH LAB,PORTSMOUTH PO3 6AD,HANTS,ENGLAND				Buys, Heloise/I-6051-2017	Buys, Heloise/0000-0001-9778-8233				AHMAD T, 1991, LANCET, V338, P674, DOI 10.1016/0140-6736(91)91242-M; AIREDE AI, 1992, J INFECTION, V25, P55, DOI 10.1016/0163-4453(92)93513-P; AUSTIN N, 1992, LANCET, V339, P65; BERGSTRO.T, 1972, J PEDIATR-US, V80, P858; CHIU N-C, 1989, Acta Paediatrica Sinica, V30, P225; KELLOGG JA, 1987, AM J MED, V83, P739, DOI 10.1016/0002-9343(87)90907-7; LEE P, 1991, ARCH DIS CHILD, V66, P1287, DOI 10.1136/adc.66.11.1287; MASKELL R, 1982, URINARY TRACT INFECT, P24; OCALLAGHAN C, 1987, ARCH DIS CHILD, V62, P1072, DOI 10.1136/adc.62.10.1072; POWELL HR, 1987, ARCH DIS CHILD, V62, P138, DOI 10.1136/adc.62.2.138; Smellie Jean M, 1967, J R Coll Physicians Lond, V1, P189; SMELLIE JM, 1991, J UROLOGY, V146, P665, DOI 10.1016/S0022-5347(17)37889-8; WOODWARD MN, 1993, BRIT MED J, V306, P1512, DOI 10.1136/bmj.306.6891.1512	13	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					690	692		10.1136/bmj.308.6930.690	http://dx.doi.org/10.1136/bmj.308.6930.690			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142792	Green Published			2022-12-28	WOS:A1994NA86900019
J	MAZEIKA, PK; REES, AJ; OAKLEY, CM; DAVIES, GJ; TAYLOR, KM				MAZEIKA, PK; REES, AJ; OAKLEY, CM; DAVIES, GJ; TAYLOR, KM			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - COMPLICATED MYOCARDIAL-INFARCTION - VENTRICULAR SEPTAL RUPTURE IS A SURGICAL EMERGENCY	BRITISH MEDICAL JOURNAL			English	Discussion							INTRAVENOUS AMIODARONE; TACHYCARDIA; FIBRILLATION; SURVIVAL; EFFICACY; DEFECTS; CLOSURE				MAZEIKA, PK (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.							BALLAL RS, 1993, AM J CARDIOL, V71, P367, DOI 10.1016/0002-9149(93)90814-S; DAGGETT WM, 1982, J THORAC CARDIOV SUR, V84, P306; DAGGETT WM, 1982, ANN SURG, V196, P269, DOI 10.1097/00000658-198209000-00005; EDWARDS BS, 1984, AM J CARDIOL, V54, P1201, DOI 10.1016/S0002-9149(84)80067-3; GRIFFITH MJ, 1990, LANCET, V336, P670, DOI 10.1016/0140-6736(90)92158-E; HACHIDA M, 1991, ANN THORAC SURG, V51, P655, DOI 10.1016/0003-4975(91)90330-S; HELMY I, 1988, J AM COLL CARDIOL, V12, P1015, DOI 10.1016/0735-1097(88)90470-6; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; JONES MT, 1987, J THORAC CARDIOV SUR, V93, P680; LOCK JE, 1988, CIRCULATION, V78, P361, DOI 10.1161/01.CIR.78.2.361; MASSEL DR, 1993, BRIT HEART J, V69, P284; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RADFORD MJ, 1981, CIRCULATION, V64, P545, DOI 10.1161/01.CIR.64.3.545; SANDERS RJ, 1956, AM HEART J, V51, P736, DOI 10.1016/S0002-8703(56)80008-2; SCHUTZENBERGER W, 1989, BRIT HEART J, V62, P367; SKEHAN JD, 1989, BRIT HEART J, V62, P268; SKILLINGTON PD, 1990, J THORAC CARDIOV SUR, V99, P798; SMYLLIE J, 1989, BRIT HEART J, V62, P260; WESTABY S, 1992, J THORAC CARDIOV SUR, V104, P1506, DOI 10.1016/S0022-5223(19)33876-0	19	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					643	645		10.1136/bmj.308.6929.643	http://dx.doi.org/10.1136/bmj.308.6929.643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148717	Green Published			2022-12-28	WOS:A1994MZ69800031
J	VARTY, K; VEITCH, PS; MORGAN, JDT; KEHINDE, EO; DONNELLY, PK; BELL, PRF				VARTY, K; VEITCH, PS; MORGAN, JDT; KEHINDE, EO; DONNELLY, PK; BELL, PRF			RESPONSE TO ORGAN SHORTAGE - KIDNEY RETRIEVAL PROGRAM USING NON-HEART-BEATING DONORS	BRITISH MEDICAL JOURNAL			English	Article							DONATION				VARTY, K (corresponding author), UNIV LEICESTER,LEICESTER ROYAL IMFIRM,DEPT SURG,LEICESTER LE2 7LX,ENGLAND.							BOOSTER MH, 1993, TRANSPLANT P, V25, P1503; CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; RUERS TJM, 1986, TRANSPLANT P, V18, P408	5	40	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					575	575		10.1136/bmj.308.6928.575	http://dx.doi.org/10.1136/bmj.308.6928.575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148681	Green Published			2022-12-28	WOS:A1994MY71400022
J	MILLER, MG; MILLER, LS; FIREMAN, B; BLACK, SB				MILLER, MG; MILLER, LS; FIREMAN, B; BLACK, SB			VARIATION IN PRACTICE FOR DISCRETIONARY ADMISSIONS - IMPACT ON ESTIMATES OF QUALITY OF HOSPITAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; MEDICAL SPECIALTIES; SELECTION BIAS; RISK-FACTORS; MORTALITY; COMORBIDITIES; SEVERITY; OUTCOMES; SYSTEMS; RATES	Objective.-To demonstrate theoretically and empirically the existence of systematic bias in commonly reported standardized hospital mortality ratios when variation in hospital admission practice is not adjusted for in the analysis. The underlying analytic model used in hospital mortality analyses is specified and the confounding effect of selection bias arising from variation in admission practice is shown. Data Sources.-An empirical example is presented using state-level data from the Health Care Financing Administration's Medicare Hospital Information Report for 1988 to 1990. Study Selection.-The Medicare Hospital Information data are used to demonstrate the effects of the bias because they contain population-based admission rates and mortality rates. Data Synthesis.-Selection bias arising from variation in admission practice causes the expected mortality rate to be overestimated for all hospitals, but especially for hospitals with more lenient admission practices. Using the Medicare Hospital Information Report, the resulting standardized hospital mortality ratios are shown to be significantly inversely correlated with higher relative risks of hospitalization (P<.01). Conclusion.-Standardized hospital mortality ratios based on analyses that do not account for Variation in admission practice among hospitals are biased. Variation in admission practice will cause any outcome measure based solely on hospitalized patients to be similarly biased. Correction for selection bias is required to produce valid measures of hospital quality.	UNIV CALIF BERKELEY,SCH SOCIAL WELF,BERKELEY,CA 94720; KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611	University of California System; University of California Berkeley; Kaiser Permanente	MILLER, MG (corresponding author), KAISER PERMANENTE MED CARE PROGRAM,DEPT QUAL & UTILIZAT,1814 FRANKLIN ST,SUITE 1000,OAKLAND,CA 94612, USA.							BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BLUMBERG MS, 1984, ADV HLTH EC HLTH SER, P5; BROOK RH, 1989, APPROPRIATENESS ACUT; BURNS R, 1993, AM J PUBLIC HEALTH, V83, P966, DOI 10.2105/AJPH.83.7.966; CHASSIN MR, 1989, APPROPRIATENESS SELE; DENNISON CF, 1985, PHS851250 US DEP HLT, V112; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; GRAVES EJ, 1990, NATIONAL CTR HLTH ST, V185; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KENNEDY P, 1992, GUIDE ECONOMETRICS, P232; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; MANHEIM LM, 1992, INQUIRY-J HEALTH CAR, V29, P55; MANNING W, 1985, CONTROLLED TRIAL EFF; PARK RE, 1991, EXPLAINING VARIATION; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROBINSON JC, 1993, MED CARE, V31, P43, DOI 10.1097/00005650-199301000-00003; ROOS NP, 1981, AM J PUBLIC HEALTH, V71, P591, DOI 10.2105/AJPH.71.6.591; SLOOS EM, 1987, EFFECT HLTH MAINTENA; SMITH DW, 1991, MED CARE, V29, P1108, DOI 10.1097/00005650-199111000-00004; SULLIVAN LW, 1992, MEDICARE HOSPITAL S, P5; SULLIVAN LW, 1992, MEDICARE HOSPITAL IN; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WELLS KB, 1989, EFFECTS PREPAID GROU; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WILSON P, 1984, HEALTH SERV RES, V19, P333; WILSON PA, 1985, AM J PUBLIC HEALTH, V75, P263, DOI 10.2105/AJPH.75.3.263; 1992, INPATIENT UTILIZATIO; 1989, HE6189 PENNS HLTH CA, P1	41	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1493	1498		10.1001/jama.271.19.1493	http://dx.doi.org/10.1001/jama.271.19.1493			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK711	8176828				2022-12-28	WOS:A1994NK71100027
J	RENNER, C; JUNG, W; SAHIN, U; DENFELD, R; POHL, C; TRUMPER, L; HARTMANN, F; DIEHL, V; VANLIER, R; PFREUNDSCHUH, M				RENNER, C; JUNG, W; SAHIN, U; DENFELD, R; POHL, C; TRUMPER, L; HARTMANN, F; DIEHL, V; VANLIER, R; PFREUNDSCHUH, M			CURE OF XENOGRAFTED HUMAN TUMORS BY BISPECIFIC MONOCLONAL-ANTIBODIES AND HUMAN T-CELLS	SCIENCE			English	Article							HUMAN OVARIAN-CARCINOMA; HUMAN LYMPHOCYTES-T; HODGKINS-DISEASE; ACTIVATION; CD28; ANTI-CD28; LYSIS; RECEPTOR; SIGNAL	Tumor immunotherapy should increase both the number of T cells that kill the tumor and the likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies (Bi-mAbs) were designed that bound to a Hodgkin's tumor-associated antigen (CD30) on the tumor and to either CD3 or CD28 on the T cell. Immunodeficient mice were cured of established human tumors when mice were treated with both the CD3-CD30 and the CD28-CD30 Bi-mAbs and then given human peripheral brood lymphocytes that had been incubated with the CD3-CD30 Bi-mAb and cells that expressed CD30. The enrichment of human T cells within the tumor and the fact that established tumors can be cured may indicate in situ activation of both the T cell receptor and the costimulatory pathway.	UNIV SAARLAND,MED KLIN & POLIKLIN,D-66421 HOMBURG,GERMANY; UNIV COLOGNE,MED KLIN 1,D-50921 COLOGNE,GERMANY; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1006 AMSTERDAM,NETHERLANDS	Saarland University; University of Cologne			Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564; van Lier, Rene/0000-0002-3201-7144				BAROJA ML, 1989, CELL IMMUNOL, V120, P205, DOI 10.1016/0008-8749(89)90188-3; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GARRIDO MA, 1990, J IMMUNOL, V144, P2891; HOMBACH A, 1993, INT J CANCER, V55, P830, DOI 10.1002/ijc.2910550523; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNG G, 1987, P NATL ACAD SCI USA, V84, P4611, DOI 10.1073/pnas.84.13.4611; Jung W., UNPUB; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; LEDBETTER JA, 1990, BLOOD, V75, P1531; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MEZZANZANICA D, 1991, CANCER RES, V51, P5716; MEZZANZANICA D, 1988, INT J CANCER, V41, P609, DOI 10.1002/ijc.2910410422; MOISER DE, 1988, NATURE, V335, P256; MOLLER SA, 1991, CANCER IMMUNOL IMMUN, V33, P210, DOI 10.1007/BF01744939; MORETTA A, 1989, IMMUNOL REV, V111, P145, DOI 10.1111/j.1600-065X.1989.tb00545.x; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POHL C, 1993, INT J CANCER, V54, P418, DOI 10.1002/ijc.2910540312; POHL C, 1993, INT J CANCER, V54, P820, DOI 10.1002/ijc.2910540517; PUPA SM, 1988, INT J CANCER, V42, P455, DOI 10.1002/ijc.2910420324; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; TAKAHASHI H, 1993, SCIENCE, V259, P1460, DOI 10.1126/science.8451642; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VONFLIEDNER V, 1992, CELL IMMUNOL, V139, P198, DOI 10.1016/0008-8749(92)90112-3	30	156	180	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					833	835		10.1126/science.8171337	http://dx.doi.org/10.1126/science.8171337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171337				2022-12-28	WOS:A1994NJ94900030
J	MANDELBOIM, O; BERKE, G; FRIDKIN, M; FELDMAN, M; EISENSTEIN, M; EISENBACH, L				MANDELBOIM, O; BERKE, G; FRIDKIN, M; FELDMAN, M; EISENSTEIN, M; EISENBACH, L			CTL INDUCTION BY A TUMOR-ASSOCIATED ANTIGEN OCTAPEPTIDE DERIVED FROM A MURINE LUNG-CARCINOMA	NATURE			English	Article							VIRAL PEPTIDES; LYMPHOCYTES-T; CELLS; GENE; PROTEIN; RECIPIENTS; REJECTION; LINES	MANY mouse and human tumours express major histocompatibility complex (MHC) class I-associated antigens that constitute targets for syngeneic cytotoxic T lymphocytes (CTL). Genes encoding such antigens were isolated from a mouse mastocytoma and from human melanomas by genetic methods(1,2). Isolation and characterization of MHC class I-associated peptides has enabled specific anchor residues to be identified that are typical of peptides that bind to distinct class I molecules(3). Moreover, CTL specific to particular MHC-peptide combinations have been used to identify naturally occurring antigenic peptides in cell extracts and enabled them to be sequenced directly(4-6). Most known MHC ligands are of viral origin or are self peptides derived from normal proteins(7). Here we use total acid extraction and repeated fractionation to isolate and sequence Lewis lung carcinoma (3LL)-specific peptide(s), which shows sequence homology to the connexin 37 protein. Synthetic octamers based on these sequences bind to 'empty' H-2K(b) molecules on RMA-S cells, sensitize RMA-S cells to lysis by specific anti-3LL CTL, and induce anti-tumour CTL. The tumour-associated peptide originates from mutated connexin 37 expressed in 3LL.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science				Mandelboim, Ofer/0000-0002-9354-1855; Eisenbach, Lea R/0000-0002-4816-1968				EGHABALI B, 1991, P NATL ACAD SCI USA, V88, P10701; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANKS LM, 1984, BRIT J CANCER, V49, P423, DOI 10.1038/bjc.1984.68; FREEMONT DH, 1992, SCIENCE, V257, P919; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2852; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; MANDELBOIM O, 1992, J IMMUNOL, V148, P3666; PLAKSIN D, 1992, INT J CANCER, V52, P771, DOI 10.1002/ijc.2910520517; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANBLEEK GM, 1990, NATURE, V348, P213; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; ZHANG W, 1992, P NATL ACAD SCI USA, V89, P4803; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	23	252	266	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					67	71		10.1038/369067a0	http://dx.doi.org/10.1038/369067a0			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164742				2022-12-28	WOS:A1994NJ86000055
J	ORTMANN, B; ANDROLEWICZ, MJ; CRESSWELL, P				ORTMANN, B; ANDROLEWICZ, MJ; CRESSWELL, P			MHC CLASS I/BETA(2)-MICROGLOBULIN COMPLEXES ASSOCIATE WITH TAP TRANSPORTERS BEFORE PEPTIDE BINDING	NATURE			English	Article							CLASS-I MOLECULES; HLA CLASS-I; ENDOPLASMIC-RETICULUM; T-CELL; ANTIGEN; BETA-2-MICROGLOBULIN; PROTEIN; LINE	MAJOR histocompatibility complex: class I molecules bind antigenic peptides in the endoplasmic reticulum (ER) and transport them to the cell surface for recognition by cytotoxic T lymphocytes. The peptides are predominantly generated from cytoplasmic proteins, probably by the action of the multicatalytic proteinase complex, or proteasome(1,2). They are transported into the ER by the transporters associated with antigen processing (TAP), a complex formed from two subunits, TAP.1 and TAP.2 (refs 3-5). Here we show that the TAP molecules are intimately involved in the assembly of the class I/beta(2)-microglobulin (beta(2)m) peptide complex. Free class I heavy chains are associated in the ER with the chaperone calnexin(6,7). In human B-cell lines, however, class I/beta(2)m dimers in the ER are physically associated with TAP molecules rather than calnexin. Our results suggest that calnexin mediates class I/beta(2)m dimerization, and subsequent binding of the dimers to TAP molecules facilitates their association with TAP-transported peptides.			ORTMANN, B (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06520, USA.							ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ANDROLEWICZ MJ, IN PRESS IMMUNITY; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1990, J IMMUNOL, V145, P127; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	28	351	355	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					864	867		10.1038/368864a0	http://dx.doi.org/10.1038/368864a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159247				2022-12-28	WOS:A1994NH71700074
J	WEIS, SE; SLOCUM, PC; BLAIS, FX; KING, B; NUNN, M; MATNEY, GB; GOMEZ, E; FORESMAN, BH				WEIS, SE; SLOCUM, PC; BLAIS, FX; KING, B; NUNN, M; MATNEY, GB; GOMEZ, E; FORESMAN, BH			THE EFFECT OF DIRECTLY OBSERVED THERAPY ON THE RATES OF DRUG-RESISTANCE AND RELAPSE IN TUBERCULOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHORT-COURSE CHEMOTHERAPY; UNITED-STATES	Background. Tuberculosis has reemerged as an important public health problem, and the frequency of drug resistance is increasing. A major reason for the development of resistant infections and relapse is poor compliance with medical regimens. In Tarrant County, Texas, we initiated a program of universal directly observed treatment for tuberculosis. We report the effect of the program on the rates of primary and acquired drug resistance and relapse among patients with tuberculosis. Methods. We collected information on all patients with positive cultures for Mycobacterium tuberculosis in Tarrant County from January 1, 1980, through December 31, 1992, Through October 1986, patients received a traditional, unsupervised drug regimen. Beginning in November 1986, nearly all patients received therapy under direct observation by health care personnel. Results. A total of 407 episodes in which patients received traditional treatment for tuberculosis (January 1980 through October 1986) were compared with 581 episodes in which therapy was directly observed (November 1986 through December 1992). Despite higher rates of intravenous drug use and homelessness and an increasing rate of tuberculosis during this 13-year period, the frequency of primary drug resistance decreased from 13.0 percent to 6.7 percent (P<0.001) after the institution of direct observation of therapy, and the frequency of acquired resistance declined from 14.0 percent to 2.1 percent (P<0.001). The relapse rate decreased from 20.9 percent to 5.5 percent (P<0.001), and the number of relapses with multidrug-resistant organisms decreased from 25 to 5 (P<0.001). Conclusions. The administration of therapy for M. tuberculosis infection under direct observation leads to significant reductions in the frequency of primary drug resistance, acquired drug resistance, and relapse.	UNIV N TEXAS,HLTH SCI CTR,DEPT MED,DIV PULM CRIT CARE,FT WORTH,TX 76107; UNIV N TEXAS,HLTH SCI CTR,DEPT MED,DIV INFECT DIS,FT WORTH,TX 76107; FT WORTH TARRANT CTY HLTH DEPT,FT WORTH,TX; JOHN PETER SMITH HOSP,FT WORTH,TX 76104	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	WEIS, SE (corresponding author), UNIV N TEXAS,HLTH SCI CTR,DEPT MED,DIV RES,SUITE 232-ME2,3500 CAMP BOWIE,FT WORTH,TX 76107, USA.				PHS HHS [U52/CCU 600 497-11] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; BLACKWELL B, 1973, NEW ENGL J MED, V289, P249, DOI 10.1056/NEJM197308022890506; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COMSTOCK GW, 1993, LUNG BIOL HLTH DIS, V66, P23; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DAVIS MS, 1967, J HEALTH SOC BEHAV, V8, P265, DOI 10.2307/2948420; DIXON WM, 1957, LANCET, V2, P871; DUTT AK, 1984, AM J MED, V77, P233, DOI 10.1016/0002-9343(84)90697-1; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; KOPANOFF DE, 1988, AM J PUBLIC HEALTH, V78, P30, DOI 10.2105/AJPH.78.1.30; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; OBRIEN RJ, 1993, LUNG BIOL HLTH DISEA, V66, P207; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SBARBARO JA, 1980, CLIN CHEST MED, V1, P253; SIMPSON J M, 1956, Tubercle, V37, P333, DOI 10.1016/S0041-3879(56)80079-2; 1990, MMWR MORB MORTAL WKL, V39, P369; 1992, MMWR MORB MORTAL WKL, V41, P507; 1970, B WORLD HEALTH ORGAN, V43, P143	25	496	503	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1179	1184		10.1056/NEJM199404283301702	http://dx.doi.org/10.1056/NEJM199404283301702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139628				2022-12-28	WOS:A1994NG58600002
J	DRAPKIN, R; REARDON, JT; ANSARI, A; HUANG, JC; ZAWEL, L; AHN, KJ; SANCAR, A; REINBERG, D				DRAPKIN, R; REARDON, JT; ANSARI, A; HUANG, JC; ZAWEL, L; AHN, KJ; SANCAR, A; REINBERG, D			DUAL ROLE OF TFIIH IN DNA EXCISION-REPAIR AND IN TRANSCRIPTION BY RNA-POLYMERASE-II	NATURE			English	Article							XERODERMA-PIGMENTOSUM; SUBUNIT; CLONING; MOTIFS	THE RNA polymerase II general transcription factor TFIIH is composed of several polypeptides. The observation that the largest subunit of TFIIH is the excision-repair protein XPB/ERCC3 (ref. 1), a helicase implicated in the human DNA-repair disorders xeroderma pigmentosum (XP) and Cockayne's syndrome(2,3), suggests a functional link between transcription and DNA repair(4,5). To understand the connection between these two cellular processes, we have extensively purified and functionally analysed TFIIH. We find that TFIIH has a dual role, being required for basal transcription of class II genes and for participation in DNA-excision repair. TFIIH is shown to complement three different cell extracts deficient in excision repair: XPB/ERCC3, XPC and XPD/ERCC2. The complementation of XPB and XPD is a consequence of ERCC3 and ERCC2 being integral subunits of TFIIH, whereas complementation of XPC is due to an association of this polypeptide with TFIIH. We found that the general transcription factor IIE negatively modulates the helicase activity of TFIIH through a direct interaction between TFIIE and the ERCC3 subunit of TFIIH.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FISHER L, 1992, SCIENCE, V257, P1392; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Qui H., 1993, GENE DEV, V7, P2161; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023	28	420	424	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					769	772		10.1038/368769a0	http://dx.doi.org/10.1038/368769a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152490				2022-12-28	WOS:A1994NG55300066
J	EARL, JW; MCCLEARY, BV				EARL, JW; MCCLEARY, BV			MYSTERY OF THE POISONED EXPEDITION	NATURE			English	Editorial Material									MEGAZYME AUST PTY LTD, WARRIEWOOD, NSW 2102, AUSTRALIA		EARL, JW (corresponding author), ROYAL ALEXANDRA HOSP CHILDREN, DEPT BIOCHEM, PYRMONT BRIDGE RD, CAMPERDOWN, NSW 2050, AUSTRALIA.							[Anonymous], 1861, BURKE WILLS EXPLORIN; BASEDOW H, 1925, AUSTR ABORIGINAL, P121; EVANS WC, 1950, BIOCHEM J, V46, pR38; Funk C, 1912, J PHYSIOL-LONDON, V44, P50, DOI 10.1113/jphysiol.1912.sp001537; Kerwin B, 1986, THIS IS WHAT HAPPENE, P16; MCCLEARY BV, 1977, PHYTOCHEMISTRY, V16, P207, DOI 10.1016/S0031-9422(00)86787-4; MUELLER FD, 1861, T P ROYAL SOC VICTOR, P134	7	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					683	684		10.1038/368683a0	http://dx.doi.org/10.1038/368683a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152477				2022-12-28	WOS:A1994NG55300023
J	PETERSON, ED; WRIGHT, SM; DALEY, J; THIBAULT, GE				PETERSON, ED; WRIGHT, SM; DALEY, J; THIBAULT, GE			RACIAL VARIATION IN CARDIAC PROCEDURE USE AND SURVIVAL FOLLOWING ACUTE MYOCARDIAL-INFARCTION IN THE DEPARTMENT-OF-VETERANS-AFFAIRS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ARTERY DISEASE; UNITED-STATES; BLACK POPULATIONS; PREHOSPITAL DELAY; MEDICARE PATIENTS; RISK-FACTORS; RACE; RATES; SURGERY	Objective.-To examine whether blacks admitted to Veterans Affairs Medical Centers (VAMCs) with an acute myocardial infarction (AMI) are less likely than whites to undergo cardiac catheterization or coronary revascularization procedures and to determine the impact of these differences on patient survival. Design.-A retrospective observational study of inpatient discharge abstracts from the Veterans Health Administration (VHA). Setting.-All one hundred fifty-eight acute care hospitals in the VHA. Patient Population.-Male veterans (n=33 641) discharged from VAMCs with an International Classification of Diseases, Ninth Revision, Clinical Modification code for AMI from January 1, 1988, to December 31, 1990. Intervention.- None. Main Outcome Measures.-The use of cardiac catheterization, coronary angioplasty, and/or bypass surgery in the 90 days after admission for AMI, and survival at 30 days, 1 year, and 2 years. Main Results.- Adjusting for patient and hospital characteristics, blacks with an AMI were 33% less likely than whites to undergo cardiac catheterization, 42% less likely to receive coronary angioplasty, and 54% less likely to receive coronary bypass surgery. Among patients who underwent catheterization, blacks were also less likely than whites to have a subsequent cardiac revascularization procedure. Adjusted 30-day survival for blacks was significantly greater than for whites. One- and 2-year survival rates after AMI were not significantly different between blacks and whites. Conclusions.-In a health care system designed to provide equivalent availability of care to all eligible patients, blacks received substantially fewer cardiac procedures after AMI than whites. Despite undergoing fewer interventional procedures, blacks had better short-term and equivalent intermediate survival rates compared with whites.	HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	PETERSON, ED (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 3236,DURHAM,NC 27710, USA.		Peterson, Eric David/ABF-5033-2021					AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; COX DR, 1972, J R STAT SOC B, V34, P187; CURRY CL, 1984, AM HEART J, V108, P653, DOI 10.1016/0002-8703(84)90650-1; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; FUNK M, 1992, CIRCULATION, V86, P99; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; GLUECK CJ, 1984, AM HEART J, V108, P815, DOI 10.1016/0002-8703(84)90677-X; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HAYWOOD LJ, 1984, AM HEART J, V108, P787; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JOHNSON KW, 1984, AM HEART J, V108, P633, DOI 10.1016/0002-8703(84)90647-1; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KEIL JE, 1985, AM HEART J, V109, P776, DOI 10.1016/0002-8703(85)90638-6; KIRKLIN JW, 1989, CIRCULATION, V79, P81; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PEPERDINE CJ, 1989, DIAGNOSTIC THERAPEUT; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; ROMANO PS, 1992, MED EFFECTIVENESS RE, P57; ROOS NP, 1988, MED CARE, V26, P221, DOI 10.1097/00005650-198803000-00001; ROWLAND ML, 1984, AM HEART J, V108, P771, DOI 10.1016/0002-8703(84)90670-7; SANE DC, 1991, CIRCULATION, V83, P170, DOI 10.1161/01.CIR.83.1.170; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SIMMONS BE, 1987, AM J CARDIOL, V59, P547, DOI 10.1016/0002-9149(87)91167-2; STERLING RP, 1984, AM HEART J, V108, P695, DOI 10.1016/0002-8703(84)90657-4; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WATKINS L, 1984, AM HEART J, V108, P695; WEISSE AB, 1977, ARCH INTERN MED, V137, P1402, DOI 10.1001/archinte.137.10.1402; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wright Steven M., 1993, Journal of the American College of Cardiology, V21, p175A; YEDIDIA MJ, 1992, ARCH INTERN MED, V152, P595, DOI 10.1001/archinte.152.3.595; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1989, PHS891232 US DEP HLT; 1989, INT CLASSIFICATION D; 1990, SURVEY MED SYSTEM US	54	312	312	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1175	1180		10.1001/jama.271.15.1175	http://dx.doi.org/10.1001/jama.271.15.1175			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151875				2022-12-28	WOS:A1994NF20700026
J	KAMB, A; GRUIS, NA; WEAVERFELDHAUS, J; LIU, QY; HARSHMAN, K; TAVTIGIAN, SV; STOCKERT, E; DAY, RS; JOHNSON, BE; SKOLNICK, MH				KAMB, A; GRUIS, NA; WEAVERFELDHAUS, J; LIU, QY; HARSHMAN, K; TAVTIGIAN, SV; STOCKERT, E; DAY, RS; JOHNSON, BE; SKOLNICK, MH			A CELL-CYCLE REGULATOR POTENTIALLY INVOLVED IN GENESIS OF MANY TUMOR TYPES	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ALPHA-INTERFERON; DELETIONS; ONCOGENE; CARCINOMAS; BCL-1	A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (pl 6) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.	NCI,LUNG CANC BIOL SECT,BETHESDA,MD 20889; MYRIAD GENET INC,SALT LAKE CITY,UT 84108; MEM SLOAN KETTERING CANC CTR,LUDWIG INST CANC RES,NEW YORK,NY 10021; CROSS CANC INST,DEPT MED,EDMONTON T6G 1Z2,ALBERTA,CANADA; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Myriad Genetics, Inc; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center; University of Alberta; Utah System of Higher Education; University of Utah	KAMB, A (corresponding author), MYRIAD GENET INC,SALT LAKE CITY,UT 84108, USA.		Yang, Chen/G-1379-2010	Gruis, Nelleke/0000-0002-5210-9150	NCI NIH HHS [CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JA, 1992, J OTOLARYNGOL, V21, P321; CHENG JQ, 1993, CANCER RES, V53, P4761; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRUIS NA, UNPUB; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, UNPUB; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MERLO A, 1994, CANCER RES, V54, P640; MIDDLETON PG, 1991, LEUKEMIA, V5, P680; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEAVERFELDHAUS J, IN PRESS P NATL ACAD; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	2711	3000	0	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					436	440		10.1126/science.8153634	http://dx.doi.org/10.1126/science.8153634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153634	Green Submitted			2022-12-28	WOS:A1994NG19400044
J	SPRATT, BG				SPRATT, BG			RESISTANCE TO ANTIBIOTICS MEDIATED BY TARGET ALTERATIONS	SCIENCE			English	Article							PENICILLIN-BINDING PROTEINS; BETA-LACTAM ANTIBIOTICS; POLYMERASE CHAIN-REACTION; STREPTOCOCCUS-PNEUMONIAE; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; NEISSERIA-GONORRHOEAE; DNA GYRASE; HORIZONTAL TRANSFER; MOLECULAR-BASIS	The development of resistance to antibiotics by reductions in the affinities of their enzymatic targets occurs most rapidly for antibiotics that inactivate a single target and that are not analogs of substrate. In these cases of resistance (for example, resistance to rifampicin), numerous single amino acid substitutions may provide large decreases in the affinity of the target for the antibiotic, leading to clinically significant levels of resistance. Resistance due to target alterations should occur much more slowly for those antibiotics (penicillin, for example) that inactivate multiple targets irreversibly by acting as close analogs of substrate. Resistance to penicillin because of target changes has emerged, by unexpected mechanisms, only in a limited number of species. However, inactivating enzymes commonly provide resistance to antibiotics that, like penicillin, are derived from natural products, although such enzymes have not been found for synthetic antibiotics. Thus, the ideal antibiotic would be produced by rational design, rather than by the modification of a natural product.			SPRATT, BG (corresponding author), UNIV SUSSEX,SCH BIOL SCI,MICROBIAL GENET GRP,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.		Spratt, Brian G/A-1676-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENEVISTE R, 1973, P NATL ACAD SCI USA, V70, P2276; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BRANNIGAN JA, 1990, MOL MICROBIOL, V4, P913, DOI 10.1111/j.1365-2958.1990.tb00664.x; COFFEY TJ, 1993, FEMS MICROBIOL LETT, V110, P335, DOI 10.1016/0378-1097(93)90125-L; COFFEY TJ, UNPUB; COLE ST, 1993, ANN I PASTEUR ACTUAL, V4, P203; CUNLIFFE E, 1990, RIBOSOME STRUCTURE F, P479; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DAVIES J, 1992, J GEN MICROBIOL, V138, P1553, DOI 10.1099/00221287-138-8-1553; DOUGHERTY TJ, 1986, ANTIMICROB AGENTS CH, V30, P649, DOI 10.1128/AAC.30.5.649; DOUGHERTY TJ, 1980, ANTIMICROB AGENTS CH, V18, P730, DOI 10.1128/AAC.18.5.730; DOWSON CG, 1989, MOL MICROBIOL, V3, P95, DOI 10.1111/j.1365-2958.1989.tb00108.x; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; DOWSON CG, 1993, MOL MICROBIOL, V9, P635, DOI 10.1111/j.1365-2958.1993.tb01723.x; DOWSON CG, UNPUB; ELWELL LP, 1989, HDB EXPT PHARM, V91, P291; FARUKI H, 1986, ANTIMICROB AGENTS CH, V30, P856, DOI 10.1128/AAC.30.6.856; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GOSWITZ JJ, 1992, ANTIMICROB AGENTS CH, V36, P1166, DOI 10.1128/AAC.36.5.1166; HAKENBECK R, 1987, J GEN MICROBIOL, V133, P755; HAKENBECK R, 1986, ANTIMICROB AGENTS CH, V30, P553, DOI 10.1128/AAC.30.4.553; HAKENBECK R, 1980, ANTIMICROB AGENTS CH, V17, P364, DOI 10.1128/AAC.17.3.364; HEDGE PJ, 1985, EUR J BIOCHEM, V151, P111, DOI 10.1111/j.1432-1033.1985.tb09075.x; HEDGE PJ, 1985, NATURE, V318, P478, DOI 10.1038/318478a0; HEISIG P, 1993, ANTIMICROB AGENTS CH, V37, P696, DOI 10.1128/AAC.37.4.696; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; HUMBERT O, 1993, DNA TRANSFER GENE EX, P23; HUMMEL H, 1989, HDB EXPT PHARM, V91, P193; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; JEPHCOTT AE, 1986, J ANTIMICROB CHEMOTH, V18, P199, DOI 10.1093/jac/18.Supplement_C.199; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KUMAR KP, 1992, BIOCHEMISTRY-US, V31, P7519, DOI 10.1021/bi00148a012; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; MARTIN C, 1992, EMBO J, V11, P3831, DOI 10.1002/j.1460-2075.1992.tb05475.x; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MENDELMAN PM, 1988, ANTIMICROB AGENTS CH, V32, P706, DOI 10.1128/AAC.32.5.706; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P2058, DOI 10.1128/JCM.30.8.2058-2063.1992; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ORAM M, 1991, ANTIMICROB AGENTS CH, V35, P387, DOI 10.1128/AAC.35.2.387; RADSTROM P, 1992, J BACTERIOL, V174, P6386; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SAEZNIETO JA, 1992, CLIN INFECT DIS, V14, P394, DOI 10.1093/clinids/14.2.394; SAEZNIETO JA, 1988, LANCET, V1, P1452; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3; SPRATT BG, 1992, J MOL EVOL, V34, P115; SPRATT BG, 1988, REV INFECT DIS, V10, P699; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SPRATT BG, 1978, NATURE, V274, P713, DOI 10.1038/274713a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; SPRATT BG, 1989, HDB EXPT PHARM, V91, P77; SPRATT BG, IN PRESS POPULATION; SPRATT BG, 1994, N COMP BIOC, V27, P517; SREEDHARAN S, 1990, J BACTERIOL, V172, P7260, DOI 10.1128/jb.172.12.7260-7262.1990; SUTCLIFFE EM, 1988, LANCET, V1, P657; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; THEN RL, 1989, HDB EXPT PHARM, V91, P249; UBUKATA K, 1990, ANTIMICROB AGENTS CH, V34, P170, DOI 10.1128/AAC.34.1.170; WEHRLI W, 1983, REV INFECT DIS, V5, P3; YAZAWA K, 1993, ANTIMICROB AGENTS CH, V37, P1313, DOI 10.1128/AAC.37.6.1313; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271; ZIGHELBOIM S, 1980, ANTIMICROB AGENTS CH, V17, P434, DOI 10.1128/AAC.17.3.434	70	454	486	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					388	393		10.1126/science.8153626	http://dx.doi.org/10.1126/science.8153626			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153626				2022-12-28	WOS:A1994NG19400029
J	ROCKOFF, A				ROCKOFF, A			A PURELY COSMETIC PROCEDURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1076	1076		10.1001/jama.271.14.1076	http://dx.doi.org/10.1001/jama.271.14.1076			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151841				2022-12-28	WOS:A1994NE22800012
J	KLEMM, JD; ROULD, MA; AURORA, R; HERR, W; PABO, CO				KLEMM, JD; ROULD, MA; AURORA, R; HERR, W; PABO, CO			CRYSTAL-STRUCTURE OF THE OCT-1 POU DOMAIN BOUND TO AN OCTAMER SITE - DNA RECOGNITION WITH TETHERED DNA-BINDING MODULES	CELL			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTION FACTOR; OPERATOR COMPLEX; NUCLEIC-ACIDS; AMINO-ACID; I-POU; HOMEODOMAIN; PROTEIN; SPECIFICITY; RESOLUTION	The structure of an Oct-1 POU domain-octamer DNA complex has been solved at 3.0 Angstrom resolution. The POU-specific domain contacts the 5' half of this site (ATG- CAAAT), and as predicted from nuclear magnetic resonance studies, the structure, docking, and contacts are remarkably similar to those of the lambda and 434 repressors. The POU homeodomain contacts the 3' half of this site (ATGCAAAT), and the docking is similar to that of the engrailed, MAT alpha 2, and Antennapedia homeodomains. The linker region is not visible and there are no protein-protein contacts between the domains, but overlapping phosphate contacts near the center of the octamer site may favor cooperative binding. This novel arrangement raises important questions about cooperativity in protein-DNA recognition.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Cold Spring Harbor Laboratory	KLEMM, JD (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546; Aurora, Rajeev/0000-0002-6609-6055	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106] Funding Source: Medline; NIGMS NIH HHS [GM-31471] Funding Source: Medline; PHS HHS [5-T32-6MO7287-18] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	57	446	458	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					21	32		10.1016/0092-8674(94)90231-3	http://dx.doi.org/10.1016/0092-8674(94)90231-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156594				2022-12-28	WOS:A1994NF21100006
J	SULLIVAN, AK; HOLDRIGHT, DR; WRIGHT, CA; SPARROW, JL; CUNNINGHAM, D; FOX, KM				SULLIVAN, AK; HOLDRIGHT, DR; WRIGHT, CA; SPARROW, JL; CUNNINGHAM, D; FOX, KM			CHEST PAIN IN WOMEN - CLINICAL, INVESTIGATIVE, AND PROGNOSTIC FEATURES	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; CARDIOVASCULAR-DISEASE; SEX-DIFFERENCES; BYPASS-SURGERY; ARTERY SURGERY; RISK-FACTORS; MEN; ARTERIOGRAMS; EXERCISE	Objective-To characterise clinical, investigative, and prognostic features of women referred with chest pain who subsequently underwent coronary angiography. Design-Analysis of all women with angina referred to one consultant during 1987-91 who subsequently underwent coronary angiography, with follow up to present day. Setting-Cardiothoracic centre. Subjects-Women with normal coronary arteries; women with coronary artery disease shown on angiography; men with coronary artery disease matched for age; men referred with chest pain during the same period subsequently found to have normal coronary arteries. Main outcome measures-Risk factor analysis; results of exercise testing and coronary angiography; intervention; morbidity and mortality. Results-Women comprised 23% (202/886) of patients referred with chest pain who subsequently underwent angiography. 83/202 women had normal coronary angiograms compared with 55/684 men (41% v 8%, P < 0.001). Diabetes mellitus was the only risk factor more frequently encountered in women with coronary artery disease (P = 0.001). The specificity and positive predictive value of exercise testing before angiography were significantly lower in women than men (71% v 93%, P<0.001 and 76% v 95%, P < 0.001, respectively). Revascularisation procedures were as common in women with coronary artery disease as in men (81 (68%) v 70 (59%)), and there was no difference in event rate during follow up. Many patients with normal coronary arteries, irrespective of sex, had symptoms during follow up (61 (73%) women, 36 (65%) men) and continued to take antianginal drugs (27 (33%) women, 14 (28%) men); 14 (17%) women and six (11%) men required hospital readmission for severe symptoms. Conclusions-In this series, although women comprised the minority of patients referred with chest pain, a diagnosis of normal coronary arteries was five times more common in women than men. Risk factor analysis and exercise testing were of limited value in predicting coronary artery disease in women. There was no sex bias regarding revascularisation procedures, and outcome was similar. A diagnosis of non-cardiac chest pain in patients with normal coronary arteries was of little benefit to the patient with regard to morbidity.	ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6NP,ENGLAND	Imperial College London								AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BAROLSKY SM, 1979, CIRCULATION, V60, P1021, DOI 10.1161/01.CIR.60.5.1021; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CHAMBERS J, 1990, DIFFICULT CARDIOLOGY, P301; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; DAVIS KB, 1987, CORONARY HEART DISEA, P247; DETRY JMR, 1977, CIRCULATION, V56, P756, DOI 10.1161/01.CIR.56.5.756; GROSSMAN W, 1991, CARDIAC CATHETERIZAT, P28; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; ISNER JM, 1981, AM HEART J, V102, P645, DOI 10.1016/0002-8703(81)90088-0; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KENNEDY JW, 1982, CIRCULATION, V66, P16; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STOKES J, 1987, CIRCULATION, V75, P65; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; WAXLER EB, 1971, AM J CARDIOL, V28, P25, DOI 10.1016/0002-9149(71)90030-0; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1991, CORONARY HEART DISEA, P30	28	196	208	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					883	886		10.1136/bmj.308.6933.883	http://dx.doi.org/10.1136/bmj.308.6933.883			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173366	Green Published			2022-12-28	WOS:A1994NE60000019
J	FERGUSON, AE; TAPPIN, DM; GIRDWOOD, RWA; KENNEDY, R; COCKBURN, F				FERGUSON, AE; TAPPIN, DM; GIRDWOOD, RWA; KENNEDY, R; COCKBURN, F			BREAST-FEEDING IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS	Objective-To measure the prevalence of breast feeding and to examine the value of using information collected on Guthrie cards (used for detecting inherited metabolic disease and hypothyroidism when newborn infants are 7 days old) to calculate this prevalence. Design-Analysis, by geographical area and maternity unit, of information on breast feeding collected on Guthrie cards for 131 759 babies born 1990 and 1991, and comparison with prevalences from other sources. Setting-Scotland. Results-Of the 131 759 babies, only 46 949 (35.6%) were breast feeding on day 7. The prevalence of breast feeding ranged from 59.1% (376/636) in Shetland to 21.1% (1836/8719) in Lanarkshire and < 8% in some postcode districts of cities. Analysis of the data by hospital of birth showed that the prevalence ranged from 51.2% (2701/5275) to 16.4% (507/3090). Conclusion-The prevalence of breast feeding in Scotland is low and varies among areas and maternity units. Intervention to increase this prevalence is essential, and information collected on Guthrie cards is a useful indication of mothers' intentions to breast feed.	STOBHILL GEN HOSP,SCOTTISH INBORN ERRORS SCREENING LAB,GLASGOW G21 3UW,SCOTLAND		FERGUSON, AE (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,SCOTLAND.							CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; DOWNHAM MAPS, 1976, BRIT MED J, V2, P274, DOI 10.1136/bmj.2.6030.274; EMERY JL, 1990, ARCH DIS CHILD-FETAL, V65, P369, DOI 10.1136/adc.65.4_Spec_No.369; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; ROBINSON M, 1951, LANCET, V1, P788; VICTORA CG, 1987, LANCET, V2, P319; WHITE A, 1990, INFANT FEEDING 1990; 1988, SUCCESSFUL BREAST FE; 1988, LANCET, V1, P975; 1988, REPORT C LAUNCH JOIN	11	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					824	825		10.1136/bmj.308.6932.824	http://dx.doi.org/10.1136/bmj.308.6932.824			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167490	Green Published			2022-12-28	WOS:A1994ND24300023
J	HEALY, B				HEALY, B			SHATTUCK LECTURE - NIH AND THE BODIES POLITIC	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HEALY, B (corresponding author), CLEVELAND CLIN FDN,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BUSH V, 1990, SCI ENDLESS FRONTIER, P5; CLINTON WJ, 1993, FED REGISTER, V58, P8207; DOWD AR, 1993, FORTUNE         0322, P30; GOTTFRIED M, SEMMELWEISS PROGRAM; HEALY B, 1992, SCIENCE, V257, P312, DOI 10.1126/science.1631548; HEALY B, 1992, SCIENCE, V257, P414; ROOSEVELT FD, E PRITCHARD PAPERS; 1992, REDUCING DEFICIT SPE; 1993, BUDGET US GOVT	9	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1493	1498		10.1056/NEJM199405263302106	http://dx.doi.org/10.1056/NEJM199405263302106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164703				2022-12-28	WOS:A1994NM06800006
J	RIVO, ML; SAULTZ, JW; WARTMAN, SA; DEWITT, TG				RIVO, ML; SAULTZ, JW; WARTMAN, SA; DEWITT, TG			DEFINING THE GENERALIST PHYSICIANS TRAINING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE SYSTEM; RESIDENCY	Objective.-To determine the extent to which various specialties prepare residents in the broad competencies required for primary care practice and to propose guidelines for improving generalist physician training. Data Sources.-Leading causes of morbidity and mortality, 1991 National Ambulatory Medical Care Survey data, expert reports, and the special requirements for residency training. Design.-From the data sources we identified the common presenting conditions and diagnoses that broadly trained generalist physicians could be expected to manage in primary care practice. We then compiled a list of 60 requisite residency training components grouped according to seven practice criteria for generalist physicians. Using the special requirements for residency training for family practice, internal medicine, pediatrics, obstetrics and gynecology, and emergency medicine, we determined the extent to which the requirements addressed the 60 components and continuity-of-care training. Results.-Almost all of the 60 generalist training components were required by family practice (95%), internal medicine (91%), and pediatrics (91%), compared with emergency medicine (42%) and obstetrics and gynecology (47%). Family practice, internal medicine, and pediatric residencies also require lengthy, well-defined continuity-of-care experiences. Conclusion.-Family practice, internal medicine, and pediatric programs prepare residents in the broad competencies necessary for primary care practice. To train competent generalist physicians, we recommend that residency programs require training in 90% or more of the 60 components, 50% or more of the components in each of the seven categories, and a continuity-of-care experience for a panel of patients during at least 10% of the entire residency training period.	OREGON HLTH SCI UNIV,SCH MED,DEPT FAMILY MED,PORTLAND,OR 97201; MT SINAI MED CTR,DEPT MED,MIAMI BEACH,FL 33140; UNIV MIAMI,SCH MED,MIAMI,FL; UNIV MASSACHUSETTS,SCH MED,DIV GEN & COMMUNITY PEDIAT,WORCESTER,MA	Oregon Health & Science University; Mount Sinai Medical Center; University of Miami; University of Massachusetts System; University of Massachusetts Worcester	RIVO, ML (corresponding author), COUNCIL GRAD MED EDUC,PARKLAWN BLDG,5600 FISHERS LANE,ROOM 9A27,ROCKVILLE,MD 20857, USA.							ALPERT J, 1973, ED PHYSICIANS PRIMAR; ANDERSON GV, 1988, ANN EMERG MED, V17, P982; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; COHEN JJ, 1993, NEW ENGL J MED, V329, P3136; CORRIGAN JM, 1992, J FAM PRACTICE, V35, P543; DUNN LJ, 1993, AM J OBSTET GYNECOL, V168, P1053, DOI 10.1016/0002-9378(93)90347-L; GEYMAN JP, 1986, JAMA-J AM MED ASSOC, V255, P2631, DOI 10.1001/jama.255.19.2631; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V268, P2082; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MOORE GT, 1993, IMPACT MANAGED CARE; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; NUTTING P, 1992, NEW ENGL J MED, V327, P424; PRUESSNER HT, 1992, ACAD MED, V67, P232, DOI 10.1097/00001888-199204000-00003; RIVO ML, 1993, ANN INTERN MED, V119, P146, DOI 10.7326/0003-4819-119-2-199307150-00009; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; SARGENT JR, 1993, PEDIATRICS, V91, P1185; SCHAPPERT SM, 1992, NATIONAL AMBULATORY; Shugars DA, 1991, HLTH AM PRACTITIONER; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; WARTMAN SA, 1992, ANN INTERN MED, V116, P1071, DOI 10.7326/0003-4819-116-12-1071; 1993, ESSENTIALS INFORMATI; 1978, MANPOWER POLICY PRIM; 1993, US PHS4TH HLTH RES S; 1993, POLICY PAPER PRIMARY; 1993, ACAD MED, V68, P1; 1990, HLTH PEOPLE 2000; 1993, RECRUITMENT EXPERIEN	32	81	81	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1499	1504		10.1001/jama.271.19.1499	http://dx.doi.org/10.1001/jama.271.19.1499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176829				2022-12-28	WOS:A1994NK71100028
J	DRANOFF, G; CRAWFORD, AD; SADELAIN, M; REAM, B; RASHID, A; BRONSON, RT; DICKERSIN, GR; BACHURSKI, CJ; MARK, EL; WHITSETT, JA; MULLIGAN, RC				DRANOFF, G; CRAWFORD, AD; SADELAIN, M; REAM, B; RASHID, A; BRONSON, RT; DICKERSIN, GR; BACHURSKI, CJ; MARK, EL; WHITSETT, JA; MULLIGAN, RC			INVOLVEMENT OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PULMONARY HOMEOSTASIS	SCIENCE			English	Article							SURFACTANT PROTEIN-A; MURINE GM-CSF; LANGERHANS CELLS; MOUSE; PHAGOCYTOSIS; RECEPTOR; INVITRO; MICE; ENHANCEMENT; EXPRESSION	The in vivo function of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in mice, carrying a null allele of the GM-CSF gene, that were generated by gene targeting techniques in embryonic stem cells. Although steady-state hematopoiesis was unimpaired in homozygous mutant animals, all animals developed the progressive accumulation of surfactant lipids and proteins in the alveolar space, the defining characteristic of the idiopathic human disorder pulmonary alveolar proteinosis. Extensive lymphoid hyperplasia associated with lung airways and blood vessels was also found, yet no infectious agents could be detected. These results demonstrate that GM-CSF is not an essential growth factor for basal hematopoiesis and reveal an unexpected, critical role for GM-CSF in pulmonary homeostasis.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; CHILDRENS HOSP,DIV PULM BIOL,CINCINNATI,OH 45229; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Tufts University; Tufts University; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Bachurski, Cindy/0000-0002-3118-0636; Neugeboren, Beverly/0000-0003-3127-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037569] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37569] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS JS, 1988, J IMMUNOL, V140, P131; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONAHUE RE, 1986, NATURE, V321, P872, DOI 10.1038/321872a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; DRANOFF G, UNPUB; FLEISCHMANN J, 1986, BLOOD, V68, P708; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; JOHNSON GR, 1980, EXP HEMATOL, V8, P549; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; Metcalf D, 1988, MOL CONTROL BLOOD CE; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; OGARRA A, 1989, CELL IMMUNOL, V123, P189, DOI 10.1016/0008-8749(89)90279-7; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; ROBERTSON SA, 1992, BIOL REPROD, V46, P1069, DOI 10.1095/biolreprod46.6.1069; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	45	716	731	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					713	716		10.1126/science.8171324	http://dx.doi.org/10.1126/science.8171324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171324				2022-12-28	WOS:A1994NH71300035
J	KINCH, JW; RYAN, TJ				KINCH, JW; RYAN, TJ			RIGHT-VENTRICULAR INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INFERIOR MYOCARDIAL-INFARCTION; RIGHT CORONARY-ARTERY; ST-SEGMENT ELEVATION; EJECTION FRACTION; PROGNOSTIC-SIGNIFICANCE; PERICARDIAL CONSTRICTION; EARLY RECOGNITION; HEART-DISEASE; HIGH-RISK; DIAGNOSIS		BOSTON UNIV, MED CTR,DEPT MED,CARDIOL SECT, EVANS MEM DEPT CLIN RES, BOSTON, MA 02118 USA	Boston University								ANDERSEN HR, 1989, AM HEART J, V117, P82, DOI 10.1016/0002-8703(89)90659-5; ANDERSEN HR, 1987, J AM COLL CARDIOL, V10, P1223, DOI 10.1016/S0735-1097(87)80122-5; BAKOS ACP, 1950, CIRCULATION, V1, P725; BARNARD D, 1987, CURR PROB CARDIOLOGY, V12, P419; BELLAMY GR, 1986, AM HEART J, V112, P304, DOI 10.1016/0002-8703(86)90266-8; BERGER PB, 1993, AM J CARDIOL, V71, P1148, DOI 10.1016/0002-9149(93)90637-R; BERGER PB, 1990, CIRCULATION, V81, P401, DOI 10.1161/01.CIR.81.2.401; BRAAT SH, 1987, AM HEART J, V113, P257, DOI 10.1016/0002-8703(87)90262-6; BRAAT SH, 1983, BRIT HEART J, V49, P368; BRAAT SH, 1984, AM HEART J, V107, P1183, DOI 10.1016/0002-8703(84)90275-8; BRAAT SH, 1984, AM J CARDIOL, V53, P1538, DOI 10.1016/0002-9149(84)90575-7; CABIN HS, 1987, AM HEART J, V113, P16, DOI 10.1016/0002-8703(87)90004-4; CALVIN JE, 1991, CIRCULATION, V84, P852, DOI 10.1161/01.CIR.84.2.852; CANDELLRIERA J, 1981, AM HEART J, V101, P281, DOI 10.1016/0002-8703(81)90191-5; CARLSON EB, 1985, CLIN CARDIOL, V8, P499, DOI 10.1002/clc.4960080909; CINTRON GB, 1981, AM J CARDIOL, V47, P224, DOI 10.1016/0002-9149(81)90389-1; COHN JN, 1974, AM J CARDIOL, V33, P209, DOI 10.1016/0002-9149(74)90276-8; COMACANELLA I, 1980, AM J CARDIOL, V45, P555, DOI 10.1016/S0002-9149(80)80004-X; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; CROSS CE, 1962, AM J PHYSIOL, V202, P12, DOI 10.1152/ajplegacy.1962.202.1.12; DARCY B, 1982, CIRCULATION, V65, P167, DOI 10.1161/01.CIR.65.1.167; DELLITALIA LJ, 1985, CIRCULATION, V72, P1327, DOI 10.1161/01.CIR.72.6.1327; DELLITALIA LJ, 1984, J AM COLL CARDIOL, V4, P931, DOI 10.1016/S0735-1097(84)80053-4; DELLITALIA LJ, 1983, ANN INTERN MED, V99, P608, DOI 10.7326/0003-4819-99-5-608; DELLITALIA LJ, 1991, CURR PROB CARDIOLOGY, V16, P659; DELLITALIA LJ, 1986, J INTENSIVE CARE MED, V1, P246; DOYLE T, 1985, J AM COLL CARDIOL, V5, P366, DOI 10.1016/S0735-1097(85)80061-9; ERHARDT LR, 1976, AM HEART J, V91, P571, DOI 10.1016/S0002-8703(76)80141-X; ERHARDT LR, 1974, ACTA MED SCAND, P1; FANTIDIS P, 1992, J CARDIOVASC SURG, V33, P229; FARRERBROWN G, 1968, BRIT HEART J, V30, P679; FERGUSON JJ, 1989, AM J CARDIOL, V64, P311, DOI 10.1016/0002-9149(89)90525-0; FORMAN MB, 1987, J AM COLL CARDIOL, V10, P1180, DOI 10.1016/S0735-1097(87)80116-X; GOLDSTEIN JA, 1983, J AM COLL CARDIOL, V2, P270, DOI 10.1016/S0735-1097(83)80163-6; GOLDSTEIN JA, 1982, CIRCULATION, V65, P513, DOI 10.1161/01.CIR.65.3.513; GOLDSTEIN JA, 1992, J AM COLL CARDIOL, V19, P704, DOI 10.1016/S0735-1097(10)80296-7; GOLDSTEIN JA, 1990, CIRCULATION, V82, P359, DOI 10.1161/01.CIR.82.2.359; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; ISNER JM, 1988, JAMA-J AM MED ASSOC, V259, P712, DOI 10.1001/jama.259.5.712; JENSEN DP, 1978, AM J CARDIOL, V42, P858, DOI 10.1016/0002-9149(78)90108-X; JUGDUTT BI, 1984, AM HEART J, V107, P505, DOI 10.1016/0002-8703(84)90093-0; KAGAN A, 1952, CIRCULATION, V5, P816, DOI 10.1161/01.CIR.5.6.816; KLEIN HO, 1983, CIRCULATION, V67, P558, DOI 10.1161/01.CIR.67.3.558; LEE F A, 1992, Cardiology Clinics, V10, P59; LEW AS, 1986, AM J CARDIOL, V57, P1047, DOI 10.1016/0002-9149(86)90672-7; LLOYD EA, 1981, AM J CARDIOL, V48, P1016, DOI 10.1016/0002-9149(81)90314-3; LOPEZSENDON J, 1981, CIRCULATION, V64, P515, DOI 10.1161/01.CIR.64.3.515; LOPEZSENDON J, 1990, J AM COLL CARDIOL, V15, P801, DOI 10.1016/0735-1097(90)90276-U; LOPEZSENDON J, 1985, J AM COLL CARDIOL, V6, P1273, DOI 10.1016/S0735-1097(85)80213-8; LOPEZSENDON J, 1990, AM HEART J, V119, P207, DOI 10.1016/S0002-8703(05)80109-7; LOPEZSENDON J, 1983, AM J CARDIOL, V51, P390, DOI 10.1016/S0002-9149(83)80070-8; LORELL B, 1979, AM J CARDIOL, V43, P465, DOI 10.1016/0002-9149(79)90001-8; LOVE JC, 1984, AM HEART J, V108, P5, DOI 10.1016/0002-8703(84)90537-4; MANNO BV, 1983, J AM COLL CARDIOL, V1, P554, DOI 10.1016/S0735-1097(83)80088-6; MAVRIC Z, 1990, AM HEART J, V119, P823; MCALLISTER RG, 1976, ARCH INTERN MED, V136, P95; MOREYRA AE, 1986, AM J MED, V81, P146, DOI 10.1016/0002-9343(86)90199-3; MOREYRA AE, 1988, CHEST, V94, P197, DOI 10.1378/chest.94.1.197; MORGERA T, 1984, AM HEART J, V108, P13, DOI 10.1016/0002-8703(84)90538-6; PFISTERER M, 1986, EUR HEART J, V7, P289, DOI 10.1093/oxfordjournals.eurheartj.a062066; POLAK JF, 1983, J AM COLL CARDIOL, V2, P217, DOI 10.1016/S0735-1097(83)80156-9; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; RIGO P, 1975, CIRCULATION, V52, P268, DOI 10.1161/01.CIR.52.2.268; ROBALINO BD, 1989, AM HEART J, V118, P138, DOI 10.1016/0002-8703(89)90084-7; ROBERTS N, 1985, AM HEART J, V110, P1047, DOI 10.1016/0002-8703(85)90208-X; Sanders AO, 1931, AM HEART J, V6, P820, DOI 10.1016/S0002-8703(31)90367-0; SCHULER G, 1984, AM J CARDIOL, V54, P951, DOI 10.1016/S0002-9149(84)80124-1; SETARO J F, 1992, Cardiology Clinics, V10, P69; SHARKEY SW, 1985, AM HEART J, V110, P1210, DOI 10.1016/0002-8703(85)90015-8; SHARPE DN, 1978, CIRCULATION, V57, P483, DOI 10.1161/01.CIR.57.3.483; Starr I, 1943, AM HEART J, V26, P291, DOI 10.1016/S0002-8703(43)90325-4; SUGIURA T, 1991, AM J CARDIOL, V67, P1135, DOI 10.1016/0002-9149(91)90879-P; TOBINICK E, 1978, CIRCULATION, V57, P1078, DOI 10.1161/01.CIR.57.6.1078; WADE WG, 1959, BRIT HEART J, V31, P545; WARTMAN WB, 1948, ANN INTERN MED, V28, P41, DOI 10.7326/0003-4819-28-1-41; WEINSHEL AJ, 1983, CIRCULATION, V68, P351; Wilson B C, 1988, Adv Intern Med, V33, P295; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	78	272	291	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1211	1217		10.1056/NEJM199404283301707	http://dx.doi.org/10.1056/NEJM199404283301707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139631				2022-12-28	WOS:A1994NG58600007
J	MATHERS, N; BRAMLEY, M; DRAPER, K; SNEAD, S; TOBERT, A				MATHERS, N; BRAMLEY, M; DRAPER, K; SNEAD, S; TOBERT, A			ASSESSMENT OF TRAINING IN PSYCHOSEXUAL MEDICINE	BRITISH MEDICAL JOURNAL			English	Article								The Institute of Psychosexual Medicine offers training in the treatment of psychosexual problems to medically qualified doctors. Training takes place in fortnightly seminars in which trainees present and discuss real cases. Assessment of cases presented at the beginning and end of the six term basic training showed appreciable improvement in doctors' abilities. The proportion of doctors meeting each of the 14 predetermined clinical objectives rose. Factors which affected the amount of improvement were the initial score, the number of cases presented at the seminars, the occupation of the leader, and the duration of training. Accreditation by the Institute of Psychosexual Medicine was shown to be an appropriate outcome measure for the achievement of the required standards for practising psychosexual medicine.	NO GEN HOSP,PSYCHOSEXUAL PROBLEM CLIN,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; LEWISHAM & N SOUTHWARK HLTH DIST,PSYCHOSEXUAL PROBLEM CLIN,LONDON,ENGLAND; WOLVERHAMPTON HLTH DIST,PSYCHOSEXUAL PROBLEM CLIN,WOLVERHAMPTON,ENGLAND; NOTTINGHAM HLTH DIST,PSYCHOSEXUAL PROBLEM CLIN,NOTTINGHAM,ENGLAND	Northern General Hospital	MATHERS, N (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BACALL H, 1979, HUMAN FACE MED, P132; BRAMLEY HM, 1992, PSYCHOSEXUAL MED STU, P134; COURTENAY MJF, 1973, 6 MINUTES PATIENT IN, P44; CROWE M, 1992, BRIT J HOSP MED, V48, P474; FRIEDMAN LJ, 1962, VIRGIN WIVES, P1; LANOUE JB, 1984, PSYHCOL WOMEN Q, V9, P337; MAIN T, 1989, AILMENT OTHER PSYCHO, P220; MASTERS W, 1975, AM J PSYCHIAT, V133, P548; RENSHAW DC, 1976, S AFR MED J, V50, P1092; SADOCK VA, 1975, AM J PSYCHIAT, V132, P858; SARREL PM, 1982, AM J PUBLIC HEALTH, V72, P839, DOI 10.2105/AJPH.72.8.839; SKRINE R, 1987, PSYCHOSEXUAL TRAININ, P11; SMITH A, 1988, IPM NEWSLETTER, V33, P4; TUNNADINE P, 1970, CONTRACEPTION SEXUAL, P8; 1990, WHAT IS I PSYCHOSEXU, P1	15	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					969	972		10.1136/bmj.308.6934.969	http://dx.doi.org/10.1136/bmj.308.6934.969			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173408	Green Published			2022-12-28	WOS:A1994NF48500024
J	HESS, B; MIKHAILOV, A				HESS, B; MIKHAILOV, A			SELF-ORGANIZATION IN LIVING CELLS	SCIENCE			English	Editorial Material							CALCIUM		MAX PLANCK GESELL,FRITZ HABER INST,D-14195 BERLIN,GERMANY	Max Planck Society; Fritz Haber Institute of the Max Planck Society	HESS, B (corresponding author), MAX PLANCK INST MED RES,JAHNSTR 29,D-69120 HEIDELBERG,GERMANY.							DEBOER RJ, 1993, B MATH BIOL, V55, P745, DOI 10.1016/S0092-8240(05)80188-0; DISSING S, 1993, CELL CALCIUM, V14, P673, DOI 10.1016/0143-4160(93)90093-L; DUPONT G, 1992, BIOPHYS CHEM, V42, P257, DOI 10.1016/0301-4622(92)80018-Z; EIGEN M, IN PRESS P NATL ACAD; FEYNMAN RP, 1963, FEYNMAN LECTURES PHY, V1; GOODWIN BC, 1990, J THEOR BIOL, V144, P303, DOI 10.1016/S0022-5193(05)80078-5; Haken H, 1993, INTERDISCIPLINARY AP; HESS B, 1992, NOVA ACTA LEOPOLDINA, V67, P73; HESSLACHER B, 1993, CHAOS, V3, P7; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LI YX, 1992, BIOPHYS J, V61, P161, DOI 10.1016/S0006-3495(92)81824-6; MANDELKOW E, 1989, SCIENCE, V246, P1291, DOI 10.1126/science.2588005; MANDELKOW E, 1992, CELL MOTIL CYTOSKEL, V21, P235; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MELAMED N, 1993, J NEUROSCI, V13, P632; Nicolis G, 1977, SELF ORG NONEQUILIBR; Pasteels J.M., 1987, INDIVIDUAL COLLECTIV; PESKIN CS, 1993, BIOPHYS J, V65, P325; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; RIGLER R, 1992, FLUORESCENCE SPECTRO, P13; Schrodinger E, 1944, WHAT IS LIFE; SMITH DA, 1994, PROTOPLASMA, V177, P171, DOI 10.1007/BF01378991; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012	25	90	91	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					223	224		10.1126/science.8146651	http://dx.doi.org/10.1126/science.8146651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146651				2022-12-28	WOS:A1994NE41000025
J	SCHMIDT, E; SCHIMMEL, P				SCHMIDT, E; SCHIMMEL, P			MUTATIONAL ISOLATION OF A SIEVE FOR EDITING IN A TRANSFER-RNA SYNTHETASE	SCIENCE			English	Article							RIBONUCLEIC-ACID SYNTHETASE; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; ISOLEUCINE; VALINE; DISCRIMINATION; RECOGNITION; DEACYLATION; MECHANISMS; RESOLUTION	Editing reactions are essential for the high fidelity of information transfer in processes such as replication, RNA splicing, and protein synthesis. The accuracy of interpretation of the genetic code is enhanced by the editing reactions of aminoacyl transfer RNA (tRNA) synthetases, whereby amino acids are prevented from being attached to the wrong tRNAs. Amino acid discrimination is achieved through sieves that may overlap with or coincide with the amino acid binding site. With the class I Escherichia coli isoleucine tRNA synthetase, which activates isoleucine and occasionally misactivates valine, as an example, a rationally chosen mutant enzyme was constructed that lacks entirely its normally strong ability to distinguish valine from isoleucine by the initial amino acid recognition sieve. The misactivated valine, however, is still eliminated by hydrolytic editing reactions. These data suggest that there is a distinct sieve for editing that is functionally independent of the amino acid binding site.			SCHMIDT, E (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BRICK P, 1988, J MOL BIOL, V208, P83; BRUNIE S, 1987, J MOL GRAPHICS, V5, P18, DOI 10.1016/0263-7855(87)80039-5; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; BURBAUM JJ, 1992, PROTEIN SCI, V1, P574; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH U, 1985, ANGEW CHEM INT EDIT, V224, P1015; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; GIEGE R, 1974, EUR J BIOCHEM, V45, P351, DOI 10.1111/j.1432-1033.1974.tb03560.x; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; IACCARINO M, 1971, J BACTERIOL, V105, P527, DOI 10.1128/JB.105.2.527-537.1971; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NORRIS AT, 1964, P NATL ACAD SCI USA, V52, P3300; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SCHMIDT EG, UNPUB; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TREIBER G, 1971, J BACTERIOL, V107, P828, DOI 10.1128/JB.107.3.828-832.1971; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	36	140	143	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					265	267		10.1126/science.8146659	http://dx.doi.org/10.1126/science.8146659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146659				2022-12-28	WOS:A1994NE41000038
J	BARTLEY, TD; HUNT, RW; WELCHER, AA; BOYLE, WJ; PARKER, VP; LINDBERG, RA; LU, HS; COLOMBERO, AM; ELLIOTT, RL; GUTHRIE, BA; HOLST, PL; SKRINE, JD; TOSO, RJ; ZHANG, M; FERNANDEZ, E; TRAIL, G; VARNUM, B; YARDEN, Y; HUNTER, T; FOX, GM				BARTLEY, TD; HUNT, RW; WELCHER, AA; BOYLE, WJ; PARKER, VP; LINDBERG, RA; LU, HS; COLOMBERO, AM; ELLIOTT, RL; GUTHRIE, BA; HOLST, PL; SKRINE, JD; TOSO, RJ; ZHANG, M; FERNANDEZ, E; TRAIL, G; VARNUM, B; YARDEN, Y; HUNTER, T; FOX, GM			B61 IS A LIGAND FOR THE ECK RECEPTOR PROTEIN-TYROSINE KINASE	NATURE			English	Article							CELL	A PROTEIN ligand for the ECK1 receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent. Initially, concentrated cell culture supernatants were screened for receptor binding activity using immobilized ECK-X in a surface plasmon resonance detection system2,3. Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha4. We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK. ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH5, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.	WEIZMANN INST SCI, DEPT CLIN IMMUNOL, IL-76100 REHOVOT, ISRAEL; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA	Weizmann Institute of Science; Salk Institute	BARTLEY, TD (corresponding author), AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA.		YARDEN, YOSEF/K-1467-2012					BOYD AW, 1992, J BIOL CHEM, V267, P3262; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; NIETO MA, 1992, DEVELOPMENT, V116, P1137; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	17	223	242	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					558	560		10.1038/368558a0	http://dx.doi.org/10.1038/368558a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139691				2022-12-28	WOS:A1994NE33500058
J	WITTUNG, P; NIELSEN, PE; BUCHARDT, O; EGHOLM, M; NORDEN, B				WITTUNG, P; NIELSEN, PE; BUCHARDT, O; EGHOLM, M; NORDEN, B			DNA-LIKE DOUBLE HELIX FORMED BY PEPTIDE NUCLEIC-ACID	NATURE			English	Article							RECOGNITION; THYMINE	ALTHOUGH the importance of the nucleobases in the DNA double helix is well understood, the evolutionary significance of the deoxyribose phosphate backbone and the contribution of this chemical entity to the overall helical structure and stability of the double helix is not so clear. Peptide nucleic acid (PNA)1-7 is a DNA analogue with a backbone consisting of N-(2-aminoethyl)glycine units (Fig. 1) which has been shown to mimic DNA in forming Watson-Crick complementary duplexes with normal DNA7. Using circular dichroism spectroscopy we show here that two complementary PNA strands can hybridize to one another to form a helical duplex. There is a seeding of preferred chirality which is induced by the presence of an L- (or D-) lysine residue attached at the carboxy terminus of the PNA strand. These results indicate that a (deoxy)ribose phosphate backbone is not an essential requirement for the formation of double helical DNA-like structures in solution.	PANUM INST,DEPT BIOCHEM B,MED BIOTECHNOL RES CTR,BLEGDAMSVEJ 3C,DK-2200 N COPENHAGEN,DENMARK; CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN; HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK	Chalmers University of Technology; University of Copenhagen			wittung-stafshede, pernilla/AAV-4392-2021; Norden, Bengt/ABE-3675-2020	wittung-stafshede, pernilla/0000-0003-1058-1964; Norden, Bengt/0000-0002-7946-200X; /0000-0001-8771-330X				Cantor C.R., 1980, BIOPHYS CHEM; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; EGHOLM M, 1993, J CHEM SOC CHEM COMM, P800, DOI 10.1039/c39930000800; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; KIM SK, 1993, J AM CHEM SOC, V115, P6477, DOI 10.1021/ja00068a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, ORIGINS LIFE EVOL B, V23, P323, DOI 10.1007/BF01582083; NRODEN B, 1992, REV BIOPHYS, V25, P51; TIBANYENDA N, 1984, EUR J BIOCHEM, V139, P19, DOI 10.1111/j.1432-1033.1984.tb07970.x	12	428	474	1	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					561	563		10.1038/368561a0	http://dx.doi.org/10.1038/368561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139692				2022-12-28	WOS:A1994NE33500059
J	STERN, LJ; BROWN, JH; JARDETZKY, TS; GORGA, JC; URBAN, RG; STROMINGER, JL; WILEY, DC				STERN, LJ; BROWN, JH; JARDETZKY, TS; GORGA, JC; URBAN, RG; STROMINGER, JL; WILEY, DC			CRYSTAL-STRUCTURE OF THE HUMAN CLASS-II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA-VIRUS PEPTIDE	NATURE			English	Article							BINDING; MOLECULES; MOTIFS; IDENTIFICATION; RECOGNITION; EPITOPES; ANTIGEN; HLA-B27; MODELS	An influenza virus peptide binds to HLA-DR1 in an extended conformation with a pronounced twist. Thirty-five per cent of the peptide surface is accessible to solvent and potentially available for interaction with the antigen receptor on T cells. pockets in the peptide-binding site accommodate five of the thirteen side chains of the bound peptide, and explain the peptide specificity of HLA-DR1. Twelve hydrogen bonds between conserved HLA-DR1 residues and the main chain of the peptide provide a universal mode of peptide binding, distinct from the strategy used by class I histocompatibility proteins.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; BRANDEIS UNIV,ROSENSTIEL RES CTR,WALTHAM,MA 02254; CHILDRENS HOSP PITTSBURGH,RANGOS RES CTR,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,PITTSBURGH,PA 15213	Harvard University; Howard Hughes Medical Institute; Harvard University; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BERMAIN RN, 1993, A REV IMMUN, V11, P403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOEHNCKE WH, 1993, J IMMUNOL, V150, P331; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUSCH R, 1991, J IMMUNOL, V147, P1292; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COPPIN HL, 1993, EUR J IMMUNOL, V23, P343, DOI 10.1002/eji.1830230207; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DRISCOLL PC, 1993, J MOL BIOL, V232, P342, DOI 10.1006/jmbi.1993.1394; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GELUK A, 1992, J IMMUNOL, V149, P2864; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREIGER JI, 1991, J IMMUNOL, V146, P2331; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEQUESTEL JY, 1993, J MOL BIOL, V231, P888, DOI 10.1006/jmbi.1993.1335; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MALCHEREK G, 1993, INT IMMUNOL, V5, P1229, DOI 10.1093/intimm/5.10.1229; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NEWTONNASH DK, 1993, J IMMUNOL, V150, P1813; OLSEN AC, IN PRESS EUR J IMMUN; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; OSULLIVAN D, 1991, J IMMUNOL, V146, P1240; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1992, NATURE, V359, P429, DOI 10.1038/359429a0; SETTE A, 1993, J IMMUNOL, V151, P3163; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STEM LJ, 1992, CELL, V68, P465; VERRECK FAW, 1993, EUR J IMMUNOL, V23, P1346, DOI 10.1002/eji.1830230624; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	51	1420	1467	0	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					215	221		10.1038/368215a0	http://dx.doi.org/10.1038/368215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145819				2022-12-28	WOS:A1994NA87000046
J	CHAPEL, HM; COLE, P; GABRIEL, C; MILLA, P; MORGAN, G; SCADDING, G; WINFIELD, D; BRENNAN, V; CARNE, S; EWART, H; HORN, A; JARVIS, F; BROWN, D; HAENEY, M; LEVINSKY, R; THOMPSON, R; WEBSTER, D; WALLINGTON, T				CHAPEL, HM; COLE, P; GABRIEL, C; MILLA, P; MORGAN, G; SCADDING, G; WINFIELD, D; BRENNAN, V; CARNE, S; EWART, H; HORN, A; JARVIS, F; BROWN, D; HAENEY, M; LEVINSKY, R; THOMPSON, R; WEBSTER, D; WALLINGTON, T			CONSENSUS ON DIAGNOSIS AND MANAGEMENT OF PRIMARY ANTIBODY DEFICIENCIES	BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS IMMUNOGLOBULIN; GAMMA-GLOBULIN; HYPOGAMMAGLOBULINEMIA; PROPHYLAXIS; INFUSION; HOME; IGA		NATL HEART & LUNG INST,LONDON,ENGLAND; ST ALBANS HOSP,ST ALBANS,HERTS,ENGLAND; INST CHILD HLTH,LONDON,ENGLAND; ROYAL NATL THROAT NOSE & EAR HOSP,LONDON,ENGLAND; HALLAMSHIRE HOSP,SHEFFIELD,S YORKSHIRE,ENGLAND; ROYAL COLL NURSING UK,IMMUNOL NURSING GRP,LONDON,ENGLAND; ROYAL COLL GEN PRACTITIONERS,LONDON,ENGLAND; DEPT HLTH,LONDON SE1 6TE,ENGLAND; ADDENBROOKES HOSP,CAMBRIDGE,ENGLAND; HOPE HOSP,MANCHESTER,LANCS,ENGLAND; BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM,W MIDLANDS,ENGLAND; ROYAL FREE HOSP,LONDON,ENGLAND; SOUTHMEAD GEN HOSP,BRISTOL,AVON,ENGLAND	Imperial College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Addenbrooke's Hospital; University of Cambridge; Heart of England NHS Foundation Trust; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Southmead Hospital	CHAPEL, HM (corresponding author), JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND.							[Anonymous], DIAGNOSIS TREATMENT; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BJORKANDER J, 1984, EUR J RESPIR DIS, V65, P529; BLORE J, 1989, BRIT MED J, V298, P516, DOI 10.1136/bmj.298.6672.516; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; GARDULF A, 1991, LANCET, V338, P162; GOOI HC, 1990, PROGR IMMUNODEFICIEN, V3, P103; HANSON LA, 1991, CLIN IMMUNOL IMMUNOP, V61, pS70, DOI 10.1016/S0090-1229(05)80040-6; HANSON LA, 1990, PROGR IMMUNE DEFICIE, V3, P1; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; HILL A, 1993, NATURE, V361, P494, DOI 10.1038/361494a0; JERRERIS R, 1990, CLIN EXP IMMUNOL, V81, P357; MISBAH SA, 1993, DRUG SAFETY, V9, P254, DOI 10.2165/00002018-199309040-00003; MITRA G, 1986, TRANSFUSION, V26, P394, DOI 10.1046/j.1537-2995.1986.26486262753.x; ROIFMAN CM, 1987, LANCET, V1, P1075; SPICKETT GP, 1991, LANCET, V337, P281, DOI 10.1016/0140-6736(91)90882-P; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; 1992, IMMUNODEFICIENCY REV, V3, P195; 1991, NEW ENGL J MED, V325, P73	22	92	93	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					581	585		10.1136/bmj.308.6928.581	http://dx.doi.org/10.1136/bmj.308.6928.581			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148684	Green Published			2022-12-28	WOS:A1994MY71400027
J	PATMORE, J; COYLE, S; JONES, R; WIERINGA, G				PATMORE, J; COYLE, S; JONES, R; WIERINGA, G			LESSON OF THE WEEK - HYPERCHOLESTEROLEMIA - NOT ALL CASES WARRANT TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							LIPOPROTEINEMIA; CHOLESTEROL; ASSOCIATION		GEN INFIRM,DEPT CHEM PATHOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT CHEM PATHOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Leeds General Infirmary; University of Leeds; Christie NHS Foundation Trust; Christie Hospital	PATMORE, J (corresponding author), ST JAMES UNIV HOSP,DEPT CHEM PATHOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							CARLSON LA, 1972, ACTA MED SCAND, V192, P29; GLUECK CJ, 1975, METABOLISM, V24, P1243, DOI 10.1016/0026-0495(75)90063-3; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; GUSTAFSON A, 1972, J CLIN ENDOCR METAB, V35, P203, DOI 10.1210/jcem-35-2-203; JOHANSSON BG, 1969, SCAND J CLIN LAB INV, V23, P231, DOI 10.3109/00365516909077654; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; LAKER MF, 1992, J CLIN PATHOL, V45, P102, DOI 10.1136/jcp.45.2.102; NEIL HAW, 1990, BMJ-BRIT MED J, V301, P584, DOI 10.1136/bmj.301.6752.584; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; WARNICK GR, 1990, CLIN CHEM, V36, P15; 1993, BRIT NATIONAL FORMUL, V25, P113; 1988, EUR HEART J, V9, P571	12	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1125	1126		10.1136/bmj.307.6912.1125	http://dx.doi.org/10.1136/bmj.307.6912.1125			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8155122	Green Published, Bronze			2022-12-28	WOS:A1993ME91800023
J	HAMOSH, A; COREY, M				HAMOSH, A; COREY, M			CORRELATION BETWEEN GENOTYPE AND PHENOTYPE IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDUCTANCE REGULATOR CFTR; NONSENSE MUTATION; DELTA-F508 MUTATION; PANCREATIC FUNCTION; EPITHELIAL-CELLS; GENETIC-ANALYSIS; COMMON MUTATION; CLINICAL STATUS; F508 DELETION; MESSENGER-RNA	Background. Cystic fibrosis is the most common lethal autosomal recessive disorder among whites. Seventy-two percent of patients with this disease are homozygotes or compound heterozygotes for eight mutations of the cystic fibrosis transmembrane conductance regulator gene on chromosome 7: DELTAF508, G542X, R553X, W1282X, N1303K, 621+1G-->T, 1717-1G-->A, and R117H. We studied the relation between genotype and phenotype in patients from 14 countries. Methods. Each of 399 patients who were compound heterozygotes for DELTAF508 and one other mutation was matched with the DELTAF508 homozygote of the same sex who was the closest in age from the same center. A paired analysis was performed of the following outcome variables: age at diagnosis, sweat chloride concentration, growth percentiles, pulmonary-function values, chest-film score, pseudomonas colonization, nasal polyps, pancreatic sufficiency, pancreatitis, diabetes mellitus, meconium ileus, distal intestinal obstruction syndrome, rectal prolapse, cirrhosis, and gallbladder disease. Results. The compound heterozygotes having the genotype R117H/DELTAF508 clearly differed from the age- and sex-matched DELTAF508 homozygotes: they more often had pancreatic sufficiency (87 percent vs. 4 percent, P<0.001), were older when the diagnosis was first made (mean [+/-SD] age, 10.2+/-10.5 vs. 2.5+/-4.3 years; P = 0.002), and had lower sweat chloride concentrations (80+/-18 vs. 108+/-14 mmol per liter, P<0.001). There were no statistically significant differences between DELTAF508 homozygotes and other compound heterozygotes with regard to any variable tested. Conclusions. Prenatal and prognostic counseling for patients with the R117H/DELTAF508 genotype should include the likelihood that they will have long-term pancreatic sufficiency. Patients with the other genotypes should expect the early onset of pancreatic insufficiency. For none of the genotypes studied can predictions be made about the occurrence of common complications or the severity or course of pulmonary disease.			HAMOSH, A (corresponding author), JOHNS HOPKINS UNIV HOSP, CMSC 1004, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.		Ferrari, Maurizio/D-9107-2013; Kadasi, Ludevit/A-4677-2013; Dörk, Thilo/J-8620-2012	Dörk, Thilo/0000-0002-9458-0282	NIDDK NIH HHS [DK02151, DK41980, DK44003] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044003, R37DK044003, P50DK041980, K08DK002151] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOS JA, 1992, PEDIATR PULM, P142; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BORGO G, 1990, J MED GENET, V27, P665, DOI 10.1136/jmg.27.11.665; BRASFIELD D, 1979, PEDIATRICS, V63, P24; CAMPBELL PW, 1991, J PEDIATR-US, V118, P239, DOI 10.1016/S0022-3476(05)80490-1; CAMPBELL PW, 1992, J PEDIATR-US, V120, P261, DOI 10.1016/S0022-3476(05)80438-X; CARROLL TP, IN PRESS CELL PHYSL; CHRISPIN AR, 1974, PEDIATR RADIOL, V2, P101, DOI 10.1007/BF01314939; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DORK T, 1991, HUM GENET, V87, P441; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; GASKIN K, 1982, J PEDIATR-US, V100, P857, DOI 10.1016/S0022-3476(82)80501-5; GASPARINI P, 1992, J MED GENET, V29, P558, DOI 10.1136/jmg.29.8.558; HAMOSH A, 1992, AM J HUM GENET, V51, P245; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HAMOSH A, 1993, CYSTIC FIBROSIS CURR, V1, P69; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; OSBORNE L, 1992, HUM GENET, V89, P653, DOI 10.1007/BF00221957; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; SANTIS G, 1992, PEDIATR PULMONOL S8, V14, P239; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SHWACHMAN H, 1958, AMA J DIS CHILD, V96, P6, DOI 10.1001/archpedi.1958.02060060008002; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; 1990, EGRET EPIDEMIOLOGICA; 1988, SAS STAT USERS GUIDE	38	408	413	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1308	1313						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8166795				2022-12-28	WOS:A1993MD55700004
J	GOSTIN, LO; LAZZARINI, Z; ALEXANDER, D; BRANDT, AM; MAYER, KH; SILVERMAN, DC				GOSTIN, LO; LAZZARINI, Z; ALEXANDER, D; BRANDT, AM; MAYER, KH; SILVERMAN, DC			HIV TESTING, COUNSELING, AND PROPHYLAXIS AFTER SEXUAL ASSAULT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; POSTEXPOSURE CHEMOPROPHYLAXIS; ZIDOVUDINE THERAPY; INFECTION; AIDS; RAPE; RISK; TRANSMISSION; ANTIBODY; VICTIMS		AMER SOC LAW MED & ETH, BOSTON, MA USA; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA USA; NATL VICTIM CTR, ARLINGTON, VA USA; MEM HOSP RHODE ISL, PROVIDENCE, RI USA; BROWN UNIV, PROVIDENCE, RI USA	Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Brown University								ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; BAYER R, 1986, JAMA-J AM MED ASSOC, V256, P1768, DOI 10.1001/jama.256.13.1768; BRANDT A, 1987, NO MAGIC BULLET; BRANDT AM, 1993, AIDS LAW TODAY GUIDE, P46; BRANDT AM, 1990, AIDS HLTH CARE SYSTE, P125; Brownmiller, 1975, AGAINST OUR WILL; BURGESS AW, 1974, AM J PSYCHIAT, V131, P981; CAMERON DW, 1988, 4TH INT C AIDS STOCK; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P509; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; EISENSTAT S, 1991, U PITT LAW REV, V52, P327; ESTREICH S, 1990, NEW ENGL J MED, V323, P1141; Estrich S., 1987, REAL RAPE LEGAL SYST; EYSTER EE, 1987, AIDS, V11, P131; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; Fee Elizabeth, 1988, AIDS BURDEN HIST; FISCHL M, 1989, Journal of the American Medical Association, V262, P2405, DOI 10.1001/jama.262.17.2405; FRANZEN C, 1988, 4TH INT C AIDS STOCK; GAINES H, 1987, LANCET, V1, P1249; GELLERT GA, 1989, PEDIATRICS, V83, P644; GELLERT GA, 1989, NEW ENGL J MED, V321, P685; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOSTIN L, 1991, ARCH INTERN MED, V151, P663, DOI 10.1001/archinte.151.4.663; Gostin Larry, 1989, MD Law Rev, V48, P12; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HAMMETT TM, 1990, NCJ124549 AIDS B PUB, P1; HENDERSON DK, 1991, AM J MED, V91, pS312, DOI 10.1016/0002-9343(91)90388-E; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; HOLMES KK, 1970, AM J EPIDEMIOL, V91, P170, DOI 10.1093/oxfordjournals.aje.a121125; HOLMSTROM LL, 1979, FAM COORD, V28, P321, DOI 10.2307/581944; HOOPER RR, 1978, AM J EPIDEMIOL, V108, P136, DOI 10.1093/oxfordjournals.aje.a112597; HORSBURGH CR, 1989, LANCET, V2, P637; JACKSON MH, 1992, AIDS AGENDA EMERGING, P239; JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101; JUDSON FN, 1981, SEX TRANSM DIS, V8, P336; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KILPATRICK DG, 1987, 84IJCX0039 NAT I JUS; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAFON SW, 1990, 30TH INT C ANT AG CH; LEWANDOWSKI C, 1989, 5TH INT C AIDS MONTR; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LIPSCOMB GH, 1992, JAMA-J AM MED ASSOC, V267, P3064, DOI 10.1001/jama.267.22.3064; MCCUUNE JM, 1991, SCIENCE, V247, P564; MORGAN M, 1990, JUDGES J, V29, P22; NACCI PL, 1982, SEX SEXUAL AGGRESSIO; OSTERHOLM MT, 1987, NEW ENGL J MED, V316, P1024; PADIAN N, 1990, CONRAD W S, P25; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN N, 1988, 28TH INT C ANT AG CH; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; SHERMAN R, 1993, NATIONAL LAW J, V15, P28; SHERMAN R, 1993, NATIONAL LAW J, V16, P33; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; SILVERMAN DC, 1978, AM J ORTHOPSYCHIAT, V48, P166, DOI 10.1111/j.1939-0025.1978.tb01298.x; SILVERMAN DC, 1992, MALE VICTIMS SEXUAL, P87; SIMOTAS L, 1991, NEW YORK U LAW REV, V66, P1881; STEIGBIGEL NHJ, 1988, 4TH INT C AIDS STOCK; WEBER JN, 1986, GENITOURIN MED, V62, P177; WHITE PN, 1981, FAM RELAT, V30, P103, DOI 10.2307/584243; ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572; 1991, MMWR MORB MORTAL WKL, V40, P1; 1993, BUREAU JUSTICE S MAR; 1993, CURRENT TRENDS CHILD; 1987, DIAGNOSTIC STATISTIC; 1988, MMWR MORB MORTAL WKL, V37, P377; 1992, CRIME US 1991; 1994, ACTG076 NIH NAT I AL; 1993, RAPE AM REPORT NATIO; 1979, CDC798195 CTR DIS CO; 1988, PEDIATRICS, V81, P595; 1992, WHOGPAINF932 GLOB PR; 1989, MMWR MORB MORTAL WKL, V38, P1; 1988, MMWR MORB MORTAL WKL, V37, P387; 1993, MMWR MORB MORTAL WKL, V42, P1; 1992, TESTING OFFENDERS HU, P1	82	70	70	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1436	1444		10.1001/jama.271.18.1436	http://dx.doi.org/10.1001/jama.271.18.1436			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176804				2022-12-28	WOS:A1994NJ69300032
J	GELPERIN, A				GELPERIN, A			NITRIC-OXIDE MEDIATES NETWORK OSCILLATIONS OF OLFACTORY INTERNEURONS IN A TERRESTRIAL MOLLUSK	NATURE			English	Article							ACTIVATION; MESSENGER; SYNTHASE; RELEASE; BRAIN; RAT	THE interneuronal messenger nitric oxide(1,2) (NO) may play a central role in the processing of olfactory information(3). Several circuit elements in the mammalian olfactory bulb contain NO synthase(4) or its functional equivalent, NADPH diaphorase(5-7). The effects of NO on cellular,excitability or circuit dynamics in the olfactory bulb are unknown, although NO effects on other rhythmic cells(8) and circuits(9) have been described. T have studied the role of NO in central olfactory processing using the procerebral (PC) lobe, the major central site of odour processing in terrestrial molluscs(10,11). As in the mammalian olfactory bulb during odour stimulation, the basic dynamics of electrical activity in the molluscan PC lobe is an oscillation(12-14). Here I report an obligatory role for NO is the oscillatory dynamics of the PC lobe of Limax maximus. Nitric oxide mediation of the olfactory oscillation may relate to the highly developed odour sensitivity and odour-learning ability of Limax(15,16).			GELPERIN, A (corresponding author), AT&T BELL LABS,BIOL COMPUTAT RES DEPT,600 MT AVE,MURRAY HILL,NJ 07974, USA.							ACHE BW, 1991, SMELL TASTE HLTH DIS, P3; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; CARTER TD, 1993, J PHYSIOL-LONDON, V467, pP165; CHASE R, 1989, J COMP NEUROL, V283, P143, DOI 10.1002/cne.902830112; CHASE R, 1993, J ELECTRON MICR TECH, V24, P214; COOKE IRC, IN PRESS CELL TISS R; CROULOTTMAN CE, 1988, BRAIN RES, V460, P323, DOI 10.1016/0006-8993(88)90376-9; DAVIS BJ, 1991, J COMP NEUROL, V314, P493, DOI 10.1002/cne.903140307; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; ELOFSSON R, 1993, NEUROREPORT, V4, P279, DOI 10.1097/00001756-199303000-00013; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GELPERIN A, 1993, J NEUROPHYSIOL, V69, P1930, DOI 10.1152/jn.1993.69.6.1930; GELPERIN A, 1989, PERSPECTIVES NEURAL, P121; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MOROZ LL, 1993, NEUROREPORT, V4, P643, DOI 10.1097/00001756-199306000-00010; NIKOLSKII AB, 1976, SOVIET J COORD CHEM, V2, P508; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; RHINES LD, 1993, J NEUROPHYSIOL, V69, P1940, DOI 10.1152/jn.1993.69.6.1940; SAHLEY CL, 1990, CONNECTIONIST MODELI, P36; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	28	203	204	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					61	63		10.1038/369061a0	http://dx.doi.org/10.1038/369061a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164740				2022-12-28	WOS:A1994NJ86000053
J	KAGI, D; LEDERMANN, B; BURKI, K; SEILER, P; ODERMATT, B; OLSEN, KJ; PODACK, ER; ZINKERNAGEL, RM; HENGARTNER, H				KAGI, D; LEDERMANN, B; BURKI, K; SEILER, P; ODERMATT, B; OLSEN, KJ; PODACK, ER; ZINKERNAGEL, RM; HENGARTNER, H			CYTOTOXICITY MEDIATED BY T-CELLS AND NATURAL-KILLER-CELLS IS GREATLY IMPAIRED IN PERFORIN DEFICIENT MICE	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PORE-FORMING PROTEIN; SERINE PROTEASES; CYTO-TOXICITY; TARGET-CELLS; STEM-CELLS; INVIVO; EXPRESSION; INFECTION; GRANULES	Perforin-deficient mice have been generated by homologous recombination to determine whether the effects of CD8(+) cytolytic T cells and natural killer cells are mediated by pore formation involving perforin. These mice are viable and fertile and have normal numbers of CD8(+) T cells and natural killer cells which do not lyse virus-infected or allogeneic fibroblasts or natural killer target cells in vitro. The mice fail to clear lymphocytic choriomeningitis virus and they eliminate fibrosarcoma tumour cells with reduced efficiency. Perforin is therefore a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND; UNIV MIAMI, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA	Novartis; Sandoz; University of Miami	KAGI, D (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND.							ACHAORBEA H, 1990, EMBO J, V9, P3815, DOI 10.1002/j.1460-2075.1990.tb07599.x; BAENZIGER J, 1988, SCAND J IMMUNOL, V28, P411, DOI 10.1111/j.1365-3083.1988.tb01470.x; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERKE G, 1987, TRANSPLANT P, V19, P412; BINDER D, 1991, J IMMUNOL, V146, P4301; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DENNERT G, 1983, J EXP MED, V157, P1483, DOI 10.1084/jem.157.5.1483; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; GARCIASANZ JA, 1987, EMBO J, V6, P933, DOI 10.1002/j.1460-2075.1987.tb04841.x; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOWELL DM, 1987, J IMMUNOL, V138, P3695; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; KAWASAKI A, 1992, EUR J IMMUNOL, V22, P1215, DOI 10.1002/eji.1830220516; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; KOHLER M, 1990, CANCER IMMUNOL IMMUN, V32, P117, DOI 10.1007/BF01754208; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x; LEHMANNGRUBE F, 1993, J VIROL, V67, P332, DOI 10.1128/JVI.67.1.332-339.1993; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; MULLER C, 1989, EUR J IMMUNOL, V19, P1253, DOI 10.1002/eji.1830190716; MULLER D, 1992, SCIENCE, V255, P1576, DOI 10.1126/science.1347959; PARR EL, 1990, J IMMUNOL, V145, P2365; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; PODACK ER, 1988, IMMUNOL REV, V103, P203, DOI 10.1111/j.1600-065X.1988.tb00756.x; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SELLINS KS, 1991, J IMMUNOL, V147, P795; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRAPANI JA, 1990, J EXP MED, V171, P545, DOI 10.1084/jem.171.2.545; YOUN BS, 1991, J EXP MED, V173, P813, DOI 10.1084/jem.173.4.813; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3; YOUNG LHY, 1990, LANCET, V336, P1019, DOI 10.1016/0140-6736(90)92486-2; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075	49	1511	1536	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 5	1994	369	6475					31	37		10.1038/369031a0	http://dx.doi.org/10.1038/369031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164737				2022-12-28	WOS:A1994NJ86000043
J	CALLAHAN, CM; DRAKE, BG; HECK, DA; DITTUS, RS				CALLAHAN, CM; DRAKE, BG; HECK, DA; DITTUS, RS			PATIENT OUTCOMES FOLLOWING TRICOMPARTMENTAL TOTAL KNEE REPLACEMENT - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ROENTGEN STEREOPHOTOGRAMMETRIC ANALYSIS; CONTINUOUS PASSIVE MOTION; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; CONDYLAR PROSTHESIS; TIBIAL COMPONENTS; MILLER-GALANTE; ARTHROPLASTY; 2-YEAR; JOINT	Objective.-To provide estimates of patient outcomes following tricompartmental knee replacement and to examine variation in outcomes due to patient and prosthesis characteristics. Data Sources.-English-language articles identified through a computerized literature search and bibliography review. Study Selection.-Studies were included it they enrolled 10 or more patients at the time of initial knee replacement and measured patient outcomes using a global knee-rating scale. Data Extraction.-Each study was subjected to a blinded qualitative assessment and unblinded abstraction of patient characteristics, surgical techniques, and outcomes. Data Synthesis.-A total of 130 studies reporting patient outcomes on 154 cohorts satisfied inclusion criteria. The total number of enrolled patients was 9879 with a mean enrollment of 64.1 patients. The mean follow-up was 4.1 years. The mean patient age was 65.0 years, 71.7% of patients were women, 62.6% had osteoarthritis, and 26.6% underwent bilateral knee replacement. Global rating scale scores improved by 100% for the typical enrolled patient, and 89.3% of patients reported good or excellent outcomes. Anatomic classification of the prosthesis, percentage of enrolled patients with osteoarthritis, publication year, and number of enrolled patients explained 27% of the variation in reported mean postoperative global rating scale scores. The weighted mean complication rate was 18.1%, and the mean mortality rate per year of follow-up was 1.5%. The overall rate of revision during 4.1 years was 3.8%. Conclusions.-Tricompartmental knee replacement was a safe and effective procedure for the patients reported in these studies. The knee pathology and the type of prosthesis were significant predictors of outcomes. Limitations in the reporting style of these articles severely constrain the ability to explore variation in outcomes due to study, patient, or prosthesis characteristics and restrict their generalizability.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT ORTHOPAED SURG, INDIANAPOLIS, IN USA; RICHARD L ROUDEBUSH VET ADM MED CTR, INDIANAPOLIS, IN USA; INDIANA UNIV, SCH MED, BOWEN RES CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, SCH PUBL & ENVIRONM AFFAIRS, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	CALLAHAN, CM (corresponding author), INDIANA UNIV, SCH MED, REGENSTRIEF INST HLTH CARE, RG5, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.				NIA NIH HHS [KO8 AG00538-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGLIETTI P, 1988, J BONE JOINT SURG BR, V70, P211, DOI 10.1302/0301-620X.70B2.3346290; Aglietti P, 1989, J Arthroplasty, V4, P1, DOI 10.1016/S0883-5403(89)80046-4; Aglietti P, 1988, J Arthroplasty, V3, P17, DOI 10.1016/S0883-5403(88)80049-4; Aglietti P, 1991, J Arthroplasty, V6, P287, DOI 10.1016/S0883-5403(06)80178-6; AGLIETTI P, 1984, CLIN ORTHOP RELAT R, P104; AGLIETTI P, 1986, Italian Journal of Orthopaedics and Traumatology, V12, P275; AGLIETTI P, 1981, Italian Journal of Orthopaedics and Traumatology, V7, P17; Aglietti P, 1977, Ital J Orthop Traumatol, V3, P139; ALBREKTSSON BEJ, 1990, J BONE JOINT SURG BR, V72, P252, DOI 10.1302/0301-620X.72B2.2312565; Altchek D, 1989, J Arthroplasty, V4, P151, DOI 10.1016/S0883-5403(89)80068-3; APEL DM, 1991, CLIN ORTHOP RELAT R, V273, P248; Armstrong R A, 1991, J Arthroplasty, V6, P357, DOI 10.1016/S0883-5403(06)80188-9; BECKER MW, 1991, CLIN ORTHOP RELAT R, V271, P122; BERGMAN NR, 1991, CLIN ORTHOP RELAT R, V273, P77; BERMAN AT, 1987, J BONE JOINT SURG AM, V69A, P1340; BERMAN AT, 1991, CLIN ORTHOP RELAT R, V271, P106; Binazzi R, 1992, J Arthroplasty, V7, P145, DOI 10.1016/0883-5403(92)90007-D; BOURNE MH, 1988, CLIN ORTHOP RELAT R, P129; Bourne R B, 1987, J Arthroplasty, V2, P285, DOI 10.1016/S0883-5403(87)80061-X; BRINKER MR, 1990, ORTHOPEDICS, V13, P831; Brugioni D J, 1990, J Arthroplasty, V5, P173, DOI 10.1016/S0883-5403(06)80237-8; CAMERON H, 1982, CLIN ORTHOP RELAT R, V165, P197; Cameron H U, 1988, Orthop Rev, V17, P983; CAMERON HU, 1991, CAN J SURG, V34, P49; CHEKOFSKY KM, 1980, NEW YORK STATE J MED, V80, P36; CHENG CL, 1988, J BONE JOINT SURG BR, V70, P377, DOI 10.1302/0301-620X.70B3.3372556; Chotivichit A L, 1991, J Arthroplasty, V6, P341, DOI 10.1016/S0883-5403(06)80186-5; Cohn B T, 1990, Orthop Rev, V19, P451; COLLINS DN, 1991, CLIN ORTHOP RELAT R, V267, P128; DENNIS DA, 1992, CLIN ORTHOP RELAT R, V281, P168; DODD CAF, 1990, CLIN ORTHOP RELAT R, V260, P66; DONALDSON WF, 1988, CLIN ORTHOP RELAT R, V226, P21; Dorr LD, 1986, CLIN ORTHOP RELAT R, V205, P153; DORR LD, 1988, CLIN ORTHOP RELAT R, V236, P36; DRAKE BG, IN PRESS J ARTHROPLA; Ebert F R, 1992, J Arthroplasty, V7, P101, DOI 10.1016/0883-5403(92)90039-S; ECKER ML, 1987, CLIN ORTHOP RELAT R, V216, P151; ENGH GA, 1988, ORTHOPEDICS, V11, P725; EWALD FC, 1984, J BONE JOINT SURG AM, V66A, P1032, DOI 10.2106/00004623-198466070-00009; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FIGGIE HE, 1986, J BONE JOINT SURG AM, V68A, P1035, DOI 10.2106/00004623-198668070-00009; FIRESTONE TP, 1991, CLIN ORTHOP RELAT R, V273, P184; FONTANESI G, 1988, Italian Journal of Orthopaedics and Traumatology, V14, P41; FREEMAN MAR, 1977, J BONE JOINT SURG BR, V59, P64, DOI 10.1302/0301-620X.59B1.845230; FREEMAN MAR, 1973, CLIN ORTHOP RELAT R, V94, P153; GALLANNAUGH C, 1992, CLIN ORTHOPAEDICS, V281, P177; GARTLAND JJ, 1988, J BONE JOINT SURG AM, V70A, P1357, DOI 10.2106/00004623-198870090-00013; GOLDBERG VM, 1980, J BONE JOINT SURG AM, V62, P1338, DOI 10.2106/00004623-198062080-00014; GOLDBERG VM, 1988, J BONE JOINT SURG AM, V70A, P802, DOI 10.2106/00004623-198870060-00002; GORE DR, 1986, ORTHOPEDICS, V9, P1363; GROH GI, 1991, CLIN ORTHOP RELAT R, V269, P58; HARRIS WH, 1990, NEW ENGL J MED, V323, P801, DOI 10.1056/NEJM199009203231206; Heck D A, 1992, J Arthroplasty, V7, P93, DOI 10.1016/0883-5403(92)90038-R; HEYWOOD AWB, 1980, S AFR MED J, V57, P272; HOFMANN AA, 1991, CLIN ORTHOP RELAT R, V271, P28; HOFMANN AA, 1991, CLIN ORTHOP RELAT R, V269, P78; HOHL WM, 1991, CLIN ORTHOP RELAT R, P91; HUNGERFORD D S, 1989, Orthopedic Clinics of North America, V20, P131; HUNGERFORD DS, 1985, CLIN ORTHOP RELAT R, P23; HUNGERFORD DS, 1982, ORTHOP CLIN N AM, V13, P103; HVID I, 1988, ACTA ORTHOP SCAND, V59, P567, DOI 10.3109/17453678809148787; Hvid I, 1987, J Arthroplasty, V2, P233, DOI 10.1016/S0883-5403(87)80043-8; INSALL J, 1979, J BONE JOINT SURG AM, V61, P173, DOI 10.2106/00004623-197961020-00003; INSALL J, 1979, CLIN ORTHOP RELAT R, V145, P68; INSALL JN, 1983, J BONE JOINT SURG AM, V65, P619, DOI 10.2106/00004623-198365050-00006; INSALL JN, 1982, J BONE JOINT SURG AM, V64, P1317, DOI 10.2106/00004623-198264090-00006; INSALL JN, 1984, CLIN ORTHOP RELAT R, V92, P13; JOSEPH J, 1990, ORTHOPEDICS, V13, P511; Kavolus C H, 1991, J Arthroplasty, V6, P39, DOI 10.1016/S0883-5403(06)80155-5; KAVOLUS CH, 1991, CLIN ORTHOP RELAT R, P170; KEBLISH PA, 1991, CLIN ORTHOP RELAT R, P52; KIM YH, 1988, J BONE JOINT SURG AM, V70A, P1322, DOI 10.2106/00004623-198870090-00008; KIM YH, 1990, J BONE JOINT SURG BR, V72, P412, DOI 10.1302/0301-620X.72B3.2341439; KJAERSGAARDANDE.P, 1989, CLIN ORTHOP RELAT R, V238, P167; KRAAY MJ, 1991, CLIN ORTHOP RELAT R, V273, P32; KRACKOW KA, 1991, CLIN ORTHOP RELAT R, P9; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LANDON GC, 1985, CLIN ORTHOP RELAT R, V192, P69; LANDON GC, 1986, CLIN ORTHOP RELAT R, V205, P49; Laskin R S, 1988, J Arthroplasty, V3, P27, DOI 10.1016/S0883-5403(88)80050-0; LASKIN RS, 1990, J BONE JOINT SURG AM, V72A, P529, DOI 10.2106/00004623-199072040-00009; LASKIN RS, 1984, REPLACEMENT KNEE; LEE JG, 1990, CLIN ORTHOP RELAT R, P87, DOI 10.1097/00003086-199011000-00016; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MALLORY TH, 1982, CLIN ORTHOP RELAT R, P197; MALONEY WJ, 1990, CLIN ORTHOP RELAT R, P162; MALONEY WJ, 1992, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086-199205000-00024; Mendenhall S, 1989, Healthc Financ Manage, V43, P48; MORAN, 1991, J BONE JOINT SURG AM, V73A, P1274; MORAN CG, 1991, J BONE JOINT SURG AM, V73A, P848, DOI 10.2106/00004623-199173060-00007; MURRAY DG, 1981, J BONE JOINT SURG AM, V63, P687, DOI 10.2106/00004623-198163050-00001; NAFEI A, 1992, J BONE JOINT SURG BR, V74, P243, DOI 10.1302/0301-620X.74B2.1544961; Nielsen P T, 1992, J Arthroplasty, V7, P137, DOI 10.1016/0883-5403(92)90006-C; NIELSEN PT, 1988, ACTA ORTHOP SCAND, V59, P580, DOI 10.3109/17453678809148789; NIELSEN S, 1985, ARCH ORTHOP TRAUM SU, V104, P227, DOI 10.1007/BF00450215; Nilsson K G, 1991, J Arthroplasty, V6, P265, DOI 10.1016/S0883-5403(06)80174-9; NILSSON KG, 1992, ACTA ORTHOP SCAND, V63, P159, DOI 10.3109/17453679209154814; NILSSON KG, 1990, CLIN ORTHOP RELAT R, P147; NILSSON KG, 1991, ACTA ORTHOP SCAND, V62, P440, DOI 10.3109/17453679108996640; OGLESBY JW, 1984, CLIN ORTHOP RELAT R, V186, P96; Orwin RG, 1983, J ED STAT, V8, P157, DOI [DOI 10.2307/1164923, 10.3102/10769986008002157]; PETERS PC, 1992, J BONE JOINT SURG AM, V74A, P864, DOI 10.2106/00004623-199274060-00007; PICETTI GD, 1990, J BONE JOINT SURG AM, V72A, P1379, DOI 10.2106/00004623-199072090-00017; Ranawat C S, 1984, Instr Course Lect, V33, P412; RANAWAT CS, 1986, CLIN ORTHOP RELAT R, P93; RANAWAT CS, 1988, CLIN ORTHOP RELAT R, P6; RANAWAT CS, 1984, INT ORTHOP, V8, P61, DOI 10.1007/BF00267742; RANAWAT CS, 1989, ORTHOP CLIN N AM, V20, P63; RANAWAT CS, 1989, CLIN EXP RHEUMATOL, V7, pS149; RANAWAT CS, 1989, CLIN ORTHOP RELAT R, V248, P27; RAND JA, 1991, CLIN ORTHOP RELAT R, V273, P52; RAND JA, 1990, CLIN ORTHOP RELAT R, V260, P110; RITTER MA, 1984, CLIN ORTHOP RELAT R, V184, P264; RITTER MA, 1981, CLIN ORTHOP RELAT R, V160, P149; RITTER MA, 1991, CLIN ORTHOP RELAT R, V267, P108; RORABECK CH, 1988, J BONE JOINT SURG AM, V70A, P483, DOI 10.2106/00004623-198870040-00002; RUTLEDGE R, 1986, CLIN ORTHOP RELAT R, P146; RYD L, 1986, ACTA ORTHOP SCAND, V57, P3, DOI 10.3109/17453678609157924; RYD L, 1987, ARCH ORTHOP TRAUM SU, V106, P82, DOI 10.1007/BF00435419; Ryd L., 1990, CLIN ORTHOP RELAT R, V251, P189; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SAMUELSON K, 1990, CLIN ORTHOP RELAT R, P93, DOI 10.1097/00003086-199011000-00017; SCHNEIDER R, 1986, SEMIN ROENTGENOL, V21, P29, DOI 10.1016/0037-198X(86)90007-6; SCOTT WN, 1988, J BONE JOINT SURG AM, V70A, P1163, DOI 10.2106/00004623-198870080-00007; SCOTT WN, 1982, ORTHOP CLIN N AM, V13, P131; SCOTT WN, 1986, CLIN ORTHOP RELAT R, P138; SCUDERI GR, 1989, CLIN ORTHOP RELAT R, V248, P93; SHAW JA, 1989, ORTHOPEDICS, V12, P647; SNEPPEN O, 1985, INT ORTHOP, V9, P65, DOI 10.1007/BF00267040; STERN SH, 1990, J BONE JOINT SURG AM, V72A, P1400, DOI 10.2106/00004623-199072090-00020; STERN SH, 1992, J BONE JOINT SURG AM, V74A, P980, DOI 10.2106/00004623-199274070-00004; STERN SH, 1991, CLIN ORTHOP RELAT R, V273, P5; STUCHIN SA, 1985, B HOSP JOINT DIS ORT, V45, P133; TAUBER C, 1986, ARCH ORTHOP TRAUM SU, V104, P352, DOI 10.1007/BF00454429; TEENY SM, 1991, CLIN ORTHOP RELAT R, V273, P19; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; TOWNLEY CO, 1988, CLIN ORTHOP RELAT R, P8; VINCE KG, 1989, J BONE JOINT SURG BR, V71, P793, DOI 10.1302/0301-620X.71B5.2584249; WASILEWSKI SA, 1990, ORTHOPEDICS, V13, P291; WHITESIDE LA, 1989, ORTHOP CLIN N AM, V20, P113; WRIGHT J, 1990, J BONE JOINT SURG AM, V72A, P1003, DOI 10.2106/00004623-199072070-00007; WRIGHT RJ, 1990, CLIN ORTHOP RELAT R, V260, P80; YAMAMOTO S, 1979, CLIN ORTHOP RELAT R, P60; YAMAMOTO S, 1989, J BONE JOINT SURG BR, V71, P505, DOI 10.1302/0301-620X.71B3.2722948; Yamamoto S, 1981, Ryumachi, V21 Suppl, P21; YELIN E, 1987, J RHEUMATOL, V14, P710; 1989, VITAL STATISTICS US	147	370	378	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1349	1357		10.1001/jama.271.17.1349	http://dx.doi.org/10.1001/jama.271.17.1349			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158821				2022-12-28	WOS:A1994NH48700028
J	ESTAGNASIE, P; LEBOURDELLES, GL; MIER, L; COSTE, F; DREYFUSS, D				ESTAGNASIE, P; LEBOURDELLES, GL; MIER, L; COSTE, F; DREYFUSS, D			USE OF INHALED NITRIC-OXIDE TO REVERSE FLOW-THROUGH A PATENT FORAMEN OVALE DURING PULMONARY-EMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Note							OVALE		HOP LOUIS MOURIER, SERV REANIMAT MED, F-75018 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite								BRIDGES ND, 1992, CIRCULATION, V86, P1902, DOI 10.1161/01.CIR.86.6.1902; DANTZKER DR, 1982, CHEST, V81, P495, DOI 10.1378/chest.81.4.495; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; HARPAZ D, 1991, CARDIOVASCULAR IMAGI, V3, P251; HART RG, 1992, LANCET, V339, P589, DOI 10.1016/0140-6736(92)90873-2; KONSTADT SN, 1991, ANESTHESIOLOGY, V74, P212, DOI 10.1097/00000542-199102000-00003; MILLER GAH, 1971, BRIT MED J, V2, P681, DOI 10.1136/bmj.2.5763.681; MOSER KM, 1988, TXB RESPIRATORY MED, P1299; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1993, CIRCULATION, V87, P447, DOI 10.1161/01.CIR.87.2.447; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605	11	40	41	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					757	759		10.7326/0003-4819-120-9-199405010-00007	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147549				2022-12-28	WOS:A1994NH25100007
J	CHARLTON, BG; CALVERT, N; WHITE, M; RYE, GP; CONRAD, W; VANZWANENBERG, T				CHARLTON, BG; CALVERT, N; WHITE, M; RYE, GP; CONRAD, W; VANZWANENBERG, T			HEALTH PROMOTION PRIORITIES FOR GENERAL-PRACTICE - CONSTRUCTING AND USING INDICATIVE PREVALENCES	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; OXFORDSHIRE; COMMUNITY; ENGLAND; ANGINA	Objective-To construct indicative prevalences for a range of diseases and risk markers and use them in planning health promotion interventions in primary health care. Design-Indicative prevalences comprised point prevalence, incidence, and mortality measures. Use of data from Office of Population Censuses and Surveys, Northern Regional Health Authority, and Newcastle health and lifestyle survey 1991, and research papers to determine prevalence adjusted for age and sex in a hypothetical practice with a list of 10 000 patients. Setting-Newcastle upon Tyne, England. Results-Indicative prevalences were highest for common risk markers such as failure to achieve exercise targets (6871), moderate to extreme obesity (2785), and smoking (2689); moderate for overt disease such as angina (175) and stroke (20/year); and low for events such as suicide (1/year) and deaths from malignant melanoma (2/10 years). Conclusions-Given limited time and resources, brief interventions to reduce smoking and the systematic case finding and management of patients with hypertension, angina, and previous myocardial infarction are likely to be the highest priorities for health promotion in primary care.	NO REG HLTH AUTHOR,NEWCASTLE TYNE NE6 4PY,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; CONRAD & RYE,NEWCASTLE TYNE NE2 1PQ,ENGLAND	Newcastle University - UK			White, Martin J. R./G-2410-2010					BAIN J, 1990, BRIT MED J, V300, P1183; BAIN J, 1990, BRIT MED J, V300, P1247; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; CANNON PJ, 1988, LANCET, V1, P979; CHISHOLM JW, 1990, BRIT MED J, V300, P853, DOI 10.1136/bmj.300.6728.853; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; FOWLER G, 1990, BMJ-BRIT MED J, V300, P1318, DOI 10.1136/bmj.300.6735.1318; FOWLER G, 1993, BRIT J GEN PRACT, V43, P78; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE; GILLAM SJ, 1992, BRIT J GEN PRACT, V42, P54; Gore, 1987, HLTH LIFESTYLE SURVE; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; HARRINGTON B, 1993, HLTH LIFESTYLE NEWCA; Hart, 1988, NEW KIND DOCTOR; HART JT, 1991, BMJ-BRIT MED J, V302, P1509, DOI 10.1136/bmj.302.6791.1509; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KELLY MP, 1992, BRIT J GEN PRACT, V42, P223; MANT D, 1994, BRIT J GEN PRACT, V44, P51; MANT D, 1985, LANCET, V1, P1114; Mausner J, 1985, EPIDEMIOLOGY INTRO T; PARIS JAG, 1992, PUBLIC HEALTH, V106, P357, DOI 10.1016/S0033-3506(05)80184-2; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STOTT N, 1994, BRIT MED J, V308, P284; UNDERWOOD MJ, 1994, BMJ-BRIT MED J, V308, P71, DOI 10.1136/bmj.308.6921.71; WADE DT, 1992, EPIDEMIOLOGICALLY BA, V3; WHITE M, 1993, NEWCASTLE HLTH LIFES; 1992, PUBLIC HLTH COMMON D, V1; 1989, GENERAL PRACTICE NAT; 1993, FHSL 93 25 GP CONTRA; 1994, BRIT MED J, V308, P313; 1977, INT CLASSIFICATION D; 1992, HLTH NATION; 1994, BRIT MED J, V308, P308; 1992, ALLIED DUNBAR NATION; 1992, THATS LIMIT GUIDE SE; 1993, 1991 CENSUS COUNTY R; 1993, ANN REPORT SEXUALLY	40	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1019	1022		10.1136/bmj.308.6935.1019	http://dx.doi.org/10.1136/bmj.308.6935.1019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167515	Green Published			2022-12-28	WOS:A1994NH08900022
J	LUNDGREN, JD; PHILLIPS, AN; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; BLOEMKOLK, D; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; GATELL, J; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; LEDERGERBER, B; OLSSON, K; GLAUSER, M; HIRSCHEL, B; JOHNSON, A; HAWKES, S; PHILLIPS, A; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D; GJPRUP, I; NIELSEN, J; NIEPORT, C; TEGLBJAERG, L; THORNVAL, A				LUNDGREN, JD; PHILLIPS, AN; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; BLOEMKOLK, D; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; GATELL, J; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; LEDERGERBER, B; OLSSON, K; GLAUSER, M; HIRSCHEL, B; JOHNSON, A; HAWKES, S; PHILLIPS, A; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D; GJPRUP, I; NIELSEN, J; NIEPORT, C; TEGLBJAERG, L; THORNVAL, A			COMPARISON OF LONG-TERM PROGNOSIS OF PATIENTS WITH AIDS TREATED AND NOT TREATED WITH ZIDOVUDINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SURVIVAL; EFFICACY; COMPLEX; AZT	Objective.-To determine the association between elapsed time since starting zidovudine and survival in patients with acquired immunodeficiency syndrome (AIDS). Design.-Inception cohort and observational study of patients treated and not treated with zidovudine. Setting.-Fifty-one centers in 17 European countries. Patients.-A total of 4484 patients diagnosed as having AIDS from 1979 to 1989 who survived their initial AIDS-defining event and who had not started zidovudine before AIDS diagnosis. Main Outcome Measures.-Use of zidovudine and mortality. Results.-Among patients who did not receive zidovudine, the death rate was approximately constant for the first 5 years after AIDS diagnosis. For patients treated with zidovudine, the death rate within the first year since starting zidovudine was markedly lower than for untreated patients who had developed AIDS at the same time (relative rate, 0.47; 95% confidence interval [CI], 0.42 to 0.51). For longer times since starting zidovudine, the association with reduced mortality rate was diminished, and for patients surviving more than 2 years since starting zidovudine, the death rate was greater than for untreated patients who had developed AIDS at the same time (relative rate, 1.35; 95% CI, 1.15 to 1.58). Adjustment for other prognostic factors failed to substantially affect this observation. Conclusions.-When initiated after the time of AIDS diagnosis, zidovudine was associated with improved prognosis but for no more than 2 years after starting therapy.	UNIV LONDON UNIV COLL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON WC1E 6BT, ENGLAND; HOP ST PIERRE & ERASME, DIV INFECT DIS, B-1000 BRUSSELS, BELGIUM; CLIN & PROVINCIAL BARCELONA, INFECT DIS UNIT, BARCELONA, SPAIN; SWISS HIV COHORT STUDY, ZURICH, SWITZERLAND; IST SUPER SANITA, CTR OPERATIVO AIDS, VIROL LAB, I-00161 ROME, ITALY; FREDERIKSBERG UNIV HOSP, DK-2000 COPENHAGEN, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; UNIV HELSINKI, CENT HOSP, SF-00100 HELSINKI 10, FINLAND; HOSP PITIE SALPETRIERE, PARIS, FRANCE; BERNHARD NOCHT INST TROP MED, W-2000 HAMBURG 4, GERMANY; MED POLIKLIN MUNICH, MUNICH, GERMANY; ATHENS GEN HOSP, ATHENS, GREECE; FIRST IKA HOSP, ATHENS, GREECE; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY; ST JAMES HOSP, DUBLIN 8, IRELAND; ICHILOV HOSP, IL-64239 TEL AVIV, ISRAEL; RAMBAM MED CTR, HAIFA, ISRAEL; HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL; UNIV ANCONA, I-60100 ANCONA, ITALY; OSPED CIVILE, PADUA, INDIA; ARCISPEDALE S MARIA NUOVA, REGGIO EMILIA, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED INFERMI, RIMINI, ITALY; OSPED CASA DEL SOLE, PALERMO, ITALY; OSPED CIVILE, VICENZA, ITALY; OORR BERGAMO, BERGAMO, ITALY; OSPED INFERMI, FAENZA, ITALY; OSPED RIUNITI PARMA, PARMA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED S ANDREA, LA SPEZIA, ITALY; UNIV CATANIA, I-95124 CATANIA, ITALY; UNIV CATTOLICA SACRO CUORE, I-00168 ROME, ITALY; UNIV SASSARI, I-07100 SASSARI, ITALY; POLICLIN MONTELUCE, PERUGIA, ITALY; OSPED GALLIERA, GENOA, ITALY; OSPED S MARIA CROCI, RAVENNA, ITALY; OSPED MAGGIORE NOVARA, NOVARA, ITALY; OSPED S MARIA MADDALENA, TRIESTE, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; CTR HOSP LUXEMBOURG, LUXEMBOURG, LUXEMBOURG; UNIV AMSTERDAM, ACAD ZIEKENHUIS, AMSTERDAM, NETHERLANDS; HOSP SANTA MARIA, LISBON, PORTUGAL; HOSP CURRY CABRAL, LISBON, PORTUGAL; INST CARLOS III, MADRID, SPAIN; HOSP GERMANS TRIAS & PUJOL, BARCELONA, SPAIN; HOSP CLIN BARCELONA, BARCELONA 36, SPAIN; KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; UNIV GENEVA, HOP CANTONAL, CH-1211 GENEVA 4, SWITZERLAND; UNIV LONDON UNIV COLL, SCH MED, LONDON WC1E 6BT, ENGLAND; CHELSEA & WESTMINSTER HOSP, ST STEPHENS CLIN, LONDON, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND	University of London; University College London; UCL Medical School; Universite Libre de Bruxelles; Istituto Superiore di Sanita (ISS); Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Bernhard Nocht Institut fur Tropenmedizin; Trinity College Dublin; Tel Aviv University; Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Marche Polytechnic University; IRCCS Arcispedale S. Maria Nuova; University of Milan; Luigi Sacco Hospital; Hospital of Rimini; Hospital of Rimini; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Milan; Luigi Sacco Hospital; University of Catania; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sassari; Ente Ospedaliero Ospedali Galliera; Luxembourg Hospital Center; University of Amsterdam; Universidade de Lisboa; Hospital Santa Maria; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Clinic de Barcelona; Karolinska Institutet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of London; University College London; UCL Medical School; Imperial College London; Imperial College London	LUNDGREN, JD (corresponding author), UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT INFECT DIS 144, COORDINATING CTR AIDS EUROPE, DK-2650 HVIDOVRE, DENMARK.		VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; VALLET, Yannick/F-9979-2011; Phillips, Andrew N/B-4427-2008; Lundgren, Jens/AAE-6876-2019; Ledergerber, Bruno/B-5656-2009; Stergiou, George/J-3083-2019; VELLA, STEFANO/D-4912-2015	Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; Stergiou, George/0000-0002-6132-0038; Johnson, Anne/0000-0003-1330-7100; Lundgren, Jens/0000-0001-8901-7850; VELLA, STEFANO/0000-0003-2347-5984				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUNDGREN JD, 1979, IN PRESS BMJ; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR MORB MORTAL S1, V36, P3	14	77	77	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1088	1092		10.1001/jama.271.14.1088	http://dx.doi.org/10.1001/jama.271.14.1088			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151850				2022-12-28	WOS:A1994NE22800030
J	MURPHY, S; KHAW, KT; MAY, H; COMPSTON, JE				MURPHY, S; KHAW, KT; MAY, H; COMPSTON, JE			MILK CONSUMPTION AND BONE-MINERAL DENSITY IN MIDDLE-AGED AND ELDERLY WOMEN	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; HIP FRACTURE; DIETARY CALCIUM; RISK; OSTEOPOROSIS; EPIDEMIOLOGY	Objectives-To study the effects of historical milk consumption on current bone mineral density at the hip and spine. Design-Cross sectional study. Subjects-284 community based women aged 4474 years recruited from four general practice age-sex registers in Cambridge. Subjects categorised their average milk consumption up to age 25, from age 2544, and from age 44 to the present time as greater-than-or-equal-to 1 glass/day, < 1 glass/day but > 1 glass/week, or < 1 glass/week. Main outcome measures-Bone mineral density at the hip and spine measured by dual energy x ray absorptiometry. Results-Data on milk consumption up to age 25 years were available for 252 women. There was a consistent upward trend in bone mineral density at all sites with increasing historical milk consumption (total hip, femoral neck, trochanter, intertrochanter, P<0.05: Ward's triangle, P=0.005). Adjustment for age and body size did not alter these trends. Milk consumption up to age 25 was a significant independent predictor of bone mineral density at all sites in multiple linear regression analyses controlling for age, body mass index, menopausal status, smoking, ever use of hormone replacement therapy or oral contraceptives, physical activity, and alcohol intake. The effects of milk consumption from age 25-44 and from age 44 to the present were similar in direction though not statistically significant. Conclusion-Frequent milk consumption before age 25 favourably influences hip bone mass in middle aged and older women.	ADDENBROOKES HOSP,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARAN D, 1990, J CLIN ENDOCR METAB, V70, P264, DOI 10.1210/jcem-70-1-264; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; GARTON MJ, 1992, BMJ-BRIT MED J, V305, P82, DOI 10.1136/bmj.305.6845.82; HOFFENBERG R, 1989, FRACTURED NCK FEMUR; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LASKEY MA, 1991, BRIT J RADIOL, V64, P1023, DOI 10.1259/0007-1285-64-767-1023; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NIEVES JW, 1992, OSTEOPOROSIS INT, V2, P122, DOI 10.1007/BF01623818; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; RECKER RR, 1985, AM J CLIN NUTR, V41, P254, DOI 10.1093/ajcn/41.2.254; ROBERTS DJ, 1988, P NUTR SOC, V47, P323, DOI 10.1079/PNS19880050; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SENTIPAL JM, 1991, AM J CLIN NUTR, V54, P425, DOI 10.1093/ajcn/54.2.425; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1990, HOUSEHOLD FOOD CONSU; 1975, 10 DEP HLTH HLTH SOC; 1992, EPIDEMIOLOGICAL OVER, V1; 1987, HLTH LIFESTYLE SURVE	26	129	130	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					939	941		10.1136/bmj.308.6934.939	http://dx.doi.org/10.1136/bmj.308.6934.939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173399	Green Published			2022-12-28	WOS:A1994NF48500014
J	HARRIS, RS; LONGERICH, S; ROSENBERG, SM				HARRIS, RS; LONGERICH, S; ROSENBERG, SM			RECOMBINATION IN ADAPTIVE MUTATION	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTANTS; RECD; REARRANGEMENTS; BREAKS; LAMBDA; MODEL; GENE	The genetic requirements for adaptive mutation in Escherichia coli parallel those for homologous recombination in the RecBCD pathway. Recombination-deficient recA and recB null mutant strains are deficient in adaptive reversion. A hyper-recombinagenic recD strain is hypermutable, and its hypermutation depends on functional recA and recB genes. Genes of subsidiary recombination systems are not required. These results indicate that the molecular mechanism by which adaptive mutation occurs includes recombination. No such association is seen for spontaneous mutation in growing cells.	UNIV ALBERTA,FAC MED,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,ALBERTA,CANADA	University of Alberta; University of Alberta				Rosenberg, Susan M./0000-0003-1444-473X				AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CAIRNS J, 1993, SCIENCE, V260, P1221, DOI 10.1126/science.8493560; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CLARK AJ, 1988, RECOMBINATION GENETI, P115; DEMEREC M, 1962, P NATL ACAD SCI USA, V48, P1696, DOI 10.1073/pnas.48.10.1696; DEVORET R, 1991, BIOCHIMIE, V73; ESPOSITO MS, 1993, CURR GENET, V23, P430, DOI 10.1007/BF00312630; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1993, SCIENCE, V260, P1222, DOI 10.1126/science.260.5112.1222; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; Luria SE, 1943, GENETICS, V28, P491; MAGNI GE, 1962, GENETICS, V47, P1097; MAHAN MJ, 1989, GENETICS, V121, P433; MCGILL C, COMMUNICATION; PASZEWSKI A, 1964, NATURE, V204, P809, DOI 10.1038/204809a0; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; THALER DS, 1990, BACTERIAL CHROMOSOME, P445; THALER DS, IN PRESS TRENDS ECOL; Von Borstel R C, 1978, Methods Cell Biol, V20, P1, DOI 10.1016/S0091-679X(08)62005-1	30	228	233	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					258	260		10.1126/science.8146657	http://dx.doi.org/10.1126/science.8146657			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146657				2022-12-28	WOS:A1994NE41000036
J	DONALDSON, C				DONALDSON, C			FORMULATE, DONT FORMULARISE	BRITISH MEDICAL JOURNAL			English	Article																			0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					905	906		10.1136/bmj.308.6933.905	http://dx.doi.org/10.1136/bmj.308.6933.905			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173374	Green Published			2022-12-28	WOS:A1994NE60000029
J	ROSS, AM; FLEMING, DM				ROSS, AM; FLEMING, DM			INCIDENCE OF ALLERGIC RHINITIS IN GENERAL-PRACTICE, 1981-92	BRITISH MEDICAL JOURNAL			English	Article							HAY-FEVER; PREVALENCE; ASTHMA	Objectives-To determine the epidemiology of hay fever and to consider the role of pollution. Design-Examination of data on weekly incidence of allergic rhinitis and hay fever by age, sex, region, and location. Setting-Royal College of General Practitioners Weekly Returns Service. Practice data were based on registered populations of 220 000 in 1991, rising to 700 000 in 1992 from England and Wales. Main outcome measures-Numbers of new cases of hay fever and allergic rhinitis. Data on pollen counts for Darlington, Derby, and London. Results-The incidence of allergic rhinitis fluctuated greatly from year to year but showed no trend. Peaks in hay fever coincided with peak pollen counts. No important differences were found between urban and rural locations or different parts of the country with respect to both size and timing of the peaks. Incidence was highest in children (5-14 years). Conclusions-The similarity of the results throughout England and Wales does not support an important role for local pollutants in hay fever. However, the possibility that levels of pollutants are high enough to act as an adjuvant in hay fever across the whole study area has not been excluded.			ROSS, AM (corresponding author), ROYAL COLL GEN PRACTITIONERS,BIRMINGHAM RES UNIT,BIRMINGHAM B17 9DB,ENGLAND.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; CHARPIN D, 1988, REV MAL RESPIR, V5, P109; CROMBIE DL, 1984, 25 ROYAL COLL GEN PR; EWAN PW, 1989, J ROY COLL PHYS LOND, V23, P68; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; FINN R, 1992, LANCET, V340, P1453; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; RICHARDS S, 1992, BRIT J GEN PRACT, V42, P284; SIBBALD B, 1991, THORAX, V46, P378, DOI 10.1136/thx.46.5.378; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; THOMAS E, 1993, AM REV RESPIR DIS, V147, pA643; VARNEY V, 1991, CLIN EXP ALLERGY, V21, P757, DOI 10.1111/j.1365-2222.1991.tb03210.x; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; 1990, MB52 DEP HLTH OFF PO; 1974, STUDIES MED POPULATI, V26; 1986, MORBIDITY STATISTICS; 1993, 934 DEP PHS LUNG AST; 1958, STUDIES MED POPULATI, V14	24	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					897	900		10.1136/bmj.308.6933.897	http://dx.doi.org/10.1136/bmj.308.6933.897			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173372	Green Published			2022-12-28	WOS:A1994NE60000025
J	MOYLE, WR; CAMPBELL, RK; MYERS, RV; BERNARD, MP; HAN, Y; WANG, XY				MOYLE, WR; CAMPBELL, RK; MYERS, RV; BERNARD, MP; HAN, Y; WANG, XY			COEVOLUTION OF LIGAND-RECEPTOR PAIRS	NATURE			English	Article							FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; BETA-SUBUNIT; CHORIOGONADOTROPIN; CHIMERAS; EXPRESSION; SEQUENCE	SPECIFIC receptors for lutropin(1,2) (luteinizing hormone; LH) and follitropin(3,4) (follicle-stimulating hormone; FSH) mediate the actions of human chorionic gonadotropin (hCG) and FSH5 on the gonads. Here we report that short independent sequences of the beta-subunit enable hCG to distinguish between the receptors for FSH and LH. Residues between the 11th and 12th cysteines restrict FSH receptor binding; residues between the 10th and 11th cysteines and, to a much lesser extent, residues carboxy-terminal to the 12th cysteine also affect LH receptor binding. CF101-109, an hCG analogue containing hFSH beta residues between the 11th and 12th cysteines, had high affinity for both LH and FSH receptors. Modifications to CF101-109 that reduce binding to either LH or FSH receptors yield gonadotropin analogues having differing ratios of LH:FSH activity. Ligand-binding specificity of the LH receptor is determined by residues encoded by parts of exons 2-4 and 7-9 which prevent hFSH binding but have little effect on hCG binding. FSH receptor specificity is controlled primarily by residues encoded by exons 5 and 6 that prevent hCG binding but have little effect on hFSH binding. These determinants can be interchanged to create receptor analogues that bind hCG and hFSH. Our observations support a model in which distinct negative determinants restrict ligand-receptor interaction. This explains coevolution of binding specificity in families of homologous ligands and their receptors. Natural or designed manipulation of these determinants leads to the 'evolution' of new, specific protein-protein interactions.			MOYLE, WR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON RUTGERS MED SCH,DEPT OBSTET & GYNECOL,PISCATAWAY,NJ 08854, USA.		Campbell, Robert/G-4112-2012					BERNARD MP, 1990, MOL CELL ENDOCRINOL, V71, pR19, DOI 10.1016/0303-7207(90)90034-6; BEWLEY TA, 1975, ADV ENZYMOL RAMB, V42, P73; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BROOKER J, 1992, ADV CYCLIC NUCLEOTID, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LEE J, 1992, J BIOL CHEM, V267, P16283; Licht P, 1976, Recent Prog Horm Res, V33, P169; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NOCE T, 1989, J MOL ENDOCRINOL, V3, P129, DOI 10.1677/jme.0.0030129; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; VANOSTADE X, 1993, NATURE, V361, P206; VILCEK J, 1991, J BIOL CHEM, V266, P7313; XIE YB, 1990, J BIOL CHEM, V265, P21411	24	312	328	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					251	255		10.1038/368251a0	http://dx.doi.org/10.1038/368251a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145825				2022-12-28	WOS:A1994NA87000058
J	OSBORNE, MJ; AUSTIN, RCT; DAWSON, KJ; LANGE, L				OSBORNE, MJ; AUSTIN, RCT; DAWSON, KJ; LANGE, L			IS THERE A PROBLEM WITH LONG-TERM USE OF SUMATRIPTAN IN ACUTE MIGRAINE	BRITISH MEDICAL JOURNAL			English	Letter											OSBORNE, MJ (corresponding author), ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND.							CADY RK, 1991, JAMA-J AM MED ASSOC, V265, P2831, DOI 10.1001/jama.265.21.2831; FENIUK W, 1991, J NEUROL, V238, pS57, DOI 10.1007/BF01642908; 1991, EUR NEUROL, V31, P314; 1991, EUR NEUROL, V31, P300; 1992, DRUG THERAPEUTICS B, V30, P85; 1991, NEW ENGL J MED, V325, P316	6	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					113	113		10.1136/bmj.308.6921.113a	http://dx.doi.org/10.1136/bmj.308.6921.113a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8166817	Green Published			2022-12-28	WOS:A1994MR17300018
J	SHIPP, MA; HARRINGTON, DP; ANDERSON, JR; ARMITAGE, JO; BONADONNA, G; BRITTINGER, G; CABANILLAS, F; CANELLOS, GP; COIFFIER, B; CONNORS, JM; COWAN, RA; CROWTHER, D; DAHLBERG, S; ENGELHARD, M; FISHER, RI; GISSELBRECHT, C; HORNING, SJ; LEPAGE, E; LISTER, TA; MEERWALDT, JH; MONTSERRAT, E; NISSEN, NI; OKEN, MM; PETERSON, BA; TONDINI, C; VELASQUEZ, WA; YEAP, BY				SHIPP, MA; HARRINGTON, DP; ANDERSON, JR; ARMITAGE, JO; BONADONNA, G; BRITTINGER, G; CABANILLAS, F; CANELLOS, GP; COIFFIER, B; CONNORS, JM; COWAN, RA; CROWTHER, D; DAHLBERG, S; ENGELHARD, M; FISHER, RI; GISSELBRECHT, C; HORNING, SJ; LEPAGE, E; LISTER, TA; MEERWALDT, JH; MONTSERRAT, E; NISSEN, NI; OKEN, MM; PETERSON, BA; TONDINI, C; VELASQUEZ, WA; YEAP, BY			A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; PROGNOSTIC FACTORS; M-BACOD; STAGING CLASSIFICATION; REGRESSION-MODELS; SURVIVAL; ABNORMALITIES; CHEMOTHERAPY; REGIMEN	Background. Although many patients with intermediate-grade or high-grade (aggressive) non-Hodgkin's lymphoma are cured by combination chemotherapy, the remainder are not cured and ultimately die of their disease. The Ann Arbor classification, used to determine the stage of this disease, does not consistently distinguish between patients with different long-term prognoses. This project was undertaken to develop a model for predicting outcome in patients with aggressive non-Hodgkin's lymphoma on the basis of the patients' clinical characteristics before treatment. Methods. Adults with aggressive non-Hodgkin's lymphoma from 16 institutions and cooperative groups in the United States, Europe, and Canada who were treated between 1982 and 1987 with combination-chemotherapy regimens containing doxorubicin were evaluated for clinical features predictive of overall survival and relapse-free survival. Features that remained independently significant in step-down regression analyses of survival were incorporated into models that identified groups of patients of all ages and groups of patients no more than 60 years old with different risks of death. Results. In 2031 patients of all ages, our model, based on age, tumor stage, serum lactate dehydrogenase concentration, performance status, and number of extranodal disease sites, identified four risk groups with predicted five-year survival rates of 73 percent, 51 percent, 43 percent, and 26 percent. In 1274 patients 60 or younger, an age-adjusted model based on tumor stage, lactate dehydrogenase level, and performance status identified four risk groups with predicted five-year survival rates of 83 percent, 69 percent, 46 percent, and 32 percent. In both models, the increased risk of death was due to both a lower rate of complete responses and a higher rate of relapse from complete response. These two indexes, called the international index and the age-adjusted international index, were significantly more accurate than the Ann Arbor classification in predicting long-term survival. Conclusions. The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; EASTERN COOPERAT ONCOL GRP, DENVER, CO USA; NEBRASKA LYMPHOMA STUDY GRP, OMAHA, NE USA; CANC & LEUKEMIA GRP B, LEBANON, NH USA; BUNDESMINIST FORSCH & TECHNOL STUDY, ESSEN, GERMANY; MD ANDERSON CANC CTR, HOUSTON, DC USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; GRP ETUD LYMPHOMES ADULTE, PARIS, FRANCE; BRITISH COLUMBIA CANC AGCY, VANCOUVER, BC, CANADA; MANCHESTER LYMPHOMA GRP, MANCHESTER, ENGLAND; SW ONCOL GRP, SAN ANTONIO, TX USA; STANFORD UNIV, STANFORD, CA 94305 USA; ST BARTHOLOMEWS HOSP, LONDON EC1A 7BE, ENGLAND; EUROPEAN ORG RES TREATMENT CANC, LYMPHOMA COOPERAT GRP, BRUSSELS, BELGIUM; HOSP CLIN BARCELONA, BARCELONA 36, SPAIN; FINSEN INST, DK-2100 COPENHAGEN, DENMARK; IST NAZL TUMORI, I-20133 MILAN, ITALY	Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; British Columbia Cancer Agency; Southwest Oncology Group; Stanford University; University of London; Queen Mary University London; European Organisation for Research & Treatment of Cancer; University of Barcelona; Hospital Clinic de Barcelona; Fondazione IRCCS Istituto Nazionale Tumori Milan	SHIPP, MA (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, 44 BINNEY ST, BOSTON, MA 02115 USA.		cowan, richard/N-7633-2015; TONDINI, CARLO ALBERTO/AAB-7786-2019; Connors, Joseph/AAF-5284-2019	cowan, richard/0000-0001-9004-8136; TONDINI, CARLO ALBERTO/0000-0003-0635-8954; Connors, Joseph/0000-0002-1361-7531; Cabanillas, Fernando/0000-0001-9234-7893				[Anonymous], 1975, BRIT J HAEMATOL, DOI DOI 10.1111/J.1365-2141.1975.TB00911.X; BASTION Y, 1991, ANN ONCOL, V2, P123, DOI 10.1093/annonc/2.suppl_2.123; Breiman L., 1984, CLASSIFICATION REGRE; CABANILLAS F, 1989, AM J MED, V87, P167; CARBONE PP, 1971, CANCER RES, V31, P1860; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COIFFIER B, 1989, BLOOD, V74, P558; COWAN RA, 1989, BRIT J CANCER, V59, P276, DOI 10.1038/bjc.1989.57; COWAN RA, 1989, BRIT J CANCER, V60, P904, DOI 10.1038/bjc.1989.388; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1989, ANAL BINARY DATA; DANIEU L, 1986, CANCER RES, V46, P5372; DIXON DO, 1986, J CLIN ONCOL, V4, P295, DOI 10.1200/JCO.1986.4.3.295; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1981, BLOOD, V58, P45; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GRAY RJ, 1990, BIOMETRICS, V46, P93, DOI 10.2307/2531633; GROGAN TM, 1988, BLOOD, V71, P1157; GULATI SC, 1988, J CLIN ONCOL, V6, P1303, DOI 10.1200/JCO.1988.6.8.1303; HOSKINS PJ, 1991, J CLIN ONCOL, V9, P220, DOI 10.1200/JCO.1991.9.2.220; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; JALKANEN S, 1990, BLOOD, V75, P1549; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE EG, 1988, ANN INTERN MED, V108, P14, DOI 10.7326/0003-4819-108-1-14; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCMASTER ML, 1991, CANCER-AM CANCER SOC, V68, P233, DOI 10.1002/1097-0142(19910715)68:2<233::AID-CNCR2820680203>3.0.CO;2-Q; MONTSERRAT E, 1991, BLOOD S, V78, pA127; Rappaport H, 1966, TUMORS HEMATOPOIETIC; ROSENBERG SA, 1977, CANCER TREAT REP, V61, P1023; ROSENBERG SA, 1982, CANCER, V49, P2112; SCHOUTEN HC, 1990, BLOOD, V75, P1841; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SHIPP MA, 1990, J CLIN ONCOL, V8, P84, DOI 10.1200/JCO.1990.8.1.84; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; THERNEAU TM, 1990, BIOMETRIKA, V77, P147, DOI 10.2307/2336057; VELASQUEZ WS, 1989, BLOOD, V74, P551; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZUTTER M, 1991, BLOOD, V78, P1062; 1985, DHHS PHS8511501 PUBL	40	4166	4322	2	84	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					987	994		10.1056/nejm199309303291402	http://dx.doi.org/10.1056/nejm199309303291402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8141877	Bronze			2022-12-28	WOS:A1993LY58700002
J	SAFFRAN, DC; PAROLINI, O; FITCHHILGENBERG, ME; RAWLINGS, DJ; AFAR, DEH; WITTE, ON; CONLEY, ME				SAFFRAN, DC; PAROLINI, O; FITCHHILGENBERG, ME; RAWLINGS, DJ; AFAR, DEH; WITTE, ON; CONLEY, ME			A POINT MUTATION IN THE SH2 DOMAIN OF BRUTONS TYROSINE KINASE IN ATYPICAL X-LINKED AGAMMAGLOBULINEMIA - BRIEF REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CELLS; SRC		UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Tennessee System; University of Tennessee Health Science Center			PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020	PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430	NCI NIH HHS [R35 CA53867, P30 CA21765] Funding Source: Medline; NIAID NIH HHS [AI 12925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R35CA053867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKER R, 1989, J EXP MED, V169, P2109, DOI 10.1084/jem.169.6.2109; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRUTON OC, 1952, PEDIATRICS, V9, P722; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLEY ME, 1988, J PEDIATR-US, V112, P688, DOI 10.1016/S0022-3476(88)80683-8; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER MD, 1992, PROG IMMUNOL, V8, P535; GUIOLI S, 1989, HUM GENET, V84, P19, DOI 10.1007/BF00210664; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWAN SP, 1986, J CLIN INVEST, V77, P649, DOI 10.1172/JCI112351; PAROLINI O, 1993, GENOMICS, V15, P342, DOI 10.1006/geno.1993.1066; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V364, P362, DOI 10.1038/364362a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VORECHOVSKY I, 1993, LANCET, V341, P1153, DOI 10.1016/0140-6736(93)93172-W; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	121	123	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1488	1491		10.1056/NEJM199405263302104	http://dx.doi.org/10.1056/NEJM199405263302104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164701	Bronze			2022-12-28	WOS:A1994NM06800004
J	DROBYSKI, WR; KNOX, KK; MAJEWSKI, D; CARRIGAN, DR				DROBYSKI, WR; KNOX, KK; MAJEWSKI, D; CARRIGAN, DR			FATAL ENCEPHALITIS DUE TO VARIANT-B HUMAN HERPESVIRUS-6 INFECTION IN A BONE MARROW-TRANSPLANT RECIPIENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EXANTHEM-SUBITUM; CHILDREN		MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin	DROBYSKI, WR (corresponding author), MED COLL WISCONSIN,BONE MARROW TRANSPLANT PROGRAM,BOX 176,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.		Drobyski, William/R-6994-2019					ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416, DOI 10.1128/JCM.31.2.416-418.1993; DROBYSKI WR, 1993, J CLIN MICROBIOL, V31, P1515, DOI 10.1128/JCM.31.6.1515-1520.1993; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; ITOYAMA Y, 1991, ANN NEUROL, V29, P285, DOI 10.1002/ana.410290310; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; PELLETT PE, 1993, VIROLOGY, V195, P521, DOI 10.1006/viro.1993.1403; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; RUSSLER SK, 1991, AM J PATHOL, V138, P1405; RUSSLER SK, 1989, LANCET, V2, P382; STREICHER HZ, 1988, J VIROL METHODS, V21, P301, DOI 10.1016/0166-0934(88)90075-4; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIKAWA T, 1992, PEDIATRICS, V89, P888	16	304	312	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1356	1360		10.1056/NEJM199405123301905	http://dx.doi.org/10.1056/NEJM199405123301905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152447				2022-12-28	WOS:A1994NK75300005
J	PATRONO, C				PATRONO, C			ASPIRIN AS AN ANTIPLATELET DRUG	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; PROSTAGLANDIN-G/H SYNTHASE; ISCHEMIC-HEART-DISEASE; UNSTABLE ANGINA; PLATELET ACTIVATION; PRIMARY PREVENTION; THROMBOXANE BIOSYNTHESIS		UNIV G DANNUNZIO, SCH MED, DEPT MED, I-66013 CHIETI, ITALY	G d'Annunzio University of Chieti-Pescara	PATRONO, C (corresponding author), UNIV G DANNUNZIO, FAC MED & CHIRURG, SCH MED, DEPT PHARMACOL, VIA VESTINI 31, I-66013 CHIETI, ITALY.			Patrono, Carlo/0000-0002-6447-2424				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1994, BMJ, V308, P159; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, Circulation, V62, P449; BEROYZ G, 1994, LANCET, V343, P619; BJORNSSON TD, 1989, J PHARMACOL EXP THER, V250, P154; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CLAGETT GP, 1992, CHEST, V102, pS516, DOI 10.1378/chest.102.4_Supplement.516S; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; CUNNINGHAM FG, 1992, NEW ENGL J MED, V326, P927; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; DECATERINA R, 1985, THROMB HAEMOSTASIS, V54, P528; DECATERINA R, 1985, EUR HEART J, V6, P409, DOI 10.1093/oxfordjournals.eurheartj.a061879; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P5056; DYKEN ML, 1992, STROKE, V23, P1395, DOI 10.1161/01.STR.23.10.1395; EZRATTY AM, 1992, CLIN RES, V40, pA201; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; HALL D, 1992, J AM COLL CARDIOL, V20, P1549, DOI 10.1016/0735-1097(92)90449-W; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAMM CW, 1987, J AM COLL CARDIOL, V10, P998, DOI 10.1016/S0735-1097(87)80336-4; HARTER HR, 1979, NEW ENGL J MED, V301, P577, DOI 10.1056/NEJM197909133011103; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIRSH J, 1992, CHEST, V102, pS327, DOI 10.1378/chest.102.4_Supplement.327S; ISHIKAWA K, 1992, CIRCULATION, V86, P643; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KEIMOWITZ RM, 1993, CIRCULATION, V88, P556, DOI 10.1161/01.CIR.88.2.556; KEIRSE MJNC, 1993, LANCET, V341, P412, DOI 10.1016/0140-6736(93)92998-9; KOUDSTAAL PJ, 1993, STROKE, V24, P219, DOI 10.1161/01.STR.24.2.219; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LANDOLFI R, 1992, BLOOD, V80, P1965; LEWIS HD, 1984, NEW ENGL J MED, V310, P122; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LORENZ RL, 1984, LANCET, V1, P1261; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MARCUS AJ, 1983, NEW ENGL J MED, V309, P1515, DOI 10.1056/NEJM198312153092410; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MEADE TW, 1990, AM J CARDIOL, V65, pC7, DOI 10.1016/0002-9149(90)90108-D; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; MINUZ P, 1990, BRIT J CLIN PHARMACO, V30, P519, DOI 10.1111/j.1365-2125.1990.tb03809.x; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1987, KIDNEY INT, V32, P1, DOI 10.1038/ki.1987.164; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; PATRONO C, 1980, THROMB RES, V17, P317, DOI 10.1016/0049-3848(80)90066-3; PATRONO C, 1986, J CLIN INVEST, V77, P590, DOI 10.1172/JCI112341; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; RATNATUNGA CP, 1992, CIRCULATION, V85, P1077, DOI 10.1161/01.CIR.85.3.1077; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; SANZ G, 1990, CIRCULATION, V82, P765, DOI 10.1161/01.CIR.82.3.765; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; SERNER GGN, 1990, LANCET, V335, P868; SERNERI GGN, 1990, LANCET, V335, P615; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; STEIN B, 1989, CIRCULATION, V80, P1501, DOI 10.1161/01.CIR.80.6.1501; SZCZEKLIK A, 1992, BLOOD, V80, P2006; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; VANKOOTEN F, 1994, STROKE, V25, P278, DOI 10.1161/01.STR.25.2.278; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; VEJAR M, 1990, CIRCULATION S1, V81, P4; WALLENTIN L, 1990, LANCET, V336, P827; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; WARLOW C, 1992, LANCET, V339, P724, DOI 10.1016/0140-6736(92)90608-6; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; 1993, LANCET, V342, P1255; 1992, SCRIP, V1726, P26; 1994, BRIT MED J, V308, P325	95	745	773	0	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1287	1294						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145785				2022-12-28	WOS:A1994NJ51200008
J	SCHLENKER, TL; FRITZ, CJ; MARK, D; LAYDE, M; LINKE, G; MURPHY, A; MATTE, T				SCHLENKER, TL; FRITZ, CJ; MARK, D; LAYDE, M; LINKE, G; MURPHY, A; MATTE, T			SCREENING FOR PEDIATRIC LEAD-POISONING - COMPARABILITY OF SIMULTANEOUSLY DRAWN CAPILLARY AND VENOUS-BLOOD SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CHILDREN	Objective.-To determine the ability of capillary blood lead levels to accurately reflect true blood lead levels in children at risk for lead poisoning. Design.-A correlation study in which lead levels of capillary blood specimens obtained by four different methods were compared with lead levels of simultaneously drawn venous blood specimens. Setting.-A central-city pediatric primary care clinic and door-to-door home visits in one central-city neighborhood. Patients.-Two hundred ninety-five children at high risk for lead poisoning aged 6 months to 6 years. Main Outcome Measures.-Blood lead levels of simultaneously drawn capillary and venous blood specimens. Results.-Lead levels of all four capillary sampling methods were highly correlated (correlation coefficient greater than or equal to 0.96) with matched venous blood lead levels, with mean capillary-venous differences less than 0.05 mu mol/L (1 mu g/dL). Conclusions.-Capillary sampling is an acceptable alternative to venipuncture for lead-poisoning screening in young children.	MED COLL WISCONSIN,CHILDRENS HOSP WISCONSIN,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT FAMILY MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226; CTR DIS CONTROL & PREVENT,LEAD POISONING BRANCH,NATL CTR ENVIRONM HLTH,ATLANTA,GA	Children's Hospital of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Centers for Disease Control & Prevention - USA	SCHLENKER, TL (corresponding author), SALT LAKE CITY CTY HLTH DEPT,2001 S STATE ST,S2500,SALT LAKE CITY,UT 84190, USA.				PHS HHS [H64/CCH507059-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1991, PREVENTING LEAD POIS; BLATT SD, 1993, AM J DIS CHILD, V147, P761, DOI 10.1001/archpedi.1993.02160310063019; BLUMENFELD TA, 1977, CLIN CHEM, V23, P1705; DELVES HT, 1970, ANALYST, V95, P431, DOI 10.1039/an9709500431; DESILVA PE, 1980, MED J AUSTRALIA, V1, P93; EDWARDS KS, 1989, AM J DIS CHILD, V143, P1455, DOI 10.1001/archpedi.1989.02150240077021; GELLERT GA, 1993, JAMA-J AM MED ASSOC, V270, P69, DOI 10.1001/jama.270.1.69; LYNGBYE T, 1990, SCAND J CLIN LAB INV, V50, P441, DOI 10.3109/00365519009091604; MCELVAINE MD, 1991, J PEDIATR-US, V119, P548, DOI 10.1016/S0022-3476(05)82402-3; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; MITCHELL DG, 1974, NEW YORK STATE J MED, V74, P1599; PARSONS PJ, 1993, SPECTROCHIM ACTA B, V48, P925, DOI 10.1016/0584-8547(93)80094-B; ROLFE PB, 1993, AM J DIS CHILD, V147, P66, DOI 10.1001/archpedi.1993.02160250068020; SAYRE JW, 1992, AM J DIS CHILD, V146, P1275, DOI 10.1001/archpedi.1992.02160230033010; Schlenker T, 1992, Wis Med J, V91, P133; SCHLENKER TL, 1992, POSTGRAD MED, V92, P69; 1993, MMWR MORB MORTAL WKL, V42, P165; 1985, 992230 CTR DIS CONTR	18	62	64	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1346	1348		10.1001/jama.271.17.1346	http://dx.doi.org/10.1001/jama.271.17.1346			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158820				2022-12-28	WOS:A1994NH48700027
J	POSTLETHWAIT, JH; JOHNSON, SL; MIDSON, CN; TALBOT, WS; GATES, M; BALLINGER, EW; AFRICA, D; ANDREWS, R; CARL, T; EISEN, JS; HORNE, S; KIMMEL, CB; HUTCHINSON, M; JOHNSON, M; RODRIGUEZ, A				POSTLETHWAIT, JH; JOHNSON, SL; MIDSON, CN; TALBOT, WS; GATES, M; BALLINGER, EW; AFRICA, D; ANDREWS, R; CARL, T; EISEN, JS; HORNE, S; KIMMEL, CB; HUTCHINSON, M; JOHNSON, M; RODRIGUEZ, A			A GENETIC-LINKAGE MAP FOR THE ZEBRAFISH	SCIENCE			English	Article							ARBITRARY PRIMERS; MUTATIONS; INDUCTION; DNA; IDENTIFICATION; RECOMBINATION; MARKERS; GENOMES; SYSTEM; LINES	To facilitate molecular genetic analysis of vertebrate development, haploid genetics was used to construct a recombination map for the zebrafish Danio (Brachydanio) rerio. The map consists of 401 random amplified polymorphic DNAs (RAPDs) and 13 simple sequence repeats spaced at an average interval of 5.8 centimorgans. Strategies that exploit the advantages of haploid genetics and RAPD markers were developed that quickly mapped lethal and Visible mutations and that placed cloned genes on the map. This map is useful for the position-based cloning of mutant genes, the characterization of chromosome rearrangements, and the investigation of evolution in vertebrate genomes.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon	POSTLETHWAIT, JH (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023915, R56NS023915] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1AI26734] Funding Source: Medline; NICHD NIH HHS [HD07470] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMENKO MA, UNPUB; ALJANABI SM, 1993, GENETICS, V134, P1249; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BROOKS LD, 1986, GENETICS, V114, P525; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH W, 1992, GENETICS, V131, P423; ENDO A, 1968, J HERED, V59, P382, DOI 10.1093/oxfordjournals.jhered.a107755; FELSENFELD AL, 1990, DEVELOPMENT, V108, P443; GOFF DJ, 1992, GENOMICS, V14, P200, DOI 10.1016/S0888-7543(05)80309-X; GRAF JD, 1989, GENETICS, V123, P389; GRUNWALD DJ, 1992, GENET RES, V59, P93, DOI 10.1017/S0016672300030305; GRUNWALD DJ, 1992, GENET RES, V59, P103, DOI 10.1017/S0016672300030317; Haldane JBS, 1919, J GENET, V8, P299; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HULBERT SH, 1988, GENETICS, V120, P947; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHNSON SB, UNPUB; JOHNSON SL, 1994, GENOMICS, V19, P152, DOI 10.1006/geno.1994.1026; KESSELI RV, 1992, APPLICATIONS RAPD TE, P31; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; KIRSCHBAUM F, 1975, Wilhelm Roux's Archives of Developmental Biology, V177, P129, DOI 10.1007/BF00848526; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER ES, 1987, GENOMICS, V1, P185; MEYER A, 1993, P ROY SOC B-BIOL SCI, V252, P231, DOI 10.1098/rspb.1993.0070; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; MORIZOT DC, 1991, GENETICS, V127, P399; MORIZOT DC, 1990, ISOZYMES STRUCTURE F, P207; MULLINS MC, 1993, CURR OPIN GENET DEV, V3, P648, DOI 10.1016/0959-437X(93)90102-U; Neale D., 1991, Probe. Newsletter of the USDA Plant Genome Research Program, V1, P1; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; PARAN I, 1993, THEOR APPL GENET, V85, P985, DOI 10.1007/BF00215038; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; RAFALSKI JA, 1993, TRENDS GENET, V9, P275, DOI 10.1016/0168-9525(93)90013-8; REITER RS, 1992, P NATL ACAD SCI USA, V89, P1477, DOI 10.1073/pnas.89.4.1477; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; SCHULTEMERKER S, IN PRESS DEVELOPMENT; Sepich Diane S., 1993, Society for Neuroscience Abstracts, V19, P1294; SILVER LM, 1992, MAMM GENOME, V3, pS241, DOI 10.1007/BF00648435; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; STUART GW, 1990, DEVELOPMENT, V109, P577; TALBOT WS, UNPUB; TANKSLEY SD, 1992, GENETICS, V132, P1141; THISSE C, 1993, DEVELOPMENT, V119, P1203; TINGEY SV, 1992, APPL RAPD TECHNOLOGY, P3; TREVARROW W, 1993, SOC NEUR ABSTR, V19, P217; WALKER C, 1983, GENETICS, V103, P125; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WICKING C, 1991, TRENDS GENET, V7, P288, DOI 10.1016/0168-9525(91)90177-R; WILLIAMS JGK, 1993, NUCLEIC ACIDS RES, V21, P2697, DOI 10.1093/nar/21.11.2697; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	58	332	368	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					699	703		10.1126/science.8171321	http://dx.doi.org/10.1126/science.8171321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171321				2022-12-28	WOS:A1994NH71300031
J	SINGHVI, R; KUMAR, A; LOPEZ, GP; STEPHANOPOULOS, GN; WANG, DIC; WHITESIDES, GM; INGBER, DE				SINGHVI, R; KUMAR, A; LOPEZ, GP; STEPHANOPOULOS, GN; WANG, DIC; WHITESIDES, GM; INGBER, DE			ENGINEERING CELL-SHAPE AND FUNCTION	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; MOUSE FIBROBLASTS; GROWTH; HEPATOCYTES; DIFFERENTIATION; FIBRONECTIN; EXPRESSION; SECRETION; INDUCTION; MEMBRANES	An elastomeric stamp, containing defined features on the micrometer scale, was used to imprint gold surfaces with specific patterns of self-assembled monolayers of alkanethiols and, thereby, to create islands of defined shape and size that support extracellular matrix protein adsorption and cell attachment. Through this technique, it was possible to place cells in predetermined locations and arrays, separated by defined distances, and to dictate their shape. Limiting the degree of cell extension provided control over cell growth and protein secretion. This method is experimentally simple and highly adaptable. It should be useful for applications in biotechnology that require analysis of individual cells cultured at high density or repeated access to cells placed in specified locations.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; MIT,CTR BIOTECHNOL PROC ENGN,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ingber, Donald E/AAC-5894-2019					BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BROWN KD, 1992, GENET ENG NEWS, V12, P1; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CARTER SB, 1967, NATURE, V213, P256, DOI 10.1038/213256a0; COLLINS VP, 1979, EUR J CELL BIOL, V29, P288; DANHEISER SL, 1993, ENG NEWS, V13, P1; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GOSPODAROWICZ D, 1978, CANCER RES, V38, P4155; HARRIS A, 1973, EXP CELL RES, V77, P285, DOI 10.1016/0014-4827(73)90579-X; INGBER DE, 1987, IN VITRO CELL DEV B, V23, P387; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KABAT D, 1985, J CELL BIOL, V101, P2274, DOI 10.1083/jcb.101.6.2274; KUMAR A, IN PRESS APPL PHYSL; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LOPEZ GP, 1993, LANGMUIR, V9, P1513, DOI 10.1021/la00030a015; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; ONEILL C, 1990, J CELL SCI, V95, P577; ONEILL C, 1986, CELL, V44, P489, DOI 10.1016/0092-8674(86)90470-8; ONEILL CH, 1979, CELL, V16, P909, DOI 10.1016/0092-8674(79)90106-5; PONTEN J, 1980, EXP CELL RES, V129, P367, DOI 10.1016/0014-4827(80)90505-4; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; PRIME KL, IN PRESS J AM CHEM S; WESTERMARK B, 1978, EXP CELL RES, V111, P295, DOI 10.1016/0014-4827(78)90173-8	28	1236	1336	4	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					696	698		10.1126/science.8171320	http://dx.doi.org/10.1126/science.8171320			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171320				2022-12-28	WOS:A1994NH71300030
J	ROSENMUND, C; CARR, DW; BERGESON, SE; NILAVER, G; SCOTT, JD; WESTBROOK, GL				ROSENMUND, C; CARR, DW; BERGESON, SE; NILAVER, G; SCOTT, JD; WESTBROOK, GL			ANCHORING OF PROTEIN-KINASE-A IS REQUIRED FOR MODULATION OF AMPA/KAINATE RECEPTORS ON HIPPOCAMPAL-NEURONS	NATURE			English	Article							METHYL-D-ASPARTATE; REGULATORY SUBUNIT; ION CHANNELS; CAMP; CLONING; KAINATE; RII; LOCALIZATION; ACCUMULATION; EXPRESSION	PHOSPHORYLATION of molecules involved in synaptic transmission by multifunctional protein kinases modulates both pre- and postsynaptic events in the central nervous system(1,2). The positioning of kinases near their substrates may be an important part of the regulatory mechanism. The A-kinase-anchoring proteins (AKAPs; ref. 3) are known to bind the regulatory subunit of cyclic AMP-dependent protein kinase A with nanomolar affinity. Here we show that anchoring of protein kinase A by AKAPs is required for the modulation of alpha-amino-3-hydroxy-5'methyl-4-isoxazole-propionic acid (AMPA)/kainate channels(4,5). Intracellular perfusion of cultured hippocampal neurons with peptides derived from the conserved kinase binding region of AKAPs prevented the protein kinase A-mediated regulation of AMPA/kainate currents as well as fast excitatory synaptic currents. This effect could be overcome by adding the purified catalytic subunit of protein kinase. A control peptide lacking kinase-binding activity had no effect. To our knowledge, these results provide the first evidence that anchoring of protein kinase A is crucial in the regulation of synaptic function.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444				BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, REV PHYSL, V54, P507; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; THREURFAUF W, 1982, J BIOL CHEM, V357, P3284; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	29	317	327	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					853	856		10.1038/368853a0	http://dx.doi.org/10.1038/368853a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159245				2022-12-28	WOS:A1994NH71700071
J	SENGPIEL, F; BLAKEMORE, C				SENGPIEL, F; BLAKEMORE, C			INTEROCULAR CONTROL OF NEURONAL RESPONSIVENESS IN CAT VISUAL-CORTEX	NATURE			English	Article							CROSS-ORIENTATION INHIBITION; BINOCULAR-RIVALRY; STRIATE CORTEX; CELLS; ADAPTATION; ORGANIZATION; MODEL	NEURONS in the cat primary visual cortex are selective for particular contour orientations' but their responsiveness can vary under certain conditions. After prolonged stimulation (adaptation), the contrast sensitivity of cortical cells is reduced(2-5) and the 'gain' (the strength of response as a function of contrast) falls(5-6). The response to an optimal contour is also reduced when,a different stimulus is superimposed on the receptive field in the same eye(7-9). Here we report that the sudden appearance of an inappropriate stimulus in one eye can interocularly suppress the activity of cortical neurons if they are already responding to an optimally oriented stimulus in the other eye. In strabismic cats, whose cortical neurons lack binocular facilitation, even contours of similar orientation shown to the two eyes trigger such suppression. This interocular control of cortical responsiveness could serve to veto signals from one eye under conditions that would otherwise cause double vision and perceptual confusion.			SENGPIEL, F (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Sengpiel, Frank/A-4682-2010	Sengpiel, Frank/0000-0002-7060-1851; Blakemore, Colin/0000-0003-2659-7899				ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKEMORE C, 1972, J PHYSIOL-LONDON, V226, P725, DOI 10.1113/jphysiol.1972.sp010006; BLAKEMORE C, 1987, J PHYSIOL-LONDON, V384, P263, DOI 10.1113/jphysiol.1987.sp016454; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; DEANGELIS GC, 1992, NEUROPHYSIOL, V68, P144; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; FREEMAN RD, 1990, VISION RES, V30, P1661, DOI 10.1016/0042-6989(90)90151-A; FREEMAN RD, 1987, J PHYSIOL-LONDON, V396, pP69; HOLOPIGIAN K, 1988, INVEST OPHTH VIS SCI, V29, P444; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KISVARDAY ZF, 1993, EUR J NEUROSCI, V6, P14; LEHKY SR, 1988, PERCEPTION, V17, P215, DOI 10.1068/p170215; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MATSUOKA K, 1984, BIOL CYBERN, V49, P201, DOI 10.1007/BF00334466; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; MORRONE MC, 1987, EXP BRAIN RES, V67, P635; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; Sengpeil Frank, 1992, Society for Neuroscience Abstracts, V18, P295; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; TONG L, 1992, VISUAL NEUROSCI, V8, P557, DOI 10.1017/S0952523800005654; TSO DY, 1986, J NEUROSCI, V6, P1160; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; XUE J-T, 1987, Investigative Ophthalmology and Visual Science, V28, P102	30	89	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					847	850		10.1038/368847a0	http://dx.doi.org/10.1038/368847a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159244				2022-12-28	WOS:A1994NH71700069
J	[Anonymous]				[Anonymous]			HEALTH MATTERS IN TRANSITION	NATURE			English	Article																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					798	798						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159234				2022-12-28	WOS:A1994NH71700032
J	MATTHES, JWA; LEWIS, PA; DAVIES, DP; BETHEL, JA				MATTHES, JWA; LEWIS, PA; DAVIES, DP; BETHEL, JA			RELATION BETWEEN BIRTH-WEIGHT AT TERM AND SYSTOLIC BLOOD-PRESSURE IN ADOLESCENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY LIFE EXPERIENCE; ADULT LIFE; CARDIOVASCULAR-DISEASE; GROWTH; RISK; MORTALITY; FETAL; AGE	Objective-To examine whether birth weight is related to systolic blood pressure during adolescence. Design-Retrospective (comparative) cohort study. The observers who traced and studied the subjects were unaware of their case-control status. Subjects-330 subjects were born in Cardiff in 1975-7. Cases who were low bit;th weight at term (<2500g) were matched with controls of normal birth weight (3000-3800 g) at term. Main outcome measures-Systolic blood pressure measured by random zero sphygmomanometry in the subject's right arm with the subject supine, corrected for size and age. Results-The mean age at examination was 15.7 years. The mean systolic blood pressure of the cases was 105.8 mm Hg and of the controls 107.5 mm Hg. The corrected difference (95% confidence interval) in systolic blood pressure between the cases and controls was 1 mm Hg (-3 to +1 mm Hg; two tailed probability 0.33). Conclusion-Systolic blood pressure in adolescents of low birth weight is not significantly different from that of adolescents of normal birth weights.	UNIV WALES COLL MED, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University								[Anonymous], 1987, PEDIATRICS, V79, P1; ARISTIMUNO GG, 1984, CIRCULATION, V69, P895, DOI 10.1161/01.CIR.69.5.895; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DAVIES DP, 1979, ARCH DIS CHILD, V54, P703, DOI 10.1136/adc.54.9.703; DAVIES DP, 1991, BRIT MED J, V303, P1474, DOI 10.1136/bmj.303.6815.1474-b; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; ELFORD J, 1992, J EPIDEMIOL COMMUN H, V46, P1, DOI 10.1136/jech.46.1.1-a; GILLMAN MW, 1993, J PEDIATR-US, V122, P837, DOI 10.1016/S0022-3476(09)90005-1; HACK M, 1993, J PEDIATR-US, V122, P887, DOI 10.1016/S0022-3476(09)90012-9; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KOLACEK S, 1993, ACTA PAEDIATR, V82, P377, DOI 10.1111/j.1651-2227.1993.tb12701.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACHIN D, 1987, STATISTICAL TABLES D; NORUSIS M, 1990, STATISTICAL PACKAGE; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; TIMIO M, 1988, HYPERTENSION, V12, P457, DOI 10.1161/01.HYP.12.4.457; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	28	73	75	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	1994	308	6936					1074	1077		10.1136/bmj.308.6936.1074	http://dx.doi.org/10.1136/bmj.308.6936.1074			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173427	Green Published			2022-12-28	WOS:A1994NH48900022
J	MADDOX, J				MADDOX, J			STUDY CONFIRMS AZTS LACK OF PROPHYLACTIC EFFECT	NATURE			English	Editorial Material																		1994, LANCET, V343, P871; 1993, LANCET, V341, P889	2	0	0	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					577	577		10.1038/368577b0	http://dx.doi.org/10.1038/368577b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145833	Bronze			2022-12-28	WOS:A1994NF39200012
J	SCHLIEWEN, UK; TAUTZ, D; PAABO, S				SCHLIEWEN, UK; TAUTZ, D; PAABO, S			SYMPATRIC SPECIATION SUGGESTED BY MONOPHYLY OF CRATER LAKE CICHLIDS	NATURE			English	Article							MITOCHONDRIAL-DNA SEQUENCES; REPRODUCTIVE ISOLATION; EVOLUTION; FISHES; MALAWI; ANIMALS; AFRICA; PISCES	THE existence of sympatric speciation-that populations diverge into species in the absence of physical or ecological barriers-is controversial1-6. The East African Great Lakes harbour hundreds of cichlid species representing only a few monophyletic lineages7,8, although palaeolimnological evidence9-11 and local restrictions on species distribution12 suggest that speciation in these lakes could have been allopatric13,14. The case for sympatry in restricted areas of Lakes Malawi and Tanganyika is stronger15-17 but not unassailable. A better case might be made for cichlid species flocks in small, ecologically monotonous crater lakes. Here we present a mitochondrial DNA analysis of cichlid species flocks endemic to two such lakes in Cameroon. The results suggest that the flocks in each lake are monophyletic: the implication being that each lake was colonized once only, the size and shape of each lake being such that subsequent diversification would have been sympatric.	MAX PLANCK INST VERHALTENSPHYSIOL,D-82319 SEEWIESEN,GERMANY	Max Planck Society	SCHLIEWEN, UK (corresponding author), INST ZOOL,POSTFACH 202136,D-80021 MUNICH,GERMANY.		Tautz, Diethard/D-4304-2011; Langerhans, R. Brian/A-7205-2009; Villsen, Kurt/C-7965-2015; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOMINEY WJ, 1988, ENVIRON BIOL FISH, V22, P155, DOI 10.1007/BF00001545; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; FELSENSTEIN JP, 1990, VERSION 3 3; FUTUYMA DJ, 1980, SYST ZOOL, V29, P254, DOI 10.2307/2412661; Grant P.R., 1989, P433; GREENWOOD PH, 1987, B BRIT MUS NAT HIST, V83, P139; HASSERT K, 1912, Z GES ERDK BERL, P135; HASSERT K, 1912, Z GES ERDK BERL, P7; HASSERT K, 1912, Z GES ERDK BERL, P203; KING GW, 1987, THESIS DUKE U PRINCE; KLING GW, 1988, LIMNOL OCEANOGR, V33, P27, DOI 10.4319/lo.1988.33.1.0027; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KONDRASHOV AS, 1986, BIOL J LINN SOC, V27, P201, DOI 10.1111/j.1095-8312.1986.tb01734.x; LIVINGSTONE DA, 1975, ANNU REV ECOL SYST, V6, P249, DOI 10.1146/annurev.es.06.110175.001341; Mayr E, 1984, EVOLUTION FISH SPECI, P3; MCKAYE ER, 1982, ZOOL J LINN SOC-LOND, V76, P91, DOI 10.1111/j.1096-3642.1982.tb01956.x; MCKAYE KR, 1984, EVOLUTION, V38, P215, DOI 10.1111/j.1558-5646.1984.tb00273.x; MCKAYE KR, 1980, ENVIRON BIOL FISH, V5, P75, DOI 10.1007/BF00000953; MEYER A, 1990, BIOL J LINN SOC, V39, P279, DOI 10.1111/j.1095-8312.1990.tb00517.x; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; NISHIDA M, 1991, EXPERIENTIA, V47, P974, DOI 10.1007/BF01929896; Otte D., 1989, SPECIATION ITS CONSE; OWEN RB, 1990, PROC R SOC SER B-BIO, V240, P519, DOI 10.1098/rspb.1990.0052; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PIMM SL, 1979, BIOL J LINN SOC, V11, P131, DOI 10.1111/j.1095-8312.1979.tb00030.x; RIBBINK AJ, 1983, AFR J ZOOL, V18, P1; Rice WR, 1987, EVOL ECOL, V1, P301, DOI 10.1007/BF02071555; RICE WR, 1990, EVOLUTION, V44, P1140, DOI 10.1111/j.1558-5646.1990.tb05221.x; Seger J., 1985, P43; SMITH JM, 1966, AM NAT, V100, P637, DOI 10.1086/282457; Stiassny M.L.J., 1992, Ichthyological Exploration of Freshwaters, V3, P311; STURMBAUER C, 1992, NATURE, V358, P578, DOI 10.1038/358578a0; TEUGELS GG, 1992, ANN SCI ZOOLOGIQUES, V266, P1; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; Tiercelin J.J., 1991, LAKE TANGANYIKA ITS, P7; TREWAVAS E, 1972, J ZOOL, V167, P41; TREWAVAS E, 1984, B BRIT MUS NAT HIST, V26, P331; UDOVIC D, 1980, AM NAT, V116, P621, DOI 10.1086/283654; VANDENAUDENAERD.DF, 1970, REV ZOOL BOT AFR, V82, P285	42	344	348	0	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					629	632		10.1038/368629a0	http://dx.doi.org/10.1038/368629a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145848				2022-12-28	WOS:A1994NF39200059
J	LOWE, HJ; BARNETT, GO				LOWE, HJ; BARNETT, GO			UNDERSTANDING AND USING THE MEDICAL SUBJECT-HEADINGS (MESH) VOCABULARY TO PERFORM LITERATURE SEARCHES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-USER; MEDLINE; INFORMATION; RETRIEVAL; STUDENTS; EDUCATION; SYSTEMS; ACCESS	The United States National Library of Medicine's (NLM) MEDLINE database is the largest and most widely used medical bibliographic database. MEDLINE is manually indexed with NLM's Medical Subject Headings (MeSH) vocabulary. Using MeSH, a searcher can potentially create powerful and unambiguous MEDLINE queries. This article reviews the structure and use of MeSH, directed toward the nonexpert, and outlines how MeSH may help resolve a number of common difficulties encountered when searching MEDLINE. The increasing importance of the MEDLINE database as an information resource and the trend toward individuals performing their own bibliographic searches makes it crucial that health care professionals become familiar with MeSH.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, COMP SCI LAB, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital								ACKERMAN MJ, 1993, RADIOGRAPHICS, V13, P939, DOI 10.1148/radiographics.13.4.8356280; BARNETT O, 1989, ACAD MED, V64, P187, DOI 10.1097/00001888-198904000-00004; BERNSTEIN F, 1988, CONTROL CLIN TRIALS, V9, P23, DOI 10.1016/0197-2456(88)90006-2; BLAIR DC, 1985, COMMUN ACM, V28, P289, DOI 10.1145/3166.3197; CHAMBLISS ML, 1991, J FAM PRACTICE, V32, P414; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DALRYMPLE PW, 1990, B MED LIBR ASSOC, V78, P224; FUNK ME, 1983, B MED LIBR ASSOC, V71, P176; HAYNES RB, 1985, ANN INTERN MED, V103, P812, DOI 10.7326/0003-4819-103-5-812; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1987, M D COMPUT, V4, P47; Hersh W, 1991, Proc Annu Symp Comput Appl Med Care, P808; HERSH WR, 1990, M D COMPUT, V7, P302; HEWISON NS, 1989, B MED LIBR ASSOC, V77, P332; HUMPHREYS BL, 1993, B MED LIBR ASSOC, V81, P170; HUMPHREYS BL, 1989, 13TH P S COMP APPL M, P475; HUTH EJ, 1989, B NEW YORK ACAD MED, V65, P647; KINGLAND LC, 1993, B MED LIBR ASSOC, V81, P178; LANCASTER F, 1968, EVALUATION MEDLARS D; LINDBERG DAB, 1989, METHOD INFORM MED, V28, P202; LINDBERG DAB, 1993, JAMA-J AM MED ASSOC, V269, P3124, DOI 10.1001/jama.269.24.3124; LINDBERG DAB, 1993, B MED LIBR ASSOC, V81, P71; Lowe H. J., 1988, Proceedings. The Twelfth Annual Symposium on Computer Applications in Medical Care (IEEE Cat. No.88CH2616-1), P535; Lowe H. J., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P445; LOWE HJ, 1987, 11TH P ANN S COMP AP, P717; MARSHALL JG, 1989, B MED LIBR ASSOC, V77, P48; McGrath F, 1993, Conn Med, V57, P155; MCKIBBON KA, 1990, COMPUT BIOMED RES, V23, P583, DOI 10.1016/0010-4809(90)90042-B; MITCHELL JA, 1990, ACAD MED, V65, P434, DOI 10.1097/00001888-199007000-00003; MITCHELL JA, 1992, COMPUT BIOMED RES, V25, P43, DOI 10.1016/0010-4809(92)90034-8; PORTER D, 1988, COMPUT BIOMED RES, V21, P488, DOI 10.1016/0010-4809(88)90007-9; PROUD VK, 1993, AM J HUM GENET, V52, P637; RADA R, 1987, COMPUT BIOMED RES, V20, P244, DOI 10.1016/0010-4809(87)90057-7; RODNICK JE, 1988, J MED EDUC, V63, P728; SALTON GS, 1983, INTR MODERN INFORMAT, P160; SCHUYLER PL, 1993, B MED LIBR ASSOC, V81, P217; Shearer B, 1989, J Am Board Fam Pract, V2, P191; SIEGEL ER, 1990, MED INFORMATICS COMP, P435; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; Walker C J, 1992, Proc Annu Symp Comput Appl Med Care, P483; WALLINGFORD KT, 1990, M D COMPUT, V7, P166; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; 1985, BASICS SEARCHING MED; 1994, MED SUBJECT HEADINGS	44	276	285	2	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1103	1108		10.1001/jama.271.14.1103	http://dx.doi.org/10.1001/jama.271.14.1103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151853				2022-12-28	WOS:A1994NE22800033
J	TONKS, A				TONKS, A			COMMUNITY CARE - THE 1ST YEAR .3. COMMUNITY CARE IN NORTHERN-IRELAND - A PROMISING START	BRITISH MEDICAL JOURNAL			English	Article								Integrated health and social services, generous funding, and a special sense of community have got Northern Ireland off to a promising start after the government's community care reforms. Public ignorance about the new arrangements remains a problem, but there is little evidence of serious hardship in any client group. The biggest threat is to nursing and residential homes, which face closure as increasing numbers of elderly and disabled people opt to stay at home. After only a year and without the benefit of formal evaluation, however, the real problems for disabled people and their carers may not yet have emerged.										ANCRAM M, 1994, HOUSE COMMONS O 0222, P238; DONNELLY M, 1991, LEAVING HOSPITAL NO; 1994, PEOPLE 1ST MONITORIN; 1992, REGIONAL STRATEGY NO; 1990, PEOPLE 1ST COMMUNITY	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					839	842		10.1136/bmj.308.6932.839	http://dx.doi.org/10.1136/bmj.308.6932.839			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND243	8167494	Green Published			2022-12-28	WOS:A1994ND24300029
J	VONMUTIUS, E; MARTINEZ, FD; FRITZSCH, C; NICOLAI, T; REITMEIR, P; THIEMANN, H				VONMUTIUS, E; MARTINEZ, FD; FRITZSCH, C; NICOLAI, T; REITMEIR, P; THIEMANN, H			SKIN-TEST REACTIVITY AND NUMBER OF SIBLINGS	BRITISH MEDICAL JOURNAL			English	Article							HAY-FEVER; HUMAN TH1; PREVALENCE; ASTHMA; CLONES; GAMMA; IL-4	Objective-To investigate the relation between skin test reactivity in children and number of siblings. Design-Cross sectional survey among school-children aged 9-11 years. Skin prick tests in the children and self completion of written questionnaire by their parents. Subjects-5030 children in Munich and 2623 children in Leipzig and Halle, Germany. Main outcome measures-Atopic status assessed by skin prick tests. Results-After possible confounders were controlled for, the prevalence of atopic sensitisation decreased linearly with increasing number of siblings (odds ratio=0.96 for one sibling, 0.67 for five or more siblings; P=0.005). In atopic children the severity of the skin test reaction as assessed by the weal size was not associated with the number of siblings. Conclusions-Factors directly or indirectly related to the number of siblings may decrease the susceptibility of children to become atopic. Thus, declining family size may in part contribute to the increased prevalence of atopic diseases reported in Western countries over the past few decades.	UNIV ARIZONA,CTR RESP SCI,DEPT PEDIAT,TUCSON,AZ; UNIV LEIPZIG,CHILDRENS HOSP,O-7010 LEIPZIG,GERMANY; MEDIS INST,ENVIRONM & HUMAN HLTH RES CTR,MUNICH,GERMANY; MARTIN LUTHER UNIV HALLE WITTENBERG,CHILDRENS HOSP,HALLE,GERMANY	University of Arizona; Leipzig University; Martin Luther University Halle Wittenberg	VONMUTIUS, E (corresponding author), UNIV MUNICH,CHILDRENS HOSP,LINDWURMSTR 4,W-8000 MUNICH 2,GERMANY.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERBIG B, 1991, ALLERGOLOGIE, V14, P51; Davis W, 1980, IARC SCI PUBL, V32, P192; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; KOMLOS L, 1992, BIOL NEONATE, V62, P379; MAGGI E, 1992, J IMMUNOL, V148, P2142; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258, DOI 10.1093/oxfordjournals.aje.a116434; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P327; SHEARER WT, 1977, J IMMUNOL, V119, P614; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VERONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, IN PRESS AM REV RESP; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; [No title captured]; 1991, SPSS STATISTICAL ALG	19	368	372	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					692	695		10.1136/bmj.308.6930.692	http://dx.doi.org/10.1136/bmj.308.6930.692			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142793	Green Published			2022-12-28	WOS:A1994NA86900020
J	SINGH, BM; PRESCOTT, JJW; GUY, R; WALFORD, S; MURPHY, M; WISE, PH				SINGH, BM; PRESCOTT, JJW; GUY, R; WALFORD, S; MURPHY, M; WISE, PH			EFFECT OF ADVERTISING ON AWARENESS OF SYMPTOMS OF DIABETES AMONG THE GENERAL PUBLIC - THE BRITISH-DIABETIC-ASSOCIATION STUDY	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; DIAGNOSIS	Objective-To determine the impact of posters advertising symptoms of diabetes on public knowledge of these symptoms. Design-Structured street interviews of members of the general public before, at the end of, and 10 weeks after a campaign advertising the main symptoms of diabetes. Setting-Basingstoke and Wolverhampton. Subjects-Three samples of 1000 members of the general public were interviewed. Samples were selected randomly but stratified to match the local population's age (20-75), sex, social class, and racial characteristics. Main outcome measures-Knowledge of symptoms of diabetes; perceived seriousness of diabetes; and induction of anxiety about symptoms in the target population. Results-Advertising significantly raised knowledge (without prompting) of symptoms: thirst, 245 before v 411 at end of campaign (P<0.0001) v 341 after (P=0.0012 v before); polyuria, 72 v 101 (P=0.0211) v 92 (P=0.5169); lethargy,; 180 v 373 (P<0.0001) v 298 (P<0.0001); knowledge of weight loss and visual disturbance was unaffected. The number of subjects lacking knowledge of any symptoms was reduced from 550 to 388 (P<0.0001). The perceived seriousness of diabetes was unaffected (mean 7.6 in each phase on a scale of 1 (not) to 10 (very). Before advertising, 449 (45%) claimed to have one or more symptoms of diabetes, but this number fell at the end of the campaign (403; P=0.0419) and 10 weeks afterwards (278; P<0.0001). Conclusions-An advertising campaign raised public knowledge of diabetes symptoms without inducing fear of diabetes or anxiety about symptoms. Its potential for achieving earlier detection of noninsulin dependent diabetes should be evaluated.	KILMARTIN BAKER LTD,LONDON WC2E 9OS,ENGLAND; BASINGSTOKE DIST GEN HOSP,BASINGSTOKE RG24 9NA,HANTS,ENGLAND; NEW CROSS HOSP,WOLVERHAMPTON WV10 0QP,W MIDLANDS,ENGLAND; BRITISH DIABET ASSOC,LONDON W1M 0BD,ENGLAND	New Cross Hospital	SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Hillson R M, 1985, Diabet Med, V2, P383; JACKSON DMA, 1991, DIABETIC MED, V8, P971, DOI 10.1111/j.1464-5491.1991.tb01540.x; MINCU I, 1970, MED INTERNAT, V304, P1331; SINGH BM, 1992, BRIT MED J, V304, P1154, DOI 10.1136/bmj.304.6835.1154; SOLER NG, 1969, BMJ-BRIT MED J, V3, P567, DOI 10.1136/bmj.3.5670.567; 1991, ADVERTISING WORKS	8	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					632	636		10.1136/bmj.308.6929.632	http://dx.doi.org/10.1136/bmj.308.6929.632			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148713	Green Published			2022-12-28	WOS:A1994MZ69800024
J	KEENE, GS; PARKER, MJ; PRYOR, GA				KEENE, GS; PARKER, MJ; PRYOR, GA			MORTALITY AND MORBIDITY AFTER HIP-FRACTURES	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL	Objective-To study the mortality and morbidity associated with proximal femoral fractures with reference to fracture type (intracapsular and extracapsular). Design-Consecutive prospective study with 12 month follow ups. Setting-Two British trauma receiving centres. Patients-1000 consecutive acute proximal femoral fractures (fractured necks of femur) in 972 patients. Results-Significantly higher mortality at one year was seen in patients with extracapsular fractures (188/490; 38%) than in those with intracapsular fractures (147/510; 29%; p < 0.01). Greater morbidity was experienced during the study period by patients with extracapsular fractures, who were less mobile and less independent at the time of their injury. Conclusions-The rise in average age of presentation with proximal femoral fracture is associated with a persistently high mortality (33%) and morbidity, greater in patients with an extracapsular fracture. Comparison with other studies, principally from outside Britain, is difficult, but despite advancing standards of care the mortality and morbidity of femoral neck fractures remains high, placing an ever increasing burden on the health service.	PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED & TRAUMA SURG,PETERBOROUGH PE3 6DA,ENGLAND		KEENE, GS (corresponding author), ADDENBROOKES HOSP,DEPT ORTHOPAED & TRAUMA SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							ALFFRAM PA, 1964, ACTA ORTHOP SCAND S, V65; Baker B R, 1978, J R Coll Gen Pract, V28, P557; CEDER L, 1980, CLIN ORTHOPAEDICS, V152, P173; COOPER A, 1824, TREATISE DISLOCATION, P108; DAHL E, 1980, ACTA ORTHOP SCAND, V51, P163, DOI 10.3109/17453678008990781; DOLK T, 1989, UPSALA J MED SCI, V94, P209, DOI 10.3109/03009738909178565; ELABDIEN BSZ, 1984, ACTA ORTHOP SCAND, V55, P284, DOI 10.3109/17453678408992357; EVANS JG, 1979, AGE AGEING, V8, P246, DOI 10.1093/ageing/8.4.246; FITTS WT, 1959, SURG GYNECOL OBSTET, V108, P7; GARDEN RS, 1961, J BONE JOINT SURG BR, V43, P647, DOI 10.1302/0301-620X.43B4.647; GRAHAM HJ, 1992, BRIT MED J, V305, P30, DOI 10.1136/bmj.305.6844.30; IONS GK, 1987, J BONE JOINT SURG BR, V69, P384, DOI 10.1302/0301-620X.69B3.3584189; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; KENZORA JE, 1984, CLIN ORTHOPAEDICS, V186, P45; KREUTZFELDT J, 1984, AGE AGEING, V13, P111, DOI 10.1093/ageing/13.2.111; LINTON P, 1944, ACTA CHIR SCAND S, V86; LIVESLEY B, 1992, BRIT MED J, V305, P2, DOI 10.1136/bmj.305.6844.2-a; Melton LI, 1983, OSTEOPOROTIC SYNDROM; PARKER MJ, 1991, ACTA ORTHOP SCAND, V62, P563, DOI 10.3109/17453679108994497; Parker MJ., 1993, HIP FRACTURE MANAGEM; PARKER MJ, 1922, J R SOC MED, V85, P152; SKINNER PW, 1988, J BONE JOINT SURG BR, V70, P677; THOMAS TG, 1974, BRIT MED J, V3, P456, DOI 10.1136/bmj.3.5928.456; WALLACE WA, 1987, INT MED S, V12, P3; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; 1989, FRACTURED NECK FEMUR	26	616	641	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1248	1250		10.1136/bmj.307.6914.1248	http://dx.doi.org/10.1136/bmj.307.6914.1248			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8166806	Bronze, Green Published			2022-12-28	WOS:A1993MH00100020
J	GINSBERG, LE; WILLIAMS, DW				GINSBERG, LE; WILLIAMS, DW			CEREBRAL INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											GINSBERG, LE (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27157, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1571	1571						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177247				2022-12-28	WOS:A1994NN21500005
J	BLACKWELL, B				BLACKWELL, B			NO MARGIN, NO MISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BLACKWELL B, 1992, HOSP COMMUNITY PSYCH, V43, P962; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; JELLINEK MS, 1993, JAMA-J AM MED ASSOC, V270, P1737, DOI 10.1001/jama.270.14.1737; MALCOLM R, 1993, JAMA-J AM MED ASSOC, V270, P90; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; SHARFSTEIN SS, 1993, AM J PSYCHIAT, V150, P7	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1466	1466		10.1001/jama.271.19.1466	http://dx.doi.org/10.1001/jama.271.19.1466			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176808				2022-12-28	WOS:A1994NK71100002
J	DEPAUW, BE; DERESINSKI, SC; FELD, R; LANEALLMAN, EF; DONNELLY, JP				DEPAUW, BE; DERESINSKI, SC; FELD, R; LANEALLMAN, EF; DONNELLY, JP			CEFTAZIDIME COMPARED WITH PIPERACILLIN AND TOBRAMYCIN FOR THE EMPIRIC TREATMENT OF FEVER IN NEUTROPENIC PATIENTS WITH CANCER - A MULTICENTER RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						CEFTAZIDIME; PIPERACILLIN; TOBRAMYCIN; NEUTROPENIA; FEVER	FEBRILE GRANULOCYTOPENIC PATIENTS; NEGATIVE BACILLARY INFECTIONS; ANTIBIOTIC-THERAPY; ANTIMICROBIAL THERAPY; PLUS PIPERACILLIN; INITIAL THERAPY; GENTAMICIN; CARBENICILLIN; CEPHALOTHIN; TICARCILLIN	Objective: To compare piperacillin and tobramycin with ceftazidime alone for the empiric treatment of fever in the neutropenic patient without evidence of skin infections or anaerobic infections. Design: A multicenter, randomized, controlled trial. Patients: 876 febrile, neutropenic episodes in 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation. Interventions: Patients received either intravenous ceftazidime (2 g every 8 h) or piperacillin (12 to 18 g/d in 4 to 6 divided doses plus tobramycin (1.7 to 2.0 mg/kg body weight every 8 h). Treatment could be modified at any time at the discretion of the investigator. Measurements: Percentage of satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events. Results: As a single agent, ceftazidime was as effective as the combination of piperacillin and tobramycin (62.7% satisfactory responses compared with 61.1%; odds ratio, 1.07; 95% CI, 0.79 to 1.44; P > 0.2). Equivalent responses were also obtained in episodes of profound neutropenia (odds ratio, 0.76; CI, 0.43 to 1.33; P > 0.2). Infectious mortality was 6% for ceftazidime and 8% for the combination therapy. Eradication of the infecting organisms was achieved in 79% of bacteremic episodes treated with ceftazidime compared with 68% of the episodes treated with the combination therapy (odds ratio, 1.76; CI, 0.92 to 3.38; P = 0.08), and rates for gram-negative rod bacteremia were also similar (95% compared with 77%; odds ratio, 5.25; CI, 1.0 to 27.5; P = 0.03). Superinfections developed in 38 episodes in each group. An adverse event occurred in 8% of episodes treated with ceftazidime compared with 20% of episodes treated with combination therapy (P < 0.001). Conclusion: Ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia.	STANFORD UNIV, SCH MED, PALO ALTO, CA 94062 USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ON, CANADA; GLAXO GRP RES LTD, GREENFORD UB6 0HE, MIDDX, ENGLAND	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; GlaxoSmithKline	DEPAUW, BE (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DIV HEMATOL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Donnelly, J Peter/AAC-1041-2019	Donnelly, J Peter/0000-0002-8521-335X				BODEY GP, 1990, CANCER, V65, P9, DOI 10.1002/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C; BODEY GP, 1976, AM J MED SCI, V271, P179, DOI 10.1097/00000441-197603000-00006; BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; CALANDRA T, 1993, ANN INTERN MED, V119, P584, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00006; DEPAUW B, 1985, ANTIMICROB AGENTS CH, V28, P824, DOI 10.1128/AAC.28.6.824; DEPAUW BE, 1983, J ANTIMICROB CHEMOTH, V12, P93, DOI 10.1093/jac/12.suppl_A.93; DONNELLY JP, 1985, J INFECTION, V11, P205, DOI 10.1016/S0163-4453(85)93063-4; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; ELLIOTT CR, 1988, CLIN INVEST MED, V11, P327; FAINSTEIN V, 1984, ARCH INTERN MED, V144, P1766, DOI 10.1001/archinte.144.9.1766; FAINSTEIN V, 1983, J ANTIMICROB CHEMOTH, V12, P101, DOI 10.1093/jac/12.suppl_A.101; FELD R, 1985, ARCH INTERN MED, V145, P1083, DOI 10.1001/archinte.145.6.1083; FELD R, 1984, ARCH INTERN MED, V144, P1005, DOI 10.1001/archinte.144.5.1005; GRANOWETTER L, 1988, PEDIATR INFECT DIS J, V7, P165, DOI 10.1097/00006454-198803000-00006; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; JOHNSON MP, 1990, J INFECT DIS, V162, P981, DOI 10.1093/infdis/162.4.981; KLASTERSKY J, 1988, EUR J CANCER CLIN ON, V24, pS35; MIDDLEMAN EL, 1972, CANCER-AM CANCER SOC, V30, P573, DOI 10.1002/1097-0142(197208)30:2<573::AID-CNCR2820300238>3.0.CO;2-O; NOVAKOVA I, 1990, SCAND J INFECT DIS, V22, P705, DOI 10.3109/00365549009027124; OHANLEY P, 1989, AM J MED, V87, P605; PICCART M, 1984, ANTIMICROB AGENTS CH, V26, P870, DOI 10.1128/AAC.26.6.870; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; RAMPHAL R, 1992, ANTIMICROB AGENTS CH, V36, P1062, DOI 10.1128/AAC.36.5.1062; RAMPHAL R, 1983, J ANTIMICROB CHEMOTH, V12, P81, DOI 10.1093/jac/12.suppl_A.81; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; SANDERS JW, 1991, J INFECT DIS, V164, P907, DOI 10.1093/infdis/164.5.907; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; VERHAGEN CS, 1987, ANTIMICROB AGENTS CH, V31, P191, DOI 10.1128/AAC.31.2.191; WADE JC, 1981, AM J MED, V71, P983, DOI 10.1016/0002-9343(81)90324-7; WADE JC, 1989, J INFECT DIS S7, V11, pS1572; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849; YOUNG LS, 1986, NEW ENGL J MED, V315, P580, DOI 10.1056/NEJM198608283150910; ZINNER SH, 1983, J CLIN ONCOL, V1, P597	36	183	187	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					834	844		10.7326/0003-4819-120-10-199405150-00004	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154643				2022-12-28	WOS:A1994NK45800004
J	WU, LJ; ERRINGTON, J				WU, LJ; ERRINGTON, J			BACILLUS-SUBTILIS SPOIIIE PROTEIN REQUIRED FOR DNA SEGREGATION DURING ASYMMETRIC CELL-DIVISION	SCIENCE			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; SPORULATION GENE; NUCLEOTIDE-SEQUENCE; ENDOSPORE FORMATION; COAT MORPHOGENESIS; SIGMA-F; REPLICATION; TRANSCRIPTION; DEPENDENCE	Sporulation in Bacillus subtilis begins with an asymmetric cell division, producing a smaller prespore and a larger mother cell, both of which contain intact copies of the chromosome. The spoIIIE gene is required for chromosome segregation into the prespore compartment. The effects of the spoIIIE36 mutation on sigma(F)-dependent transcription are an indirect consequence of the failure of certain genes to enter the cellular compartment in which their transcription factor has become active. SpoIIIE may also be required to prevent sigma(F) from becoming active in the mother cell.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Oxford			Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388; Wu, Ling Juan/0000-0003-2432-8820				ALLMANSBERGER R, UNPUB; Anagnostopoulos C., 1993, P425; BARER MR, UNPUB; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BENJAMIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6214, DOI 10.1073/pnas.80.20.6214; BUTLER PD, 1987, J GEN MICROBIOL, V133, P2359; BYLUND JE, 1993, J BACTERIOL, V175, P1886, DOI 10.1128/JB.175.7.1886-1890.1993; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DANIEL RA, 1993, J MOL BIOL, V232, P468, DOI 10.1006/jmbi.1993.1403; EAST AK, 1989, GENE, V81, P35, DOI 10.1016/0378-1119(89)90334-X; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; FOULGER D, 1989, MOL MICROBIOL, V3, P1247, DOI 10.1111/j.1365-2958.1989.tb00275.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; LAFFAN JJ, 1988, P NATL ACAD SCI USA, V85, P7452, DOI 10.1073/pnas.85.20.7452; LEWIS PJ, IN PRESS P NATL ACAD; LEWIS PM, UNPUB; LOBNEROLESEN A, 1992, J BACTERIOL, V174, P7883; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MCGINNESS T, 1979, J MOL BIOL, V134, P251, DOI 10.1016/0022-2836(79)90035-4; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; ROELS S, 1992, J BACTERIOL, V174, P575, DOI 10.1128/jb.174.2.575-585.1992; RYTER A, 1965, ANN I PASTEUR PARIS, V108, P40; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SETLOW P, UNPUB; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STEVENS CM, 1992, J BACTERIOL, V174, P586, DOI 10.1128/jb.174.2.586-594.1992; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P243; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; VANITERSON W, 1976, MICROBIOLOGY 1976, P128; WINSTON S, 1980, P NATL ACAD SCI-BIOL, V77, P2834, DOI 10.1073/pnas.77.5.2834; WU LB, UNPUB	45	280	290	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					572	575		10.1126/science.8160014	http://dx.doi.org/10.1126/science.8160014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160014				2022-12-28	WOS:A1994NH01000038
J	COLLINGHAM, DP				COLLINGHAM, DP			YOUR FUTURE IN YOUR HANDS	NATURE			English	Article											COLLINGHAM, DP (corresponding author), RUSTON POOLE INT,11-12 BUCKINGHAM GATE,LONDON SW1E 6LB,ENGLAND.							COLLINGHAM DP, 1993, BIOTECHNOLOGY, V2, pS44; INKSON K, 1993, I MANAGEMENT REPORT	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					777	778		10.1038/368777a0	http://dx.doi.org/10.1038/368777a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152491				2022-12-28	WOS:A1994NG55300067
J	NOBORI, T; MIURA, K; WU, DJ; LOIS, A; TAKABAYASHI, K; CARSON, DA				NOBORI, T; MIURA, K; WU, DJ; LOIS, A; TAKABAYASHI, K; CARSON, DA			DELETIONS OF THE CYCLIN-DEPENDENT KINASE-4 INHIBITOR GENE IN MULTIPLE HUMAN CANCERS	NATURE			English	Article							HUMAN GLIOMAS; SHORT ARM; CHROMOSOME-9; MELANOMA	CYTOGENETIC abnormalities of chromosome 9p21 are characteristic of malignant melanomas(1,2), gliomas(3), lung cancers(4) and leukaemias(5). From a panel of 46 human malignant cell lines, we localized by positional cloning the most frequently deleted region on 9p21. Sequence analysis of the isolated fragment reveals two open reading frames identical to the recently described complementary DNA for the inhibitor of cyclin-dependent kinase 4 (CDK4)(6). Polymerase chain reaction and Southern blot analysis confirmed the frequent deletion or rearrangement of the CDK4-inhibitor gene in melanomas, gliomas, lung cancers and leukaemias, and the absence of detectable gene transcripts. One carcinoma had a deletion entirety within the CDK4-inhibitor gene. The CDK4-inhibitor gene from a patient with dysplastic nevus syndrome had a germ-line nonsense mutation. The CDK4 inhibitor is thought to be a physiological suppressor of proliferation. Cells unable to produce the inhibitor may be prone to neoplastic transformation.	CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Novartis	NOBORI, T (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HARPER JW, 1993, CELL, V75, P805; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1993, CANCER RES, V53, P1098; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PETTY EM, 1993, AM J HUM GENET, V53, P96; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	13	1720	1855	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					753	756		10.1038/368753a0	http://dx.doi.org/10.1038/368753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152487				2022-12-28	WOS:A1994NG55300062
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW FOOD CODE PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V271, P812	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-28	WOS:A1994NE22800006
J	CHUNG, H; CAFFREY, M				CHUNG, H; CAFFREY, M			THE CURVATURE ELASTIC-ENERGY FUNCTION OF THE LIPID-WATER CUBIC MESOPHASE	NATURE			English	Article							X-RAY-DIFFRACTION; MEMBRANE-LIPIDS; PHASES; LAMELLAR; TRANSITIONS; SYSTEMS; CRYSTALS; SURFACE	CELL and lipid membranes are able to bend, as manifested during membrane fusion and the formation of non-lamellar lyotropic mesophases in water. But there is an energy cost to bending of lipid layers, called the curvature elastic energy. Although the functional form of this energy is known(1), a complete quantitative knowledge of the curvature elastic energy, which is central to predicting the relative stability of the large number of phases that lipid membranes can adopt, has been lacking. Here we use X-ray synchrotron diffraction measurements of the variation of lattice parameter with pressure and temperature for the periodic Ia3d (Q(230)) cubic phase of hydrated monoolein to calculate the complete curvature elastic-energy function for the lipid cubic mesophase. This allows us to predict the stabilities of different cubic and lamellar phases for this system as a function of composition.			CHUNG, H (corresponding author), OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210, USA.							ANDERSON DM, 1988, P NATL ACAD SCI USA, V85, P5364, DOI 10.1073/pnas.85.15.5364; ANDERSSON S, 1988, CHEM REV, V88, P221, DOI 10.1021/cr00083a011; CAFFREY M, 1987, BIOCHEMISTRY-US, V26, P6349, DOI 10.1021/bi00394a008; CHUNG H, IN PRESS BIOPHYS J; CHUNG HS, 1992, BIOPHYS J, V63, P438, DOI 10.1016/S0006-3495(92)81621-1; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HYDE ST, 1984, Z KRISTALLOGR, V168, P213, DOI 10.1524/zkri.1984.168.1-4.213; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; KOZLOV MM, 1991, J PHYS II, V1, P1077, DOI 10.1051/jp2:1991201; LARSSON K, 1983, NATURE, V304, P664, DOI 10.1038/304664c0; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1979, J AM CHEM SOC, V101, P5465, DOI 10.1021/ja00513a002; LONGLEY W, 1983, NATURE, V303, P612, DOI 10.1038/303612a0; MARIANI P, 1988, J MOL BIOL, V204, P165, DOI 10.1016/0022-2836(88)90607-9; MICHEL BE, 1973, PLANT PHYSIOL, V51, P914, DOI 10.1104/pp.51.5.914; NANAVATI C, 1992, BIOPHYS J, V63, P1118, DOI 10.1016/S0006-3495(92)81679-X; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; RAND RP, 1990, BIOCHEMISTRY-US, V29, P76, DOI 10.1021/bi00453a010; SCRIVEN LE, 1976, NATURE, V263, P123, DOI 10.1038/263123a0; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; TATE MW, 1991, CHEM PHYS LIPIDS, V57, P147, DOI 10.1016/0009-3084(91)90073-K; TEMPLER RH, IN PRESS BIOPHYSICAL; TURNER DC, 1992, J PHYS II, V2, P2039, DOI 10.1051/jp2:1992250	24	107	108	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					224	226		10.1038/368224a0	http://dx.doi.org/10.1038/368224a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145820				2022-12-28	WOS:A1994NA87000048
J	FINER, JT; SIMMONS, RM; SPUDICH, JA				FINER, JT; SIMMONS, RM; SPUDICH, JA			SINGLE MYOSIN MOLECULE MECHANICS - PICONEWTON FORCES AND NANOMETER STEPS	NATURE			English	Article							RABBIT PSOAS MUSCLE; KINESIN MOLECULES; SLIDING DISTANCE; SKELETAL-MUSCLE; ACTIN FILAMENT; MOVEMENT; INVITRO; FIBERS; CONTRACTION; ATP	A new in vitro assay using a feedback enhanced laser trap system allows direct measurement of force and displacement that results from the interaction of a single myosin molecule with a single suspended actin filament. Discrete stepwise movements averaging ai nm were seen under conditions of low load, and single force transients averaging 3-4 pN were measured under isometric conditions. The magnitudes of the single forces and displacements are consistent with predictions of the conventional swinging-crossbridge model of muscle contraction.	STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOL,STANFORD,CA 94305; KINGS COLL LONDON,RANDALL INST,MRC MUSCLE & CELL MOTIL UNIT,LONDON WC2B 5RL,ENGLAND	Stanford University; Stanford University; University of London; King's College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGSHAW CR, 1993, MUSCLE CONTRACTION, P98; BERGER CL, 1993, BIOCHEMISTRY-US, V32, P3812, DOI 10.1021/bi00065a038; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRENNER B, 1991, J PHYSIOL-LONDON, V441, P703, DOI 10.1113/jphysiol.1991.sp018774; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P10490, DOI 10.1073/pnas.88.23.10490; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FAJER PG, 1990, P NATL ACAD SCI USA, V87, P5538, DOI 10.1073/pnas.87.14.5538; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1988, CELL MOTIL CYTOSKEL, V10, P71, DOI 10.1002/cm.970100112; HASELGROVE JC, 1973, J MOL BIOL, V77, P549, DOI 10.1016/0022-2836(73)90222-2; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1957, PROG BIOPHYS BIOPHYS, V7, P225; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SIMMONS RM, 1993, MECHANISM MYOFILAMEN; SIMMONS RM, UNPUB BIOPHYS J; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, IN PRESS REV BIOPHYS; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1993, METHOD CELL BIOL, P1; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, P103; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YOSHINO S, 1978, BIOPHYS CHEM, V8, P317, DOI 10.1016/0301-4622(78)80014-3	45	1518	1547	6	211	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					113	119		10.1038/368113a0	http://dx.doi.org/10.1038/368113a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139653				2022-12-28	WOS:A1994NA03000055
J	TENNISON, M; GREENWOOD, R; LEWIS, D; THORN, M				TENNISON, M; GREENWOOD, R; LEWIS, D; THORN, M			DISCONTINUING ANTIEPILEPTIC DRUGS IN CHILDREN WITH EPILEPSY - A COMPARISON OF A 6-WEEK AND A 9-MONTH TAPER PERIOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; CHILDHOOD EPILEPSY; WITHDRAWAL; THERAPY; PROGNOSIS; SEIZURES; MEDICATION	Background. The optimal regimen for discontinuing antiepileptic medications in children with epilepsy is unknown. Methods. We randomly assigned 149 children to either a six-week or a nine-month period of drug tapering, after which therapy was discontinued. Each group was composed of patients who had been seizure-free for either two or four years before drug tapering was begun. Most patients were receiving one antiepileptic drug; none were taking more than two. The children were evaluated periodically during and after the taper period. Sixteen patients were lost to follow-up before the beginning of the taper period. Proportional-hazards regression analysis was used to assess the risk of seizure recurrence among the remaining 133 patients. Results. Seizures recurred in 53 patients (40 percent). The mean duration of follow-up was 39 months (range, 11 to 105) for the patients who did not have a recurrence of seizures. Neither the length of the taper period (six weeks vs, nine months, P = 0.38) nor the length of time the patients were free of seizures before the taper period was begun (two years vs. four years, P = 0.20) significantly influenced the risk of seizure recurrence. The presence of mental retardation (relative risk, 3.1; 95 percent confidence interval, 1.5 to 6.2) or spikes in the electroencephalogram at the time of tapering (relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.4) increased the risk of seizure recurrence. Conclusions. The risk of seizure recurrence during drug tapering and after the discontinuation of antiepileptic drug therapy in children with epilepsy is not different whether the medications are tapered over a six-week or a nine-month period.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM NEUROBIOL,CHAPEL HILL,NC 27599; DUKE UNIV,DEPT PEDIAT,DURHAM,NC 27706; BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Burroughs Wellcome Fund	TENNISON, M (corresponding author), UNIV N CAROLINA,DEPT NEUROL,CB 7025,CHAPEL HILL,NC 27599, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 000046] Funding Source: Medline; NIDCR NIH HHS [R01-DE-06541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1981, EPILEPSIA, V22, P489; ARTS WFM, 1988, EPILEPSIA, V29, P244, DOI 10.1111/j.1528-1157.1988.tb03713.x; BOUMA PAD, 1987, J NEUROL NEUROSUR PS, V50, P1579, DOI 10.1136/jnnp.50.12.1579; BROMFIELD EB, 1989, NEUROLOGY, V39, P905, DOI 10.1212/WNL.39.7.905; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; DUNCAN JS, 1987, EPILEPSY RES, V1, P357, DOI 10.1016/0920-1211(87)90060-X; EMERSON R, 1981, NEW ENGL J MED, V304, P1125, DOI 10.1056/NEJM198105073041902; ESSIG C. F., 1967, EPILEPSIA, V8, P21; Fox JT, 1927, LANCET, V2, P589; GOTMAN J, 1984, CLIN NEUROPHARMAC S1, V7, P132; GRINKER RR, 1929, JAMA-J AM MED ASSOC, V93, P1218; HOLOWACH J, 1972, NEW ENGL J MED, V286, P169, DOI 10.1056/NEJM197201272860401; ISBELL H, 1950, ARCH NEURO PSYCHIATR, V64, P1; JANZ D, 1976, EPILEPTOLOGY, P228; JUULJENSEN P, 1964, EPILEPSIA, V5, P352, DOI 10.1111/j.1528-1157.1964.tb03341.x; Kalinowsky LB, 1942, ARCH NEURO PSYCHIATR, V48, P946, DOI 10.1001/archneurpsyc.1942.02290120098006; MARCIANI MG, 1985, NEUROLOGY, V35, P1537, DOI 10.1212/WNL.35.11.1537; MASTROPAOLO C, 1992, EUR NEUROL, V32, P141, DOI 10.1159/000116811; MATRICARDI M, 1989, EPILEPSIA, V30, P582, DOI 10.1111/j.1528-1157.1989.tb05476.x; MERRITT HH, 1958, BRIT MED J, V1, P666, DOI 10.1136/bmj.1.5072.666; OLLERDAURELLA L, 1976, EPILEPTOLOGY, P218; OLLERDAURELLA L, 1977, EPILEPSY, P69; Overweg J, 1981, ADV EPILEPTOLOGY 12, P503; PESTRE M, 1987, REV NEUROL, V143, P40; RODIN EA, 1980, ADV EPILEPTOL, P183; SHINNAR S, 1985, NEW ENGL J MED, V313, P976, DOI 10.1056/NEJM198510173131603; THEODORE WH, 1983, ANN NEUROL, V13, P320, DOI 10.1002/ana.410130316; THEODORE WH, 1987, ANN NEUROL, V22, P644, DOI 10.1002/ana.410220515; THURSTON JH, 1982, NEW ENGL J MED, V306, P831, DOI 10.1056/NEJM198204083061403; TODT H, 1984, EPILEPSIA, V25, P137, DOI 10.1111/j.1528-1157.1984.tb04169.x; WIKLER A, 1955, ELECTROEN CLIN NEURO, V7, P1, DOI 10.1016/0013-4694(55)90054-7; WULFF MH, 1959, ELECTROENCEPHALOGR S, P14; ZENKER C, 1957, Z KINDERHEILKD, V2, P152; 1991, LANCET, V337, P1175	35	105	108	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1407	1410		10.1056/NEJM199405193302002	http://dx.doi.org/10.1056/NEJM199405193302002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159193	Bronze			2022-12-28	WOS:A1994NK97200002
J	INNIS, BL; SNITBHAN, R; KUNASOL, P; LAORAKPONGSE, T; POOPATANAKOOL, W; KOZIK, CA; SUNTAYAKORN, S; SUKNUNTAPONG, T; SAFARY, A; TANG, DB; BOSLEGO, JW				INNIS, BL; SNITBHAN, R; KUNASOL, P; LAORAKPONGSE, T; POOPATANAKOOL, W; KOZIK, CA; SUNTAYAKORN, S; SUKNUNTAPONG, T; SAFARY, A; TANG, DB; BOSLEGO, JW			PROTECTION AGAINST HEPATITIS-A BY AN INACTIVATED VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							A VIRUS; EPIDEMIC; TABLES	Objective.-To evaluate the safety and efficacy of a new inactivated hepatitis A vaccine. Design.-Double-blind randomized controlled trial stratified by community. Setting.-Community-based in Thailand. Study Participants.-A total of 40119 children, aged 1 to 16 years, attending 148 primary schools: 38157 (95%) entered surveillance a mean of 138 days after receiving vaccine dose 1; 33586 (84%) completed the controlled trial of 532 days; and 31075 (81%) received crossover vaccine and remained under surveillance until day 844. Intervention.-Participants received hepatitis A vaccine or control hepatitis B vaccine starting January 7, 1991 (doses in months 0, 1, and 12), and crossed over to the alternate vaccine 18 months later. Main Outcome Measure.-Cases of hepatitis A (symptoms, alanine aminotransferase levels of 45 U/L or higher, and IgM to hepatitis A virus) were identified by evaluating school absences of 2 or more days. Results.-There were no serious adverse reactions despite administration of more than 109 000 doses of hepatitis A vaccine. Among initially seronegative recipients of two doses of hepatitis A vaccine, the proportion with 20 mlU/mL or more of antibody to hepatitis A virus before and 5 months after a 1-year booster was 94% and 99%, respectively. Of 6976 episodes of illness during the controlled trial, there were 40 cases of hepatitis A; 38 were in the control group. Of the 40 cases, six, all in controls, occurred after the 1-year booster dose. Following two doses of hepatitis A vaccine (days 138 through 386), protective efficacy was 94% (95% confidence interval, 79% to 99%); cumulative efficacy including the postbooster period (days 138 to 532) was 95% (95% confidence interval, 82% to 99%). The two hepatitis A vaccine recipients who had symptomatic infections (257 and 267 days after dose 1) appeared to have been partially protected since their illnesses were brief and associated with only slight increases in alanine aminotransferase. Conclusions.-Inactivated hepatitis A vaccine is safe; when administered in two doses, it protects against hepatitis A for at least 1 year.	ARMED FORCES RES INST MED SCI, USA MED COMPONENT, DEPT VIROL, BANGKOK, THAILAND; MINIST PUBL HLTH, DEPT COMMUNICABLE DIS CONTROL, BANGKOK, THAILAND; KAMPHAENG PHET PROV HOSP, KAMPHAENG PHET, THAILAND; KAMPHAENG PHET PROV PUBL HLTH OFF, KAMPHAENG PHET, THAILAND; SMITHKLINE BEECHAM BIOL, RIXENSART, BELGIUM	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Ministry of Public Health - Thailand; GlaxoSmithKline	INNIS, BL (corresponding author), WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, DIV BIOMETR, WASHINGTON, DC 20307 USA.			Innis, Bruce/0000-0002-1753-7248				ANDRE FE, 1990, PROG MED VIROL, V37, P72; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; ANDRE FE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P85; BINN LN, 1986, J INFECT DIS, V153, P749, DOI 10.1093/infdis/153.4.749; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEM A, 1993, VACCINE, V11, P479, DOI 10.1016/0264-410X(93)90291-5; ELLERBECK E, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P91; FLEHMIG B, 1989, LANCET, V1, P1039; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; HALL WT, 1977, AM J EPIDEMIOL, V106, P72, DOI 10.1093/oxfordjournals.aje.a112435; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; INNIS BL, 1992, VACCINE, V10, pS159, DOI 10.1016/0264-410X(92)90575-5; INNIS BL, 1991, J INFECT DIS, V163, P989, DOI 10.1093/infdis/163.5.989; LEDNAR WM, 1985, AM J EPIDEMIOL, V122, P226, DOI 10.1093/oxfordjournals.aje.a114093; LEE SD, 1993, GASTROENTEROLOGY, V104, P1129, DOI 10.1016/0016-5085(93)90283-I; MIETTIMEN OS, 1985, THEORETICAL EPIDEMIO; MOSLEY JW, 1968, AM J EPIDEMIOL, V87, P539, DOI 10.1093/oxfordjournals.aje.a120845; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; PROVOST PJ, 1986, J MED VIROL, V19, P23, DOI 10.1002/jmv.1890190105; ROBERTSON BH, 1991, J INFECT DIS, V163, P286, DOI 10.1093/infdis/163.2.286; SJOGREN MH, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P88; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WOODSON RD, 1969, J AMER MED ASSOC, V209, P1053, DOI 10.1001/jama.209.7.1053; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1991, STATXACT STATISTICAL	25	343	356	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1328	1334		10.1001/jama.271.17.1328	http://dx.doi.org/10.1001/jama.271.17.1328			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158817				2022-12-28	WOS:A1994NH48700024
J	DETOGNI, P; GOELLNER, J; RUDDLE, NH; STREETER, PR; FICK, A; MARIATHASAN, S; SMITH, SC; CARLSON, R; SHORNICK, LP; STRAUSSSCHOENBERGER, J; RUSSELL, JH; KARR, R; CHAPLIN, DD				DETOGNI, P; GOELLNER, J; RUDDLE, NH; STREETER, PR; FICK, A; MARIATHASAN, S; SMITH, SC; CARLSON, R; SHORNICK, LP; STRAUSSSCHOENBERGER, J; RUSSELL, JH; KARR, R; CHAPLIN, DD			ABNORMAL-DEVELOPMENT OF PERIPHERAL LYMPHOID ORGANS IN MICE DEFICIENT IN LYMPHOTOXIN	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-BETA LYMPHOTOXIN; HUMAN-ENDOTHELIAL CELLS; FACTOR-ALPHA; INTERFERON-GAMMA; GROWTH-FACTOR; MOUSE; EXPRESSION; PROLIFERATION; ACTIVATION	Mice rendered deficient in lymphotoxin (LT) by gene targeting in embryonic stem cells have no morphologically detectable lymph nodes or Peyer's patches, although development of the thymus appears normal. Within the white pulp of the spleen, there is failure of normal segregation of B and T cells. Spleen and peripheral blood contain CD4(+)CD8(-) and CD4(-)CD8(+) T cells in a normal ratio, and both T cell subsets have an apparently normal lytic function. Lymphocytes positive for immunoglobulin M are present in increased numbers in both the spleen and peripheral blood: These data suggest an essential role for LT in the normal development of peripheral lymphoid organs.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; MONSANTO CO, DEPT IMMUNOL, ST LOUIS, MO 63198 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Monsanto; Yale University; Washington University (WUSTL)				Chaplin, David/0000-0002-1354-3069; Russell, John/0000-0002-3680-9587; Shornick, Laurie/0000-0001-6652-1878	NCI NIH HHS [CA 28533, CA 16885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016885, R01CA028533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROUDY VC, 1987, J IMMUNOL, V138, P4298; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CASEY ML, 1989, J CLIN INVEST, V83, P430, DOI 10.1172/JCI113901; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CONTA BS, 1985, J IMMUNOL, V134, P2185; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; EARDLEY DD, 1980, J IMMUNOL, V124, P1199; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GRANGER GA, 1968, NATURE, V218, P1253, DOI 10.1038/2181253a0; GRAY PW, 1987, NUCLEIC ACIDS RES, V15, P3937, DOI 10.1093/nar/15.9.3937; KEHRL JH, 1987, SCIENCE, V238, P1144, DOI 10.1126/science.3500512; KRANGEL MS, 1990, J EXP MED, V172, P847, DOI 10.1084/jem.172.3.847; LI CB, 1987, J IMMUNOL, V138, P4496; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLET I, IN PRESS J IMMUNOL; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; OHSAWA T, 1989, DEV BIOL, V135, P459, DOI 10.1016/0012-1606(89)90194-2; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PEPPEL K, 1993, J IMMUNOL, V151, P5699; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1987, J IMMUNOL, V138, P3319; POWELL MB, 1985, LYMPHOKINE RES, V4, P13; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; ROSENAU W, 1979, CELL IMMUNOL, V43, P235, DOI 10.1016/0008-8749(79)90169-2; RUDDLE NH, 1967, SCIENCE, V157, P1060, DOI 10.1126/science.157.3792.1060; RUDDLE NH, 1968, J EXP MED, V128, P1267, DOI 10.1084/jem.128.6.1267; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI DOI 10.1084/JEM.172.4.1193; RUSSELL JH, 1980, J IMMUNOL, V125, P1256; SAKSELA E, 1989, International Journal of Developmental Biology, V33, P173; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C	36	805	827	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	1994	264	5159					703	707		10.1126/science.8171322	http://dx.doi.org/10.1126/science.8171322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171322				2022-12-28	WOS:A1994NH71300032
J	KELLER, M; BLOCHL, E; WACHTERSHAUSER, G; STETTER, KO				KELLER, M; BLOCHL, E; WACHTERSHAUSER, G; STETTER, KO			FORMATION OF AMIDE BONDS WITHOUT A CONDENSATION AGENT AND IMPLICATIONS FOR ORIGIN OF LIFE	NATURE			English	Article							PYRITE FORMATION; EVOLUTION; BIOCHEMISTRY; WORLD	AMIDE bonds are of central importance for biochemistry; in the guise of peptide bonds, they form the backbone of proteins. The formation of amide bonds without the assistance of enzymes poses a major challenge for theories of the orgin of life. Enzyme-free formation of amide bonds between amino acids has been demonstrated in the presence of condensing agents such as cyanamide(1-4) Here we report the formation of amide bonds in aqueous solution in the absence of any condensing agent. We find that the formation of pyrite (FeS2) from FeS and H2S can provide the driving force for reductive acetylation of amino acids,vith mercaptoacetic acid (HSCH2COOH). The redox energy of pyrite formation permits the activation of the carboxylic acid group, which is converted to a species that reacts readily with amines. This process provides support for the chemo-autotrophic theory(5-8) for the origin of life, in which pyrite formation supplies the energy source for the first autocatalytic reproduction cycle.	LEHRSTUHL MIKROBIOL,D-93040 REGENSBURG,GERMANY				Keller, Martin/C-4416-2012					BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BRACK A, 1993, PURE APPL CHEM, V65, P1143, DOI 10.1351/pac199365061143; de Duve, 1991, BLUEPRINT CELL; DROBNER E, 1990, NATURE, V346, P742, DOI 10.1038/346742a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAWKER JR, 1981, ORIGINS LIFE, P225; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; ORO J, 1963, ANN NY ACAD SCI, V108, P464, DOI 10.1111/j.1749-6632.1963.tb13402.x; STREHLER BL, 1982, J MOL EVOL, V19, P1, DOI 10.1007/BF02100218; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; WEBER AL, 1984, ORIGINS LIFE EVOL B, V15, P17, DOI 10.1007/BF01809390	15	54	56	0	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					836	838		10.1038/368836a0	http://dx.doi.org/10.1038/368836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159243				2022-12-28	WOS:A1994NH71700065
J	HAYNES, RB; TAYLOR, DW; SACKETT, DL; THORPE, K; FERGUSON, GG; BARNETT, HJM				HAYNES, RB; TAYLOR, DW; SACKETT, DL; THORPE, K; FERGUSON, GG; BARNETT, HJM			PREVENTION OF FUNCTIONAL IMPAIRMENT BY ENDARTERECTOMY FOR SYMPTOMATIC HIGH-GRADE CAROTID STENOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; INDEX; ADL	Objective.-To determine whether carotid endarterectomy prevents deterioration of functional status among patients with transient ischemic attacks or nondisabling strokes and ipsilateral carotid stenosis of 70% to 99%. Design.-Multicentered randomized controlled trial with an average 18-month follow-up. Setting.-Fifty clinical centers in North America. Patients.-A total of 659 patients presenting with recent transient attacks or nondisabling stroke and ipsilateral atherosclerotic carotid stenosis of 70% to 99% were included. Patients were stable neurologically at the time of entry. No patient was lost to follow-up. Intervention.-Vascular surgeons and neurosurgeons were prescreened for low perioperative complication rates. Patients were randomly allocated to carotid endarterectomy plus continuing medical care (n=328) or medical care alone (n=331), including antiplatelet therapy. Main Outcome Measures.-All patients were assessed by neurologists for the occurrence of stroke and functional status at scheduled intervals after entry. Results.-In addition to a previously reported risk reduction for ipsilateral stroke for patients assigned to carotid endarterectomy, there was an absolute risk reduction (and relative risk reduction [RRR]) for functional status impairment of 5.6% (RRR, 69%) for vision, 4.6% (RRR, 87%) for comprehension of language, 8.3% (RRR, 88%) for fluency of speech, 4.3% (RRR, 84%) for swallowing, 6.0% (RRR, 53%) for lower-limb function, 9.3% (RRR, 75%) for upper-limb function, 7.4% (RRR, 60%) for shopping, and 10.5% (RRR, 50%) for visiting outside usual residence (P<.05, two-tailed, for all items). Conclusions.-Carotid endarterectomy reduced the risk for impairment of function among patients with recent symptomatic cerebral ischemia and ipsilateral high-grade carotid stenosis.	UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON,CANADA; ROBARTS RES INST,LONDON,ON,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	HAYNES, RB (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1200 MAIN ST W,ROOM 3H7,HAMILTON L8N 3Z5,ON,CANADA.			Haynes, Robert Brian/0000-0002-1453-3196; Thorpe, Kevin/0000-0002-7586-3893	NINDS NIH HHS [R01-NS-24456] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; BRORSSON B, 1984, SCAND J REHABIL MED, V16, P125; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247; FOX AJ, 1993, RADIOLOGY, V186, P316, DOI 10.1148/radiology.186.2.8421726; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HAYNES RB, 1987, JAMA-J AM MED ASSOC, V257, P2043, DOI 10.1001/jama.257.15.2043; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KATZ S, 1966, MEDICINE, V45, P236; North American Symptomatic Carotid Endarterectomy Trial, 1991, STROKE, V22, P711; POINDEXTER JM, 1991, J CARDIOVASC SURG, V32, P64; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; SUNDT TM, 1990, MAYO CLIN PROC, V65, P625, DOI 10.1016/S0025-6196(12)65124-6; 1991, LANCET, V337, P1235; 1985, NEW ENGL J MED, V313, P1191; 1991, NEW ENGL J MED, V325, P445	18	22	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1256	1259		10.1001/jama.271.16.1256	http://dx.doi.org/10.1001/jama.271.16.1256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	8151900				2022-12-28	WOS:A1994NG36200025
J	BAILEY, JJ; BLACK, ME; WILKIN, D				BAILEY, JJ; BLACK, ME; WILKIN, D			SPECIALIST OUTREACH CLINICS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC CLINICS; PRIMARY CARE	Objectives-To establish the extent and nature of specialist outreach clinics in primary care and to describe specialists' and general practitioners' views on outreach clinics. Design-Telephone interviews with hospital managers. Postal questionnaire surveys of specialists and general practitioners. Setting-50 hospitals in England and Wales. Subjects-50 hospital managers, all of whom responded. 96 specialists and 88 general practitioners involved in outreach clinics in general practice, of whom 69 (72%) and 46 (52%) respectively completed questionnaires. 122 additional general practitioner fundholders, of whom 72 (59%) completed questionnaires. Main outcome measures-Number of specialist outreach clinics; organisation and referral mechanism; waiting times; perceived benefits and problems. Results-28 of the hospitals had a total of 96 outreach clinics, and 32 fundholders identified a further 61 clinics. These clinics covered psychiatry (43), medical specialties (38),and surgical specialties (76). Patients were seen by the consultant in 96% (107) of clinics and general practitioners attended at only six clinics. 61 outreach clinics had shorter waiting times for first outpatient appointment than hospital clinics. The most commonly reported benefits for patients were ease of access and shorter waiting times. Conclusions-Specialist outreach clinics cover a wide range of specialties and are popular, especially in fundholding practices. These clinics do not seem to have increased the interaction between general practitioners and specialists.			BAILEY, JJ (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,CTR PRIMARY CARE RES,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.							ALLAN S, 1993, BRIT MED J, V306, P860, DOI 10.1136/bmj.306.6881.860-c; BENADY S, 1992, FUNDHOLDING, V1, P13; BUNCE C, 1992, FUNDHOLDING, V1, P12; BUNCE C, 1993, FUNDHOLDING, V2, P9; CREED F, 1989, J ROY COLL GEN PRACT, V39, P514; CROUCHMAN MR, 1986, PRACTITIONER, V230, P667; FARRELL WJ, 1993, BRIT MED J, V306, P860, DOI 10.1136/bmj.306.6881.860-a; GILES S, 1993, PULSE, V53, P9; Hughes J., 1993, HOSPITALS PRIMARY CA; JONES RR, 1993, BRIT MED J, V306, P586, DOI 10.1136/bmj.306.6877.586-a; LITTLE BC, 1993, EYE, V7, P180, DOI 10.1038/eye.1993.38; SPENCER NJ, 1993, ARCH DIS CHILD, V68, P496, DOI 10.1136/adc.68.4.496; STRATHDEE G, 1984, J ROY COLL GEN PRACT, V34, P615; TYRER P, 1984, BRIT J PSYCHIAT, V145, P15, DOI 10.1192/bjp.145.1.15; TYRER P, 1984, BRIT J PSYCHIAT, V145, P9, DOI 10.1192/bjp.145.1.9; WOOD J, 1991, BRIT J GEN PRACT, V41, P26; 1993, PRACTICES MAKE PERFE	17	71	71	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1083	1086		10.1136/bmj.308.6936.1083	http://dx.doi.org/10.1136/bmj.308.6936.1083			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173432	Green Published			2022-12-28	WOS:A1994NH48900027
J	SAWYERS, CL; DENNY, CT				SAWYERS, CL; DENNY, CT			CHRONIC MYELOMONOCYTIC LEUKEMIA - TEL-A-KINASE WHAT ETS ALL ABOUT	CELL			English	Review							CHRONIC MYELOGENOUS LEUKEMIA; ABL GENE; RECEPTOR; REARRANGEMENT; ACTIVATION; MUTATIONS		UNIV CALIF LOS ANGELES, INST MOLEC BIOL,DEPT PEDIAT,DIV HEMATOL ONCOL, GWYNNE HAZEN MEM LAB, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MED, DIV HEMATOL ONCOL, GWYNNE HAZEN MEM LAB, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					AFAR DHE, 1994, IN PRESS SCIENCE; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; COGSWELL PC, 1989, BLOOD, V74, P2629; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1992, ONCOGENE, V7, P237; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SHERR CJ, 1990, BLOOD, V75, P1; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	25	86	90	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					171	173		10.1016/0092-8674(94)90307-7	http://dx.doi.org/10.1016/0092-8674(94)90307-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168126				2022-12-28	WOS:A1994NH63400002
J	CONSTANT, P; DAVODEAU, F; PEYRAT, MA; POQUET, Y; PUZO, G; BONNEVILLE, M; FOURNIE, JJ				CONSTANT, P; DAVODEAU, F; PEYRAT, MA; POQUET, Y; PUZO, G; BONNEVILLE, M; FOURNIE, JJ			STIMULATION OF HUMAN GAMMA-DELTA T-CELLS BY NONPEPTIDIC MYCOBACTERIAL LIGANDS	SCIENCE			English	Article							HEAT-SHOCK PROTEIN; LYMPHOCYTES; RECEPTOR; TUBERCULOSIS; RECOGNITION; ANTIGEN; RESPONSES; SUBSET	Most human peripheral blood gammadelta T lymphocytes respond to hitherto unidentified mycobacterial antigens. Four ligands from Mycobacterium tuberculosis strain H37Rv that stimulated proliferation of a major human gammadelta T cell subset were isolated and partially characterized. One of these ligands, TUBag4, is a 5' triphosphorylated thymidine-containing compound, to which the three other stimulatory molecules are structurally related. These findings support the hypothesis that some gammadelta T cells recognize nonpeptidic ligands.	CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,DEPT 3,118 RTE NARBONNE,F-31062 TOULOUSE,FRANCE; INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Fournie, Jean-Jacques/J-7805-2013; Davodeau, Francois/M-1888-2015; François, Davodeau/GLU-4061-2022	Fournie, Jean-Jacques/0000-0001-6542-6908; François, Davodeau/0000-0001-8181-0192				AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BREITMAIER E, 1987, CARBON 13 NMR SPECTR, P401; CONSTANT P, UNPUB; DAVODEAU F, 1993, J IMMUNOL, V151, P1214; DAVODEAU F, 1993, J BIOL CHEM, V268, P15455; DAVODEAU F, UNPUB; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; FISCH P, 1992, J IMMUNOL, V148, P2315; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HAPP MP, 1989, NATURE, V342, P696, DOI 10.1038/342696a0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KABELITZ D, 1991, J EXP MED, V173, P1331, DOI 10.1084/jem.173.6.1331; KAUR I, 1993, J IMMUNOL, V150, P2046; MCCLOSKEY JA, 1974, BASIC PRINCIPLES NUC, V1, pCH3; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; PFEFFER K, 1992, J IMMUNOL, V148, P575; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; RAJAGOPALAN S, 1990, P NATL ACAD SCI USA, V87, P7020, DOI 10.1073/pnas.87.18.7020; RAULET DH, 1989, NATURE, V339, P342, DOI 10.1038/339342a0; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7	27	640	657	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					267	270		10.1126/science.8146660	http://dx.doi.org/10.1126/science.8146660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146660				2022-12-28	WOS:A1994NE41000039
J	BRONNER, CE; BAKER, SM; MORRISON, PT; WARREN, G; SMITH, LG; LESCOE, MK; KANE, M; EARABINO, C; LIPFORD, J; LINDBLOM, A; TANNERGARD, P; BOLLAG, RJ; GODWIN, AR; WARD, DC; NORDENSKJOLD, M; FISHEL, R; KOLODNER, R; LISKAY, RM				BRONNER, CE; BAKER, SM; MORRISON, PT; WARREN, G; SMITH, LG; LESCOE, MK; KANE, M; EARABINO, C; LIPFORD, J; LINDBLOM, A; TANNERGARD, P; BOLLAG, RJ; GODWIN, AR; WARD, DC; NORDENSKJOLD, M; FISHEL, R; KOLODNER, R; LISKAY, RM			MUTATION IN THE DNA MISMATCH REPAIR GENE HOMOLOG HMLH1 IS ASSOCIATED WITH HEREDITARY NONPOLYPOSIS COLON-CANCER	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; INSITU HYBRIDIZATION; PMS1; MUTL; HEXB	THE human DNA mismatch repair gene homologue, hMSH2, on chromosome 2p is involved in hereditary non-polyposis colon cancer (HNPCC)(1,2). On the basis of linkage data, a second HNPCC locus was assigned to chromosome 3p21-23 (ref. 3). Here we report that a human gene encoding a protein, hMLH1 (human MutL homologue), homologous to the bacterial DNA mismatch repair protein MutL, is located on human chromosome 3p21.3-23. We propose that hMLH1 is the HNPCC gene located on 3p because of the similarity of the hMLH1 gene product to the yeast DNA mismatch repair protein, MLH1(4,5), the coincident location of the hMLH1 gene and the HNPCC locus on chromosome 3, and hMLH1 missense mutations in affected individuals from a chromosome 3-linked HNPCC family.	OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,PORTLAND,OR 97201; DANA FARBER CANC INST,MOLEC BIOL CORE FACIL,BOSTON,MA 02115; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; KAROLINSKA HOSP,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN	Oregon Health & Science University; Harvard University; Dana-Farber Cancer Institute; Yale University; Yale University; University of Vermont; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Karolinska Institutet; Karolinska University Hospital				Smith, Leslie/0000-0001-6452-6624				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DT, 1990, CANCER SURV, V9, P585; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAN HJ, 1993, CANCER RES, V53, P5087; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LATIF F, 1992, CANCER RES, V52, P1451; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lyon M. F., 1993, Mouse Genome, V91, P40; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RISINGER JI, 1993, CANCER RES, V53, P5100; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WILLIAMSON MS, 1985, GENETICS, V110, P609; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135	30	1838	1911	0	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					258	261		10.1038/368258a0	http://dx.doi.org/10.1038/368258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145827				2022-12-28	WOS:A1994NA87000060
J	BROWN, CJ; WILLARD, HF				BROWN, CJ; WILLARD, HF			THE HUMAN X-INACTIVATION CENTER IS NOT REQUIRED FOR MAINTENANCE OF X-CHROMOSOME INACTIVATION	NATURE			English	Article							XIST GENE; LOCALIZATION; EXPRESSION; NUCLEUS; REGION; LOCUS; CELLS	X-CHROMOSOME inactivation occurs early in mammalian female development to achieve dosage compensation with males(1). Although it is widely accepted that this inactivation requires the presence in cis of the X-inactivation centre (XIC)(2-5), it is not known whether the XIC is required for the initiation, promulgation or maintenance of X inactivation(6,7). The XIST gene, which is localized within the XIC interval on both the human and mouse X chromosomes, is constitutively expressed from inactive X chromosomes(8-10), suggesting a possible role in the maintenance of X inactivation. To address whether the presence of the XIC, including the XIST gene, is continuously required for the maintenance of X-chromosome inactivation, we have analysed the transcriptional activity of a number of X-linked genes in mouse/human somatic cell hybrids retaining an intact human inactive X chromosome or derivatives of the inactive X chromosome lacking the XIC. Genes subject to X inactivation remain transcriptionally silent despite the loss of the XIC, demonstrating that the presence of the XIC is not required for the maintenance of X inactivation in somatic cells.			BROWN, CJ (corresponding author), CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,DEPT GENET,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.		Brown, Carolyn J/A-5159-2014	Brown, Carolyn J/0000-0002-8959-0101				[Anonymous], ADV DEV BIO; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1989, AM J HUM GENET, V45, P592; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; BROWN CJ, 1989, CYTOGENET CELL GENET, V51, P970; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN RM, 1989, GENOMICS, V4, P174, DOI 10.1016/0888-7543(89)90297-8; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GARTLER SM, 1992, MOL GENETIC MED, P121; GILES RE, 1979, GENETICS, V93, P975; GOODFELLOW P, 1984, AM J HUM GENET, V36, P777; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; LYON MF, 1963, 2ND INT C CONG MALF, P67; LYON MFA, 1992, REV GENET, V26, P17; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RIGGS AD, 1990, AUST J ZOOL, V37, P419, DOI 10.1071/ZO9890419; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196	26	238	245	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					154	156		10.1038/368154a0	http://dx.doi.org/10.1038/368154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139659				2022-12-28	WOS:A1994NA03000068
J	MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, C				MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, C			AN EVALUATION OF THE CARCINOEMBRYONIC ANTIGEN (CEA) TEST FOR MONITORING PATIENTS WITH RESECTED COLON-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; CARCINOMA; THERAPY	Objective.-To determine the effectiveness of carcinoembryonic antigen (CEA) monitoring in detecting surgically curable recurrence of colon cancer. Design.-Clinical data were collected from a national surgical adjuvant trial in which CEA monitoring was elective. Setting.-Cancer centers, universities, and community clinics. Patients.-A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring. Main Outcome Measures.-Sensitivity and specificity of CEA testing for cancer recurrence and CEA-motivated diagnostic and surgical interventions and their end results. Results.-Among 417 monitored patients with recurrence, 59% had a preceding elevation of CEA concentration. Sixteen percent of 600 patients without recurrence showed a false-positive test result. Carcinoembryonic antigen testing was most sensitive for hepatic or retroperitoneal metastasis and relatively insensitive for local, pulmonary, or peritoneal involvement. Surgical explorations were performed in 115 patients with CEA elevations, and 47 recurrences, usually hepatic, were resected with curative intent. On the other hand, 38 patients with normal CEA concentrations and 23 patients not monitored also underwent such resections-usually for pulmonary or local recurrence. Of all CEA-monitored patients, 2.3% are alive and disease free more than 1 year after salvage surgery (2.9% of those with CEA elevations and 1.9% of those with no elevations). Of patients with no CEA monitoring, 2.0% are also alive and disease free more than 1 year after salvage surgery. Conclusions.-Cancer cures attributable to CEA monitoring are, at best, infrequent. It is questionable whether this small gain justifies the substantial cost in dollars and physical and emotional stress that this intervention may cause for patients.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, PHILADELPHIA, PA 19140 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; GRAND FORKS CLIN LTD, GRAND FORKS, ND USA	Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	MOERTEL, CG (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL CANCER INSTITUTE [U10CA037404, U10CA025224, U10CA021115] Funding Source: NIH RePORTER; NCI NIH HHS [CA-25224, CA-37404, CA-21115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; Beatty J D, 1982, Prog Clin Cancer, V8, P9; BOEY J, 1984, WORLD J SURG, V8, P279, DOI 10.1007/BF01655052; DENTSMAN F, 1986, CANCER, V58, P2089; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; FUCINI C, 1983, TUMORI, V69, P359, DOI 10.1177/030089168306900415; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; KOCH M, 1982, J NATL CANCER I, V69, P813; MARTIN EW, 1980, J SURG RES, V28, P389, DOI 10.1016/0022-4804(80)90100-6; MINTON JP, 1985, CANCER, V55, P1284, DOI 10.1002/1097-0142(19850315)55:6<1284::AID-CNCR2820550622>3.0.CO;2-B; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NORTHOVER J, 1986, GUT, V27, P117, DOI 10.1136/gut.27.2.117; STEELE G, 1982, ANN SURG, V196, P162, DOI 10.1097/00000658-198208000-00008; WANEBO HJ, 1989, SURG GYNECOL OBSTET, V169, P479; WOLMARK N, 1984, ANN SURG, V199, P375, DOI 10.1097/00000658-198404000-00001; 1981, BMJ, V282, P373	16	403	415	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					943	947		10.1001/jama.270.8.943	http://dx.doi.org/10.1001/jama.270.8.943			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8141873				2022-12-28	WOS:A1993LT56700024
J	MILLER, RH; LUFT, HS				MILLER, RH; LUFT, HS			MANAGED CARE PLAN PERFORMANCE SINCE 1980 - A LITERATURE ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FEE-FOR-SERVICE; HEALTH-MAINTENANCE-ORGANIZATIONS; TRADITIONAL MEDICAID PLANS; PREPAID GROUP-PRACTICE; RHEUMATOID-ARTHRITIS; RESOURCE UTILIZATION; INSURANCE-COVERAGE; COLORECTAL-CANCER; RANDOMIZED TRIAL; CESAREAN-SECTION	Objective.-To compare the health care utilization, expenditure, quality of care, and satisfaction since 1980 of enrollees in managed care and indemnity plans. Data Sources and Study Selection.-Studies selected met the following criteria: data from 1980 forward, private insurance or Medicare enrollees, a comparison group, a reasonable attempt at statistical adjustment for noncomparable managed care and indemnity plan enrollees, and peer-reviewed findings (with two exceptions). Few studies on preferred provider organization plan performance met the selection criteria. Data Synthesis.-Compared with indemnity plans, health maintenance organization plans had somewhat lower hospital admission rates, 1% to 20% shorter hospital length of stay, the same or more physician office visits per enrollee, less use of expensive procedures and tests, greater use of preventive services, mixed results on outcomes, and somewhat lower enrollee satisfaction with services but higher satisfaction with costs. The evidence does not support the hypothesis that prepaid group practice or staff model health maintenance organizations are more effective than individual practice association or network model health maintenance organizations. Conclusions.-Although this literature analysis found several clear patterns of results, several factors, including unmeasured selection bias, diverse and rapidly changing health plans and local market conditions, and relatively few research results, suggest that generalizations must be made with caution.	UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MILLER, RH (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH & AGING, BOX 0646, LAUREL HTS, SAN FRANCISCO, CA 94143 USA.				PHS HHS [282-92-0040] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNOULD RJ, 1984, INQUIRY-J HEALTH CAR, V21, P243; BERNSTEIN AB, 1991, MED CARE, V29, P196; BRADBURY RC, 1991, INQUIRY-J HEALTH CAR, V28, P87; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; Bredfeldt R C, 1990, Fam Pract Res J, V9, P85; BROWN RS, 1993, MEDICARE RISK PROGRA; BROWN RS, 1993, DOES MODEL TYPE PLAY; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; CAREY TS, 1991, HEALTH SERV RES, V26, P165; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLEMENT DG, 1992, EVALUATION ACCESS SA; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P345, DOI 10.1001/archinte.149.2.345; DOWD B, 1991, REV ECON STAT, V73, P85, DOI 10.2307/2109690; FELDMAN R, 1993, HEALTH SERV RES, V27, P779; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; FRIEDMAN B, 1988, HEALTH SERV RES, V23, P237; GABEL J, 1991, HEALTH AFFAIR, V10, P48, DOI 10.1377/hlthaff.10.4.48; GABEL JR, 1992, HEALTH AFFAIR, V11, P186, DOI 10.1377/hlthaff.11.4.186; GARNICK DW, 1990, MED CARE, V28, P894, DOI 10.1097/00005650-199010000-00004; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HADLEY J, 1989, INQUIRY-J HEALTH CAR, V26, P35; HIGGINS F, 1992, F HIGGINS HLTH CARE; HILL J, 1992, IMPACT MEDICARE RISK; HLATKY MA, 1983, ARCH INTERN MED, V143, P1886, DOI 10.1001/archinte.143.10.1886; HURLEY RE, 1993, MANAGED CARE MEDICAI; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; KRIEGER JW, 1992, AM J PUBLIC HEALTH, V82, P185, DOI 10.2105/AJPH.82.2.185; LESSLER DS, 1992, ARCH INTERN MED, V152, P1665; LICHTENSTEIN R, 1992, MED CARE, V30, P329, DOI 10.1097/00005650-199204000-00004; LUBECK DP, 1985, MED CARE, V23, P266, DOI 10.1097/00005650-198503000-00008; LUFT HS, 1980, MED CARE, V18, P1, DOI 10.1097/00005650-198001000-00001; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1981, HLTH MAINTENANCE ORG; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MCCLOSKEY L, 1992, MED CARE, V30, P126, DOI 10.1097/00005650-199202000-00004; MCCOMBS JS, 1990, HEALTH SERV RES, V25, P593; MCCUSKER J, 1988, INQUIRY-J HEALTH CAR, V25, P263; MCLAUGHLIN CG, 1987, HEALTH SERV RES, V22, P183; MCLAUGHLIN CG, 1988, HEALTH SERV RES, V23, P421; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; MILLER NA, 1992, INT J ADDICT, V27, P533, DOI 10.3109/10826089209063467; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NEWCOMER R, 1993, SATISFACTION SOCIAL; NEWHOUSE JP, 1985, MED CARE, V23, P960, DOI 10.1097/00005650-198508000-00003; NORQUIST GS, 1991, AM J PSYCHIAT, V148, P96; ORNSTEIN SM, 1989, J FAM PRACTICE, V29, P163; PALSBO SJ, 1990, HMO IND PROFILE, V3; PRESTON JA, 1991, J AM GERIATR SOC, V39, P683, DOI 10.1111/j.1532-5415.1991.tb03622.x; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; RETCHIN SM, 1991, ARCH INTERN MED, V151, P2244, DOI 10.1001/archinte.151.11.2244; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RETCHIN SM, 1991, AM J MED, V90, P236; RETCHIN SM, 1992, QUALITY CARE TEFRA H; RILEY G, 1991, HEALTH SERV RES, V26, P137; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; ROSSITER LF, 1989, JAMA-J AM MED ASSOC, V262, P57, DOI 10.1001/jama.262.1.57; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SHORT PF, 1988, HEALTH AFFAIR, V7, P186, DOI 10.1377/hlthaff.7.3.186; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; SZILAGYI PG, 1990, JAMA-J AM MED ASSOC, V263, P2198, DOI 10.1001/jama.263.16.2198; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; UDVARHELYI IS, 1991, ANN INTERN MED, V327, P424; VERNON SW, 1992, CANCER, V69, P2418, DOI 10.1002/1097-0142(19920515)69:10<2418::AID-CNCR2820691006>3.0.CO;2-1; WARE JE, 1986, LANCET, V1, P1017; WELCH WP, 1985, J HEALTH ECON, V4, P293, DOI 10.1016/0167-6296(85)90010-4; WELLS KB, 1992, MED CARE, V30, P412, DOI 10.1097/00005650-199205000-00004; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298; WOLFE F, 1986, J RHEUMATOL, V13, P277; WOUTERS AV, 1990, MED CARE, V28, P573, DOI 10.1097/00005650-199007000-00004; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; ZWANZIGER J, 1991, MED CARE, V29, P142, DOI 10.1097/00005650-199102000-00006; 1993, 1992 HAY HUGGINS BEN; 1992, HLTH BENEFITS 1992	83	558	559	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1512	1519		10.1001/jama.271.19.1512	http://dx.doi.org/10.1001/jama.271.19.1512			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176832				2022-12-28	WOS:A1994NK71100031
J	CASH, JM; KLIPPEL, JH				CASH, JM; KLIPPEL, JH			2ND-LINE DRUG-THERAPY FOR RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DOSE METHOTREXATE; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED CLINICAL-TRIAL; LONG-TERM; DOUBLE-BLIND; FOLLOW-UP; LIVER BIOPSIES; ANTIRHEUMATIC DRUGS; D-PENICILLAMINE; 2ND-LINE DRUGS		NIAMS, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; CLEVELAND CLIN FDN, DEPT RHEUMAT & IMMUNOL DIS, CLEVELAND, OH 44195 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Cleveland Clinic Foundation								ALTMAN RD, 1992, AM J MED, V93, P396, DOI 10.1016/0002-9343(92)90169-C; ANTONELLI MAS, 1991, AM J MED, V90, P295, DOI 10.1016/0002-9343(91)80008-A; APONTE J, 1988, ARTHRITIS RHEUM, V31, P1457, DOI 10.1002/art.1780311201; BAILIN PL, 1975, JAMA-J AM MED ASSOC, V232, P359, DOI 10.1001/jama.232.4.359; BAKER GL, 1987, AM J MED, V83, P1, DOI 10.1016/0002-9343(87)90490-6; BAX DE, 1985, ANN RHEUM DIS, V44, P194, DOI 10.1136/ard.44.3.194; BOERS M, 1991, J RHEUMATOL, V18, P316; BORG G, 1988, J RHEUMATOL, V15, P1747; BRADLEY JD, 1989, ARTHRITIS RHEUM, V32, P45, DOI 10.1002/anr.1780320108; BRICK JE, 1989, SEMIN ARTHRITIS RHEU, V19, P31, DOI 10.1016/0049-0172(89)90085-1; CANNON GW, 1990, SEMIN ARTHRITIS RHEU, V19, P353, DOI 10.1016/0049-0172(90)90072-N; CARROLL GJ, 1994, J RHEUMATOL, V21, P51; CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002; CLEGG DO, 1989, J RHEUMATOL, V16, P1123; COOK GC, 1992, J INFECTION, V25, P1, DOI 10.1016/0163-4453(92)93369-2; CRONSTEIN BN, 1992, INFLAMMATION, V16, P411, DOI 10.1007/BF00918968; CROOCK A D, 1989, Arthritis and Rheumatism, V32, pS60; CSUKA ME, 1986, JAMA-J AM MED ASSOC, V255, P2315, DOI 10.1001/jama.255.17.2315; CURREY HLF, 1974, BMJ-BRIT MED J, V3, P763, DOI 10.1136/bmj.3.5934.763; DIAZ CJ, 1951, ANN RHEUM DIS, V10, P144, DOI 10.1136/ard.10.2.144; DWOSH IL, 1977, ARTHRITIS RHEUM, V20, P685, DOI 10.1002/art.1780200208; EPSTEIN WV, 1991, ANN INTERN MED, V114, P437, DOI 10.7326/0003-4819-114-6-437; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P140, DOI 10.1002/art.1780330119; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; FIRESTEIN GS, 1994, ARTHRITIS RHEUM, V37, P193, DOI 10.1002/art.1780370207; FLOOD DA, 1991, J RHEUMATOL, V18, P1254; FREEDMAN A, 1952, LANCET, V263, P321; FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303; FURST DE, 1990, J RHEUMATOL, V17, P1628; GIBSON T, 1987, BRIT J RHEUMATOL, V26, P279; GUBNER R, 1951, AM J MED SCI, V221, P176, DOI 10.1097/00000441-195102000-00009; HALL CL, 1988, BRIT MED J, V296, P1083, DOI 10.1136/bmj.296.6629.1083; HANNONEN P, 1993, HRITIS RHEUM, V36, P1501; HARGREAVES MR, 1992, THORAX, V47, P628, DOI 10.1136/thx.47.8.628; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1008; HIRATA S, 1989, ARTHRITIS RHEUM, V32, P1065, DOI 10.1002/anr.1780320903; HOCHBERG MC, 1993, J RHEUMATOL, V20, P1265; JAFFE IA, 1963, ANN RHEUM DIS, V22, P71, DOI 10.1136/ard.22.2.71; JEURISSEN MEC, 1991, ARTHRITIS RHEUM-US, V34, P961, DOI 10.1002/art.1780340805; JEURISSEN MEC, 1991, ANN INTERN MED, V114, P999, DOI 10.7326/0003-4819-114-12-999; JEURISSEN MEC, 1990, ANN RHEUM DIS, V49, P25, DOI 10.1136/ard.49.1.25; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KEERS RY, 1980, THORAX, V35, P884, DOI 10.1136/thx.35.12.884; KINGSMORE SF, 1992, J RHEUMATOL, V19, P1462; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1985, AM J MED S1A, V78, pA1; KIRSHON B, 1988, OBSTET GYNECOL, V72, P462; KREMER JM, 1994, J RHEUMATOL, V21, P1; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; KREMER JM, 1992, SEMIN ARTHRITIS RHEU, V21, P376, DOI 10.1016/0049-0172(92)90038-F; KREMER JM, 1990, ARTHRITIS RHEUM, V33, P810, DOI 10.1002/art.1780330607; KUSHNER I, 1993, RHEUM DIS CLIN N AM, V19, P163; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LANG B, 1991, J RHEUMATOL, V18, P1257; LAW KF, 1993, J RHEUMATOL, V20, P872; LOPEZMENDEZ A, 1993, IS RHEUM, V36, P1364; MACKINNON SK, 1985, SEMIN ARTHRITIS RHEU, V15, P119, DOI 10.1016/0049-0172(85)90029-0; MADHOK R, 1991, J RHEUMATOL, V18, P1485; MASON M, 1969, BMJ-BRIT MED J, V1, P420, DOI 10.1136/bmj.1.5641.420; MCHENRY PM, 1992, BRIT J DERMATOL, V127, P122, DOI 10.1111/j.1365-2133.1992.tb08043.x; MCKENDRY RJR, 1993, J RHEUMATOL, V20, P1850; MEENAN RF, 1991, ARTHRITIS RHEUM, V34, P761, DOI 10.1002/art.1780340618; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; MORAND EF, 1992, J RHEUMATOL, V19, P1998; MORAND EF, 1992, J RHEUMATOL, V19, P704; MORASSUT P, 1989, J RHEUMATOL, V16, P302; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; OLSEN NJ, 1989, ARTHRITIS RHEUM, V32, P378, DOI 10.1002/anr.1780320404; PENN I, 1986, TRANSPLANT P, V18, P210; PHILLIPS CA, 1992, J RHEUMATOL, V19, P229; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PORTER DR, 1993, J RHEUMATOL, V20, P645; RAU R, 1989, J RHEUMATOL, V16, P489; ROENIGK HH, 1988, J AM ACAD DERMATOL, V19, P145, DOI 10.1016/S0190-9622(88)80237-8; SAKKAS LI, 1993, ANN RHEUM DIS, V52, P300, DOI 10.1136/ard.52.4.300; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; SHERGY WJ, 1988, AM J MED, V85, P771; SHIROKY JB, 1993, ARTHRITIS RHEUM, V36, P795, DOI 10.1002/art.1780360609; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; SILVERBERG DS, 1970, ARTHRITIS RHEUM-US, V13, P812, DOI 10.1002/art.1780130611; SINGH G, 1991, J RHEUMATOL, V18, P188; SMITH PJ, 1982, BRIT MED J, V285, P595, DOI 10.1136/bmj.285.6342.595; SPERLING RI, 1992, ARTHRITIS RHEUM, V35, P376, DOI 10.1002/art.1780350403; Svartz N, 1942, ACTA MED SCAND, V110, P577; TAILLAN B, 1993, CLIN RHEUMATOL, V12, P93, DOI 10.1007/BF02231567; THOMAS MH, 1984, J RHEUMATOL, V11, P764; THOMAS R, 1993, ARTHRITIS RHEUM-US, V36, P1244, DOI 10.1002/art.1780360909; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; TUNN EJ, 1993, BRIT J RHEUMATOL, V32, P97; UROWITZ MB, 1973, ARTHRITIS RHEUM, V16, P411, DOI 10.1002/art.1780160319; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; VERSCHUUR AC, 1992, INT J DERMATOL, V31, P404, DOI 10.1111/j.1365-4362.1992.tb02669.x; WALKER AM, 1993, ARTHRITIS RHEUM, V36, P329, DOI 10.1002/art.1780360307; WEINBLATT, 1993, ARTHRITIS RHEUM, V36, P1028; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WHITINGOKEEFE QE, 1991, AM J MED, V90, P711; WILKINSON SM, 1993, BRIT J RHEUMATOL, V32, P798; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILLKENS RF, 1992, ARTHRITIS RHEUM-US, V35, P849, DOI 10.1002/art.1780350802; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1993, J RHEUMATOL, V20, P797; WOLFE F, 1991, J RHEUMATOL, V18, P1298; WOLFE F, 1993, J RHEUMATOL, V20, P2005; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1991, J RHEUMATOL, V18, P1774; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863; ZACHARIAE H, 1980, BRIT J DERMATOL, V102, P407, DOI 10.1111/j.1365-2133.1980.tb06553.x; ZACHARIAE H, 1991, J AM ACAD DERMATOL, V25, P50, DOI 10.1016/0190-9622(91)70173-Y; ZIJLMANS JMJM, 1992, NEW ENGL J MED, V326, P1363; 1970, NEW ENGL J MED, V283, P883	118	146	148	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1368	1375						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152450				2022-12-28	WOS:A1994NK75300008
J	SHORES, J; BERGER, KR; MURPHY, EA; PYERITZ, RE				SHORES, J; BERGER, KR; MURPHY, EA; PYERITZ, RE			PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM BETA-ADRENERGIC-BLOCKADE IN MARFANS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; PROPRANOLOL; ANEURYSM; SURVIVORSHIP; COLLAGEN; DISEASE; INFANCY; MODEL; AGE	Background. The aortic root enlarges progressively in Marfan's syndrome, and this enlargement is associated with aortic regurgitation and dissection. Longterm treatment with beta-adrenergic blockade, by reducing the impulse (i.e., the rate of pressure change in the aortic root) of left ventricular ejection and the heart rate, may protect the aortic root. Methods. We conducted an open-label, randomized trial of propranolol in adolescent and adult patients with classic Marfan's syndrome (32 treated and 38 untreated [control] patients). Aortic-root dimensions and clinical end points (aortic regurgitation, aortic dissection, cardiovascular surgery, congestive heart failure, and death) were monitored for an average of 9.3 years in the control group and 10.7 years in the treatment group. All 70 patients were included in the analysis according to the intention-to-treat principle. Results. The dose of propranolol was individualized; the mean (+/-SE) dose was 212+/-68 mg per day. The mean slope of the regression line for the aortic-root dimensions, which reflect the rate of dilatation, was significantly lower in the treatment group than in the control group (0.023 vs. 0.084 per year, P<0.001). Clinical end points were reached in five patients in the treatment group and nine in the control group. The Kaplan-Meier survival curve for the treatment group differed significantly from that for the control group during the middle years of the trial and remained better for the treatment group throughout the study. Conclusions. Prophylactic beta-adrenergic blockade is effective in slowing the rate of aortic dilatation and reducing the development of aortic complications in some patients with Marfan's syndrome.	JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,BALTIMORE,MD 21205	Johns Hopkins University			Pyeritz, Reed/A-1364-2010		NCRR NIH HHS [RR-00722] Funding Source: Medline; NHLBI NIH HHS [HL-35877] Funding Source: Medline; NIADDK NIH HHS [AM-23066] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baer RW, 1943, B JOHNS HOPKINS HOSP, V72, P309; BEAVEN DW, 1956, BRIT MED J, V1, P77, DOI 10.1136/bmj.1.4958.77; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BEYLOT M, 1984, METABOLISM, V33, P124, DOI 10.1016/0026-0495(84)90123-9; BOUCEK RJ, 1983, BIOCHEM PHARMACOL, V32, P275, DOI 10.1016/0006-2952(83)90555-5; BOUDOULAS H, 1979, J CARDIOVASC PHARM, V1, P503, DOI 10.1097/00005344-197909000-00003; BROPHY C, 1988, J SURG RES, V44, P687, DOI 10.1016/0022-4804(88)90101-1; BROPHY CM, 1989, J SURG RES, V46, P330, DOI 10.1016/0022-4804(89)90197-2; CRAWFORD ES, 1983, ANN SURG, V198, P487, DOI 10.1097/00000658-198310000-00009; DESANCTIS RW, 1987, NEW ENGL J MED, V317, P1060, DOI 10.1056/NEJM198710223171705; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Etter LE, 1943, JAMA-J AM MED ASSOC, V123, P88; GOTT VL, 1991, ANN THORAC SURG, V52, P38, DOI 10.1016/0003-4975(91)91414-Q; HALPERN BL, 1971, JOHNS HOPKINS MED J, V129, P123; HAOUZI A, 1992, CIRCULATION, V86, P662; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; HIRATA K, 1989, CIRCULATION S2, V80, P529; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEACH SD, 1988, ARCH SURG-CHICAGO, V123, P606; LIMA SD, 1985, AM J CARDIOL, V55, P739, DOI 10.1016/0002-9149(85)90148-1; LINDENSCHMIDT RC, 1985, J PHARMACOL EXP THER, V232, P346; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MARSALESE DL, 1989, J AM COLL CARDIOL, V14, P422, DOI 10.1016/0735-1097(89)90197-6; MCKUSICK VA, 1955, CIRCULATION, V11, P321, DOI 10.1161/01.CIR.11.3.321; MORSE RP, 1990, PEDIATRICS, V86, P888; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; MURPHY EA, 1987, AM J MED GENET, V28, P703, DOI 10.1002/ajmg.1320280318; NICOD P, 1989, J AM COLL CARDIOL, V13, P811, DOI 10.1016/0735-1097(89)90221-0; Ose L, 1977, Birth Defects Orig Artic Ser, V13, P163; PROKOP EK, 1970, CIRC RES, V27, P121, DOI 10.1161/01.RES.27.1.121; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; PYERITZ RE, 1981, CLIN RES, V29, pA315; PYERITZ RE, 1991, CIRCULATION S2, V84, P351; Pyeritz Reed E., 1993, P437; ROBERTS WC, 1982, AM HEART J, V104, P115, DOI 10.1016/0002-8703(82)90650-0; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; ROSEN SE, 1993, AM J MED GENET, V47, P157; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALIM MA, IN PRESS AM J CARDIO; SIMPSON C F, 1970, Toxicology and Applied Pharmacology, V16, P143, DOI 10.1016/0041-008X(70)90170-5; SIMPSON CF, 1976, TOXICOL APPL PHARM, V38, P169, DOI 10.1016/0041-008X(76)90170-8; SISK HE, 1983, AM J CARDIOL, V52, P353, DOI 10.1016/0002-9149(83)90138-8; SVENSSON LG, 1989, CIRCULATION, V80, P233; TIMCHAK DM, 1991, CIRCULATION S2, V84, P351; WHEAT MW, 1965, J THORAC CARDIOV SUR, V50, P364, DOI 10.1016/S0022-5223(19)33192-7; YIN FCP, 1989, CIRCULATION, V79, P854, DOI 10.1161/01.CIR.79.4.854; ZAHKA K G, 1989, Journal of the American College of Cardiology, V13, p119A	50	692	716	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1335	1341		10.1056/NEJM199405123301902	http://dx.doi.org/10.1056/NEJM199405123301902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152445				2022-12-28	WOS:A1994NK75300002
J	TAGLIALATELA, M; WIBLE, BA; CAPORASO, R; BROWN, AM				TAGLIALATELA, M; WIBLE, BA; CAPORASO, R; BROWN, AM			SPECIFICATION OF PORE PROPERTIES BY THE CARBOXYL-TERMINUS OF INWARDLY RECTIFYING K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; INTERNAL MG-2+; SHAKER; GENE; DROSOPHILA; REGION; CELLS; RECTIFICATION; INACTIVATION	Inwardly rectifying potassium (K+) channels (IRKs) maintain the resting membrane potential of cells and permit prolonged depolarization, such as during the cardiac action potential. Inward rectification may result from block of the ion conduction pore by intracellular magnesium (Mg-i(2+)). Two members of this family, IRK1 and ROMK1, which share 40 percent amino acid identity, differ markedly in single-channel K+ conductance and sensitivity to block by Mg-i(2+). The conserved H-5 regions were hypothesized to determine these pore properties because they have this function in voltage-dependent K+ channels and in cyclic nucleotide-gated channels. However, exchange of the H-5 region between IRK1 and ROMK1 had no effect on rectification and little or no effect on K+ conductance. By contrast, exchange of the amino- and carboxyl-terminal regions together transferred Mg2+ blockade and K+ conductance of IRK1 to ROMK1. Exchange of the carboxyl but not the amino terminus had a similar effect. Therefore, the carboxyl terminus appears to have a major role in specifying the pore properties of IRKs.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT HUMAN COMMUN SCI,PHARMACOL SECT,I-80121 NAPLES,ITALY	Baylor College of Medicine; University of Naples Federico II			Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/A-2062-2019	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36930, HL37044] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELLINOR T, 1993, NATURE, V363, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HELLEN G, 1991, SCIENCE, V251, P939; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; NICHOLS CG, 1993, TRENDS PHARMACOL SCI, V14, P320; NICHOLS CG, 1993, P PHYSL SOC, P46; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; TAGLIALATELA M, IN PRESS J BIOL CHEM; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	39	144	145	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					844	847		10.1126/science.8171340	http://dx.doi.org/10.1126/science.8171340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171340				2022-12-28	WOS:A1994NJ94900034
J	MAIER, RF; OBLADEN, M; SCIGALLA, P; LINDERKAMP, O; DUC, G; HIERONIMI, G; HALLIDAY, HL; VERSMOLD, HT; MORIETTE, G; JORCH, G; VERELLEN, G; SEMMEKROT, BA; GRAUEL, EL; HOLLAND, BM; WARDROP, CAJ				MAIER, RF; OBLADEN, M; SCIGALLA, P; LINDERKAMP, O; DUC, G; HIERONIMI, G; HALLIDAY, HL; VERSMOLD, HT; MORIETTE, G; JORCH, G; VERELLEN, G; SEMMEKROT, BA; GRAUEL, EL; HOLLAND, BM; WARDROP, CAJ			THE EFFECT OF EPOETIN-BETA (RECOMBINANT-HUMAN-ERYTHROPOIETIN) ON THE NEED FOR TRANSFUSION IN VERY-LOW-BIRTH-WEIGHT INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROID PROGENITORS; PREMATURITY; ANEMIA; INVIVO	Background. Anemia of prematurity is characterized by low reticulocyte counts and inadequate erythropoietin response, for which many very-low-birth-weight infants receive multiple blood transfusions. We investigated whether early treatment of such infants with recombinant human erythropoietin would reduce their need for transfusions. Methods. We performed a controlled, blinded trial in 241 infants with very low birth weights at 12 centers in six European countries. When three days old, the infants were randomly assigned either to the epoetin group or to the control group. Those in the epoetin group received 250 IU of epoetin beta per kilogram of body weight subcutaneously three times a week from day 3 to day 42 (for a total of 17 doses); those in the control group did not receive this drug. Infants in both groups received oral iron (2 mg per day) from day 14 onward. Results. The control infants needed a mean of 1.25 transfusions each, as compared with 0.87 transfusion for epoetin-treated infants (P = 0.013). The median cumulative volume of blood transfused per kilogram per day was 0.41 mi in the control group (first quartile, 0 ml; third quartile, 0.8 ml) and 0.09 ml in the epoetin group (first quartile, 0 ml; third quartile, 0.8 ml) (P = 0.044). The rate of success, defined as an absence of need for transfusions and a hematocrit that never fell below 32 percent, was 4.1 percent in the control group and 27.5 percent in the epoetin group (P = 0.008). Epoetin was most beneficial in boys with birth weights of 1200 g or more and a base-line hematocrit of 48 percent or more. No toxic effects were observed in the epoetin group; as compared with the control group, the epoetin group had an increased incidence of septicemia (14 vs. 7 episodes, P not significant) and reduced weight gain (520 vs. 571 g, P = 0.02). Conclusions, Infants with very low birth weights have less need of transfusions if given epoetin beta during the first six weeks of life (250 IU per kilogram three times a week). We recommend early epoetin treatment for all such infants, but further studies of nutrition and iron supplementation during treatment are needed.	FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT NEONATOL, D-14059 BERLIN, GERMANY; FREE UNIV BERLIN, KLINIKUM STEGLITZ, W-1000 BERLIN, GERMANY; BOEHRINGER MANNHEIM GMBH, W-6800 MANNHEIM, GERMANY; UNIV HEIDELBERG, HEIDELBERG, GERMANY; UNIV ZURICH, ZURICH, SWITZERLAND; ROYAL MATERN HOSP, BELFAST, NORTH IRELAND; CHU COCHIN PORT ROYAL, PARIS, FRANCE; UNIV MUNSTER, W-4400 MUNSTER, GERMANY; UNIV CATHOLIQUE LOUVAIN, B-1200 BRUSSELS, BELGIUM; UNIV NIJMEGEN HOSP, 6500 HB NIJMEGEN, NETHERLANDS; HUMBOLDT UNIV BERLIN, BERLIN, GERMANY; UNIV GLASGOW, QUEEN MOTHERS HOSP, GLASGOW, SCOTLAND; UNIV WALES COLL CARDIFF, DEPT HEMATOL, CARDIFF, WALES; OLGA HOSP, STUTTGART, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Ruprecht Karls University Heidelberg; University of Zurich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munster; Universite Catholique Louvain; Radboud University Nijmegen; Humboldt University of Berlin; University of Glasgow; Cardiff University; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart				Halliday, Henry/0000-0001-7978-4992				BECHENSTEEN AG, 1993, ARCH DIS CHILD-FETAL, V69, P19, DOI 10.1136/adc.69.1_Spec_No.19; BECK D, 1991, EUR J PEDIATR, V150, P767, DOI 10.1007/BF02026707; BROWN MS, 1984, J PEDIATR-US, V105, P793, DOI 10.1016/S0022-3476(84)80309-1; BROWN MS, 1990, J PEDIATR-US, V116, P773, DOI 10.1016/S0022-3476(05)82670-8; CARNIELLI V, 1992, J PEDIATR-US, V121, P98, DOI 10.1016/S0022-3476(05)82552-1; DESSYPRIS EN, 1988, BLOOD, V72, P2060; EMMERSON AJB, 1993, ARCH DIS CHILD-FETAL, V68, P291, DOI 10.1136/adc.68.3_Spec_No.291; GARNER A, 1984, PEDIATRICS, V74, P127; HALPERIN DS, 1990, J PEDIATR-US, V116, P779, DOI 10.1016/S0022-3476(05)82671-X; HALPERIN DS, 1992, EUR J PEDIATR, V151, P661, DOI 10.1007/BF01957568; KINMOND S, 1993, BMJ-BRIT MED J, V306, P172, DOI 10.1136/bmj.306.6871.172; KOENIG JM, 1990, PEDIATR RES, V27, P583, DOI 10.1203/00006450-199006000-00009; OBLADEN M, 1988, EUR J PEDIATR, V147, P399, DOI 10.1007/BF00496419; OBLADEN M, 1991, CONTRIB NEPHROL, V88, P314; OHLS RK, 1991, J PEDIATR-US, V119, P781, DOI 10.1016/S0022-3476(05)80303-8; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; RHONDEAU SM, 1988, J PEDIATR-US, V112, P935, DOI 10.1016/S0022-3476(88)80223-3; SHANNON KM, 1991, J PEDIATR-US, V118, P949, DOI 10.1016/S0022-3476(05)82217-6; SHANNON KM, 1990, AM J PEDIAT HEMATOL, V12, P14; SHANNON KM, 1992, J PEDIATR-US, V120, P586, DOI 10.1016/S0022-3476(05)82488-6; SHANNON KM, 1987, NEW ENGL J MED, V317, P728, DOI 10.1056/NEJM198709173171203; STOCKMAN JA, 1984, J PEDIATR-US, V105, P786, DOI 10.1016/S0022-3476(84)80308-X; STRAUSS RG, 1991, AM J DIS CHILD, V145, P904, DOI 10.1001/archpedi.1991.02160080082025; WARDROP CAJ, 1978, ARCH DIS CHILD, V53, P855, DOI 10.1136/adc.53.11.855; 1988, PEDIATRICS, V82, P37	25	212	213	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1173	1178		10.1056/NEJM199404283301701	http://dx.doi.org/10.1056/NEJM199404283301701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139627	Bronze			2022-12-28	WOS:A1994NG58600001
J	WEISS, PJ; DEMARCO, JK				WEISS, PJ; DEMARCO, JK			PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WEISS, PJ (corresponding author), NAVAL MED CTR, SAN DIEGO, CA 92134 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1197	1197						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139630				2022-12-28	WOS:A1994NG58600005
J	TUN, RYM; PEAKMAN, M; ALVIGGI, L; HUSSAIN, MJ; LO, SSS; SHATTOCK, M; PYKE, DA; BOTTAZZO, GF; VERGANI, D; LESLIE, RDG				TUN, RYM; PEAKMAN, M; ALVIGGI, L; HUSSAIN, MJ; LO, SSS; SHATTOCK, M; PYKE, DA; BOTTAZZO, GF; VERGANI, D; LESLIE, RDG			IMPORTANCE OF PERSISTENT CELLULAR AND HUMORAL IMMUNE CHANGES BEFORE DIABETES DEVELOPS - PROSPECTIVE-STUDY OF IDENTICAL-TWINS	BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED LYMPHOCYTES-T; INSULIN; MELLITUS; ANTIBODIES; AUTOANTIBODIES; MARKERS; DECARBOXYLASE; RELATIVES; DISEASE; ANTIGEN	Objectives-To determine the pattern of cellular and humoral immune changes associated with insulin dependent diabetes before diabetes develops. Design-Prospective study over 10 years of 25 non-diabetic identical twins of patients with insulin dependent diabetes. The non-diabetic twins were followed up either till they developed diabetes or to the end of the study. Setting-Teaching hospital. Subjects-25 non-diabetic identical cotwins of patients with diabetes; 46 controls of the same sex and similar age tested over the same period. Of the 25 twins (total follow up 144 patient years), 10 developed diabetes (prediabetic twins); the remainder were followed up for a mean of 7.7 years. Main outcome measures-Results of glucose tolerance tests or fasting blood glucose concentrations at each sample point. Measurements of activated T lymphocytes, expressing the HLA-DR antigen, islet cell antibodies, and insulin autoantibodies in samples. Results-All 10 prediabetic twins had both cellular and humoral changes initially and in most samples before diabetes was diagnosed (activated T lymphocytes in 39/40, islet cell antibodies in 45/47, and insulin autoantibodies to islet cells and insulin were detected infrequently (in 8/54, 6/69, and 0/69 samples, respectively). The combination of cellular and humoral (islet cell antibodies or insulin autoantibodies) immune changes were detected in all 10 of the prediabetic twins but in only one of the 15 nondiabetic twins (P<0.001). The positive predictive value in this cohort of increased percentages of activated T cells and the presence of antibodies to islet cells or insulin on two consecutive occasions was 100%. Conclusion-Most of the twins had cellular or humoral immune changes at some stage. A combination of cellular and humoral immune changes and their tendency to persist is highly predictive of insulin dependent diabetes and distinguishes twins who develop diabetes from those who do not.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; UNIV LONDON KINGS COLL,DEPT IMMUNOL,LONDON WC2R 2LS,ENGLAND; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND	University of London; Queen Mary University London; University of London; King's College London; University of London; Queen Mary University London			Vergani, Diego/H-7610-2019; Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSAKKAF L, 1992, ACTA DIABETOL, V28, P189, DOI 10.1007/BF00778996; ALSAKKAF L, 1989, DIABETOLOGIA, V32, P322, DOI 10.1007/BF00265550; ALVIGGI L, 1984, LANCET, V2, P4; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BARMEIER H, 1991, DIABETOLOGIA, V34, P727, DOI 10.1007/BF00401518; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1993, DIABETES CARE, V16, P45, DOI 10.2337/diacare.16.1.45; BOTTAZZO GF, 1980, LANCET, V1, P668; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; GORSUCH AN, 1981, LANCET, V2, P1363; JACKSON RA, 1982, NEW ENGL J MED, V306, P785, DOI 10.1056/NEJM198204013061305; JOHNSTON C, 1983, BMJ-BRIT MED J, V286, P253, DOI 10.1136/bmj.286.6361.253; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LESLIE RDG, 1991, BRIT MED J, V302, P1103, DOI 10.1136/bmj.302.6785.1103; LOBOYEO A, 1987, CLIN EXP IMMUNOL, V67, P96; MILLWARD BA, 1986, BRIT MED J, V292, P793, DOI 10.1136/bmj.292.6523.793; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; PEAKMAN M, 1989, J CLIN LAB IMMUNOL, V30, P1; ROBERT JJ, 1991, DIABETES CARE, V14, P718, DOI 10.2337/diacare.14.8.718; SRIKANTA S, 1984, DIABETES, V33, P717, DOI 10.2337/diabetes.33.8.717; TARN AC, 1988, LANCET, V1, P845; THIVOLET C, 1992, DIABETOLOGIA, V35, P570, DOI 10.1007/BF00400486; THIVOLET C, 1991, DIABETOLOGIA, V34, P186, DOI 10.1007/BF00418274; WILKIN T, 1985, LANCET, V1, P480; 1979, DIABETES, V28, P1038	27	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1063	1068		10.1136/bmj.308.6936.1063	http://dx.doi.org/10.1136/bmj.308.6936.1063			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173426	Green Published			2022-12-28	WOS:A1994NH48900020
J	HENDRY, SHC; YOSHIOKA, T				HENDRY, SHC; YOSHIOKA, T			A NEUROCHEMICALLY DISTINCT 3RD CHANNEL IN THE MACAQUE DORSAL LATERAL GENICULATE-NUCLEUS	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; MONKEY VISUAL-CORTEX; BROAD-BAND CHANNELS; STRIATE CORTEX; GALAGO-CRASSICAUDATUS; LAMINAR ORGANIZATION; CONTRAST-SENSITIVITY; RHESUS-MONKEY; RESPONSE PROPERTIES; SQUIRREL-MONKEY	The primate visual system is often divided into two channels, designated M and P, whose signals are relayed to the cerebral cortex by neurons in the magnocellular and parvicellular layers of the dorsal lateral geniculate nucleus. We have identified a third population of geniculocortical neurons in the dorsal lateral geniculate nucleus of macaques, which is immunoreactive for the a subunit of type II calmodulin-dependent protein kinase. This large third population occupies interlaminar regions (intercalated layers) ventral to each principal layer. Retrograde labeling of kinase-immunoreactive cells from the primary visual cortex shows that they provide the geniculocortical input to cytochrome oxidase-rich puffs in layers II and III.	JOHNS HOPKINS UNIV, DEPT NEUROSCI, BALTIMORE, MD 21218 USA	Johns Hopkins University	HENDRY, SHC (corresponding author), JOHNS HOPKINS UNIV, ZANVYL KRIEGER MIND BRAIN INST, BALTIMORE, MD 21218 USA.				NEI NIH HHS [EY 06432] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006432, R23EY006432] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENSON DL, 1991, J NEUROSCI, V11, P1540; Clark WEL, 1941, J ANAT, V75, P419; DEBRUYN EJ, 1993, J NEUROPHYSIOL, V69, P3, DOI 10.1152/jn.1993.69.1.3; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; FITZPATRICK D, 1983, J NEUROSCI, V3, P673; GUILLERY RW, 1970, Z ZELLFORSCH MIK ANA, V103, P90, DOI 10.1007/BF00335403; HENDRY SHC, 1986, P NATL ACAD SCI USA, V83, P1536, DOI 10.1073/pnas.83.5.1536; HUBEL DH, 1987, J NEUROSCI, V7, P3378; HUBEL DH, 1990, J NEUROSCI, V10, P2223, DOI 10.1523/jneurosci.10-07-02223.1990; IRVIN GE, 1986, BRAIN RES, V362, P254, DOI 10.1016/0006-8993(86)90450-6; ITAYA SK, 1984, BRAIN RES, V304, P303, DOI 10.1016/0006-8993(84)90334-2; KAAS JH, 1978, J COMP NEUROL, V182, P517, DOI 10.1002/cne.901820308; KRUBITZER L, 1990, VISUAL NEUROSCI, V5, P609, DOI 10.1017/S0952523800000778; LACHICA EA, 1992, J COMP NEUROL, V319, P141, DOI 10.1002/cne.903190112; LACHICA EA, 1993, J COMP NEUROL, V329, P163, DOI 10.1002/cne.903290203; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1982, P NATL ACAD SCI-BIOL, V79, P6098, DOI 10.1073/pnas.79.19.6098; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; Martin Kevan A. C., 1992, Current Biology, V2, P555, DOI 10.1016/0960-9822(92)90037-B; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1990, VISUAL NEUROSCI, V5, P347, DOI 10.1017/S0952523800000432; MERIGAN WH, 1991, J NEUROSCI, V11, P994; NORTON TT, 1982, J NEUROPHYSIOL, V47, P715, DOI 10.1152/jn.1982.47.4.715; NORTON TT, 1988, J NEUROPHYSIOL, V59, P1639, DOI 10.1152/jn.1988.59.6.1639; RAUSELL E, 1991, J NEUROSCI, V11, P226; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1983, VISION RES, V23, P1631, DOI 10.1016/0042-6989(83)90177-3; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; TSO DY, 1988, J NEUROSCI, V8, P1712; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1979, ANNU REV NEUROSCI, V2, P227, DOI 10.1146/annurev.ne.02.030179.001303; WEBER JT, 1983, J COMP NEUROL, V213, P135, DOI 10.1002/cne.902130203; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; YOSHIOKA T, IN PRESS VISUAL NEUR; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0; ZEKI S, 1983, PROC R SOC SER B-BIO, V217, P449, DOI 10.1098/rspb.1983.0020; ZEKI SM, 1978, J PHYSIOL-LONDON, V277, P273, DOI 10.1113/jphysiol.1978.sp012272	44	233	235	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					575	577		10.1126/science.8160015	http://dx.doi.org/10.1126/science.8160015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160015				2022-12-28	WOS:A1994NH01000039
J	WILLETT, WC				WILLETT, WC			DIET AND HEALTH - WHAT SHOULD WE EAT	SCIENCE			English	Review							CORONARY HEART-DISEASE; TRANS-FATTY-ACIDS; LIPOPROTEIN-CHOLESTEROL LEVELS; BREAST-CANCER; BLOOD-PRESSURE; SERUM-CHOLESTEROL; FISH CONSUMPTION; UNITED-STATES; COLON CANCER; HIGH-DENSITY	Many recent studies have implicated dietary factors in the cause and prevention of important diseases, including cancer, coronary heart disease, birth defects, and cataracts. There is strong evidence that vegetables and fruits protect against these diseases; however, the active constituents are incompletely identified. Whether fat per se is a major cause of disease is a question still under debate, although saturated and partially hydrogenated fats probably increase the risk of coronary heart disease. One clear conclusion from existing epidemiologic evidence is that many individuals in the United States have suboptimal diets and that the potential for disease prevention by improved nutrition is substantial.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	WILLETT, WC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA.							ABELOW BJ, 1992, CALCIFIED TISSUE INT, V50, P14, DOI 10.1007/BF00297291; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; Appleton B S, 1986, Adv Exp Med Biol, V206, P99; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P191, DOI 10.1016/0891-5849(90)90091-V; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BOOYENS J, 1986, MED HYPOTHESES, V21, P387, DOI 10.1016/0306-9877(86)90034-4; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BOSTICK RM, 1993, AM J EPIDEMIOL, V137, P1302, DOI 10.1093/oxfordjournals.aje.a116640; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; BROWNER WS, 1991, JAMA-J AM MED ASSOC, V265, P3285, DOI 10.1001/jama.265.24.3285; BURR ML, 1989, LANCET, V2, P757; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHARNOCK JS, 1992, MOL CELL BIOCHEM, V116, P19, DOI 10.1007/BF01270564; CORREA P, 1975, LANCET, V2, P58; CURB JD, 1985, NEW ENGL J MED, V313, P821; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DENKE MA, 1991, AM J CLIN NUTR, V54, P1036, DOI 10.1093/ajcn/54.6.1036; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FONTHAM ETH, 1990, INT J EPIDEMIOL, V19, pS32, DOI 10.1093/ije/19.Supplement_1.S32; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FREEDMAN LS, 1990, CANCER RES, V50, P5710; GARG A, 1992, DIABETES CARE, V15, P1572, DOI 10.2337/diacare.15.11.1572; GEY KF, 1987, AM J CLIN NUTR, V45, P1368, DOI 10.1093/ajcn/45.5.1368; GINSBERG HN, 1990, NEW ENGL J MED, V322, P574, DOI 10.1056/NEJM199003013220902; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; GRAHAM S, 1983, JNCI-J NATL CANCER I, V70, P687; GRAHAM S, 1992, AM J EPIDEMIOL, V136, P1327, DOI 10.1093/oxfordjournals.aje.a116445; GRUBERG ER, 1981, CHOLESTEROL; HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; HEGSTED DM, 1986, AM J CLIN NUTR, V44, P299, DOI 10.1093/ajcn/44.2.299; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HJERMANN I, 1986, AM J MED, V80, P7, DOI 10.1016/0002-9343(86)90154-3; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; Junshi C., 1990, DIET LIFESTYLE MORTA; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KASIM SE, 1993, J CLIN NUTR, V57, P146; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KEYS A, 1984, AM J CLIN NUTR, V40, P351, DOI 10.1093/ajcn/40.2.351; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOLONEL LN, 1988, AM J EPIDEMIOL, V127, P999, DOI 10.1093/oxfordjournals.aje.a114903; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; LUTZ J, 1981, AM J CLIN NUTR, V34, P2178, DOI 10.1093/ajcn/34.10.2178; MANOUSOS O, 1985, GUT, V26, P544, DOI 10.1136/gut.26.6.544; MANTTARI M, 1990, EUR HEART J, V11, P26, DOI 10.1093/eurheartj/11.suppl_H.26; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MENSINK RP, 1992, J LIPID RES, V33, P1493; Meyer F, 1990, Epidemiology, V1, P377, DOI 10.1097/00001648-199009000-00007; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; MORRIS MC, 1992, CIRCULATION, V86, P463; NESTEL P, 1992, J LIPID RES, V33, P1029; NORDIN B. E. C., 1966, CLIN ORTHO RELAT RES, V45, P17; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; RAPER NR, 1992, USDA50 HOM EC RES RE; REAVEN P, 1993, J CLIN INVEST, V91, P668, DOI 10.1172/JCI116247; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; SACKS FM, 1991, NEW ENGL J MED, V325, P1740, DOI 10.1056/NEJM199112123252411; SCHROEDER HA, 1971, AM J CLIN NUTR, V24, P562; SEIDELL JC, 1994, PHARMACOECONOMICS, V5, P38, DOI 10.2165/00019053-199400051-00008; SENTI FR, 1985, HLTH ASPECTS T FATTY; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; SIGUEL EN, 1993, AM J CARDIOL, V71, P916, DOI 10.1016/0002-9149(93)90906-S; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; SWANSON CA, 1988, CANCER RES, V48, P5363; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; VANDENBRANDT PA, 1993, CANCER RES, V53, P75; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WELSCH CW, 1992, CANCER RES, V52, pS2040; Welsh S., 1992, NUTR TODAY, V26, P12, DOI [10.1097/00017285-199211000-00005, DOI 10.1097/00017285-199211000-00005]; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WHITTEMORE AS, 1990, JNCI-J NATL CANCER I, V82, P915, DOI 10.1093/jnci/82.11.915; WILCKEN DEL, 1985, METABOLISM, V34, P1115, DOI 10.1016/0026-0495(85)90156-8; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1990, NUTR REV, V48, P201, DOI 10.1111/j.1753-4887.1990.tb02936.x; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; YOUNGMAN LD, 1992, CANCER LETT, V66, P165, DOI 10.1016/0304-3835(92)90229-O; ZOCK PL, 1992, J LIPID RES, V33, P399; 1993, FOOD HLTH INDICATORS; 1984, JAMA-J AM MED ASSOC, V252, P799; [No title captured]; 1989, RECOMMENDED DIETARY; 1968, CIRCULATION S, V18, P1	130	740	769	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					532	537		10.1126/science.8160011	http://dx.doi.org/10.1126/science.8160011			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160011				2022-12-28	WOS:A1994NH01000026
J	HINRICHS, W; KISKER, C; DUVEL, M; MULLER, A; TOVAR, K; HILLEN, W; SAENGER, W				HINRICHS, W; KISKER, C; DUVEL, M; MULLER, A; TOVAR, K; HILLEN, W; SAENGER, W			STRUCTURE OF THE TET REPRESSOR TETRACYCLINE COMPLEX AND REGULATION OF ANTIBIOTIC-RESISTANCE	SCIENCE			English	Article							TURN-HELIX MOTIF; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; DNA-BINDING; ESCHERICHIA-COLI; OPERATOR COMPLEX; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; LAC-REPRESSOR; TN10	The most frequently occurring resistance of Gram-negative bacteria against tetracyclines is triggered by drug recognition of the Tet repressor. This causes dissociation of the repressor-operator DNA complex and enables expression of the resistance protein TetA, which is responsible for active efflux of tetracycline. The 2.5 angstrom resolution crystal structure of the homodimeric Tet repressor complexed with tetracycline-magnesium reveals detailed drug recognition. The orientation of the operator-binding helix-turn-helix motifs of the repressor is inverted in comparison with other DNA binding proteins. The repressor-drug complex is unable to interact with DNA because the separation of the DNA binding motifs is 5 angstroms wider than usually observed.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg	HINRICHS, W (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY.			Kisker, Caroline/0000-0002-0216-6026; Hinrichs, Winfried/0000-0002-0435-4565				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAUMEISTER R, 1992, PROTEINS, V14, P168, DOI 10.1002/prot.340140204; BAUMEISTER R, 1992, J MOL BIOL, V226, P1257, DOI 10.1016/0022-2836(92)91065-W; BERENS C, 1992, J BIOL CHEM, V267, P1945; BERTRAND KP, 1983, GENE, V23, P149, DOI 10.1016/0378-1119(83)90046-X; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAUTER Z, 1990, ACTA CRYSTALLOGR B, V46, P833, DOI 10.1107/S0108768190008059; DEGENKOLB J, 1991, ANTIMICROB AGENTS CH, V35, P1591, DOI 10.1128/AAC.35.8.1591; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HEUER C, 1988, J MOL BIOL, V202, P407, DOI 10.1016/0022-2836(88)90274-4; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HILLEN W, 1983, J MOL BIOL, V169, P707, DOI 10.1016/S0022-2836(83)80166-1; HLAVKA JJ, 1985, HDB EXPT PHARM, V78, P332; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KOSTREWA D, 1992, J MOL BIOL, V226, P209, DOI 10.1016/0022-2836(92)90134-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMERICHS RMJN, 1990, EUR J BIOCHEM, V194, P629, DOI 10.1111/j.1432-1033.1990.tb15662.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; MENDEZ B, 1980, PLASMID, V3, P99, DOI 10.1016/0147-619X(80)90101-8; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PARGE HE, 1984, J MOL BIOL, V180, P1189, DOI 10.1016/0022-2836(84)90279-1; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SIZEMORE C, 1990, NUCLEIC ACIDS RES, V18, P2875, DOI 10.1093/nar/18.10.2875; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; SUZUKI S, 1992, SCIENCE, V257, P942, DOI 10.1126/science.257.5072.942; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; TOVAR K, 1989, NUCLEIC ACIDS RES, V17, P6515, DOI 10.1093/nar/17.16.6515; TOVAR K, 1988, MOL GEN GENET, V215, P76, DOI 10.1007/BF00331306; UNGER B, 1984, NUCLEIC ACIDS RES, V12, P7693, DOI 10.1093/nar/12.20.7693; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WISSMANN A, 1991, EMBO J, V10, P4145, DOI 10.1002/j.1460-2075.1991.tb04992.x; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO J, 1992, MICROBIOL IMMUNOL, V36, P1051, DOI 10.1111/j.1348-0421.1992.tb02109.x; [No title captured]	46	333	355	6	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					418	420		10.1126/science.8153629	http://dx.doi.org/10.1126/science.8153629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153629				2022-12-28	WOS:A1994NG19400038
J	FABRIZIO, P; ESSER, S; KASTNER, B; LUHRMANN, R				FABRIZIO, P; ESSER, S; KASTNER, B; LUHRMANN, R			ISOLATION OF SACCHAROMYCES-CEREVISIAE SNRNPS - COMPARISON OF U1 AND U4/U6.U5 TO THEIR HUMAN COUNTERPARTS	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SACCHAROMYCES-CEREVISIAE; YEAST; PROTEIN; U2; IDENTIFICATION; SPLICEOSOME; U5; PURIFICATION; CONSERVATION	Small nuclear ribonucleoprotein (snRNP) particles are essential for pre-messenger RNA splicing. In human HeLa cells, 40 proteins associated with snRNPs have been identified. Yet, the function of many of these proteins remains unknown. Here, the immunoaffinity purification of the spliceosomal snRNPs U1, U2, U4/U6.U5, and several nucleolar snRNP species from the yeast Saccharomyces cerevisiae is presented. The U1 and U4/U6.U5 snRNPs were purified extensively and their protein composition and ultrastructure analyzed. The yeast U1 snRNP is larger and contains three times more specific proteins than its human counterpart. In contrast, the size, protein composition, and morphology of the yeast and the human U4/U6.U5 snRNPs are significantly similar. The preparative isolation of yeast snRNPs will allow the cloning as well as genetic and phylogenetic analysis of snRNP proteins which will accelerate our understanding of their function.			FABRIZIO, P (corresponding author), PHILIPPS UNIV, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY.							ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BRINGMANN P, 1986, EMBO J, V5, P3509, DOI 10.1002/j.1460-2075.1986.tb04676.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, UNPUB; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HINTERBERGER M, 1983, J BIOL CHEM, V258, P2604; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; KASTNER B, 1989, EMBO J, V8, P277, DOI 10.1002/j.1460-2075.1989.tb03374.x; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LEHMEIER T, 1990, NUCLEIC ACIDS RES, V18, P6475, DOI 10.1093/nar/18.22.6475; LIAO XC, 1993, GENE DEV, V7, P41; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; Moore M., 1993, RNA WORLD, P303; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	33	76	79	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	1994	264	5156					261	265		10.1126/science.8146658	http://dx.doi.org/10.1126/science.8146658			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146658				2022-12-28	WOS:A1994NE41000037
J	GASIC, GP				GASIC, GP			BASIC-HELIX-LOOP-HELIX TRANSCRIPTION FACTOR AND STEROL SENSOR IN A SINGLE MEMBRANE-BOUND MOLECULE	CELL			English	Review							CHOLESTEROL; PROTEIN				GASIC, GP (corresponding author), CELL PRESS,50 CHURCH ST,CAMBRIDGE,MA 02138, USA.							BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; LANGE Y, 1992, J LIPID RES, V33, P315; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MORI K, 1993, CELL, V74, P743; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; URBANI L, 1990, J BIOL CHEM, V265, P1919; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	18	26	27	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					17	19		10.1016/0092-8674(94)90230-5	http://dx.doi.org/10.1016/0092-8674(94)90230-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156593				2022-12-28	WOS:A1994NF21100005
J	SALZMAN, CD; NEWSOME, WT				SALZMAN, CD; NEWSOME, WT			NEURAL MECHANISMS FOR FORMING A PERCEPTUAL DECISION	SCIENCE			English	Article							TEMPORAL VISUAL AREA; SUPERIOR COLLICULUS; FUNCTIONAL-PROPERTIES; EYE-MOVEMENTS; TOPOGRAPHIC ORGANIZATION; NEURONAL POPULATION; MACAQUE MONKEY; RHESUS-MONKEY; DIRECTION; MOTION	Cognitive and behavioral responses to environmental stimuli depend on an evaluation of sensory signals within the cerebral cortex. The mechanism by which this occurs in a specific visual task was investigated with a combination of physiological and psychophysical techniques. Rhesus monkeys discriminated among eight possible directions of motion while directional signals were manipulated in visual area MT. One directional signal was generated by a visual stimulus and a second signal was introduced by electrically stimulating neurons that encoded a specific direction of motion. The decisions made by the monkeys in response to the two signals allowed a distinction to be made between two possible mechanisms for interpreting directional signals in MT. The monkeys tended to cast decisions in favor of one or the other signal, indicating that the signals exerted independent effects on performance and that an interactive mechanism such as vector averaging of the two signals was not operative. Thus, the data suggest a mechanism in which monkeys chose the direction encoded by the largest signal in the representation of motion direction, a ''winner-take-all'' decision process.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Newsome, William T./W-7171-2019		NEI NIH HHS [EY 5603] Funding Source: Medline; NINDS NIH HHS [NS 07158-14] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005603, R01EY005603] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; ALBRIGHT TD, 1987, EXP BRAIN RES, V65, P582; ALBRIGHT TD, 1993, VISUAL MOTION ITS RO, P177; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; BRITTEN KH, UNPUB; Cox DR., 1989, ANAL BINARY DATA; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; FINDLAY JM, 1982, VISION RES, V22, P1033, DOI 10.1016/0042-6989(82)90040-2; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Graham N.V.S, 1989, VISUAL PATTERN ANAL; HENN V, 1976, BRAIN RES, V108, P307, DOI 10.1016/0006-8993(76)90188-8; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; MARSHAK W, 1979, SCIENCE, V205, P1399, DOI 10.1126/science.472756; MAUNSELL JHR, 1987, J COMP NEUROL, V266, P535, DOI 10.1002/cne.902660407; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; McIlwain J. T., 1976, INT REV PHYSIOL, Vii, P223; MCILWAIN JT, 1991, VISUAL NEUROSCI, V6, P3, DOI 10.1017/S0952523800000857; MCILWAIN JT, 1982, J NEUROPHYSIOL, V47, P167, DOI 10.1152/jn.1982.47.2.167; Movshon J. A., 1985, PATTERN RECOGNITION; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; NEWSOME WT, IN PRESS COGNITIVE N; OTTES FP, 1984, VISION RES, V24, P1169, DOI 10.1016/0042-6989(84)90172-X; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DA, 1969, J NEUROPHYSIOL, V32, P637, DOI 10.1152/jn.1969.32.5.637; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SCHILLER PH, 1983, EXP BRAIN RES, V49, P381; SCHOR RH, 1984, J NEUROPHYSIOL, V51, P136, DOI 10.1152/jn.1984.51.1.136; SHADLEN MN, 1992, ABSTR SOC NEUROSCI, V18, P1101; SPARKS DL, 1976, BRAIN RES, V113, P21, DOI 10.1016/0006-8993(76)90003-2; SPARKS DL, 1983, J NEUROPHYSIOL, V49, P45, DOI 10.1152/jn.1983.49.1.45; STEINMETZ MA, 1987, J NEUROSCI, V7, P177; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; SUZUKI I, 1985, J NEUROPHYSIOL, V54, P123, DOI 10.1152/jn.1985.54.1.123; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302; WILLIAMS DW, 1984, VISION RES, V24, P55, DOI 10.1016/0042-6989(84)90144-5; WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386; WILSON VJ, 1984, J NEUROPHYSIOL, V51, P567, DOI 10.1152/jn.1984.51.3.567; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	49	189	189	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					231	237		10.1126/science.8146653	http://dx.doi.org/10.1126/science.8146653			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146653				2022-12-28	WOS:A1994NE41000028
J	MORRIS, P; SHAMAN, J; ATTAYA, M; AMAYA, M; GOODMAN, S; BERGMAN, C; MONACO, JJ; MELLINS, E				MORRIS, P; SHAMAN, J; ATTAYA, M; AMAYA, M; GOODMAN, S; BERGMAN, C; MONACO, JJ; MELLINS, E			AN ESSENTIAL ROLE FOR HLA-DM IN ANTIGEN PRESENTATION BY CLASS-II MAJOR HISTOCOMPATIBILITY MOLECULES	NATURE			English	Article							INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; DR MOLECULES; BINDING-SITE; CELL LINE; COMPLEX; REGION; GENE; EXPRESSION; RESPONSES	IN antigen-presenting cells, class II molecules of the major histocompatibility complex (MHC) bind peptides derived from endocytosed proteins1. In certain B-lymphoblastoid cell mutants, MHC class II molecule-peptide complex formation is impaired, resulting in deficient antigen-presenting function2. MHC deletion mutants with this defect map the responsible gene(s) to the class II region of the MHC3-5. Here we report that multiple independent mutants with the class II presentation defect harbour lesions in HLA-DMB, an MHC-linked gene encoding a class II-like beta-chain6,7. Expression of DMB complementary DNA in mutants lacking DMB messenger RNA restores the wild-type phenotype. These results establish HLA-DM as a critical regulatory molecule in class II-restricted antigen presentation and suggest that it functions at an intracellular site to promote class II molecule-peptide association.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	University of Pennsylvania; Virginia Commonwealth University				Mellins, Elizabeth/0000-0003-2577-139X				BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CEMAN S, 1992, J IMMUNOL, V149, P754; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JOHNSON AH, 1984, IMMUNOBIOLGOY HLA, P202; JOHNSON JP, 1982, J EXP MED, V156, P104, DOI 10.1084/jem.156.1.104; KELLY AP, 1991, NATURE, V353, P5741; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MELLINS E, 1987, HUM IMMUNOL, V18, P211, DOI 10.1016/0198-8859(87)90086-3; PIOUS D, 1985, J EXP MED, V162, P1193, DOI 10.1084/jem.162.4.1193; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SANT AJ, 1993, HUM IMMUNOL, V37, P3; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHAW S, 1980, J EXP MED, V152, P565, DOI 10.1084/jem.152.3.565; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; XIE W, 1991, BIOTECHNIQUES, V11, P325	29	361	367	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					551	554		10.1038/368551a0	http://dx.doi.org/10.1038/368551a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139689				2022-12-28	WOS:A1994NE33500056
J	UYEDA, TQP; RUPPEL, KM; SPUDICH, JA				UYEDA, TQP; RUPPEL, KM; SPUDICH, JA			ENZYMATIC-ACTIVITIES CORRELATE WITH CHIMERIC SUBSTITUTIONS AT THE ACTIN-BINDING FACE OF MYOSIN	NATURE			English	Article							HEAVY-CHAIN GENE; ADENOSINE-TRIPHOSPHATASE; SUBFRAGMENT-1; MEROMYOSIN; ACTOMYOSIN; SITE; ATP; DISRUPTION; HYDROLYSIS; MECHANISM	MYOSINS are a functionally divergent group of mechanochemical enzymes involved in various motile activities in cells1. Despite a high degree of conservation in the amino-acid sequence of the 130K motor domain2,3 (head region) of the molecule, there are large differences in the enzymatic and motile activities (Tables 1 and 2) of myosins from diverse species and cell types. However, the degree of conservation is not uniform throughout the head sequence4; therefore, one reasonable hypothesis is that the functional differences between myosins derive from the poorly conserved areas. The most prominent divergent region occurs at the 50K/20K junction, a region of the molecule sensitive to proteolytic digestion5 and a binding site for actin6-12. We have now constructed chimaeras of this region of myosin by substituting the 9-amino-acid Dictyostelium junction region with those from myosins from other species and find that the actin-activated ATPase correlates well with the activity of the myosin from which the junction region was derived. Our results suggest that this region, likely to be part of the myosin head that interacts directly with actin10,13,14, is important in deter mining the enzymatic activity of myosin.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University; Stanford University								BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTS J, 1982, BIOCHEMISTRY-US, V21, P6903, DOI 10.1021/bi00269a043; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kniesmeijer Joke, 1987, PAROOL 1109; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; POPE B, 1980, FEBS LETT, V118, P205, DOI 10.1016/0014-5793(80)80219-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SPUDICH JA, 1989, CELL REGUL, V1, P1; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARSHAW D, 1991, BIOPHYS J, V58, pA186; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1863, DOI 10.1093/oxfordjournals.jbchem.a132709; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035	30	183	189	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					567	569		10.1038/368567a0	http://dx.doi.org/10.1038/368567a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139694				2022-12-28	WOS:A1994NE33500061
J	MCKENZIE, B				MCKENZIE, B			ACCURACY OF PEAK FLOW METERS - DONT INTERCHANGE DEVICES	BRITISH MEDICAL JOURNAL			English	Letter											MCKENZIE, B (corresponding author), CHESTERFIELD & N DERBYSHIRE ROYAL HOSP,CHESTERFIELD S44 5BL,DERBY,ENGLAND.							SLY PD, 1994, BRIT MED J, V308, P572, DOI 10.1136/bmj.308.6928.572	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					917	917		10.1136/bmj.308.6933.917	http://dx.doi.org/10.1136/bmj.308.6933.917			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173382	Green Published			2022-12-28	WOS:A1994NE60000048
J	PERRETT, DI; MAY, KA; YOSHIKAWA, S				PERRETT, DI; MAY, KA; YOSHIKAWA, S			FACIAL SHAPE AND JUDGMENTS OF FEMALE ATTRACTIVENESS	NATURE			English	Article							PHYSICAL ATTRACTIVENESS; FACES; PERCEPTION; AVERAGE; BEAUTY	THE finding that photographic(1-4) and digital(5) composites (blends) of faces are considered to be attractive has led to the claim that attractiveness is averageness(5). This would encourage stabilizing selection, favouring phenotypes with an average facial structure(5). The 'averageness hypothesis' would account for the low distinctiveness of attractive faces(6) but is difficult to reconcile with the finding that some facial measurements correlate with attractiveness(7,8). An average face shape is attractive but may not be optimally attractive(9). Human preferences may exert directional selection pressures, as with the phenomena of optimal outbreeding and sexual selection for extreme characteristics(10-14). Using composite faces, we show here that, contrary to the averageness hypothesis, the mean shape of a set of attractive faces is preferred to the mean shape of the sample from which the faces were selected. In addition, attractive composites can be made more attractive by exaggerating the shape differences from the sample mean. Japanese and caucasian observers showed the same direction of preferences for the same facial composites, suggesting that aesthetic judgements of face shape are similar across different cultural backgrounds. Our finding that highly attractive facial configurations are not average shows that preferences could exert a directional selection pressure on the evolution of human face shape.	OTEMON GAKUIN UNIV,FAC LETTERS,DEPT PSYCHOL,IBARAKI,OSAKA 567,JAPAN		PERRETT, DI (corresponding author), UNIV ST ANDREWS,SCH PSYCHOL,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.		May, Keith/F-8686-2011	May, Keith/0000-0001-8114-5989; Perrett, David/0000-0002-6025-0939; d, muthu/0000-0003-3996-3333				ALLEY TR, 1991, PSYCHOL SCI, V2, P123, DOI 10.1111/j.1467-9280.1991.tb00113.x; ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; BENSON PJ, 1993, PERCEPTION, V22, P257, DOI 10.1068/p220257; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; BERNSTEIN IH, 1982, PERCEPT PSYCHOPHYS, V32, P495, DOI 10.3758/BF03204202; BRENNAN SE, 1985, LEONARDO, V18, P170, DOI 10.2307/1578048; CROSS JF, 1971, DEV PSYCHOL, V5, P433, DOI 10.1037/h0031591; CUNNINGHAM MR, 1990, J PERS SOC PSYCHOL, V59, P61, DOI 10.1037/0022-3514.59.1.61; CUNNINGHAM MR, 1986, J PERS SOC PSYCHOL, V50, P925, DOI 10.1037/0022-3514.50.5.925; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; Galton F., 1878, J ANTHR I GREAT BRIT, V18, P97, DOI 10.2307/2841021; Galton F. J., 1878, NATURE, V18, P97, DOI DOI 10.1038/018097A0; Jastrow J, 1885, Science, V6, P165, DOI 10.1126/science.ns-6.134.165; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x; Light L.L., 1981, PERSONALITY SOCIAL P, V7, P269, DOI [10.1177/014616728172014, DOI 10.1177/014616728172014]; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; Stoddard J T, 1886, Science, V8, P89, DOI 10.1126/science.ns-8.182.89-a; Symons D, 1979, EVOLUTION HUMAN SEXU; TENCATE C, 1988, EVOLUTION, V42, P1355, DOI 10.1111/j.1558-5646.1988.tb04196.x	20	524	536	5	141	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					239	242		10.1038/368239a0	http://dx.doi.org/10.1038/368239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NA870	8145822				2022-12-28	WOS:A1994NA87000054
J	MURRAY, SA; TAPSON, J; TURNBULL, L; MCCALLUM, J; LITTLE, A				MURRAY, SA; TAPSON, J; TURNBULL, L; MCCALLUM, J; LITTLE, A			LISTENING TO LOCAL VOICES - ADAPTING RAPID APPRAISAL TO ASSESS HEALTH AND SOCIAL NEEDS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore the use of rapid appraisal in defining the health and social needs of a community and to formulate joint action plans between the residents and service providers. Design-Collection of data by an extended primary care team from three sources: existing documents about the neighbourhood, interviews with a range of informants, and direct observations to build a profile of the community. Setting-Council estate of 670 homes in Edinburgh. Main outcome measures-Perceived problems of the community and suggestions for change. Results-The interviews and focus groups identified six priorities for change, many of which were not health related. These changes have been or are being implemented. Conclusions-An expanded primary care team can use rapid appraisal as a first step in identifying and meeting local health needs. It facilitates a multidisciplinary approach and complements quantitative methods of assessing need.	MACKENZIE MED CTR,EDINBURGH EH8 9DX,SCOTLAND; S BRIDGE RESOURCE CTR,EDINBURGH,SCOTLAND; VICTORIA ST SOCIAL WORK CTR,EDINBURGH,SCOTLAND		MURRAY, SA (corresponding author), UNIV EDINBURGH,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							Brody H, 1992, DOING QUALITATIVE RE; COULTER A, 1991, BRIT J GEN PRACT, V41, P140; Cumberlege J., 1986, REPORT COMMUNITY NUR; GILLAM SJ, 1992, BRIT J GEN PRACT, V42, P404; Hart, 1988, NEW KIND DOCTOR; HASTINGS A, 1993, BRIT J GEN PRACT, V43, P47; Johnson J. C., 1990, SELECTING ETHNOGRAPH, V22; Macdonald J.J., 2013, PRIMARY HLTH CARE ME; MANT D, 1985, LANCET, V2, P1114; ONG BN, 1991, SOC SCI MED, V32, P909, DOI 10.1016/0277-9536(91)90246-9; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; STOTT N, 1994, BRIT J GEN PRACT, V44, P2; 1992, SCOTLANDS HLTH CHALL; 1977, JR COLL GEN PRACT, V27, P117; 1992, GUIDELINES RAPID APP; 1992, LOCAL VOICES VIEWS L; 1981, GLOBAL STRATEGY HLTH	17	78	78	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					698	700		10.1136/bmj.308.6930.698	http://dx.doi.org/10.1136/bmj.308.6930.698			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142796	Green Published			2022-12-28	WOS:A1994NA86900024
J	TREASURE, J; SCHMIDT, U; TROOP, N; TILLER, J; TODD, G; KEILEN, M; DODGE, E				TREASURE, J; SCHMIDT, U; TROOP, N; TILLER, J; TODD, G; KEILEN, M; DODGE, E			FIRST STEP IN MANAGING BULIMIA-NERVOSA - CONTROLLED TRIAL OF THERAPEUTIC MANUAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA; OLDER ADULTS; BIBLIOTHERAPY; MANAGEMENT; EFFICACY	Objective-To test the short term efficacy of a self directed treatment manual for bulimia nervosa. Design-Randomised controlled trial of the manual against cognitive behavioural therapy and a waiting list. Setting-Tertiary referral centre. Subjects-81 consecutive referrals presenting with bulimia nervosa or atypical bulimia nervosa. Main outcome measures-Frequency of binge eating, vomiting, and other behaviours to control weight as well as abstinence from these behaviours. Results-Cognitive behavioural treatment produced a significant reduction in the frequency of binge eating, vomiting, and other behaviours to control weight. The manual significantly reduced frequency of binge eating and weight control behaviours other than vomiting, and there was no change in the group on the waiting list. Full remission was achieved in five (24%) of the group assigned to cognitive behavioural treatment, nine (22%) of the group who used the manual, and two (11%) of the group on the waiting list. Conclusions-A self directed treatment manual may be a useful first intervention in the treatment of bulimia nervosa.	ST MARYS HOSP, DEPT PSYCHIAT, LONDON W2 1NY, ENGLAND; UNIV COLOGNE, W-5000 COLOGNE, GERMANY	Imperial College London; University of Cologne	TREASURE, J (corresponding author), INST PSYCHIAT, EATING DISORDER RES GRP, LONDON SE5 8AF, ENGLAND.			Treasure, Janet/0000-0003-0871-4596				AGRAS WS, 1992, AM J PSYCHIAT, V149, P82; ALBERT T, 1992, BRIT MED J, V305, P1266, DOI 10.1136/bmj.305.6864.1266; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; DAVIS R, 1990, J CONSULT CLIN PSYCH, V58, P882, DOI 10.1037/0022-006X.58.6.882; DONNAN P, 1990, BRIT J GEN PRACT, V40, P498; Fairburn C. G., 1989, COGNITIVE BEHAV THER, P277; FAIRBURN CG, 1991, ARCH GEN PSYCHIAT, V48, P463; FAIRBURN CG, 1990, GUT, V31, P1220, DOI 10.1136/gut.31.11.1220; First M.B., 1989, STRUCTURED CLIN INTE; FREEMAN CP, 1991, J PSYCHOSOM RES, V35, P41, DOI 10.1016/0022-3999(91)90112-2; GARDNER MJ, 1991, BRIT MED J; GARNER DM, 1993, AM J PSYCHIAT, V150, P37; GARNER DM, 1986, PSYCHOTHER PSYCHOSOM, V46, P67, DOI 10.1159/000287963; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; GHOSH A, 1988, BRIT J PSYCHIAT, V152, P234, DOI 10.1192/bjp.152.2.234; GUY W, 1976, ECDEU ASSESSMENT MAN, P516; HENDERSON M, 1987, BRIT J PSYCHIAT, V150, P18, DOI 10.1192/bjp.150.1.18; Hoek Hans Wijbrand, 1993, International Review of Psychiatry, V5, P61, DOI 10.3109/09540269309028295; KENDLER KS, 1991, AM J PSYCHIAT, V148, P1627; NORMAN DK, 1986, PSYCHIAT RES, V19, P199, DOI 10.1016/0165-1781(86)90098-3; NORUSIS MJ, 1988, SPSS PC PLUS V20 BAS; OLMSTED MP, 1991, BEHAV RES THER, V29, P71, DOI 10.1016/S0005-7967(09)80009-0; ROBSON P, 1989, PSYCHOL MED, V19, P513, DOI 10.1017/S003329170001254X; RUSSELL G, 1979, PSYCHOL MED, V9, P429, DOI 10.1017/S0033291700031974; SAVAGE SA, 1990, BRIT J CLIN PSYCHOL, V29, P373, DOI 10.1111/j.2044-8260.1990.tb00900.x; SCHMIDT U, 1993, INT J EAT DISORDER, V13, P273, DOI 10.1002/1098-108X(199304)13:3&lt;273::AID-EAT2260130305&gt;3.0.CO;2-B; Schmidt U., 1993, GETTING BETTER BIT E; SCOGIN F, 1989, J CONSULT CLIN PSYCH, V57, P403, DOI 10.1037/0022-006X.57.3.403; SCOGIN F, 1990, J CONSULT CLIN PSYCH, V58, P665; SORBY NGD, 1991, BRIT J GEN PRACT, V41, P417; TROOP N, 1993, BMJ-BRIT MED J, V307, P577, DOI 10.1136/bmj.307.6904.577; WALSH BT, 1991, AM J PSYCHIAT, V148, P1206; 1992, CR14 ROYAL COLL PSYC; 1992, LONDON HLTH CARE 201; 1991, ARCH GEN PSYCHIAT, V49, P139	35	72	72	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	1994	308	6930					686	689		10.1136/bmj.308.6930.686	http://dx.doi.org/10.1136/bmj.308.6930.686			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142791	Green Published			2022-12-28	WOS:A1994NA86900018
J	FISH, EM; MOLITORIS, BA				FISH, EM; MOLITORIS, BA			ALTERATIONS IN EPITHELIAL POLARITY AND THE PATHOGENESIS OF DISEASE STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CELL-ADHESION MOLECULE; E-CADHERIN EXPRESSION; ACUTE-RENAL-FAILURE; TUMOR DEDIFFERENTIATION; CATENIN COMPLEX; PROXIMAL TUBULE; APICAL MEMBRANE; ATP DEPLETION; BRUSH-BORDER; MDCK CELLS		UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN; VET AFFAIRS MED CTR,DENVER,CO; VET AFFAIRS MED CTR,INDIANAPOLIS,IN	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [R01 DK-41126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; AVNER E D, 1992, Journal of the American Society of Nephrology, V3, P292; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BEHREN SJ, 1992, SEMIN CELL BIOL, V3, P169; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; CARRUTHERS L, 1986, CLIN GASTROENTEROL, V15, P105; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; CUTZ E, 1989, NEW ENGL J MED, V320, P646, DOI 10.1056/NEJM198903093201006; DAVIDSON GP, 1978, GASTROENTEROLOGY, V75, P783; EIDELMAN S, 1989, AM J PATHOL, V135, P101; FRICKER G, 1989, J CLIN INVEST, V84, P876, DOI 10.1172/JCI114248; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GABBERT H, 1985, CLIN EXP METASTAS, V3, P257, DOI 10.1007/BF01585081; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; GOLIGORSKY MS, 1993, P NATL ACAD SCI USA, V90, P5700, DOI 10.1073/pnas.90.12.5700; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MOLITORIS BA, 1991, J CLIN INVEST, V88, P462, DOI 10.1172/JCI115326; MOLITORIS BA, 1993, AM J PHYSIOL, V265, pF693, DOI 10.1152/ajprenal.1993.265.5.F693; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PAVELKA M, 1983, J ULTRA MOL STRUCT R, V85, P249, DOI 10.1016/S0022-5320(83)90037-0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; VEGASALAS DE, 1988, J CELL BIOL, V107, P1717, DOI 10.1083/jcb.107.5.1717; VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56	49	168	172	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1580	1588						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177249				2022-12-28	WOS:A1994NN21500007
J	SOLDATI, T; SHAPIRO, AD; SVEJSTRUP, ABD; PFEFFER, SR				SOLDATI, T; SHAPIRO, AD; SVEJSTRUP, ABD; PFEFFER, SR			MEMBRANE TARGETING OF THE SMALL GTPASE RAB9 IS ACCOMPANIED BY NUCLEOTIDE EXCHANGE	NATURE			English	Article							GDP DISSOCIATION INHIBITOR; BINDING PROTEIN; VESICULAR TRANSPORT; ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; PURIFICATION; CYTOSOL	THE Rab GTPases are key regulators of vesicular transport(1-6). A fraction of Rab proteins is present in the cytosol, bound with GDP, complexed tb a protein termed GDI(7-10). Rab9 is localized primarily to late endosomes, where it aids the transport of mannose 6-phosphate receptors to the trans-Golgi network(11). It has been proposed that Rab proteins are delivered to specific membranes by GDI, and that this process is accompanied by the exchange of bound GDP for GTP(1-3). In addition, Rab localization requires carboxy-terminal prenylation and specific structural determinants(12-14). Here we describe the reconstitution of the selective targeting of prenylated Rab9 protein onto late endosome membranes and show that this process is accompanied by endosome-triggered nucleotide exchange.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			SOLDATI, Thierry/A-2902-2009; SOLDATI, Thierry/U-6494-2019	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DUNN B, 1993, NATURE, V362, P533; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHAPIRO AD, 1993, J BIOL CHEM, V268, P6925; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	26	166	168	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					76	78		10.1038/369076a0	http://dx.doi.org/10.1038/369076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164745	Green Published			2022-12-28	WOS:A1994NJ86000057
J	NATANSON, C; HOFFMAN, WD; SUFFREDINI, AF; EICHACKER, PQ; DANNER, RL				NATANSON, C; HOFFMAN, WD; SUFFREDINI, AF; EICHACKER, PQ; DANNER, RL			SELECTED TREATMENT STRATEGIES FOR SEPTIC SHOCK BASED ON PROPOSED MECHANISMS OF PATHOGENESIS	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHESIS; RESPIRATORY-DISTRESS SYNDROME; GRAM-NEGATIVE BACTEREMIA; COLONY-STIMULATING FACTOR; MONOMETHYL-L-ARGININE; ESCHERICHIA-COLI J5; METHYL-L-ARGININE; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES	Purpose: To review selected new therapies for septic shock designed to inhibit bacterial toxins or endogenous mediators of inflammation. Data Sources: Scientific journals, scientific meeting proceedings, and Food and Drug Administration advisory committee proceedings. Study Selection and Extraction: Preclinical and clinical data from trials using core-directed antiendotoxin antibodies and anticytokine therapies for sepsis and studies in animal models of sepsis from our laboratory. Results of Data Synthesis: Ten clinical trials using core-directed antiendotoxin antibodies produced inconsistent results and did not conclusively establish the safety or benefit of this approach. Both anti-interleukin-1 and anti-tumor necrosis factor (TNF) therapies have been beneficial in some animal models of sepsis, but did not clearly improve survival in initial human trials, and one anti-TNF therapy actually produced harm. Neutrophils, another target for therapeutic intervention, protect the host from infection but may also contribute to the development of tissue injury during sepsis. In a canine model of septic shock, granulocyte colony-stimulating factor increased the number of circulating neutrophils and improved survival, but an anti-integrin (CD11/18) antibody that inhibits neutrophil function worsened outcome. Nitric oxide, a vasodilator produced by the host, causes hypotension during septic shock but may also protect the endothelium and maintain organ blood flow. In dogs challenged with endotoxin, the inhibition of nitric oxide production decreased cardiac index and did not improve survival. Conclusions: No new therapy for sepsis has shown clinical efficacy. Perhaps more accurate clinical and laboratory predictors are needed to identify patients who may benefit from a given treatment strategy. On the other hand, the therapeutic premises may be flawed. Targeting a single microbial toxin such as endotoxin may not represent a viable strategy for treating a complex inflammatory response to diverse gram-negative bacteria. Similarly, the strategy of inhibiting the host inflammatory response may not be beneficial because immune cells and cytokines play both pathogenic and protective roles. Finally, our scientific knowledge of the complex timing of mediator release and balance during sepsis may be insufficient to develop successful therapeutic interventions for this syndrome.			NATANSON, C (corresponding author), NIH, CTR CLIN, DEPT CRIT CARE MED, BLDG 10, ROOM 7D43, BETHESDA, MD 20892 USA.							ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ADI S, 1992, J CLIN INVEST, V89, P1603, DOI 10.1172/JCI115755; AISAKA K, 1991, JPN J PHARMACOL, V56, P245, DOI 10.1254/jjp.56.245; ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; ALLENDOERFER R, 1993, J INFECT DIS, V167, P1168, DOI 10.1093/infdis/167.5.1168; ARNAOUT MA, 1990, BLOOD, V75, P1037; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Baumgartner J D, 1991, Infect Dis Clin North Am, V5, P915; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BAUMGARTNER JD, 1985, LANCET, V2, P59; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; Bermudez LE, 1989, REV INFECT DIS    S7, V11, pS1564; BERSTEN A, 1989, CRIT CARE CLIN, V5, P49; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BOUJOUKOS AJ, 1993, J APPL PHYSIOL, V74, P3027, DOI 10.1152/jappl.1993.74.6.3027; BRUINS SC, 1977, INFECT IMMUN, V17, P16, DOI 10.1128/IAI.17.1.16-20.1977; CAIRO MS, 1990, BLOOD, V76, P1788; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P31; COBB JP, 1993, CRIT CARE MED, V21, P1261; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; COMETTA A, 1992, NEW ENGL J MED, V327, P234; CORRIVEAU CC, 1993, INFECT AGENT DIS, V2, P35; CROSS AS, 1984, J INFECT DIS, V149, P184, DOI 10.1093/infdis/149.2.184; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Densen P., 1990, PRINCIPLES PRACTICES, P81; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DING AH, 1992, P SOC EXP BIOL MED, V200, P458; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; EICHACKER PQ, 1993, J APPL PHYSIOL, V74, P1885, DOI 10.1152/jappl.1993.74.4.1885; EICHACKER PQ, 1991, J APPL PHYSIOL, V71, P1979, DOI 10.1152/jappl.1991.71.5.1979; EICHACKER PQ, 1992, AM REV RESPIR DIS, V145, P1023, DOI 10.1164/ajrccm/145.5.1023; EICHACKER PQ, 1993, CLIN RES, V41, P240; ENDRES S, 1989, EUR J IMMUNOL, V19, P2327, DOI 10.1002/eji.1830191222; ESTRADA C, 1992, BIOCHEM BIOPH RES CO, V186, P475, DOI 10.1016/S0006-291X(05)80832-0; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FISCHER E, 1992, BLOOD, V79, P2196; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; FISHER CJ, 1993, CLIN INTENSIVE CARE, V4, pS8; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; Gabrilove J L, 1990, Cancer Chemother Biol Response Modif, V11, P631; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIRARDIN E, 1992, J INFECT DIS, V165, P695, DOI 10.1093/infdis/165.4.695; GOLDE DW, 1992, INFLAMMATION BASIC P, P291; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GREISMAN SE, 1969, J CLIN INVEST, V48, P613, DOI 10.1172/JCI106020; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HARBRECHT BG, 1992, CRIT CARE MED, V20, P1568, DOI 10.1097/00003246-199211000-00015; HEFLIN AC, 1981, J CLIN INVEST, V68, P1253, DOI 10.1172/JCI110371; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HINSHAW LB, 1992, J TRAUMA, V33, P568, DOI 10.1097/00005373-199210000-00013; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; HOFFMAN WD, 1994, J INFECT DIS, V169, P553, DOI 10.1093/infdis/169.3.553; HOLLENBERG SM, 1993, AM J PHYSIOL, V264, pH660, DOI 10.1152/ajpheart.1993.264.2.H660; HOTCHKISS RS, 1992, LANCET, V339, P434, DOI 10.1016/0140-6736(92)90127-O; HUTCHESON IR, 1990, BRIT J PHARMACOL, V101, P815, DOI 10.1111/j.1476-5381.1990.tb14163.x; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLABUNDE RE, 1992, RES COMMUN CHEM PATH, V78, P57; KLABUNDE RE, 1991, BIOCHEM BIOPH RES CO, V178, P1135, DOI 10.1016/0006-291X(91)91010-A; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KRIEGER JI, 1993, J INFECT DIS, V167, P865, DOI 10.1093/infdis/167.4.865; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LORENTE JA, 1993, CRIT CARE MED, V21, P759, DOI 10.1097/00003246-199305000-00021; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; LUCE JM, 1993, CRIT CARE MED, V21, P1233, DOI 10.1097/00003246-199308000-00026; MAY GR, 1991, BRIT J PHARMACOL, V102, P759, DOI 10.1111/j.1476-5381.1991.tb12246.x; MCCABE WR, 1981, CURRENT CLIN TOPICS, V2, P121; MCCUTCHAN JA, 1983, SCHWEIZ MED WOCHEN S, V113, P40; MEYER J, 1992, J APPL PHYSIOL, V73, P324, DOI 10.1152/jappl.1992.73.1.324; MICHIE HR, 1988, SURGERY, V104, P280; MINER KM, 1986, INFECT IMMUN, V52, P56, DOI 10.1128/IAI.52.1.56-62.1986; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOONEY DP, 1988, ARCH SURG-CHICAGO, V123, P1353; MULLIGAN MS, 1993, J IMMUNOL, V150, P2401; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; NAKANE A, 1988, INFECT IMMUN, V56, P2563, DOI 10.1128/IAI.56.10.2563-2569.1988; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1992, J CARDIOVASC PHARM, V20, pS132, DOI 10.1097/00005344-199204002-00037; NELSON S, 1991, J INFECT DIS, V164, P901, DOI 10.1093/infdis/164.5.901; NGUYEN T, 1992, BIOCHEMISTRY-US, V89, P3030; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARKER JL, 1993, CIRC RES, V72, P539, DOI 10.1161/01.RES.72.3.539; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; QUEZADO ZMN, 1994, J EXP MED, V179, P569, DOI 10.1084/jem.179.2.569; QUEZADO ZMN, 1993, JAMA-J AM MED ASSOC, V269, P2221, DOI 10.1001/jama.269.17.2221; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RELMAN AS, 1990, NEW ENGL J MED, V323, P1355; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; SADOFF J, 1994, 3RD INT C IMM CONS T; Sadoff J C, 1985, Antibiot Chemother (1971), V36, P134; SHARAR SR, 1991, SURGERY, V110, P213; SIEGEL JP, 1992, NEW ENGL J MED, V327, P890; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; TAKASHI K, 1992, INFLAMMATION BASIC P, P353; TENAILLON A, 1993, AM REV RESPIR DIS, V147, pA196; TENG NNH, 1985, P NATL ACAD SCI USA, V82, P1790, DOI 10.1073/pnas.82.6.1790; TOLINS JP, 1990, INT CONGR SER, V897, P463; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VANDERVORT AL, 1993, CLIN RES, V41, pA281; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WALDER CE, 1991, BRIT J PHARMACOL, V102, P967, DOI 10.1111/j.1476-5381.1991.tb12285.x; WALSH CJ, 1991, SURGERY, V110, P205; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WENZEL R, 1991, 31ST INT C ANT AG CH, P294; WESTPHAL O, 1983, PROG ALLERGY, V33, P9; WHEELER AP, 1990, AM REV RESPIR DIS, V142, P775, DOI 10.1164/ajrccm/142.4.775; WHERRY J, 1993, 33RD INT C ANT AG CH; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; YOUNG LS, 1975, J CLIN INVEST, V56, P850, DOI 10.1172/JCI108164; Young LS, 1990, PRINCIPLES PRACTICE, P611; ZANETTI G, 1992, J IMMUNOL, V148, P1890; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZIEGLER EJ, 1973, J IMMUNOL, V111, P433; ZIMMERMAN JJ, 1992, CRIT CARE CLIN, V8, P163, DOI 10.1016/S0749-0704(18)30273-2	150	390	424	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					771	783		10.7326/0003-4819-120-9-199405010-00009	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00009			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147551				2022-12-28	WOS:A1994NH25100009
J	CHAPUY, MC; ARLOT, ME; DELMAS, PD; MEUNIER, PJ				CHAPUY, MC; ARLOT, ME; DELMAS, PD; MEUNIER, PJ			EFFECT OF CALCIUM AND CHOLECALCIFEROL TREATMENT FOR 3 YEARS ON HIP-FRACTURES IN ELDERLY WOMEN	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D		HOP EDOUARD HERRIOT,INSERM,U234,SERV RHUMATOL & PATHOL OSSEUSE,F-69437 LYON 3,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								CHAPUY MC, 1987, AM J CLIN NUTR, V46, P324, DOI 10.1093/ajcn/46.2.324; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405	5	504	521	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1081	1082		10.1136/bmj.308.6936.1081	http://dx.doi.org/10.1136/bmj.308.6936.1081			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173430	Green Published			2022-12-28	WOS:A1994NH48900025
J	ZENG, FG; SHANNON, RV				ZENG, FG; SHANNON, RV			LOUDNESS-CODING MECHANISMS INFERRED FROM ELECTRIC-STIMULATION OF THE HUMAN AUDITORY-SYSTEM	SCIENCE			English	Article							COCHLEAR NUCLEUS; NERVE-FIBERS; LEVEL	Two distinct physiological mechanisms underlying loudness sensation were inferred from electric stimulation of the human auditory nerve and brainstem. In contrast to a power function relating loudness and stimulus intensity in acoustic hearing, loudness in electric stimulation of the auditory nerve depends on stimulus frequency. Loudness is an exponential function of electric amplitude for high frequencies and is a power function for low frequencies. A frequency-dependent, two-stage model is suggested to explain the loudness function, in which the first stage of processing is performed by a mechanical mechanism in the cochlea for high-frequency stimuli and by a neural mechanism in the cochlear nucleus for low-frequency stimuli.			ZENG, FG (corresponding author), HOUSE EAR RES INST,LOS ANGELES,CA 90057, USA.		Zeng, Fan-Gang/G-4875-2012		NIDCD NIH HHS [R03-DC01464, R01-DC01526] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC001464, R01DC001526] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BRACKMANN DE, 1993, OTOLARYNG HEAD NECK, V108, P624, DOI 10.1177/019459989310800602; BURNS EM, 1976, J ACOUST SOC AM, V60, P963; CLARK GM, 1987, ADV OTORHINOLARYNGOL, V38, P1; DORMAN MF, 1993, EAR HEARING, V14, P290, DOI 10.1097/00003446-199308000-00008; ECCLES JC, 1966, TOUCH HEAT PAIN; EDDINGTON D K, 1978, Annals of Otology Rhinology and Laryngology, V87, P5; EGGERMONT JJ, 1991, HEARING RES, V56, P153, DOI 10.1016/0378-5955(91)90165-6; FRISINA RD, 1990, HEARING RES, V44, P99, DOI 10.1016/0378-5955(90)90074-Y; KIM DO, 1979, J NEUROPHYSIOL, V42, P16, DOI 10.1152/jn.1979.42.1.16; MACKAY DM, 1963, SCIENCE, V139, P1213, DOI 10.1126/science.139.3560.1213-a; MOLLER AR, 1973, BRAIN RES, V57, P443, DOI 10.1016/0006-8993(73)90148-0; ROSEN S, 1992, J ACOUST SOC AM, V92, P773, DOI 10.1121/1.403946; SACHS MB, 1974, J ACOUST SOC AM, V56, P1835, DOI 10.1121/1.1903521; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SHANNON RV, 1993, OTOLARYNG HEAD NECK, V108, P634, DOI 10.1177/019459989310800603; SHANNON RV, 1992, IEEE T BIO-MED ENG, V39, P424, DOI 10.1109/10.126616; STEVENS SS, 1955, J ACOUST SOC AM, V27, P815, DOI 10.1121/1.1908048; STEVENS SS, 1953, SCIENCE, V118, P576; STEVENS SS, 1970, SCIENCE, V170, P1043, DOI 10.1126/science.170.3962.1043; VUREK LS, 1981, ANN OTO RHINOL LARYN, V90, P21, DOI 10.1177/00034894810902S208; WILSON P, 1992, AUDITORY PHYSL PERCE; YATES GK, 1992, TRENDS NEUROSCI, V15, P57, DOI 10.1016/0166-2236(92)90027-6; ZENG FG, 1992, HEARING RES, V60, P231, DOI 10.1016/0378-5955(92)90024-H	23	88	89	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					564	566		10.1126/science.8160013	http://dx.doi.org/10.1126/science.8160013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160013				2022-12-28	WOS:A1994NH01000035
J	DARIANSMITH, C; GILBERT, CD				DARIANSMITH, C; GILBERT, CD			AXONAL SPROUTING ACCOMPANIES FUNCTIONAL REORGANIZATION IN ADULT CAT STRIATE CORTEX	NATURE			English	Article							MASSIVE CORTICAL REORGANIZATION; VISUAL-CORTEX; SOMATOSENSORY CORTEX; DIGIT AMPUTATION; MOTOR CORTEX; OWL MONKEYS; SPINAL-CORD; CONNECTIONS; NEURONS; LESIONS	REMOVAL Of sensory input from a focal region of adult neocortex can lead to a large reorganization of cortical topography within the deprived area during subsequent months(1-9). Although this form of functional recovery is now well documented across several sensory systems, the underlying cellular mechanisms remain elusive. Weeks after binocular retinal lesions silence a corresponding portion of striate cortex in the adult cat, this cortex again becomes responsive, this time to retinal loci immediately outside the scotoma. Earlier findings showed a lack of reorganization in the lateral geniculate nucleus and an inadequate spread of geniculocortical afferents to account for the cortical reorganization, suggesting the involvement of intrinsic cortical connections(4,10). We investigated the possibility that intracortical axonal sprouting mediates long-term reorganization of cortical functional architecture. The anterograde label biocytin was used to compare the density of lateral projections into reorganized and non-deprived cortex. We report here that structural changes in the form of axonal sprouting of long-range laterally projecting neurons accompany topographic remodelling of the visual cortex.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University				Darian-Smith, Corinna/0000-0002-4753-4574				ALLARD T, 1991, J NEUROPHYSIOL, V66, P1048, DOI 10.1152/jn.1991.66.3.1048; BAILEY CH, 1983, NEUROSCIENCE, V8, P2452; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A; Darian-Smith C., 1992, Society for Neuroscience Abstracts, V18, P11; FITZGERALD M, 1990, J COMP NEUROL, V300, P370, DOI 10.1002/cne.903000308; FLORENCE SL, 1993, BRAIN RES, V601, P343, DOI 10.1016/0006-8993(93)91734-A; GANCHROW D, 1981, EXP NEUROL, V71, P437, DOI 10.1016/0014-4886(81)90022-4; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KELLER A, 1990, EXP BRAIN RES, V80, P23; KELLER A, 1992, J NEUROPHYSIOL, V68, P295, DOI 10.1152/jn.1992.68.1.295; LAMOTTE CC, 1993, J COMP NEUROL, V330, P83, DOI 10.1002/cne.903300107; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MCMAHON SB, 1991, J COMP NEUROL, V304, P307, DOI 10.1002/cne.903040211; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MOLANDER C, 1988, J COMP NEUROL, V276, P436, DOI 10.1002/cne.902760308; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAJAN R, 1993, J COMP NEUROL, V338, P17, DOI 10.1002/cne.903380104; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; RECANZONE GH, 1993, J NEUROSCI, V13, P87; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; Steward O., 1991, CEREB CORTEX, V9, P81; WALL JT, 1984, J NEUROSCI, V4, P1499; WELLS J, 1987, J COMP NEUROL, V255, P466, DOI 10.1002/cne.902550312	32	493	501	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					737	740		10.1038/368737a0	http://dx.doi.org/10.1038/368737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152484				2022-12-28	WOS:A1994NG55300057
J	ELLIS, P; CUNNINGHAM, D				ELLIS, P; CUNNINGHAM, D			CURRENT ISSUES IN CANCER .3. MANAGEMENT OF CARCINOMAS OF THE UPPER GASTROINTESTINAL-TRACT	BRITISH MEDICAL JOURNAL			English	Article							GASTRIC-CANCER; PANCREATIC-CANCER; CHEMOTHERAPY; RADIATION; DOXORUBICIN; ESOPHAGUS; THERAPY; TRIAL; 5-FLUOROURACIL; FLUOROURACIL	Patients with oesophageal, gastric, and pancreatic carcinomas present a common and difficult problem for the clinician. Surgery is the best option for curative treatment but overall survival figures remain low. Recent improvements in our understanding of the biology of these tumours and improvements in their clinical staging, along with the development of combined modality approaches to local-regional disease, have led to renewed optimism that survival figures may be improved. This is particularly so for oesophageal and gastric carcinomas. In addition, there have been advances in the palliative management of all three tumours. This article examines some of these developments and looks at future prospects.	ROYAL MARSDEN HOSP,DEPT MED,SUTTON SM2 5PT,SURREY,ENGLAND; INST CANC RES,GASTROINTESTINAL UNIT,SUTTON SM2 5PX,SURREY,ENGLAND; INST CANC RES,CANC RES CAMPAIGN,MED SECT,SUTTON SM2 5PX,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK				Cunningham, David/0000-0001-5158-1069				AMIN Z, 1993, RADIOLOGY, V187, P339, DOI 10.1148/radiology.187.2.8475270; BONENKAMP JJ, 1993, P AN M AM SOC CLIN, V12, P554; CULLINAN S, 1993, P AN M AM SOC CLIN, V12, P200; CULLINAN SA, 1985, JAMA-J AM MED ASSOC, V253, P2061, DOI 10.1001/jama.253.14.2061; FINDLAY M, IN PRESS ANN ONCOLOG; FORASTIERE AA, 1990, J CLIN ONCOL, V8, P119, DOI 10.1200/JCO.1990.8.1.119; FREY C, 1981, CANCER, V47, P27, DOI 10.1002/1097-0142(19810101)47:1<27::AID-CNCR2820470106>3.0.CO;2-F; GIRLING DJ, 1992, J CLIN ONCOL, V10, P1031, DOI 10.1200/JCO.1992.10.7.1031; GRACE PA, 1990, BRIT J SURG, V77, P968, DOI 10.1002/bjs.1800770906; GRAU JJ, 1993, EUR J CANCER, V29A, P340, DOI 10.1016/0959-8049(93)90381-O; HAGIWARA A, 1992, LANCET, V339, P629, DOI 10.1016/0140-6736(92)90792-2; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HARPER PG, 1992, P AM SOC CLIN ONCOL, V11, P472; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAMBE M, 1993, P AN M AM SOC CLIN, V12, P584; KANEKO E, 1977, GUT, V18, P6; KELSEN D, 1992, J CLIN ONCOL, V10, P541, DOI 10.1200/JCO.1992.10.4.541; KIM NK, 1993, CANCER, V71, P3813, DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5; KLAASSEN DJ, 1985, J CLIN ONCOL, V3, P373, DOI 10.1200/JCO.1985.3.3.373; LEONARD RC, 1992, BR J CANCER S16, V65, P8; MALLINSON CN, 1980, BRIT MED J, V281, P1589, DOI 10.1136/bmj.281.6255.1589; MAUNOURY V, 1992, GUT, V33, P1602, DOI 10.1136/gut.33.12.1602; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PYRONEN S, 1992, ANN ONCOL S3, V3, P47; SALTZ L, 1992, ANN ONCOL, V3, P793, DOI 10.1093/oxfordjournals.annonc.a058098; SARGEANT IR, IN PRESS GASTROENTER; SISCHY B, 1990, P AN M AM SOC CLIN, V9, P407; TIO TL, 1989, GASTROENTEROLOGY, V96, P1478, DOI 10.1016/0016-5085(89)90515-5; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011; WALKER H, 1989, J CLIN ONCOL, V7, P1318; WILS JA, 1991, J CLIN ONCOL, V9, P827, DOI 10.1200/JCO.1991.9.5.827; 1988, J NATL CANCER I, V80, P751; 1993, LANCET, V341, P1359	36	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					834	838		10.1136/bmj.308.6932.834	http://dx.doi.org/10.1136/bmj.308.6932.834			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167493	Green Published			2022-12-28	WOS:A1994ND24300027
J	MOHER, M; JOHNSON, N				MOHER, M; JOHNSON, N			USE OF ASPIRIN BY GENERAL-PRACTITIONERS IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, OXON, ENGLAND	Radcliffe Infirmary	MOHER, M (corresponding author), SOUTHMEAD SURG, FARNHAM SL2 3ER, BUCKS, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555	3	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					760	760		10.1136/bmj.308.6931.760	http://dx.doi.org/10.1136/bmj.308.6931.760			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142831	Green Published			2022-12-28	WOS:A1994NC34800020
J	GODFREYFAUSSETT, P; BAGGALEY, R; SCOTT, G; SICHONE, M				GODFREYFAUSSETT, P; BAGGALEY, R; SCOTT, G; SICHONE, M			HIV IN ZAMBIA - MYTH OR MONSTER	NATURE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; KAPOSIS SARCOMA; TUBERCULOSIS; MORTALITY; NAIROBI		LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; KARA COUNSELLING & TRAINING TRUST,LUSAKA,ZAMBIA	University of London; London School of Hygiene & Tropical Medicine	GODFREYFAUSSETT, P (corresponding author), UNIV ZAMBIA,TEACHING HOSP,DEPT MED,ZAMBART PROJECT,POB 50110,LUSAKA,ZAMBIA.							BAYLEY AC, 1985, LANCET, V1, P359; BAYLEY AC, 1984, LANCET, V1, P1318; BIGGAR RJ, 1985, LANCET, V2, P520; BUVE A, IN PRESS AIDS; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GILKS CF, 1992, Q J MED, V82, P25; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; HODGKINSON N, 1993, SUNDAY TIMES    1003, P10; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MELBYE M, 1986, LANCET, V2, P1113; NKOWANE BM, 1991, AIDS, V5, pS7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; 7TH MAR INT C AIDS A; 1992, WHO WKLY EPIDEM REC, V67, P145	17	3	3	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					183	184		10.1038/368183a0	http://dx.doi.org/10.1038/368183a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145813				2022-12-28	WOS:A1994NA87000023
J	LINDBLAD, U; RASTAM, L; RYDEN, L; RANSTAM, J; ISACSSON, SO; BERGLUND, G				LINDBLAD, U; RASTAM, L; RYDEN, L; RANSTAM, J; ISACSSON, SO; BERGLUND, G			CONTROL OF BLOOD-PRESSURE AND RISK OF FIRST ACUTE MYOCARDIAL-INFARCTION - SKARABORG HYPERTENSION PROJECT	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; PRIMARY PREVENTION TRIAL; MEDICAL-CARE PROGRAM; ANTIHYPERTENSIVE THERAPY; TREATED HYPERTENSION; SERUM-CHOLESTEROL; FOLLOW-UP; REDUCTION; CURVE	Objective-To analyse the relation between treated blood pressure and concomitant risk factor and morbidity from acute myocardial infarction. Design-Prospective longitudinal study. Treated blood pressures and other variables were used to predict acute myocardial infarction. Setting-Primary health care in Skaraborg, Sweden. Subjects-1121 men and 1453 women aged 40-69 years at registration at outpatient clinics, 1977-81, with no evidence of previous myocardial infarction were followed up for an average of 7.4 years. Subjects were undergoing treatment with drugs to lower blood pressure or had blood pressure that exceeded the systolic or diastolic limits, or both, for diagnosis (>170/>105 mm Hg (patients aged 40-60 years) and >180/>110 mm Hg (older than 60 years)) on three different occasions, or both. Main outcome measures-First validated event of fatal or non-fatal acute myocardial infarction. Results-In men but not in women there was a negative relation between treated diastolic blood pressure and risk of acute myocardial infarction. Left ventricular hypertrophy and smoking were contributory risk factors in both sexes, as was serum cholesterol concentration in men. In men with normal electrocardiograms (n=345) risk increased with increasing diastolic blood pressure (P=0.047), whereas the opposite was found in men with electrocardiograms suggesting ischaemia or hypertrophy, or both (n=499, P=0.009). In those with a reading of 95-99 mm Hg the relative risk was 0.30 (P=0.034); at greater than or equal to 100 mm Hg it was 0.37 (P=0.027). No similar relations were seen in women or for systolic blood pressure. Conclusion-It may be hazardous to lower diastolic blood pressure below 95 mm Hg in hypertensive men with possible ischaemia or hypertrophy, or both. Electrocardiographic findings should be considered when treatment goals are decided for men with hypertension.	LUND UNIV,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT MED,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,DEPT CARDIOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Lund University; Karolinska Institutet; Karolinska University Hospital			Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON TW, 1978, LANCET, V2, P1139; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BERGLUND G, 1987, LANCET, V1, P1154; BERGLUND G, 1989, AM J HYPERTENS, V2, P586, DOI 10.1093/ajh/2.7.586; BERGLUND G, 1977, PROGRAM MANAGEMENT H; BERGLUND G, 1979, ACTA MED SCAND S626, V205, P64; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPER SP, 1988, AM J EPIDEMIOL, V127, P387, DOI 10.1093/oxfordjournals.aje.a114812; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DUNN FG, 1990, J HYPERTENS, V8, P775, DOI 10.1097/00004872-199008000-00012; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; KALBFLEISCH JD, 1979, STATISTICAL ANAL FAI; KANNEL WB, 1987, AM J CARDIOL, V59, pA80, DOI 10.1016/0002-9149(87)90182-2; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDBLAD U, 1993, J INTERN MED, V233, P155, DOI 10.1111/j.1365-2796.1993.tb00668.x; LINDBLAD U, 1993, EUR HEART J, V14, P291, DOI 10.1093/eurheartj/14.3.291; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; RASTAM L, 1986, ACTA MED SCAND, V219, P249; RASTAM L, 1986, ACTA MED SCAND, V219, P261; ROSE GA, 1968, MONOGRAPH SERIES, V56, P98; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; SAMUELSSON O, 1985, ACTA MED SCAND S, V702, P1; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; STEWART IMG, 1979, LANCET, V1, P861; STRANDEGAARD S, 1987, LANCET, V1, P658; WALLER PC, 1988, J HUM HYPERTENS, V2, P7; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; ZACHETTI A, 1989, J HYPERTENS, V7, pS338; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1980, LANCET, V1, P1261; 1984, CIRCULATION, V70, P996; 1985, BRIT MED J, V291, P97; 1987, LANCET, V2, P251; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1990, CIRCULATION, V82, P1616; 1989, J HYPERTENS, V7, P689	50	43	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					681	686		10.1136/bmj.308.6930.681	http://dx.doi.org/10.1136/bmj.308.6930.681			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142790	Green Published			2022-12-28	WOS:A1994NA86900017
J	ERNFORS, P; LEE, KF; JAENISCH, R				ERNFORS, P; LEE, KF; JAENISCH, R			MICE LACKING BRAIN-DERIVED NEUROTROPHIC FACTOR DEVELOP WITH SENSORY DEFICITS	NATURE			English	Article							FACTOR PREVENTS; CELL-DEATH; NEURONS; SURVIVAL; MOTONEURONS; INVIVO	DURING vertebrate development, neuronal survival depends on target-derived neurotrophic factors(1,2). Brain-derived neurotrophic factor(3) (BDNF), a member of the neurotrophin family, can prevent the death of particular peripheral sensory neurons in vitro(4-6), and of central motor neurons as well as dopaminergic and cholinergic neurons of the basal forebrain during development(7-9). It also prevents the death of motor neurons and midbrain dopaminergic neurons induced by lesions(8,10-12). Here we show that mutant mice lacking BDNF have severe deficiencies in coordination and balance, associated with excessive degeneration in several sensory ganglia including the vestibular ganglion. The few remaining vestibular axons fail to contact the vestibular sensory epithelia, and terminate in the adjacent connective tissue. Survival of sympathetic, midbrain dopaminergic and motor neurons is not affected. These results indicate that BDNF is required for the survival and target innervation of particular neuronal populations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	ERNFORS, P (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DAVIES AM, 1986, J NEUROSCI, V6, P1897; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LE E, 1992, CELL, V69, P915; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LYON MF, 1989, GENETIC VARIANT STRA; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	23	825	841	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					147	150		10.1038/368147a0	http://dx.doi.org/10.1038/368147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139657				2022-12-28	WOS:A1994NA03000066
J	SHENG, M; CUMMINGS, J; ROLDAN, LA; JAN, YN; JAN, LY				SHENG, M; CUMMINGS, J; ROLDAN, LA; JAN, YN; JAN, LY			CHANGING SUBUNIT COMPOSITION OF HETEROMERIC NMDA RECEPTORS DURING DEVELOPMENT OF RAT CORTEX	NATURE			English	Article							VISUAL-CORTEX; CHANNEL; CURRENTS; CLONING; NEURONS; BRAIN	ACTIVATION Of the N-methyl-D-aspartate (NMDA) receptor is important for certain forms of activity-dependent synaptic plasticity, such as long-term potentiation (reviewed in ref. 1), and the patterning of connections during development of the visual system (reviewed in refs 2, 3). Several subunits of the NMDA receptor have been cloned: these are NMDAR1 (NR1), and NMDAR2A, 2B, 2C and 2D (NR2A-D)(4-8). Based on heterologous co-expression studies, it is inferred that NR1 encodes an essential subunit of NMDA receptors and that functional diversity of NMDA receptors in vivo is effected by differential incorporation of subunits NR2A-NR2D(5-8). Little is known, however, about the actual subunit composition or heterogeneity of NMDA receptors in the brain. By co-immunoprecipitation with subunit-specific antibodies, we present here direct evidence that NMDA receptors exist in rat neocortex as heteromeric complexes of considerable heterogeneity, some containing both NR2A and NR2B subunits. A progressive alteration in subunit composition seen postnatally could contribute to NMDA-receptor variation and changing synaptic plasticity during cortical development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SHENG, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Sheng, Morgan/0000-0002-8703-5366; Jan, Lily/0000-0003-3938-8498				ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; ISHII T, 1993, J BIOL CHEM, V268, P2836; KATO N, 1993, P NATL ACAD SCI USA, V90, P7114, DOI 10.1073/pnas.90.15.7114; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; SCHATZ CJ, 1990, NEURON, V5, P745; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K	28	1100	1120	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					144	147		10.1038/368144a0	http://dx.doi.org/10.1038/368144a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139656				2022-12-28	WOS:A1994NA03000065
J	ALJUBOURI, MA; BRISTON, PG; SINCLAIR, D; CHINN, RH; YOUNG, RM				ALJUBOURI, MA; BRISTON, PG; SINCLAIR, D; CHINN, RH; YOUNG, RM			LESSON OF THE WEEK - MYXEDEMA REVEALED BY SIMVASTATIN-INDUCED MYOPATHY	BRITISH MEDICAL JOURNAL			English	Article							RENAL-FAILURE; HYPOTHYROIDISM		HAVANT HLTH CTR,HAVANT PO9 2AQ,HANTS,ENGLAND		ALJUBOURI, MA (corresponding author), QUEEN ALEXANDRA HOSP,DEPT CHEM PATHOL,PORTSMOUTH PO6 3LY,HANTS,ENGLAND.							BAGLIN A, 1987, THERAPIE, V42, P247; BOURRIER P, 1990, THERAPIE, V45, P360; HARLE JR, 1990, REV MED INTERNE, V11, P336, DOI 10.1016/S0248-8663(05)80871-9; LITIN SC, 1989, AM J MED, V86, P481, DOI 10.1016/0002-9343(89)90352-5; NORMAN DJ, 1988, NEW ENGL J MED, V318, P46; OKANE MJ, 1991, ANN CLIN BIOCHEM, V28, P509, DOI 10.1177/000456329102800515; PIERIDES AM, 1975, LANCET, V2, P1279; WHITE GH, 1984, CLIN CHEM, V30, P323	8	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					588	588		10.1136/bmj.308.6928.588	http://dx.doi.org/10.1136/bmj.308.6928.588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148686	Green Published			2022-12-28	WOS:A1994MY71400030
J	NEWMAN, AB; SUTTONTYRRELL, K; VOGT, MT; KULLER, LH				NEWMAN, AB; SUTTONTYRRELL, K; VOGT, MT; KULLER, LH			MORBIDITY AND MORTALITY IN HYPERTENSIVE ADULTS WITH A LOW ANKLE ARM BLOOD-PRESSURE INDEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the relationship between the ankle/arm blood pressure index (AAI, the ratio of ankle to arm systolic blood pressure, a measure of peripheral arterial disease) and short-term cardiovascular morbidity and mortality in older adults with systolic hypertension. Design.-Prospective cohort study, 1- to 2-year follow-up (mean, 16 months). Setting.-Eleven of 16 field centers from the Systolic Hypertension in the Elderly Program. Participants.-1537 older men and women with systolic hypertension. Main Outcome Measures.- All-cause mortality, coronary heart disease (CHD) mortality, cardiovascular disease (CVD) mortality, and CHD and CVD morbidity and mortality. Results.-The AAI was measured at the 1989-1990 clinic examination and was 0.9 or less in 25.5% of 1537 participants. A low AAI was associated with most major CHD and CVD risk factors. In those with a low AAI (less-than-or-equal-to 0.9) compared with those with an AAI of more than 0.9, age- and sex-adjusted relative risks for mortality end points at follow-up were as follows: total mortality, 3.8 (95% confidence interval [CI], 2.1 to 6.9); CHD mortality, 3.24 (95% CI, 1.4 to 7.5); and CVD mortality, 3.7 (95% CI, 1.8 to 7.7). For CVD morbidity and mortality, the age- and sex-adjusted relative risk was 2.5 (95% CI, 1.5 to 4.3). After adjustment for baseline CVD and other cardiovascular risk factors, the relative risk for total mortality was 4.1 (95% CI, 2.0 to 8.3) and for CVD morbidity and mortality, 2.4 (95% CI, 1.3 to 4.4). Results were similar when participants with clinical CVD at baseline were excluded. Conclusion.-A low AAI appears to be an important predictor of morbidity and mortality among older adults with systolic hypertension.	UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	NATIONAL INSTITUTE ON AGING [R29AG008047] Funding Source: NIH RePORTER; NIA NIH HHS [R29-AG08047-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, JAMA, V265, P3255; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; NEWMAN AB, 1991, J CLIN EPIDEMIOL, V44, P15, DOI 10.1016/0895-4356(91)90196-G; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X	11	267	282	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					487	489		10.1001/jama.270.4.487	http://dx.doi.org/10.1001/jama.270.4.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8147959				2022-12-28	WOS:A1993LN42600029
J	NOLAN, JP				NOLAN, JP			WE SHOULD RESIST EFFORTS TO SPLIT INTERNAL-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											NOLAN, JP (corresponding author), SUNY BUFFALO,BUFFALO,NY 14215, USA.							GLICKMAN RM, 1993, ANN INTERN MED, V118, P903, DOI 10.7326/0003-4819-118-11-199306010-00014; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; MYERBURG RJ, 1994, NEW ENGL J MED, V330, P1453, DOI 10.1056/NEJM199405193302013; 1993, ARCH INTERN MED, V153, P2305	4	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1456	1457		10.1056/NEJM199405193302014	http://dx.doi.org/10.1056/NEJM199405193302014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159205				2022-12-28	WOS:A1994NK97200014
J	OLENICH, M; SCHATTNER, E				OLENICH, M; SCHATTNER, E			POSTPARTUM THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) COMPLICATING PREGNANCY-ASSOCIATED IMMUNE THROMBOCYTOPENIC PURPURA (ITP)	ANNALS OF INTERNAL MEDICINE			English	Note									CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital								BURROWS RF, 1990, AM J OBSTET GYNECOL, V162, P731, DOI 10.1016/0002-9378(90)90996-K; MCCRAE KR, 1992, BLOOD, V80, P2697; SCHWARTZ ML, 1985, OBSTET GYNECOL, V65, pS53; SCHWARTZ ML, 1978, AM J OBSTET GYNECOL, V131, P18, DOI 10.1016/0002-9378(78)90468-4; WEINER CP, 1987, SEMIN HEMATOL, V24, P119	5	15	16	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					845	847		10.7326/0003-4819-120-10-199405150-00005	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154644				2022-12-28	WOS:A1994NK45800005
J	AMIGORENA, S; DRAKE, JR; WEBSTER, P; MELLMAN, I				AMIGORENA, S; DRAKE, JR; WEBSTER, P; MELLMAN, I			TRANSIENT ACCUMULATION OF NEW CLASS-II MHC MOLECULES IN A NOVEL ENDOCYTIC COMPARTMENT IN B-LYMPHOCYTES	NATURE			English	Article							BINDING PROTEIN RAB4; INVARIANT CHAIN; ANTIGEN PRESENTATION; SURFACE EXPRESSION; T-CELLS; ENDOSOMES; TRANSPORT; COMPLEX; PEPTIDE; LYSOSOMES	Endocytosis of antigen by antigen-presenting cells results in the production of peptides that bind to newly synthesized class II molecules of the major histocompatibility complex. A new population of class II-enriched vesicles has been discovered in B lymphocytes that accumulate internalized antigen but are distinct from endosomes and lysosomes. These vesicles also transiently accumulate newly synthesized class II and class II-peptide complexes and appear to be a compartment specialized for the transport and loading of class II molecules.	YALE UNIV, SCH MED, CTR CELL IMAGING, NEW HAVEN, CT 06520 USA	Yale University	AMIGORENA, S (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, 333 CEDAR ST, POB 208002, NEW HAVEN, CT 06520 USA.		Mellman, Ira/ABG-5896-2020	Amigorena, Sebastian/0000-0001-8583-8416				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BLAKE O, 1990, CELL, V63, P707; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; FUCHS R, 1989, J BIOL CHEM, V264, P2212; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANZEL D, 1992, SEMIN CELL BIOL, V2, P341; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KELLY RB, 1993, NATURE, V364, P487, DOI 10.1038/364487a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313	38	424	432	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	1994	369	6476					113	120		10.1038/369113a0	http://dx.doi.org/10.1038/369113a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177316				2022-12-28	WOS:A1994NK97100039
J	DONALDSON, MS; LOHR, KN; BULGER, RJ				DONALDSON, MS; LOHR, KN; BULGER, RJ			HEALTH DATA IN THE INFORMATION AGE - USE, DISCLOSURE, AND PRIVACY .2.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									NATL ACAD SCI, INST MED, COMM REG HLTH DATA NETWORKS, WASHINGTON, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	DONALDSON, MS (corresponding author), NATL ACAD SCI, INST MED, DIV HLTH CARE SERV, 2101 CONSTITUT AVE NW, WASHINGTON, DC 20418 USA.							DONALDSON MS, 1994, INFORMATION AGE USE	1	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1392	1392						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176789				2022-12-28	WOS:A1994NJ69300005
J	KREISBERG, R				KREISBERG, R			HALF A LOAF	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DEXAMETHASONE SUPPRESSION TEST; CUSHINGS-SYNDROME; DIFFERENTIAL-DIAGNOSIS; ECTOPIC SECRETION; CORTICOTROPIN; HORMONE				KREISBERG, R (corresponding author), UNIV ALABAMA,SCH MED,BIRMINGHAM,AL, USA.							CAREY RM, 1984, NEW ENGL J MED, V311, P13, DOI 10.1056/NEJM198407053110103; CONNOLLY CK, 1968, BRIT MED J, V2, P665, DOI 10.1136/bmj.2.5606.665; CRONIN C, 1990, CLIN ENDOCRINOL, V33, P27, DOI 10.1111/j.1365-2265.1990.tb00462.x; Doppman JL, 1992, ENDOCRINOLOGIST, V2, P41; EDDY RL, 1973, AM J MED, V55, P621, DOI 10.1016/0002-9343(73)90184-8; FINDLING JW, 1991, J CLIN ENDOCR METAB, V73, P408, DOI 10.1210/jcem-73-2-408; FINDLING JW, 1986, ARCH INTERN MED, V146, P929, DOI 10.1001/archinte.146.5.929; FINDLING JW, 1990, MAYO CLIN PROC, V65, P1377, DOI 10.1016/S0025-6196(12)62150-8; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LIMPER AH, 1992, ANN INTERN MED, V117, P209, DOI 10.7326/0003-4819-117-3-209; MEIKLE AW, 1993, ENDOCRINOLOGIST, V3, P311; NUGENT CA, 1964, J CLIN ENDOCR METAB, V24, P621, DOI 10.1210/jcem-24-7-621; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; ROSS EJ, 1982, LANCET, V2, P646; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180	16	16	16	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1295	1299		10.1056/NEJM199405053301809	http://dx.doi.org/10.1056/NEJM199405053301809			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145786				2022-12-28	WOS:A1994NJ51200009
J	AKAHANE, Y; KOJIMA, M; SUGAI, Y; SAKAMOTO, M; MIYAZAKI, Y; TANAKA, T; TSUDA, F; MISHIRO, S; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M				AKAHANE, Y; KOJIMA, M; SUGAI, Y; SAKAMOTO, M; MIYAZAKI, Y; TANAKA, T; TSUDA, F; MISHIRO, S; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M			HEPATITIS-C VIRUS-INFECTION IN SPOUSES OF PATIENTS WITH TYPE-C CHRONIC LIVER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; MARRIAGE; LIVER DISEASES; SEXUALLY TRANSMITTED DISEASES	NON-B-HEPATITIS; POLYMERASE CHAIN-REACTION; NON-A; HETEROSEXUAL TRANSMISSION; RISK-FACTORS; ANTIBODIES; DIAGNOSIS; GENOTYPES; PARTNERS; DISTINCT	Objective: Survey for markers of hepatitis C virus (HCV) infection in spouses of patients with HCV-related chronic liver disease. Design: Cross-sectional clinical, serologic, and molecular biological study of spouses of patients with HCV viremia and chronic liver disease. Setting: University and city hospitals. Participants: Spouses (52 men and 102 women; mean age, 56 +/- 11 years) of 154 patients with HCV viremia (102 men and 52 women; mean age, 58 +/- 10 years), of whom 66 had chronic hepatitis, 49 had liver cirrhosis, and 39 had primary hepatocellular carcinoma. Methods: Tests for HCV-associated antibodies were done using a second-generation enzyme immunoassay and immunoassays with synthetic oligopeptides deduced from the HCV core gene. Hepatitis C virus RNA was detected by polymerase chain reaction with primers deduced from the 5'-noncoding region and HCV genotypes by reaction with type-specific primers deduced from the HCV core gene. Results: Hepatitis C virus-associated antibodies were detected in 42 (27%) spouses, of whom 25 were also positive for HCV RNA. Of 112 (73%) spouses without detectable antibodies, 2 had chronic liver disease. The development of markers of HCV infection in spouses increased with the duration of marriage, ranging from 1 to 60 years (30 +/- 11 years). Conclusions: Spouses of patients with HCV viremia and chronic liver disease have an increased risk for acquiring HCV, which is proportional to the duration of marriage. They should be followed routinely for markers of HCV infection and liver disease.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KOJIMA CLIN, GIFU, JAPAN; IWAKI KYORITSU GEN HOSP, FUKUSHIMA, JAPAN; YAMANASHI MED COLL, YAMANASHI, JAPAN; VIRAL HEPATITIS RES FDN JAPAN, TOKYO, JAPAN; INST IMMUNOL, TOKYO, JAPAN; MITA INST, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BRETTLER DB, 1992, BLOOD, V80, P540; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; GORDON SC, 1992, AM J GASTROENTEROL, V87, P1849; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORI S, 1992, BIOCHEM BIOPH RES CO, V183, P334, DOI 10.1016/0006-291X(92)91648-A; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OKAMOTO H, 1992, HEPATOLOGY, V15, P180, DOI 10.1002/hep.1840150203; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; OSHITA M, 1993, J MED VIROL, V41, P251, DOI 10.1002/jmv.1890410314; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66; PEANO GM, 1992, BRIT MED J, V305, P1473, DOI 10.1136/bmj.305.6867.1473; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; SHEV S, 1991, SCAND J INFECT DIS, V23, P407, DOI 10.3109/00365549109075087; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; WATANABE J, 1993, VOX SANG, V65, P199, DOI 10.1111/j.1423-0410.1993.tb02148.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887	32	163	167	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					748	752		10.7326/0003-4819-120-9-199405010-00005	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147548				2022-12-28	WOS:A1994NH25100005
J	BROCK, DW; DANIELS, N				BROCK, DW; DANIELS, N			ETHICAL FOUNDATIONS OF THE CLINTON ADMINISTRATIONS PROPOSED HEALTH-CARE SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; UNITED-STATES; VALUES; REFORM; OREGON		BROWN UNIV,CTR BIOMED ETH,PROVIDENCE,RI 02912; TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02155	Brown University; Tufts University	BROCK, DW (corresponding author), BROWN UNIV,DEPT PHILOSOPHY,BOX 1918,PROVIDENCE,RI 02912, USA.							BRANDT RB, 1979, THEORY GOOD RIGHT, pCH16; BROCK DW, 1991, KENNEDY INST ETHIC J, V1, P28; BROCK DW, 1993, LIFE DEATH PHILOS ES; Buchanan Allen, 1981, JUSTICE HLTH CARE; CALLAHAN D, 1989, WHAT KIND LIFE; Callahan D., 1987, MED GOALS AGEING SOC; DANIELS N, 1990, MILBANK Q, V68, P497, DOI 10.2307/3350192; DANIELS N, 1985, JUST HLTH CARE; Daniels N, 1988, AM I MY PARENTS KEEP; DANIELS NS, 1986, NEW ENGL J MED, V314, P1381; DOUGHERTY CJ, 1992, JAMA-J AM MED ASSOC, V268, P2409, DOI 10.1001/jama.268.17.2409; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; JENNINGS B, 1988, HASTINGS CENT REP, V18, pS1; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MENZEL PT, 1990, STRONG MED ETHICAL R; MILL JS, 1977, COLLECTED WORKS J ST, V18; MORREIM H, 1991, NEW MED ETHICS MED N; Nagel T, 1979, MORTAL QUESTIONS; PRIESTER R, 1992, HEALTH AFFAIR, V11, P84, DOI 10.1377/hlthaff.11.1.84; RAWLS J, 1993, POLITICAL LIBERALISM, pCH4; Rawls J., 1971, THEORY JUSTICE; Rodwin M. A., 1993, MED MONEY MORALS PHY; Sen A, 1992, INEQUALITY RE EXAMIN; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WIKLER DI, 1978, MILBANK FUND Q, V56, P303, DOI 10.2307/3349651; Wolf Susan M, 1992, Law Med Health Care, V20, P278; 1983, SECURING ACCESS HLTH; 1953, PRESIDENTS COMMISSIO, P3	34	57	58	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1189	1196		10.1001/jama.271.15.1189	http://dx.doi.org/10.1001/jama.271.15.1189			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF207	8151877				2022-12-28	WOS:A1994NF20700028
J	FINK, M; FREEMAN, AH; DIXON, AK; CONI, NK				FINK, M; FREEMAN, AH; DIXON, AK; CONI, NK			COMPUTED-TOMOGRAPHY OF THE COLON IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED ELDERLY,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Fink, Michelle/I-7102-2013	Fink, Michelle/0000-0001-6531-1908				BALTHAZAR EJ, 1991, AM J ROENTGENOL, V156, P23, DOI 10.2214/ajr.156.1.1898566; COOK IJ, 1986, BRIT MED J, V292, P1380, DOI 10.1136/bmj.292.6532.1380; DAY JJ, 1993, CLIN RADIOL, V48, P48, DOI 10.1016/S0009-9260(05)80108-4; MCINTYRE AS, 1993, GUT, V34, P1102, DOI 10.1136/gut.34.8.1102	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1018	1018		10.1136/bmj.308.6935.1018	http://dx.doi.org/10.1136/bmj.308.6935.1018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167514	Green Published			2022-12-28	WOS:A1994NH08900021
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON PROPOSED SWITCH OF ACYCLOVIR FROM PRESCRIPTION TO OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V59, P10650	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-28	WOS:A1994NE22800005
J	MCWHIRTER, JP; PENNINGTON, CR				MCWHIRTER, JP; PENNINGTON, CR			INCIDENCE AND RECOGNITION OF MALNUTRITION IN-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							SURGICAL PATIENTS; NORMS	Objectives-To determine incidence of malnutrition among patients on admission to hospital, to monitor their changes in nutritional status during stay, and to determine awareness of nutrition in different clinical units. Design-Prospective study of consecutive admissions. Setting-Acute teaching hospital. Subjects-500 patients admitted to hospital: 100 each from general surgery, general medicine, respiratory medicine, orthopaedic surgery, and medicine for the elderly. Main outcome measures-Nutritional status of patients on admission and reassessment on discharge, review of case notes for information about nutritional status. Results-On admission, 200 of the 500 patients were undernourished (body mass index less than 20) and 34% were overweight (body mass index >25). The 112 patients reassessed on discharge had mean weight loss of 5.4%, with greatest weight loss in those initially most undernourished. But the 10 patients referred for nutritional support showed mean weight gain of 7.9%. Review of case notes revealed that, of the 200 undernourished patients, only 96 had any nutritional information documented. Conclusion-Malnutrition remains a largely unrecognised problem in hospital and highlights the need for education on clinical nutrition.			MCWHIRTER, JP (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							ARORA NS, 1982, AM REV RESPIR DIS, V126, P5; BISHOP CW, 1981, AM J CLIN NUTR, V34, P2530, DOI 10.1093/ajcn/34.11.2530; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; Garrow JS., 1981, TREAT OBESITY SERIOU; Gregory F., 1990, DIETARY NUTR SURVEY; HEYMSFIELD SB, 1978, AM HEART J, V95, P584, DOI 10.1016/0002-8703(78)90300-9; HILL GL, 1977, LANCET, V1, P689; KEYS AJ, 1950, BIOL HUMAN STARVATIO, P140; PINCHCOFSKY GD, 1985, J AM COLL NUTR, V4, P471, DOI 10.1080/07315724.1985.10720089; REILLY JJ, 1988, J PARENTER ENTERAL N, V12, P372; ROBINSON G, 1987, JPEN-PARENTER ENTER, V11, P49, DOI 10.1177/014860718701100149; WALKER MA, 1988, HLTH B EDINB, V1, P42; WEBB AR, 1989, JPEN-PARENTER ENTER, V13, P30, DOI 10.1177/014860718901300130; WINDSOR JA, 1988, ANN SURG, V17, P181	16	902	958	0	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					945	948		10.1136/bmj.308.6934.945	http://dx.doi.org/10.1136/bmj.308.6934.945			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173401	Green Published			2022-12-28	WOS:A1994NF48500016
J	NORDSTROM, M; LINDBLAD, B; ANDERSON, H; BERGQVIST, D; KJELLSTROM, T				NORDSTROM, M; LINDBLAD, B; ANDERSON, H; BERGQVIST, D; KJELLSTROM, T			DEEP VENOUS THROMBOSIS AND OCCULT MALIGNANCY - AN EPIDEMIOLOGIC-STUDY	BRITISH MEDICAL JOURNAL			English	Article							VEIN THROMBOSIS; CANCER; DIAGNOSIS	Objective-To determine the risk of subsequent cancer in patients with deep venous thrombosis confirmed by venography. Design-Follow up of all patients who had venography for suspected deep venous thrombosis during 1984-88. Patients were traced through a cancer registry up to 1 January 1991. Subjects-4399 patients who had phlebography in one hospital. Setting-General hospital in Malmo, Sweden, serving a population of 230 000. Main outcome measure-Number of cancers recorded. Results-4399 patients had venography for suspected deep venous thrombosis; 604 were known to have a malignancy at the time of venography and were excluded from further analysis. 1383 had deep venous thrombosis, 150 of whom subsequently developed cancer. 182 of the 2412 patients without thrombosis developed cancer. During the first six months after venography 66 patients with thrombosis developed malignancy compared with 37 patients without thrombosis (P < 0.0001). 38 of the cancers in the deep venous thrombosis group were detected by history, physical examination, and laboratory tests. Three patients had postoperative or post-traumatic deep venous thromboses. Only two of the remaining patients would have benefited from early detection by extensive screening. After six months the incidence of cancer was identical in patients with and without thrombosis. Conclusion-Deep venous thrombosis is associated with a significantly higher frequency of malignancy during the first six months after diagnosis. Malignancies can be found with simple clinical and diagnostic methods and extensive screening is not required.	UNIV HOSP LUND,REG TUMOUR REGISTRY,LUND,SWEDEN; HELSINGBORG HOSP,DEPT MED,HELSINGBORG,SWEDEN; UNIV UPPSALA,ACAD HOSP,DEPT SURG,S-75105 UPPSALA,SWEDEN	Lund University; Skane University Hospital; Helsingborgs Hospital; Uppsala University	NORDSTROM, M (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT MED & SURG,S-21401 MALMO,SWEDEN.							Breslow NE, 1987, IARC SCI PUBL, V82, P109; Carlsson U, 1986, Lakartidningen, V83, P598; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; MYRUP B, 1991, UGESKRIFT LAEGER, V43, P2996; NASCHITZ JE, 1989, INT ANGIOL, V8, P28; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; RANFT J, 1991, INT ANGIOL, V10, P66; Trousseau A., 1865, PHLEGMASIA ALBA DOLE, V3, P654; Trousseau A, 1865, CLIN MED HOTEL DIEU, P654; WRIGHT IS, 1952, CIRCULATION, V5, P161, DOI 10.1161/01.CIR.5.2.161	17	190	199	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					891	894		10.1136/bmj.308.6933.891	http://dx.doi.org/10.1136/bmj.308.6933.891			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173368	Green Published			2022-12-28	WOS:A1994NE60000021
J	GOOPTU, C; MULLEY, GP				GOOPTU, C; MULLEY, GP			SURVEY OF ELDERLY PEOPLE WHO GET STUCK IN THE BATH	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								Clarke M, 1984, Health Trends, V16, P3; PENN ND, 1989, BRIT MED J, V298, P1158, DOI 10.1136/bmj.298.6681.1158-a; 1990, OLD CLEAN REPORT BAT	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					762	762		10.1136/bmj.308.6931.762	http://dx.doi.org/10.1136/bmj.308.6931.762			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142833	Green Published			2022-12-28	WOS:A1994NC34800023
J	KOHTZ, JD; JAMISON, SF; WILL, CL; ZUO, P; LUHRMANN, R; GARCIABLANCO, MA; MANLEY, JL				KOHTZ, JD; JAMISON, SF; WILL, CL; ZUO, P; LUHRMANN, R; GARCIABLANCO, MA; MANLEY, JL			PROTEIN-PROTEIN INTERACTIONS AND 5'-SPLICE-SITE RECOGNITION IN MAMMALIAN MESSENGER-RNA PRECURSORS	NATURE			English	Article							PRE-MESSENGER-RNA; 5' SPLICE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; U1 SNRNA; ASSEMBLY PATHWAY; BINDING PROTEINS; FACTOR SC35; COMPLEX; INVITRO; PURIFICATION	Exactly how specific splice sites are recognized during the processing of complex precursor messenger RNAs is not clear. Small nuclear ribonucleoprotein particles (snRNPs) are involved, but are not sufficient by themselves to define splice sites. Now a human protein essential for splicing in vitro, called alternative splicing factor/splicing factor 2, is shown to cooperate with the U1 snRNP particle in binding pre-mRNA. This cooperation is probably achieved by specific interactions between the arginine/serine-rich domain of the splicing factor and a similar region in a U1 snRNP-specific protein.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University	KOHTZ, JD (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BACH M, 1990, METHOD ENZYMOL, V181, P232; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; CHABOT B, 1987, MOL CELL BIOL, V7, P698, DOI 10.1128/MCB.7.2.698; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FU XD, 1992, P NATN ACAD SCI US, V89; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; SMTH CWJ, 1989, A REV GENET, V3, P527; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TATEI K, 1987, J BIOL CHEM, V262, P11667; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x; ZUO P, IN PRESS P NATN ACAD	50	547	553	3	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					119	124		10.1038/368119a0	http://dx.doi.org/10.1038/368119a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139654				2022-12-28	WOS:A1994NA03000056
J	ULLRICH, O; HORIUCHI, H; BUCCI, C; ZERIAL, M				ULLRICH, O; HORIUCHI, H; BUCCI, C; ZERIAL, M			MEMBRANE ASSOCIATION OF RAB5 MEDIATED BY GDP-DISSOCIATION INHIBITOR AND ACCOMPANIED BY GDP/GTP EXCHANGE	NATURE			English	Article							GTP-BINDING PROTEIN; REGULATORY PROTEIN; SMG P25A	THE Rab GTPases function as specific regulators of membrane transport(1-4) The GTP/GDP cycle is believed to control shuttling of Rab proteins between the cytosol and organelle membranes. In vitro, Rab proteins are removed from membranes by a protein that inhibits GDP dissociation (rabGDI)(5), which leads to formation of a cytosolic complex of Rab with the inhibitor protein(6-8). Here we use a purified Rab5-rabGDI complex in a permeabilized cell system to investigate how the cytosolic complexed form of Rab reassociates with the membrane. We find that exogenous Rab5 is correctly targeted and induces the formation of enlarged early endosomes, demonstrating that it is functionally active. Binding of Rab5 to the acceptor membrane is accompanied by release of the rabGDI protein into the cytosol. A transient GDP-Rab5 intermediate was detected which was subsequently converted into the GTP-bound form. Our results indicate that there is a multistep mechanism for the insertion of Rab5 into the membrane which is mediated by a guanine-nucleotide-exchange factor.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Bucci, Cecilia/F-6699-2012	Bucci, Cecilia/0000-0002-6232-6183				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, IN PRESS EMBO J; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	17	268	269	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					157	160		10.1038/368157a0	http://dx.doi.org/10.1038/368157a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139660				2022-12-28	WOS:A1994NA03000069
J	ROTH, JS				ROTH, JS			CUTANEOUS LESIONS OF DISSEMINATED CANDIDIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital									0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1650	1650						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177271				2022-12-28	WOS:A1994NP22000005
J	BERGMAN, AB				BERGMAN, AB			MEETING MANIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BERGMAN, AB (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SEATTLE,WA 98104, USA.							BALINT M, 1957, DOCTOR HIS PATIENT I, P76; MILLER M, 1992, J GEN INTERN MED, V7, P646, DOI 10.1007/BF02599208; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	3	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1622	1623		10.1056/NEJM199406023302223	http://dx.doi.org/10.1056/NEJM199406023302223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177267				2022-12-28	WOS:A1994NN21500035
J	FAGAN, MJ; POLAND, GA				FAGAN, MJ; POLAND, GA			TUBERCULIN SKIN TESTING IN MEDICAL-STUDENTS - A SURVEY OF US MEDICAL-SCHOOLS	ANNALS OF INTERNAL MEDICINE			English	Note									MAYO CLIN & MAYO FDN, VACCINE RES GRP, ROCHESTER, MN 55905 USA	Mayo Clinic	FAGAN, MJ (corresponding author), RHODE ISL HOSP, DIV GEN INTERNAL MED, 593 EDDY ST, PROVIDENCE, RI 02903 USA.							CANTANZARO A, 1982, AM REV RESPIR DIS, V125, P559; COCCHIARELLA L, 1992, American Review of Respiratory Disease, V145, pA102; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1992, MMWR MORB MORTAL WKL, V41, P240; 1990, AAMC DIRECTORY AM ME	10	16	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					930	931		10.7326/0003-4819-120-11-199406010-00005	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172438				2022-12-28	WOS:A1994NN11000005
J	JANG, IK				JANG, IK			ACUTE MYOCARDIAL-INFARCTION AND CORONARY SPASM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											JANG, IK (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1420	1420						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159196				2022-12-28	WOS:A1994NK97200005
J	STODDARD, JJ; STPETER, RF; NEWACHECK, PW				STODDARD, JJ; STPETER, RF; NEWACHECK, PW			HEALTH-INSURANCE STATUS AND AMBULATORY CARE FOR CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A STREPTOCOCCAL INFECTIONS; ACUTE RHEUMATIC-FEVER; UNITED-STATES; MEDICAL-CARE; OTITIS-MEDIA; ACCESS; SERVICES; DIAGNOSIS; LANGUAGE; DECADE	Background. Many children in the United States lack health insurance. We tested the hypothesis that these children are less likely than children with insurance to visit a physician when they have specific conditions for which care is considered to be indicated. Methods. We examined the association between whether children were covered by health insurance and whether they received medical attention from a physician for pharyngitis, acute earache, recurrent ear infections, or asthma. Data were obtained on the subsample of 7578 children and adolescents 1 through 17 years of age who were included in the 1987 National Medical Expenditures Survey, a national probability sample of the civilian, noninstitutionalized population. Results. Uninsured children were more likely than children with health insurance to receive no care from a physician for all four conditions (unadjusted odds ratios, 2.38 for pharyngitis; 2.04 for acute earache; 2.84 for recurrent ear infections; and 1.87 for asthma). Multiple logistic-regression analysis was subsequently used to control for age, sex, family size, race or ethnic group, region of the country, place of residence (rural vs. urban), and household income. After adjustment for these factors, uninsured children remained significantly more likely than insured children to go without a visit to a physician for pharyngitis (adjusted odds ratio, 1.72; 95 percent confidence interval, 1.11 to 2.68), acute earache (1..85; 95 percent confidence interval, 1.15 to 2.99), recurrent ear infections (2.12; 95 percent confidence interval, 1.28 to 3.51), and asthma (1.72; 95 percent confidence interval, 1.05 to 2.83). Conclusions. As compared with children with health insurance, children who lack health insurance are less likely to receive medical care from a physician when it seems reasonably indicated and are therefore at risk for substantial avoidable morbidity.	US DEPT HHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	STODDARD, JJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT & ADOLESCENT MED,H6-4 CLIN SCI CTR,MADISON,WI 53792, USA.							BAKER RB, 1992, PEDIATRICS, V90, P1006; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BUTLER JA, 1985, PEDIATRICS, V76, P495; CUNNINGHAM PJ, 1990, HEALTH AFFAIR, V9, P76, DOI 10.1377/hlthaff.9.4.76; DAJANI AS, 1991, PEDIATR INFECT DIS J, V10, pS25, DOI 10.1097/00006454-199110001-00006; HARDY AM, 1991, DEP HLTH HUMAN SE 10, V180; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P838; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; KASPER JD, 1987, MED CARE, V25, P386, DOI 10.1097/00005650-198705000-00003; KLEIN JO, 1991, PEDIATR INFECT DIS J, V10, pS3, DOI 10.1097/00006454-199110001-00001; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; LEVEY LA, 1986, AM J PUBLIC HEALTH, V76, P1000, DOI 10.2105/AJPH.76.8.1000; Lohr K N, 1986, Med Care, V24, pS1; MYER CM, 1991, PEDIATR ANN, V20, P622, DOI 10.3928/0090-4481-19911101-10; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; PARADISE JL, 1978, NEW ENGL J MED, V298, P409, DOI 10.1056/NEJM197802232980801; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; SHAH BV, 1984, RTILOGIT PROCEDURE L; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WOOD DL, 1990, PEDIATRICS, V86, P666; WRIGHT PF, 1991, PEDIATR ANN, V20, P617, DOI 10.3928/0090-4481-19911101-09; 1993, PRESIDENTS HLTH SECU; [No title captured]; 1991, PB91190165	29	134	134	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1421	1425		10.1056/NEJM199405193302006	http://dx.doi.org/10.1056/NEJM199405193302006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK972	8159197				2022-12-28	WOS:A1994NK97200006
J	PERKINS, TT; QUAKE, SR; SMITH, DE; CHU, S				PERKINS, TT; QUAKE, SR; SMITH, DE; CHU, S			RELAXATION OF A SINGLE DNA MOLECULE OBSERVED BY OPTICAL MICROSCOPY	SCIENCE			English	Article							ENTANGLED POLYMER-SOLUTIONS; LIGHT-SCATTERING; TRANSLATIONAL DIFFUSION; ELONGATIONAL FLOW; GOOD SOLVENT; MACROMOLECULES; TEMPERATURE; POLYSTYRENE; PARTICLES; DYNAMICS	Single molecules of DNA, visualized in video fluorescence microscopy, were stretched to full extension in a flow, and their relaxation was measured when the flow stopped. The molecules, attached by one end to a 1-micrometer bead, were manipulated in an aqueous solution with optical tweezers. Inverse Laplace transformations of the relaxation data yielded spectra of decaying exponentials with distinct peaks, and the longest time component (tau) increased with length (L) as tau similar to L(1.66 +/- 0.10). A rescaling analysis showed that most of the relaxation curves had a universal shape and their characteristic times (lambda(t)) increased as lambda t similar to L(1.65 +/- 0.13). These results are in qualitative agreement with the theoretical prediction of dynamical scaling.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM M, 1976, J PHYS-PARIS, V37, P1045, DOI 10.1051/jphys:019760037090104500; ADAM M, 1977, MACROMOLECULES, V10, P1229, DOI 10.1021/ma60060a014; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Brandrup J., 1989, POLYM HDB, V3rd ed.; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; CHU S, 1980, INT C QUANTUM ELECTR, V8, P202; CROTHERS DM, 1965, J MOL BIOL, V12, P525, DOI 10.1016/S0022-2836(65)80310-2; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1976, MACROMOLECULES, V9, P594, DOI 10.1021/ma60052a012; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; DESCLOIZEAUX J, 1978, J PHYS LETT-PARIS, V39, P99; Doi M., 1988, THEORY POLYM DYNAMIC; Flory P., 1989, STAT MECH CHAIN MOL; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; MATSUMOTO M, 1992, J POLYM SCI POL PHYS, V30, P779, DOI 10.1002/polb.1992.090300716; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; NARH KA, 1992, J POLYM SCI POL PHYS, V30, P335, DOI 10.1002/polb.1992.090300403; NEMOTO N, 1984, MACROMOLECULES, V17, P425, DOI 10.1021/ma00133a029; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TW, UNPUB; PRESS WH, 1989, NUMERICAL RECIPES C, P309; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; ROUSE PE, 1953, J CHEM PHYS, V21, P1272, DOI 10.1063/1.1699180; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; RYSKIN G, 1987, J FLUID MECH, V178, P423, DOI 10.1017/S0022112087001290; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TSUNASHIMA Y, 1983, MACROMOLECULES, V16, P584, DOI 10.1021/ma00238a020; TSUNASHIMA Y, 1983, MACROMOLECULES, V16, P1184, DOI 10.1021/ma00241a027; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1956, J CHEM PHYS, V24, P279, DOI 10.1063/1.1742463	34	556	611	1	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					822	826		10.1126/science.8171336	http://dx.doi.org/10.1126/science.8171336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171336				2022-12-28	WOS:A1994NJ94900026
J	BALDWIN, L; HENDERSON, A; HICKMAN, P				BALDWIN, L; HENDERSON, A; HICKMAN, P			EFFECT OF POSTOPERATIVE LOW-DOSE DOPAMINE ON RENAL FUNCTION AFTER ELECTIVE MAJOR VASCULAR-SURGERY	ANNALS OF INTERNAL MEDICINE			English	Article						DOPAMINE; VASCULAR SURGERY; POSTOPERATIVE PERIOD; CREATININE; UREA	ABDOMINAL AORTIC-ANEURYSM; FAILURE; INFUSION	Objective: To determine the effect on renal function of postoperative low-dose dopamine in volume-replete patients after elective, major vascular abdominal surgery. Design: Randomized, double-blind, placebo-controlled trial. Setting: Intensive care unit of a referral hospital in Brisbane, Australia. Patients:37 patients having elective repair of an abdominal aortic aneurysm or having aortobifemoral grafting; 18 received dopamine, and 19 received placebo. Two patients were excluded from the 5-day analysis because of perioperative death. Interventions: Patients were randomly assigned to receive either placebo or a low-dose infusion of dopamine (3 mu g/kg per minute) in saline. Patients in both groups were given sufficient crystalloid to maintain a urine flow of more than 1 mL/kg per hour during the first 24 postoperative hours. Care in the intensive care unit was otherwise usual and was the same for each group. Measurements: Plasma creatinine levels, urea levels, and creatinine clearance were measured preoperatively and postoperatively (at 24 hours and 5 days). Urine flow and the volume of crystalloid during the first 24 hours were recorded. Results: Two postoperative deaths occurred in the dopamine group (from renal failure and myocardial infarction). Four patients had myocardial infarction, three of whom received dopamine. Plasma creatinine levels remained unchanged in both groups. At 24 hours, the mean plasma urea level decreased by 1.07 mmol/L in the dopamine group compared with 1.84 mmol/L in the placebo group, a difference of 0.77 (95% Cl, -0.12 to 1.67). The mean 24-hour creatinine clearance increased by 0.165 mL/s (9.89 mL/min) in the dopamine group and by 0.199 mL/s (11.98 mL/min) in the placebo group (P > 0.2). Urine volumes were slightly higher in those receiving dopamine (1.83 mL/kg compared with 1.6 mL/kg, a difference of 0.23 [Cl, -0.18 to 0.64]). None of these differences were statistically or clinically significant. Conclusions: Within the limits of the small size of the study, low-dose dopamine appeared to offer no advantage to euvolemic patients after elective abdominal aortic surgery. However, patients with acute oliguric renal failure were not included in the study.	PRINCESS ALEXANDRA HOSP, BRISBANE, QLD 4102, AUSTRALIA				hickman, peter/E-4144-2010; Henderson, Alan/K-2846-2012					BERISA F, 1990, Q J MED, V76, P689; DUKE GJ, 1992, ANAESTH INTENS CARE, V20, P277, DOI 10.1177/0310057X9202000302; GRAZIANI G, 1984, NEPHRON, V37, P39, DOI 10.1159/000183205; LINDNER A, 1983, NEPHRON, V33, P121, DOI 10.1159/000182925; MCCOMBS PR, 1979, SURG GYNECOL OBSTET, V148, P175; ODONNELL D, 1989, AUST NZ J SURG, V59, P405; PARKER S, 1981, CRIT CARE MED, V9, P630, DOI 10.1097/00003246-198109000-00002; PASS LJ, 1988, J THORAC CARDIOV SUR, V95, P608; PAUL MD, 1986, AM J NEPHROL, V6, P427, DOI 10.1159/000167248; POLSON RJ, 1987, ANAESTHESIA, V42, P15, DOI 10.1111/j.1365-2044.1987.tb02938.x; SCHNERMANN J, 1990, AM J PHYSIOL, V258, pF790, DOI 10.1152/ajprenal.1990.258.4.F790; SCHWARTZ LB, 1988, J SURG RES, V45, P574, DOI 10.1016/0022-4804(88)90147-3; SHOEMAKER WC, 1989, CHEST, V96, P120, DOI 10.1378/chest.96.1.120; SIMS EA, 1958, J CLIN INVEST, V27, P1; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005; TERWEE PM, 1986, AM J NEPHROL, V6, P42, DOI 10.1159/000167051	16	105	109	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					744	747		10.7326/0003-4819-120-9-199405010-00004	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147547				2022-12-28	WOS:A1994NH25100004
J	MORRIS, JK; COOK, DG; SHAPER, AG				MORRIS, JK; COOK, DG; SHAPER, AG			LOSS OF EMPLOYMENT AND MORTALITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOCIAL RISK-FACTORS; MIDDLE-AGED MEN; CORONARY-DISEASE; UNEMPLOYMENT; HEALTH; BRITAIN	Objective-To assess effect of unemployment and early retirement on mortality in a group of middle aged British men. Design-Prospective cohort study (British Regional Heart Study). Five years after initial screening, information on employment experience was obtained with a postal questionnaire. Setting-One general practice in each of 24 towns in Britain. Subjects-6191 men aged 40-59 who had been continuously employed for at least five years before initial screening in 1978-80: 1779 experienced some unemployment or retired during the five years after screening, and 4412 remained continuously employed. Main outcome measure-Mortality during 5.5 years after postal questionnaire. Results-Men who experienced unemployment in the five years after initial screening were twice as likely to die during the following 5.5 years as men who remained continuously employed (relative risk 2.13 (95% confidence interval 1.71 to 2.65). After adjustment for socioeconomic variables (town and social class), health related behaviour (smoking, alcohol consumption, and body weight), and health indicators (recall of doctor diagnoses) that had been assessed at initial screening the relative risk was slightly reduced, to 1.95 (1.57 to 2.43). Even men who retired early for reasons other than illness and who appeared to be relatively advantaged and healthy had a significantly increased risk of mortality compared with men who remained continuously employed (relative risk 1.87 (1.35 to 2.60)). The increased risk of mortality from cancer was similar to that of mortality from cardiovascular disease (adjusted relative risk 2.07 and 2.13 respectively). Conclusions-In this group of stably employed middle aged men loss of employment was associated with an increased risk of mortality even after adjustment for background variables, suggesting a causal effect. The effect was non-specific, however, with the increased mortality involving both cancer and cardiovascular disease.	ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND	St Georges University London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1970, CLASSIFICATION OCCUP; ARBER S, 1987, BRIT MED J, V294, P1069, DOI 10.1136/bmj.294.6579.1069; ASTRAND NE, 1988, BRIT J IND MED, V45, P387; BRAY GA, 1978, INT J OBESITY, V2, P99; CHIRIKOS TN, 1981, WORK RETIREMENT LONG; COLLEDGE M, 1990, EMPLOYMENT GAZETTE, V1, P9; COOK DG, 1982, LANCET, V1, P1290; COOPER CL, 1982, B BRIT PSYCHOL SOC, V35, P456; COSTA G, 1987, BRIT MED J, V294, P1550, DOI 10.1136/bmj.294.6586.1550-b; DARCY C, 1986, CAN J PUBLIC HEALTH, V77, P124; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; JENKINS CD, 1976, NEW ENGL J MED, V294, P987, DOI 10.1056/NEJM197604292941806; JENKINS CD, 1976, NEW ENGL J MED, V294, P1033, DOI 10.1056/NEJM197605062941904; LACZKO F, 1988, J SOC POLICY, V17, P313, DOI 10.1017/S0047279400016834; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; MORRIS JK, 1992, BRIT MED J, V304, P536, DOI 10.1136/bmj.304.6826.536; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; MOSER KA, 1986, LANCET, V1, P365; MOYLAN S, 1981, EMPLOYMENT GAZETTE, V1, P29; MOYLAN S, 1982, EMPLOYMENT GAZETTE, V8, P334; NARENDRANTHAN W, 1985, J R STAT SOC A STAT, V148, P254, DOI 10.2307/2981970; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PIACHAUD D, 1986, J SOC POLICY, V15, P145, DOI 10.1017/S0047279400001641; PLATT S, 1984, SOC SCI MED, V19, P93, DOI 10.1016/0277-9536(84)90276-4; RAMSDEN S, 1981, EMPLOYMENT GAZETTE, V9, P397; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SORLIE PD, 1990, AM J EPIDEMIOL, V132, P983, DOI 10.1093/oxfordjournals.aje.a115741; STEFANSSON CG, 1991, SOC SCI MED, V32, P419, DOI 10.1016/0277-9536(91)90343-B; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; 1992, P229 SAS I TECHN REP	31	220	222	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	1994	308	6937					1135	1139		10.1136/bmj.308.6937.1135	http://dx.doi.org/10.1136/bmj.308.6937.1135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173455	Green Published			2022-12-28	WOS:A1994NK18200019
J	BUHL, EH; HALASY, K; SOMOGYI, P				BUHL, EH; HALASY, K; SOMOGYI, P			DIVERSE SOURCES OF HIPPOCAMPAL UNITARY INHIBITORY POSTSYNAPTIC POTENTIALS AND THE NUMBER OF SYNAPTIC RELEASE SITES	NATURE			English	Article							GUINEA-PIG HIPPOCAMPUS; CA1 PYRAMIDAL CELLS; GRANULE CELLS; DENTATE GYRUS; GABA-A; NEURONS; INTERNEURONS; SLICES; RAT; CONNECTIONS	Dual intracellular recordings from microscopically identified neurons in the hippocampus reveal that the synaptic terminals of three morphologically distinct types of interneuron act through GABA(A) receptors. Each type of interneuron forms up to 12 synaptic contacts with a postsynaptic principal neuron, but each interneuron innervates a different domain of the surface of the postsynaptic neuron. Different kinetics of the postsynaptic effects, together with the strategic placement of synapses, indicate that these GABAergic interneurons serve distinct functions in the cortical network.	ATTILA JOZSEF UNIV,DEPT ZOOL,H-6701 SZEGED,HUNGARY	Szeged University	BUHL, EH (corresponding author), UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,MANSFIELD RD,OXFORD OX1 3TH,OXON,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1979, NATURE, V281, P315, DOI 10.1038/281315a0; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P592, DOI 10.1152/jn.1964.27.4.592; BUHL EH, IN PRESS J NEUROPHYS; CADDICK SJ, IN PRESS J PHYSL LON; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1993, NEUROPHARMACOLOGY, V32, P1071, DOI 10.1016/0028-3908(93)90073-C; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; Douglas RJ, 1990, NEURAL COMPUT, V2, P283, DOI 10.1162/neco.1990.2.3.283; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FROESTL W, 1992, PHARM COMMUN, V2, P52; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HODGSON AJ, 1985, J HISTOCHEM CYTOCHEM, V33, P229, DOI 10.1177/33.3.3973378; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P225, DOI 10.1152/jn.1961.24.3.225; KAWAGUCHI Y, 1988, EXP BRAIN RES, V72, P494; KNOWLES WD, 1981, J NEUROSCI, V1, P318; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MILES R, 1984, J PHYSIOL-LONDON, V356, P97, DOI 10.1113/jphysiol.1984.sp015455; MILES R, 1990, J PHYSIOL-LONDON, V431, P659, DOI 10.1113/jphysiol.1990.sp018353; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; MULLER W, 1990, J NEUROPHYSIOL, V64, P46, DOI 10.1152/jn.1990.64.1.46; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; OTIS TS, 1992, J NEUROPHYSIOL, V67, P227, DOI 10.1152/jn.1992.67.1.227; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; RIBAK CE, 1978, BRAIN RES, V140, P315, DOI 10.1016/0006-8993(78)90463-8; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; SEGAL M, 1990, BRAIN RES, V511, P163, DOI 10.1016/0006-8993(90)90236-5; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; SOMOGYI P, 1983, BRAIN RES, V259, P137, DOI 10.1016/0006-8993(83)91076-4; SOMOGYI P, 1982, NEUROSCIENCE, V7, P2577, DOI 10.1016/0306-4522(82)90086-0; SOMOGYI P, 1985, BRAIN RES, V332, P143, DOI 10.1016/0006-8993(85)90397-X; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Szentagothai J, 1974, Neurosci Res Program Bull, V12, P305; THOMSON AM, 1991, EUR J NEUROSCI, V3, P587, DOI 10.1111/j.1460-9568.1991.tb00845.x; VU ET, 1992, SCIENCE, V255, P1710, DOI 10.1126/science.1553559	45	611	613	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					823	828		10.1038/368823a0	http://dx.doi.org/10.1038/368823a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159242				2022-12-28	WOS:A1994NH71700061
J	TOMASZ, A				TOMASZ, A			MULTIPLE-ANTIBIOTIC-RESISTANT PATHOGENIC BACTERIA - A REPORT ON THE ROCKEFELLER-UNIVERSITY WORKSHOP	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE; METHICILLIN-RESISTANT; PENICILLIN-RESISTANT; STAPHYLOCOCCUS-AUREUS; PNEUMOCOCCI; MENINGITIS; ENTEROCOCCUS; INFECTIONS; MORTALITY; FAILURE				TOMASZ, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.			Tomasz, Alexander/0000-0003-1520-1983				AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; CASSELL GH, 1994, ASM NEWS, V60, P90; COL NF, 1987, REV INFECT DIS, V9, pS232; COLEMAN DC, 1992, METHICILLIN RESISTAN, P37; DUPONT HL, 1987, REV INFECT DIS, V9, P447; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; HERSHOW RC, 1992, INFECT CONT HOSP EP, V13, P587, DOI 10.2307/30148461; JABES D, 1989, J INFECT DIS, V159, P16, DOI 10.1093/infdis/159.1.16; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J., 1992, EMERGING INFECTIONS; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MCGOWAN JE, 1991, REV MED MICROBIOL, V2, P161; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; Shlaes D, 1991, ASM NEWS, V57, P455; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; TENOVER FC, 1991, AM J MED, V91, pS76, DOI 10.1016/0002-9343(91)90347-Z; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; 1992, SCIENCE, V257, P1016; 1992, MMWR MORB MORTAL WKL, V41, P783; 1993, US NEWS WORLD R 0719, P16	35	354	360	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1247	1251		10.1056/NEJM199404283301725	http://dx.doi.org/10.1056/NEJM199404283301725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139650	Bronze			2022-12-28	WOS:A1994NG58600036
J	LEE, PR; VLADECK, BC				LEE, PR; VLADECK, BC			CHILDHOOD IMMUNIZATION INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1230	1230						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	8151886				2022-12-28	WOS:A1994NG36200003
J	CRONAN, JJ				CRONAN, JJ			OPERATIVE CHOLANGIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CRONAN, JJ (corresponding author), BROWN UNIV,RHODE ISL HOSP,SCH MED,PROVIDENCE,RI 02903, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1210	1210		10.1001/jama.1994.03510390082037	http://dx.doi.org/10.1001/jama.1994.03510390082037			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151881				2022-12-28	WOS:A1994NF20700034
J	PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL				PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL			EARLY IDENTIFICATION OF PATIENTS AT LOW-RISK OF DEATH AFTER MYOCARDIAL-INFARCTION AND POTENTIALLY SUITABLE FOR EARLY HOSPITAL DISCHARGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL	Objectives-To find (a) whether data available shortly after admission for acute myocardial infarction can provide a reliable prognostic indicator of survival at 28 days, and (b) whether such an indicator might be used to identify patients at low risk of death and suitable for early discharge. Design-Retrospective analysis of data collected on patients admitted to a coronary care unit for acute myocardial infarction. A validation sample was selected at random from these patients. Setting-Coronary care units in Perth, Western Australia. Subjects-6746 patients aged under 65 and resident in the Perth Statistical Division who during 1984-92 were admitted to a coronary care unit with symptoms of myocardial infarction. Main outcome measures-Sensitivity and specificity of several models for predicting survival at 28 days after myocardial infarction, and detailed performance characteristics of a particular model. Results-Patients with a pulse rate of 100 beats/min or less, aged 60 or under, and with symptoms typical of myocardial infarction, no past history of myocardial infarction or diabetes, and no significant Q wave in the admission electrocardiogram had a very high chance of survival at 28 days (99.2%). These patients made up one third of all patients studied. Conclusion-The prognostic index identifies patients very soon after admission who are at low risk of death and potentially eligible for early discharge from hospital or the coronary care unit. Computing the index does not need complex cardiac investigations.	QUEEN ELIZABETH II MED CTR, DEPT CARDIOVASC MED, PERTH, WA 6009, AUSTRALIA	University of Western Australia	PARSONS, RW (corresponding author), UNIV WESTERN AUSTRALIA, DEPT PUBL HLTH, PERTH, WA 6009, AUSTRALIA.							ABRAHAM AS, 1975, NEW ENGL J MED, V292, P719, DOI 10.1056/NEJM197504032921403; AHLMARK G, 1979, ACTA MED SCAND, V206, P87; BLOCH A, 1974, AM J CARDIOL, V34, P152, DOI 10.1016/0002-9149(74)90193-3; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GRODEN B. M., 1967, SCOT MED J, V12, P435; HANDS ME, 1986, CIRCULATION, V73, P885, DOI 10.1161/01.CIR.73.5.885; HARPUR JE, 1971, LANCET, V2, P1331; HAYES MJ, 1974, BRIT MED J, V2, P10; HUTTER AM, 1973, NEW ENGL J MED, V288, P1141, DOI 10.1056/NEJM197305312882201; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; Mallory GK, 1939, AM HEART J, V18, P647; MARIK PE, 1991, HEART LUNG, V20, P16; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; MOLSTAD P, 1993, J INTERN MED, V233, P393, DOI 10.1111/j.1365-2796.1993.tb00690.x; NORRIS RM, 1969, LANCET, V1, P274; OH W, 1976, SMJ Singapore Medical Journal, V17, P40; PRINEAS RJ, 1982, MANUAL ELECTROCARDIO; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; Rose G, 1972, Mod Concepts Cardiovasc Dis, V41, P59; Swan H J, 1976, Am J Cardiol, V37, P413, DOI 10.1016/0002-9149(76)90292-7; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WENGER NK, 1982, CIRCULATION, V65, P421, DOI 10.1161/01.CIR.65.3.421; WENGER NK, 1973, JAMA-J AM MED ASSOC, V224, P511, DOI 10.1001/jama.224.4.511; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1991, SAS RELEASE 6 07; 1990, EGRET EPIDEMIOLOGICA; 1990, MONICA MANUAL	28	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1006	1010		10.1136/bmj.308.6935.1006	http://dx.doi.org/10.1136/bmj.308.6935.1006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167512	Green Published			2022-12-28	WOS:A1994NH08900018
J	FLORIN, EL; MOY, VT; GAUB, HE				FLORIN, EL; MOY, VT; GAUB, HE			ADHESION FORCES BETWEEN INDIVIDUAL LIGAND-RECEPTOR PAIRS	SCIENCE			English	Article							MICROSCOPE; CELLS; MOLECULES; CRYSTALS	The adhesion force between the tip of an atomic force microscope cantilever derivatized with avidin and agarose beads functionalized with biotin, desthiobiotin, or iminobiotin was measured. Under conditions that allowed only a limited number of molecular pairs to interact, the force required to separate tip and bead was found to be quantized in integer multiples of 160 +/- 20 piconewtons for biotin and 85 +/- 15 piconewtons for iminobiotin. The measured force quanta are interpreted as the unbinding forces of individual molecular pairs.	TECH UNIV MUNICH,DEPT PHYS,D-85748 GARCHING,GERMANY	Technical University of Munich								[Anonymous], 1992, INTERMOLECULAR SURFA; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; EGGER M, 1992, BIOCHIM BIOPHYS ACTA, V1104, P45, DOI 10.1016/0005-2736(92)90130-E; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; EVANS EH, IN PRESS; FLORIN EL, 1994, REV SCI INSTRUM, V65, P639, DOI 10.1063/1.1145130; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; KARRASCH S, 1993, BIOPHYS J, V65, P2437, DOI 10.1016/S0006-3495(93)81327-4; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MARCHAND P, 1983, REV SCI INSTRUM, V54, P1034, DOI 10.1063/1.1137498; MOY VT, UNPUB; PETHICA JB, 1987, PHYS SCRIPTA, VT19A, P61, DOI 10.1088/0031-8949/1987/T19A/010; Pierce M., UNPUB; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161	24	1662	1718	7	288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					415	417		10.1126/science.8153628	http://dx.doi.org/10.1126/science.8153628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153628				2022-12-28	WOS:A1994NG19400037
J	STORM, EE; HUYNH, TV; COPELAND, NG; JENKINS, NA; KINGSLEY, DM; LEE, SJ				STORM, EE; HUYNH, TV; COPELAND, NG; JENKINS, NA; KINGSLEY, DM; LEE, SJ			LIMB ALTERATIONS IN BRACHYPODISM MICE DUE TO MUTATIONS IN A NEW MEMBER OF THE TGF-BETA-SUPERFAMILY	NATURE			English	Article							MOUSE; BONE; MORPHOGENESIS; PROTEIN; LINKAGE; FAMILY; LOCUS	THE mutation brachypodism (bp) alters the length and number of bones in the limbs of mice but spares the axial skeleton1,2. It illustrates the importance of specific genes in controlling the morphogenesis of individual skeletal elements in the tetrapod limb3,4. We now report the isolation of three new members of the transforming growth factor-beta (TGF-beta) superfamily5 (growth/differentiation factors (GDF) 5, 6 and 7) and show by mapping, expression patterns and sequencing that mutations in Gdf5 are responsible for skeletal alterations in bp mice. GDF5 and the closely related GDF6 and GDF7 define a new subgroup of factors related to known bone- and cartilage-inducing molecules, the bone morphogenetic proteins (BMPs)6. Studies of Bmp5 mutations in short ear mice have shown that at least one other BMP gene is also required for normal skeletal development7. The highly specific skeletal alterations in bp and short ear mice suggest that different members of the BMP family control the formation of different morphological features in the mammalian skeleton.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,BECKMAN CTR B300,STANFORD,CA 94305; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Stanford University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AHMAD M, 1990, AM J MED GENET, V36, P292, DOI 10.1002/ajmg.1320360309; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; ELMER WA, 1975, J EMBRYOL EXP MORPH, V33, P371; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; GRUNEBERG H, 1973, J EMBRYOL EXP MORPH, V30, P119; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LANDAUER W, 1952, J HERED, V43, P293, DOI 10.1093/oxfordjournals.jhered.a106335; LANE PW, 1993, LIST MUTATIONS MUTAN; MALININA N A, 1984, Ontogenez, V15, P514; Massague J., 1990, REV CELL BIOL, V6, P597; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; OSEBOLD WR, 1985, AM J MED GENET, V22, P791, DOI 10.1002/ajmg.1320220414; OWENS EM, 1982, DEV BIOL, V91, P376, DOI 10.1016/0012-1606(82)90043-4; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; SIRACUSA LD, 1989, GENETICS, V122, P669; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SIRACUSA LD, 1993, MAMM GENOME, V4, pS31, DOI 10.1007/BF00360828; TEMTAMY SA, 1978, GENETICS HAND MALFOR, P1; [No title captured]	26	723	768	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					639	643		10.1038/368639a0	http://dx.doi.org/10.1038/368639a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145850				2022-12-28	WOS:A1994NF39200062
J	WACKETT, LP; SADOWSKY, MJ; NEWMAN, LM; HUR, HG; LI, SY				WACKETT, LP; SADOWSKY, MJ; NEWMAN, LM; HUR, HG; LI, SY			METABOLISM OF POLYHALOGENATED COMPOUNDS BY A GENETICALLY-ENGINEERED BACTERIUM	NATURE			English	Article							TOLUENE DIOXYGENASE; TRICHLOROETHYLENE; OXIDATION; BIOSYNTHESIS; DEGRADATION; PSEUDOMONAS	THE decomposition of organic compounds by bacteria has been studied for almost a century1, during which time selective enrichment culture has generated microoganisms capable of metabolizing thousands of organic compounds. But attempts to obtain pure cultures of bacteria that can metabolize highly halogenated compounds2, a large and important class of pollutants 3,4, have been largely unsuccessful. Polyhalogenated compounds are most frequently metabolized by anaerobic bacteria as a result of reductive dehalogenation reactions5, the products of which are typically substrates for bacterial oxygenases6. Complete metabolism of polyhalogenated compounds therefore necessitates the sequential use of anaerobic and aerobic bacteria7. Here we combine seven genes encoding two multi-component oxygenases in a single strain of Pseudomonas which as a result metabolizes polyhalogenated compounds by means of sequential reductive and oxidative reactions to yield non-toxic products. Cytochrome P450(cam) monooxygenase reduces polyhalogenated compounds8, which are bound at the camphor-binding site9,10, under subatmospheric oxygen tensions9. We find that these reduction products are oxidizable substrates for toluene dioxygenase. Perhalogenated chlorofluorocarbons also act as substrates for the genetically engineered strain.	UNIV MINNESOTA,DEPT MICROBIOL,ST PAUL,MN 55108; UNIV MINNESOTA,GORTNER LAB,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT SOIL SCI,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	WACKETT, LP (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108, USA.		Sadowsky, Michael/J-2507-2016	Sadowsky, Michael/0000-0001-8779-2781				ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; Anders M. W., 1985, BIOACTIVATION FOREIG, P284; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BRADSHAW WH, 1959, J AM CHEM SOC, V81, P5507, DOI 10.1021/ja01529a060; CASTRO CE, 1985, BIOCHEMISTRY-US, V24, P204, DOI 10.1021/bi00322a029; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GIBSON DT, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P121; LEONG SA, 1982, J BIOL CHEM, V257, P8724; LI SY, 1993, BIOCHEMISTRY-US, V32, P9355, DOI 10.1021/bi00087a014; LI SY, 1992, BIOCHEM BIOPH RES CO, V185, P443, DOI 10.1016/S0006-291X(05)81005-8; Logan Michael S. P., 1993, Biodegradation, V4, P39, DOI 10.1007/BF00701453; ORNSTEIN RL, 1991, P HAZMACON, P470; PAULSEN MD, 1993, PROTEIN SCI, V2, P357; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; REINEKE W, 1984, MICROBIAL DEGRADATIO, P319; Stanier R., 1976, MICROBIAL WORLD; Wackett Lawrence P., 1992, Biodegradation, V3, P19, DOI 10.1007/BF00189633; WACKETT LP, 1989, APPL ENVIRON MICROB, V55, P2960, DOI 10.1128/AEM.55.11.2960-2964.1989; WACKETT LP, 1988, APPL ENVIRON MICROB, V54, P1703, DOI 10.1128/AEM.54.7.1703-1708.1988; Zylstra G J, 1991, Genet Eng (N Y), V13, P183	24	69	80	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					627	629		10.1038/368627a0	http://dx.doi.org/10.1038/368627a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145847				2022-12-28	WOS:A1994NF39200058
J	RUDLAND, SV; JACOBS, AG				RUDLAND, SV; JACOBS, AG			VISITING BAGS - A LABILE THERMAL ENVIRONMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To define usual colour and site of storage of visiting bags in general practitioners' cars and to investigate effect of these variables on temperature inside bag. Design-Questionnaire to general practitioners; serial temperature measurements from paired black visiting bags at different storage sites and from bags of different colour. Setting-South Devon coastal town during May and June. Subjects-200 general practitioners, of whom 145 returned legible questionnaires. Main outcome measures-Bag colour, duration and site of storage, temperature inside black bags at defined storage sites, and effects of bag colour on internal temperature. Results-111 (77%) of the general practitioners carried a black visiting bag, and 76 kept their bag in their car all day. The bag was coolest in the car boot, but irrespective of storage site, maximum internal temperature of the bag was always over 25-degrees-C and reached up to 80-degrees-C. Spraying a black bag silver significantly reduced the bag's internal temperature (mean difference 8.37-degrees-C (95% confidence interval 6.68 to 9.86-degrees-C) df=59, t=10.29, P<0.001). Conclusions-General practitioners should use a silver coloured visiting bag; when visiting, they should store it in their car boot; at other times they should remove it to a cooler site.			RUDLAND, SV (corresponding author), BARTON SURG, DAWLISH EX7 9HQ, DEVON, ENGLAND.							Abu Reid I, 1990, INT PHARM J, V4, P6; Carson N E, 1981, Aust Fam Physician, V10, P966; DUNCAN G, 1989, PRACTITIONER, V233, P1435; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; LONGLAND PW, 1989, PHARM J, V243, P589; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; READ N, 1990, GP TRAINING HDB, P213; 1993, ABPI DATA SHEET COMP; 1992, III333592EN EUR COMM; 1989, DRUG THER B, V27, P17; 1990, ESSENTIAL DRUG MONIT, V11, P3	12	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	1994	308	6934					954	956		10.1136/bmj.308.6934.954	http://dx.doi.org/10.1136/bmj.308.6934.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173404	Green Published			2022-12-28	WOS:A1994NF48500019
J	TOBIAS, JS				TOBIAS, JS			CURRENT ISSUES IN CANCER - CANCER OF THE HEAD AND NECK	BRITISH MEDICAL JOURNAL			English	Article							PROGNOSTIC FACTORS; ORAL CAVITY; CHEMOTHERAPY; RADIOTHERAPY; CARCINOMA; PHARYNX; TONGUE; TRIAL	Cancers of the upper aerodigestive tract, collectively known as head and neck cancers, arise from a multiplicity of sites. In the West, excess tobacco and alcohol consumption are the most important of the known predisposing factors; elsewhere in the world, notably in India and China, the aetiology, pattern of primary sites, and clinical behaviour are different. Clinically these tumours pose exceptional problems in management, and skilled multidisciplinary teams are necessary in order to achieve the highest level of service and research. Historically, surgery and radiotherapy have been the most important treatment modalities; chemotherapy is now increasingly employed but not yet fully established. Successful rehabilitation of patients with head and neck cancers requires access to high quality speech therapists and other support staff with training in functional pharyngeal disorders. Current research efforts are largely directed towards defining the proper role of chemotherapy and assessing the possible advantage of unconventional radiation approaches. In recent years the roles of primary, reconstructive, and salvage surgery have also become better defined. Many patients are suitable for randomisation into ongoing prospective clinical trials which have been specifically designed to address these issues.			TOBIAS, JS (corresponding author), MIDDLESEX HOSP,MEYERSTEIN INST CLIN ONCOL,LONDON W1N 8AA,ENGLAND.							ALSARRAF M, 1990, ADV ONCOL, V6, P11; [Anonymous], 1991, NEW ENGL J MED, V324, P1685; [Anonymous], 1986, EUR J SURG ONCOL, V12, P289; BROWN B, 1989, CANCER, V64, P1195, DOI 10.1002/1097-0142(19890915)64:6<1195::AID-CNCR2820640606>3.0.CO;2-7; CLAVEL M, 1991, EUR J CANCER, V27, P349, DOI 10.1016/0277-5379(91)90544-N; DISCHE S, 1990, INT J RADIAT ONCOL, V19, P1339; FRANCESCHI S, 1991, INT J CANCER, V47, P20, DOI 10.1002/ijc.2910470105; GUPTA NK, 1987, CLIN RADIOL, V38, P575, DOI 10.1016/S0009-9260(87)80327-6; HENK M, 1993, CANCER ORAL CAVITY; HORIOT JC, 1990, EUR J CANCER, V26, P779, DOI 10.1016/0277-5379(90)90150-R; HUTCHISON IL, 1994, BRIT MED J, V308, P669, DOI 10.1136/bmj.308.6930.669; JACOBS C, 1990, ANN INTERN MED, V113, P771, DOI 10.7326/0003-4819-113-10-771; Lippman S M, 1992, Important Adv Oncol, P93; MERLANO M, 1992, NEW ENGL J MED, V327, P1115, DOI 10.1056/NEJM199210153271602; MILLION RR, 1989, CANCER PRINCIPLES PR, P488; MOLLER H, 1989, J ORAL PATHOL MED, V18, P224, DOI 10.1111/j.1600-0714.1989.tb00767.x; SHANTA V, 1980, CLIN RADIOL, V31, P617, DOI 10.1016/S0009-9260(80)80069-9; STELL PM, 1990, BRIT J CANCER, V61, P779, DOI 10.1038/bjc.1990.175; TOBIAS JS, 1990, BRIT J CANCER, V61, P649, DOI 10.1038/bjc.1990.146; TOBIAS JS, 1992, DRUGS, V43, P333, DOI 10.2165/00003495-199243030-00004; TOBIAS JS, 1991, CANCER COLOUR ATLAS; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; 1988, 9 CANC RES CAMP FACT; 1993, 14 CANC RES CAMP FAC	24	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					961	966		10.1136/bmj.308.6934.961	http://dx.doi.org/10.1136/bmj.308.6934.961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173406	Green Published			2022-12-28	WOS:A1994NF48500022
J	DRAPKIN, R; SANCAR, A; REINBERG, D				DRAPKIN, R; SANCAR, A; REINBERG, D			WHERE TRANSCRIPTION MEETS REPAIR	CELL			English	Review							XERODERMA-PIGMENTOSUM; COCKAYNES-SYNDROME; DNA-REPAIR; CTD KINASE; DHFR GENE; FACTOR-B; STRAND; INITIATION; REMOVAL; INVITRO		UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	DRAPKIN, R (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DRAPKIN R, 1994, IN PRESS NATURE; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Qui H., 1993, GENE DEV, V7, P2161; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	29	156	158	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					9	12		10.1016/0092-8674(94)90228-3	http://dx.doi.org/10.1016/0092-8674(94)90228-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156601				2022-12-28	WOS:A1994NF21100003
J	TABONY, J				TABONY, J			MORPHOLOGICAL BIFURCATIONS INVOLVING REACTION-DIFFUSION PROCESSES DURING MICROTUBULE FORMATION	SCIENCE			English	Article							ORGANIZATION; PATTERN; MODELS	Nonlinear chemically dissipative mechanisms have been proposed as providing a possible underlying process for some aspects of biological self-organization, pattern formation, and morphogenesis. Nonlinearities during the formation of microtubular solutions result in a chemical instability and bifurcation between pathways leading to macroscopically self-organized states of different morphology. The self-organizing process, which contains reactive and diffusive contributions, involves chemical waves and differences in microtubule concentration in the sample. Patterns of similar appearance are observed at different distance scales. This behavior is in agreement with theories of chemically dissipative systems.			TABONY, J (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,RESONANCE MAGNET BIOL & MED LAB,85X,F-38041 GRENOBLE,FRANCE.							ABRTAHAM R, 1988, DYNAMICS 4; Alberts B., 1983, MOL BIOL CELL, V4; BABYLOYANTZ A, 1986, DYNAMICS LIFE; BUXBAUM RE, 1987, SCIENCE, V235, P1511, DOI 10.1126/science.2881354; CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; GRAY P, 1990, CHEM OSCILLATIONS IN, pCH10; HALL SS, 1992, SCIENCE, V257, P344, DOI 10.1126/science.1631556; HARRISON LG, 1987, J THEOR BIOL, V125, P369, DOI 10.1016/S0022-5193(87)80208-4; HITT AL, 1990, J BIOL CHEM, V265, P1639; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; JOHNSON K, 1977, J MOL BIOL, V117, P31; MACNEAL RK, 1977, BIOCHEM BIOPH RES CO, V74, P440, DOI 10.1016/0006-291X(77)90323-0; MANDELKOW E, 1989, SCIENCE, V246, P1291, DOI 10.1126/science.2588005; MANDELKOW EM, 1980, NATURE, V287, P595, DOI 10.1038/287595a0; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MURRAY JD, 1984, J MATH BIOL, V19, P265, DOI 10.1007/BF00277099; Nicolis G, 1977, SELF ORG NONEQUILIBR; Nicolis G., 1989, EXPLORING COMPLEXITY; PATZELT W, 1974, POLARISING MICROSCOP; PEACOCKE AR, 1983, PHYSICAL CHEM BIOL O; PURICH DL, 1984, ADV PROTEIN CHEM, V36, P133, DOI 10.1016/S0065-3233(08)60297-1; ROBERT C, 1990, BIOL CELL, V68, P177, DOI 10.1016/0248-4900(90)90306-N; SOMERS M, 1990, EUR BIOPHYS J, V18, P239, DOI 10.1007/BF00183377; TABONY J, 1990, NATURE, V346, P448, DOI 10.1038/346448a0; TABONY J, 1992, P NATL ACAD SCI USA, V89, P6948, DOI 10.1073/pnas.89.15.6948; Tabony J, 1992, NANOBIOLOGY, V1, P131; Thompson J.M.T., 1982, INSTABILITIES CATAST; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012	32	85	86	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					245	248		10.1126/science.8146654	http://dx.doi.org/10.1126/science.8146654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146654				2022-12-28	WOS:A1994NE41000032
J	RIDDIHOUGH, G				RIDDIHOUGH, G			SHAPE-SHIFTING SERPINS	NATURE			English	Editorial Material																		Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; CARELL RW, 1992, CURR OPIN STRUCT BIO, V2, P438; CARRELL RW, IN PRESS STRUCTURE; Engh R A, 1993, Behring Inst Mitt, P41; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; WEI A, 1994, NAT STRUCT BIOL, V1, P250	7	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					570	570		10.1038/368570a0	http://dx.doi.org/10.1038/368570a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139695	Bronze			2022-12-28	WOS:A1994NE33500063
J	MOHER, M; MOHER, D; HAVELOCK, P				MOHER, M; MOHER, D; HAVELOCK, P			SURVEY OF WHETHER GENERAL-PRACTITIONERS CARRY ASPIRIN IN THEIR DOCTORS BAG	BMJ-BRITISH MEDICAL JOURNAL			English	Article									LOEB MED RES INST, CLIN EPIDEMIOL UNIT, OTTAWA K1Y 4E9, ON, CANADA; POUND HOUSE SURG, WOOBURN GREEN HP10 0EE, BUCKS, ENGLAND	University of Ottawa; Ottawa Hospital Research Institute	MOHER, M (corresponding author), SOUTHMEAD SURG, FARNHAM SL2 3ER, BUCKS, ENGLAND.			Moher, David/0000-0003-2434-4206				[Anonymous], 1988, LANCET, V2, P349; DEAN AG, 1990, EPIINFO VERSION 5 WO; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760	4	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					761	762		10.1136/bmj.308.6931.761	http://dx.doi.org/10.1136/bmj.308.6931.761			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142832	Green Published			2022-12-28	WOS:A1994NC34800022
J	KLEIN, R; SILOSSANTIAGO, I; SMEYNE, RJ; LIRA, SA; BRAMBILLA, R; BRYANT, S; ZHANG, L; SNIDER, WD; BARBACID, M				KLEIN, R; SILOSSANTIAGO, I; SMEYNE, RJ; LIRA, SA; BRAMBILLA, R; BRYANT, S; ZHANG, L; SNIDER, WD; BARBACID, M			DISRUPTION OF THE NEURATROPHIN-3 RECEPTOR GENE TRKC ELIMINATES LA MUSCLE AFFERENTS AND RESULTS IN ABNORMAL MOVEMENTS	NATURE			English	Article							MOTOR NEURONS; STEM-CELLS; RNA	THE trkC gene(1,2) is expressed throughout the mammalian nervous system(3-5) and encodes a series of tyrosine protein kinase isoforms that serve as receptors for neurotrophin-3 (NT3), a member of the nerve growth factor (NGF) family of neurotrophic factors(2,6-8). One of these isoforms, gp145(trkC)/TrkC K1, mediates the trophic properties of NT3 in cultured Cells(2,6-8). Here we show that homozygous mice defective for TrkC tyrosine protein kinase receptors lack Ia muscle afferent projections to spinal motor neurons and have fewer large myelinated axons in the dorsal root and posterior columns of the spinal cord. These mice display abnormal movements and postures, indicating that NT3/TrkC-dependent sensory neurons may play a primary role in proprioception, the sense of position and movement of the limbs.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT NEUROL & NEUROL SURG,ST LOUIS,MO 63110	European Molecular Biology Laboratory (EMBL); Washington University (WUSTL)	KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008; Brambilla, Riccardo/A-6082-2010	Klein, Ruediger/0000-0002-3109-0163; Smeyne, Richard/0000-0002-8459-5472; Brambilla, Riccardo/0000-0003-3569-5706				Barbacid Mariano, 1993, P123; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; Kandel E.R., 1991, PRINC NEUROSCI, V3rd ed.; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MU XJ, 1993, J NEUROSCI, V13, P4029; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; SNIDER WD, 1992, J NEUROSCI, V12, P3494; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Willis WD, 1991, SENSORY MECH SPINAL	24	538	555	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					249	251		10.1038/368249a0	http://dx.doi.org/10.1038/368249a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145824				2022-12-28	WOS:A1994NA87000057
J	SMEYNE, RJ; KLEIN, R; SCHNAPP, A; LONG, LK; BRYANT, S; LEWIN, A; LIRA, SA; BARBACID, M				SMEYNE, RJ; KLEIN, R; SCHNAPP, A; LONG, LK; BRYANT, S; LEWIN, A; LIRA, SA; BARBACID, M			SEVERE SENSORY AND SYMPATHETIC NEUROPATHIES IN MICE CARRYING A DISRUPTED TRK/NGF RECEPTOR GENE	NATURE			English	Article							NERVE GROWTH-FACTOR; ROOT GANGLION NEURONS; PROTO-ONCOGENE; EXPRESSION; NGF	NERVE growth factor (NGF) induces neurite outgrowth and promotes survival of embryonic sensory and sympathetic neurons in culture(1,2). In vivo, NGF decreases the extent of naturally occurring cell death in developing sympathetic ganglia and protects cholinergic neurons of the basal forebrain and caudatoputamen(1-3). NGF interacts with the low-affinity p75 receptor and with Trk, a receptor tyrosine kinase encoded by the trk proto-oncogene(4,5). To study the role of Trk in vivo, we have ablated the gene in embryonic stem cells by homologous recombination. Mice lacking Trk have severe sensory and sympathetic neuropathies and most die within one month of birth. They have extensive neuronal cell loss in trigeminal, sympathetic and dorsal root ganglia, as well as a decrease in the cholinergic basal forebrain projections to the hippocampus and cortex. These findings demonstrate that Trk is the primary mediator of the trophic actions of NGF in vivo and that this signalling pathway plays a crucial role in the development of both the peripheral and the central nervous systems.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	SMEYNE, RJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Smeyne, Richard/0000-0002-8459-5472				BARBACID M, 1993, ONCOGENE, V8, P2033; BRADSHAW RA, 1993, TRENDS BIOCHEM SCI, V18, P48, DOI 10.1016/0968-0004(93)90052-O; BUTCHER LL, 1984, HDB CHEM NEUROANATOM, V2; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MU XJ, 1993, J NEUROSCI, V13, P4029; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; STEININGER TL, 1993, BRAIN RES, V612, P330, DOI 10.1016/0006-8993(93)91681-H; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463	20	809	827	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					246	249		10.1038/368246a0	http://dx.doi.org/10.1038/368246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145823				2022-12-28	WOS:A1994NA87000056
J	MIDDEKE, M; SCHRADER, J				MIDDEKE, M; SCHRADER, J			NOCTURNAL BLOOD-PRESSURE IN NORMOTENSIVE SUBJECTS AND THOSE WITH WHITE COAT, PRIMARY, AND SECONDARY HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							RHYTHM	Objective-To compare the mean nocturnal blood pressure of patients with various forms of renal and endocrine hypertension with that in patients with primary and white coat hypertension, and normal blood pressure. Design-Ambulatory monitoring of blood pressure over 24 hours in a prospective study. Setting-Two German centres for outpatients with hypertension and kidney diseases. Subjects-176 normotensive subjects, 490 patients with primary hypertension including mild and severe forms, 42 with white coat hypertension, 208 patients with renal and renovascular hypertension, 43 with hypertension and endocrine disorders, and three with coarctation of the aorta. Main outcome measures-Fall in nocturnal blood pressure. Results-Blood pressure in normotensive subjects fell by a mean of 14 mm Hg (11%) systolic and 13 mm Hg (17%) diastolic overnight (2200 to 0600). The falls in patients with primary and white coat hypertension were not significantly different. In all patients with renal and renovascular hypertension, however, the fall was significantly reduced (range of fall from 3/3 mm Hg to 7/9 mm Hg). In patients with hypertension and endocrine disorders the pattern of night time blood pressure was not uniform: patients with hyperthyroidism, primary hyperaldosteronism, and Cushing's syndrome had significantly smaller reductions in blood pressure (6/8, 4/7, 3/6 mm Hg, respectively). In patients with phaeochromocytoma the mean night time blood pressure increased by 4/2 mm Hg. In patients with hypertension, primary hyperparathyroidism, and unoperated coarctation of the aorta the falls in blood pressure were normal. Conclusions-In normotensive subjects and those with primary hypertension there is usually a reduction in blood pressure at night. In all renal forms of secondary hypertension and in most endocrine forms the reduction in blood pressure is only a third to a half of normal. Patients with primary hyperparathyroidism and unoperated coarctation of the aorta show a normal reduction.	ST JOSEFS HOSP,D-49661 CLOPPENBURG,GERMANY		MIDDEKE, M (corresponding author), REHA ZENTRUM SPREEWALD,D-03096 BURG SPREEWALD,GERMANY.							HANY S, 1987, J HYPERTENS       S5, V5, P487; Howell W H, 1897, J Exp Med, V2, P313, DOI 10.1084/jem.2.3.313; IMAI Y, 1988, HYPERTENSION, V12, P11, DOI 10.1161/01.HYP.12.1.11; KATSCH G, 1992, MUNCHEN MED WOCHEN, V69, P1715; KEM DC, 1973, J CLIN INVEST, V52, P2272, DOI 10.1172/JCI107414; MIDDEKE M, 1991, CHRONOBIOL INT, V8, P451, DOI 10.3109/07420529109059181; MIDDEKE M, 1989, KLIN WOCHENSCHR, V67, P713, DOI 10.1007/BF01721289; OBRIEN E, 1988, LANCET, V2, P397; SCHRADER J, 1989, KLIN WOCHENSCHR, V67, P659, DOI 10.1007/BF01718026; Schrader J, 1990, J AMBUL MONIT, V3, P203; Zadek J., 1881, Z KLIN MED, V2, P509	11	128	129	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					630	632		10.1136/bmj.308.6929.630	http://dx.doi.org/10.1136/bmj.308.6929.630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148712	Green Published			2022-12-28	WOS:A1994MZ69800023
J	DRUMMOND, N; ABDALLA, M; BEATTIE, JAG; BUCKINGHAM, JK; LINDSAY, T; OSMAN, LM; ROSS, SJ; ROYCHAUDHURY, A; RUSSELL, L; TURNER, M; FRIEND, JAR; LEGGE, JS; DOUGLAS, JG				DRUMMOND, N; ABDALLA, M; BEATTIE, JAG; BUCKINGHAM, JK; LINDSAY, T; OSMAN, LM; ROSS, SJ; ROYCHAUDHURY, A; RUSSELL, L; TURNER, M; FRIEND, JAR; LEGGE, JS; DOUGLAS, JG			EFFECTIVENESS OF ROUTINE SELF-MONITORING OF PEAK FLOW IN PATIENTS WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT; SCALE	Objective-To evaluate the effectiveness of routine self monitoring of peak flow for asthma outpatients. Design-Pragmatic randomised trial. Setting-Hospital outpatient clinics and general practices in north east Scotland. Main outcome measures-Use of bronchodilators and inhaled and oral steroids; number of general practice consultations and hospital admissions for asthma; sleep disturbance and other restrictions on normal activity; psychological aspects of health including perceived control of asthma. Results-After one year there were no significant differences between patients randomised between self monitoring of peak flow and conventional monitoring. However, those given a peak flow meter recorded an increase in general practice consultations that was nearly significant. Among patients whose asthma was judged on entry to be more severe, those allocated to self monitoring used more than twice as many oral steroids (2.2; 95% confidence interval 1.1 to 4.6). Patients who already possessed a peak flow meter at the start of the study recorded higher morbidity over the course of the year than those eligible for randomisation. Conclusion-Prescribing peak flow meters and giving self management guidelines to all asthma patients is unlikely to improve mortality or morbidity. Patients whose asthma is severe may benefit from such an intervention.	CITY HOSP,ABERDEEN ROYAL HOSP TRUST,THORAC MED UNIT,ABERDEEN AB9 8AU,ABERDEEN,SCOTLAND		DRUMMOND, N (corresponding author), UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,ABERDEEN,SCOTLAND.		Russell, Ian T/H-1181-2012					AITKEN M, 1989, STATISTICAL MODELLIN; [Anonymous], 1990, SPSS REFERENCE GUIDE; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; CHARLTON I, 1990, PRACTITIONER, V234, P30; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CONNOLLY CK, 1987, RESPIRATION, V52, P22, DOI 10.1159/000195300; HYLAND ME, 1991, RESP MED, V85, P13, DOI 10.1016/S0954-6111(06)80163-0; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; JONES K, 1991, BRIT J GEN PRACT, V41, P224; NUNN AJ, 1989, BRIT MED J, V298, P1068, DOI 10.1136/bmj.298.6680.1068; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RUSSELL I, 1983, EC MED EVALUATION HL; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; TOBIN DL, 1987, ANN ALLERGY, V59, P273; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1994, BRIT MED J, V308, P559; 1987, SIR VERSION 3 ENV MA; 1982, BRIT MED J, V2, P1251; [No title captured]	23	101	102	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					564	567		10.1136/bmj.308.6928.564	http://dx.doi.org/10.1136/bmj.308.6928.564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148679				2022-12-28	WOS:A1994MY71400019
J	BEALE, R; GROVER, ER; SMITHIES, M; BIHARI, D				BEALE, R; GROVER, ER; SMITHIES, M; BIHARI, D			ACUTE RESPIRATORY-DISTRESS SYNDROME (ARDS) - NO MORE THAN A SEVERE ACUTE LUNG INJURY	BRITISH MEDICAL JOURNAL			English	Article							MECHANICAL VENTILATION; INTRAVENOUS OXYGENATOR; AIRWAY PRESSURES; MORTALITY; MANAGEMENT; PROGNOSIS; TOXICITY; VOLUME; FLOW		GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND; GUYS HOSP,DEPT SURG,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								Artigas A., 1991, ADULT RESP DISTRESS, P37; ARTIGAS A, 1988, REANIM SOINS INTENS, V4, P339; ASHBAUGH DG, 1967, LANCET, V2, P319; CHINN A, 1993, AM REV RESPIR DIS, V147, pA349; DENEKE SM, 1980, NEW ENGL J MED, V303, P76, DOI 10.1056/NEJM198007103030204; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DREYFUSS D, 1992, INTENS CARE MED, V18, P139, DOI 10.1007/BF01709236; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GROVER ER, 1993, AM REV RESPIR DIS S, V147, pA350; GROVER ER, IN PRESS RESPIR PHYS; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HIGH KM, 1992, ANESTHESIOLOGY, V77, P856, DOI 10.1097/00000542-199211000-00004; HYERS TM, 1986, FASEB J, V45, P25; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LAIN DC, 1989, CHEST, V95, P1081, DOI 10.1378/chest.95.5.1081; LEWANDOWSKI K, 1993, AM REV RESPIR DIS, V147, pA349; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LODATO RF, 1990, CRIT CARE CLIN, V6, P749; MAYNARD N, IN PRESS JAMA; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PESENTI A, 1993, CRIT CARE MED, V21, P78, DOI 10.1097/00003246-199301000-00016; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RINALDO JE, 1986, CHEST, V90, P470, DOI 10.1378/chest.90.4.470; ROBIN ED, 1972, ARCH INTERN MED, V130, P66, DOI 10.1001/archinte.130.1.66; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SIM KM, 1993, BRIT MED J, V307, P1293, DOI 10.1136/bmj.307.6915.1293; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THOMSEN GE, 1993, AM REV RESPIR DIS, V147, pA347; TIMMONS OD, 1991, J PEDIATR-US, V119, P896, DOI 10.1016/S0022-3476(05)83039-2; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; VILLAR J, 1989, AM REV RESPIR DIS, V140, P814, DOI 10.1164/ajrccm/140.3.814; VILLAR J, 1990, CRIT CARE CLIN, V6, P579; WAGNER PD, 1991, AM REV RESPIR DIS, V143, P883, DOI 10.1164/ajrccm/143.4_Pt_1.883; WEBSTER NR, 1988, ANAESTHESIA, V43, P923, DOI 10.1111/j.1365-2044.1988.tb05652.x; YOUNES M, 1987, J APPL PHYSIOL, V62, P344, DOI 10.1152/jappl.1987.62.1.344; ZAPOL WM, 1992, ANESTHESIOLOGY, V77, P847, DOI 10.1097/00000542-199211000-00002; 1972, DHEW NIH74432 PUBL, P167; 1991, LANCET, V337, P706	45	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1335	1339		10.1136/bmj.307.6915.1335	http://dx.doi.org/10.1136/bmj.307.6915.1335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8166803	Bronze, Green Published			2022-12-28	WOS:A1993MH55600027
J	CANNON, RO; QUYYUMI, AA; MINCEMOYER, R; STINE, AM; GRACELY, RH; SMITH, WB; GERACI, MF; BLACK, BC; UHDE, TW; WACLAWIW, MA; MAHER, K; BENJAMIN, SB				CANNON, RO; QUYYUMI, AA; MINCEMOYER, R; STINE, AM; GRACELY, RH; SMITH, WB; GERACI, MF; BLACK, BC; UHDE, TW; WACLAWIW, MA; MAHER, K; BENJAMIN, SB			IMIPRAMINE IN PATIENTS WITH CHEST PAIN DESPITE NORMAL CORONARY ANGIOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; POSTHERPETIC NEURALGIA; DIABETIC NEUROPATHY; CONTRACTION ABNORMALITIES; PSYCHIATRIC-ILLNESS; ANGINA-PECTORIS; PANIC DISORDER; FLOW RESERVE; ARTERIES; AMITRIPTYLINE	Background. Ten to 30 percent of patients undergoing cardiac catheterization because of chest pain are found to have normal coronary angiograms. Because these patients may have a Visceral pain syndrome unrelated to myocardial ischemia, we investigated whether drugs that are useful in chronic pain syndromes might also be beneficial in such patients. Methods. Sixty consecutive patients underwent cardiac, esophageal, psychiatric, and pain-sensitivity testing and then participated in a randomized, double-blind, placebo-controlled three-week trial of clonidine at a dose of 0.1 mg twice daily (20 patients), imipramine at a dose of 50 mg nightly with a morning placebo (20 patients), or placebo twice daily (20 patients); this treatment phase was compared with an identical period of twice-daily placebo for all patients (placebo phase). Results. Thirteen (22 percent) of the 60 patients had ischemic-appearing electrocardiographic responses to exercise, 22 of the 54 tested (41 percent) had abnormal esophageal motility, 38 of 60 (63 percent) had one or more psychiatric disorders, and 52 of 60 (87 percent) had their characteristic chest pain provoked by right ventricular electrical stimulation or intracoronary infusion of adenosine. During the treatment phase, the imipramine group had a mean (+/-SD) reduction of 52+/-25 percent in episodes of chest pain, the clonidine group had a reduction of 39+/-51 percent, and the placebo group a reduction of 1+/-86 percent, all as compared with the placebo phase of the trial. Only the improvement with imipramine was statistically significant (P = 0.03). Repeat assessment of sensitivity to cardiac pain while the patients were receiving treatment showed significant improvement only in the imipramine group (P = 0.01). The response to imipramine did not depend on the results of cardiac, esophageal, or psychiatric testing at base line, or on the change in the psychiatric profile during the course of the study, which generally improved in all three study groups. Conclusions. Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect.	NHLBI,BIOSTAT RES BRANCH,BETHESDA,MD 20892; NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892; NIMH,ANXIETY & AFFECT DISORDERS SECT,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,DIV GASTROENTEROL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Georgetown University	CANNON, RO (corresponding author), NHLBI,CARDIOL BRANCH,BLDG 10,RM 7B-15,BETHESDA,MD 20892, USA.							BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; BASS C, 1983, LANCET, V1, P605; BEITMAN BD, 1989, AM J CARDIOL, V63, P1399, DOI 10.1016/0002-9149(89)91056-4; BIGGER JT, 1977, NEW ENGL J MED, V296, P206, DOI 10.1056/NEJM197701272960407; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; BRAND DL, 1977, AM J DIG DIS, V22, P300, DOI 10.1007/BF01072186; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; BUNNEY WE, 1963, ARCH GEN PSYCHIAT, V9, P280; CANNON RO, 1990, J AM COLL CARDIOL, V16, P1359, DOI 10.1016/0735-1097(90)90377-2; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1983, J AM COLL CARDIOL, V1, P1359, DOI 10.1016/S0735-1097(83)80037-0; CLOUSE RE, 1983, NEW ENGL J MED, V309, P1337, DOI 10.1056/NEJM198312013092201; CLOUSE RE, 1987, GASTROENTEROLOGY, V92, P1027, DOI 10.1016/0016-5085(87)90979-6; COUCH JR, 1976, NEUROLOGY, V26, P121, DOI 10.1212/WNL.26.2.121; Dart A M, 1980, Eur Heart J, V1, P97; DAY LJ, 1976, LANCET, V2, P334; DUBNER R, 1983, ANNU REV NEUROSCI, V6, P381, DOI 10.1146/annurev.ne.06.030183.002121; EGBUNIKE IG, 1990, PHARMACOTHERAPY, V10, P262; GOMERSALL JD, 1973, J NEUROL NEUROSUR PS, V36, P684, DOI 10.1136/jnnp.36.4.684; GOMEZPEREZ FJ, 1985, PAIN, V23, P395, DOI 10.1016/0304-3959(85)90010-7; GRACELY RH, 1979, SCIENCE, V203, P1261, DOI 10.1126/science.424753; GREENBERG MA, 1987, J AM COLL CARDIOL, V9, P743, DOI 10.1016/S0735-1097(87)80227-9; ISNER JM, 1981, AM HEART J, V102, P645, DOI 10.1016/0002-8703(81)90088-0; JANSSENS J, 1986, GASTROENTEROLOGY, V90, P1978, DOI 10.1016/0016-5085(86)90270-2; KATON W, 1988, AM J MED, V84, P1, DOI 10.1016/0002-9343(88)90001-0; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KEMP HG, 1973, AM J MED, V54, P735, DOI 10.1016/0002-9343(73)90060-0; KVINESDAL B, 1984, JAMA-J AM MED ASSOC, V251, P1727, DOI 10.1001/jama.251.13.1727; LAGERQVIST B, 1992, BRIT HEART J, V68, P282; LANTINGA LJ, 1988, AM J CARDIOL, V62, P209, DOI 10.1016/0002-9149(88)90213-5; LEGRAND V, 1985, J AM COLL CARDIOL, V6, P1245, DOI 10.1016/S0735-1097(85)80209-6; MANNUZZA S, 1989, ARCH GEN PSYCHIAT, V46, P1093; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; OCKENE IS, 1980, NEW ENGL J MED, V303, P1249, DOI 10.1056/NEJM198011273032201; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; RICHTER JE, 1986, GASTROENTEROLOGY, V91, P845, DOI 10.1016/0016-5085(86)90685-2; ROYBYRNE PP, 1989, INT J PSYCHIAT MED, V19, P315; SCHLEYER B, 1990, SCHEDULE AFFECTIVE D; SHAPIRO LM, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170-a; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; TRAUBE M, 1983, JAMA-J AM MED ASSOC, V250, P2655, DOI 10.1001/jama.250.19.2655; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; ZEIGLER D, 1992, PAIN, V48, P403, DOI 10.1016/0304-3959(92)90092-P; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; 1987, DIAGNOSTIC STATISTIC; 1985, PSYCHOPHARMACOL B, V21, P839; 1985, SAS USERS GUIDE STAT, P433	54	322	331	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1411	1417		10.1056/NEJM199405193302003	http://dx.doi.org/10.1056/NEJM199405193302003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159194	Bronze			2022-12-28	WOS:A1994NK97200003
J	COLDITZ, GA				COLDITZ, GA			ORAL-CONTRACEPTIVE USE AND MORTALITY DURING 12 YEARS OF FOLLOW-UP - THE NURSES-HEALTH-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CONTRACEPTIVES, ORAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RISK; RISK FACTORS	BREAST-CANCER; PAST USE; RISK; METAANALYSIS; WOMEN	Objective: To examine prospectively the risk for mortality among women who had ever used oral contraceptives compared with those who had never used oral contraceptives. Design: Prospective cohort study. Setting: Nurses' Health Study. Participants: 166 755 women aged 30 to 55 years in 1976, followed through 1988 (1.3 million person-years of follow-up). Results: On the basis of 2879 deaths, we found no overall difference in mortality among women who had ever used oral contraceptives compared with women who had never used oral contraceptives; the relative risk for ever-users, adjusted for age, body mass index, and cigarette smoking was 0.93 (95% CI, 0.85 to 1.01). We observed no trend in risk for total mortality with increasing duration of past use of oral contraceptives. After adjusting for age, body mass index, and cigarette smoking, women who had used oral contraceptives for 10 or more years had a relative risk of 1.06 (CI, 0.83 to 1.35). Conclusion: Use of oral contraceptives is safe; no evidence from this study indicates that long durations of oral contraceptive use adversely affect long-term risk for mortality.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40936] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLDITZ GA, 1986, AM J EPIDEMIOL, V124, P520; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; KAY CR, 1984, CLIN OBSTET GYNAECOL, V11, P759; KAY CR, 1981, LANCET, V1, P541; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILNE R, 1992, J PUBLIC HEALTH MED, V14, P9; ORY HW, 1982, FAM PLANN PERSPECT, V14, P182, DOI 10.2307/2134636; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSENBERG L, 1992, AM J EPIDEMIOL, V136, P1437, DOI 10.1093/oxfordjournals.aje.a116464; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1986, AM J EPIDEMIOL, V124, P520; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; THOMAS DB, 1990, BRIT J CANCER, V61, P110; THOMAS DB, 1993, JNCI-J NATL CANCER I, V85, P359, DOI 10.1093/jnci/85.5.359; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; Tietze C, 1978, Int J Gynaecol Obstet, V16, P456; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P1221; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WINGO PA, 1993, CANCER-AM CANCER SOC, V71, P1506, DOI 10.1002/cncr.2820710416; 1991, ORAL CONTRACEPTIVES, P1	26	89	90	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					821	826		10.7326/0003-4819-120-10-199405150-00002	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154642				2022-12-28	WOS:A1994NK45800002
J	MIDDLEBROOKS, JC; CLOCK, AE; XU, L; GREEN, DM				MIDDLEBROOKS, JC; CLOCK, AE; XU, L; GREEN, DM			A PANORAMIC CODE FOR SOUND LOCATION BY CORTICAL-NEURONS	SCIENCE			English	Article							PRIMARY AUDITORY-CORTEX; SUPERIOR COLLICULUS; SINGLE UNITS; SPACE; SENSITIVITY; PATTERNS; CATS	By conventional spike count measures, auditory neurons in the cat's anterior ectosylvian sulcus cortical area are broadly tuned for the location of a sound source. Nevertheless, an artificial neural network was trained to classify the temporal spike patterns of single neurons according to sound location. The spike patterns of 73 percent of single neurons coded sound location with more than twice the chance level of accuracy, and spike patterns consistently carried more information than spike counts alone. In contrast to neurons that are sharply tuned for location, these neurons appear to encode sound locations throughout 360 degrees of azimuth.	UNIV FLORIDA,INST BRAIN,DEPT OTOLARYNGOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PSYCHOL,PSYCHOACOUST LAB,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida	MIDDLEBROOKS, JC (corresponding author), UNIV FLORIDA,INST BRAIN,DEPT NEUROSCI,GAINESVILLE,FL 32610, USA.		Xu, Li/C-5908-2008	Xu, Li/0000-0002-0988-7934				BRITTEN KH, 1992, J NEUROSCI, V12, P4745; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; GREEN DM, 1974, SIGNAL DETECTION THE; IMIG TJ, 1990, J NEUROPHYSIOL, V63, P1448, DOI 10.1152/jn.1990.63.6.1448; JENKINS WM, 1982, J NEUROPHYSIOL, V47, P987, DOI 10.1152/jn.1982.47.6.987; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; MIDDLEBROOKS JC, 1981, J NEUROSCI, V1, P107, DOI 10.1523/JNEUROSCI.01-01-00107.1981; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; PALMER AR, 1982, NATURE, V299, P248, DOI 10.1038/299248a0; RAJAN R, 1990, J NEUROPHYSIOL, V64, P872, DOI 10.1152/jn.1990.64.3.872; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; WIDROW B, 1960, IRE WESCON CONVENTIO, V4, P96	14	267	274	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					842	844		10.1126/science.8171339	http://dx.doi.org/10.1126/science.8171339			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171339	Green Submitted			2022-12-28	WOS:A1994NJ94900033
J	LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW				LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW			WITHDRAWING CARE - EXPERIENCE IN A MEDICAL INTENSIVE-CARE UNIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-SUPPORT; PATIENT; ILLUSION; FAMILIES; FUTILITY	Objective.-To describe the process and outcomes of withdrawing life-sustaining interventions in a medical intensive care unit (MICU). Design.-Retrospective case series. Setting.-Medical intensive care unit in a community teaching hospital. Patients.-Consecutive series of 28 patients in whom mechanical ventilation, dialysis, and/or vasopressors were withdrawn. We distinguished physiological, neurological, and functional rationales for care withdrawal. Main Outcome Measures.-Duration of discussions, MICU length of stay, and hospital survival. Results.-Mean +/-SD Acute Physiology and Chronic Health Evaluation (APACHE II) score was 27.1 +/- 7.3 on MICU admission, and average +/-SD predicted hospital mortality was 61% +/- 22%. Discussions leading to withdrawal of care occurred over an average +/-SD of 5.2 +/- 5.5 days, with decisions achieved soonest in cases with poor neurological prognosis. Average +/-SD MICU length of stay was 1.4 +/- 1.8 days following a decision to withdraw MICU care, and only four patients received more than 48 hours of additional MICU care. Four patients were discharged alive from the hospital. Conclusions.-Patients and their surrogates willingly considered outcomes in addition to mortality when considering withdrawal of life-sustaining interventions. Finding an accommodation between physician judgments and patient preferences took time and effort but was an effective means of limiting ineffective life-sustaining efforts. Withdrawing futile or unwanted care was not always fatal.	UNIV ROCHESTER,SCH MED & DENT,DEPT DERMATOL,ROCHESTER,NY 14642	University of Rochester	LEE, DKP (corresponding author), ROCHESTER GEN HOSP,PULM UNIT,1425 PORTLAND AVE,ROCHESTER,NY 14621, USA.							[Anonymous], 1991, ANN INTERN MED, V115, P478; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANTOS JD, 1989, AM J MED, V87, P81; LUCE JM, 1992, CHEST, V101, P1185, DOI 10.1378/chest.101.5.1185; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; PELLEGRINO ED, 1981, B NEW YORK ACAD MED, V57, P70; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SIEGLER M, 1981, B NEW YORK ACAD MED, V57, P56; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SNIDER GL, 1991, AM REV RESPIR DIS, V143, P665, DOI 10.1164/ajrccm/143.3.665; SPICHER JE, 1987, ARCH INTERN MED, V147, P421, DOI 10.1001/archinte.147.3.421; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; 1987, GUIDELINES TERMINATI; 1991, JAMA-J AM MED ASSOC, V265, P1868	30	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1358	1361		10.1001/jama.271.17.1358	http://dx.doi.org/10.1001/jama.271.17.1358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158822				2022-12-28	WOS:A1994NH48700029
J	ZADNIK, K; SATARIANO, WA; MUTTI, DO; SHOLTZ, RI; ADAMS, AJ				ZADNIK, K; SATARIANO, WA; MUTTI, DO; SHOLTZ, RI; ADAMS, AJ			THE EFFECT OF PARENTAL HISTORY OF MYOPIA ON CHILDRENS EYE SIZE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OCULAR COMPONENT DIMENSIONS; TUPAIA-BELANGERI; QUESTIONNAIRE; EMMETROPIZATION; VALIDATION; VISION	Objective.-To evaluate whether eye size and shape are different in children based on their parental history of myopia. Design.-A community-based cohort study of schoolchildren (aged 6 to 14 years), the Orinda (Calif) Longitudinal Study of Myopia. Setting.-Four campuses of the Orinda Union School District, a predominantly white, high socioeconomic status community. Participants.-A cross-sectional volunteer sample of 716 children (662 nonmyopic) in the first, third, and sixth grades in 1989, 1990, and 1991. All children in those grades were eligible for inclusion in the study. Intervention(s).-None. Main Outcome Measures.-Refractive error (measured by autorefraction), corneal curvature (measured by photokeratoscopy), crystalline lens power (measured by video phakometry), and axial ocular dimensions (measured by ultrasonography). Results.-With prevalent cases of myopia excluded and grade in school and ''near work'' controlled for, children with two myopic parents had longer eyes and less hyperopic refractive error (analysis of covariance, P less than or equal to.01) than children with only one myopic parent or no myopic parents. A model incorporating parental history is only improved by the addition of near work for the prediction of refractive error. Conclusions.-Even before the onset of juvenile myopia, children of myopic parents have longer eyes. These results suggest that the premyopic eye in children with a family history of myopia already resembles the elongated eye present in myopia.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California Berkeley	ZADNIK, K (corresponding author), UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720, USA.				NEI NIH HHS [R01 EY08893] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008893] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALSBIRK PH, 1979, ACTA OPHTHALMOL, V57, P84; ANGLE J, 1980, AM J EPIDEMIOL, V111, P220, DOI 10.1093/oxfordjournals.aje.a112889; ASHTON GC, 1985, J BIOSOC SCI, V17, P223, DOI 10.1017/S0021932000015686; ASHTON GC, 1985, HUM HERED, V35, P232, DOI 10.1159/000153551; BASU SK, 1983, HUM HERED, V33, P163, DOI 10.1159/000153369; Blum HL, 1959, VISION SCREENING ELE; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; FINEGAN JAK, 1991, ARCH SEX BEHAV, V20, P393, DOI 10.1007/BF01542619; FLEDELIUS HC, 1980, ACTA OPHTHALMOL, V58, P889; FLEDELIUS HC, 1982, ACTA OPHTHALMOL, V60, P393; FLEDELIUS HC, 1982, ACTA OPHTHALMOL, V60, P403; GARNER LF, 1990, OPHTHAL PHYSL OPT, V10, P234, DOI 10.1111/j.1475-1313.1990.tb00857.x; GARNER LF, 1988, AM J OPTOM PHYS OPT, V65, P182; Goldschmidt E., 1968, ACTA OPHTHALMOL, V98, P1; Goss D A, 1988, J Am Optom Assoc, V59, P875; GWIAZDA J, 1993, CLIN VISION SCI, V8, P337; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; KIMURA T, 1965, NIPPON GANKA GAKKAI, V69, P963; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P427; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P239; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P441; MCBRIEN NA, 1992, VISION RES, V32, P843, DOI 10.1016/0042-6989(92)90027-G; MCBRIEN NA, 1989, OPHTHAL PHYSL OPT, V4, P201; MELTZER JW, 1970, PUBLIC HLTH REP, V85, P1057; MILES FA, 1990, VISION RES, V30, P339, DOI 10.1016/0042-6989(90)90076-W; MINKOVITZ JB, 1993, INVEST OPHTH VIS SCI, V34, P1218; MURPHY JM, 1992, J AM ACAD CHILD PSY, V31, P1105, DOI 10.1097/00004583-199211000-00019; MUTTI DO, 1992, INVEST OPHTH VIS SCI, V33, P1771; NAKAJIMA A, 1968, Japanese Journal of Human Genetics, V13, P20; NORTON TT, 1992, VISION RES, V32, P833, DOI 10.1016/0042-6989(92)90026-F; RABIN J, 1981, INVEST OPHTH VIS SCI, V20, P561; RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505; RICHLER A, 1980, ACTA OPHTHALMOL, V58, P468; ROSNER M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1508; SORSBY A, 1966, Journal of Medical Genetics, V3, P269, DOI 10.1136/jmg.3.4.269; Sorsby A, 1957, EMMETROPIA ITS ABERR; Sorsby A., 1962, REFRACTION ITS COMPO; SORSBY A, 1961, REFRACTION ITS COMPO; Sorsby A, 1970, LONGITUDINAL STUDY R; SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011; TEIKARI JM, 1991, HUM HERED, V41, P151, DOI 10.1159/000153994; TEIKARI JM, 1992, SCAND J SOC MED, V20, P73; Tokoro T, 1969, JPN J OPHTHALMOL, V13, P27; WALLMAN J, 1987, VISION RES, V27, P1139, DOI 10.1016/0042-6989(87)90027-7; WOLD KC, 1949, ARCH OPHTHALMOL-CHIC, V42, P225; YOUNG FA, 1969, AMER J OPT ARCH AM A, V46, P676; YOUNG FA, 1963, INVEST OPHTH VISUAL, V2, P571; YOUNG FA, 1972, AMER J OPT ARCH AM A, V49, P546; ZADNIK K, 1993, OPTOMETRY VISION SCI, V70, P750, DOI 10.1097/00006324-199309000-00012; 1989, MYOPIA PREVALENCE PR; 1987, VISION RES NATIONAL	51	224	230	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1323	1327		10.1001/jama.271.17.1323	http://dx.doi.org/10.1001/jama.271.17.1323			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158816				2022-12-28	WOS:A1994NH48700023
J	DANZIGER, R				DANZIGER, R			DISCRIMINATION AGAINST PEOPLE WITH HIV AND AIDS IN POLAND	BRITISH MEDICAL JOURNAL			English	Article								The recent increase in HIV seroprevalence in Poland, particularly among injecting drug users, has been accompanied by widespread discrimination against people affected by HIV and AIDS. As in other countries,this discrimination may be attributed to a large extent to fear and ignorance about HIV and AIDS together with pre-existing prejudices against the people who are most commonly associated with the epidemic. In Poland extreme hostility towards drug users combined with the powerful influence of a traditional Catholic church have so far impeded effective education about HIV and AIDS and antidiscrimination strategies,	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								CHOPIN K, 1992, BRIT MED J, V304, P1429, DOI 10.1136/bmj.304.6839.1429; EASTERBROOK P, 1992, NEW SCI, V135, P11; RICH V, 1994, LANCET, V343, P47, DOI 10.1016/S0140-6736(94)90889-3; 1993, SLOWO DZIENNIK  0721; 1993, ECONOMIST       0718, P42; 1992, COOPERATION CENTRAL; 1990, REPORT AIDS; 1991, BRIDGING PLAN PREVEN, P39; 1992, DISCRIMINATION OTHER, P82; 1993, ZYCIE WARSZAWY  0527, P5; 1993, CESCHR CDDH937 SWISS; 1993, GAZETA WYBORCZA 0216, P10; 1992, SPOLECZENSTWO WOBEC; 1991, WIEDZA POSTAURY WOBE; 1993, RZECZPOSPOLITA   JUN	15	22	22	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1145	1147		10.1136/bmj.308.6937.1145	http://dx.doi.org/10.1136/bmj.308.6937.1145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173458	Green Published			2022-12-28	WOS:A1994NK18200022
J	HUSSAIN, LM; REDMOND, AD				HUSSAIN, LM; REDMOND, AD			ARE PREHOSPITAL DEATHS FROM ACCIDENTAL INJURY PREVENTABLE	BRITISH MEDICAL JOURNAL			English	Article							SEVERITY SCORE; TRAUMA DEATHS; EMERGENCY; CARE	Objective-To determine what proportion of prehospital deaths from accidental injury-deaths at the scene of the accident and those that occur before the person has reached hospital-are preventable. Design-Retrospective study of all deaths from accidental injury that occurred between 1 January 1987 and 31 December 1990 and were reported to the coroner. Setting-North Staffordshire. Main outcome measures-Injury severity score, probability of survival (probit analysis), and airway obstruction. Results-There were 152 pre-hospital deaths from accidental injury (110 males and 42 females). In the same period there were 257 deaths in hospital from accidental injury (136 males and 121 females). The average age at death was 41.9 years for those who died before reaching hospital, and their average injury severity score was 29.3. In contrast, those who died in hospital were older and equally likely to be males or females. Important neurological injury occurred in 113 pre-hospital deaths, and evidence of airway obstruction in 59. Eighty six pre-hospital deaths were due to road traffic accidents, and 37 of these were occupants in cars. On the basis of the injury severity score and age, death was found to have been inevitable or highly likely in 92 cases. In the remaining 60 cases death had not been inevitable and airway obstruction was present in up to 51 patients with injuries that they might have survived. Conclusion-Death was potentially preventable in at least 39% of those who died from accidental injury before they reached hospital. Training in first aid should be available more widely, and particularly to motorists as many pre-hospital deaths that could be prevented are due to road accidents.	N STAFFORDSHIRE HOSP,STOKE ON TRENT ST4 4LN,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								ALLAN AN, 1992, J BRIT ASS IMMEDIATE, V15, P50; ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Finney DJ., 1947, PROBIT ANAL; FISCHER H, 1991, COLOUR ATLAS TRAUMA, P83; GORDON MWG, 1989, ARCH EMERG MED, V6, P107; LENWORTH MJ, 1984, J TRAUMA, V24, P8; Redmond A D, 1993, J R Coll Surg Edinb, V38, P248; TRUNKEY D, 1985, ARCH EMERG MED, V2, P181; UNDERHILL TJ, 1989, ARCH EMERG MED, V6, P90; YATES DW, 1977, BRIT MED J, V2, P1249, DOI 10.1136/bmj.2.6097.1249; 1988, MANAGEMENT PATIENT M; 1990, AIS 90 HDB ABBREVIAT	17	139	145	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1077	1080		10.1136/bmj.308.6936.1077	http://dx.doi.org/10.1136/bmj.308.6936.1077			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173428	Green Published			2022-12-28	WOS:A1994NH48900023
J	ROSS, M; GROSSMAN, AB; MURDOCH, S; BUNDEY, R; GOLDING, J; PURCHASE, S; MUNYARD, T; SCOTT, M; BRIDGER, A				ROSS, M; GROSSMAN, AB; MURDOCH, S; BUNDEY, R; GOLDING, J; PURCHASE, S; MUNYARD, T; SCOTT, M; BRIDGER, A			PRISON - SHIELD FROM THREAT, OR THREAT TO SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND; LIVERPOOL PERSONAL SERV SOC,LIVERPOOL L1 6AN,ENGLAND	University of London; Queen Mary University London	ROSS, M (corresponding author), ASHWELL MED CTR,BRADFORD BD8 9DB,ENGLAND.							BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; CHRISTIE B, 1993, BRIT MED J, V307, P151; GOLDSTEIN A, 1989, MOL CELLULAR ASPECTS; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GOSSOP M, 1987, ADDICT BEHAV, V12, P1, DOI 10.1016/0306-4603(87)90002-5; LIEBLING A, 1993, BRIT MED J, V307, P399, DOI 10.1136/bmj.307.6901.399; WOOL R, 1993, GUARDIAN        1123; 1993, STATISTICAL B, V15; 1988, RIGHTS RESPONSIBILIT, P64; 1992, STATISTICS DRUG ADDI; 1991, CARING DRUG USERS MU; 1991, DRUGS MISUSE DEPENDE, P21	12	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1092	1095		10.1136/bmj.308.6936.1092	http://dx.doi.org/10.1136/bmj.308.6936.1092			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173433	Green Published			2022-12-28	WOS:A1994NH48900033
J	STRANG, J; GRIFFITHS, P; ABBEY, J; GOSSOP, M				STRANG, J; GRIFFITHS, P; ABBEY, J; GOSSOP, M			SURVEY OF USE OF INJECTED BENZODIAZEPINES AMONG DRUG-USERS IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							TEMAZEPAM				STRANG, J (corresponding author), MAUDSLEY INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				CARNWATH T, 1993, BRIT MED J, V307, P385, DOI 10.1136/bmj.307.6900.385-c; GREEN S, 1992, BRIT J ADDICT, V87, P941; LAUNCHBURY AP, 1989, MANUF CHEMIST, V60, P38; RUBEN SM, 1992, BRIT J ADDICT, V87, P1387; Strang J., 1993, BENZODIAZEPINE DEPEN, P128	5	45	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1082	1082		10.1136/bmj.308.6936.1082	http://dx.doi.org/10.1136/bmj.308.6936.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173431	Green Published			2022-12-28	WOS:A1994NH48900026
J	BETZ, AG; MILSTEIN, C; GONZALEZFERNANDEZ, A; PANNELL, R; LARSON, T; NEUBERGER, MS				BETZ, AG; MILSTEIN, C; GONZALEZFERNANDEZ, A; PANNELL, R; LARSON, T; NEUBERGER, MS			ELEMENTS REGULATING SOMATIC HYPERMUTATION OF AN IMMUNOGLOBULIN-KAPPA GENE - CRITICAL ROLE FOR THE INTRON ENHANCER MATRIX ATTACHMENT REGION	CELL			English	Article							ANTIGEN-DRIVEN SELECTION; CELL-SPECIFIC ENHANCER; HEAVY-CHAIN LOCUS; GERMINAL-CENTERS; IMMUNE-RESPONSE; TRANSGENIC MICE; VARIABLE GENES; B-CELLS; MUTATION; MATURATION	Following encounter with antigen, the immunoglobulin genes in B lymphocytes undergo somatic hypermutation. Most nucleotide substitutions are introduced into a region flanked by the V gene promoter and intron enhancer. Experiments described here using transgenic mice revealed that the V kappa promoter does not contain specific signals since hypermutation was retained on substituting it by a beta-globin promoter. However, both the kappa intron and kappa 3' enhancer regions were found to be essential for full hypermutation. This dependence of hypermutation on both enhancers contrasts with transgene expression in hybridomas in which only the 3' enhancer (and not the intron enhancer) is necessary to achieve high mRNA levels. The results show that full hypermutation depends on multiple elements, removal of some of which may drastically impair but not totally abolish the process.			BETZ, AG (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Betz, Alexander/GQQ-2221-2022; González-Fernández, África/E-2641-2012	González-Fernández, África/0000-0002-9226-4825				ADETUGBO K, 1977, NATURE, V265, P299, DOI 10.1038/265299a0; APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; AZUMA T, 1993, INT IMMUNOL, V5, P121, DOI 10.1093/intimm/5.2.121; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DREHER ML, 1991, J IMMUNOL METHODS, V139, P197, DOI 10.1016/0022-1759(91)90189-M; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; Galfre G, 1981, Methods Enzymol, V73, P3; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GIUSTI AM, 1993, J EXP MED, V177, P797, DOI 10.1084/jem.177.3.797; GOLDING GB, 1987, GENETICS, V115, P169; GONZALEZFERNANDEZ A, 1993, P NATL ACAD SCI USA, V90, P9862, DOI 10.1073/pnas.90.21.9862; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAARTINEN M, 1991, EUR J IMMUNOL, V21, P2863, DOI 10.1002/eji.1830211131; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACLENNAN I, 1991, NATURE, V354, P352, DOI 10.1038/354352a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MAX EE, 1981, J BIOL CHEM, V256, P5116; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P3565; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; NOSSAL GJV, 1992, CELL, V68, P1, DOI 10.1016/0092-8674(92)90198-L; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RADA C, 1991, P NATL ACAD SCI USA, V88, P5508, DOI 10.1073/pnas.88.13.5508; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROTHENFLUH HS, 1993, EUR J IMMUNOL, V23, P2152, DOI 10.1002/eji.1830230916; SHARPE MJ, 1990, EUR J IMMUNOL, V20, P1379, DOI 10.1002/eji.1830200625; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SOHN J, 1993, J EXP MED, V177, P493, DOI 10.1084/jem.177.2.493; STEELE EJ, 1992, IMMUNOL CELL BIOL, V70, P129, DOI 10.1038/icb.1992.18; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; WEBER JS, 1991, J IMMUNOL, V146, P3652; XU M, 1989, J BIOL CHEM, V264, P21190	58	354	373	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					239	248		10.1016/0092-8674(94)90316-6	http://dx.doi.org/10.1016/0092-8674(94)90316-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168132				2022-12-28	WOS:A1994NH63400009
J	KURIHARA, Y; KURIHARA, H; SUZUKI, H; KODAMA, T; MAEMURA, K; NAGAI, R; ODA, H; KUWAKI, T; CAO, WH; KAMADA, N; JISHAGE, K; OUCHI, Y; AZUMA, S; TOYODA, Y; ISHIKAWA, T; KUMADA, M; YAZAKI, Y				KURIHARA, Y; KURIHARA, H; SUZUKI, H; KODAMA, T; MAEMURA, K; NAGAI, R; ODA, H; KUWAKI, T; CAO, WH; KAMADA, N; JISHAGE, K; OUCHI, Y; AZUMA, S; TOYODA, Y; ISHIKAWA, T; KUMADA, M; YAZAKI, Y			ELEVATED BLOOD-PRESSURE AND CRANIOFACIAL ABNORMALITIES IN MICE DEFICIENT IN ENDOTHELIN-1	NATURE			English	Article							DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; VENTRAL SURFACE; BINDING-SITES; RAT MEDULLA; GENE; EXPRESSION; PEPTIDE; CELLS; HYPERTENSION	The endothelin-l (ET-1) gene was disrupted in mouse embryonic stem cells by homologous recombination to generate mice deficient in ET-1. These: ET-1(-/-) homozygous mice die of respiratory failure at birth and have morphological abnormalities of the pharyngeal-arch-derived craniofacial tissues and organs. ET-1(+/-) heterozygous mice, which produce lower levels of ET-1 than wild-type mice, develop elevated blood pressure. These results suggest that ET-1 is essential for normal mouse development and may also play a physiological role in cardiovascular homeostasis.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT PATHOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT PHYSIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT GERIATR, BUNKYO KU, TOKYO 113, JAPAN; CHUGAI PHARMACEUT CO LTD, GOTEMBA, SHIZUOKA 412, JAPAN; UNIV TOKYO, INST MED SCI, DEPT REPROD & DEV BIOL, MINATO KU, TOKYO 108, JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo								ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; CAO WH, 1993, J CARDIOVASC PHARM, V22, pS196, DOI 10.1097/00005344-199322008-00053; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; FUKUDA Y, 1988, BIOCHEM BIOPH RES CO, V155, P167, DOI 10.1016/S0006-291X(88)81064-7; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOHNSTON MC, 1991, J CRAN GENET DEV BIO, V11, P227; KAY ED, 1987, TERATOLOGY, V35, P105, DOI 10.1002/tera.1420350114; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSEKI C, 1989, NEUROSCI RES, V6, P581, DOI 10.1016/0168-0102(89)90047-3; KRONMILLER JE, 1991, DEV BIOL, V147, P485, DOI 10.1016/0012-1606(91)90307-O; KUMADA M, 1990, PROG NEUROBIOL, V35, P331, DOI 10.1016/0301-0082(90)90036-G; KUWAKI T, 1991, NEUROCHEM INT, V18, P519, DOI 10.1016/0197-0186(91)90150-C; KUWAKI T, 1991, J AUTONOM NERV SYST, V36, P149, DOI 10.1016/0165-1838(91)90111-F; KUWAKI T, 1990, JPN J PHYSIOL, V40, P827, DOI 10.2170/jjphysiol.40.827; KUWAKI T, 1991, J CARDIOVASC PHARM, V17, pS343, DOI 10.1097/00005344-199100177-00098; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LUSCHER TF, 1992, HYPERTENSION, V19, P117, DOI 10.1161/01.HYP.19.2.117; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MCKENZIE J, 1958, ARCH DIS CHILD, V33, P477, DOI 10.1136/adc.33.171.477; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V160, P628, DOI 10.1016/0006-291X(89)92479-0; MORTENSEN LH, 1990, HYPERTENSION, V15, P729, DOI 10.1161/01.HYP.15.6.729; MOSQUEDAGARCIA R, 1993, CIRC RES, V72, P20, DOI 10.1161/01.RES.72.1.20; NODEN DM, 1991, BRAIN BEHAV EVOLUT, V38, P190, DOI 10.1159/000114388; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; OUCHI Y, 1989, AM J PHYSIOL, V256, pH1747, DOI 10.1152/ajpheart.1989.256.6.H1747; RAKUGI H, 1988, BIOCHEM BIOPH RES CO, V155, P1244, DOI 10.1016/S0006-291X(88)81273-7; SAIDA K, 1989, J BIOL CHEM, V264, P14613; SPYER KM, 1991, J CARDIOVASC PHARM, V17, pS385, DOI 10.1097/00005344-199100177-00108; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; TAKAGI Y, 1991, AM J HYPERTENS, V4, P389, DOI 10.1093/ajh/4.4.389; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YASUJIMA M, 1990, AM J HYPERTENS, V3, P635, DOI 10.1093/ajh/3.8.635; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213	47	863	873	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					703	710		10.1038/368703a0	http://dx.doi.org/10.1038/368703a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152482				2022-12-28	WOS:A1994NG55300048
J	ROYSTON, CMS; LANSDOWN, MRJ; BROUGH, WA				ROYSTON, CMS; LANSDOWN, MRJ; BROUGH, WA			TEACHING LAPAROSCOPIC SURGERY - THE NEED FOR GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article								There is a risk that minimally invasive surgery will fall into disrepute unless adequate steps are taken to reassure the public. Some form of accreditation after a recognised training scheme would go a long way towards allaying these fears. The cost of training surgeons must be addressed. Adequate training will probably pay dividends in reduced litigation. The royal colleges should be responsible for maintaining standards of teaching on recognised courses, setting criteria for accreditation, and supervising a national audit of all laparoscopic procedures.	ST JAMESS UNIV HOSP,LEEDS,ENGLAND; STEPPING HILL HOSP,STOCKPORT,ENGLAND	Saint James's University Hospital; University of Leeds	ROYSTON, CMS (corresponding author), HULL ROYAL INFIRM,KINGSTON HULL HU3 2JZ,N HUMBERSIDE,ENGLAND.							CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; Cuschieri A, 1992, J R Coll Surg Edinb, V37, P213; DENT TL, 1991, AM J SURG, V161, P399, DOI 10.1016/0002-9610(91)90607-F; DUNN DC, 1991, BRIT MED J, V303, P1272, DOI 10.1136/bmj.303.6812.1272-b; MACINTYRE IMC, 1993, BRIT J SURG, V80, P552, DOI 10.1002/bjs.1800800505; 1990, MINIMAL ACCESS SURGE; 1991, NEW ENGL J MED, V324, P10173; 1991, AM J SURG, V161, P324	8	49	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1023	1025		10.1136/bmj.308.6935.1023	http://dx.doi.org/10.1136/bmj.308.6935.1023			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167516	Green Published			2022-12-28	WOS:A1994NH08900024
J	SMITH, GD; EGGER, M				SMITH, GD; EGGER, M			STATISTICAL PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CHOLESTEROL CONCENTRATION; DENSITY-LIPOPROTEIN; MORTALITY; TIME; RISK		UNIV BERN,DEPT SOCIAL & PREVENT MED,CH-3012 BERN,SWITZERLAND	University of Bern	SMITH, GD (corresponding author), UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,SCOTLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; SHESTOV DB, 1993, CIRCULATION, V88, P846, DOI 10.1161/01.CIR.88.3.846; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, CORONARY ARTERY DIS, V4, P860, DOI 10.1097/00019501-199310000-00004; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; 1978, BRIT HEART J, V4, P1069; 1991, PREDICTION BASED ONE; 1984, JAMA-J AM MED ASSOC, V251, P351	24	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1025	1027		10.1136/bmj.308.6935.1025	http://dx.doi.org/10.1136/bmj.308.6935.1025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167517	Green Published			2022-12-28	WOS:A1994NH08900025
J	SHALLICE, T; FLETCHER, P; FRITH, CD; GRASBY, P; FRACKOWIAK, RSJ; DOLAN, RJ				SHALLICE, T; FLETCHER, P; FRITH, CD; GRASBY, P; FRACKOWIAK, RSJ; DOLAN, RJ			BRAIN-REGIONS ASSOCIATED WITH ACQUISITION AND RETRIEVAL OF VERBAL EPISODIC MEMORY	NATURE			English	Article							PREFRONTAL CORTEX; HIPPOCAMPUS; ATTENTION; NETWORKS; AMNESIA; HUMANS; PET	IT is widely held that conscious recall of past experiences involves a specific system-episodic memory1. Patients with amnesia have gross impairments of episodic memory while other kinds of memory remain intact2,3, suggesting that a separable brain system underlies episodic memory. We have used positron emission tomography (PET) to identify components of this system in normal volunteers. A dual-task interference paradigm4 was used to isolate brain areas associated with acquisition, and a cueing paradigm5 to isolate the areas concerned with retrieval from verbal episodic memory. Acquisition was associated with activity in the left prefrontal cortex and the retrosplenial area, whereas retrieval was associated with activity in right prefrontal cortex and the precuneus. Our results provide clear evidence that episodic memory involves a network of specific prefrontal and posterior structures6,7 which can be fractionated into different component processes.	UCL, DEPT PSYCHOL, GOWER ST, LONDON WC1E 6TB, ENGLAND; HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, LONDON W12 0HS, ENGLAND; ROYAL FREE HOSP, SCH MED, LONDON NW3 2QG, ENGLAND; NATL HOSP NEUROL & NEUROSURG, LONDON WC1 3BG, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND	University of London; University College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London			Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Frith, Chris D/A-2171-2009; Fletcher, Paul/F-5380-2011	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Fletcher, Paul/0000-0001-8257-1517; Dolan, Ray/0000-0001-9356-761X				[Anonymous], 1983, CANADIAN PSYCHOL; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Baddeley A. D., 1990, HUMAN MEMORY; Baddeley A.D., 1986, WORKING MEMORY THOUG; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM; BURGESS PW, 1992, THESIS U LONDON; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Jacoby L.L., 1993, ATTENTION SELECTION; Mayes A. R., 1988, HUMAN ORGANIC MEMORY; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBB R A, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P9; ROLAND PE, 1989, WENNER-GR C, V53, P141; Rolls ET, 1990, NETWORK-COMP NEURAL, V1, P407, DOI 10.1088/0954-898X/1/4/002; RUDGE P, 1991, BRAIN, V114, P349, DOI 10.1093/brain/114.1.349; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; Talairach I., 1988, COPLANAR STEREOTACTI; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; WARRINGTON EK, 1982, NEUROPSYCHOLOGIA, V20, P233, DOI 10.1016/0028-3932(82)90099-9; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803	30	722	730	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	1994	368	6472					633	635		10.1038/368633a0	http://dx.doi.org/10.1038/368633a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145849	Green Published			2022-12-28	WOS:A1994NF39200060
J	ETCHEBERRIGARAY, R; ITO, E; KIM, CS; ALKON, DL				ETCHEBERRIGARAY, R; ITO, E; KIM, CS; ALKON, DL			SOLUBLE BETA-AMYLOID INDUCTION OF ALZHEIMERS PHENOTYPE FOR HUMAN FIBROBLAST K+ CHANNELS	SCIENCE			English	Article							PROTEIN-PRECURSOR; DISEASE; DERIVATIVES	Although beta-amyloid is the main constituent of neurite plaques and may play a role in the pathophysiology of Alzheimer's disease, mechanisms by which soluble beta-amyloid might produce early symptoms such as memory loss before diffuse plaque deposition have not been implicated. Treatment of fibroblasts with beta-amyloid (10 nM) induced the same potassium channel dysfunction previously shown to occur specifically in fibroblasts from patients with Alzheimer's disease-namely, the absence of a 113-picosiemen potassium channel. A tetraethylammonium-induced increase of intracellular concentrations of calcium, [Ca2+]i, a response that depends on functional 113-picosiemen potassium channels. was also eliminated or markedly reduced by 10 nM beta-amyloid. Increased [Ca2+]i induced by high concentrations of extracellular potassium and 166-picosiemen potassium channels were unaffected by 10 nM beta-amyloid. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.	NINCDS,ADAPT SYST LAB,ROOM B205,BLDG 36,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ALKON DL, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0789-42; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BORDEN LA, 1991, NEUROBIOL AGING, V13, P33; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1992, PHARMACOL THERAPEUT, V56, P97, DOI 10.1016/0163-7258(92)90039-3; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Cole G. M., 1993, Society for Neuroscience Abstracts, V19, P1275; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; ETCHEBERRIGARAY R, UNPUB; FRENCH AS, 1988, PROC R SOC SER B-BIO, V232, P395, DOI 10.1098/rspb.1988.0003; Galdzicki Zygmunt, 1993, Society for Neuroscience Abstracts, V19, P397; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; JOHNSTON J, 1993, HUM MOL GENET, V2, P1045, DOI 10.1093/hmg/2.7.1045; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON P, 1993, TRENDS NEUROSCI, V16, P409; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STGEORGEHYSLOP P, COMMUNICATION; TANZI RE, 1992, AM J HUM GENET, V51, P273; TESCO G, 1993, EXP GERONTOL, V28, P51, DOI 10.1016/0531-5565(93)90019-A; Whitson J. S., 1993, Society for Neuroscience Abstracts, V19, P1250; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	34	174	188	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					276	279		10.1126/science.8146663	http://dx.doi.org/10.1126/science.8146663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146663				2022-12-28	WOS:A1994NE41000042
J	HAM, C; MAYNARD, A				HAM, C; MAYNARD, A			MANAGING THE NHS MARKET	BRITISH MEDICAL JOURNAL			English	Article								The purpose of the present NHS reforms is to introduce a managed market; developing some of the incentives for greater efficiency that are often found in markets while still being able to regulate proceedings to prevent market failures. If government intervenes too much there will be no incentive to improve efficiency and streamline operations: too little intervention may result in some areas having inadequate health service cover or monopoly powers abusing their position. Effective management of the NHS market requires eight core elements: openness of information, control of labour and capital markets, regulation of mergers and takeovers, arbitrating in disputes, protection of unprofitable functions such as research and development, overseeing national provision of health services, protection of basic principles of the NHS, and handling of closures and redundancy. Management of the market would best be performed by the NHS management executive and health authority purchasers acting within a framework set by politicians.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV BIRMINGHAM,CTR HLTH SERV MANAGEMENT,BIRMINGHAM B15 2RT,ENGLAND	University of York - UK; University of Birmingham									0	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					845	847		10.1136/bmj.308.6932.845	http://dx.doi.org/10.1136/bmj.308.6932.845			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND243	8167496	Green Published			2022-12-28	WOS:A1994ND24300031
J	COGGON, D; INSKIP, H				COGGON, D; INSKIP, H			IS THERE AN EPIDEMIC OF CANCER .1.	BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI; TESTICULAR CANCER; GASTRIC-CANCER; STOMACH-CANCER; MORTALITY; ENGLAND; WALES; INFECTION; CHILDHOOD; TRENDS	Trends in cancer mortality in England and Wales are dominated by a slowly evolving epidemic of lung cancer attributable to smoking. When the substantial effects of tobacco are discounted there is no evidence that the overall incidence of cancer is rising, but striking trends are apparent for several specific tumours. These may offer important clues to aetiology.			COGGON, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; COGGON D, 1983, THORAX, V38, P721, DOI 10.1136/thx.38.10.721; COGGON D, 1989, J NATL CANCER I, V81, P1178, DOI 10.1093/jnci/81.15.1178; DAVIES JM, 1981, LANCET, V1, P928; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GILLIS CR, 1992, BRIT MED J, V302, P1331; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; Lee JAH, 1982, CANC EPIDEMIOLOGY PR, P984; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MODAN B, 1974, LANCET, V1, P277; NOMURA A, 1991, NEW ENGL J MED, V325, P1170; OSMOND C, 1983, OPCS SERIES DH1, V11; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; SHORE RE, 1976, ARCH ENVIRON HEALTH, V31, P21, DOI 10.1080/00039896.1976.10667184; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; 1992, DOCUMENTS NRPB, V31, P1; 1983, SERIES DH2; [No title captured]	21	16	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					705	708		10.1136/bmj.308.6930.705	http://dx.doi.org/10.1136/bmj.308.6930.705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142798	Green Published			2022-12-28	WOS:A1994NA86900026
J	SLY, PD; CAHILL, P; WILLET, K; BURTON, P				SLY, PD; CAHILL, P; WILLET, K; BURTON, P			ACCURACY OF MINI PEAK FLOW METERS IN INDICATING CHANGES IN LUNG-FUNCTION IN CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess whether mini flow meters used to measure peak expiratory flow can track changes in lung function and indicate clinically important changes. Design-Comparison of measurements with a spirometer and different brands of mini flow meter; the meters were allocated to subjects haphazardly. Subjects-12 boys with asthma aged 11 to 17 attending boarding school. Main outcome measures-Peak expiratory flow measured twice daily for three months with a spirometer and at least one of four brands of mini flow meter. Results-The relation between changes in lung function measured with the spirometer and those measured with the mini flow meters was generally poor. In all, 26 episodes (range 1-3 in an individual child) of clinically important deterioration in lung function were detected from the records obtained with the spirometer. One mini flow meter detected six of 19 episodes, one detected six of 15, one detected six of 18, and one detected three of 21. Conclusions-Not only are the absolute values of peak expiratory flow obtained with mini flow meters inaccurate but the clinical message may also be incorrect. These findings do not imply that home monitoring of peak expiratory flow has no place in the management of childhood asthma but that the values obtained should be interpreted cautiously.	CHRIST CHURCH GRAMMAR SCH MED CTR,PERTH,WA,AUSTRALIA		SLY, PD (corresponding author), WESTERN AUSTRALIA RES INST CHILD HLTH,DIV CLIN SCI,POB D184,PERTH,WA 6001,AUSTRALIA.		Burton, Paul R/H-7527-2016; Sly, Peter D/F-1486-2010	Sly, Peter D/0000-0001-6305-2201				HENRY R, 1991, J PAEDIATR CHILD H, V27, P218, DOI 10.1111/j.1440-1754.1991.tb00395.x; MILLER MR, 1992, THORAX, V47, P904, DOI 10.1136/thx.47.11.904; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; Sly PD, 1992, EUR RESPIR J, V5, p105S; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WOOLCOCK A, 1989, AUSTR ASTHMA MANAGEM	7	90	91	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					572	574		10.1136/bmj.308.6928.572	http://dx.doi.org/10.1136/bmj.308.6928.572			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148680	Green Published			2022-12-28	WOS:A1994MY71400021
J	HYLEK, EM; SINGER, DE				HYLEK, EM; SINGER, DE			RISK-FACTORS FAR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; CEREBRAL AMYLOID ANGIOPATHY; ATRIAL-FIBRILLATION; INTRACEREBRAL HEMATOMAS; STROKE; COMPLICATIONS; PREVENTION; HYPERTENSION; INTENSITIES; POPULATION	Objective: To explore the rational use of anticoagulants, especially among the elderly, balancing antithrombotic efficacy and risk for hemorrhage. Previous prospective studies have not provided powerful assessments of risk factors for intracranial hemorrhage, the dominant complication in reversing the anticoagulant decision. Design: Case-control analysis. Setting: A large general hospital and its anticoagulant therapy unit. Patients: 121 consecutive adult patients taking warfarin who were hospitalized with intracranial hemorrhage were each matched to three contemporaneous controls randomly selected from among outpatients managed by our hospital anticoagulant therapy unit. Results: 77 patients had intracerebral hemorrhage (46% fatal) and 44 had subdural hemorrhage (20% fatal). The prothrombin time ratio (PTR) was the dominant risk factor for intracranial hemorrhage. For each 0.5 increase in PTR over the entire range, the risk for intracerebral hemorrhage doubled (odds ratio, 2.1; 95% CI, 1.4 to 2.9). For subdural hemorrhage, the risk was unchanged over the PTR range from 1.0 to 2.0 but rose dramatically above a PTR of 2.0 (approximate international normalized ratio, 4.0). Age was the only other significant independent risk factor for subdural hemorrhage (odds ratio, 2.0 per decade; CI, 1.3 to 3.1). For intracerebral hemorrhage, age was of borderline significance (odds ratio, 1.3 per decade; CI, 1.0 to 1.6) after controlling for PTR and the two other independent risk factors: history of cerebrovascular disease (odds ratio, 3.1; CI, 1.7 to 5.6) and presence of a prosthetic heart valve (odds ratio, 2.8; CI, 1.3 to 5.8). Conclusions: The results emphasize the importance of maintaining the prothrombin time ratios under 2.0 and the need for especially careful use of warfarin in the elderly.			HYLEK, EM (corresponding author), MASSACHUSETTS GEN HOSP, GEN INTERNAL MED UNIT, BULFINCH 1, BOSTON, MA 02114 USA.			Hylek, Elaine/0000-0001-8263-8304				BRODERICK J, 1993, STROKE, V24, P49, DOI 10.1161/01.STR.24.1.49; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FLEISS JL, 1981, STATISTICAL METHODS, P123; FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HART RG, 1984, STROKE, V15, P779; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HOSMER DW, 1989, APPL LOGISTIC REGRES, P187; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LANDEFELD CS, 1989, AM J MED, V87, P144; LEVINE M, 1986, STROKE, V17, P111, DOI 10.1161/01.STR.17.1.111; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LOELIGER EA, 1982, LANCET, V1, P64; MASUDA J, 1988, STROKE, V19, P205, DOI 10.1161/01.STR.19.2.205; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; MCBRIDE R, 1994, LANCET, V343, P687; MEADE TW, 1990, AM J CARDIOL, V65, pC7, DOI 10.1016/0002-9149(90)90108-D; PETERSEN P, 1989, LANCET, V1, P175; RADBERG JA, 1991, STROKE, V22, P571, DOI 10.1161/01.STR.22.5.571; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P63; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; TURPIE AGG, 1988, LANCET, V1, P1242; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; WHISNANT JP, 1978, ANN NEUROL, V3, P107, DOI 10.1002/ana.410030204; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; WINTZEN AR, 1982, ARCH NEUROL-CHICAGO, V39, P69, DOI 10.1001/archneur.1982.00510140003001; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; 1990, NEW ENGL J MED, V322, P863; 1994, IN PRESS ARCH INTERN	37	742	762	3	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					897	902		10.7326/0003-4819-120-11-199406010-00001	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172435				2022-12-28	WOS:A1994NN11000001
J	KINNEY, HC; KOREIN, J; PANIGRAHY, A; DIKKES, P; GOODE, R				KINNEY, HC; KOREIN, J; PANIGRAHY, A; DIKKES, P; GOODE, R			NEUROPATHOLOGICAL FINDINGS IN THE BRAIN OF QUINLAN,KAREN,ANN - THE ROLE OF THE THALAMUS IN THE PERSISTENT VEGETATIVE STATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSOCIATION CORTEX; CEREBRAL-CORTEX; CARDIAC-ARREST; BEHAVIOR; DESTRUCTION; NETWORK; NEGLECT; INJURY; MONKEY; DEATH	Background. Karen Ann Quinlan had a cardiopulmonary arrest in 1975 and died 10 years later, having never regained consciousness. Her story prompted a national debate about the appropriateness of life-sustaining treatment in patients who are in a persistent vegetative state and led to the development of medicolegal guidelines for the care of such patients. This report describes the neuropathologic features of Quinlan's brain. Methods. The entire brain and spinal cord were systematically sampled for histologic examination. The brain stem and central cerebrum were embedded en bloc and serially sectioned. Three-dimensional computer reconstructions helped visualize the topographic features of the lesions. Results. Contrary to expectation, the most severe damage was not in the cerebral cortex but in the thalamus, and the brain stem was relatively intact. The neuropathological findings included extensive bilateral thalamic scarring, bilateral cortical scars primarily in the occipital pole and parasagittal parieto-occipital region, and bilateral damage to cerebellar and focal-basal-ganglia regions. The brain stem and basal forebrain and the hypothalamic components of the ascending arousal systems and brain-stem regions critical to cardiac and respiratory control were undamaged. The lesions were consistent with hypoxia-ischemia after the cardiopulmonary arrest. Conclusions. Although the neuropathological findings in the case of Karen Ann Quinlan were complex, the disproportionately severe damage in the thalamus as compared with the cerebral cortex supports the hypothesis that the thalamus is critical for cognition and awareness and may be less essential for arousal.	CHILDRENS HOSP, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; NYU, MED CTR, DEPT NEUROL, NEW YORK, NY USA; BELLEVUE HOSP CTR, NEW YORK, NY USA; NEW JERSEY MED EXAMINERS OFF, NEWARK, NJ USA; EDWIN H ALBANO INST FORENS SCI, NEWARK, NJ USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; New York University; Bellevue Hospital Center	KINNEY, HC (corresponding author), CHILDRENS HOSP, DEPT PATHOL, ENDERS BLDG, RM 209, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.				NICHD NIH HHS [P30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRICH MS, 1987, ANN NEUROL, V21, P149, DOI 10.1002/ana.410210207; [Anonymous], 1989, NEUROLOGY, V39, P125; ARENSI C, 1981, ACTA NEUROCHIR WIEN, V59, P45; ARMSTRONG PW, 1988, HASTINGS CENT REP, V18, P37, DOI 10.2307/3562016; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BRIERLEY JB, 1971, LANCET, V2, P560; BRIERLEY JB, 1966, LANCET, V2, P869; CAMBIER J, 1980, REV NEUROL, V136, P105; CASTAIGNE P, 1966, REV NEUROL-FRANCE, V114, P89; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FILIANO JJ, 1992, J NEUROPATH EXP NEUR, V51, P394, DOI 10.1097/00005072-199207000-00002; FOOTE SL, 1987, ANNU REV NEUROSCI, V10, P67, DOI 10.1146/annurev.ne.10.030187.000435; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P727, DOI 10.1001/archneurpsyc.1952.02320240002001; GINSBERG MD, 1976, ARCH NEUROL-CHICAGO, V33, P5, DOI 10.1001/archneur.1976.00500010007002; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; Ingvar D H, 1978, Ann N Y Acad Sci, V315, P184; INGVAR DH, 1970, ARCH NEUROL-CHICAGO, V23, P1; JELLINGER K, 1977, APALLIC SYNDROME, P14; JONES BE, 1990, DIENCEPHALON AND SLEEP, P31; KINNEY H, 1980, J NEUROL SCI, V45, P73, DOI 10.1016/S0022-510X(80)80008-6; Korein J, 1978, Ann N Y Acad Sci, V315, P1, DOI 10.1111/j.1749-6632.1978.tb50324.x; KOREIN J, 1971, CLIN ELECTROENCEPHAL, V2, P178; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LINDENBERG R, 1955, J NEUROPATH EXP NEUR, V14, P223, DOI 10.1097/00005072-195507000-00001; MAMOLI B, 1977, APALLIC SYNDROME, P14; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; Mesulam M. M., 1985, PRINCIPLES BEHAVIORA, P1; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; Olszewski J, 1981, CYTOARCHITECTURE HUM; PLUM F, 1980, CONT NEUROLOGY SERIE, V19, P1; RELKIN NR, 1990, ANN NEUROL, V28, P221; SCHULMAN S, 1957, J NEUROPATH EXP NEUR, V16, P446, DOI 10.1097/00005072-195710000-00002; SELEMON LD, 1988, J NEUROSCI, V8, P4049; SQUIRE LR, 1979, ANN NEUROL, V6, P503, DOI 10.1002/ana.410060607; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WATSON RT, 1981, ARCH NEUROL-CHICAGO, V38, P501, DOI 10.1001/archneur.1981.00510080063009	42	145	150	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1469	1475		10.1056/NEJM199405263302101	http://dx.doi.org/10.1056/NEJM199405263302101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164698	Bronze			2022-12-28	WOS:A1994NM06800001
J	NATHAN, BP; BELLOSTA, S; SANAN, DA; WEISGRABER, KH; MAHLEY, RW; PITAS, RE				NATHAN, BP; BELLOSTA, S; SANAN, DA; WEISGRABER, KH; MAHLEY, RW; PITAS, RE			DIFFERENTIAL-EFFECTS OF APOLIPOPROTEINS E3 AND E4 ON NEURONAL GROWTH IN-VITRO	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; CHOLESTEROL TRANSPORT; CEREBROSPINAL-FLUID; PLASMA-LIPOPROTEINS; RECEPTOR-BINDING; PROTEIN; REGENERATION; APOPROTEIN; BRAIN	Apolipoprotein E4 (apoE4), one of the three common isoforms of apoE, has been implicated in Alzheimer's disease. The effects of apoE on neuronal growth were determined in cultures of dorsal root ganglion neurons. In the presence of beta-migrating very low density lipoproteins (beta-VLDL), apoE3 increased neurite outgrowth, whereas apoE4 decreased outgrowth. The effects of apoE3 or apoE4 in the presence of beta-VLDL were prevented by incubation with a monoclonal antibody to apoE or by reductive methylation of apoE, both of which block the ability of apoE to interact with lipoprotein receptors. The data suggest that receptor-mediated binding or internalization (or both) of apoE-enriched beta-VLDL leads to isoform-specific differences in interactions with cellular proteins that affect neurite outgrowth.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes			Bellosta, Stefano/B-4473-2010	Bellosta, Stefano/0000-0001-5344-7824	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1982, J BIOL CHEM, V257, P9788; BELLOSTA S, UNPUB; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS HK, 1985, J BIOL CHEM, V260, P6240; DELREE P, 1989, J NEUROSCI RES, V23, P198, DOI 10.1002/jnr.490230210; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; JI ZS, 1994, J BIOL CHEM, V269, P2764; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BE, UNPUB; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	37	744	756	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					850	852		10.1126/science.8171342	http://dx.doi.org/10.1126/science.8171342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171342				2022-12-28	WOS:A1994NJ94900036
J	TURNER, CA; MACK, DH; DAVIS, MM				TURNER, CA; MACK, DH; DAVIS, MM			BLIMP-1, A NOVEL ZINC FINGER-CONTAINING PROTEIN THAT CAN DRIVE THE MATURATION OF B-LYMPHOCYTES INTO IMMUNOGLOBULIN-SECRETING CELLS	CELL			English	Article							MESSENGER-RNA; J-CHAIN; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; GENE; EXPRESSION; SEQUENCE; KRUPPEL; FAMILY	We describe a novel gene, Blimp-1 (for B lymphocyte-induced maturation protein), transcripts of which are rapidly induced during the differentiation of B lymphocytes into immunoglobulin secretory cells and whose expression is characteristic of late B and plasma cell lines. The 856 amino acid open reading frame contains five Kruppel-type zinc finger motifs and proline-rich and acidic regions similar to those of known transcription factors. Serological studies show an similar to 100 kd protein that localizes to the nucleus. Stable or transient transfection of Blimp-1 into B cell lymphoma lines leads to the expression of many of the phenotypic changes associated with B cell differentiation into an early plasma cell stage, including induction of J chain message and immunoglobulin secretion, up-regulation of Syndecan-1, and increased cell size and granularity. Thus, Blimp-1 appears to be a pleiotropic regulatory factor capable of at least partially driving the terminal differentiation of B cells.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University				Davis, Mark/0000-0001-6868-657X	NIAID NIH HHS [AI-19512] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANZE A, 1991, GENOMICS, V9, P728, DOI 10.1016/0888-7543(91)90367-N; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HANLEYHYDE JM, 1986, ANNU REV IMMUNOL, V4, P621, DOI 10.1146/annurev.iy.04.040186.003201; HARLOW E, 1988, ANTIBODIES LABORATOR; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOY MV, 1993, CELL, V72, P587; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KIM KJ, 1979, J IMMUNOL, V122, P549; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LASKOV R, 1981, EUR J IMMUNOL, V11, P462, DOI 10.1002/eji.1830110605; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LIN KH, 1991, BIOTECHNIQUES, V11, P748; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI K, 1989, J IMMUNOL, V142, P2918; MELCHERS F, 1976, COLD SPRING HARB SYM, V41, P147; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RANDALL TD, 1992, EUR J IMMUNOL, V4, P171; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WALL R, 1977, ANAL BIOCHEM, V82, P115, DOI 10.1016/0003-2697(77)90140-3; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	60	623	660	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					297	306		10.1016/0092-8674(94)90321-2	http://dx.doi.org/10.1016/0092-8674(94)90321-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168136				2022-12-28	WOS:A1994NH63400014
J	WOOD, JB; HILLS, E; KETO, FJK				WOOD, JB; HILLS, E; KETO, FJK			HANDS ACROSS THE EQUATOR - THE HEREFORD-MUHEZA LINK 8 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article								Short elective sabbatical visits have been arranged between Herefordshire Health Authority in England and Muheza Health District in Tanzania over the past eight years. Any employee can apply, and the 64 who have participated include midwives, physiotherapists, engineers, and nurse tutors. The possibility of being chosen adds to the attractiveness of working in both districts, and costs have been small. The visits are believed to have led to new ideas and a willingness and confidence to consider change.	HOSP TEULE,MUHEZA,TANZANIA		WOOD, JB (corresponding author), CTY HOSP,HEREFORD HR1 2ER,ENGLAND.							MOORE B, 1991, MATURITAS, V13, P229, DOI 10.1016/0378-5122(91)90197-X; MOORE B, 1987, LANCET, V2, P331; WOOD JB, 1988, BRIT MED J, V297, P604, DOI 10.1136/bmj.297.6648.604	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1029	1032		10.1136/bmj.308.6935.1029	http://dx.doi.org/10.1136/bmj.308.6935.1029			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167519	Green Published			2022-12-28	WOS:A1994NH08900027
J	GABAY, JE				GABAY, JE			UBIQUITOUS NATURAL ANTIBIOTICS	SCIENCE			English	Editorial Material							PERMEABILITY-INCREASING PROTEIN; ANTIBACTERIAL PEPTIDES; AMINO; IMMUNITY				GABAY, JE (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INFECT DIS,1300 YORK AVE,NEW YORK,NY 10021, USA.							AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; BEVINS CL, IN PRESS CIBA F S, P186; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MANNION BA, 1990, J CLIN INVEST, V85, P853, DOI 10.1172/JCI114512; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	14	111	126	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					373	374		10.1126/science.8153623	http://dx.doi.org/10.1126/science.8153623			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153623				2022-12-28	WOS:A1994NG19400026
J	FLING, SP; ARP, B; PIOUS, D				FLING, SP; ARP, B; PIOUS, D			HLA-DMA AND HLA-DMB GENES ARE BOTH REQUIRED FOR MHC CLASS-II PEPTIDE COMPLEX-FORMATION IN ANTIGEN-PRESENTING CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; MONOCLONAL-ANTIBODY; PROCESSING MUTANT; DR MOLECULES; EXPRESSION; POPULATIONS; REGION; VECTOR; LINE	MAJOR histocompatibility complex (MHC) class II molecules are highly polymorphic cell-surface glycoproteins that present antigenic peptides to CD4+ T lymphocytes. The normal assembly of class II molecules with cognate peptides for antigen presentation requires an accessory function provided by a gene mapping to the class II region of the HLA complex1,2. The isolation of somatic cell mutants of antigen-presenting cells (APC) has shown that at least one gene which maps between HLA-DP and HLA-DQ, provisionally designated c2p-1 (ref. 3), mediates this process1,2,4. Here we describe a unique new mutant 2.2.93, which manifests defective formation of class II/peptide complexes like that described in c2p-1 mutants. We show that (1) mutant 2.2.93 contains a mutation in HLA-DMA5, and a representative c2p-1 mutant, 9.5.3, contains a mutation in HLA-DMB5; and (2) transfection and expression of DMA complementary DNA in 2.2.93, and DMB cDNA in 9.5.3, reverses their mutant phenotypes. These results show that HLA-DMA and -DMB, genes of previously unknown function mapping between HLA-DP and HLA-DQ5, are required for the normal assembly of peptides with MHC class II molecules. They suggest that HLA-DMA and -DMB encode subunits of a functional heterodimer which is critical in the pathway of class II antigen presentation.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ANTONELLI P, 1984, HUM IMMUNOL, V11, P11, DOI 10.1016/0198-8859(84)90052-1; BODMER JG, 1985, HISTOCOMPATIBILITY T; CAMPBELL DR, 1993, IMMUNOL TODAY, V14, P349; CEMAN S, 1992, J IMMUNOL, V149, P754; CLARK EA, 1989, J IMMUNOL, V143, P3873; CLARK EA, 1984, LEUCOCYTE TYPING; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JOHNSON JP, 1982, J EXP MED, V156, P104, DOI 10.1084/jem.156.1.104; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KONING F, 1984, HUM IMMUNOL, V9, P221, DOI 10.1016/0198-8859(84)90027-2; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LEVINE F, 1985, J IMMUNOL, V134, P637; LEVINE F, 1985, P NATL ACAD SCI USA, V82, P3741, DOI 10.1073/pnas.82.11.3741; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PIOUS D, 1985, J EXP MED, V162, P1193, DOI 10.1084/jem.162.4.1193; PIOUS D, 1977, IMMUNOGENETICS, V4, P437, DOI 10.1007/BF01575679; PIOUS D, IN PRESS ANTIGEN PRO; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; VIKEN HD, 1989, TISSUE ANTIGENS, V34, P250, DOI 10.1111/j.1399-0039.1989.tb02100.x	30	282	283	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					554	558		10.1038/368554a0	http://dx.doi.org/10.1038/368554a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139690				2022-12-28	WOS:A1994NE33500057
J	TAX, FE; YEARGERS, JJ; THOMAS, JH				TAX, FE; YEARGERS, JJ; THOMAS, JH			SEQUENCE OF C-ELEGANS LAG-2 REVEALS A CELL-SIGNALING DOMAIN SHARED WITH DELTA AND SERRATE OF DROSOPHILA	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; EGF-LIKE REPEATS; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; HOMOLOGOUS GENES; NEUROGENIC GENE; LIN-12; GLP-1; ENCODES; NOTCH	THE lin-12 and glp-1 genes of Caenorhabditis elegans encode members of the Notch family of transmembrane proteins(1,2). Genetic studies indicate that the lin-12 and glp-1 proteins act as receptors in specific developmental cell interactions(3-6) and that their functions are partially redundant(7). lin-12 glp-1 double mutants display certain embryonic defects not found in either single mutant(7,8). The phenotype of this double mutant is called Lag, and recessive mutations in either of the genes lag-1 or lag-2 can also result in the Lag phenotype(7), indicating that these two genes may participate in the same cell interactions that require lin-12 or glp-1. We report here that lag-2 encodes a predicted transmembrane protein of 402 amino acids. The predicted extracellular region of lag-2 is similar to amino-terminal regions of Delta and Serrate, two Drosophila proteins that are thought to function as ligands for Notch(9-14). The region of similarity includes sequences related to epidermal growth factor (EGF) repeats. We have isolated lag-2(sa37), a dominant allele that shows specific genetic interactions with lin-12. The sa37 mutation causes a Gly-->Asp change in a conserved residue of an EGF motif. Because of its overall structure, its sequence similarity to Delta and Serrate, and its genetic interactions, ne suggest that lag-2 encodes an intercellular signal for the lin-12 and glp-1 receptors.			TAX, FE (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.			Tax, Frans/0000-0002-1386-3310				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DELONG L, 1987, GENETICS, V117, P657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; JOHNSEN RC, 1991, GENETICS, V129, P735; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLUTH RE, 1981, GENETICS, V99, P415; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	31	232	263	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					150	154		10.1038/368150a0	http://dx.doi.org/10.1038/368150a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139658				2022-12-28	WOS:A1994NA03000067
J	JONES, HW; TONER, JP				JONES, HW; TONER, JP			THE INFERTILE COUPLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GAMETE INTRAFALLOPIAN TRANSFER; FOLLICLE-STIMULATING-HORMONE; ENDOMETRIOSIS-ASSOCIATED INFERTILITY; POST-COITAL TEST; INVITRO FERTILIZATION; INTRAUTERINE INSEMINATION; UNEXPLAINED INFERTILITY; PREGNANCY RATES; POSTCOITAL TEST; WOMEN				JONES, HW (corresponding author), EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, JONES INST REPROD MED, 601 COLLEY AVE, NORFOLK, VA 23501 USA.			Toner, James/0000-0002-1401-7722				Acosta A A, 1989, Obstet Gynecol Surv, V44, P1, DOI 10.1097/00006254-198901000-00001; ACOSTA AA, 1992, HUM REPROD, V7, P1067, DOI 10.1093/oxfordjournals.humrep.a137794; ARAL SO, 1983, JAMA-J AM MED ASSOC, V250, P2327, DOI 10.1001/jama.250.17.2327; BALASCH J, 1992, HUM REPROD, V7, P973, DOI 10.1093/oxfordjournals.humrep.a137782; BELSEY MA, 1986, INFERTILITY MALE FEM, P631; CHECK JH, 1990, FERTIL STERIL, V53, P811; CODDINGTON CC, 1992, FERTIL STERIL, V57, P783; COLLINS JA, 1983, NEW ENGL J MED, V309, P1201, DOI 10.1056/NEJM198311173092001; COLLINS JA, 1984, FERTIL STERIL, V41, P703; DEATON JL, 1990, FERTIL STERIL, V54, P1083; DIAMOND MP, 1991, 46TH ANN M AM FERT S, pS1; DODSON WC, 1987, FERTIL STERIL, V48, P441; FRIBERG J, 1980, FERTIL STERIL, V33, P351; FRIEDMAN AJ, 1991, FERTIL STERIL, V55, P1005; GINDOFF PR, 1986, FERTIL STERIL, V46, P989; GOLDENBERG M, 1991, J IN VITRO FERTIL EM, V8, P336, DOI 10.1007/BF01133024; GREENHALL E, 1990, FERTIL STERIL, V54, P978; Greenhill JP, 1937, AM J OBSTET GYNECOL, V33, P39, DOI 10.1016/S0002-9378(15)32741-1; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; HALME J, 1991, ANN NY ACAD SCI, V622, P266; HARTZ SC, 1991, FERTIL STERIL, V55, P14; Hassiakos D K, 1991, Va Med Q, V118, P26; HIRSCH MB, 1987, FERTIL STERIL, V47, P618; HOLST N, 1991, FERTIL STERIL, V55, P140; HUGGINS GR, 1992, JAMA-J AM MED ASSOC, V268, P384; HUGHES EG, 1992, FERTIL STERIL, V57, P275; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; HULL MGR, 1982, BRIT J OBSTET GYNAEC, V89, P299, DOI 10.1111/j.1471-0528.1982.tb04700.x; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; JONES HW, 1990, FERTIL STERIL, V53, P780; KARAMARDIAN LM, 1992, AM J OBSTET GYNECOL, V167, P1391, DOI 10.1016/S0002-9378(11)91724-4; KATAYAMA KP, 1979, AM J OBSTET GYNECOL, V135, P207, DOI 10.1016/0002-9378(79)90345-4; KAUFMANN RA, 1992, J REPROD MED, V37, P428; KERIN JF, 1992, FERTIL STERIL, V57, P731; KOVACS GT, 1978, BRIT MED J, V1, P818, DOI 10.1136/bmj.1.6116.818; KRUGER TF, 1986, FERTIL STERIL, V46, P1118; MOGHISSI KS, 1983, FERTIL STERIL, V39, P5; MOSHER WD, 1985, DEMOGRAPHY, V22, P415, DOI 10.2307/2061069; MOSHER WD, 1990, DHHS PHS911250 PUBL; OEHNINGER S, 1992, AM J OBSTET GYNECOL, V167, P1760, DOI 10.1016/0002-9378(92)91772-3; OEHNINGER S, 1991, AM J OBSTET GYNECOL, V164, P1210, DOI 10.1016/0002-9378(91)90684-J; OLIVE DL, 1987, FERTIL STERIL, V48, P18; PAGE H, 1989, FERTIL STERIL, V51, P571; PANG S, 1985, J CLIN ENDOCR METAB, V60, P428, DOI 10.1210/jcem-60-3-428; RISI GF, 1989, OBSTET GYN CLIN N AM, V16, P611; SCHLAFF WD, 1990, FERTIL STERIL, V54, P984; SCOTT RT, 1989, FERTIL STERIL, V51, P651; STANTON AL, 1991, INFERTILITY PERSPECT; TANBO T, 1990, HUM REPROD, V5, P266, DOI 10.1093/oxfordjournals.humrep.a137086; TONER JP, 1991, FERTIL STERIL, V55, P784; TONER JP, 1991, HUM REPROD, V6, P284, DOI 10.1093/oxfordjournals.humrep.a137323; VANDERMERWE JP, 1990, FERTIL STERIL, V53, P682; WALTERS L, 1987, HASTINGS CENT REP, V17, P3; WENTZ AC, 1993, JAMA-J AM MED ASSOC, V269, P46, DOI 10.1001/jama.1993.03500010056023; WENTZ AC, 1992, FERTILITY NEWS, V26, P4; WESSELS PH, 1991, FERTIL STERIL, V56, P485; WILCOX L, 1993, 48TH ANN M AM FERT S, pS138; 1990, NIH901008 CTR POP RE; 1982, VITAL HLTH STAT, V23, P1; 1987, DONUM VITAE DON VIE; 1992, STATE FORUM, V3, P1	61	61	62	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1710	1715		10.1056/NEJM199312023292307	http://dx.doi.org/10.1056/NEJM199312023292307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8166801				2022-12-28	WOS:A1993MJ70700007
J	BLACK, HS; HERD, JA; GOLDBERG, LH; WOLF, JE; THORNBY, JI; ROSEN, T; BRUCE, S; TSCHEN, JA; FOREYT, JP; SCOTT, LW; JAAX, S; ANDREWS, K				BLACK, HS; HERD, JA; GOLDBERG, LH; WOLF, JE; THORNBY, JI; ROSEN, T; BRUCE, S; TSCHEN, JA; FOREYT, JP; SCOTT, LW; JAAX, S; ANDREWS, K			EFFECT OF A LOW-FAT DIET ON THE INCIDENCE OF ACTINIC KERATOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOLAR KERATOSES; SKIN-CANCER; EXPOSURE; HEALTH	Background. Actinic keratoses are premalignant lesions and are a sensitive and important manifestation of sun-induced skin damage. Studies in animals have shown that dietary fat influences the incidence of sun-induced skin cancer, but the effect of diet on the incidence of actinic keratosis in humans is not known. Methods. We randomly assigned 76 patients with nonmelanoma skin cancer either to continue their usual diet (control group) or to eat a diet with 20 percent of total caloric intake as fat (dietary-intervention group). For 24 months, the patients were examined for the presence of new actinic keratoses by physicians unaware of their assigned diets. Results. At base line, the mean (+/-SD) percentage of caloric intake as fat was 40+/-4 percent in the control group and 39+/-3 percent in the dietary-intervention group. After 4 months of dietary therapy the percentage of calories as fat had decreased to 21 percent in the dietary-intervention group, and it remained below this level throughout the 24-month study period. The percentage of calories as fat in the control group did not fall below 36 percent at any time. The cumulative number of new actinic keratoses per patient from months 4 through 24 was 10+/-13 in the control group and 3+/-7 in the dietary-intervention group (P = 0.001). Conclusions In patients with a history of nonmelanoma skin cancer, a low-fat diet reduces the incidence of actinic keratosis.	BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	BLACK, HS (corresponding author), VET AFFAIRS MED CTR,BLDG 109,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Goldberg, Leonard/AGR-0657-2022		NATIONAL CANCER INSTITUTE [R01CA044383] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN CARL A., 1939, AMER JOUR CANCER, V35, P213; Black H S, 1983, Nutr Cancer, V5, P59, DOI 10.1080/01635588309513780; BLACK HS, 1985, CANCER RES, V45, P6254; BLACK HS, 1992, PHOTOCHEM PHOTOBIOL, V56, P195, DOI 10.1111/j.1751-1097.1992.tb02147.x; CALLEN JP, 1991, CANCER SKIN, P22; CONNOR W E, 1972, Preventive Medicine, V1, P49, DOI 10.1016/0091-7435(72)90077-1; DENNIS B, 1980, J AM DIET ASSOC, V77, P641; DOLL R, 1992, CANCER RES, V52, pS2024; ENGEL A, 1988, ARCH DERMATOL, V124, P72, DOI 10.1001/archderm.124.1.72; FOREYT JP, 1984, PROG BEHAV MODIFIC, V16, P231; FOREYT JP, 1984, ENCY PSYCHOL, V1, P231; FREEDMAN LS, 1990, CANCER RES, V50, P5710; GRAHAM JH, 1966, ADV BIOL SKIN CARCIN, V7, P277; GRAHAM S, 1983, CANCER RES, V43, P2409; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HENDERSON MM, 1992, CANCER RES, V52, pS2030; HIGGINSON J, 1976, CANCER DETECT PREV, V1, P79; HURSTING SD, 1990, PREV MED, V19, P242, DOI 10.1016/0091-7435(90)90025-F; JOHNSON MLT, 1978, DHEW PHS791660 PUBL; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P489; LYON JL, 1983, CANCER RES S, V43, pS232; MACKIE RM, 1992, TXB DERMATOLOGY, V2, P1477; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1988, ARCH DERMATOL, V124, P1039, DOI 10.1001/archderm.124.7.1039; MARKS R, 1990, BRIT J DERMATOL, V122, P49, DOI 10.1111/j.1365-2133.1990.tb16125.x; PATHAK MA, 1993, DERMATOLOGY GENERAL, V1, P1689; Ponsford M W, 1983, Australas J Dermatol, V24, P79, DOI 10.1111/j.1440-0960.1983.tb00256.x; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; SCOTTO J, 1980, NCI NIH802154 PUBL; Sternberg B, 1985, RELAPSE PREVENTION M, P521; VITALIANO PP, 1978, AM J EPIDEMIOL, V108, P402, DOI 10.1093/oxfordjournals.aje.a112638; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; WEISBURGER JH, 1977, ORIGINS HUMAN CANCER, V4, P567; WELSCH CW, 1992, CANCER RES, V52, pS2040; [No title captured]; 1990, SAS P200 SAS I REP	36	123	124	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1272	1275		10.1056/NEJM199405053301804	http://dx.doi.org/10.1056/NEJM199405053301804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145782	Bronze			2022-12-28	WOS:A1994NJ51200004
J	MEYER, TJ; HILL, NS				MEYER, TJ; HILL, NS			NONINVASIVE POSITIVE PRESSURE VENTILATION TO TREAT RESPIRATORY-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Review							OBSTRUCTIVE SLEEP-APNEA; CHRONIC ALVEOLAR HYPOVENTILATION; DUCHENNE MUSCULAR-DYSTROPHY; NOCTURNAL NASAL VENTILATION; MECHANICAL VENTILATION; PULMONARY-DISEASE; NEUROMUSCULAR DISEASE; SUPPORT VENTILATION; FACE MASK; BODY RESPIRATORS	Purpose: To review the clinical use of noninvasive positive pressure ventilation, including its efficacy with acute and chronic forms of respiratory failure, its mechanism of action, and its implementation. Data Sources: Studies were identified through a MEDLINE search using the keywords respiratory failure and mechanical ventilation and through a manual review of reference lists of published articles. Study Selection: All original studies relating to the use of noninvasive positive pressure ventilation in respiratory failure were included. Because of the paucity of controlled trials, cohort studies were not excluded. Data Extraction: Study design, numbers and diagnoses of patients, ventilator modes, and success and complication rates were extracted and compiled. Results: For acute respiratory failure, studies report improved gas exchange and avoidance of intubation in 60% to 80% of patients with chronic obstructive pulmonary disease, restrictive thoracic disease, congestive heart failure, pneumonia, or postoperative extubation failure. However, the patients were highly selected, and relatively few studies have been published, only one of which was a randomized controlled trial. For chronic respiratory failure due to restrictive thoracic disease, all studies report improved gas exchange and symptoms of hypoventilation after prolonged nocturnal use, although no study was controlled. Some cohort studies of patients with severe chronic obstructive pulmonary disease yielded favorable results, but longer-term, randomized, controlled studies showed minimal, if any, benefit. Conclusion: Noninvasive positive pressure ventilation is effective in the treatment of chronic respiratory failure due to restrictive thoracic diseases. The routine use of such treatment for chronic respiratory failure due to chronic obstructive pulmonary disease and for acute respiratory failure needs to be studied in randomized controlled trials in better-defined patient subsets.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA	Brown University					NHLBI NIH HHS [HL-45050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBA A, 1984, REHABILITATION GAZET, V24, P47; AMBROSINO N, 1990, EUR RESPIR J, V3, P502; AMBROSINO N, 1992, CHEST, V101, P385, DOI 10.1378/chest.101.2.385; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; BACH JR, 1987, CHEST, V92, P168, DOI 10.1378/chest.92.1.168; BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BACH JR, 1987, CHEST, V91, P859, DOI 10.1378/chest.91.6.859; BARACH AL, 1950, B NEW YORK ACAD MED, V26, P370; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERGOFSKY EH, 1979, AM REV RESPIR DIS, V119, P643; BERTHONJONES M, 1987, AM REV RESPIR DIS, V135, P144; BLITZER B, DIRECTORY SOURCES VE; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BRANTHWAITE MA, 1991, THORAX, V46, P208, DOI 10.1136/thx.46.3.208; BRAUN N M T, 1984, Chest, V85, p59S, DOI 10.1378/chest.85.6_Supplement.59S-a; BRAUN NMT, 1988, CLIN CHEST MED, V9, P153; BRAUN NMT, 1987, AM REV RESPIR DIS, V135, P523; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRYANT LR, 1967, J AMER MED ASSOC, V199, P149; CARREY Z, 1990, CHEST, V97, P150, DOI 10.1378/chest.97.1.150; CARROLL N, 1988, THORAX, V43, P349, DOI 10.1136/thx.43.5.349; CELLI B, 1989, AM REV RESPIR DIS, V140, P1251, DOI 10.1164/ajrccm/140.5.1251; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; COLLIER CR, 1954, J APPL PHYSIOL, V6, P531, DOI 10.1152/jappl.1954.6.9.531; CROPP A, 1987, AM REV RESPIR DIS, V135, P1056; CULLEN JH, 1957, AM REV TUBERC PULM, V76, P33; CURRAN FJ, 1981, ARCH PHYS MED REHAB, V62, P270; CURTIS JK, 1968, J AMER MED ASSOC, V206, P1037, DOI 10.1001/jama.1968.03150050025004; DIMARCO AF, 1987, CHEST, V92, P952, DOI 10.1378/chest.92.5.952; Drinker P, 1929, J CLIN INVEST, V7, P229, DOI 10.1172/JCI100226; ELLIOTT M, 1990, American Review of Respiratory Disease, V141, pA322; ELLIOTT MW, 1991, EUR RESPIR J, V4, P1044; ELLIS ER, 1987, AM REV RESPIR DIS, V136, P188, DOI 10.1164/ajrccm/136.1.188; ELLIS ER, 1987, AM REV RESPIR DIS, V135, P148; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; Emerson JH, 1978, EVOLUTION IRON LUNGS; Eve FC, 1932, LANCET, V2, P995; FRAIMOW W, 1960, AM REV RESPIR DIS, V81, P815; GAIL DB, 1990, AM REV RESPIR DIS, V142, P474; GARAY SM, 1981, AM J MED, V70, P269, DOI 10.1016/0002-9343(81)90761-0; GAY PC, 1991, MAYO CLIN PROC, V66, P695, DOI 10.1016/S0025-6196(12)62081-3; GOGLIO C, 1992, CHEST, V101, P1533; GOLDSTEIN RS, 1987, AM REV RESPIR DIS, V135, P1049; GOLDSTEIN RS, 1991, CHEST, V99, P408, DOI 10.1378/chest.99.2.408; GRENVIK A, 1980, International Anesthesiology Clinics, V18, P1; GUTIERREZ M, 1988, AM REV RESPIR DIS, V138, P617, DOI 10.1164/ajrccm/138.3.617; HECKMATT JZ, 1990, LANCET, V335, P579, DOI 10.1016/0140-6736(90)90357-B; HILL NS, 1992, AM REV RESPIR DIS, V145, P365, DOI 10.1164/ajrccm/145.2_Pt_1.365; HILL NS, 1986, CHEST, V90, P897, DOI 10.1378/chest.90.6.897; HILL NS, 1992, CHEST, V102, P1656, DOI 10.1378/chest.102.6.1656; HODSON ME, 1991, EUR RESPIR J, V4, P524; HOEPPNER VH, 1984, AM REV RESPIR DIS, V129, P240; HOO GWS, 1991, AM REV RESPIR DIS, V143, pA79; HYLAND RH, 1981, AM REV RESPIR DIS, V124, P180; KACMAREK R M, 1988, Respiratory Care, V33, P99; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; LASSEN HCA, 1953, LANCET, V264, P37; LEGER P, 1989, Respiratory Care, V34, P73; LEVY RD, 1989, CHEST, V95, P95, DOI 10.1378/chest.95.1.95; MACINTYRE NR, 1986, CHEST, V89, P677, DOI 10.1378/chest.89.5.677; MACKLEM PT, 1990, AM REV RESPIR DIS, V142, P274, DOI 10.1164/ajrccm/142.2.274; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; MILLMAN RP, 1988, AM J RHINOL, V2, P177; MOHR CH, 1990, CHEST, V97, P91, DOI 10.1378/chest.97.1.91; NAVA S, 1993, CHEST, V103, P143, DOI 10.1378/chest.103.1.143; OLSEN KD, 1990, MAYO CLIN PROC, V65, P1095, DOI 10.1016/S0025-6196(12)62722-0; PENNOCK BE, 1991, CHEST, V100, P1371, DOI 10.1378/chest.100.5.1371; PIPER AJ, 1992, CHEST, V102, P846, DOI 10.1378/chest.102.3.846; PLUM F, 1951, NEW ENGL J MED, V245, P235, DOI 10.1056/NEJM195108162450701; PLUM F, 1951, AM J MED SCI, V221, P417, DOI 10.1097/00000441-195104000-00009; RIDEAU Y, 1986, 4TH INT C NEUR DIS L, V9, P55; ROCHESTER DF, 1977, AM J MED, V63, P223, DOI 10.1016/0002-9343(77)90236-4; ROCHESTER DF, 1988, AM REV RESPIR DIS, V138, P516, DOI 10.1164/ajrccm/138.3.516; RODENSTEIN DO, 1989, EUR RESPIR J, V2, P473; ROUSSOS C, 1985, CHEST, V88, pS124, DOI 10.1378/chest.88.2.124S; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SANDERS MH, 1990, CHEST, V98, P317, DOI 10.1378/chest.98.2.317; SCANO G, 1990, CHEST, V97, P322, DOI 10.1378/chest.97.2.322; SCHARF SM, 1978, AM REV RESPIR DIS, V117, P391; SEIKER HO, 1956, AM REV TUBERC, V74, P309; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SPLAINGARD ML, 1985, ARCH PHYS MED REHAB, V66, P239, DOI 10.1016/0003-9993(85)90157-1; SPLAINGARD ML, 1983, CHEST, V84, P376, DOI 10.1378/chest.84.4.376; STAUFFER JL, 1982, RESPIR CARE, V27, P417; STERNBURG L, 1986, VIEW SEESAW; STROHL KP, 1980, J APPL PHYSIOL, V49, P638, DOI 10.1152/jappl.1980.49.4.638; STRUMPF D A, 1990, Respiratory Care, V35, P415; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; STRUMPF DA, 1990, CHEST, V98, P474, DOI 10.1378/chest.98.2.474; SULLIVAN CE, 1981, LANCET, V1, P862; SURATT PM, 1986, CHEST, V90, P324, DOI 10.1378/chest.90.3.324; UDWADIA ZF, 1992, THORAX, V47, P715, DOI 10.1136/thx.47.9.715; WALDHORN RE, 1992, CHEST, V101, P516, DOI 10.1378/chest.101.2.516; WEINGARTEN WS, 1978, REHABILITATION GAZET, V21, P34; WIERS PWJ, 1977, THORAX, V32, P221, DOI 10.1136/thx.32.2.221; WOOLLAM CHM, 1976, ANAESTHESIA, V31, P666, DOI 10.1111/j.1365-2044.1976.tb11849.x; WOOLLAM CHM, 1976, ANAESTHESIA, V31, P537, DOI 10.1111/j.1365-2044.1976.tb12364.x; ZIBRAK JD, 1988, AM REV RESPIR DIS, V138, P1515, DOI 10.1164/ajrccm/138.6.1515; 1983, CHEST, V84, P76	103	146	152	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					760	770		10.7326/0003-4819-120-9-199405010-00008	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147550				2022-12-28	WOS:A1994NH25100008
J	BERLIN, A; WAGSTAFF, R; BHOPAL, R; SPENCER, J				BERLIN, A; WAGSTAFF, R; BHOPAL, R; SPENCER, J			POSTMORTEM EXAMINATIONS - GENERAL-PRACTITIONERS KNOWLEDGE, BEHAVIOR, AND ATTITUDES	BRITISH MEDICAL JOURNAL			English	Article							NECROPSIES		UNIV NEWCASTLE UPON TYNE,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,ENGLAND; MED SCH NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH MED,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK								MCPHEE SJ, 1986, AM J MED, V80, P665, DOI 10.1016/0002-9343(86)90822-3; PUXTY JAH, 1983, LANCET, V1, P1262; SLAVIN G, 1991, AUTOPSY AUDIT REPORT; WHITTY P, 1991, BRIT MED J, V303, P1244, DOI 10.1136/bmj.303.6812.1244; 1971, COMMITTEE DEATH CERT	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1080	1081		10.1136/bmj.308.6936.1080	http://dx.doi.org/10.1136/bmj.308.6936.1080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173429	Green Published			2022-12-28	WOS:A1994NH48900024
J	JAMESON, BA; MCDONNELL, JM; MARINI, JC; KORNGOLD, R				JAMESON, BA; MCDONNELL, JM; MARINI, JC; KORNGOLD, R			A RATIONALLY DESIGNED CD4 ANALOG INHIBITS EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS	NATURE			English	Article							MONOCLONAL-ANTIBODY	EXPERIMENTAL allergic encephalomyelitis (EAE) is an acute inflammatory autoimmune disease of the central nervous system that can be elicited in rodents and is the major animal model for the study of multiple sclerosis (MS)(1,2). The pathogenesis of both EAE and MS directly involves the CD4(+) helper T-cell subset(3-5) Anti-CD4 monoclonal antibodies inhibit the development of EAE in rodents(6-9), and are currently being used in human clinical trials for MS. We report here that similar therapeutic effects can be achieved in mice using a small (rationally designed) synthetic analogue of the CD4 protein surface. It greatly inhibits both clinical incidence and severity of EAE with a single injection, but does so without depletion of the CD4(+) subset and without the inherent immunogenicity of an antibody. Furthermore, this analogue is capable of exerting its effects on disease even after the onset of symptoms.			JAMESON, BA (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA.			McDonnell, James/0000-0001-9037-2980				BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERNARD CCA, 1976, EUR J IMMUNOL, V6, P655, DOI 10.1002/eji.1830060912; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; ONEILL JK, 1993, NEUROIMMUNOLOGY, V45, P1; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; SRIRAM S, 1986, J IMMUNOL, V136, P4464; SU CM, 1991, HORM METAB RES, V23, P15, DOI 10.1055/s-2007-1003601; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574	14	134	202	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					744	746		10.1038/368744a0	http://dx.doi.org/10.1038/368744a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152486				2022-12-28	WOS:A1994NG55300059
J	HARRIS, B; LOVETT, L; NEWCOMBE, RG; READ, GF; WALKER, R; RIADFAHMY, D				HARRIS, B; LOVETT, L; NEWCOMBE, RG; READ, GF; WALKER, R; RIADFAHMY, D			MATERNITY BLUES AND MAJOR ENDOCRINE CHANGES - CARDIFF PUERPERAL MOOD AND HORMONE STUDY .2.	BRITISH MEDICAL JOURNAL			English	Article							SALIVARY CORTISOL DETERMINATIONS; DEXAMETHASONE SUPPRESSION TEST; POST PARTUM; PROGESTERONE; PLASMA; METABOLITES; CHILDBIRTH; ESTRADIOL	Objectives-To define relation between mood and concentrations of progesterone and cortisol during perinatal period to test hypothesis that rapid physiological withdrawal of steroid hormones after delivery is associated with depression. Design-Prospective study of Primiparous women from two weeks before expected date of delivery to 35 days postpartum. Setting-Antenatal clinic in university hospital, obstetric inpatient unit, patients' homes. Subjects-120 of 156 primiparous women interviewed. Remainder excluded because of major marital, socioeconomic, or medical problems or because caesarean section required. Main outcome measures-Concentrations of progesterone and cortisol in saliva samples; women's moods assessed by various scores for depression. Results-Changes in salivary progesterone and cortisol concentrations were similar to those already characterised for plasma. Peak mean score for maternity blues (5.3 on Stein scale) was on day five postpartum (P < 0.02 compared with mean scores on other postpartum days). High postpartum scores for maternity blues were associated with high antenatal progesterone concentrations on day before delivery (P < 0.05), with high rate of rise of antenatal progesterone concentrations (P<0.05), with decreasing progesterone concentrations from day of delivery to day of peak blues score (P greater-than-or-equal-to 0.01), and with low progesterone concentrations on day of peak blues score (P<0.01). Seventy eight women were designated as having maternity blues (peak score greater-than-or-equal-to 8 on Stein scale) while 39 had no blues. Women with blues had significantly higher antenatal progesterone concentrations and lower postnatal concentrations than women without blues (geometric mean progesterone concentrations: one day before delivery 3860 pmol/l v 3210 pmol/l respectively, P=0.03; ten days postpartum 88 pmol/l v 114 pmol/l, P=0.048). Cortisol concentrations were not significantly associated with mood. Conclusion-Maternal mood in the days immediately after delivery is related to withdrawal of naturally occurring progesterone.	UNIV WALES COLL MED,DEPT MED COMP & STAT,CARDIFF CF4 4XN,S GLAM,WALES; LEIGHTON HOSP,DEPT PSYCHIAT,CREWE CW1 4QJ,ENGLAND; UNIV HOSP WALES,TENOVUS INST,STEROID ASSAY LAB,CARDIFF CF4 4XW,S GLAM,WALES	Cardiff University; Cardiff University	HARRIS, B (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF CF6 2YA,WALES.		Newcombe, Robert G/B-4897-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON PJB, 1985, J ENDOCRINOL, V104, P7, DOI 10.1677/joe.0.1040007; ARAFAT ES, 1988, AM J OBSTET GYNECOL, V159, P1203, DOI 10.1016/0002-9378(88)90448-6; BACKSTROM T, 1976, J STEROID BIOCHEM, V7, P469, DOI 10.1016/0022-4731(76)90114-X; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COOK N, 1986, PSYCHIAT RES, V18, P143, DOI 10.1016/0165-1781(86)90026-0; COX JL, 1982, BRIT J PSYCHIAT, V140, P111, DOI 10.1192/bjp.140.2.111; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DALTON K, 1989, INT J PRENATAL PERIN, P322; GYERMEK L, 1975, ANESTHESIOLOGY, V42, P331, DOI 10.1097/00000542-197503000-00017; HANDLEY SL, 1980, BRIT J PSYCHIAT, V136, P498, DOI 10.1192/bjp.136.5.498; HARRIS B, 1993, HORM RES, V39, P138, DOI 10.1159/000182714; HARRIS B, 1990, BIOL PSYCHIAT, V27, P897, DOI 10.1016/0006-3223(90)90471-D; KENDELL RE, 1981, J AFFECT DISORDERS, V3, P317, DOI 10.1016/0165-0327(81)90001-X; KENNERLEY H, 1989, BRIT J PSYCHIAT, V155, P356, DOI 10.1192/bjp.155.3.356; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MARTIN MC, 1986, BASIC CLIN ENDOCRINO, P476; METZ A, 1983, LANCET, V1, P495; MONHEIT A G, 1980, Clinical Obstetrics and Gynecology, V23, P973; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801; PITT B, 1973, BRIT J PSYCHIAT, V122, P431, DOI 10.1192/bjp.122.4.431; READ GF, 1983, IMMUNOASSAYS CLIN CH, P163; RIADFAHMY D, 1987, J REPROD MED, V32, P254; RILEY DM, 1979, EMOTIONS REPRODUCTIO, P829; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; STEIN G, 1981, J PSYCHOSOM RES, V25, P395, DOI 10.1016/0022-3999(81)90054-4; STEIN GS, 1980, J PSYCHOSOM RES, V24, P1165; TREADWAY CR, 1969, AM J PSYCHIAT, V125, P1380, DOI 10.1176/ajp.125.10.1380; Victoroff VM, 1952, DIS NERV SYST, V13, P291; WALKER RF, 1979, CLIN CHEM, V25, P2030	31	116	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					949	953		10.1136/bmj.308.6934.949	http://dx.doi.org/10.1136/bmj.308.6934.949			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF485	8173402	Green Published			2022-12-28	WOS:A1994NF48500017
J	BURATOWSKI, S				BURATOWSKI, S			THE BASICS OF BASAL TRANSCRIPTION BY RNA-POLYMERASE-II	CELL			English	Review							C-TERMINAL DOMAIN; PREINITIATION COMPLEX; NONPHOSPHORYLATED FORM; REQUIREMENT; INITIATION; PROMOTER; SUBUNIT; MECHANISM; INVITRO				BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CONAWAY RC, 1993, ANN REV BIOCH, V62, P16; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOLESKE AJ, 1994, IN PRESS NATURE; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; PRINCE DH, 1989, MOL CELL BIOLL, V9, P1465; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; TIMMERS TTM, 1994, EMBO J, V13, P391; TJIAN R, 1994, CELL, V74, P5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	32	293	299	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					1	3		10.1016/0092-8674(94)90226-7	http://dx.doi.org/10.1016/0092-8674(94)90226-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156586				2022-12-28	WOS:A1994NF21100001
J	NORRIS, DP; PATEL, D; KAY, GF; PENNY, GD; BROCKDORFF, N; SHEARDOWN, SA; RASTAN, S				NORRIS, DP; PATEL, D; KAY, GF; PENNY, GD; BROCKDORFF, N; SHEARDOWN, SA; RASTAN, S			EVIDENCE THAT RANDOM AND IMPRINTED XIST EXPRESSION IS CONTROLLED BY PREEMPTIVE METHYLATION	CELL			English	Article							X-CHROMOSOME INACTIVATION; CPG-RICH ISLANDS; DNA METHYLATION; MOUSE EMBRYOS; SEQUENCE SPECIFICITY; CELLS; GENE; DIFFERENTIATION; TRANSGENE; NUCLEUS	The mouse Xist gene is expressed exclusively from the inactive X chromosome and may control the initiation of X inactivation. We show that in somatic tissues the 5' end of the silent Xist allele on the active X chromosome is fully methylated, while the expressed allele on the inactive X is completely unmethylated. In tissues that undergo imprinted paternal Xist expression and imprinted X inactivation, the paternal Xist allele is unmethylated, and the silent maternal allele is fully methylated. In the male germline, a developmentally regulated demethylation of Xist occurs at the onset of meiosis and is retained in mature spermatozoa. This may be the cause of imprinted expression of the paternal Xist allele. A role for methylation in the control of Xist expression is further supported by the finding that in differentiating embryonic stem cells during the initiation of X inactivation, differential methylation of Xist alleles precedes the onset of Xist expression.			NORRIS, DP (corresponding author), MRC,CLIN RES CTR,COMPARAT BIOL SECT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GOETZ P, 1984, J CELL SCI, V65, P249; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; LEVAKSVA.B, 1969, EXPERIENTIA, V25, P1311, DOI 10.1007/BF01897519; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; LYON MF, 1984, DIFFERENTIATION, V26, P63, DOI 10.1111/j.1432-0436.1984.tb01375.x; LYON MF, 1961, NATURE, V190, P373; LYON MF, 1989, GENETIC VARIANTS STA; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCLAREN A, 1984, SOC EXP BIOL S, V38, P2; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MONK M, 1987, P139; MONK M, 1987, DEVELOPMENT, V99, P371; MONK M, 1990, PHILOS T ROY SOC B, V326, P179; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SCHEDL A, 1992, GENOMICS, V14, P288, DOI 10.1016/S0888-7543(05)80218-6; SMITH AG, 1992, CELL BIOL, V3, P385; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MA, 1988, DEVELOPMENT, V103, P171; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TADA T, 1994, IN PRESS DEVELOPMENT; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0	58	223	225	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					41	51		10.1016/0092-8674(94)90233-X	http://dx.doi.org/10.1016/0092-8674(94)90233-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156596				2022-12-28	WOS:A1994NF21100008
J	HEALY, E; SIMPSON, N				HEALY, E; SIMPSON, N			FORTNIGHTLY REVIEW - ACNE-VULGARIS	BRITISH MEDICAL JOURNAL			English	Article							ISOTRETINOIN TREATMENT; CYPROTERONE-ACETATE; THERAPY; WOMEN		UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK				Healy, Eugene/0000-0001-5591-6970				BOTTOMLEY WW, 1993, DERMATOLOGY, V186, P253, DOI 10.1159/000247364; BURKE BM, 1984, BRIT J DERMATOL, V111, P83, DOI 10.1111/j.1365-2133.1984.tb04020.x; Cunliffe W J, 1989, Acta Derm Venereol Suppl (Stockh), V143, P31, DOI 10.2340/000155551433134; CUNLIFFE WJ, 1986, BRIT J DERMATOL, V115, P386, DOI 10.1111/j.1365-2133.1986.tb05757.x; Cunliffe WJ, 1991, J DERMATOL TREAT, V1, P285; DARLEY CR, 1984, CLIN EXP DERMATOL, V9, P28, DOI 10.1111/j.1365-2230.1984.tb00751.x; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; EADY EA, 1990, J DERMATOL TREAT, V1, P215, DOI DOI 10.3109/09546639009086737; GREENWOOD R, 1985, BRIT MED J, V291, P1231, DOI 10.1136/bmj.291.6504.1231; HAMMERSTEIN J, 1975, J STEROID BIOCHEM, V6, P827, DOI 10.1016/0022-4731(75)90311-8; HARKAWAY KS, 1992, BRIT J DERMATOL, V126, P586; JICK SS, 1993, LANCET, V341, P1181, DOI 10.1016/0140-6736(93)91004-6; KARVONEN SL, 1993, J AM ACAD DERMATOL, V28, P572, DOI 10.1016/0190-9622(93)70076-6; KNITZER RH, 1991, SEMIN ARTHRITIS RHEU, V20, P247, DOI 10.1016/0049-0172(91)90020-Z; KROWCHUK DP, 1991, PEDIATR DERMATOL, V8, P332, DOI 10.1111/j.1525-1470.1991.tb00945.x; LAYTON AM, 1992, J AM ACAD DERMATOL, V27, pS2, DOI 10.1016/S0190-9622(08)80252-6; LAYTON AM, 1993, BRIT J DERMATOL, V129, P292, DOI 10.1111/j.1365-2133.1993.tb11849.x; LIPSON AH, 1993, LANCET, V341, P1352, DOI 10.1016/0140-6736(93)90868-H; PERKINS W, 1991, BRIT J DERMATOL, V124, P429, DOI 10.1111/j.1365-2133.1991.tb00620.x; RADEMAKER M, 1989, BRIT MED J, V298, P1217, DOI 10.1136/bmj.298.6682.1217; RADEMAKER M, 1991, BRIT J DERMATOL, V124, P361, DOI 10.1111/j.1365-2133.1991.tb00598.x; SIMPSON NB, 1992, ACNE MATURE FEMALE; SIMPSON NB, 1993, J DERMATOL TREAT S2, V4, pS6; VAHLQUIST A, 1990, J INVEST DERMATOL, V94, P496, DOI 10.1111/1523-1747.ep12874677; WALKER BR, 1990, BRIT J DERMATOL, V122, P531, DOI 10.1111/j.1365-2133.1990.tb14730.x	25	39	50	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					831	833		10.1136/bmj.308.6932.831	http://dx.doi.org/10.1136/bmj.308.6932.831			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167492	Green Published			2022-12-28	WOS:A1994ND24300026
J	RYDER, SD; OREILLY, S; MILLER, RJ; ROSS, J; JACYNA, MR; LEVI, AJ				RYDER, SD; OREILLY, S; MILLER, RJ; ROSS, J; JACYNA, MR; LEVI, AJ			LONG-TERM ACID SUPPRESSING TREATMENT IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI; H2-RECEPTOR ANTAGONISTS; DOUBLE-BLIND; CIMETIDINE; DYSPEPSIA; THERAPY; PLACEBO; PREVENTION; EFFICACY	Objective-To determine the current practice in selected general practices for prescribing long term (>6 months) treatment to suppress gastric acid secretion. Setting-Seven general practices in the Harrow area that always or usually refer to Northwick Park Hospital. Subjects-60148 patients on lists of the general practices. Design-Identification of patients receiving long term treatment through repeat prescribing data followed by a manual and computer survey of patients' notes for indications and investigations Patient compliance and views on treatment were sought by a postal questionnaire. Main outcome measures-Indications for treatment, treatment given, investigations undertaken before and during treatment. Results-492 patients (0.82% of the population) were taking long term acid suppressing treatment The most common diagnosis was duodenal ulcer disease (183 (37%) of all patients); oesophageal disease (118 (24%)) was also common. 93 patients (19%) were treated for abdominal pain where no diagnosis had been reached or who had only a diagnosis of gastritis on endoscopy. Ranitidine was prescribed in 394 (80%) patients. 298 (74%) patients found treatment helpful, but 108 (27%) had a poor understanding of their diagnosis. 317 patients (78%) took their drug as prescribed. 37 patients were also taking prescribed non-steroidal anti-inflammatory drugs and an additional 43 patients took regular aspirin or ibuprofen without prescription. Conclusions-Long term acid suppressing treatment is common, and a substantial number of patients are taking these drugs long term without a diagnosis having been reached. It is hoped that protocols for investigation and treatment will improve these figures. Patients need to be better informed about their disease and the possible adverse effects of taking non-steroidal anti-inflammatory drugs in acid related upper gastrointestinal disease.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT GASTROENTEROL,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London				Ryder, Stephen David/0000-0001-9649-4444				BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; CHIVERTON SG, 1988, BAILLIERE CLIN GASTR, V2, P655, DOI 10.1016/S0950-3528(88)80012-5; COCCO AE, 1981, NEW ENGL J MED, V304, P1281, DOI 10.1056/NEJM198105213042108; DOOLEY CP, 1991, ALIMENT PHARM THERAP, V5, P129; FRESTON JW, 1987, AM J GASTROENTEROL, V82, P1242; FRY J, 1984, BRIT MED J, V2, P809; GILLILAND AEW, 1990, FAM PRACT, V7, P43, DOI 10.1093/fampra/7.1.43; GOTTHARD R, 1988, SCAND J GASTROENTERO, V23, P7, DOI 10.3109/00365528809093840; GRAHAM DY, 1986, LANCET, V1, P462; HEATLEY RV, 1992, ALIMENT PHARM THERAP, V6, P291; HIRSCHOWITZ BI, 1986, J CLIN GASTROENTEROL, V8, P359, DOI 10.1097/00004836-198606002-00006; HIXSON LJ, 1992, ARCH INTERN MED, V152, P726, DOI 10.1001/archinte.152.4.726; JOHANNESSEN T, 1988, SCAND J GASTROENTERO, V23, P327, DOI 10.3109/00365528809093874; KLINKENBERGKNOL EC, 1992, HEPATO-GASTROENTEROL, V39, P27; KRAUSE U, 1963, ACTA CHIR SCAND S310, V125, P1; LANZA FL, 1989, AM J GASTROENTEROL, V84, P633; MENDELOWITZ PC, 1990, ANN INTERN MED, V112, P140, DOI 10.7326/0003-4819-112-2-140; MILLAR MR, 1992, ANTIMICROB AGENTS CH, V36, P185, DOI 10.1128/AAC.36.1.185; Norrelund N, 1980, Ugeskr Laeger, V142, P1750; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; SAULTZ JW, 1985, MIL MED, V150, P300, DOI 10.1093/milmed/150.6.300; TALLEY NJ, 1986, GASTROENTEROLOGY, V91, P149, DOI 10.1016/0016-5085(86)90451-8; WALAN A, 1987, SCAND J GASTROE S132, V22, P12; WORMSLEY KG, 1991, ALIMENT PHARM THERAP, V5, P37; 1990, MEREC B, V1, P9	25	89	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					827	830		10.1136/bmj.308.6932.827	http://dx.doi.org/10.1136/bmj.308.6932.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167491	Green Published			2022-12-28	WOS:A1994ND24300025
J	ROSE, L				ROSE, L			HOMOPHOBIA AMONG DOCTORS	BRITISH MEDICAL JOURNAL			English	Article								Homophobia creates stress for gay men and women. An interview study of 28 doctors, 20 gay and eight non-gay, was performed to assess whether homophobia is strong among the medical profession, the stress it causes, and whether the advent of AIDS and HIV infection has increased the stress. The doctors, recruited by word of mouth and by a letter in the medical and gay press, were asked about their own attitudes to homosexuality and AIDS. Only one (non-gay) doctor thought that there was no prejudice against gay doctors in the medical profession. The gay doctors certainly perceived prejudice, which they claimed caused them extra stress; the advent of AIDS had increased this stress to an extent. Doctors who had not openly declared themselves to be gay feared doing so because of the effect on their job prospects, but those who had declared themselves openly reported less stress than previously. Homophobia clearly exists within the medical profession. Non-gay doctors should use the power of the profession to challenge homophobia in the profession and in society. HIV infection could then be treated as a purely medical condition; sufferers would receive wider understanding and the pressures of extra workload could be more equally shared.			ROSE, L (corresponding author), FDN AIDS COUNSELLING TREATMENT & SUPPORT,LONDON N8 9SY,ENGLAND.							BOLLING DR, 1987, JAMA-J AM MED ASSOC, V258, P474; Feyerabend Paul K., 1993, METHOD; FOX DM, 1988, AIDS BURDEN HIST; GILLON R, 1987, BRIT MED J, V2, P1332; Goffman E., 1963, BEHAV PUBLIC PLACES, P3; Goffman E., 1969, REPRESENTATION SELF; TONKS A, 1994, BRIT MED J, V308, P289, DOI 10.1136/bmj.308.6924.289; Turner B., 1987, MED POWER SOCIAL KNO; 1992, STRESS MED PROFESSIO	9	53	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					586	587		10.1136/bmj.308.6928.586	http://dx.doi.org/10.1136/bmj.308.6928.586			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148685	Green Published			2022-12-28	WOS:A1994MY71400029
J	ANDERSEN, JC				ANDERSEN, JC			RESPONSE OF RESISTANT IDIOPATHIC THROMBOCYTOPENIC PURPURA TO PULSED HIGH-DOSE DEXAMETHASONE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS GAMMA-GLOBULIN; IMMUNE THROMBOCYTOPENIA; ADULTS; MANAGEMENT; MYELOMA; CHEMOTHERAPY; IGG	Background. Most patients with chronic idiopathic thrombocytopenic purpura have a response to corticosteroids or intravenous immune globulin, but improvement is often transitory. Splenectomy may provide only a short-term benefit. Because pulsed high-dose therapy with potent synthetic corticosteroids is inexpensive, well tolerated, and effective in patients with secretory B-cell neoplasms, a similar regimen was examined for its efficacy in patients with chronic idiopathic thrombocytopenic purpura that was resistant to other treatments. Methods. Ten consecutively referred patients who had persistent symptomatic idiopathic thrombocytopenic purpura after undergoing at least two standard therapies were treated with six cycles of dexamethasone (40 mg per day for 4 sequential days every 28 days). Results. All patients had increased platelet counts (mean [+/-SD] count before treatment, 12,000+/-8200 per cubic millimeter; after treatment, 248,000+/-130,000 per cubic millimeter). The platelet counts remained above 100,000 per cubic millimeter for at least six months after the last cycle of treatment. There were no serious side effects. Features of hyperadrenocorticism due to prior corticosteroid therapy resolved during treatment. The cost of the drug was approximately $100 per patient. Conclusions. Although the possibility of spontaneous remission and a delayed benefit from prior therapy cannot be excluded in this small group of patients, pulsed high-dose treatment with dexamethasone may provide a low-cost therapeutic option with minimal side effects in patients with refractory idiopathic thrombocytopenic purpura.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,DETROIT,MI 48201	Wayne State University	ANDERSEN, JC (corresponding author), WAYNE STATE UNIV,HARPER HOSP,403 VIOLET S,3990 JOHN R ST,DETROIT,MI 48201, USA.							AHN YS, 1984, ANN INTERN MED, V100, P192, DOI 10.7326/0003-4819-100-2-192; AHN YS, 1987, ANN INTERN MED, V107, P177, DOI 10.7326/0003-4819-107-2-177; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ASTER RH, 1969, BRIT J HAEMATOL, V16, P61, DOI 10.1111/j.1365-2141.1969.tb00379.x; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BERCHTOLD P, 1989, BLOOD, V74, P2309; BLANCHETTE VS, 1984, TRANSFUSION, V14, P388; BORNE AEG, 1988, BRIT MED J, V296, P249; BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1988, BLOOD, V72, P121; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1986, CANCER RES, V46, P5125; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; GUTHRIE TH, 1989, SEMIN HEMATOL, V26, P3; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; IMBACH P, 1981, LANCET, V1, P1228; KELSEY PR, 1985, BRIT J HAEMATOL, V60, P197, DOI 10.1111/j.1365-2141.1985.tb07400.x; KOLLER CA, 1980, MED CLIN N AM, V64, P761; LOBUGLIO AF, 1983, NEW ENGL J MED, V309, P459, DOI 10.1056/NEJM198308253090804; MCVERRY BA, 1985, BRIT J HAEMATOL, V61, P145, DOI 10.1111/j.1365-2141.1985.tb04070.x; MCVERRY BA, 1985, BRIT J HAEMATOL, V59, P203, DOI 10.1111/j.1365-2141.1985.tb02985.x; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; Rothfield NF, 1989, ARTHRITIS ALLIED CON, P1022; SALAMA A, 1986, AM J HEMATOL, V22, P241, DOI 10.1002/ajh.2830220304; SCHMIDT RE, 1984, BLUT, V48, P19, DOI 10.1007/BF00320713; SCHMIDT RE, 1981, LANCET, V2, P475; SHULMAN NR, 1965, ANN NY ACAD SCI, V124, P499, DOI 10.1111/j.1749-6632.1965.tb18984.x; SONNENBLICK M, 1986, ONCOLOGY, V43, P349, DOI 10.1159/000226400; STROTHER SV, 1984, ARCH INTERN MED, V144, P2198, DOI 10.1001/archinte.144.11.2198; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; WILSON WH, 1993, J CLIN ONCOL, V11, P1573, DOI 10.1200/JCO.1993.11.8.1573	32	201	212	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1560	1564		10.1056/NEJM199406023302203	http://dx.doi.org/10.1056/NEJM199406023302203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177245	Bronze			2022-12-28	WOS:A1994NN21500003
J	MENICHETTI, F; DELFAVERO, A; MARTINO, P; BUCANEVE, G; MICOZZI, A; DANTONIO, D; RICCI, P; CAROTENUTO, M; LISO, V; NOSARI, AM; BARBUI, T; FASOLA, G; MANDELLI, F; MONTILLO, M; BARBABIETOLA, G; DINOTA, A; PAGANO, L; JACOPINO, P; ISABELLA, N; FONTANA, R; LANDONIO, G; BROCCIA, G; CUDILLO, L; DIFAZIO, S; PACILLI, L; MONACO, M; CARELLA, AM; CHIERICHINI, A; QUINTINI, G; GABBAS, A; CITARELLA, P; DALLASTA, A; RONCONI, F; DORE, F; GALIENI, P				MENICHETTI, F; DELFAVERO, A; MARTINO, P; BUCANEVE, G; MICOZZI, A; DANTONIO, D; RICCI, P; CAROTENUTO, M; LISO, V; NOSARI, AM; BARBUI, T; FASOLA, G; MANDELLI, F; MONTILLO, M; BARBABIETOLA, G; DINOTA, A; PAGANO, L; JACOPINO, P; ISABELLA, N; FONTANA, R; LANDONIO, G; BROCCIA, G; CUDILLO, L; DIFAZIO, S; PACILLI, L; MONACO, M; CARELLA, AM; CHIERICHINI, A; QUINTINI, G; GABBAS, A; CITARELLA, P; DALLASTA, A; RONCONI, F; DORE, F; GALIENI, P			PREVENTING FUNGAL INFECTION IN NEUTROPENIC PATIENTS WITH ACUTE-LEUKEMIA - FLUCONAZOLE COMPARED WITH ORAL AMPHOTERICIN-B	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CANDIDIASIS; TRIAL	Objective: To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia. Design: A randomized, controlled, multicenter trial. Setting: 30 hematologic units in tertiary care or university hospitals. Patients: 820 consecutive, afebrile, adult patients with acute leukemia and chemotherapy-induced neutropenia. Intervention: Patients were randomly assigned to receive fluconazole, 150 mg, as a once-daily capsule, or amphotericin B suspension, 500 mg every 6 hours. Measurements: An intention-to-treat analysis was done for 820 patients: 420 treated with fluconazole and 400 treated with oral amphotericin B. Results: Definite systemic fungal infection occurred in 2.6% of fluconazole recipients and 2.5% of amphotericin B recipients; suspected systemic fungal infection requiring the empiric use of intravenous amphotericin B occurred in 16% of fluconazole recipients and 21% of oral amphotericin B recipients, a difference of 5 percentage points (95% CI for difference, - 0.02% to 10%; P = 0.07). Superficial fungal infection was documented in 1.7% of fluconazole recipients compared with 2.7% of amphotericin B recipients, a difference of one percentage point (CI of difference, - 0.9% to 3%; P > 0.2). The distribution of fungal isolates in systemic and superficial fungal infection was similar in both groups. The overall mortality rate accounted for 10% in both groups. An excellent compliance was documented for 90% of patients treated with fluconazole compared with 72% of those treated with amphotericin B suspension, a difference of 18 percentage points (CI for difference, 13% to 23%). Side effects were documented less frequently in fluconazole than in amphotericin B recipients (1.4% compared with 7%, a difference of 5.6 percentage points; CI for difference, 2% to 8%; P < 0.01). Conclusion: Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated.	UNIV PERUGIA, IST CLIN MED 1, PERUGIA, ITALY; UNIV ROMA LA SAPIENZA, IST EMATOL, ROME, ITALY; OSPED PESCARA, DIV EMATOL, PESCARA, ITALY; UNIV BOLOGNA, IST EMATOL, BOLOGNA, ITALY; UNIV BARI, IST EMATOL, BARI, ITALY; OSPED NIGUARDA CA GRANDA, DIV TALAMONA, MILAN, ITALY; OSPED RIUNITI BERGAMO, DIV EMATOL, I-24100 BERGAMO, ITALY; OSPED UDINE, CATTEDRA EMATOL, UDINE, ITALY; UNIV ANCONA, IST CLIN MED, ANCONA, ITALY; OSPED POTENZA, DIV EMATOL, POTENZA, ITALY; UNIV CATTOLICA SACRO CUORE, IST SEMEIOT MED, ROME, ITALY; OSPED REGGIO CALABRIA, DIV EMATOL, CALABRIA, ITALY; OSPED MOLINETTE, DIV EMATOL, TURIN, ITALY; UNIV NAPLES, SEZ EMATOL, NAPLES, ITALY; OSPED NIGUARDA CA GRANDA, DIV FALCK, MILAN, ITALY; OSPED ONCOL BUSINCO, CAGLIARI, ITALY; OSPED S EUGENIO, DIV EMATOL, ROME, ITALY; UNIV CATANIA, CATTEDRA EMATOL, CATANIA, ITALY; OSPED SCLAVO, DIV EMATOL, SIENA, ITALY; OSPED S CAMILLO ROMA, DIV EMATOL, ROME, ITALY; OSPED FOGGIA, DIV EMATOL, FOGGIA, ITALY; OSPED SAN MARTINO GENOVA, DIV EMATOL, GENOA, ITALY; OSPED LATINA, DIV EMATOL, LATINA, ITALY; UNIV PALERMO, MED CLIN, PALERMO, ITALY; OSPED NUORO, DIV EMATOL, NUORO, ITALY; UNIV PALERMO, CATTEDRA EMATOL, PALERMO, ITALY; OSPED REGGIO EMILIA, DIV EMATOL, REGGIO EMILIA, ITALY; OSPED AVELLINO, DIV EMATOL, AVELLINO, ITALY; OSPED SASSARI, IST EMATOL, SASSARI, ITALY	University of Perugia; Sapienza University Rome; University of Bologna; Universita degli Studi di Bari Aldo Moro; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Ospedali Riuniti di Bergamo; University of Udine; Marche Polytechnic University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Naples Federico II; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sant'Eugenio Hospital; University of Catania; University of Genoa; IRCCS AOU San Martino IST; University of Palermo; University of Palermo	MENICHETTI, F (corresponding author), UNIV PERUGIA, OSPED POLICLIN MONTELUCE, IST MALATTIE INFETT, I-06122 PERUGIA, ITALY.		pagano, livio/A-2024-2008; pagano, livio/J-3020-2018	pagano, livio/0000-0001-8287-928X				CLIFT RA, 1984, AM J MED, V77, P34; DEGREGORIO MW, 1982, AM J MED, V73, P543, DOI 10.1016/0002-9343(82)90334-5; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; EZDINLI EZ, 1979, JAMA-J AM MED ASSOC, V242, P258, DOI 10.1001/jama.242.3.258; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; MERZ WG, 1984, J CLIN MICROBIOL, V20, P1194, DOI 10.1128/JCM.20.6.1194-1195.1984; MEUNIER F, 1991, DRUG INVEST, V3, P258, DOI 10.1007/BF03259575; MEUNIER F, 1987, REV INFECT DIS, V9, P408; MEUNIER F, 1989, AM J MED, V86, P668; MILLIKEN S, 1988, BONE MARROW TRANSPL, V3, P324; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SCHIMPFF SC, 1972, ANN INTERN MED, V77, P707, DOI 10.7326/0003-4819-77-5-707; SCHULER U, 1992, NEW ENGL J MED, V326, P892; SCHULER U, 1992, 18TH ANN M EUR GROUP, P86; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; 1990, BLOOD S1, V76, P314; 1990, BLOOD S1, V76, P340	21	121	122	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					913	918		10.7326/0003-4819-120-11-199406010-00003	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172437				2022-12-28	WOS:A1994NN11000003
J	KREMER, B; GOLDBERG, P; ANDREW, SE; THEILMANN, J; TELENIUS, H; ZEISLER, J; SQUITIERI, F; LIN, BY; BASSETT, A; ALMQVIST, E; BIRD, TD; HAYDEN, MR				KREMER, B; GOLDBERG, P; ANDREW, SE; THEILMANN, J; TELENIUS, H; ZEISLER, J; SQUITIERI, F; LIN, BY; BASSETT, A; ALMQVIST, E; BIRD, TD; HAYDEN, MR			A WORLDWIDE STUDY OF THE HUNTINGTONS-DISEASE MUTATION - THE SENSITIVITY AND SPECIFICITY OF MEASURING CAG REPEATS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DNA MARKERS; MYOTONIC-DYSTROPHY; REGION; GENE	Background. Huntington's disease is associated with an expanded sequence of CAG repeats in a gene on chromosome 4p16.3. However, neither the sensitivity of expanded CAG repeats in affected persons of different ethnic origins nor the specificity of such repeats for Huntington's disease as compared with other neuropsychiatric disorders has been determined. Methods. We studied 1007 patients with diagnosed Huntington's disease from 565 families and 43 national and ethnic groups. In addition, the length of the CAG repeat was determined in 113 control subjects with a family history of Alzheimer's disease (44 patients), schizophrenia (39), major depression (16), senile chorea (5), benign heriditary chorea (5), neuroacanthocytosis (2), and dentatorubropallidoluysian atrophy (2). The number of CAG repeats was also assessed in 1595 control chromosomes, with the size of adjacent polymorphic CCG trinucleotide repeats taken into account. Results. Of 1007 patients with signs and symptoms compatible with a diagnosis of Huntington's disease, 995 had an expanded CAG repeat that included from 36 to 121 repeats (median, 44) (sensitivity, 98.8 percent; 95 percent confidence interval, 97.7 to 99.4 percent). There were no significant differences among national and ethnic groups in the number of repeats. No CAG expansion was found in the 113 control subjects with other neuropsychiatric disorders (specificity, 100 percent; 95 percent confidence interval, 95.2 to 100 percent). In 1581 of the 1595 control chromosomes (99.1 percent), the number of CAG repeats ranged from 10 to 29 (median, 18). In 12 control chromosomes (0.75 percent), intermediate-sized CAG sequences with 30 to 35 repeats were found, and 2 normal chromosomes unexpectedly had expanded CAG sequences, of 39 and 37 repeats. Conclusions. CAG trinucleotide expansion is the molecular basis of Huntington's disease worldwide and is a highly sensitive and specific marker for inheritance of the disease mutation.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z4,BC,CANADA; UNIV TORONTO,CLARKE INST PSYCHIAT,TORONTO,ON,CANADA; KAROLINSKA HOSP,S-10401 STOCKHOLM,SWEDEN; VET AFFAIRS MED CTR,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of British Columbia; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Karolinska Institutet; Karolinska University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle			Hayden, Michael R/D-8581-2011; Squitieri, Ferdinando/N-1852-2019	Hayden, Michael R/0000-0001-5159-1419; Squitieri, Ferdinando/0000-0002-7397-1727	NATIONAL INSTITUTE ON AGING [P50AG005136] Funding Source: NIH RePORTER; NIA NIH HHS [AGO 5136] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ANDREW SE, 1994, AM J HUM GENET, V54, P852; BABUL R, 1993, JAMA-J AM MED ASSOC, V270, P2321, DOI 10.1001/jama.270.19.2321; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GOLDBERG YP, 1993, HUM MOL GENET, V2, P635, DOI 10.1093/hmg/2.6.635; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; Griner P F, 1981, Ann Intern Med, V94, P557; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MACMILLAN JC, 1993, LANCET, V342, P954, DOI 10.1016/0140-6736(93)92002-B; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; MYERS RH, 1989, AM J HUM GENET, V45, P615; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RIESS O, 1993, HUM MOL GENET, V2, P637, DOI 10.1093/hmg/2.6.637; RUBENSZTEIN DC, 1993, HUM MOL GENET, V2, P1713; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; VALDES JM, 1993, HUM MOL GENET, V2, P633, DOI 10.1093/hmg/2.6.633; VOGEL F, 1986, HUMAN GENETICS; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327; 1993, CELL, V72, P971	36	411	432	0	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1401	1406		10.1056/NEJM199405193302001	http://dx.doi.org/10.1056/NEJM199405193302001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159192				2022-12-28	WOS:A1994NK97200001
J	LURIE, KG; SHULTZ, JJ; CALLAHAM, ML; SCHWAB, TM; GISCH, T; RECTOR, T; FRASCONE, RJ; LONG, L				LURIE, KG; SHULTZ, JJ; CALLAHAM, ML; SCHWAB, TM; GISCH, T; RECTOR, T; FRASCONE, RJ; LONG, L			EVALUATION OF ACTIVE COMPRESSION-DECOMPRESSION CPR IN VICTIMS OF OUT-OF-HOSPITAL CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESUSCITATION	Objective.-Active compression-decompression (ACD) cardiopulmonary resuscitation (CPR) appears to improve ventilation and coronary perfusion when compared with standard CPR. The objective was to evaluate potential benefits of this new CPR technique in patients with out-of-hospital cardiac arrest in St Paul, Minn. Design.-Ten-month, prospective, randomized parallel-group design. Setting.-St Paul, Minn, population 270 000. Patients.-All normothermic victims of nontraumatic cardiac arrest older than 8 years who received CPR. Main Outcome Measures.-Return of spontaneous circulation, admission to the intensive care unit (ICU), return of baseline neurological function (alert and oriented to person, place, and time), survival to hospital discharge, survival to hospital discharge with return of baseline neurological function, and complications. Results.-Seventy-seven patients received standard CPR and 53 patients received ACD CPR. The mean emergency medical services call response interval was less than 3.5 minutes. When all patients were considered, a higher percentage of ACD CPR patients had a return of spontaneous circulation and were admitted to the ICU vs standard CPR (45% vs 31%, and 40% vs 26%, respectively), but these trends were not statistically significant (P<.10 and P<.10). No statistically significant differences were found between hospital discharge rates (12 [23%] of 53 for ACD CPR vs 13 [17%] of 77 for standard CPR), return to baseline neurological function (10 [19%] of 53 for ACD CPR vs 13 [17%] of 77 for standard CPR), or return to baseline neurological function at hospital discharge (nine [17%] of 53 for ACD CPR vs 12 [16%] of 77 for standard CPR). Return of spontaneous circulation, ICU admission, and neurological recovery in both CPR groups were highly correlated with downtime (time from collapse to emergency medical system personnel arrival to the scene in witnessed arrests). With less than 10 minutes' downtime, survival to the ICU was 59% (19/32) with ACD CPR and 33% (16/49) with standard CPR (P<.02), return to baseline neurological function was 31% (10/32) with ACD CPR and 20% (10/49) with standard CPR (P=.27), and hospital discharge rate was 38% (12/32) with ACD CPR and 20% (10/49) with standard CPR (P=.17). Complication rates in patients admitted to the hospital were similar in both groups. Conclusions.-This study demonstrates that ACD CPR appears to be more effective than standard CPR in a well-defined subset of victims of out-of-hospital cardiac arrest during the critical early phases of resuscitation. Based on this study, a larger study should be performed to evaluate the potential long-term benefits of ACD CPR.	UNIV MINNESOTA, SCH MED, DEPT MED, DIV CARDIOVASC, MINNEAPOLIS, MN 55455 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT EMERGENCY MED, SAN FRANCISCO, CA USA; ST PAUL RAMSEY MED CTR, EMERGENCY MED SERV, ST PAUL, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco; Saint Paul Ramsey Medical Center				Callaham, Michael/0000-0003-2284-256X				BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CHANG MW, IN PRESS CHEST; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; MALZER R, 1993, INTENSIVMEDIZIN NOTF, V30, P260; MATEER JR, 1985, AM J EMERG MED, V3, P143, DOI 10.1016/0735-6757(85)90038-5; RIVERS EP, 1993, CIRCULATION, V88, P193; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; TUCKER KJ, 1993, CIRCULATION, V88, P10; 1992, JAMA-J AM MED ASSOC, V268, P2171	17	119	119	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1405	1411		10.1001/jama.271.18.1405	http://dx.doi.org/10.1001/jama.271.18.1405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176802				2022-12-28	WOS:A1994NJ69300027
J	POWER, C				POWER, C			HEALTH AND SOCIAL-INEQUALITY IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article							INFANT-MORTALITY; ENGLAND; SWEDEN; WALES	In most European countries health has been shown to be linked to social circumstances-gradients in health status have persisted for decades, despite major changes in the principal causes of death. In central and eastern Europe life expectancy has stagnated since the mid-60s, whereas in the West it has increased; but even in the West it is related to income distribution. Social differences in mortality in men are three times as large in some countries as in others, and are influenced by factors other than conventional risk factors. Substantial declines in mortality and morbidity could result from a narrowing of health inequalities even when differences in health risk between social groups are comparatively small. Policies to reduce health inequalities can be introduced in smaller communities and organisations such as the school and workplace. National policies are variable; factors generating inequalities require action across several policy areas.			POWER, C (corresponding author), INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							[Anonymous], 1980, INEQUALITIES HLTH RE; BENEZEVAL M, 1994, TACKLING INEQUALITIE; CARRHILL R, 1990, SOC SCI MED, V31, P393, DOI 10.1016/0277-9536(90)90286-2; Charny M C, 1987, Health Trends, V19, P3; Dahlgren G., 1992, POLICIES STRATEGIES; DAVEYSMITH G, 1990, BRIT MED J, V301, P373; FOX AJ, 1985, J EPIDEMIOL COMMUN H, V39, P1, DOI 10.1136/jech.39.1.1; HASAN J, 1989, HLTH INEQUALITIES EU; HERTZMAN C, 1993, ENV HLTH CENTRAL E E; Illsley R., 1990, Social Science and Medicine, V31, P223; KUNST AE, 1992, INT VARIATION SOCIOE; KUNST AE, 1992, INT COMPARISON SOCIO; LECLERC A, 1990, INT J EPIDEMIOL, V4, P1; LEON DA, 1992, BMJ-BRIT MED J, V305, P687, DOI 10.1136/bmj.305.6855.687; MACKENBACH JP, 1992, SOC SCI MED, V34, P213, DOI 10.1016/0277-9536(92)90264-Q; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; Power C., 1991, HLTH CLASS EARLY YEA; Rose G., 1992, STRATEGY PREVENTIVE; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; WAGSTAFF A, 1991, SOC SCI MED, V33, P547; WENNEMO I, 1993, SOCIOL HEALTH ILL, V15, P429, DOI 10.1111/1467-9566.ep11372773; WHITEHEAD M, 1993, BRIT MED J, V306, P783, DOI 10.1136/bmj.306.6880.783; WHITEHEAD M, 1988, INEQUALITIES HLTH; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1992, BRIT MED J, V305, P1227, DOI 10.1136/bmj.305.6863.1227-b; 1992, TARGETS HLTH ALL HLT; 1993, BRIT MED J, V306, P1636; 1992, EUROPE SOLIDARITY IN; [No title captured]; 1991, NURTURING HLTH FRAME; 1993, STATISTICS ANN 1992; 1992, P INT COLLABORATIVE	34	46	46	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1153	1156		10.1136/bmj.308.6937.1153	http://dx.doi.org/10.1136/bmj.308.6937.1153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK182	8173460	Green Published			2022-12-28	WOS:A1994NK18200024
J	TIRELLI, U; FRANCESCHI, S; CARBONE, A				TIRELLI, U; FRANCESCHI, S; CARBONE, A			MALIGNANT-TUMORS IN PATIENTS WITH HIV-INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; NON-HODGKINS-LYMPHOMA; AIDS-RELATED LYMPHOMA; LOW-DOSE CHEMOTHERAPY; KAPOSIS-SARCOMA; HOMOSEXUAL MEN; POSITIVE PATIENTS; RANDOMIZED TRIAL; CELL LYMPHOMA	One of the most important though somewhat neglected aspects of research in HIV infection concerns the development, clinicopathological characteristics, and treatment of malignant tumours in infected patients. With the improved survival of patients with AIDS owing to the better prevention and treatment of infectious complications there may well be an increase in AIDS related malignancies. This paper reviews the epidemiology, pathology, and treatment of malignant tumours in patients with HIV.	CTR REG RIFERIMENTO ONCOL, IST NAZL RICOVERO & CURA CARATTERE SCI, EPIDEMIOL UNIT, I-33081 AVIANO, ITALY; CTR REG RIFERIMENTO ONCOL, IST NAZL RICOVERO & CURA CARATTERE SCI, DIV PATHOL, I-33081 AVIANO, ITALY	IRCCS Aviano (CRO); IRCCS Aviano (CRO)	TIRELLI, U (corresponding author), CTR REG RIFERIMENTO ONCOL, IST NAZL RICOVERO & CURA CARATTERE SCI, DIV MED ONCOL & AIDS, I-33081 AVIANO, ITALY.		Carbone, Antonino/AAA-2217-2019; franceschi, silvia/M-2452-2014	Carbone, Antonino/0000-0003-2211-639X; franceschi, silvia/0000-0003-4181-8071				AUDOUIN J, 1992, J PATHOL, V167, P381, DOI 10.1002/path.1711670406; BALLERINI P, 1992, AIDS RES HUM RETROV, V8, P731; BALLERINI P, 1991, BLOOD S, V78, pA327; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BIESERT L, 1988, AIDS, V2, P449, DOI 10.1097/00002030-198812000-00007; BIGGAR RJ, 1987, AM J EPIDEMIOL, V126, P578, DOI 10.1093/oxfordjournals.aje.a114697; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BOIOCCHI M, 1993, INT J CANCER, V54, P53, DOI 10.1002/ijc.2910540110; BOIOCCHI M, 1993, AM J PATHOL, V142, P33; Buchbinder Aby, 1992, Current Opinion in Oncology, V4, P867, DOI 10.1097/00001622-199210000-00009; CARBONE A, 1991, CANCER, V68, P842, DOI 10.1002/1097-0142(19910815)68:4<842::AID-CNCR2820680429>3.0.CO;2-E; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CARBONE A, 1993, AM J CLIN PATHOL, V99, P289, DOI 10.1093/ajcp/99.3.289; CASABONA J, 1991, INT J CANCER, V47, P49, DOI 10.1002/ijc.2910470110; CHAPPUIS BB, 1990, VIRCHOWS ARCH B, V58, P199; COIFFIER B, 1989, J CLIN ONCOL, V7, P1018, DOI 10.1200/JCO.1989.7.8.1018; COOPER JS, 1987, ARCH OTOLARYNGOL, V113, P327; COOPER JS, 1991, INT J RADIAT ONCOL, V20, P419, DOI 10.1016/0360-3016(91)90051-5; COTE TR, 1991, AIDS, V5, P49, DOI 10.1097/00002030-199101000-00007; ELFORD J, IN PRESS AIDS; FISCHL MA, 1991, J ACQ IMMUN DEF SYND, V4, P1; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; GISSELBRECHT C, 1993, AM J MED, V95, P188, DOI 10.1016/0002-9343(93)90259-R; GONZALEZCLEMENTE JM, 1991, AIDS, V5, P751, DOI 10.1097/00002030-199106000-00017; GUARNER J, 1991, CANCER-AM CANCER SOC, V68, P2460, DOI 10.1002/1097-0142(19911201)68:11<2460::AID-CNCR2820681123>3.0.CO;2-0; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HESSOL NA, 1992, ANN INTERN MED, V117, P309, DOI 10.7326/0003-4819-117-4-309; HUI PK, 1988, HISTOPATHOLOGY, V12, P127, DOI 10.1111/j.1365-2559.1988.tb01924.x; IOACHIM HL, 1991, HUM PATHOL, V22, P659, DOI 10.1016/0046-8177(91)90288-Z; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84; LEVINE AM, 1992, BLOOD, V80, P8; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; Miles Steven A., 1992, Current Opinion in Oncology, V4, P875, DOI 10.1097/00001622-199210000-00010; MONFARDINI S, 1989, AIDS, V3, P449, DOI 10.1097/00002030-198907000-00008; NORTHFELT DW, 1993, P AN M AM SOC CLIN, V51, P8; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PEDERSEN C, 1991, EUR J CANCER, V27, P1416, DOI 10.1016/0277-5379(91)90023-7; PRESENT CA, 1992, P AN M AM SOC CLIN, V11, P47; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RAPHAEL M, 1991, ARCH PATHOL LAB MED, V115, P15; REE HJ, 1991, CANCER-AM CANCER SOC, V67, P1614, DOI 10.1002/1097-0142(19910315)67:6<1614::AID-CNCR2820670624>3.0.CO;2-#; REYNOLDS P, 1993, AM J EPIDEMIOL, V137, P19, DOI 10.1093/oxfordjournals.aje.a116598; RUTGERS JL, 1986, AM J PATHOL, V122, P493; SCADDEN DT, 1991, AM J CLIN ONCOL-CANC, V14, pS40, DOI 10.1097/00000421-199112001-00008; SERFLING U, 1991, ARCH DERMATOL, V127, P1479, DOI 10.1001/archderm.127.10.1479; SERRAINO D, 1992, AIDS, V6, P1015, DOI 10.1097/00002030-199209000-00016; SERRAINO D, 1992, ANN ONCOL, V3, P595, DOI 10.1093/oxfordjournals.annonc.a058283; SERRAINO D, 1992, BRIT J CANCER, V66, P912, DOI 10.1038/bjc.1992.384; SERRAINO D, 1993, EUR J CANCER, V29A, P1948, DOI 10.1016/0959-8049(93)90450-T; SHIBATA D, 1991, BLOOD, V77, P1527; Spina Michele, 1992, Current Opinion in Oncology, V4, P907, DOI 10.1097/00001622-199210000-00014; STANSFELD AG, 1988, LANCET, V1, P292; STEIN H, 1985, BLOOD, V66, P848; SUBAR M, 1988, BLOOD, V72, P667; TIRELLI U, 1993, ANN INTERN MED, V118, P313, DOI 10.7326/0003-4819-118-4-199302150-00016; TIRELLI U, 1992, ANN ONCOL, V3, pS69, DOI 10.1093/annonc/3.suppl_4.S69; TIRELLI U, 1992, ANN ONCOL, V3, P843, DOI 10.1093/oxfordjournals.annonc.a058108; TIRELLI U, 1993, P AN M AM SOC CLIN, V53, P13; UCCINI S, 1989, LANCET, V1, P1458; VOELKERDING KV, 1989, AM J CLIN PATHOL, V92, P222, DOI 10.1093/ajcp/92.2.222; WEICH HA, 1991, AM J PATHOL, V139, P1251; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904	71	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	1994	308	6937					1148	1153		10.1136/bmj.308.6937.1148	http://dx.doi.org/10.1136/bmj.308.6937.1148			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173459	Green Published			2022-12-28	WOS:A1994NK18200023
J	HILLIS, DM; HUELSENBECK, JP; CUNNINGHAM, CW				HILLIS, DM; HUELSENBECK, JP; CUNNINGHAM, CW			APPLICATION AND ACCURACY OF MOLECULAR PHYLOGENIES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MAXIMUM-LIKELIHOOD APPROACH; RIBOSOMAL-RNA SEQUENCES; EVOLUTIONARY TREES; DENTAL PRACTICE; PARSIMONY; MUTATION; GENES; DNA; SUBSTITUTIONS	Molecular investigations of evolutionary history are being used to study subjects as diverse as the epidemiology of acquired immune deficiency syndrome and the origin of life. These studies depend on accurate estimates of phylogeny. The performance of methods of phylogenetic analysis can be assessed by numerical simulation studies and by the experimental evolution of organisms in controlled laboratory situations. Both kinds of assessment indicate that existing methods are effective at estimating phylogenies over a wide range of evolutionary conditions, especially if information about substitution bias is used to provide differential weightings for character transformations.			HILLIS, DM (corresponding author), UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA.		Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019; Huelsenbeck, John P/C-6398-2013; Cunningham, Clifford/B-9807-2014; Kissinger, Jessica C/E-9610-2010	Kissinger, Jessica C/0000-0002-6413-1101; Cunningham, Clifford/0000-0002-5434-5122				ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BREMER B, 1991, PLANT SYST EVOL, V175, P39, DOI 10.1007/BF00942144; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; BULL JJ, 1993, EVOLUTION, V47, P993, DOI 10.1111/j.1558-5646.1993.tb02130.x; CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI C, COMMUNICATION; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; DIXON MT, 1993, MOL BIOL EVOL, V10, P256; Dowling TE, 1990, MOL SYSTEMATICS, P250; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1986, SYST ZOOL, V35, P617, DOI 10.2307/2413121; FELSENSTEIN J, 1992, EVOLUTION, V46, P159, DOI [10.2307/2409811, 10.1111/j.1558-5646.1992.tb01991.x]; FELSENSTEIN J, 1981, BIOL J LINN SOC, V16, P183, DOI 10.1111/j.1095-8312.1981.tb01847.x; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1986, PHILOS T ROY SOC B, V312, P317, DOI 10.1098/rstb.1986.0010; GOJOBORI T, 1982, J MOL EVOL, V18, P360, DOI 10.1007/BF01733904; GOLDING B, 1990, J MOL EVOL, V31, P511, DOI 10.1007/BF02102078; GOLDMAN N, 1993, J MOL EVOL, V36, P182, DOI 10.1007/BF00166252; GOLDMAN N, 1990, SYST ZOOL, V39, P345, DOI 10.2307/2992355; GOUY M, 1989, NATURE, V339, P145, DOI 10.1038/339145a0; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hillis D.M., 1990, SCIENCE, V250, P1022; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; HILLIS DM, 1993, SYST BIOL, V42, P90, DOI 10.2307/2992559; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HILLIS DM, 1991, SCIENCE, V254, P528, DOI 10.1126/science.1948027; HILLIS WD, 1993, SCIENCE, V261, P856, DOI 10.1126/science.261.5123.856; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; JUKES T H, 1969, P21; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1987, MOL BIOL EVOL, V4, P167; LARDER BA, 1990, J ACQ IMMUN DEF SYND, V3, P743; LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; Miyamoto MM, 1991, PHYLOGENETIC ANAL DN; MORIYAMA EN, 1991, J MOL EVOL, V32, P360, DOI 10.1007/BF02101275; NEI M, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P90; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PENNY D, 1992, TRENDS ECOL EVOL, V7, P73, DOI 10.1016/0169-5347(92)90244-6; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANKOFF D, 1975, SIAM J APPL MATH, V28, P35, DOI 10.1137/0128004; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SIDOW A, 1994, NATURE, V367, P26, DOI 10.1038/367026a0; SOBER E, 1993, SYST BIOL, V42, P85, DOI 10.2307/2992558; SOKAL RR, 1958, U KANSAS SCI B, V38, P1409; SWOFFORD D., 1990, MOL SYSTEMATICS, P441; WHEELER WC, 1990, CLADISTICS, V6, P269, DOI 10.1111/j.1096-0031.1990.tb00543.x; WHEELER WC, 1988, MOL BIOL EVOL, V5, P90; WILLIAMS PL, 1989, INT CONGR SER, V824, P453; 1993, MORB MORTAL WKLY REP, V42, P329	58	411	419	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	1994	264	5159					671	677		10.1126/science.8171318	http://dx.doi.org/10.1126/science.8171318			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171318				2022-12-28	WOS:A1994NH71300024
J	NELSON, DE; GIOVINO, GA; EMONT, SL; BRACKBILL, R; CAMERON, LL; PEDDICORD, J; MOWERY, PD				NELSON, DE; GIOVINO, GA; EMONT, SL; BRACKBILL, R; CAMERON, LL; PEDDICORD, J; MOWERY, PD			TRENDS IN CIGARETTE-SMOKING AMONG US PHYSICIANS AND NURSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; MEDICAL-STUDENTS; BEHAVIOR; ATTITUDES; HEALTH	Objective.-To determine trends in cigarette smoking prevalence among physicians, registered nurses, and licensed practical nurses since 1974. Design.-Analyses of data on smoking prevalence among persons 20 years of age and older using combined National Health interview Survey data sets from 1974, 1976, and 1977; 1978, 1979, and 1980; 1983 and 1985; 1987 and 1988; and 1990 and 1991. Main Outcome Measures.-Prevalence of cigarette smoking and average annual change in smoking prevalence. Results.-Based on the data for 1990 and 1991, there were an estimated 18 000 physicians, 322 000 registered nurses, and 128 000 licensed practical nurses who smoked cigarettes in the United States. Compared with 1974, 1976, and 1977, by 1990 and 1991 cigarette smoking prevalence had declined from 18.8% to 3.3% among physicians (average annual decline of 1.15 percentage points); from 31.7% to 18.3% among registered nurses (average annual decline of 0.88 percentage point); and from 37.1% to 27.2% among licensed practical nurses (average annual decline of 0.62 percentage point). Conclusion.-Since 1974, cigarette smoking has declined most rapidly among physicians, at an intermediate rate among registered nurses, and at a lower rate among licensed practical nurses. Because of their important roles as exemplars and health educators, persons in these occupations should not smoke.	CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SMOKING & HLTH,ATLANTA,GA 30342; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SURVEILLANCE & ANAL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NIOSH,ATLANTA,GA 30341; BATELLE INC,ARLINGTON,VA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)								BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BECKER DM, 1986, AM J PUBLIC HEALTH, V76, P1449, DOI 10.2105/AJPH.76.12.1449; BRACKBILL R, 1988, AM J IND MED, V13, P5, DOI 10.1002/ajim.4700130103; COE RM, 1980, AM J PUBLIC HEALTH, V70, P169, DOI 10.2105/AJPH.70.2.169; Dalton J A, 1986, Oncol Nurs Forum, V13, P45; DAWLEY HH, 1981, INT J ADDICT, V16, P905, DOI 10.3109/10826088109038898; ELKIND AK, 1980, INT J NURS STUD, V17, P261, DOI 10.1016/0020-7489(80)90034-6; FELDMAN BM, 1986, RES NURS HEALTH, V9, P131, DOI 10.1002/nur.4770090208; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; Garfinkel L, 1976, CA Cancer J Clin, V26, P373, DOI 10.3322/canjclin.26.6.373; GARFINKEL L, 1986, CA-CANCER J CLIN, V36, P2, DOI 10.3322/canjclin.36.1.2; HARVEY LK, 1987, PHYSICIAN OPINION HL; HENSRUD DD, 1993, AM J PUBLIC HEALTH, V83, P415, DOI 10.2105/AJPH.83.3.415; KOTTKE TE, 1985, MINN MED, V68, P53; Levitt E E, 1970, J Indiana State Med Assoc, V63, P336; MASSEY JT, 1989, VITAL HLTH STAT 110, V2; MYERS AH, 1987, AM J PUBLIC HEALTH, V77, P628, DOI 10.2105/AJPH.77.5.628; NOLL CE, 1969, NORC4001 U CHIC NAT; PIERCE JP, 1987, PREV MED, V16, P252, DOI 10.1016/0091-7435(87)90088-0; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; SHAH BV, 1989, SOFTWARE SURVEY DATA; WELLS KB, 1984, JAMA-J AM MED ASSOC, V252, P2846, DOI 10.1001/jama.252.20.2846; 1990, 9M902004 US DEP HLTH; [No title captured]; 1991, NCI NIH923316 PUBL; 1976, ADULT USE TOBACCO 19, P23; 1990, CDC908416 US DEP HLT, P17; 1976, SURVEY HLTH PROFESSI; 1991, MMWR MORB MORTAL WKL, V40, P757; 1985, PHS8550207 US DEP HL; 1993, MMWR MORB MORTAL WKL, V42, P230; 1992, MMWR MORB MORTAL WKL, V41, P354; 1985, VITAL HLTH STAT 18, V1; 1982, PHCC80R4 US DEP COMM; 1979, DHEW PHS7950065 PUBL; 1971, 1970 CENSUS POPULATI	36	142	145	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1273	1275		10.1001/jama.271.16.1273	http://dx.doi.org/10.1001/jama.271.16.1273			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NG362	8151902				2022-12-28	WOS:A1994NG36200028
J	RAMSAY, AJ; HUSBAND, AJ; RAMSHAW, IA; BAO, SS; MATTHAEI, KI; KOEHLER, G; KOPF, M				RAMSAY, AJ; HUSBAND, AJ; RAMSHAW, IA; BAO, SS; MATTHAEI, KI; KOEHLER, G; KOPF, M			THE ROLE OF INTERLEUKIN-6 IN MUCOSAL IGA ANTIBODY-RESPONSES IN-VIVO	SCIENCE			English	Article							B-CELL DIFFERENTIATION; RECOMBINANT VACCINIA VIRUS; GROWTH-FACTOR-BETA; PEYERS PATCH; IMMUNOGLOBULIN-A; T-CELLS; IFN-GAMMA; TERMINAL DIFFERENTIATION; EXPRESSION; TISSUES	In mice with targeted disruption of the gene that encodes interleukin-6 (IL-6), greatly reduced numbers of immunoglobulin A (IgA)-producing cells were observed at mucosae and grossly deficient local antibody responses were recorded after mucosal challenge with either ovalbumin or vaccinia virus. The IgA response in the lungs was completely restored after intranasal infection with recombinant vaccinia viruses engineered to express IL-6. These findings demonstrate a critical role for IL-6 in vivo in the development of local IgA antibody responses and illustrate the effectiveness of vector-directed cytokine gene therapy.	UNIV SYDNEY, DEPT VET PATHOL, SYDNEY, NSW 2006, AUSTRALIA; MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	University of Sydney; Max Planck Society	RAMSAY, AJ (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, CANBERRA, ACT 0200, AUSTRALIA.		Bao, Shisan/AAF-6464-2020; Klaus, Matthaei/D-8691-2011; Kopf, Manfred/B-6907-2009; Bao, Shisan/C-6072-2014	Bao, Shisan/0000-0002-6687-3846; Kopf, Manfred/0000-0002-0628-7140; 				ADA G, 1993, NATURE, V364, P489, DOI 10.1038/364489a0; ANDREW ME, 1986, MICROB PATHOGENESIS, V1, P443, DOI 10.1016/0882-4010(86)90006-9; BAO S, 1993, IMMUNOLOGY, V80, P666; BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133; BEAGLEY KW, 1991, CYTOKINE, V3, P107, DOI 10.1016/1043-4666(91)90030-H; BOYLE DB, 1985, GENE, V35, P169, DOI 10.1016/0378-1119(85)90169-6; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BUTLER JL, 1984, P NATL ACAD SCI-BIOL, V81, P2475, DOI 10.1073/pnas.81.8.2475; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; COHEN J, 1993, SCIENCE, V260, P1254, DOI 10.1126/science.8493564; COUPAR BEH, 1987, J GEN VIROL, V68, P2299, DOI 10.1099/0022-1317-68-9-2299; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DUNKLEY ML, 1990, IMMUNOLOGY, V71, P16; DUNKLEY ML, 1990, IMMUNOL LETT, V26, P165, DOI 10.1016/0165-2478(90)90140-L; DUNKLEY ML, 1991, REG IMMUNOL, V3, P336; FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284; HARRIMAN GR, 1988, J IMMUNOL, V140, P3033; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSBAND AJ, UNPUB; KARUPIAH G, 1990, J IMMUNOL, V144, P290; KAWANISHI H, 1983, J EXP MED, V158, P649, DOI 10.1084/jem.158.3.649; KELLY EAB, 1991, J IMMUNOL, V147, P306; KIYONO H, 1982, J EXP MED, V156, P1115, DOI 10.1084/jem.156.4.1115; KIYONO H, 1984, J EXP MED, V159, P798, DOI 10.1084/jem.159.3.798; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kroese FGM, 1989, INT IMMUNOL, V1, P75, DOI 10.1093/intimm/1.1.75; LEBMAN DA, 1990, J IMMUNOL, V144, P952; MEGA J, 1992, J IMMUNOL, V148, P2030; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER CJ, 1993, LAB INVEST, V68, P129; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MURRAY PD, 1987, J IMMUNOL, V139, P2669; OKADA M, 1983, J EXP MED, V157, P583, DOI 10.1084/jem.157.2.583; RAMSAY AJ, 1993, EUR J IMMUNOL, V23, P3141, DOI 10.1002/eji.1830231215; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RUDZIK R, 1975, J IMMUNOL, V114, P1599; TAGUCHI T, 1990, J IMMUNOL, V145, P68; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309; [No title captured]	45	391	405	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					561	563		10.1126/science.8160012	http://dx.doi.org/10.1126/science.8160012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160012				2022-12-28	WOS:A1994NH01000034
J	CORNELIUSSEN, B; HOLM, M; WALTERSSON, Y; ONIONS, J; HALLBERG, B; THORNELL, A; GRUNDSTROM, T				CORNELIUSSEN, B; HOLM, M; WALTERSSON, Y; ONIONS, J; HALLBERG, B; THORNELL, A; GRUNDSTROM, T			CALCIUM/CALMODULIN INHIBITION OF BASIC-HELIX-LOOP-HELIX TRANSCRIPTION FACTOR DOMAINS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING PROTEINS; MOUSE RETROVIRUS SL3-3; DNA-BINDING; SEQUENCE; ENHANCER; MYOD; ACTIVATION; CELLS; GENE	THE ubiquitous Ca2+-binding protein calmodulin (CaM) is a key protein in Ca2+ homeostasis and activation of eukaryotic cells. CaM is the molecular link between free Ca2+ in the cell and the inhibition, or activation, of numerous enzymes. Many nuclear functions are under Ca2+/CaM control, and some transcriptional activators are known to be Ca2+ modulated indirectly through Ca2+/CaM-dependent protein kinases(1-4). But Ca2+/CaM has not yet been found to directly modulate any transcription factor or other DNA-binding protein. Transcription factors of the basic-helix-loop-helix (bHLK) group are important regulators in numerous systems(5-11). Here we report that binding of Ca2+-loaded CaM to the bHLH domains of several bHLH proteins directly inhibits their DNA binding. Other bHLH proteins are either less sensitive or resistant. Ca2+ ionophore selectively inhibits transcriptional activation by Ca2+/CaM-sensitive bHLH proteins in vivo, implying that Ca2+ can directly influence transcription through differential CaM inhibition of bHLH domains.	UMEA UNIV,DEPT APPL CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN	Umea University			Holm, Magnus/B-8932-2008					BACHS O, 1987, J BIOL CHEM, V262, P10786; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; HALLBERG B, 1988, NUCLEIC ACIDS RES, V16, P5927, DOI 10.1093/nar/16.13.5927; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; THORNELL A, 1993, J BIOL CHEM, V268, P21946; VENDRELL M, 1991, J NEUROCHEM, V57, P622, DOI 10.1111/j.1471-4159.1991.tb03793.x; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	30	144	147	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					760	764		10.1038/368760a0	http://dx.doi.org/10.1038/368760a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152489				2022-12-28	WOS:A1994NG55300064
J	KAHN, KL; PEARSON, ML; HARRISON, ER; DESMOND, KA; ROGERS, WH; RUBENSTEIN, LV; BROOK, RH; KEELER, EB				KAHN, KL; PEARSON, ML; HARRISON, ER; DESMOND, KA; ROGERS, WH; RUBENSTEIN, LV; BROOK, RH; KEELER, EB			HEALTH-CARE FOR BLACK AND POOR HOSPITALIZED MEDICARE PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT SYSTEM; WHITE MORTALITY CROSSOVER; SOCIOECONOMIC-STATUS; QUALITY; RACE; TRANSPLANTATION; IMPLEMENTATION; MASSACHUSETTS; DISCHARGE; OUTCOMES	Objective.-To analyze whether elderly patients who are black or from poor neighborhoods receive worse hospital care than other patients, taking account of hospital effects and using validated measures of quality of care. Design.-We compare quality of care provided to insured, hospitalized Medicare patients who are black or live in poor neighborhoods as compared with others, using simple and multivariable comparisons of clinically detailed measures of sickness at admission, quality, and outcomes. Setting.-Two hundred ninety-seven acute care hospitals in 30 areas within five states. Patients or Other Participants.-The sample includes a nationally representative sample of 9932 patients 65 years of age or older who lived at home prior to hospitalization for congestive heart failure, acute myocardial infarction, pneumonia, or stroke. Interventions.-This was an observational study. Main Outcome Measures.-Processes of care, length of stay, instability at discharge, discharge destination, and mortality. Results.-Within rural, urban nonteaching, and urban teaching hospitals, patients who are black or from poor neighborhoods have worse processes of care and greater instability at discharge than other patients (P<.05). However, this worse quality is offset by patients who are black or from poor neighborhoods being 1.8 times more likely to receive care in urban teaching hospitals that have been shown to provide better quality of care (P<.001). Because these patients receive more of their care in better-quality hospitals, there are no overall differences in quality by race and poverty status. Death rates did not vary by race or poverty status. Conclusions.-Quality of hospital care for insured Medicare patients is influenced both by the patient's race and financial characteristics and by the hospital type in which the patient receives care.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT HLTH SERV,LOS ANGELES,CA 90024; VET HLTH ADM MED CTR,SEPULVEDA,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA)	KAHN, KL (corresponding author), RAND CORP,HLTH PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90407, USA.		Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455	AHRQ HHS [5-RO1-HSO6546-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1984, ACCESS MED CARE; Aday LA, 1980, HLTH CARE US EQUITAB; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1992, JAMA-J AM MED ASSOC, V268, P1321, DOI 10.1001/jama.268.10.1321; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; DRAPER D, 1990, JAMA-J AM MED ASSOC, V264, P1956, DOI 10.1001/jama.264.15.1956; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FLAHERTY JA, 1980, AM J PSYCHIAT, V137, P679; FORD AB, 1990, J GERONTOL, V45, pS163, DOI 10.1093/geronj/45.4.S163; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HOOPER EM, 1982, MED CARE, V20, P630, DOI 10.1097/00005650-198206000-00009; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KAHN KL, 1992, RAND R3931HCFA PUBL; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KEIL JE, 1992, AM J PUBLIC HEALTH, V82, P1133, DOI 10.2105/AJPH.82.8.1133; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; KOTZ S, 1983, ENCY STAT SCI, V3, P24; LEVY DR, 1985, PEDIATRICS, V75, P639; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; Manton K.G., 1982, MINORITY AGING SOCIO, P63; MANTON KG, 1980, GERONTOLOGIST, V20, P480, DOI 10.1093/geront/20.4.480; MANTON KG, 1987, MILBANK Q, V65, P129, DOI 10.2307/3349954; MANTON KG, 1979, GERONTOLOGIST, V19, P291, DOI 10.1093/geront/19.3.291; MANUEL RC, 1988, BLACK AMERICAN ELDERLY, P25; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; PAPPER S, 1970, J CHRON DIS, V22, P777, DOI 10.1016/0021-9681(70)90079-2; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; RIMM AA, 1992, JAMA-J AM MED ASSOC, V267, P1473; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; ROTH JA, 1969, POVERTY HLTH SOCIOLO, P214; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; Steward A., 1992, MEASURING FUNCTIONIN, P345; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; Wolkon G H, 1978, J Natl Med Assoc, V70, P185; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1992, STATA REF MANUAL, V2; 1990, RURAL URBAN CONTINUO; [No title captured]; 1990, JAMA-J AM MED ASSOC, V263, P2344	51	271	272	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1169	1174		10.1001/jama.271.15.1169	http://dx.doi.org/10.1001/jama.271.15.1169			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF207	8151874				2022-12-28	WOS:A1994NF20700025
J	THALER, DS				THALER, DS			THE EVOLUTION OF GENETIC INTELLIGENCE	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; DIRECTED MUTATION; ORIGIN				THALER, DS (corresponding author), ROCKEFELLER UNIV,MOLEC GENET & INFORMAT LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							ARNDT W, 1956, MICROB GENET B, V14, P5; BATSON G, 1971, STEPS ECOLOGY MIND; CAIRNS J, 1993, SCIENCE, V260, P1221, DOI 10.1126/science.8493560; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DELBRUCK M, 1986, MIND MATTER ESSAY EV; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; GRAFEN A, 1988, NATURE, V336, P525, DOI 10.1038/336525b0; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; KELLER EF, 1992, PERSPECT BIOL MED, V35, P292; Kolter R, 1992, ASM NEWS, V58, P75; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LURIA SE, 1943, GENETICS, V28, P490; MCCLINTOCK B, 1983, PRIX NOBEL, P174; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; RUDNER R, 1981, MUTAT RES, V83, P321, DOI 10.1016/0027-5107(81)90015-4; SHAPIRO JA, 1989, J BACTERIOL, V171, P5975, DOI 10.1128/jb.171.11.5975-5986.1989; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SHAPIRO JA, 1993, J BACTERIOL, V175, P2825; STAHL FW, 1992, GENETICS, V132, P865; STRAUSS BS, 1992, CANCER RES, V52, P249; THALER DS, 1994, TRENDS ECOL EVOL, V9, P108, DOI 10.1016/0169-5347(94)90208-9; THALER DS, 1990, BACTERIAL CHROMOSOME, P445; WALKER GC, 1987, ESCHERICHIA COLI SAL, P1346	30	57	59	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					224	225		10.1126/science.8146652	http://dx.doi.org/10.1126/science.8146652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146652				2022-12-28	WOS:A1994NE41000026
J	WANG, XD; SATO, R; BROWN, MS; HUA, XX; GOLDSTEIN, JL				WANG, XD; SATO, R; BROWN, MS; HUA, XX; GOLDSTEIN, JL			SREBP-1, A MEMBRANE-BOUND TRANSCRIPTION FACTOR RELEASED BY STEROL-REGULATED PROTEOLYSIS	CELL			English	Article							PROTEIN; CHOLESTEROL; RECEPTOR; REPRESSION; INHIBITORS; SEQUENCES; PROMOTER; SYNTHASE; PATHWAY; BINDING	Sterol regulatory element-binding protein 1 (SREBP-1), a member of the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) family of transcription factors, is synthesized as a 125 kd precursor that is attached to the nuclear envelope and endoplasmic reticulum. In sterol-depleted cells, the membrane-bound precursor is cleaved to generate a soluble NH2-terminal fragment (apparent molecular mass, 68 kd) that translocates to the nucleus. This fragment, which includes the bHLH-ZIP domain, activates transcription of the genes for the LDL receptor and HMG coA synthase. Sterols inhibit the cleavage of SREBP-1, and the 68 kd nuclear form is rapidly catabolized, thereby reducing transcription. ALLN, an inhibitor of neutral cysteine proteases, blocks the breakdown of the 68 kd form and superinduces sterol-regulated genes. Sterol-regulated proteolysis of a membrane-bound transcription factor provides a novel mechanism by which transcription can be regulated by membrane lipids.			WANG, XD (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Wang, Xiaodong/0000-0001-9885-356X	FOGARTY INTERNATIONAL CENTER [F05TW004571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; FIC NIH HHS [FO5 TWO4571] Funding Source: Medline; NHLBI NIH HHS [HL-20948] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GIL G, 1987, P NATL ACAD SCI USA, V84, P1863, DOI 10.1073/pnas.84.7.1863; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; INOUE S, 1991, J BIOL CHEM, V266, P13311; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1992, J LIPID RES, V33, P315; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JR, 1988, J BIOL CHEM, V263, P18480; URBANI L, 1990, J BIOL CHEM, V265, P1919; WANG XD, 1993, J BIOL CHEM, V268, P14497; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	25	824	854	3	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					53	62		10.1016/0092-8674(94)90234-8	http://dx.doi.org/10.1016/0092-8674(94)90234-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156598				2022-12-28	WOS:A1994NF21100009
J	FEI, YJ; KANAI, Y; NUSSBERGER, S; GANAPATHY, V; LEIBACH, FH; ROMERO, MF; SINGH, SK; BORON, WF; HEDIGER, MA				FEI, YJ; KANAI, Y; NUSSBERGER, S; GANAPATHY, V; LEIBACH, FH; ROMERO, MF; SINGH, SK; BORON, WF; HEDIGER, MA			EXPRESSION CLONING OF A MAMMALIAN PROTON-COUPLED OLIGOPEPTIDE TRANSPORTER	NATURE			English	Article							NA+ GLUCOSE COTRANSPORTER; BORDER MEMBRANE-VESICLES; BETA-LACTAM ANTIBIOTICS; GLYCYL-L-PROLINE; SMALL-INTESTINE; RABBIT; PH; SPECIFICITY; ABSORPTION; CDNA	IN mammals, active transport of organic solutes across plasma membranes was thought to be primarily driven by the Na+ gradient1-3. Here we report the cloning and functional characterization of a H+-coupled transporter of oligopeptides and peptide-derived antibiotics from rabbit small intestine. This new protein, named PepT1, displays an unusually broad substrate specificity. PepT1-mediated uptake is electrogenic, independent of extracellular Na+, K+ and Cl-, and of membrane potential. PepT1 messenger RNA was found in intestine, kidney and liver and in small amounts in brain. In the intestine, the PepT1 pathway constitutes a major mechanism for absorption of the products of protein digestion. To our knowledge, the PepT1 primary structure is the first reported for a proton-coupled organic solute transporter in vertebrates and represents an interesting evolutionary link between prokaryotic H+-coupled and vertebrate Na+-coupled transporters of organic solutes.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University System of Georgia; Augusta University; Yale University			Boron, Walter/ABI-1564-2020	Hediger, Matthias/0000-0003-1946-027X; Boron, Walter/0000-0003-4741-7287; Romero, Michael F/0000-0002-1555-7835; Nussberger, Stephan/0000-0003-3619-4452	NIDDK NIH HHS [F32 DK009342-03, F32 DK009342-02, F32 DK009342-01, F32 DK009342] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1987, J PHYSIOL-LONDON, V394, P481, DOI 10.1113/jphysiol.1987.sp016882; ADEDOYIN A, 1993, DRUG METAB DISPOS, V21, P184; ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; CRANE RK, 1961, MEMBRANE TRANSPORT M, P439; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; DAVIS BA, 1992, AM J PHYSIOL, V263, pC246, DOI 10.1152/ajpcell.1992.263.1.C246; DYER J, 1990, BIOCHEM J, V269, P565, DOI 10.1042/bj2690565; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1985, BIOCHIM BIOPHYS ACTA, V816, P234, DOI 10.1016/0005-2736(85)90490-0; Ganapathy Vadivel, 1994, P1773; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; KABACK HR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P210, DOI 10.1016/0005-2728(92)90227-S; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; LOMBARDO YB, 1988, J BIOL CHEM, V263, P12920; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; SINKO PJ, 1989, J PHARM SCI, V78, P723, DOI 10.1002/jps.2600780904; THWAITES DT, 1993, J BIOL CHEM, V268, P7340; TRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	30	739	779	2	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					563	566		10.1038/368563a0	http://dx.doi.org/10.1038/368563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139693				2022-12-28	WOS:A1994NE33500060
J	FREEMAN, WT				FREEMAN, WT			THE GENERIC VIEWPOINT ASSUMPTION IN A FRAMEWORK FOR VISUAL-PERCEPTION	NATURE			English	Article							REGULARIZATION; VISION	A VISUAL system makes assumptions in order to interpret visual data. The assumption of 'generic view'1-4 states that the observer is not in a special position relative to the scene. Researchers commonly use a binary decision of generic or accidental view to disqualify scene interpretations that assume accidental viewpoints5-10. Here we show how to use the generic view assumption, and others like it, to quantify the likelihood of a view, adding a new term to the probability of a given image interpretation. The resulting framework better models the visual world and reduces the reliance on other prior assumptions. It may lead to computer vision algorithms of greater power and accuracy, or to better models of human vision. We show applications to the problems of inferring shape, surface reflectance properties, and motion from images.			FREEMAN, WT (corresponding author), MITSUBISHI ELECT RES LABS, 201 BROADWAY, CAMBRIDGE, MA 02139 USA.							Berger J.O., 1985, STAT DECISION THEORY, P74; Bichsel M., 1992, Proceedings. 1992 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (Cat. No.92CH3168-2), P459, DOI 10.1109/CVPR.1992.223150; BIEDERMAN I, 1985, COMPUT VISION GRAPH, V32, P29, DOI 10.1016/0734-189X(85)90002-7; BINFORD TO, 1981, ARTIF INTELL, V17, P205, DOI 10.1016/0004-3702(81)90025-4; COOK RL, 1981, SIGGRAPH 81; Freeman W. T., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P347, DOI 10.1109/ICCV.1993.378193; FREEMAN WT, IN PRESS INT J COMP; HORN BKP, 1981, ARTIF INTELL, V17, P185, DOI 10.1016/0004-3702(81)90024-2; JEPSON AD, 1992, SPATIAL VISION HUMAN; KOENDERINK JJ, 1979, BIOL CYBERN, V32, P211, DOI 10.1007/BF00337644; Leclerc Y. G., 1991, Proceedings 1991 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (91CH2983-5), P552, DOI 10.1109/CVPR.1991.139752; LOWE DG, 1985, IEEE T PATTERN ANAL, V7, P320, DOI 10.1109/TPAMI.1985.4767660; MACKAY DJC, 1992, NEURAL COMPUT, V4, P415, DOI 10.1162/neco.1992.4.3.448; MALIK J, 1987, INT J COMPUT VISION, V1, P73, DOI 10.1007/BF00128527; Marr D., 1982, VISION; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; NAKAYAMA K, 1988, VISION RES, V28, P739, DOI 10.1016/0042-6989(88)90052-1; PENTLAND AP, 1990, INT J COMPUT VISION, V4, P153, DOI 10.1007/BF00127815; POGGIO T, 1985, NATURE, V317, P314, DOI 10.1038/317314a0; RICHARDS WA, 1987, J OPT SOC AM A, V4, P1168, DOI 10.1364/JOSAA.4.001168; SZELISKI R, 1989, BAYESIAN MODELING UN; TERZOPOULOS D, 1986, IEEE T PATTERN ANAL, V8, P413, DOI 10.1109/TPAMI.1986.4767807; Tikhonov A., 1977, SOLUTION ILL POSED P; WEINSHALL D, 1994, 3RD P EUR C COMP VIS	24	139	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					542	545		10.1038/368542a0	http://dx.doi.org/10.1038/368542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139687				2022-12-28	WOS:A1994NE33500053
J	MALTBY, N; BROE, GA; CREASEY, H; JORM, AF; CHRISTENSEN, H; BROOKS, WS				MALTBY, N; BROE, GA; CREASEY, H; JORM, AF; CHRISTENSEN, H; BROOKS, WS			EFFICACY OF TACRINE AND LECITHIN IN MILD-TO-MODERATE ALZHEIMERS-DISEASE - DOUBLE-BLIND TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MUSCARINIC AGONIST THERAPY; SENILE DEMENTIA; ORAL TETRAHYDROAMINOACRIDINE; MEMORY; TERM; PHYSOSTIGMINE; MULTICENTER; ENHANCEMENT; THA	Objective-To assess the efficacy of tacrine and lecithin in treating Alzheimer's disease over nine months. Design-Double blind randomised controlled Setting-Outpatients clinic of university department of geriatric medicine. Subjects-53 subjects (26 women, 27 men) with probable Alzheimer's disease. 41 completed the dose finding phase and were randomised to treatment. 32 (14 tacrine, 18 placebo) completed nine months' treatment. Interventions-Lecithin and tacrine or lecithin and placebo for 36 weeks. Main outcome measures--Scores on neuropsychological tests sensitive to deficits in the cholinergic system; mini-mental state score; behaviour change; mood; functional state; and stress in carers. Results-The tacrine and placebo groups were similar except that the tacrine group had a longer duration of disease (mean 5.4 v 2.5 years in placebo group; P=0.003). Only 17 of the 32 patients could tolerate the maximum dose of tacrine (100 mg). No significant difference was found between the groups for any of the tests after nine months' treatment except for the digit backwards test, which is insensitive to cholinergic deficit. Analysis of subjects taking the maximum dose of tacrine and of subjects with mild dementia also found no differences. Conclusions-Tacrine produces no clinically relevant improvement over 36 weeks at the doses tolerated by these patients.	UNIV SYDNEY, REPATRIAT GEN HOSP, DEPT GERIATR MED, CONCORD 2139, AUSTRALIA; AUSTRALIAN NATL UNIV, NATL HLTH & MRC, SOCIAL PSYCHIAT RES UNIT, CANBERRA 0200, AUSTRALIA	Concord Repatriation General Hospital; University of Sydney; Australian National University			Jorm, Anthony F/B-5555-2009; Christensen, Helen/F-5053-2012	Jorm, Anthony F/0000-0002-1424-4116; Christensen, Helen/0000-0003-0435-2065; Brooks, William Seymour/0000-0001-8603-4233				AMES DJ, 1990, AUST NZ J MED, V20, P193, DOI 10.1111/j.1445-5994.1990.tb01309.x; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1207; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BELLER SA, 1988, J CLIN PSYCHIAT, V49, P400; Brink TL., 1982, CLIN GERON, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; BRUNO G, 1986, ARCH NEUROL-CHICAGO, V43, P659, DOI 10.1001/archneur.1986.00520070017009; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; CHRISTENSEN H, 1992, BRAIN, V115, P1681, DOI 10.1093/brain/115.6.1681; Cohen J, 1977, STATISTICAL POWER AN; DAVIES B, 1990, INT J GERIATR PSYCH, V5, P317, DOI 10.1002/gps.930050508; DAVIS KL, 1982, AM J PSYCHIAT, V139, P1421; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FITTEN LJ, 1990, AM J PSYCHIAT, V147, P239; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORSYTH DR, 1989, AGE AGEING, V18, P223, DOI 10.1093/ageing/18.4.223; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; HAMMEL P, 1990, J CLIN GASTROENTEROL, V12, P329, DOI 10.1097/00004836-199006000-00021; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P618; HERSCH EL, 1978, J AM GERIATR SOC, V26, P348, DOI 10.1111/j.1532-5415.1978.tb03682.x; HOLLANDER E, 1986, BRIT MED BULL, V42, P97, DOI 10.1093/oxfordjournals.bmb.a072106; JORM AF, 1986, AUST NZ J PSYCHIAT, V20, P237, DOI 10.3109/00048678609161337; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KRAEMER HC, 1983, PSYCHOL BULL, V94, P367, DOI 10.1037/0033-2909.94.2.367; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEVY R, 1987, LANCET, V1, P322; LITTLE A, 1985, J NEUROL NEUROSUR PS, V48, P736, DOI 10.1136/jnnp.48.8.736; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCNAIR DM, 1978, MANUAL PROFILE MOOD; MOLLOY DW, 1991, CAN MED ASSOC J, V144, P29; MOURADIAN MM, 1988, NEUROLOGY, V38, P606, DOI 10.1212/WNL.38.4.606; MURAMOTO O, 1984, CORTEX, V20, P461, DOI 10.1016/S0010-9452(84)80052-0; Nelson H.E., 1982, NATIONAL ADULT READI; PENN RD, 1988, NEUROLOGY, V38, P219, DOI 10.1212/WNL.38.2.219; PETERS BH, 1979, ANN NEUROL, V6, P219, DOI 10.1002/ana.410060307; PIROZZOLO FJ, 1987, NEW ENGL J MED, V316, P1603; RELMAN AS, 1991, NEW ENGL J MED, V324, P349, DOI 10.1056/NEJM199101313240525; STERN Y, 1988, NEUROLOGY, V38, P1837, DOI 10.1212/WNL.38.12.1837; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; SUMMERS WK, 1989, EUR NEUROL, V29, P28, DOI 10.1159/000116478; TARIOT PN, 1988, ARCH GEN PSYCHIAT, V45, P901; Walsh K. W., 1966, NEUROPSYCHOLOGY CLIN; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Weigl E, 1941, J ABNORM SOC PSYCH, V36, P3, DOI 10.1037/h0055544; WILCOCK GK, 1993, AGE AGEING, V22, P316, DOI 10.1093/ageing/22.5.316; WURTMAN RJ, 1988, CURRENT RES ALZHEIME; 1987, DIAGNOSTIC STATISTIC	49	81	83	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	1994	308	6933					879	883		10.1136/bmj.308.6933.879	http://dx.doi.org/10.1136/bmj.308.6933.879			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173365	Green Published			2022-12-28	WOS:A1994NE60000018
J	GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A				GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A			CASE-CONTROL STUDY OF INTRAPARTUM CARE, CEREBRAL-PALSY, AND PERINATAL DEATH	BRITISH MEDICAL JOURNAL			English	Article							ASPHYXIA	Objective-To investigate the relation between suboptimal intrapartum obstetric care and cerebral palsy or death. Design-Case-control study. Setting-Oxford Regional Health Authority. Subjects-141 babies who subsequently developed cerebral palsy and 62 who died intrapartum or neonatally, 1984-7. All subjects were born at term of singleton pregnancies and had no congenital anomaly. Two controls, matched for place and time of birth, were selected for each index case. Main outcome measures-Adverse antenatal factors and suboptimal intrapartum care (by using predefined criteria). Results-Failure to respond to signs of severe fetal distress was more common in cases of cerebral palsy (odds ratio 4.5; 95% confidence interval 2.4 to 8.4) and in cases of death (26.1; 6.2 to 109.7) than among controls. This association persisted even after adjustment for increased incidence of a complicated obstetric history in cases of cerebral palsy. Neonatal encephalopathy is regarded as the best clinical indicator of birth asphyxia; only two thirds (23/33) of the children with cerebral palsy in whom there had been a suboptimal response to fetal distress, however, had evidence of neonatal encephalopathy; these 23 formed 6.8% of all children with cerebral palsy born to residents of the region in the four years studied. Conclusion-There is an association between quality of intrapartum care and death. The findings also suggest an association between suboptimal care and cerebral palsy, but this seems to have a role in only a small proportion of all cases of cerebral palsy. The contribution of adverse antenatal factors in the origin of cerebral palsy needs further study.	RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,OXON,ENGLAND; JOHN RADCLIFFE MATERN HOSP,OXFORD OX3 9DU,OXON,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,OXON,ENGLAND	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Johnson, Anne/0000-0003-1330-7100				BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; FREEMAN JM, 1988, PEDIATRICS, V82, P240; Gilles FH, 1983, DEV HUMAN BRAIN GROW, P227; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; JOHNSON A, 1989, COMMUNITY MED, V11, P352; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1989, CLIN PERINATOL, V16, P995, DOI 10.1016/S0095-5108(18)30617-1; NISWANDER K, 1984, LANCET, V2, P827; PANETH N, 1983, OBSTET GYNECOL, V61, P547; RICHMOND S, IN PRESS OBSTET GYNE; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SIMS ME, 1985, AM J OBSTET GYNECOL, V151, P721, DOI 10.1016/0002-9378(85)90503-4; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, WORKING PARTY RESUSC; 1989, EGRET EPIDEMIOLOGICA; 1988, OPCS MONITOR, pDH3	25	128	129	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					743	750		10.1136/bmj.308.6931.743	http://dx.doi.org/10.1136/bmj.308.6931.743			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142827	Green Published			2022-12-28	WOS:A1994NC34800016
J	KAS, J; STREY, H; SACKMANN, E				KAS, J; STREY, H; SACKMANN, E			DIRECT IMAGING OF REPTATION FOR SEMIFLEXIBLE ACTIN-FILAMENTS	NATURE			English	Article							F-ACTIN; DYNAMICS; CHAIN; MOTION	ACCORDING to the reptation model of polymer diffusion(1), a polymer chain exhibits snake-like motion through the entangled mesh of surrounding molecules, in which the undulations of the chain are restricted to a tubelike region(2). The reptation model can account for many of the dynamic properties of entangled polymer solutions and melts, and has received support from observations of block copolymer diffusion across an interface(3); but reptative motion has not previously been imaged directly(4,5). Here we report such a direct observation of reptation, obtained by video microscopy of fluorescently labelled single, semiflexible filaments of actin in a solution of unlabelled actin filaments. From the restricted thermal undulations of these filaments we can measure the diameter of the confining tube, and we also observe the characteristic thermally excited sliding of the filament out of the end of the tube. We find that the chain self-diffusion coefficient decreases approximately linearly as the filament length increases, in agreement with the reptation model.	TECH UNIV MUNICH, DEPT PHYS, BIOPHYS GRP, D-85748 GARCHING, GERMANY	Technical University of Munich	KAS, J (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV EXPTL MED, BOSTON, MA 02115 USA.		Strey, Helmut/B-5456-2009	Kas, Josef A./0000-0003-3158-2480; Strey, Helmut/0000-0002-6554-5322				Alberts B., 1989, MOL BIOL CELL; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; DEGENNES PG, 1976, J PHYS-PARIS, V37, P1461, DOI 10.1051/jphys:0197600370120146100; Doi M., 1988, THEORY POLYM DYNAMIC; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; GRAESSLEY WW, 1980, J POLYM SCI, V13, P17; HIGGINS J, 1993, NATURE, V365, P205, DOI 10.1038/365205a0; HONDA H, 1986, J MOL BIOL, V191, P131, DOI 10.1016/0022-2836(86)90428-6; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; KAS J, 1993, EUROPHYS LETT, V21, P865, DOI 10.1209/0295-5075/21/8/012; KAUFMANN S, 1992, FEBS LETT, V314, P203, DOI 10.1016/0014-5793(92)80975-M; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Landau L. D., 1980, STAT PHYS, P544; LODGE TP, 1990, ADV CHEM PHYS, V79, P1; RUSSELL TP, 1993, NATURE, V365, P235, DOI 10.1038/365235a0; SACKMANN E, 1994, MACROMOL CHEM PHYSIC, V195, P7, DOI 10.1002/macp.1994.021950103; SCHMIDT CF, 1989, MACROMOLECULES, V22, P3638, DOI 10.1021/ma00199a023; SEMENOV AN, 1986, J CHEM SOC FARAD T 2, V82, P317, DOI 10.1039/f29868200317; WENDEL H, 1982, MACROMOLECULES, V15, P1318, DOI 10.1021/ma00233a020; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	20	211	211	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 17	1994	368	6468					226	229		10.1038/368226a0	http://dx.doi.org/10.1038/368226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145821				2022-12-28	WOS:A1994NA87000049
J	OHKUMA, Y; ROEDER, RG				OHKUMA, Y; ROEDER, RG			REGULATION OF TFIIH ATPASE AND KINASE-ACTIVITIES BY TFIIE DURING ACTIVE INITIATION COMPLEX-FORMATION	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR TFIIE; CARBOXYL-TERMINAL-DOMAIN; PREINITIATION COMPLEX; LARGEST SUBUNIT; NONPHOSPHORYLATED FORM; TATA FACTOR; PHOSPHORYLATION; PURIFICATION; MOTIFS	THE general transcripton factor TFIIE, together with other general transcription factors, is essential for transcription initiation by RNA polymerase II1-5 TFIIE stimulates the TFIIH-dependent kinase activity that phosphorylates the carboxy-terminal domain of the largest subunit of RNA polymerase II6, and possesses a helicase activity(7). Here we show that human TFIIH has DNA-dependent ATPase activity and we characterize the stimulatory effect of TFIIE on both the ATPase and kinase activities. We demonstrate that extensive phosphorylation of RNA polymerase II occurs in a TFIIE-dependent manner in both the absence and presence of DNA but, in the latter case, only at a late stage of preinitiation complex assembly. We also show that TFIIH specifically phosphorylates three general transcription factors, human TFIID tau (TBP), TFIIE-alpha and TFIIF-alpha (RAP74).			OHKUMA, Y (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RAPPAPORT J, 1987, J BIOL CHEM, V262, P17510; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; ZAWAL L, 1993, PROG NUCLEIC ACID RE, V44, P67	29	143	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					160	163		10.1038/368160a0	http://dx.doi.org/10.1038/368160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8166891				2022-12-28	WOS:A1994NA03000070
J	REICHARD, P; NILSSON, BY; ROSENQVIST, U				REICHARD, P; NILSSON, BY; ROSENQVIST, U			THE EFFECT OF LONG-TERM INTENSIFIED INSULIN-TREATMENT ON THE DEVELOPMENT OF MICROVASCULAR COMPLICATIONS OF DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METABOLIC CONTROL; NERVE-CONDUCTION; RETINOPATHY; NEUROPATHY; INTERVENTION; PROGRESSION; NEPHROPATHY; SDIS; NORMOGLYCEMIA; THRESHOLDS	Background. A cause-and-effect relation between blood glucose concentrations and microvascular complications in patients with insulin-dependent diabetes mellitus has not been established. Methods. We randomly assigned 102 patients with insulin-dependent diabetes' mellitus, nonproliferative retinopathy, normal serum creatinine concentrations, and unsatisfactory blood glucose control to intensified insulin treatment (48 patients) or standard insulin treatment (54 patients). We then evaluated them for microvascular complications after 18 months and 3, 5, and 7.5 years. Results. Mean (+/-SD) glycosylated hemoglobin values were reduced from 9.5+/-1.3 percent to 7.1+/-0.7 percent in the group receiving intensified treatment and from 9.4+/-1.4 percent to 8.5+/-0.7 percent in the group receiving standard treatment (P = 0.001). In 12 of the patients receiving intensified treatment (27 percent of those included in the analysis) and 27 of those receiving standard treatment (52 percent), serious retinopathy requiring photocoagulation developed (P = 0.01). Visual acuity decreased in 6 patients receiving intensified treatment (14 percent) and in 18 receiving standard treatment (35 percent) (P = 0.02). Nephropathy (urinary albumin excretion, >200 mug per minute) developed in one patient in the group receiving intensified treatment, as compared with nine patients in the group receiving standard treatment (P = 0.01). No patient in the intensified-treatment group had nephropathy with subnormal glomerular filtration rates, as compared with six patients in the standard-treatment group (P = 0.02). The conduction velocities of the ulnar, tibial, peroneal, and sural nerves decreased significantly more in the standard-treatment group than in the intensified-treatment group. The odds ratio for serious retinopathy was 0.4 (95 percent confidence interval, 0.2 to 1.0; P = 0.04) in the intensified-treatment group as compared with the standard-treatment group. The corresponding odds ratio for nephropathy was 0.1 (95 percent confidence interval, 0 to 0.8; P = 0.04). Conclusions. Long-term intensified insulin treatment, as compared with standard treatment, retards the development of microvascular complications in patients with insulin-dependent diabetes mellitus.	STOCKHOLM CTY COUNCIL TEACHING CTR DIABET,STOCKHOLM,SWEDEN; SODER SJUKHUSET,DEPT CLIN NEUROPHYSIOL,S-10064 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,S-10401 STOCKHOLM 60,SWEDEN	Stockholm County Council; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital	REICHARD, P (corresponding author), SODER SJUKHUSET,DEPT INTERNAL MED,S-11883 STOCKHOLM,SWEDEN.		Rosenqvist, Urban/Q-1986-2016					Beck-Nielsen H, 1990, Diabetes Res, V15, P185; BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; CHANTLER C, 1969, CLIN SCI, V37, P169; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DYCK PJ, 1989, DIABETES CARE, V12, P649, DOI 10.2337/diacare.12.9.649; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GARDNER MJ, 1989, STATISTICS CONFIDENC, P29; GERSOVITZ M, 1978, J AM DIET ASSOC, V73, P48; GOLDBERG JM, 1979, J NEUROL NEUROSUR PS, V42, P793, DOI 10.1136/jnnp.42.9.793; KALM H, 1989, ACTA OPHTHALMOL, V67, P554; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LUDIN HP, 1980, ELECTROMYOGRAPHY PRA, P31; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; REICHARD P, 1992, DIABETES RES CLIN PR, V16, P151, DOI 10.1016/0168-8227(92)90087-8; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; REICHARD P, 1989, J INTERN MED, V226, P81, DOI 10.1111/j.1365-2796.1989.tb01359.x; REICHARD P, 1990, J INTERN MED, V228, P511, DOI 10.1111/j.1365-2796.1990.tb00271.x; REICHARD P, 1988, ACTA MED SCAND, V224, P115; REICHARD P, 1991, OPHTHALMOLOGY, V98, P1587; SERVICE FJ, 1985, DIABETOLOGIA, V28, P722; 1982, LANCET, V1, P121; 1988, JAMA-J AM MED ASSOC, V260, P37; 1984, NEW ENGL J MED, V311, P365; 1984, DIABETOLOGIA, V311, P365	31	1021	1052	2	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					304	309		10.1056/NEJM199307293290502	http://dx.doi.org/10.1056/NEJM199307293290502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8147960				2022-12-28	WOS:A1993LN62100002
J	GALLANT, JE; MOORE, RD; CHAISSON, RE				GALLANT, JE; MOORE, RD; CHAISSON, RE			PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS IN PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; MYCOBACTERIUM-AVIUM COMPLEX; IMMUNE-DEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; WEEKLY DAPSONE-PYRIMETHAMINE; RHODOCOCCUS-EQUI INFECTION; AMPHOTERICIN-B THERAPY; TRIMETHOPRIM-SULFAMETHOXAZOLE	Objective: To review the efficacy of chemoprophylaxis for opportunistic infections in persons infected with human immunodeficiency virus (HIV). Data Sources: English-language articles on the prevention of HIV-related opportunistic infections were identified through MEDLINE (1985 to 1993) and through review of abstracts presented at the International Conferences on AIDS, the Interscience Conferences on Antimicrobial Agents and Chemotherapy, and the National Conference on Human Retroviruses and Related Diseases. Study Selection: Importance was assigned in descending order to controlled clinical trials, uncontrolled trials and retrospective studies, and prospective observational studies. Data Synthesis: Persons infected with HIV who are at risk for Pneumocystis carinii pneumonia should receive prophylaxis, preferably with trimethoprim-sulfamethoxazole. Alternative agents are aerosolized pentamidine, dapsone, and dapsone-pyrimethamine. Patients who are seropositive for Toxoplasma gondii may benefit from primary prophylaxis against toxoplasmosis using trimethoprim-sulfamethoxazole or dapsone-pyrimethamine, Life-long secondary prophylaxis is indicated for all patients previously treated for toxoplasmic encephalitis. Long-term suppressive therapy is required for all patients with cryptococcal meningitis and histoplasmosis, and many patients with recurrent mucosal candidiasis also benefit from long-term suppression. The role of primary prophylaxis of fungal infections, however, is uncertain. Rifabutin has been approved to prevent disseminated infection with Mycobacterium avium complex and is indicated for all patients with CD4 counts less than 100/mm(3). Chemoprophylaxis with isoniazid for 12 months is indicated in all patients infected with HIV who have or are at high risk for M. tuberculosis infection. No effective primary prophylactic agent is available for cytomegalovirus disease, although several investigational drugs are being studied. Acyclovir is effective in decreasing recurrences of herpes simplex virus infection. The incidence of common bacterial infections is decreased by trimethoprim-sulfamethoxazole. Pneumococcal polysaccharide vaccine is recommended for adult patients infected with HIV, and Haemophilus influenzae type b conjugate vaccine is recommended for children infected with HIV. Conclusions: A growing number of infections related to the acquired immunodeficiency syndrome are preventable with currently available agents. Issues of drug interactions, toxicity, and cost-effectiveness will become increasingly important in the management of patients with advanced HIV disease.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	GALLANT, JE (corresponding author), JOHNS HOPKINS UNIV, SCH MED, AIDS SERV, 1830 E MONUMENT ST, SUITE 7401, BALTIMORE, MD 21205 USA.							ABRAMS DI, 1993, J INFECT DIS, V167, P1459, DOI 10.1093/infdis/167.6.1459; ALLEGRA CJ, 1990, J CLIN INVEST, V85, P371, DOI 10.1172/JCI114448; AMPEL NM, 1993, AM J MED, V94, P235, DOI 10.1016/0002-9343(93)90054-S; ANTINORI A, 1992, LANCET, V340, P788, DOI 10.1016/0140-6736(92)92326-B; ARAUJO FG, 1988, ANTIMICROB AGENTS CH, V32, P755, DOI 10.1128/AAC.32.5.755; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BERMUDEZ LE, 1992, 32ND INT C ANT AG CH, P388; BETTY B, 1992, 32ND INT C ANT ANT C, P114; BLACK JR, 1991, EUR J CLIN MICROBIOL, V10, P204, DOI 10.1007/BF01964465; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CAIAFFA WT, 1993, AM J EPIDEMIOL, V138, P909, DOI 10.1093/oxfordjournals.aje.a116812; CARPENTER CCJ, 1989, AM J MED, V86, P771, DOI 10.1016/0002-9343(89)90471-3; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CHAISSON RE, 1992, 32ND INT C ANT AG CH, P259; CHANG HR, 1988, J ANTIMICROB CHEMOTH, V22, P359, DOI 10.1093/jac/22.3.359; CHANG HR, 1988, ANTIMICROB AGENTS CH, V32, P524, DOI 10.1128/AAC.32.4.524; CHEN CH, 1989, AM REV RESPIR DIS, V140, P987, DOI 10.1164/ajrccm/140.4.987; CHITWOOD K, 1992, 32ND INT C ANT AG CH, P348; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CHUENG TW, 1993, CLIN INVEST DIS, V16, P22; CLOTET B, 1991, AIDS, V5, P601, DOI 10.1097/00002030-199105000-00024; COKER RJ, 1992, LANCET, V340, P1099, DOI 10.1016/0140-6736(92)93120-C; CONANT MA, 1988, J AM ACAD DERMATOL, V18, P186, DOI 10.1016/S0190-9622(88)70024-9; CONCES DJ, 1989, AM J ROENTGENOL, V152, P1193, DOI 10.2214/ajr.152.6.1193; CONTE JE, 1987, ANN INTERN MED, V107, P495, DOI 10.7326/0003-4819-107-4-495; COOPER DA, 1993, AIDS, V7, P197, DOI 10.1097/00002030-199302000-00007; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; DEROUIN F, 1991, ANTIMICROB AGENTS CH, V35, P252, DOI 10.1128/AAC.35.2.252; DEROUIN F, 1990, J ANTIMICROB CHEMOTH, V25, P708, DOI 10.1093/jac/25.4.708; DIAMOND RD, 1991, REV INFECT DIS, V13, P480; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; DREW WL, 1992, CLIN INFECT DIS, V14, P608, DOI 10.1093/clinids/14.2.608-a; DREW WL, 1992, MED MANAGEMENT AIDS, P359; EMMONS W, 1991, REV INFECT DIS, V13, P91; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FEINBERG J, 1992, 8 INT C AIDS AMST, V2, pB238; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1986, ANN INTERN MED, V105, P629, DOI 10.7326/0003-4819-105-4-629_1; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FISH DG, 1990, MEDICINE, V69, P384, DOI 10.1097/00005792-199011000-00006; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GALGIANI JN, 1990, J INFECT DIS, V162, P1165, DOI 10.1093/infdis/162.5.1165; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GERARD L, 1993, 33RD INT C ANT AG CH, P314; GIRARD PM, 1989, LANCET, V1, P1348; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; GLESBY MJ, 1993, J INFECT DIS, V168, P1264, DOI 10.1093/infdis/168.5.1264; GODOFSKY EW, 1992, AM J MED, V93, P163, DOI 10.1016/0002-9343(92)90046-E; GONZALEZ AH, 1989, J ANTIMICROB CHEMOTH, V24, P19, DOI 10.1093/jac/24.1.19; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; GRUNEWALD T, 1993, 9 INT C AIDS BERL, V1, P56; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HARVEY RL, 1991, REV INFECT DIS, V13, P139; HEWITT RG, 1993, 9 INT C AIDS BERL, V1, P333; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HIRSCHTICK R, 1993, AM REV RESPIR DIS, V147, pA1003; Hopewell P C, 1989, Semin Respir Infect, V4, P73; HOROWITZ HW, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90649-N; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; HUGHES WT, 1991, J INFECT DIS, V163, P843, DOI 10.1093/infdis/163.4.843; HUGHES WT, 1990, LANCET, V336, P1066, DOI 10.1016/0140-6736(90)92533-N; HUGHES WT, 1988, ANTIMICROB AGENTS CH, V32, P623, DOI 10.1128/AAC.32.5.623; HUGHES WT, 1992, ANN INTERN MED, V116, P953, DOI 10.7326/0003-4819-116-11-953; HUSKINSONMARK J, 1991, J INFECT DIS, V164, P170, DOI 10.1093/infdis/164.1.170; ISRAELSKI DM, 1992, MED MANAGEMENT AIDS, P319; JACOBSON MA, 1992, LANCET, V339, P333, DOI 10.1016/0140-6736(92)91649-S; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; JACOBSON MA, 1994, J INFECT DIS, V169, P384, DOI 10.1093/infdis/169.2.384; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JANOFF EN, 1991, 31ST INT C ANT AG CH, P191; JAVALY K, 1992, MEDICINE, V71, P128, DOI 10.1097/00005792-199205000-00003; JORDE UP, 1993, AIDS, V7, P355, DOI 10.1097/00002030-199303000-00008; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; KATZMAN M, CHEST, V1201, P79; KEMPER CA, 1990, AIDS, V4, P1145, DOI 10.1097/00002030-199011000-00015; KERKERING TM, 1991, 7 INT C AIDS FLOR, V2, P98; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KOVACS JA, 1992, CLIN INFECT DIS, V14, P1005, DOI 10.1093/clinids/14.5.1005; LAINE L, 1992, ANN INTERN MED, V117, P655, DOI 10.7326/0003-4819-117-8-655; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; LAVILLA P, 1990, 6 INT C AIDS SAN FRA, V1, P238; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; LEEN CLS, 1990, J INFECTION, V21, P55, DOI 10.1016/0163-4453(90)90646-P; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEPORT C, 1993, 1ST NAT C HUM RETR R, P62; LESLIE JM, 1993, 33RD INT C ANT AG CH, P215; LESLIE JM, 1992, INFECT DIS CLIN PRAC, V1, P308; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; LUCAS CR, 1989, MED J AUSTRALIA, V151, P30, DOI 10.5694/j.1326-5377.1989.tb128450.x; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MALLOLAS J, 1993, AIDS, V7, P59, DOI 10.1097/00002030-199301000-00009; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; MASUR H, 1993, J ACQ IMMUN DEF SYND, V6, P46; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; MASUR H, 1991, 7 INT C AIDS FLOR, V2, P30; MAYER HB, 1993, AIDS, V7, P1687, DOI 10.1097/00002030-199312000-00029; MCAVINUE SM, 1992, 8 INT C AIDS AMST, V3, P107; MCKINSEY DS, 1989, ANN INTERN MED, V111, P655, DOI 10.7326/0003-4819-111-8-655; MCKINSEY DS, 1992, AM J MED, V92, P225, DOI 10.1016/0002-9343(92)90121-Q; MELBYE M, 1987, LANCET, V1, P728; METROKA CE, 1991, NEW ENGL J MED, V325, P737; MICHELET C, 1993, 33RD INT C ANT AG CH, P315; MOFENSON LM, 1992, JAMA-J AM MED ASSOC, V268, P483, DOI 10.1001/jama.268.4.483; MONTGOMERY AB, 1987, LANCET, V2, P480; MONTGOMERY AB, 1988, AM REV RESPIR DIS, V137, P477, DOI 10.1164/ajrccm/137.2.477; MOORE RD, 1992, AIDS, V6, P671, DOI 10.1097/00002030-199207000-00009; MOORE RD, 1991, ARCH INTERN MED, V151, P981, DOI 10.1001/archinte.151.5.981; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NARANG PK, 1993, 33RD INT C ANT AG CH, P228; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; OFARRELL N, 1991, LANCET, V337, P986, DOI 10.1016/0140-6736(91)91629-9; OPRAVIL M, 1993, 33RD INT C ANT AG CH, P316; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERFECT JR, 1993, AM J MED, V94, P233, DOI 10.1016/0002-9343(93)90053-R; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PINCHING AJ, 1988, AIDS, V2, P335, DOI 10.1097/00002030-198810000-00002; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; POWDERLY WG, 1992, AIDS, V6, P604, DOI 10.1097/00002030-199206000-00020; POWDERLY WG, 1992, NEW ENGL J MED, V326, P93; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; REICHERT CM, 1983, AM J PATHOL, V112, P357; RODRIGUEZBARRADAS MC, 1992, J INFECT DIS, V165, P553, DOI 10.1093/infdis/165.3.553; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; SANGUINETI A, 1993, ARCH INTERN MED, V153, P1122, DOI 10.1001/archinte.153.9.1122; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SCHUMANN D, 1993, 9 INT C AIDS BERL, V1, P57; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SEPKOWITZ KA, 1991, ANN INTERN MED, V114, P455, DOI 10.7326/0003-4819-114-6-455; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; SINGH N, 1992, 32ND INT C ANT AG CH, P348; SKOUTELIS AT, 1990, J ACQ IMMUN DEF SYND, V3, P335; SLAVIN MA, 1992, AIDS, V6, P1169, DOI 10.1097/00002030-199210000-00017; SMITH RM, 1987, ANN INTERN MED, V106, P335, DOI 10.7326/0003-4819-106-2-335_1; STEIN DS, 1991, ANTIMICROB AGENTS CH, V35, P1705, DOI 10.1128/AAC.35.9.1705; STEINHART R, 1992, JAMA-J AM MED ASSOC, V268, P3350; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STELLBRINK HJ, 1992, AIDS, V6, P746, DOI 10.1097/00002030-199207000-00025; STEVENS DA, 1991, ARCH INTERN MED, V151, P2458, DOI 10.1001/archinte.151.12.2458; STRAUS SE, 1984, ANN INTERN MED, V100, P522, DOI 10.7326/0003-4819-100-4-522; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X; TORGOVNICK J, 1990, AM J MED, V88, P548, DOI 10.1016/0002-9343(90)90443-H; TOURNERIE C, 1993, 9 INT C AIDS BERL, V1, P56; WADHAWAN D, 1990, 6 INT C AIDS SAN FRA, P249; WALDMAN RH, 1973, AM REV RESPIR DIS, V108, P1004; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WILKES MS, 1988, LANCET, V2, P85; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; WITT MD, 1993, 9TH INT C AIDS BERL, V1, P55; WORMSER GP, 1991, ARCH INTERN MED, V151, P688, DOI 10.1001/archinte.151.4.688; ZAMORA L, 1991, 7 INT C AIDS FLOR RO, V2, P267; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; ZANGERLE R, 1991, MED MICROBIOL IMMUN, V180, P59, DOI 10.1007/BF00193846; ZURLO JJ, 1993, ANN INTERN MED, V118, P12, DOI 10.7326/0003-4819-118-1-199301010-00003; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, MMWR MORB MORTAL WKL, V40, P27; 1990, GUIDE ADULT IMMUNIZA; 1992, MMWR MORB MORTAL WKL, V41, P61; 1991, HIVAIDS3 CTR DIS CON	188	133	137	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					932	944		10.7326/0003-4819-120-11-199406010-00006	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00006			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172439				2022-12-28	WOS:A1994NN11000006
J	LEE, KL; CALIFF, RM; SIMES, J; VANDEWERF, F; TOPOL, EJ				LEE, KL; CALIFF, RM; SIMES, J; VANDEWERF, F; TOPOL, EJ			HOLDING GUSTO UP TO THE LIGHT	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; PATIENT	The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, a recent randomized ''megatrial'' of thrombolytic therapies in acute myocardial infarction, showed a statistically significant decrease of 30-day mortality in patients treated with accelerated-dose tissue plasminogen activator (tPA) compared with streptokinase. The therapeutic and cost implications of the results have been intensely scrutinized, and several commentaries have been written on the interpretation of the study. Questions have been raised about the treatment benefit in certain subgroups, the validity of the results because of the open-label design, the relevance of a 1% absolute benefit in mortality rates, the cost-effectiveness of the drug, and the generalizability of the results. These issues are all important considerations for translating the results of this study into clinical practice worldwide. This article sheds additional light on the interpretation of GUSTO, clarifies misconceptions that may have clouded understanding of the trial results, and discusses the contributions of this trial in advancing our understanding of modern myocardial reperfusion therapy.	UNIV SYDNEY, CTR NHMRC CLIN TRIALS, SYDNEY, NSW 2006, AUSTRALIA; UNIV ZIEKENHUIZEN LEUVEN, UZ GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA	University of Sydney; KU Leuven; University Hospital Leuven; Cleveland Clinic Foundation	LEE, KL (corresponding author), DUKE UNIV, MED CTR, CTR CLIN TRIALS COORDINATING, BOX 3363, DURHAM, NC 27710 USA.		Simes, Robert John/P-1497-2014	Topol, Eric/0000-0002-1478-4729				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281, DOI 10.1016/0735-1097(93)90664-M; CONTI CR, 1993, CLIN CARDIOL, V16, P635, DOI 10.1002/clc.4960160902; FUSTER V, 1993, NEW ENGL J MED, V329, P723, DOI 10.1056/NEJM199309023291009; HUNT D, 1992, LANCET, V339, P753; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEE KL, 1980, CIRCULATION, V61, P508, DOI 10.1161/01.CIR.61.3.508; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Rapaport E., 1993, J MYOCARDIAL ISCHEMI, V5, P15; RIDKER PM, 1993, ANN INTERN MED, V119, P530, DOI 10.7326/0003-4819-119-6-199309150-00017; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Sleight P, 1993, J MYOCARDIAL ISCHEMI, V5, P25; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; VANDEWERF F, 1990, LANCET, V336, P71; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	22	41	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					876	881		10.7326/0003-4819-120-10-199405150-00009	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154647				2022-12-28	WOS:A1994NK45800009
J	AWAN, KJ				AWAN, KJ			... FOR MY FATHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1386	1386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176786				2022-12-28	WOS:A1994NJ69300001
J	DAVIS, A; SAGE, CR; DOUGHERTY, CA; FARRELL, KW				DAVIS, A; SAGE, CR; DOUGHERTY, CA; FARRELL, KW			MICROTUBULE DYNAMICS MODULATED BY GUANOSINE TRIPHOSPHATE HYDROLYSIS ACTIVITY OF BETA-TUBULIN	SCIENCE			English	Article							GTP-BINDING PROTEIN; SITE; ENCODES; FAMILY	Microtubule dynamic instability underlies many cellular functions, including spindle morphogenesis and chromosome movement. The role of guanosine triphosphate (GTP) hydrolysis in dynamic instability was investigated by introduction of four mutations into yeast beta-tubulin at amino acids 103 to 109, a site thought to participate in GTP hydrolysis. Three of the mutations increased both the assembly-dependent rate of GTP hydrolysis and the average length of steady-state microtubules over time, a measure of dynamic instability. The fourth mutation did not substantially affect the rate of GTP hydrolysis or the steady-state microtubule lengths. These results demonstrate that the rate of GTP hydrolysis can modulate microtubule length and hence dynamic instability.			DAVIS, A (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.				NIGMS NIH HHS [GM 41751] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041751] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES G, 1992, MOL BIOL CELL, V1, P1; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DAVIS A, 1993, BIOCHEMISTRY-US, V32, P8823, DOI 10.1021/bi00085a013; DAVIS A, UNPUB; DUSTIN P, 1987, MICROTUBULES; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KATZ WS, 1988, MOL CELL BIOL, V8, P2730, DOI 10.1128/MCB.8.7.2730; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVI A, 1974, BIOCHIM BIOPHYS ACTA, V365, P450, DOI 10.1016/0005-2795(74)90022-1; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAGE CR, UNPUB; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	22	58	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					839	842		10.1126/science.8171338	http://dx.doi.org/10.1126/science.8171338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171338				2022-12-28	WOS:A1994NJ94900032
J	QIU, D; KUMAR, M; RAGSDALE, SW; SPIRO, TG				QIU, D; KUMAR, M; RAGSDALE, SW; SPIRO, TG			NATURES CARBONYLATION CATALYST - RAMAN-SPECTROSCOPIC EVIDENCE THAT CARBON-MONOXIDE BINDS TO IRON, NOT NICKEL, IN CO DEHYDROGENASE	SCIENCE			English	Article							CLOSTRIDIUM-THERMOACETICUM; RESONANCE RAMAN; SULFUR PROTEIN; ENZYMOLOGY; COMPLEXES; RHODIUM	Carbon monoxide dehydrogenase catalyzes the synthesis of acetyl-coenzyme A from coenzyme A, a methyl group, and carbon monoxide. The carbon monoxide binds to a mixed metal center of the enzyme, which contains nickel bridged to an iron-sulfur cluster. Resonance Raman spectroscopy has been used to identify both C-O stretching and metal-CO stretching vibrations of the carbon monoxide adduct of the enzyme. This adduct was shown by isotopic exchange to be on the pathway for acetyl-coenzyme A synthesis. The metal to which carbon monoxide is bound was established to be iron, not nickel, by preparation of enzyme from bacteria grown on iron-54 and nickel-64. The Fe-CO frequency is low, 360 wave numbers, implying a weak bond, probably because of electron donation from sulfide and thiolate ligands of the iron. A bimetallic mechanism is proposed, in which carbon monoxide binds to an iron atom and is subsequently attacked by a methyl group on a nearby nickel atom, forming an acetyl ligand, which is then transferred to coenzyme A.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583; PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	University of Nebraska System; University of Nebraska Lincoln; Princeton University					NIGMS NIH HHS [GM13498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013498, R37GM013498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; AVERILL BA, 1978, J AM CHEM SOC, V100, P5234, DOI 10.1021/ja00484a067; BARTHOLOMEW CH, 1991, NEW TRENDS CO ACTIVA, P158; CHENG CH, 1977, J AM CHEM SOC, V99, P2791, DOI 10.1021/ja00450a062; CZERNUSZEWICZ RS, 1983, APPL SPECTROSC, V37, P297, DOI 10.1366/0003702834634550; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FORSTER D, 1979, ADV ORGANOMET CHEM, V17, P255; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; KUMAR M, 1993, J AM CHEM SOC, V115, P11646, DOI 10.1021/ja00077a093; KUMAR M, 1992, J AM CHEM SOC, V114, P8713, DOI 10.1021/ja00048a062; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LU WP, 1990, J BIOL CHEM, V265, P3124; MAGNUSON RH, 1982, J AM CHEM SOC, V104, P5790, DOI 10.1021/ja00385a042; Papp H., 1991, NEW TRENDS CO ACTIVA, P430; QIU D, UNPUB; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; Spiro T. G., 1988, BIOL APPLICATIONS RA, P523; WALTERS MA, 1984, ADV NITROGEN FIXATIO, P100; [No title captured]	24	58	58	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					817	819		10.1126/science.8171334	http://dx.doi.org/10.1126/science.8171334			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171334				2022-12-28	WOS:A1994NJ94900024
J	YOUVAN, DC				YOUVAN, DC			IMAGING SEQUENCE SPACE	NATURE			English	Article							MOLECULAR-BIOLOGY; SPECTROSCOPY				YOUVAN, DC (corresponding author), PALO ALTO INST MOLEC MED,2462 WYANDOTTE ST,MT VIEW,CA 94043, USA.							ARKIN AP, 1990, BIO-TECHNOL, V8, P746, DOI 10.1038/nbt0890-746; ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; DELAGRAVE S, 1993, BIO-TECHNOL, V11, P1548, DOI 10.1038/nbt1293-1548; DELAGRAVE S, 1993, PROTEIN ENG, V6, P327, DOI 10.1093/protein/6.3.327; GOLDMAN ER, 1992, BIO-TECHNOL, V10, P1557, DOI 10.1038/nbt1292-1557; YANG MM, 1988, BIO-TECHNOL, V6, P939, DOI 10.1038/nbt0888-939; YANG MM, IN PRESS AM BIOTECH; YOUVAN DC, IN PRESS METH ENZYM	9	25	35	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					79	80		10.1038/369079a0	http://dx.doi.org/10.1038/369079a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164746				2022-12-28	WOS:A1994NJ86000059
J	GIBBS, JB; OLIFF, A; KOHL, NE				GIBBS, JB; OLIFF, A; KOHL, NE			FARNESYLTRANSFERASE INHIBITORS - RAS RESEARCH YIELDS A POTENTIAL CANCER THERAPEUTIC	CELL			English	Review							PROTEINS; CELLS				GIBBS, JB (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,W POINT,PA 19486, USA.							ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GEORGES RN, 1993, CANCER RES, V53, P1743; Gibbs J B, 1992, Semin Cancer Biol, V3, P383; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; NIGAM M, 1993, J BIOL CHEM, V268, P20695; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260	26	496	518	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					175	178		10.1016/0092-8674(94)90308-5	http://dx.doi.org/10.1016/0092-8674(94)90308-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168127				2022-12-28	WOS:A1994NH63400003
J	KARASUYAMA, H; ROLINK, A; SHINKAI, Y; YOUNG, F; ALT, FW; MELCHERS, F				KARASUYAMA, H; ROLINK, A; SHINKAI, Y; YOUNG, F; ALT, FW; MELCHERS, F			THE EXPRESSION OF V-PRE-B/LAMBDA-5 SURROGATE LIGHT-CHAIN IN EARLY BONE-MARROW PRECURSOR B-CELLS OF NORMAL AND B-CELL-DEFICIENT MUTANT MICE	CELL			English	Article							LYMPHOCYTES-PRE-B; HEAVY-CHAIN; LAMBDA-5; MOUSE; GENE; SURFACE; PROTEIN; VPREB; LOCUS; LINES	Precursor B (pre-B) cells in bone marrow of normal and B cell-deficient mutant mice were analyzed for the expression of V-pre-B/lambda 5 surrogate light chain (SL). The surface expression of SL is confined to the early stages (pro-B and pre-B-I) of pre-B cell development and becomes undetectable once C heavy chain (pH) is produced. The cell-cycle analysis revealed that cytoplasmic mu H+ large cells (large pre-B-II), similar to 30% of which coexpressed SL in the cytoplasm, were most actively cycling, whereas cytoplasmic mu H+ small cells (small pre-b-II) were SL(-) and not in cycle. The analysis of pre-B cells in B cell-deficient mice suggests that the large pre-B-II stage is a critical step for the selection and amplification of cells carrying functionally rearranged mu H genes.	CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	KARASUYAMA, H (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.		Karasuyama, Hajime/A-7966-2011; Shinkai, Yoichi/N-3909-2014	Karasuyama, Hajime/0000-0003-0689-0836; Shinkai, Yoichi/0000-0002-6051-2484	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GROETTRUP M, 1993, CELL, V75, P238; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARLOW E, 1988, ANTIBODIES LABORATOR; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KERR WG, 1989, INT IMMUNOL, V7, P354; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1992, INT IMMUNOL, V4, P831, DOI 10.1093/intimm/4.8.831; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MATSUO T, 1993, J IMMUNOL, V150, P3766; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MISENER V, 1990, J IMMUNOL, V145, P905; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; REICHMANFRIED M, 1993, INT IMMUNOL, V5, P303, DOI 10.1093/intimm/5.3.303; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROLINK A, 1993, BLOOD, V81, P2290; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	41	230	236	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					133	143		10.1016/0092-8674(94)90241-0	http://dx.doi.org/10.1016/0092-8674(94)90241-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156589				2022-12-28	WOS:A1994NF21100016
J	MELLO, CC; DRAPER, BW; PRIESS, JR				MELLO, CC; DRAPER, BW; PRIESS, JR			THE MATERNAL GENES APX-1 AND GLP-1 AND ESTABLISHMENT OF DORSAL-VENTRAL POLARITY IN THE EARLY C-ELEGANS EMBRYO	CELL			English	Article							CELL-CELL-INTERACTIONS; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; POSTERIOR DETERMINANT; NEMATODE EMBRYOS; SERRATE ENCODES; GERM-LINE; PATTERN; LIN-12	The sister blastomeres ABp and ABa are equipotent at the beginning of the 4-cell stage in C. elegans embryos, but soon become committed to different fates. We show that the glp-1 gene, a homolog of the Notch gene of Drosophila, functions in two distinct cell-cell interactions that specify the ABp and ABa fates. These interactions both require maternal expression of glp-1. We show that a second maternal gene, apx-1, functions with glp-1 only in the specification of the ABp fate and that apx-1 can encode a protein homologous to the Delta protein of Drosophila. Our results suggest how interactions mediated by glp-1 and apx-1 contribute to the establishment of the dorsal-ventral axis in the early C. elegans embryo.	UNIV WASHINGTON, DEPT ZOOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	MELLO, CC (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98109 USA.			Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1985, CELL, V45, P583; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; JOHNSEN RC, 1991, GENETICS, V129, P735; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1992, ROUX ARCH DEV BIOL, V202, P10, DOI 10.1007/BF00364592; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAX F, 1994, IN PRESS NATURE; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3433; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; WOOD WB, 1991, CIBA F SYMP, V162, P143; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	52	190	202	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 8	1994	77	1					95	106		10.1016/0092-8674(94)90238-0	http://dx.doi.org/10.1016/0092-8674(94)90238-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156602				2022-12-28	WOS:A1994NF21100013
J	GEDDES, J; NEWTON, R; YOUNG, G; BAILEY, S; FREEMAN, C; PRIEST, R				GEDDES, J; NEWTON, R; YOUNG, G; BAILEY, S; FREEMAN, C; PRIEST, R			COMPARISON OF PREVALENCE OF SCHIZOPHRENIA AMONG RESIDENTS OF HOSTELS FOR HOMELESS PEOPLE IN 1966 AND 1992	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE ASSESSMENT; MENTALLY-ILL; MRC NEEDS; HEALTH; WOMEN; MEN	Objective-To determine whether the prevalence of schizophrenia among the homeless population of Edinburgh resident in hostels has changed between 1966 and 1992. Design-Comparison of two cross sectional surveys. Settings-Hostels for homeless people in Edinburgh. Subjects-In 1966 a random sample of 98 residents of three common lodging houses. In 1992 a random sample of 198 residents of nine hostels. Main outcome measure-Prevalence of schizophrenia. Results-The prevalence of schizophrenia in 1992 was 12/136 (9%) compared with 20/79 (25%) in 1966 (odds ratio 0.29; 95% confidence interval 0.13 to 0.62; P=0.001). Adjustment for confounding by age, current hostel, and duration of unemployment by means of logistic regression produced an adjusted odds ratio of 0.22 (0.08 to 0.58). Conclusions-The prevalence of schizophrenia was lower in 1992 even after other changes in the population resident in hostels occurring between 1966 and 1992 were taken into account. The findings are not consistent with an increase in the prevalence of schizophrenia among homeless people despite a 66% reduction in adult psychiatric beds in the region during 1966-92.	ST MARYS HOSP, SCH MED, LONDON W2 1NY, ENGLAND	Imperial College London	GEDDES, J (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP, DEPT PSYCHIAT, MORNINGSIDE PK, EDINBURGH EH10 5HF, SCOTLAND.			Geddes, John/0000-0002-5281-5960; Newton, J R/0000-0003-1160-171X				ARMITAGE P, 1987, STATISTICAL METHODS, P183; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BREWIN CR, 1987, PSYCHOL MED, V17, P971, DOI 10.1017/S0033291700000787; DAYSON D, 1993, BR J PSYCHIATRY S, V19, P43; Dennis D.L., 1991, HOUS POLICY DEBATE, V2, P815, DOI [https://doi.org/10.1080/10511482.1991.9521073, DOI 10.1080/10511482.1991.9521073]; FOULDS GA, 1968, MANUAL SYMPTOM SIGN; HOGG LI, 1992, PSYCHOL MED, V22, P1027, DOI 10.1017/S0033291700038599; Hopper Kim, 1991, HOUS POLICY DEBATE, V2, P757; Johnstone E., 1991, BR J PSYCHIATRY S, V13, P5; KENDELL RE, 1988, COMPANION PSYCHIATRI; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; LEFF J, 1993, BMJ-BRIT MED J, V306, P669, DOI 10.1136/bmj.306.6879.669; MARSHALL EJ, 1992, BRIT J PSYCHIAT, V160, P761, DOI 10.1192/bjp.160.6.761; MARSHALL M, 1989, BRIT MED J, V299, P706, DOI 10.1136/bmj.299.6701.706; PATCH ICL, 1970, P ROY SOC MED, V63, P437, DOI 10.1177/003591577006300505; POWELL PV, 1987, J ROY COLL GEN PRACT, V37, P444; PRIEST RG, 1971, AM J PSYCHOTHER, V25, P194, DOI 10.1176/appi.psychotherapy.1971.25.2.194; PULLEN I, 1993, BRIT MED J, V306, P710, DOI 10.1136/bmj.306.6879.710; ROSSI PH, 1990, AM PSYCHOL, V45, P954, DOI 10.1037/0003-066X.45.8.954; SCOTT J, 1993, BRIT J PSYCHIAT, V162, P314, DOI 10.1192/bjp.162.3.314; STURT E, 1981, PSYCHOL MED, V11, P185, DOI 10.1017/S003329170005340X; Timms P W, 1989, Health Trends, V21, P70; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WING JK, 1977, PSYCHOL MED, V7, P505, DOI 10.1017/S0033291700004487; Wong T, 1991, PSYCHIATRIC B, V15, P735; 1987, DIAGNOSTIC STATISTIC; 1991, EGRET EPIDEMIOLOGICA	28	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	1994	308	6932					816	819		10.1136/bmj.308.6932.816	http://dx.doi.org/10.1136/bmj.308.6932.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167488	Green Published			2022-12-28	WOS:A1994ND24300019
J	LU, W; HAN, DS; YUAN, J; ANDRIEU, JM				LU, W; HAN, DS; YUAN, J; ANDRIEU, JM			MULTITARGET PCR ANALYSIS BY CAPILLARY ELECTROPHORESIS AND LASER-INDUCED FLUORESCENCE	NATURE			English	Article							POLYMERASE CHAIN-REACTION				LU, W (corresponding author), UNIV PARIS 05,HOP LAENNEC,TUMOR IMMUNOL LAB,F-75007 PARIS,FRANCE.							ALBIN M, 1991, ANAL CHEM, V63, P417, DOI 10.1021/ac00005a006; ANDRIEU JM, 1991, VIRAL QUANTITATION H, P191; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; HORSBURGH CR, 1989, LANCET, V2, P637; ISAACS ST, 1991, NUCLEIC ACIDS RES, V19, P109, DOI 10.1093/nar/19.1.109; LEFRERE JJ, 1992, LANCET, V339, P999, DOI 10.1016/0140-6736(92)91585-V; LU W, 1993, J INFECT DIS, V167, P1498, DOI 10.1093/infdis/167.6.1498; LU W, 1993, AIDS, V7, pS111, DOI 10.1097/00002030-199311002-00021; LU W, 1993, J INFECT DIS, V167, P1014, DOI 10.1093/infdis/167.5.1014; Lu Wei, 1993, Lancet (North American Edition), V341, P113, DOI 10.1016/0140-6736(93)92589-L; LUCKEY JA, 1990, NUCLEIC ACIDS RES, V18, P4417, DOI 10.1093/nar/18.15.4417; OU CY, 1991, BIOTECHNIQUES, V10, P442; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SHULDINER AR, 1991, BIOTECHNIQUES, V11, P760; SIMONDS RJ, 1993, AIDS, V7, pS35, DOI 10.1097/00002030-199311002-00008	15	78	84	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					269	271		10.1038/368269a0	http://dx.doi.org/10.1038/368269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145828				2022-12-28	WOS:A1994NA87000063
J	CUKIER, J; BEAUCHAMP, RA; SPINDLER, JS; SPINDLER, S; LORENZO, C; TRENTHAM, DE				CUKIER, J; BEAUCHAMP, RA; SPINDLER, JS; SPINDLER, S; LORENZO, C; TRENTHAM, DE			ASSOCIATION BETWEEN BOVINE COLLAGEN DERMAL IMPLANTS AND A DERMATOMYOSITIS OR A POLYMYOSITIS-LIKE SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						DERMATOMYOSITIS; POLYMYOSITIS; COLLAGEN; IMPLANTS, ARTIFICIAL	CONNECTIVE-TISSUE DISEASE; HUMAN ADJUVANT DISEASE; INJECTABLE COLLAGEN; IMMUNE-RESPONSES; AUGMENTATION MAMMOPLASTY; BREAST AUGMENTATION; CLINICAL USE; IMMUNOGENICITY; BEHAVIOR; ZYPLAST	Objective: To determine whether an excess incidence of dermatomyositis or polymyositis or both exist in patients treated with injectable bovine collagen implants and to characterize the clinical picture. Design: Historical cohort study (July 1980 through June 1988). Patients: Patients were identified from personal experience or adverse reaction reports received by the manufacturer. Setting: An 8-year period in the United States during which approximately 345 000 patients received implants. Results: Eight patients with dermatomyositis and an additional patient with polymyositis were identified from approximately 345 000 patients receiving injectable bovine collagen implants from July 1980 through June 1988. The nine patients with dermatomyositis or polymyositis were diagnosed an average of 6.4 months (range, 0.7 to 24.9 months) after collagen implant or skin test exposure or both. Eight of the nine patients had a delayed-type hypersensitivity response at the test or treatment sites or both, and five of six patients tested were found to have increased serum antibodies to collagen. Compared with the general population, the incidence of dermatomyositis or polymyositis among collagen-treated patients was statistically increased (standardized incidence ratio, 5.05; 95% CI, 2.31 to 9.59; P < 0.0001). A similar analysis of the eight dermatomyositis case patients produced a standardized incidence ratio of 18.8 (CI, 8.1 to 37.0; P < 0.0001). Using a Monte Carlo simulation, an interval of 6.4 months or less from exposure to onset of disease was found to be an extremely rare event, occurring less than 72 times per one million simulation trials (CI, 57 to 91). Conclusions: Because these data suggest that an immunologic response to bovine type I or type III collagen or both caused this dermatomyositis or polymyositis-like syndrome, the risks versus benefits for the cosmetic use of collagen implants should be reassessed.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; TEXAS DEPT HLTH, BUR DIS CONTROL & EPIDEMIOL, AUSTIN, TX 78755 USA; ARTHRITIS CLIN HOUSTON, HOUSTON, TX 77030 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD THORNDIKE LAB, BOSTON, MA USA	Harvard University; Harvard Medical School; Texas Department of State Health Services; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University	CUKIER, J (corresponding author), BAYLOR COLL MED, DEPT PLAST SURG, 7000 FANNIN, SUITE 1470, HOUSTON, TX 77030 USA.							Bailin P L, 1988, J DERMATOL SURG O S1, V14, P21; Besag J., 1977, J R STAT SOC SER C A, V26, P327, DOI [10.2307/2346974, DOI 10.2307/2346974]; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; CASTROW FF, 1983, J AM ACAD DERMATOL, V9, P889, DOI 10.1016/S0190-9622(83)70204-5; CHAOUAT Y, 1986, REV RHUM, V53, P485; CLARK DP, 1989, J AM ACAD DERMATOL, V21, P992, DOI 10.1016/S0190-9622(89)70288-7; COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P647, DOI 10.1016/S0190-9622(84)80272-8; COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P638, DOI 10.1016/S0190-9622(84)80271-6; COOPERMAN LS, 1985, AESTHET PLAST SURG, V9, P145, DOI 10.1007/BF01570347; DALAKAS MC, 1988, POLYMYOSITIS DERMATO, P1; DELUSTRO F, 1987, PLAST RECONSTR SURG, V79, P581, DOI 10.1097/00006534-198704000-00012; Delustro F, 1988, J DERMATOL SURG O S1, V14, P49; DELUSTRO F, 1988, J DERMATOL SURG O S1, V14, P57; DOANE DP, 1988, EXPLORING STATISTICS, P181; ELLINGSWORTH LR, 1986, J IMMUNOL, V136, P877; FREUND JE, 1973, MODERN ELEMENTARY ST, P238; FUKUI M, 1981, KANTO RYUMACHI, V5, P151; HELFGOTT SM, 1991, LANCET, V337, P387, DOI 10.1016/0140-6736(91)91165-Q; HOFFMAN GS, 1991, ARTHRITIS RHEUM, V34, P1466; KAISER W, 1990, ANN RHEUM DIS, V49, P937, DOI 10.1136/ard.49.11.937; Kalos M.H., 1986, MONTE CARLO METHODS, V1; KAMMERER WH, 1982, ARTHRITIS RHEUM, V25, P1024, DOI 10.1002/art.1780250820; Klein A, 1988, J DERMATOL SURG O S1, V14, P27; Kligman M, 1988, J DERMATOL SURG ONC, V14, P35; KNAPP TR, 1977, J SURG RES, V23, P96, DOI 10.1016/0022-4804(77)90196-2; KNAPP TR, 1977, PLAST RECONSTR SURG, V60, P398; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; LAW AM, 1991, SIMULATION MODELING, P449; LYON MG, 1989, J RHEUMATOL, V16, P1218; MATTI BA, 1990, AESTHET PLAST SURG, V14, P227, DOI 10.1007/BF01578354; MCCOY JP, 1985, ARCH DERMATOL, V121, P990, DOI 10.1001/archderm.121.8.990; MCCOY JP, 1987, J AM ACAD DERMATOL, V16, P315; MCCOY JP, 1987, J AM ACAD DERMATOL, V16, P955, DOI 10.1016/S0190-9622(87)70120-0; MCPHERSON JM, 1988, J DERMATOL SURG O S1, V14, P13; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; ROGERS AS, 1988, ARCH INTERN MED, V148, P1596, DOI 10.1001/archinte.148.7.1596; SIEGLE RJ, 1984, ARCH DERMATOL, V120, P183, DOI 10.1001/archderm.120.2.183; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; Stegman S, 1988, J DERMATOL SURG O S1, V14, P39; STEGMAN SJ, 1987, ARCH DERMATOL, V123, P1644, DOI 10.1001/archderm.123.12.1644; STEIGERWALD JC, 1988, IMMUNOLOGICAL DISEAS, V2, P1437; TRENTHAM DE, 1986, ARCH DERMATOL, V122, P643, DOI 10.1001/archderm.122.6.643; VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P650, DOI 10.1001/archderm.122.6.650; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WONNACOTT RJ, 1985, INTRO STATISTICS, P180	48	62	62	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					920	928		10.7326/0003-4819-118-12-199306150-00002	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8141865				2022-12-28	WOS:A1993LF93700002
J	ASHWAL, S; CRANFORD, R; BERNAT, JL; CELESIA, G; COULTER, D; EISENBERG, H; MYER, E; PLUM, F; WALKER, M; WATTS, C; ROGSTAD, T				ASHWAL, S; CRANFORD, R; BERNAT, JL; CELESIA, G; COULTER, D; EISENBERG, H; MYER, E; PLUM, F; WALKER, M; WATTS, C; ROGSTAD, T			MEDICAL ASPECTS OF THE PERSISTENT VEGETATIVE STATE .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROLONGED UNCONSCIOUSNESS; HEAD-INJURY; RECOVERY; PAIN; UNAWARENESS; STIMULATION; CHILDREN; COMA		LOMA LINDA UNIV,SCH MED,LOMA LINDA,CA; HENNEPIN CTY MED CTR,MINNEAPOLIS,MN; DARTMOUTH COLL,SCH MED,HANOVER,NH 03755; LOYOLA UNIV,STRITCH SCH MED,MAYWOOD,IL 60153; BOSTON UNIV,SCH MED,BOSTON,MA 02118; MARYLAND INST EMERGENCY MED SERV SYST,BALTIMORE,MD 21201; AMER ACAD NEUROL,MINNEAPOLIS,MN; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298; AMER ACAD PEDIAT,EVANSTON,IL; CORNELL UNIV,NEW YORK HOSP,COLL MED,NEW YORK,NY; PRIMARY CHILDRENS HOSP & MED CTR,SALT LAKE CITY,UT; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX	Loma Linda University; Hennepin County Medical Center; Dartmouth College; Loyola University Chicago; Boston University; Virginia Commonwealth University; American Academy of Pediatrics; Cornell University; NewYork-Presbyterian Hospital; University of Texas System; University of Texas Health San Antonio	ASHWAL, S (corresponding author), AMER ACAD NEUROL,MULTI SOC TASK FORCE PVS,2221 UNIV AVE SE,MINNEAPOLIS,MN 55414, USA.							AHRONHEIM JC, 1990, LANCET, V335, P278, DOI 10.1016/0140-6736(90)90084-I; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALFONSO I, 1992, ANN NEUROL, V32, P454; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; Casey K., 1991, PAIN CENTRAL NERVOUS; COLE HA, 1990, ONE MILLION; CRANFORD RE, 1984, SEMIN NEUROL, V4, P36, DOI 10.1055/s-2008-1041530; DeYoung S, 1987, Rehabil Nurs, V12, P121; DOMAN G, 1993, NEUROPSYCHOL REHABIL, V3, P202; FALK RH, 1990, POSTGRAD MED J, V66, P384, DOI 10.1136/pgmj.66.775.384; FIELD RE, 1981, CONN MED, V45, P717; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1992, BRIT MED J, V305, P886, DOI 10.1136/bmj.305.6858.886-b; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; KATAYAMA Y, 1991, PACE, V14, P116, DOI 10.1111/j.1540-8159.1991.tb04055.x; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LANGECOSACK H, 1981, NEUROPEDIATRICS, V12, P337, DOI 10.1055/s-2008-1059666; LEWINN EB, 1978, LANCET, V2, P156; MCGRATH PA, 1990, COMPREHENSIVE NEUROL, V2, P88; MCQUILLEN MP, 1991, ISSUES LAW MED, V6, P373; PAPASTRAT LA, 1990, GUIDELINES RESERVING; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; PRINTZ LA, 1988, GERIATRICS, V43, P84; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; Sibbison J B, 1991, Lancet, V337, P102, DOI 10.1016/0140-6736(91)90752-B; SNYDER BD, 1983, ANN NEUROL, V14, P152; STEINBOCK B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562294; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; TSUBOKAWA T, 1990, Brain Injury, V4, P315, DOI 10.3109/02699059009026185; WEINER JD, 1990, PHYS MED REHABIL, V4, P569; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WHYTE J, 1989, TRAUMATIC BRAIN INJU, P13; Wood R L, 1992, Brain Inj, V6, P411, DOI 10.3109/02699059209008137; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; 1993, GUIDELINES STATE COU; 1987, GUIDELINES TERMINATI	45	522	533	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1572	1579						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177248				2022-12-28	WOS:A1994NN21500006
J	KAHN, CR				KAHN, CR			PICKING A RESEARCH PROBLEM - THE CRITICAL DECISION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KAHN, CR (corresponding author), JOSLIN DIABET CTR,1 JOSLIN PL,BOSTON,MA 02215, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				ABBOUD FM, 1987, J LAB CLIN MED, V110, P3; FISHER AA, 1991, PROG CLIN BIOL RES, V371, P367; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; LEDERBERG J, 1982, ACADEMIC MED PRESENT, P202; LUFT R, 1980, CLIN RES, V28, P329; ROTH J, 1980, J CLIN INVEST, V66, P616, DOI 10.1172/JCI109896	6	27	27	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1530	1533		10.1056/NEJM199405263302113	http://dx.doi.org/10.1056/NEJM199405263302113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164709				2022-12-28	WOS:A1994NM06800013
J	KUGLER, JD; DANFORD, DA; DEAL, BJ; GILLETTE, PC; PERRY, JC; SILKA, MJ; VANHARE, GF; WALSH, AEP				KUGLER, JD; DANFORD, DA; DEAL, BJ; GILLETTE, PC; PERRY, JC; SILKA, MJ; VANHARE, GF; WALSH, AEP			RADIOFREQUENCY CATHETER ABLATION FOR TACHYARRHYTHMIAS IN CHILDREN AND ADOLESCENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACCESSORY ATRIOVENTRICULAR CONNECTIONS; PARKINSON-WHITE SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; PATHWAY CONDUCTION; RADIATION EXPOSURE; NODAL REENTRY; RECURRENCE; JUNCTION; REGISTRY; ENERGY	Background. Although radiofrequency catheter ablation has been used extensively to treat refractory supraventricular tachycardia in adults, few data are available on its safety and efficacy in children and adolescents. We reviewed registry data obtained from 24 centers to evaluate the indications, early results, complications, and short-term follow-up data in young patients who underwent this procedure. Methods. Standardized data were submitted for 652 patients who underwent 725 procedures between January 1, 1991, and September 1, 1992. The mean length of follow-up was 13.5 months. Results. The median age of the patients was 13.5 years, and 84 percent of them had structurally normal hearts. The initial success rates for ablation of atrioventricular accessory pathways (508 of 615 procedures) and atrioventricular-node reentry (63 of 76 procedures) were both 83 percent. Greater institutional experience in performing ablation in children and location of the accessory pathway in the left free wall correlated with greater likelihood of sustained success. Conversely, a right free-wall pathway, the presence of other heart disease, and higher body weight were all associated with a lesser chance of sustained success. Recurrences of arrhythmia accounted for 45 percent of the failures overall in the series. Atrial ectopic-focus tachycardia had the highest recurrence rate, The total complication rate was 4.8 percent (35 of 725 procedures), and the only variables that independently correlated with a higher complication rate were very low weight and less institutional experience. Conclusions. These early results suggest that radiofrequency catheter ablation has a good success rate and a low complication rate in pediatric patients, especially when it is carried out in experienced pediatric cardiology centers.	CHILDRENS MEM HOSP, CHICAGO, IL USA; S CAROLINA CHILDRENS HEART CTR, CHARLESTON, SC USA; TEXAS CHILDRENS HOSP, HOUSTON, TX USA; OREGON HLTH SCI UNIV, PORTLAND, OR USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Baylor College of Medicine; Oregon Health & Science University; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital	KUGLER, JD (corresponding author), UNIV NEBRASKA, MED CTR, PEDIAT CARDIOL SECT, 600 S 42ND ST, OMAHA, NE 68198 USA.							[Anonymous], 1988, Pediatrics, V81, P736; CALKINS H, 1991, CIRCULATION, V84, P2376, DOI 10.1161/01.CIR.84.6.2376; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CASE C, 1992, Journal of the American College of Cardiology, V19, p274A; CASE CL, 1992, J AM COLL CARDIOL, V20, P1405, DOI 10.1016/0735-1097(92)90255-L; CASSIDY SC, 1992, J AM COLL CARDIOL, V19, P1285, DOI 10.1016/0735-1097(92)90336-L; DICK M, 1991, CIRCULATION, V84, P2318, DOI 10.1161/01.CIR.84.6.2318; GARSON A JR, 1990, Journal of Cardiovascular Electrophysiology, V1, P132, DOI 10.1111/j.1540-8167.1990.tb01055.x; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; LANGBERG JJ, 1992, J AM COLL CARDIOL, V19, P1588, DOI 10.1016/0735-1097(92)90622-T; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; LESH MD, 1992, J AM COLL CARDIOL, V19, P1303, DOI 10.1016/0735-1097(92)90338-N; LINDSAY BD, 1992, AM J CARDIOL, V70, P218, DOI 10.1016/0002-9149(92)91278-C; MULLINS CE, 1990, AM J CARDIOL, V65, P802, DOI 10.1016/0002-9149(90)91392-J; RUSKIN JN, 1991, NEW ENGL J MED, V324, P1660, DOI 10.1056/NEJM199106063242309; SAUL JP, 1993, J AM COLL CARDIOL, V21, P571, DOI 10.1016/0735-1097(93)90087-H; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; SCHLUTER M, 1991, CIRCULATION, V84, P1644, DOI 10.1161/01.CIR.84.4.1644; SCHLUTER M, 1992, PEDIATRICS, V89, P930; SHIH HT, 1991, AM J CARDIOL, V68, P422; TICHO BS, 1992, AM J CARDIOL, V70, P1559, DOI 10.1016/0002-9149(92)90457-A; TWIDALE N, 1991, PACE, V14, P2042, DOI 10.1111/j.1540-8159.1991.tb02812.x; VANHARE GF, 1991, J AM COLL CARDIOL, V17, P1613, DOI 10.1016/0735-1097(91)90656-T; WALSH EP, 1992, CIRCULATION, V86, P1138, DOI 10.1161/01.CIR.86.4.1138	25	264	274	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1481	1487		10.1056/NEJM199405263302103	http://dx.doi.org/10.1056/NEJM199405263302103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164700				2022-12-28	WOS:A1994NM06800003
J	FRIEDMAN, E				FRIEDMAN, E			MONEY ISNT EVERYTHING - NONFINANCIAL BARRIERS TO ACCESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; CARE											ANDERS G, 1993, WALL ST J       1109, pB1; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BOSSI A, 1993, NY TIMES        1020; BOYD L, 1994, HONOLULU ADVERT 0129, pB6; CARLISE DM, 1993, 10TH ANN M ASS HLTH; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; FOSSETT JW, 1991, 119TH ANN M AM PUBL; FRIEDMAN E, 1993, HLTH BUSINESS, V8, pT1; FRIEDMAN EA, 1993, ALOHA WAY HLTH CARE; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GREENBERG ER, 1988, NEW ENGL J MED, V318, P612, DOI 10.1056/NEJM198803103181006; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HUNT GC, 1994, MAR RW JOHNS F C WAS; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Kindig D A, 1991, J Rural Health, V7, P313; LEE J, 1993, US TODAY        1012, pA10; PASSARO V, 1993, NY TIMES        1011, pA11; PEAR R, 1992, NY TIMES        1110, pA9; PERLOFF JD, 1991, 119TH ANN M AM PUBL; RIPORTELLAMULLE.R, 1993, 10TH ANN M ASS HLTH; SHAPIRO MF, 1992, JAMA-J AM MED ASSOC, V268, P510, DOI 10.1001/jama.268.4.510; SULLIVAN W, 1993, OCT ED C DAUGHT CHAR; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WOOD DL, 1990, PEDIATRICS, V86, P666; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; 1993, AIDS RELATED CLAIMS; 1993, 932 PHYS PAYM REV CO; 1993, 1993 PHYS PAYM REV C; 1994, SOURCES HLTH INSURAN; 1992, 925 PHYS PAYM REV CO; 1993, UNTITLED PRESS  1020; 1994, HOSPITAL CLOSURES 19; 1989, BLUR CROSS BLUE 0717; 1993, HAOHRD9341 US GEN AC; 1994, GAOHEHS9468 US GEN A; 1993, MED HLTH        1011, V47, P4; 1993, EC TRENDS, V9, P4; 1992, FAMILIAR FACES STATU	42	78	78	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1535	1538		10.1001/jama.271.19.1535	http://dx.doi.org/10.1001/jama.271.19.1535			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176836				2022-12-28	WOS:A1994NK71100035
J	JOST, TS				JOST, TS			HEALTH SYSTEM REFORM - FORWARD OR BACKWARD WITH QUALITY OVERSIGHT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; INFORMATION; MORTALITY				JOST, TS (corresponding author), OHIO STATE UNIV, CTR HLTH POLICY STUDIES, 55 W 12TH AVE, COLUMBUS, OH 43210 USA.							AHARONY L, 1992, MED CARE REV, V50, P49; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BOONE DJ, 1992, ARCH PATHOL LAB MED, V116, P681; DONALDSON MS, 1994, HLTH DATA INFORMATIO; EPSTEIN AM, 1993, NEW ENGL J MED, V329, P1672, DOI 10.1056/NEJM199311253292229; Feldman S E, 1993, Med Care Rev, V50, P123, DOI 10.1177/107755879305000202; FINDLAY S, 1993, BUSINESS HLTH    JUN, P30; GOLDFARB B, 1993, MED WORLD NEWS  0815, P46; GRAEATHER DM, 1986, SOUTH CALIF LAW REV, V59, P277; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; Green J, 1992, BROOKLYN LAW R, V58, P55; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOST TS, 1989, OHIO ST LJ, V50, P1; JOST TS, 1988, HOUSTON LAW REV, V25, P525; LOHR KN, 1993, JAMA-J AM MED ASSOC, V270, P1911, DOI 10.1001/jama.270.16.1911; Lohr KN, 1990, MEDICARE STRATEGY QU; LUSSIER DA, 1979, J CONSUM RES, V6, P154, DOI 10.1086/208758; MALHOTRA NK, 1982, J CONSUM RES, V8, P419, DOI 10.1086/208882; MARWICK C, 1992, JAMA-J AM MED ASSOC, V268, P2142, DOI 10.1001/jama.268.16.2142; MCNEIL BJ, 1992, PHYSICIAN PAYMENT RE, P46; NELSON P, 1970, J POLIT ECON, V78, P311, DOI 10.1086/259630; OBERMAN L, 1992, AM MED NEWS     1207, P2; OBERMAN L, 1993, AM MED NEWS     1115, P1; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; 1993, POLICY COMPENDIUM; 1993, EXPLANATION ADM PROP	29	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1508	1511		10.1001/jama.271.19.1508	http://dx.doi.org/10.1001/jama.271.19.1508			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176831				2022-12-28	WOS:A1994NK71100030
J	MCFADDEN, ER; GILBERT, IA				MCFADDEN, ER; GILBERT, IA			EXERCISE-INDUCED ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESPIRATORY HEAT-LOSS; COLD AIR; DRY AIR; INDUCED BRONCHOCONSTRICTION; ISOCAPNIC HYPERVENTILATION; REFRACTORY PERIOD; REACTION SEQUENCE; INSPIRED AIR; WATER-LOSS; AIRWAYS		UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH	Case Western Reserve University	MCFADDEN, ER (corresponding author), UNIV CLEVELAND HOSP,DIV PULM & CRIT CARE MED,2074 ABINGTON RD,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117, R01HL033791, R29HL044495] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-37117, HL-33791, HL-44495] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; BAROR O, 1977, J ALLERGY CLIN IMMUN, V60, P163, DOI 10.1016/0091-6749(77)90119-1; BECK KC, 1994, AM J RESP CRIT CARE, V149, P352, DOI 10.1164/ajrccm.149.2.8306029; BELCHER NG, 1988, J ALLERGY CLIN IMMUN, V81, P100, DOI 10.1016/0091-6749(88)90227-8; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V74, P701, DOI 10.1016/0091-6749(84)90233-1; BLACKIE SP, 1990, AM REV RESPIR DIS, V142, P1133, DOI 10.1164/ajrccm/142.5.1133; BOULET LP, 1991, EUR RESPIR J, V4, P979; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; BUNDGAARD A, 1982, SCAND J CLIN LAB INV, V42, P15; BUNDGAARD A, 1982, EUR J RESPIR DIS, V63, P239; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; GILBERT IA, 1992, J CLIN INVEST, V90, P699, DOI 10.1172/JCI115940; GILBERT IA, 1990, AM REV RESPIR DIS, V142, P826, DOI 10.1164/ajrccm/142.4.826; GILBERT IA, 1991, CLIN SCI, V81, P655, DOI 10.1042/cs0810655; GODFREY S, 1975, PEDIATRICS, V56, P851; GREEN CP, 1992, ARCH DIS CHILD, V67, P1014, DOI 10.1136/adc.67.8.1014; INMAN MD, 1990, AM REV RESPIR DIS, V141, P1414, DOI 10.1164/ajrccm/141.6.1414; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MCFADDEN ER, 1990, LANCET, V335, P880, DOI 10.1016/0140-6736(90)90478-N; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; MCFADDEN ER, 1984, AM REV RESPIR DIS, V129, pS84, DOI 10.1164/arrd.1984.129.2P2.S84; MCNEILL RS, 1966, Q J MED, V35, P55; MIHALYKA M, 1988, J ALLERGY CLIN IMMUN, V82, P842, DOI 10.1016/0091-6749(88)90088-7; MUSSAFFI H, 1986, J ALLERGY CLIN IMMUN, V77, P48, DOI 10.1016/0091-6749(86)90321-0; PERSSON CGA, 1987, AM REV RESPIR DIS, V135, pS71; PERSSON CGA, 1986, LANCET, V2, P1126; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; PICHURKO BM, 1986, J ALLERGY CLIN IMMUN, V77, P796, DOI 10.1016/0091-6749(86)90376-3; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; ROBINSON P J, 1990, American Review of Respiratory Disease, V141, pA476; ROSSING TH, 1982, J APPL PHYSIOL, V52, P1119, DOI 10.1152/jappl.1982.52.5.1119; RUBINSTEIN I, 1987, NEW ENGL J MED, V317, P482, DOI 10.1056/NEJM198708203170805; SHEPPARD D, 1984, J ALLERGY CLIN IMMUN, V73, P640, DOI 10.1016/0091-6749(84)90297-5; SMITH CM, 1989, AM REV RESPIR DIS, V140, P590; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; VARGA EM, 1990, LUNG, V168, P267, DOI 10.1007/BF02719703; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3; ZAWADSKI DK, 1988, AM REV RESPIR DIS, V137, P837, DOI 10.1164/ajrccm/137.4.837; ZAWADSKI DK, 1988, J APPL PHYSIOL, V64, P812, DOI 10.1152/jappl.1988.64.2.812; 1991, DHHS NIH913042 DEP H, P119	60	295	300	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1362	1367		10.1056/NEJM199405123301907	http://dx.doi.org/10.1056/NEJM199405123301907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152449				2022-12-28	WOS:A1994NK75300007
J	CASSEDAY, JH; EHRLICH, D; COVEY, E				CASSEDAY, JH; EHRLICH, D; COVEY, E			NEURAL TUNING FOR SOUND DURATION - ROLE OF INHIBITORY MECHANISMS IN THE INFERIOR COLLICULUS	SCIENCE			English	Article							SUPERIOR OLIVARY COMPLEX; BAT; NEURONS; ECHOLOCATION; NUCLEI; BRAIN; GABA	Duration is a biologically important feature of sound. Some neurons in the inferior colliculus of the big brown bat, Eptesicus fuscus, are tuned to sound duration, but it is unclear at what level the tuning originates or what neural mechanisms are responsible for it. The application of antagonists of the inhibitory neurotransmitters gamma-aminobutyric acid or glycine to neurons in the inferior colliculus eliminated duration tuning. Whole-cell patch-clamp recordings of synaptic currents suggested that inhibition produces a temporal frame within which excitation can occur. A model is proposed in which duration tuning arises when an early, sustained inhibitory input interacts with a delayed, transient excitatory input.			CASSEDAY, JH (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.				NIDCD NIH HHS [DC-00607, DC-00287] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000607] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Casseday J.H., 1987, P109; CASSEDAY JH, 1992, J COMP NEUROL, V319, P34, DOI 10.1002/cne.903190106; CASSEDAY JH, 1988, J COMP NEUROL, V278, P313, DOI 10.1002/cne.902780302; COVEY E, 1993, J NEUROPHYSIOL, V69, P842, DOI 10.1152/jn.1993.69.3.842; COVEY E, 1991, J NEUROPHYSIOL, V66, P1080, DOI 10.1152/jn.1991.66.3.1080; COVEY E, 1991, J NEUROSCI, V11, P3456; Covey E., 1993, Society for Neuroscience Abstracts, V19, P535; EDGAR PP, 1990, J NEUROSCI, V10, P603; FAINGOLD CL, 1991, HEARING RES, V52, P201, DOI 10.1016/0378-5955(91)90200-S; FENG AS, 1990, PROG NEUROBIOL, V34, P313, DOI 10.1016/0301-0082(90)90008-5; GOOLER DM, 1992, J NEUROPHYSIOL, V67, P1, DOI 10.1152/jn.1992.67.1.1; GOULD E, 1971, Communications in Behavioral Biology Part A Original Articles, V5, P263; Griffin DR, 1958, LISTENING DARK; HAPLEA S, IN PRESS J COMP PH A; HAVEY DC, 1980, ELECTROEN CLIN NEURO, V48, P249, DOI 10.1016/0013-4694(80)90313-2; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KALKO EKV, 1993, J BEHAV ECOL SOCIOBI, V33, P415; KONISHI M, 1993, SCI AM, V268, P66, DOI 10.1038/scientificamerican0493-66; Kuwada S., 1987, P146; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; PARK TJ, 1993, J NEUROSCI, V13, P2050; PINHEIRO AD, 1991, J COMP PHYSIOL A, V169, P69; Pollak G.D., 1989, NEURAL BASIS ECHOLOC; POTTER HD, 1965, J NEUROPHYSIOL, V28, P1155, DOI 10.1152/jn.1965.28.6.1155; REPP BH, 1978, J EXP PSYCHOL HUMAN, V4, P621, DOI 10.1037/0096-1523.4.4.621; ROBERTS RC, 1987, J COMP NEUROL, V258, P267, DOI 10.1002/cne.902580207; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHWARTZ IR, 1992, HDB AUDITARY RES, V1, P117; SIMMONS JA, 1989, COGNITION, V33, P155, DOI 10.1016/0010-0277(89)90009-7; SIMMONS JA, 1979, SCIENCE, V203, P16, DOI 10.1126/science.758674; SIMMONS JA, 1988, ANIMAL SONAR PROCESS, P353; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; VATER M, 1992, J COMP NEUROL, V325, P183, DOI 10.1002/cne.903250205; VATER M, 1992, J COMP PHYSIOL A, V171, P541; YANG LC, 1992, J NEUROPHYSIOL, V68, P1760, DOI 10.1152/jn.1992.68.5.1760	35	332	343	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					847	850		10.1126/science.8171341	http://dx.doi.org/10.1126/science.8171341			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171341				2022-12-28	WOS:A1994NJ94900035
J	KOLLER, CA				KOLLER, CA			THE SMELL OF GARDENIAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1366	1366						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158825				2022-12-28	WOS:A1994NH48700032
J	EVERETT, ED; EVANS, KA; HENRY, RB; MCDONALD, G				EVERETT, ED; EVANS, KA; HENRY, RB; MCDONALD, G			HUMAN EHRLICHIOSIS IN ADULTS AFTER TICK EXPOSURE - DIAGNOSIS USING POLYMERASE CHAIN-REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						EHRLICHIOSIS; DIAGNOSIS, DIFFERENTIAL; TICK-BORNE DISEASES; DOXYCYCLINE; POLYMERASE CHAIN REACTION	HUMAN INFECTION; CHAFFEENSIS; CANIS; PATIENT; AGENT	Objective: To identify and prospectively follow patients with suspected human ehrlichiosis regarding clinical manifestations, laboratory variables, methods for confirming the diagnosis, and complications. Design: Prospective case study. Setting: University and Veterans Affairs hospital and clinics. Patients: Observations in 30 adult patients with acute febrile illness or with unexplained fevers and cytopenias or abnormal liver profiles or both. Measurements:Serial clinical examinations, hematologic profiles, liver profiles, electrolyte determinations, chest radiographs, and response to therapy; other studies appropriate for patient care. Intervention: Therapy with doxycycline. Results: Thirty cases of ehrlichiosis were identified between 1989 and 1992. Tick exposure was strongly associated with the illness (P = 0.0001). Symptoms were nonspecific; fever, chills, and headache predominated but many other symptoms also occurred. Fever and skin rashes with various morphologic characteristics were the most common physical findings. Laboratory investigations indicate that the hematologic, hepatic, and central nervous systems are commonly involved in human ehrlichiosis. Twenty of 23 patients (87%) tested by the polymerase chain reaction using Ehrlichia chaffeensis sequences and whole blood samples were positive for E. chaffeensis. Conclusions: The syndrome of human ehrlichiosis is not commonly recognized by physicians. Ehrlichiosis should be considered in the differential diagnosis of patients with febrile illness after known or possible tick exposure, particularly if accompanying cytopenias or abnormal liver profiles or both are present. The therapeutic response to doxycycline is prompt, and complications are uncommon in promptly treated patients. The polymerase chain reaction applied to whole blood samples is a promising test for rapid confirmation of the diagnosis within 24 to 48 hours.	UNIV MISSOURI, HLTH SCI CTR, COLUMBIA, MO USA; HARRY S TRUMAN MEM VET HOSP, COLUMBIA, MO USA	University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital								ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BARTON LL, 1989, PEDIATRICS, V84, P580; BROUQUI P, 1992, ANTIMICROB AGENTS CH, V36, P2799, DOI 10.1128/AAC.36.12.2799; DAWSON JE, 1991, J INFECT DIS, V163, P564, DOI 10.1093/infdis/163.3.564; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DIMMITT DC, 1989, AM J MED, V87, P677, DOI 10.1016/S0002-9343(89)80404-8; DUNN BE, 1992, J CLIN MICROBIOL, V30, P2207, DOI 10.1128/JCM.30.8.2207-2210.1992; EDWARDS MS, 1988, PEDIATR INFECT DIS J, V7, P651, DOI 10.1097/00006454-198809000-00010; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; HARKESS JR, 1990, SOUTHERN MED J, V83, P1341, DOI 10.1097/00007611-199011000-00031; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MOSKOVITZ M, 1991, J CLIN GASTROENTEROL, V13, P86, DOI 10.1097/00004836-199102000-00019; PEARCE CJ, 1988, AM J HEMATOL, V28, P53, DOI 10.1002/ajh.2830280111; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; Sambrook J., 1989, MOL CLONING LAB MANU, P931; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; WALLACE RB, 1987, GUIDE MOL CLONING TE, P432	21	100	105	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					730	735		10.7326/0003-4819-120-9-199405010-00002	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147545				2022-12-28	WOS:A1994NH25100002
J	STRAUSS, RG				STRAUSS, RG			ERYTHROPOIETIN AND NEONATAL ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PREMATURITY; INFANTS				STRAUSS, RG (corresponding author), UNIV IOWA,COLL MED,IOWA CITY,IA 52242, USA.							BECHENSTEEN AG, 1993, ARCH DIS CHILD-FETAL, V69, P19, DOI 10.1136/adc.69.1_Spec_No.19; BECK D, 1991, EUR J PEDIATR, V150, P767, DOI 10.1007/BF02026707; CARNIELLI V, 1992, J PEDIATR-US, V121, P98, DOI 10.1016/S0022-3476(05)82552-1; EMMERSON AJB, 1993, ARCH DIS CHILD-FETAL, V68, P291, DOI 10.1136/adc.68.3_Spec_No.291; HALPERIN DS, 1991, AM J PEDIAT HEMATOL, V13, P351; MAIER RF, 1994, NEW ENGL J MED, V330, P1173, DOI 10.1056/NEJM199404283301701; MESSER J, 1993, PEDIATRICS, V92, P519; OHLS RK, 1991, J PEDIATR-US, V119, P781, DOI 10.1016/S0022-3476(05)80303-8; PHIBBS RH, 1994, PEDIATR RES, V35, pA248; SHANNON KM, 1991, J PEDIATR-US, V118, P949, DOI 10.1016/S0022-3476(05)82217-6; SHANNON KM, 1992, J PEDIATR-US, V120, P586, DOI 10.1016/S0022-3476(05)82488-6; SOUBASI V, 1993, PEDIATR RES, V34, P675, DOI 10.1203/00006450-199311000-00022	12	34	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1227	1228		10.1056/NEJM199404283301709	http://dx.doi.org/10.1056/NEJM199404283301709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139633				2022-12-28	WOS:A1994NG58600009
J	LAW, MR; WALD, NJ				LAW, MR; WALD, NJ			DISAGREEMENTS ARE NOT SUBSTANTIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	6	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1027	1029		10.1136/bmj.308.6935.1027	http://dx.doi.org/10.1136/bmj.308.6935.1027			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167518	Green Published			2022-12-28	WOS:A1994NH08900026
J	GEORGOPAPADAKOU, NH; WALSH, TJ				GEORGOPAPADAKOU, NH; WALSH, TJ			HUMAN MYCOSES - DRUGS AND TARGETS FOR EMERGING PATHOGENS	SCIENCE			English	Editorial Material							PNEUMOCYSTIS-CARINII PNEUMONIA; ELONGATION FACTOR-III; AMPHOTERICIN-B; CANDIDA-ALBICANS; IMMUNOCOMPROMISED PATIENTS; SACCHAROMYCES-CEREVISIAE; FUNGAL-INFECTIONS; THERAPY; DNA; TOPOISOMERASES		NCI, INFECT DIS SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GEORGOPAPADAKOU, NH (corresponding author), ROCHE RES CTR, DEPT ONCOL, NUTLEY, NJ 07110 USA.							BALOCH RI, 1987, PHYTOCHEMISTRY, V26, P663, DOI 10.1016/S0031-9422(00)84762-7; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P381, DOI 10.1128/AAC.34.3.381; BROWN MS, 1981, SCIENCE, V212, P628, DOI 10.1126/science.6261329; CABIB E, 1987, ADV ENZYMOL RAMB, V59, P59; COLTHURST DR, 1991, FEMS MICROBIOL LETT, V80, P45, DOI 10.1111/j.1574-6968.1991.tb04634.x; Debono M, 1988, Ann N Y Acad Sci, V544, P152, DOI 10.1111/j.1749-6632.1988.tb40398.x; DIAMOND RD, 1991, REV INFECT DIS, V13, P480; FRANCIS P, 1992, CLIN INFECT DIS, V15, P1003, DOI 10.1093/clind/15.6.1003; FROMTILING R A, 1988, Clinical Microbiology Reviews, V1, P187; GALGIANI JN, 1993, ANTIMICROB AGENTS CH, V37, P2517, DOI 10.1128/AAC.37.12.2517; GALLIS HA, 1990, REV INFECT DIS, V12, P308; Georgopapadakou N., 1992, EMERGING TARGETS ANT, P476; GEORGOPAPADAKOU NH, 1992, ANTIMICROB AGENTS CH, V36, P1779, DOI 10.1128/AAC.36.8.1779; Girijavallabhan V., 1993, P192; HANGER DP, 1988, ANTIMICROB AGENTS CH, V32, P646, DOI 10.1128/AAC.32.5.646; HANSON LH, 1992, ANTIMICROB AGENTS CH, V36, P486, DOI 10.1128/AAC.36.2.486; HECTOR RF, 1992, ANTIMICROB AGENTS CH, V36, P1284, DOI 10.1128/AAC.36.6.1284; HECTOR RF, 1986, ANTIMICROB AGENTS CH, V29, P389, DOI 10.1128/AAC.29.3.389; HUGHES WT, 1991, PEDIATR INFECT DIS J, V10, P391, DOI 10.1097/00006454-199105000-00009; IWASAKI S, 1993, MED RES REV, V13, P183, DOI 10.1002/med.2610130205; JONES SK, 1990, ANTIMICROB AGENTS CH, V34, P1026, DOI 10.1128/AAC.34.6.1026; KAMATH A, 1989, J BIOL CHEM, V264, P15423; KONISHI M, 1989, J ANTIBIOT, V42, P1749, DOI 10.7164/antibiotics.42.1749; LIPSCHIK GY, 1992, EMERGING TARGETS ANT, P568; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOPEZBERESTEIN G, 1989, ARCH INTERN MED, V149, P2533, DOI 10.1001/archinte.149.11.2533; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; Meunier F., 1989, REV INFECT DIS    S7, V11, pS1605; ODDS FC, 1993, ANTIMICROB AGENTS CH, V31, P463; OEHLSCHLAGER AC, 1992, EMERGING TARGETS ANT, P437; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PANNUTI C, 1992, CANCER-AM CANCER SOC, V69, P2653, DOI 10.1002/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8; Parks L. W., 1992, EMERGING TARGETS ANT, P393; PATTERSON TF, 1989, J INFECT DIS, V159, P717, DOI 10.1093/infdis/159.4.717; PIERCE AM, 1978, CAN J BIOCHEM CELL B, V56, P135, DOI 10.1139/o78-023; QIN SL, 1987, J BIOL CHEM, V262, P7802; RINGDEN O, 1991, J ANTIMICROB CHEMOTH, V28, P73, DOI 10.1093/jac/28.suppl_B.73; Ryder N S, 1988, Ann N Y Acad Sci, V544, P208, DOI 10.1111/j.1749-6632.1988.tb40405.x; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; SHEN LL, 1992, ANTIMICROB AGENTS CH, V36, P2778, DOI 10.1128/AAC.36.12.2778; Tkacz JS, 1992, EMERGING TARGETS ANT, P495; VANDENBOSSCHE H, 1993, NATO ASI SERIES H, V69; WALSH TJ, 1991, REV INFECT DIS, V13, P496; YAMAKI H, 1990, BIOCHEM BIOPH RES CO, V168, P837, DOI 10.1016/0006-291X(90)92397-I	45	183	202	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	1994	264	5157					371	373		10.1126/science.8153622	http://dx.doi.org/10.1126/science.8153622			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153622				2022-12-28	WOS:A1994NG19400025
J	FORSTALL, GJ; MACKNIN, ML; YENLIEBERMAN, BR; MEDENDORP, SV				FORSTALL, GJ; MACKNIN, ML; YENLIEBERMAN, BR; MEDENDORP, SV			EFFECT OF INHALING HEATED VAPOR ON SYMPTOMS OF THE COMMON COLD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To test the efficacy of steam inhalation in treating common cold symptoms. Design.-An in vitro study determined the temperature that inactivated rhinovirus: a temperature of 43-degrees-C lasting at least 1 hour was needed. We then conducted a double-blind, placebo-controlled, randomized in vivo study. Setting.-The virology laboratory and the outpatient department of the Cleveland (Ohio) Clinic Foundation. Patients.-Sixty-eight Cleveland Clinic employee volunteers with symptoms of the common cold at the time of enrollment. Intervention.-A single 60-minute treatment was given to the volunteers. The steam treatment group (n=32) received 40 L/min of heated saturated air that raised the intranasal temperature to 43-degrees-C. The placebo group (n=36) received 2 L/min of ambient air at 20-degrees-C to 24-degrees-C. Main Outcome Measures.-Subjective symptom scores for nasal congestion, nasal drainage, and sneezing and objective measures of nasal resistance were studied during a 7-day follow-up observation period. Results.-There were no significant differences in daily symptom scores between the groups (P=.59 to .83). The only statistically significant differences between the groups were lower nasal resistances at baseline in the steam group (P=.04) and percent improvement in nasal resistance favoring the placebo group on day 7 (P=.01). However, these differences were of questionable clinical significance. Conclusion.-We conclude that steam inhalation treatment had no beneficial effect on the cold symptoms of our volunteers.	CLEVELAND CLIN FDN,DEPT PEDIAT & ADOLESCENT MED,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MICROBIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT INFECT DIS,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT BIOSTAT,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation								ALNAKIB W, 1989, J MED VIROL, V29, P268, DOI 10.1002/jmv.1890290410; ALNAKIB W, 1992, J ANTIMICROB CHEMOTH, V30, P115, DOI 10.1093/jac/30.2.115; COUCH R B, 1985, P465; MACKNIN ML, 1990, JAMA-J AM MED ASSOC, V264, P989; MCCAFFREY TV, 1979, ARCH OTOLARYNGOL, V105, P542; OPHIR D, 1987, AM J OTOLARYNG, V8, P149, DOI 10.1016/S0196-0709(87)80037-6; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; YERUSHALMI A, 1980, CR ACAD SCI D NAT, V291, P957	9	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1109	1111		10.1001/jama.271.14.1109	http://dx.doi.org/10.1001/jama.271.14.1109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151854				2022-12-28	WOS:A1994NE22800034
J	WOLFFE, AP				WOLFFE, AP			TRANSCRIPTION - IN TUNE WITH THE HISTONES	CELL			English	Review							CHROMATIN STRUCTURE; TERMINAL MUTATIONS; YEAST; NUCLEOSOME; REPRESSION; PROMOTER; COMPLEX; SWI1				WOLFFE, AP (corresponding author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA.							ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CULLEN KE, 1993, SCIENCE, V261, P203, DOI 10.1126/science.8327891; Grunstein M., 1992, TRANSCRIPTIONAL REGU, P1295; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WOLFFE A, 1992, CHROMATIN STRUCTURE; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	26	241	242	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					13	16		10.1016/0092-8674(94)90229-1	http://dx.doi.org/10.1016/0092-8674(94)90229-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156588				2022-12-28	WOS:A1994NF21100004
J	SCHOMER, DF; MARKS, MP; STEINBERG, GK; JOHNSTONE, IM; BOOTHROYD, DB; ROSS, MR; PELC, NJ; ENZMANN, DR				SCHOMER, DF; MARKS, MP; STEINBERG, GK; JOHNSTONE, IM; BOOTHROYD, DB; ROSS, MR; PELC, NJ; ENZMANN, DR			THE ANATOMY OF THE POSTERIOR COMMUNICATING ARTERY AS A RISK FACTOR FOR ISCHEMIC CEREBRAL INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL CAROTID-ARTERY; CT FINDINGS; OCCLUSION; ANGIOGRAPHY; PROGNOSIS; STENOSIS	Background. After the occlusion of an internal carotid artery the principal source of collateral flow is through the arteries of the circle of Willis, but the size and patency of these arteries are quite variable. Study of the anatomy of the collateral pathways in patients with internal-carotid-artery occlusion with or without infarction in the watershed area of the deep white matter may identify patterns that afford protection from ischemic infarction. Methods. Using conventional magnetic resonance imaging and three-dimensional phase-contrast magnetic resonance angiography, we evaluated 29 consecutive patients (32 hemispheres at risk) with angiographically proved occlusion of the internal carotid artery. Four collateral pathways to the occluded vessel were evaluated: the proximal segment of the anterior cerebral artery, the posterior communicating artery, the ophthalmic artery, and leptomeningeal collateral vessels from the posterior cerebral artery. Results. Only features of the ipsilateral posterior communicating artery were related to the risk of watershed infarction. The presence of posterior communicating arteries measuring at least 1 mm in diameter was associated with the absence of watershed infarction (13 hemispheres, no infarcts; P < 0.001). Conversely, there were 4 water-shed infarcts in the 6 hemispheres with posterior communicating arteries measuring less than 1 mm in dimeter and 10 infarcts in the 13 hemispheres with no detectable flow in the ipsilateral posterior communicating artery. Conculsions. A small (< 1 mm in diameter) or absent ipsilateral posterior communicating artery is a risk factor for ischemic cerebral infarction in patients with internal-carotid-artery occlusion.	STANFORD UNIV,MED CTR S072,DEPT RADIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT NEUROSURG,STANFORD,CA 94305; STANFORD UNIV,DEPT STAT,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University				Boothroyd, Derek Brian/0000-0001-5387-6995; Pelc, Norbert/0000-0002-8922-8989; Steinberg, Gary/0000-0001-6374-1058				Baird A E, 1991, Clin Exp Neurol, V28, P50; CAVESTRI R, 1991, ITAL J NEUROL SCI, V12, P383, DOI 10.1007/BF02335778; HARRISON MJG, 1988, J NEUROL NEUROSUR PS, V51, P269, DOI 10.1136/jnnp.51.2.269; HEDERA P, 1992, STROKE, V23, P1069, DOI 10.1161/01.STR.23.8.1069; HEISERMAN JE, 1992, RADIOLOGY, V185, P667, DOI 10.1148/radiology.185.3.1438743; MARKS MP, 1992, RADIOLOGY, V182, P467, DOI 10.1148/radiology.182.2.1732966; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Osborne AG, 1980, INTRO CEREBRAL ANGIO, P146; PERLER BA, 1991, J VASC SURG, V14, P821, DOI 10.1067/mva.1991.32077; PRICE RR, 1992, INVEST RADIOL, V27, pS27, DOI 10.1097/00004424-199212002-00006; RAUTENBERG W, 1990, J NEUROL SCI, V98, P213, DOI 10.1016/0022-510X(90)90262-L; ROSS MR, 1993, AM J NEURORADIOL, V14, P19; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P1057, DOI 10.2214/ajr.159.5.1414775; STEINBERG GK, 1993, J NEUROSURG, V79, P161, DOI 10.3171/jns.1993.79.2.0161; TAKAHASHI S, 1992, NEURORADIOLOGY, V34, P504, DOI 10.1007/BF00598961; 1990, SAS STAT USERS GUIDE, V1	16	263	280	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1565	1570		10.1056/NEJM199406023302204	http://dx.doi.org/10.1056/NEJM199406023302204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177246	Bronze			2022-12-28	WOS:A1994NN21500004
J	ANNAS, GJ				ANNAS, GJ			ASKING THE COURTS TO SET THE STANDARD OF EMERGENCY CARE - THE CASE OF BABY-K	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1988, JUDGING MED; ELIAS S, 1987, REPRODUCTIVE GENETIC; INGELFINGER FJ, 1975, NEW ENGL J MED, V293, P825, DOI 10.1056/NEJM197510162931610; KRUSHE H, 1985, SHOULD BABY LIVE; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; PARIS JJ, 1993, NEW ENGL J MED, V329, P354, DOI 10.1056/NEJM199307293290512; 1984, FED REGISTER, V49, P1621; 1985, FED REGISTER, V50, P1488; 1990, NEW ENGL J MED, V322, P669	9	72	72	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1542	1545		10.1056/NEJM199405263302120	http://dx.doi.org/10.1056/NEJM199405263302120			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164726	Green Published			2022-12-28	WOS:A1994NM06800036
J	WEINER, J				WEINER, J			FINANCING LONG-TERM-CARE - A PROPOSAL BY THE AMERICAN-COLLEGE-OF-PHYSICIANS AND THE AMERICAN-GERIATRICS-SOCIETY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOME CARE				WEINER, J (corresponding author), AMER COLL PHYSICIANS, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.			Weiner, Janet/0000-0001-5810-5807				ADAMS EK, 1993, MED CARE, V31, P1, DOI 10.1097/00005650-199301000-00001; ARLING G, 1992, MED CARE, V30, P699, DOI 10.1097/00005650-199208000-00003; BALL RM, 1990, J AM GERIATR SOC, V38, P156, DOI 10.1111/j.1532-5415.1990.tb03478.x; Buchanan R J, 1991, Health Care Financ Rev, V13, P55; Clauser S B, 1992, Health Care Financ Rev, V13, P135; COBURN AF, 1993, HEALTH SERV RES, V28, P45; COHEN MA, 1993, GERONTOLOGIST, V33, P105, DOI 10.1093/geront/33.1.105; COUGHLIN TA, 1992, HEALTH SERV RES, V27, P453; EDELMAN P, 1990, J GERONTOL, V45, pS74, DOI 10.1093/geronj/45.2.S74; FRIEDLAND RB, 1990, FACING COSTS LONG TE; Garfinkel S A, 1988, Health Care Financ Rev, V9, P41; GINSBURG JA, 1988, ANN INTERN MED, V108, P279, DOI 10.7326/0003-4819-108-2-279; GOLD SD, 1992, HEALTH AFFAIR, V11, P135, DOI 10.1377/hlthaff.11.4.135; HARRINGTON C, 1991, JAMA-J AM MED ASSOC, V266, P3023, DOI 10.1001/jama.266.21.3023; KANE RL, 1990, J AM GERIATR SOC, V38, P704, DOI 10.1111/j.1532-5415.1990.tb01432.x; KEMPER P, 1988, HEALTH SERV RES, V23, P161; KEMPER P, 1991, INQUIRY, V28, P3333; LAIR T, 1990, PHS903470 US DEP HLT; LETSCH SW, 1992, HLTH CARE FINANC REV, V14, P6; LEUTZ W, 1993, GERONTOLOGIST, V33, P92, DOI 10.1093/geront/33.1.92; MAHONEY KJ, 1992, J AM GERIATR SOC, V40, P1026, DOI 10.1111/j.1532-5415.1992.tb04482.x; MERRILL J, 1992, INQUIRY-J HEALTH CAR, V29, P176; MOON M, 1989, J AM GERIATR SOC, V37, P1165, DOI 10.1111/j.1532-5415.1989.tb06683.x; PAWLSON LG, 1990, J AM GERIATR SOC, V38, P696, DOI 10.1111/j.1532-5415.1990.tb01431.x; PAWLSON LG, 1989, J AM GERIATR SOC, V37, P631, DOI 10.1111/j.1532-5415.1989.tb01254.x; RIVLIN AM, 1988, CARING DISABLED ELDE; Scott HD, 1992, ANN INTERN MED, V117, P511, DOI 10.7326/0003-4819-117-6-511; SHORT P, 1990, PHS903466 US DEP HLT; SHORT PF, 1992, MILBANK Q, V70, P277, DOI 10.2307/3350060; Spillman B C, 1992, Home Health Care Serv Q, V13, P5; Zawadski R T, 1988, Health Care Financ Rev, VSpec No, P75; 1993, NURSING HOME INSURAN; 1991, COMMITMENT CHANGE F; 1993, POSITION PAPER HLTH; 1991, POLICY CHOICES LONG; 1993, MED HLTH, V47, P1; 1991, AGING AM TRENDS PROJ; 1990, 101114 US HIP COMM C; 1989, AM ASS RETIRED PERSO, V8908	39	7	7	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1525	1529		10.1001/jama.271.19.1525	http://dx.doi.org/10.1001/jama.271.19.1525			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176834				2022-12-28	WOS:A1994NK71100033
J	CIAPA, B; PESANDO, D; WILDING, M; WHITAKER, M				CIAPA, B; PESANDO, D; WILDING, M; WHITAKER, M			CELL-CYCLE CALCIUM TRANSIENTS DRIVEN BY CYCLIC CHANGES IN INOSITOL TRISPHOSPHATE LEVELS	NATURE			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; INTRACELLULAR FREE CALCIUM; SEA-URCHIN EMBRYOS; TRANSLATIONAL CONTROL; EGGS; FERTILIZATION; ANAPHASE; CA2+	TRANSIENT changes in intracellular calcium ([Ca2+](i)) have been shown to punctuate the cell cycle in various types of cells in culture(1-5) and in early embryos(6-12). The [Ca2+](i) transients are correlated with cell-cycle events: pronuclear migration, nuclear envelope breakdown, the metaphase-anaphase transition of mitosis, and cytokinesis. Mitotic events fan be induced by injecting calcium and prevented by injecting calcium chelators into the sea urchin embryo(10,13). Cell-cycle calcium transients differ from the transients linked to membrane signal transduction pathways: they are generated by an endogenous mechanism, not by plasma membrane receptor complexes, and their trigger is unknown. We report here that the phosphoinositide messenger system oscillates during the early embryonic cell cycle in the sea urchin, leading to cyclic increases in inositol trisphosphate that trigger cell-cycle [Ca2+](i) transients and mitosis by calcium release from intracellular stores.	FAC SCI NICE,PHYSIOL CELLULAIRE & COMPAREE LAB,F-06108 NICE,FRANCE; INSERM,U303,F-06230 VILLEFRANCHE MER,FRANCE; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNE CL, 1992, BIOL BULL, V183, P270; Chatfield C, 1980, ANAL TIME SERIES INT; CIAPA B, 1993, DEV BIOL, V159, P114, DOI 10.1006/dbio.1993.1225; CIAPA B, 1992, DEVELOPMENT, V115, P187; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; EDGECOMBE M, 1991, EMBO J, V10, P3769, DOI 10.1002/j.1460-2075.1991.tb04946.x; FLUCK RA, 1991, J CELL BIOL, V115, P1259, DOI 10.1083/jcb.115.5.1259; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GRANDIN N, 1991, J CELL SCI, V99, P5; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; HEPLER PK, 1992, INT REV CYTOL, V138, P239, DOI 10.1016/S0074-7696(08)61590-9; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LI LH, 1984, CANCER LETT, V23, P279, DOI 10.1016/0304-3835(84)90095-8; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATAN RR, 1986, P NATL ACAD SCI USA, V83, P5136, DOI 10.1073/pnas.83.14.5136; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SOLOMON MJ, 1990, CELL, V63, P113; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UNO I, 1988, NATURE, V333, P366; WHITAKER MJ, 1990, DEVELOPMENT, V105, P525	28	165	166	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					875	878		10.1038/368875a0	http://dx.doi.org/10.1038/368875a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159248				2022-12-28	WOS:A1994NH71700077
J	STRYNADKA, NCJ; JENSEN, SE; JOHNS, K; BLANCHARD, H; PAGE, M; MATAGNE, A; FRERE, JM; JAMES, MNG				STRYNADKA, NCJ; JENSEN, SE; JOHNS, K; BLANCHARD, H; PAGE, M; MATAGNE, A; FRERE, JM; JAMES, MNG			STRUCTURAL AND KINETIC CHARACTERIZATION OF A BETA-LACTAMASE-INHIBITOR PROTEIN	NATURE			English	Article							CLAVULANIC ACID; RESOLUTION; RESISTANCE; REFINEMENT	THE past decade has seen an alarming worldwide increase in resistance to beta-lactam antibiotics among many pathogenic bacteria1, which is due mainly to plasmid- or chromosomally encoded beta-lactamases that specifically cleave penicillin and cephalosporins, rendering them inactive. There is therefore a need to develop new strategies in the design of effective inhibitors of beta-lactamase. All the small-molecule inhibitors in clinical use are not very effective and are rapidly degraded2,3. Furthermore, newly characterized mutants of the plasmid-mediated beta-lactamase TEM-1 are highly resistant to these small-molecule inhibitors, including clavulanic acid and tazobactam4. It has been shown that Streptomyces clavuligerus produces an exocellular beta-lactamase inhibitory protein (BLIP; M(r) 17.5 K)5. Here we present data defining BLIP as the most effective known inhibitor of a variety of beta-lactamases, with K(i) values in the subnanomolar to picomolar range. To identify those features in BLIP that make it such a potent inhibitor, we have determined its molecular structure at 2.1 angstrom resolution. BLIP is a relatively flat molecule with a unique fold, comprising a tandem repeat of a 76-amino-acid domain. Each domain consists of a helix-loop-helix motif that packs against a four-stranded antiparallel beta-sheet (Fig. 1a). To our knowledge, BLIP is the first example of a protein inhibitor having two similarly folded domains that interact with and inhibit a single target enzyme.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2G7,ALBERTA,CANADA; UNIV ALBERTA,DEPT MICROBIOL,EDMONTON T6G 2E9,ALBERTA,CANADA; F HOFFMANN LA ROCHE & CO LTD,DEPT PRECLIN RES PHARMADIV INFECT DIS,CH-4002 BASEL,SWITZERLAND; STATE UNIV LIEGE,ENZYMOL LAB,B-4000 LIEGE,BELGIUM; STATE UNIV LIEGE,CTR PROT ENGN,B-4000 LIEGE,BELGIUM	University of Alberta; University of Alberta; Roche Holding; University of Liege; University of Liege			Blanchard, Helen/A-4681-2009; Jensen, Susan/C-8701-2013	Blanchard, Helen/0000-0003-3372-5027; Matagne, Andre/0000-0001-6417-6791				BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BRUNGER AT, 1987, XPLOR MANUAL VERSION; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P264, DOI 10.1128/AAC.33.3.264; DORAN JC, 1990, J BACTERIOL, V172, P4904; Frere J M, 1976, Methods Enzymol, V45, P610; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; READ RJ, 1986, PROTEINASE INHIBITOR, P301; READING C, 1979, BIOCHEM J, V179, P67, DOI 10.1042/bj1790067; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; SOUGAKOFF W, 1988, REV INFECT DIS, V10, P879; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0	22	110	118	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					657	660		10.1038/368657a0	http://dx.doi.org/10.1038/368657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145854				2022-12-28	WOS:A1994NF39200067
J	KIRBY, RS				KIRBY, RS			FORTNIGHTLY REVIEW - IMPOTENCE - DIAGNOSIS AND MANAGEMENT OF MALE ERECTILE DYSFUNCTION	BRITISH MEDICAL JOURNAL			English	Review							INFLATABLE PENILE PROSTHESIS; INTRACAVERNOUS INJECTION; YOHIMBINE; DISEASE; PROGRAM				KIRBY, RS (corresponding author), ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND.							AMIN Z, 1993, BRIT J RADIOL, V66, P398, DOI 10.1259/0007-1285-66-785-398; ANDERSSON KE, 1991, INT J IMPOT RES, V3, P155; [Anonymous], 1981, LANCET, V2, P539; BANCROFT J, 1983, ARCH SEX BEHAV, V12, P59, DOI 10.1007/BF01542116; Batra AK, 1991, IMPOTENCE DIAGNOSIS, P19; BOOKSTEIN JJ, 1987, J UROLOGY, V137, P333, DOI 10.1016/S0022-5347(17)44017-1; BRINDLEY GS, 1986, BRIT J PHARMACOL, V87, P495, DOI 10.1111/j.1476-5381.1986.tb10191.x; DJAMILIAN M, 1993, J UROLOGY, V149, P1296, DOI 10.1016/S0022-5347(17)36372-3; EARDLEY I, 1991, IMPOTENCE DIAGNOSIS, P109; EK A, 1983, J UROLOGY, V129, P964, DOI 10.1016/S0022-5347(17)52486-6; FRANKS S, 1978, CLIN ENDOCRINOL, V8, P277, DOI 10.1111/j.1365-2265.1978.tb02770.x; FURLOW WL, 1985, MED ASPECTS HUM SEX, V19, P13; Goldstein I, 1986, Semin Urol, V4, P252; HOLLANDER JB, 1992, UROLOGY, V39, P439, DOI 10.1016/0090-4295(92)90242-O; Karacan I, 1970, MEDICAL ASPECTS HUMA, V4, P27; KIRBY RS, 1991, IMPOTENCE DIAGNOSIS, P149; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; LEE LM, 1988, J UROLOGY, V141, P54; LERNER SE, 1993, J UROLOGY, V149, P1246, DOI 10.1016/S0022-5347(17)36359-0; LUE TF, 1987, J UROLOGY, V137, P829, DOI 10.1016/S0022-5347(17)44267-4; LUE TF, 1985, RADIOLOGY, V155, P777, DOI 10.1148/radiology.155.3.3890009; MALLOY TR, 1986, UROLOGY, V28, P385, DOI 10.1016/0090-4295(86)90067-1; MCCULLOCH DK, 1980, DIABETOLOGIA, V18, P279; MICHAL V, 1982, CLIN ENDOCRINOL META, V11, P725, DOI 10.1016/S0300-595X(82)80010-8; PADMANATHAN H, 1987, WORLD J UROL, V5, P160, DOI 10.1007/BF00326824; REID K, 1987, LANCET, V2, P421; STACKL W, 1988, J UROLOGY, V140, P66, DOI 10.1016/S0022-5347(17)41488-1; SUSSET JG, 1989, J UROLOGY, V141, P1360, DOI 10.1016/S0022-5347(17)41308-5; TROY K, 1985, AM J HEMATOL, V19, P237, DOI 10.1002/ajh.2830190305; VIRAG R, 1982, LANCET, V2, P938; VONHEYDEN B, 1993, J UROLOGY, V149, P1288, DOI 10.1016/S0022-5347(17)36370-X; WESPES E, 1993, J UROLOGY, V149, P1238, DOI 10.1016/S0022-5347(17)36358-9; WILSON JD, 1980, METABOLISM, V29, P1278, DOI 10.1016/0026-0495(80)90159-6; WILSON SK, 1988, J UROLOGY, V139, P951, DOI 10.1016/S0022-5347(17)42726-1; WITHERINGTON R, 1989, J UROLOGY, V141, P320, DOI 10.1016/S0022-5347(17)40752-X; 1991, ARCH INTERN MED, V151, P1413	36	37	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					957	961		10.1136/bmj.308.6934.957	http://dx.doi.org/10.1136/bmj.308.6934.957			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173405	Green Published			2022-12-28	WOS:A1994NF48500021
J	GOODRICH, JA; TJIAN, R				GOODRICH, JA; TJIAN, R			TRANSCRIPTION FACTORS IIE AND IIH AND ATP HYDROLYSIS DIRECT PROMOTER CLEARANCE BY RNA-POLYMERASE-II	CELL			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; INITIATION-FACTOR; ABORTIVE INITIATION; TERMINAL-DOMAIN; FACTOR-DELTA; MECHANISM; BINDING; PURIFICATION; ACTIVATION	Using a defined RNA polymerase II(pol II) transcription system, we have investigated the roles of basal factors at discrete stages during the transcription cycle (e.g., initiation, promoter clearance, and transcript elongation). Abortive initiation assays revealed that TATA-binding protein, transcription factors TFIIB and TFIIF, and pol II were necessary and sufficient to form functional initiation complexes on both linear and supercoiled templates. By contrast, TFIIE, TFIIH, and ATP hydrolysis were additionally required during promoter clearance from linear templates, while negative supercoiling obviated the need for these auxiliary factors. Furthermore, TFIIE, TFIIH, and supercoiling were not required during elongation. Our results suggest a role for TFIIH-associated helicase activity or supercoiling during promoter clearance rather than open complex formation. These results establish abortive initiation as a useful assay for studying functional initiation complex formation in defined eukaryotic transcription systems and provide a framework for investigating regulation at different stages of the eukaryotic transcription cycle.			GOODRICH, JA (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	49	301	302	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					145	156		10.1016/0092-8674(94)90242-9	http://dx.doi.org/10.1016/0092-8674(94)90242-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156590				2022-12-28	WOS:A1994NF21100017
J	SIOMI, H; CHOI, MY; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G				SIOMI, H; CHOI, MY; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G			ESSENTIAL ROLE FOR KH DOMAINS IN RNA-BINDING - IMPAIRED RNA-BINDING BY A MUTATION IN THE KH DOMAIN OF FMR1 THAT CAUSES FRAGILE-X SYNDROME	CELL			English	Article							PROTEIN; GENE; REPEAT; DNA; INSTABILITY; SEQUENCE; SITE	The KH domain is an evolutionarily conserved sequence motif present in many RNA-binding proteins, including the pre-mRNA-binding (hnRNP) K protein and the fragile X mental retardation gene product (FMR1). We assessed the role of KH domains in RNA binding by mutagenesis of KH domains in hnRNP K and FMR1. Conserved residues of all three hnRNP K KH domains are required for its wild-type RNA binding. Interestingly, while fragile X syndrome is usually caused by lack of FMR1 expression, a previously reported mutation in a highly conserved residue of one of its two KH domains (lle-304-->Asn) also results in mental retardation. We found that the binding of this mutant protein to RNA is severely impaired. These results demonstrate an essential role for KH domains in RNA binding. Furthermore, they strengthen the connection between fragile X syndrome and loss of the RNA binding activity of FMR1.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	SIOMI, H (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013; Siomi, Haruhiko/A-7020-2015	Dreyfuss, Gideon/0000-0001-8129-8774; Siomi, Haruhiko/0000-0001-8690-3822				ABITBOL M, 1993, NAT GENET, V4, P147, DOI 10.1038/ng0693-147; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BACHNER D, 1993, NAT GENET, V4, P115, DOI 10.1038/ng0693-115; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; BURD CG, 1994, IN PRESS EMBO J; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GEDEON AK, 1992, NAT GENET, V1, P341, DOI 10.1038/ng0892-341; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; NUSSBAUM RL, 1994, METABOLIC BASIS INHE; OOSTRA BA, 1992, CHROMOSOMA, V101, P381, DOI 10.1007/BF00582832; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, TRENDS GENET, V8, P249, DOI 10.1016/0168-9525(92)90124-M; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WOHRLE D, 1992, AM J HUM GENET, V51, P299; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	39	393	401	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					33	39		10.1016/0092-8674(94)90232-1	http://dx.doi.org/10.1016/0092-8674(94)90232-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156595				2022-12-28	WOS:A1994NF21100007
J	SMITH, CL; DELOTTO, R				SMITH, CL; DELOTTO, R			VENTRALIZING SIGNAL DETERMINED BY PROTEASE ACTIVATION IN DROSOPHILA EMBRYOGENESIS	NATURE			English	Article							SERINE PROTEASE; DORSAL; PATTERN; EMBRYO; POLARITY; EASTER; GENES	SPECIFICATION of dorsal-ventral cell fate during Drosophila embryogenesis is mediated by a signal transduction pathway1-4. Asymmetry of cell fates arises through the spatially restricted production of a ligand in an extracellular compartment called the perivitelline space5. The snake and easter genes are required for the production of the ligand17 and they encode the proenzyme form of secreted extracellular serine proteases6,7. We have examined the effect of producing a preactivated form of the snake protease on the generation of dorsal-ventral polarity. SP6 RNA microinjection experiments reveal that different cell fates acquired at cellular blastoderm can be specified by the amount and spatial distribution of activated snake protein. Our results support a protease cascade model in which localized activation of uniformly distributed protease proenzymes leads to the spatially restricted production of ligand in the perivitelline space on the ventral side of the embryo.	CORNELL UNIV,GRAD SCH MED SCI,DEPT CELL BIOL,NEW YORK,NY 10021	Cornell University	SMITH, CL (corresponding author), SLOAN KETTERING INST CANC RES,DEPT MICROBIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Smith, Cynthia L/A-5646-2009; Smith, Cynthia/AAY-6219-2020	Smith, Cynthia L/0000-0003-3691-0324; Smith, Cynthia/0000-0003-3691-0324				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEPTIN M, 1990, DEVELOPMENT, V110, P73; ROTH S, 1991, DEVELOPMENT, V112, P371; Rushlow C, 1990, Semin Cell Biol, V1, P137; Sambrook J, 1989, MOL CLONING LABORATO; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; Santamaria P., 1986, DROSOPHILA PRACTICAL, P159; SMITH C, 1994, GENETICS, V136, P1355; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STJOHNSTON D, 1992, CELL, V68, P201; Wieschaus E., 1986, P199	17	67	67	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					548	551		10.1038/368548a0	http://dx.doi.org/10.1038/368548a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139688				2022-12-28	WOS:A1994NE33500055
J	BOGLE, SM; HARRIS, CM				BOGLE, SM; HARRIS, CM			MEASURING PRESCRIBING - THE SHORTCOMINGS OF THE ITEM	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the validity of the item as a measure of the volume of a drug prescribed; and to investigate the possibility that higher quantities per item are prescribed for patients who are not exempt from the prescription charge. Design-Five substudies. For the first, a frequency distribution was derived of the different quantities per item of 10 commonly used drugs prescribed by 20 randomly selected practices in each of five family health service authority areas. For the second, the variation in average quantity per item for the same drugs in the same practices was calculated. For the third and fourth, variation in average quantity per item for 90 commonly used drugs was calculated for all 90 family health service authorities and for all 14 regional health authorities in England. For the fifth, the average quantity per item for each of the 90 drugs was regressed on the percentage of items exempt from the prescription charge, at family health service authority level, and the percentage of variation explained by the regression found. Main outcome measure-Distribution of quantity per item; variation in average quantity per item between the practices, between family health service authorities, and between regions; and percentage of variation between family health service authorities accounted for by exemption from the prescription charge. Results-Wide variation was found in the quantities per item prescribed by the practices, and in the average quantity per item between practices and between family health service authorities. No family health service authority was consistently high or low in quantity per item across the 90 drugs. Variation in average quantity per item was less at regional than at family health service authority level, though still high for many of the drugs. The proportion of variation accounted for by exemption from prescription charges ranged from 0% to 49% across the 90 drugs. Conclusions-The item is unsuitable as a measure of prescribing volume, even at regional level: a new measure, based on standard daily dosages, is needed. The percentage of the variation in quantity per item accounted for by exemption is inconsistent, and in over half the 90 drugs it was below 20%-therefore it is not a useful predictor.	UNIV LEEDS,ACAD UNIT GEN PRACTICE,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,ENGLAND	University of Leeds								HARRIS CM, 1994, BRIT MED J, V308, P207, DOI 10.1136/bmj.308.6922.207; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCGAVOCK H, 1993, BRIT MED J, V307, P1118, DOI 10.1136/bmj.307.6912.1118; 1993, ANATOMICAL THERAPEUT	4	40	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					637	640		10.1136/bmj.308.6929.637	http://dx.doi.org/10.1136/bmj.308.6929.637			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148715	Green Published			2022-12-28	WOS:A1994MZ69800026
J	COLE, TJ				COLE, TJ			DO GROWTH CHART CENTILES NEED A FACE LIFT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								European height and weight growth charts commonly extend from the 3rd to the 97th centile, whereas in North America the extremes are usually the 5th and 95th centiles. There is no good reason for the difference, and neither chart is particularly useful for screening owing to the high false positive rate associated with a cut off based on the lowest centile. The World Health Organisation's international growth reference uses cut offs based on standard deviation scores rather than centiles, which are more suitable for the extremes of growth status seen in the developing world. This chart, however, is incompatible with charts based on centiles. sere a unified growth chart is proposed: it has nine rather than seven centiles, and they are spaced two thirds of a standard deviation score apart rather than the more usual unit spacing. This gives a set of curves very like the conventional 3rd to 97th centiles, but with additional curves at 2.67 standard deviation below and above the mean (roughly the 0.4th and 99.6th centiles). The 0.4th centile is a more practical cut off for screening purposes than the 3rd or 5th centile.			COLE, TJ (corresponding author), MRC, DUNN NUTR UNIT, CAMBRIDGE CB4 1XJ, ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				COLE TJ, 1988, J R STAT SOC A STAT, V151, P385, DOI 10.2307/2982992; DIDLEY MJ, 1987, AM J CLIN NUTR, V46, P736; HAMILL PVV, 1977, VITAL HLTH STATISTIC, V11; HEALY MJR, 1988, ANN HUM BIOL, V15, P17, DOI 10.1080/03014468800009421; ROEDE MJ, 1985, TIJDSCHR SOC GEZON S, V63, P1, DOI DOI 10.1007/978-1-4471-1721-6_10; STUART HC, 1950, MITCHELL NELSONS TXB, P14; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613	7	84	86	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	1994	308	6929					641	642		10.1136/bmj.308.6929.641	http://dx.doi.org/10.1136/bmj.308.6929.641			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148716	Green Published, Green Submitted			2022-12-28	WOS:A1994MZ69800029
J	HAIDER, R; KHAN, AKA; ROY, SK; DEWAN, N; ALAM, AN; MAHALANABIS, D				HAIDER, R; KHAN, AKA; ROY, SK; DEWAN, N; ALAM, AN; MAHALANABIS, D			MANAGEMENT OF ACUTE DIARRHEA IN DIABETIC-PATIENTS USING ORAL REHYDRATION SOLUTIONS CONTAINING GLUCOSE, RICE, OR GLYCINE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the risk of hyperglycaemia with two standard oral rehydration solutions that contain carbohydrate compared with a carbohydrate free solution during rehydration of diabetic patients with acute diarrhoea. Design-Prospective randomised allocation to one of three oral rehydration solutions (World Health Organisation (glucose), rice, or glycine) groups after admission to hospital with acute diarrhoea. Setting-Dhaka hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects-45 diabetic patients aged between 15 and 60 who had had diarrhoea for fewer than three days on admission. Main outcome measures-Fluctuation of blood glucose concentrations measured three times a day, daily stool output, and time taken for recovery from diarrhoea. Results-There were no significant differences in blood glucose concentrations, stool output, and duration of recovery from diarrhoea among the three groups. Conclusions-Oral rehydration solutions containing glucose, rice powder, or glycine can be safely administered to diabetic patients with acute diarrhoea and some dehydration.			HAIDER, R (corresponding author), INT CTR DIARRHOEAL DIS RES,GPO BOX 128,DHAKA 1000,BANGLADESH.							MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; NALIN D R, 1987, Journal of Diarrhoeal Diseases Research, V5, P283; 1984, PROGRAMME CONTROL DI, P25; 1985, WHO TECH REP SER, P727	4	3	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					624	626		10.1136/bmj.308.6929.624	http://dx.doi.org/10.1136/bmj.308.6929.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148710	Green Published			2022-12-28	WOS:A1994MZ69800020
J	CAULFIELD, M; LAVENDER, P; FARRALL, M; MUNROE, P; LAWSON, M; TURNER, P; CLARK, AJL				CAULFIELD, M; LAVENDER, P; FARRALL, M; MUNROE, P; LAWSON, M; TURNER, P; CLARK, AJL			LINKAGE OF THE ANGIOTENSINOGEN GENE TO ESSENTIAL-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIGREE-MEMBER METHOD; BLOOD-PRESSURE; PREECLAMPSIA; DISEASE; SYSTEM; RAT	Background. The renin-angiotensin system is a powerful presser system with a major influence on salt and water homeostasis. Angiotensinogen (also called renin substrate) is a key component of this system; it is cleaved by renin to yield angiotensin I, which is then cleaved by angiotensin-converting enzyme to yield angiotensin II, The observation that plasma angiotensinogen levels correlate with blood pressure and track through families suggests that angiotensinogen may have a role in essential hypertension. We therefore investigated whether there is linkage between the angiotensinogen gene on chromosome 1q42-43 and essential hypertension. Methods. Samples of DNA from 63 white European families in which two or more members had essential hypertension were tested for linkage of the angiotensinogen gene to this disorder. Affected cousins, nephews, nieces, and half-siblings were included when possible. To test for linkage, we used as a marker a dinucleotide-repeat sequence flanking this gene, and we employed the affected-pedigree-member method of linkage analysis. Two molecular variants of the angiotensinogen gene, one encoding threonine instead of methionine at position 235 (M235T) and the other encoding methionine rather than threonine at position 174 (T174M), were also tested for possible association with essential hypertension. Results. We found significant linkage (t = 5.00, P<0.001) and association (chi-square = 53.3, P<0.001) of the angiotensinogen-gene locus to essential hypertension in the 63 multiplex families. This linkage was consistently maintained in the subgroup of subjects with diastolic pressure above 100 mm Hg and in the subgroups classified according to sex. It has been proposed previously that T174M and M235T are associated with essential hypertension. However, we found no association in our population between either polymorphism and this disorder. Conclusions. This study provides strong and consistent support for the linkage to essential hypertension of regions within or close to the angiotensinogen gene. Precisely how mutations in this region may result in hypertension remains to be determined.	ST BARTHOLOMEWS HOSP,DEPT CHEM ENDOCRINOL,LONDON,ENGLAND; ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,LONDON,ENGLAND	University of London; Queen Mary University London; Imperial College London	CAULFIELD, M (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND.			Munroe, Patricia/0000-0002-4176-2947; Caulfield, Mark/0000-0001-9295-3594; Lavender, Paul/0000-0001-8710-0263				ARNGRIMSSON R, 1993, NAT GENET, V4, P114, DOI 10.1038/ng0693-114; BISHOP DT, 1990, AM J HUM GENET, V46, P254; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOTELEVTSEV YV, 1991, MOL CLONING LABORATO, V19, P6978; KURTZ TW, 1993, AM J MED, V94, P77, DOI 10.1016/0002-9343(93)90124-8; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; MACGREGOR GA, 1981, NATURE, V291, P329, DOI 10.1038/291329a0; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PICKERING G, 1965, BMJ-BRIT MED J, V2, P1021, DOI 10.1136/bmj.2.5469.1021; Sambrook J, 1989, MOL CLONING LABORATO; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Ward R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WEEKS DE, 1988, AM J HUM GENET, V42, P315; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WILLIAMS RR, 1989, J HYPERTENS, V7, pS8, DOI 10.1097/00004872-198900076-00003; 1992, NAT GENET, V1, P231	25	513	537	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1629	1633		10.1056/NEJM199406093302301	http://dx.doi.org/10.1056/NEJM199406093302301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177268				2022-12-28	WOS:A1994NP22000001
J	SCHWARTZ, RM; LUBY, NM; SCANLON, JW; KELLOGG, RJ				SCHWARTZ, RM; LUBY, NM; SCANLON, JW; KELLOGG, RJ			EFFECT OF SURFACTANT ON MORBIDITY, MORTALITY, AND RESOURCE USE IN NEWBORN-INFANTS WEIGHING 500 TO 1500 G	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; BOVINE SURFACTANT; CONTROLLED TRIAL; SYNTHETIC SURFACTANT; REPLACEMENT THERAPY; PREMATURE-INFANTS; PREVENTION; SURVIVAL; BIRTH	Background. The administration of surfactant decreased mortality, morbidity, and costs of care for very-low-birth-weight infants in clinical trials. The extent to which these benefits can be achieved in the usual clinical settings is not known. Methods. We analyzed clinical and financial data obtained from 1985 to 1990 at 14 perinatal centers in the United States on 5629 neonates weighing 500 to 1500 g. The infants were divided into groups according to whether they were born before or after surfactant was introduced into clinical practice. Regression models controlling for race, sex, and birth weight were used to assess mortality, morbidity, and use of resources. Mortality rates specific for these variables were projected to the nation as a whole with reference to the 1985 U.S. birth cohort. Results. The odds of death in the hospital for very-low-birth-weight infants were reduced by 30 percent after surfactant was introduced. Among infants with bronchopulmonary dysplasia, mortality declined 40 percent. Projections of mortality nationwide declined 5 percent. Eighty percent of the decline in the U.S. infant mortality rate between 1989 and 1990 could be attributed solely to the use of surfactant. Among the survivors, the overall odds of morbidity did not change, whether or not we adjusted for changes in race, sex, and birth weight. The odds of respiratory distress syndrome and pulmonary interstitial emphysema among the survivors declined by 20 percent and 40 percent, respectively, with surfactant. Inflation-adjusted charges per survivor declined by 10 percent, or $5,800, whereas the cost of care for each infant who died declined by 31 percent, or $4,400. Conclusions. The introduction of surfactant has led to decreased mortality and morbidity in very-low-birth-weight infants and to decreased use of resources both for infants who survive and for those who die.	COLUMBIA HOSP WOMEN, DIV NEONATOL, WASHINGTON, DC USA		SCHWARTZ, RM (corresponding author), NATL PERINATAL INFORMAT CTR, 1 STATE ST, SUITE 102, PROVIDENCE, RI 02908 USA.				PHS HHS [N01-H0-29024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; CORBET A, 1991, J PEDIATR-US, V118, P277, DOI 10.1016/S0022-3476(05)80502-5; HALLMAN M, 1991, ANN MED, V23, P693, DOI 10.3109/07853899109148105; HENNES HM, 1991, AM J DIS CHILD, V145, P102, DOI 10.1001/archpedi.1991.02160010108027; HENNES HM, 1992, AM J DIS CHILD, V146, P534; Hilts Philip J, 1991, N Y Times Web, P7; HILTS PJ, 1991, NY TIMES        0406, P8; HOEKSTRA RE, 1991, PEDIATRICS, V88, P10; HORBAR JD, 1989, NEW ENGL J MED, V320, P959; LIECHTY EA, 1991, PEDIATRICS, V88, P19; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MANISCALCO WM, 1989, PEDIATRICS, V83, P1; MUGFORD M, 1991, ARCH DIS CHILD-FETAL, V66, P757, DOI 10.1136/adc.66.7_Spec_No.757; PHIBBS CS, 1992, 1991 P EX NEON TREAT, P109; RAJU TNK, 1987, LANCET, V1, P651; ROBERTSON B, 1988, PEDIATRICS, V82, P683; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOLL RF, 1990, PEDIATRICS, V85, P1092; WEGMAN ME, 1991, PEDIATRICS, V88, P1081; 1976, IMPROVING OUTCOME PR; 1994, ICD9CM INT CLASSIFIC; 1991, PEDIATRICS, V87, P946	23	225	227	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1476	1480		10.1056/NEJM199405263302102	http://dx.doi.org/10.1056/NEJM199405263302102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164699				2022-12-28	WOS:A1994NM06800002
J	BEVAN, MJ; HOGQUIST, KA; JAMESON, SC				BEVAN, MJ; HOGQUIST, KA; JAMESON, SC			SELECTING THE T-CELL RECEPTOR REPERTOIRE	SCIENCE			English	Editorial Material							VIRAL PEPTIDES		UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	BEVAN, MJ (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195, USA.		Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146; Hogquist, Kristin/0000-0001-9963-5687				ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	13	68	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					796	797		10.1126/science.8171333	http://dx.doi.org/10.1126/science.8171333			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171333				2022-12-28	WOS:A1994NJ94900020
J	RIDDIHOUGH, G				RIDDIHOUGH, G			A TWIST IN THE TAIL OF HUMAN ENDOTHELIN	NATURE			English	Article																		JANES RW, 1994, NATURE STRUCT BIOL, V1, P331; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					84	84		10.1038/369084a0	http://dx.doi.org/10.1038/369084a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164749	Bronze			2022-12-28	WOS:A1994NJ86000060
J	KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA				KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA			RELATION OF THE CONTENT OF PRENATAL-CARE TO THE RISK OF LOW-BIRTH-WEIGHT - MATERNAL REPORTS OF HEALTH BEHAVIOR ADVICE AND INITIAL PRENATAL-CARE PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPACT; POPULATION; PROGRAMS; OUTCOMES; WOMEN	Objective.-Numerous studies have found a relationship between the quantity of prenatal care received and birth outcomes. Few studies have had the opportunity to examine the content of prenatal care. This study examined the relationship between two components of the content of prenatal care: maternal reports of health behavior advice received and initial prenatal care procedures performed during the first two visits and low birth weight in a national sample of women. Advice and initial procedures were categorized based on the recommendations of the US Public Health Service Expert Panel on the Content of Prenatal Care. Design.-Interview survey of a nationally representative sample of women who had live births in 1988. Participants.-A total of 9394 women, with data from the National Maternal and Infant Health Survey. Main Outcome Measure.-Low birth weight (<2500 g) as reported on the birth certificate. Results.-After controlling for other sociodemographic, utilization, medical, and behavioral factors, women who reported not receiving all the types of advice recommended by the Expert Panel on the Content of Prenatal Care were more likely to have a low-birth-weight infant compared with women who reported receiving the optimal level of advice (odds ratio=1.38; 95% confidence interval, 1.18 to 1.60). There were no differences between women who reported receiving all the recommended initial prenatal care procedures and those who reported not receiving all recommended prenatal care (odds ratio=1.00; 95% confidence interval, 0.87 to 1.14). Conclusion.-These data suggest that women who report receiving sufficient health behavior advice as part of their prenatal care are at lower risk of delivering a low-birth-weight infant.	UNIV MINNESOTA,DEPT MATERNAL & CHILD HLTH,MINNEAPOLIS,MN 55455; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PREVENT MED,BALTIMORE,MD 21201	University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.							ALEXANDER GR, 1987, AM J PREV MED, V3, P243; DAVIDSON EC, 1992, NEW ENGL J MED, V327, P1022, DOI 10.1056/NEJM199210013271409; FINK A, 1992, OBSTET GYNECOL, V80, P867; FISHER ES, 1985, AM J PUBLIC HEALTH, V75, P866, DOI 10.2105/AJPH.75.8.866; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HEMMINKI E, 1988, MED CARE, V26, P199, DOI 10.1097/00005650-198802000-00010; KESSEL SS, 1988, CLIN PERINATOL, V15, P745, DOI 10.1016/S0095-5108(18)30671-7; Kessner DM, 1973, CONTRASTS HLTH STATU; KOGAN MD, 1994, AM J PUBLIC HEALTH, V84, P82, DOI 10.2105/AJPH.84.1.82; Koonin L M, 1991, MMWR CDC Surveill Summ, V40, P1; KOTELCHUCK M, IN PRESS AM J PUBLIC; LIBBUS MK, 1991, BIRTH-ISS PERINAT C, V18, P78, DOI 10.1111/j.1523-536X.1991.tb00064.x; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; MCLAUGHLIN FJ, 1992, PEDIATRICS, V89, P128; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; NAGEY DA, 1989, OBSTET GYNECOL, V74, P516; PEOPLES MD, 1983, MED CARE, V21, P586, DOI 10.1097/00005650-198306000-00002; PEOPLESSHEPS MD, 1991, AM J OBSTET GYNECOL, V164, P514, DOI 10.1016/S0002-9378(11)80011-6; PEOPLESSHEPS MD, 1988, HEALTH SERV RES, V23, P359; PETTITI DB, 1991, BIRTH-ISS PERINAT C, V18, P21; POLAND ML, 1991, J PERINAT MED, V19, P427, DOI 10.1515/jpme.1991.19.6.427; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; 1993, SURVEY DATA ANAL VER; 1989, CARING OUR FUTURE CO	29	153	156	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1340	1345		10.1001/jama.271.17.1340	http://dx.doi.org/10.1001/jama.271.17.1340			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NH487	8158819				2022-12-28	WOS:A1994NH48700026
J	BEUTLER, B; VANHUFFEL, C				BEUTLER, B; VANHUFFEL, C			UNRAVELING FUNCTION IN THE TNF LIGAND AND RECEPTOR FAMILIES	SCIENCE			English	Editorial Material							APOPTOSIS; RESOLUTION; BINDING; ANTIGEN; CDNA; FAS				BEUTLER, B (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Van Huffel, Christophe/0000-0001-6127-3027				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; BAENS M, 1993, J IMMUNOL, V16, P214; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MICHL J, 1991, CURR OPIN IMMUNOL, V3, P373, DOI 10.1016/0952-7915(91)90040-8; Moore M., COMMUNICATION; PEPPEL K, 1993, J IMMUNOL, V151, P5699; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	29	434	458	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					667	668		10.1126/science.8171316	http://dx.doi.org/10.1126/science.8171316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171316				2022-12-28	WOS:A1994NH71300021
J	BECKER, TM; WHEELER, CM; MCGOUGH, NS; PARMENTER, CA; JORDAN, SW; STIDLEY, CA; MCPHERSON, RS; DORIN, MH				BECKER, TM; WHEELER, CM; MCGOUGH, NS; PARMENTER, CA; JORDAN, SW; STIDLEY, CA; MCPHERSON, RS; DORIN, MH			SEXUALLY-TRANSMITTED DISEASES AND OTHER RISK-FACTORS FOR CERVICAL DYSPLASIA AMONG SOUTHWESTERN HISPANIC AND NON-HISPANIC WHITE WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; HERPES-SIMPLEX INFECTIONS; GENITAL INFECTIONS; CANCER; NEOPLASIA; GLYCOPROTEIN; POPULATION; DIAGNOSIS	Objective.-To assess risk factors for high-grade cervical dysplasia among southwestern Hispanic and non-Hispanic white women. Design.-Clinic-based case-control study. Setting.-University-affiliated gynecology clinics. Subjects.-Cases were Hispanic and non-Hispanic white women with biopsy proven high-grade cervical dysplasia (n=201). Controls were Hispanic and non-Hispanic white women from the same clinics with normal cervical epithelium (n=337). Methods.-Study design included interviews focused on histories of sexually transmitted diseases, sexual behavior, reproductive histories, hygienic practices, contraceptive use, cigarette smoking, and diet. Laboratory studies included bacterial and protozoal cultures of the cervix; hybridization tests to identify human papillomavirus (HPV) genome with commercial (ViraPap and ViraType) and polymerase chain reaction-based assays; and serum antibody tests for herpes simplex virus, Chlamydia trachomatis, syphilis, hepatitis B, and hepatitis C. Results.-For both ethnic groups combined, after adjustment for ethnicity, age, and sexual behavior, the strongest risks for cervical dysplasia were associated with cervical HPV infection as identified by ViraPap (odds ratio [OR], 12.8; 95% confidence interval [CI], 8.2 to 20.0) or with polymerase chain reaction (OR, 20.8; 95% CI, 10.8 to 40.2). Other factors associated with dysplasia included cigarette smoking at the time of diagnosis (OR, 1.8; 95% CI, 1.2 to 2.8); low income (OR, 2.2; 95% CI, 1.2 to 4.0); low educational level (OR, 6.2; 95% CI, 3.4 to 11.1); history of any sexually transmitted disease (OR, 1.9; 95% CI, 1.3 to 2.7); and seroprevalence of antibodies to hepatitis B (OR, 1.8; 95% CI, 0.9 to 3.5). For Hispanic women, HPV 16/18 identified by ViraType was strongly associated with cervical dysplasia (OR, 171.0; 95% CI, 22.8 to 1280.5). Antibodies to herpes simplex virus type 2 were not associated with dysplasia in Hispanic women but were significantly associated with dysplasia among non-Hispanic whites. Risks associated with cigarette smoking also varied by ethnic group. Conclusions.-The strongest risk factor associated With high-grade cervical dysplasia among clinic attendees was HPV infection. Although most of the risk factors we examined showed similar associations for dysplasia for both ethnic groups, our data suggest that several different risk factors may be relevant to the development of cervical dysplasia in Hispanics compared with non-Hispanic whites who attend the same clinics.	UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX 77025 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	BECKER, TM (corresponding author), UNIV NEW MEXICO, SCH MED, CTR CANC, NEW MEXICO TUMOR REGISTRY, ALBUQUERQUE, NM 87131 USA.				NCI NIH HHS [CA-48003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BECKER TM, 1992, WESTERN J MED, V156, P376; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; Franco E L, 1991, Epidemiology, V2, P98, DOI 10.1097/00001648-199103000-00003; HERRERO R, 1990, CANCER-AM CANCER SOC, V65, P380, DOI 10.1002/1097-0142(19900115)65:2<380::AID-CNCR2820650234>3.0.CO;2-9; JORDAN SW, 1981, CANCER, V47, P2523, DOI 10.1002/1097-0142(19810515)47:10<2523::AID-CNCR2820471036>3.0.CO;2-T; KJAER SK, 1991, INT J CANCER, V48, P39; KLITZ W, 1992, NATURE, V356, P17, DOI 10.1038/356017a0; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; Linstead D., 1989, TRICHOMONADS PARASIT, P91; MANOS MM, 1989, CANCER CEL, V7, P209; MANOS MM, 1991, JUL PAP WORKSH SEATT; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MUNOZ N, 1992, EPIDEMIOLOGY CERVICA, P251; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; Odds FC, 1979, CANDIDA CANDIDOSIS; Paavonen J, 1990, SEXUALLY TRANSMITTED, V2, P561; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; Sampson L., 1985, CLIN NUTR, V4, P171; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHMAUZ R, 1989, INT J CANCER, V43, P805, DOI 10.1002/ijc.2910430511; SCHNEIDER A, 1992, OBSTET GYNECOL, V79, P683; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STAMM WE, 1986, DIAGN MICROBIOL, V4, P935; THAYER JD, 1966, HLTH LAB REP, V81, P559; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1989, SAS STAT USERS GUIDE; 1969, MANUAL TESTS SYPHILI	38	84	85	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1181	1188						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151876				2022-12-28	WOS:A1994NF20700027
J	ASHBY, J				ASHBY, J			CHANGE THE RULES FOR FOOD-ADDITIVES	NATURE			English	Editorial Material							CARCINOGENS				ASHBY, J (corresponding author), ZENECA CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,CHESHIRE,ENGLAND.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; ASHBY J, 1993, MUTAGENESIS, V8, P489, DOI 10.1093/mutage/8.6.489; ASHBY J, 1991, NATURE, V352, P185, DOI 10.1038/352185a0; ASHBY J, 1994, MUTAT RES, V306, P107, DOI 10.1016/0027-5107(94)90173-2; HILDEBRAND B, 1991, MUTAT RES, V248, P211; JUKES TH, 1972, PREV MED, V2, P133; SWENBERG JA, 1993, ENVIRON HEALTH PERSP, V101, P39, DOI 10.1289/ehp.93101s639; SWENBERG JA, 1993, ENV HLTH PERSPECT S, V5; 1993, NATURE, V363, P287; 1993, NTP431 TECHN REP; 1986, NTP250 TECHN REP	11	4	4	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					582	582		10.1038/368582a0	http://dx.doi.org/10.1038/368582a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145840	Bronze			2022-12-28	WOS:A1994NF39200026
J	CONWAY, AS; MELZER, D; HALE, AS				CONWAY, AS; MELZER, D; HALE, AS			THE OUTCOME OF TARGETING COMMUNITY MENTAL-HEALTH-SERVICES - EVIDENCE FROM THE WEST LAMBETH SCHIZOPHRENIA COHORT	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CARE; MANAGEMENT; ILL	Objectives-To report outcome of targeting community mental health services to people with schizophrenia in an inner London district who had been shown; one year after discharge, to have high levels of psychotic symptomatology and social disability but very low levels of supported housing and structured day activity. Design-Repeat interview survey of symptoms, disability, and receipt of care four years after index discharge. Setting-Inner London health district with considerable social deprivation and a mental hospital in the process of closure. Subjects-51 patients originally aged 20-65 years who satisfied the research diagnostic criteria for schizophrenia. Main outcome measures-Contact with services during the three months before interview, levels of symptoms (from present state examination), global social disability rating. Results-65% (33/51) of the study group had been readmitted at least once in the three years between surveys. Recent contacts with community psychiatric nurses and rates of hospital admission increased (8 at one year v 24 at four years, p < 0.01; 5 v 13, p < 0.06). Conversely, fewer patients were in contact with social workers (17 v 7, p < 0.03). Proportions in supported housing, day care, or sheltered work did not change. Unemployment rates remained very high. A considerable reduction (almost a halving) in psychiatric symptoms was observed, but there was no significant change in mean levels of social disability. Conclusions-The policy of targeting the long term mentally ill resulted in significant increases in professional psychiatric input to the cohort but failed to improve access to social workers or suitable accommodation. Improvements in social functioning did not follow from reductions in the proportions of patients with psychotic mental states. Social interventions are likely to be crucial to achieving the Health of the Nation target of improving social functioning for the seriously mentally ill, as improving mental state seems in itself to be insufficient.	FULBOURNE HOSP,CAMBRIDGE HLTH AUTH,CAMBRIDGE CB1 5EF,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Melzer, David/0000-0002-0170-3838				ADDINGTON DE, 1992, ACTA PSYCHIAT SCAND, V85, P288, DOI 10.1111/j.1600-0447.1992.tb01471.x; BHUGRA TS, 1988, BRIT J PSYCHIAT, V155, P777; BREIER A, 1991, ARCH GEN PSYCHIAT, V48, P239; CARONE BJ, 1991, ARCH GEN PSYCHIAT, V48, P247; CIOMPI L, 1984, BRIT J PSYCHIAT, V145, P636, DOI 10.1192/bjp.145.6.636; Craig T., 1992, J MENTAL HLTH, V1, P265, DOI DOI 10.3109/09638239209005459; ELLIS RH, 1984, COMMUNITY MENT HLT J, V20, P72; HARDING CM, 1988, BR J PSYCHIATRY S5, V155, P100; HIRSCH SR, 1988, PSYCHIATRIC BEDS RES; INTAGLIATA J, 1982, SCHIZOPHRENIA BULL, V8, P655, DOI 10.1093/schbul/8.4.655; JOHNSTONE EC, 1984, BRIT J PSYCHIAT, V145, P586, DOI 10.1192/bjp.145.6.586; JOHNSTONE EC, 1991, BR J PSYCHAITRY  S13, V159, P13; KENDRICK T, 1991, BRIT MED J, V302, P508, DOI 10.1136/bmj.302.6775.508; KING MB, 1992, BRIT J GEN PRACT, V42, P310; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; LAWRENCE RE, 1991, CLOSURE MENTAL HOSPI; LEE PWH, 1991, ACTA PSYCHIAT SCAND, V84, P346, DOI 10.1111/j.1600-0447.1991.tb03158.x; MELZER D, 1991, BRIT MED J, V303, P1023, DOI 10.1136/bmj.303.6809.1023; NORUSIS MJ, 1986, STATISTICAL PACKAGE; OLFSON M, 1990, HOSP COMMUNITY PSYCH, V41, P634; RICE P, 1984, INFORMATION DISTRICT; SHANKS J, 1989, HOSP COMMUNITY PSYCH, V40, P878; SHEPHERD G, 1990, HLTH TRENDS, V2, P59; SHEPHERD G, 1992, PRIMARY CARE SCHIZOP; SPITZER RL, 1975, RES DIAGNOSTIC CRITE, V58; THORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475, DOI 10.1192/bjp.158.4.475; THORNICROFT G, 1991, BRIT J PSYCHIAT, V159, P245, DOI 10.1192/bjp.159.2.245; WATT DC, 1983, PSYCHOL MED, V13, P663, DOI 10.1017/S0033291700048091; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WING JK, 1990, SOC PSYCH PSYCH EPID, V25, P2; 1992, HLTH NATION STRATEGY; 1988, WHO PSYCHIATRIC DISA; 1989, ACTA PSYCHIAT SCAND, V80, P597	33	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					627	630		10.1136/bmj.308.6929.627a	http://dx.doi.org/10.1136/bmj.308.6929.627a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MZ698	8148711	Green Published			2022-12-28	WOS:A1994MZ69800022
J	ROBERTS, J				ROBERTS, J			ZIDOVUDINE COULD CUT TRANSMISSION OF HIV BY MOTHERS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					614	614		10.1136/bmj.308.6929.614	http://dx.doi.org/10.1136/bmj.308.6929.614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148707				2022-12-28	WOS:A1994MZ69800009
J	CAI, Q; HODGSON, SF; KAO, PC; LENNON, VA; KLEE, GG; ZINSMIESTER, AR; KUMAR, R				CAI, Q; HODGSON, SF; KAO, PC; LENNON, VA; KLEE, GG; ZINSMIESTER, AR; KUMAR, R			INHIBITION OF RENAL PHOSPHATE-TRANSPORT BY A TUMOR PRODUCT IN A PATIENT WITH ONCOGENIC OSTEOMALACIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PARATHYROID-HORMONE; RICKETS; 1,25-DIHYDROXYVITAMIN-D; 25-HYDROXYVITAMIN-D; DEFICIENCY; LESIONS		MAYO CLIN & MAYO FDN,NEPHROL RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,NEUROIMMUNOL RES LAB,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL & IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic				Kumar, Rajiv/0000-0003-3497-3057	NCI NIH HHS [CA-37343] Funding Source: Medline; NIDDK NIH HHS [R01 DK058546, DK 25409, DK 42971, R01 DK025409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK042971, R01DK025409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMAHROUQ HA, 1991, J TISSUE CULT METHOD, V13, P185; ASCHINBERG LC, 1977, J PEDIATR-US, V91, P56, DOI 10.1016/S0022-3476(77)80444-7; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; DREZNER MK, 1977, J CLIN INVEST, V60, P1046, DOI 10.1172/JCI108855; DREZNER MK, 1982, VITAMIN D CHEM BIOCH, P949; FANCONI A, 1974, HELV PAEDIATR ACTA, V29, P187; FUKUMOTO Y, 1979, J CLIN ENDOCR METAB, V49, P873, DOI 10.1210/jcem-49-6-873; HARRISON HE, 1973, PEDIATRICS, V52, P432; HODGSON SF, 1986, MAYO CLIN PROC, V61, P28, DOI 10.1016/S0025-6196(12)61395-0; HORTON JK, 1992, J IMMUNOL METHODS, V155, P31, DOI 10.1016/0022-1759(92)90268-X; KAO PC, 1990, MAYO CLIN PROC, V65, P1399, DOI 10.1016/S0025-6196(12)62163-6; KAO PC, 1984, CLIN CHEM, V30, P56; KAO PC, 1993, CLIN CHEM, V39, P1369; KLEE GG, 1992, CLIN CHEM, V38, P628; Lobaugh B, 1984, VITAMIN D BASIC CLIN, P665; MCCANCE RA, 1947, Q J MED, V16, P33; MIYAUCHI A, 1988, J CLIN ENDOCR METAB, V67, P46, DOI 10.1210/jcem-67-1-46; POPOVTZER MM, 1981, CLIN RES, V29, pA418; RIBOVICH ML, 1978, ARCH BIOCHEM BIOPHYS, V188, P145, DOI 10.1016/0003-9861(78)90367-3; RYAN EA, 1984, AM J MED, V77, P501, DOI 10.1016/0002-9343(84)90112-8; SALASSA RM, 1970, NEW ENGL J MED, V283, P65, DOI 10.1056/NEJM197007092830204; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PK, 1987, ANAL BIOCHEM, V163, P279; SWEET RA, 1980, ANN INTERN MED, V93, P279, DOI 10.7326/0003-4819-93-2-279; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; WEIDNER N, 1991, ULTRASTRUCT PATHOL, V15, P317, DOI 10.3109/01913129109016242; WEIDNER N, 1985, CANCER-AM CANCER SOC, V55, P1691, DOI 10.1002/1097-0142(19850415)55:8<1691::AID-CNCR2820550814>3.0.CO;2-S	27	252	264	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1645	1649		10.1056/NEJM199406093302304	http://dx.doi.org/10.1056/NEJM199406093302304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177270	Bronze			2022-12-28	WOS:A1994NP22000004
J	TUNIS, SR; HAYWARD, RSA; WILSON, MC; RUBIN, HR; BASS, EB; JOHNSTON, M; STEINBERG, EP				TUNIS, SR; HAYWARD, RSA; WILSON, MC; RUBIN, HR; BASS, EB; JOHNSTON, M; STEINBERG, EP			INTERNISTS ATTITUDES ABOUT CLINICAL-PRACTICE GUIDELINES	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY CARE PHYSICIANS; MEDICAL-PRACTICE; HEALTH-CARE; BEHAVIOR; CHOLESTEROL; MANAGEMENT; PROGRAM; BELIEFS; IMPACT	Objective: To assess internists' familiarity with, confidence in, and attitudes about practice guidelines issued by various organizations. Design: Cross-sectional, self-administered survey. Participants: Questionnaires were mailed to a stratified random sample of 2600 members of the American College of Physicians (ACP) in 1992. Of the 2513 internists who met our eligibility criteria, 1513 responded (60%). Measurements and Results: Familiarity with guidelines varied from 11% of responders for the ACP guideline on exercise treadmill testing to 59% of responders for the National Cholesterol Education Program guideline. Confidence was reported in ACP guidelines by 82% of responders but by only 6% for Blue Cross and Blue Shield guidelines. Subspecialists had greatest confidence in guidelines developed by their own subspecialty organizations. It was thought that guidelines would improve the quality of health care by 70% of responders, increase health care costs by 43%, be used to discipline physicians by 68%, and make practice less satisfying by 34%. More favorable attitudes were held by internists who were paid a fixed salary, saw patients for less than 20 hours per week, had recently graduated from medical school, or were not in private practice. Conclusions: Although most ACP members studied recognized the potential benefits of practice guidelines, many were concerned about possible effects on clinical autonomy, health care costs, and satisfaction with clinical practice.	MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8N 3Z5, ON, CANADA; JOHNS HOPKINS UNIV, DIV INTERNAL MED, BALTIMORE, MD 21205 USA	McMaster University; Johns Hopkins University				Bass, Eric/0000-0001-9106-527X; Wilson, Mark/0000-0003-1271-9664	BHP HRSA HHS [2D28 PE 53014-07] Funding Source: Medline	BHP HRSA HHS		[Anonymous], 1989, GUIDE CLIN PREVENTIV; [Anonymous], 1990, CLIN PRACTICE GUIDEL; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CHARNOW JA, 1990, ACP OBSERVER, V10, P1; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; DIXON AS, 1990, MED CARE, V28, P201, DOI 10.1097/00005650-199003000-00002; DONALDSON MS, 1990, FOCUS GROUPS SURGEON; DONALDSON RM, 1990, CORTLANDT FORUM  DEC, P24; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2243; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; EPSTEIN AM, 1986, AM J MED, V80, P865, DOI 10.1016/0002-9343(86)90630-3; FLETCHER RH, 1990, ANN INTERN MED, V113, P645, DOI 10.7326/0003-4819-113-9-645; GOLDMAN L, 1990, NEW ENGL J MED, V322, P1524, DOI 10.1056/NEJM199005243222110; GOODSPEED RB, 1990, J GEN INTERN MED, V5, P271, DOI 10.1007/BF02600551; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JF, 1992, J ORAL MAXIL SURG, V50, P50, DOI 10.1016/0278-2391(92)90196-7; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MAIMAN LA, 1991, AM J PREV MED, V7, P273, DOI 10.1016/S0749-3797(18)30899-7; MITTMAN BS, 1992, IMPROVING HLTH POLIC; ROMM FJ, 1981, SOUTHERN MED J, V74, P265, DOI 10.1097/00007611-198103000-00004; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SHEA S, 1990, J GEN INTERN MED, V5, P327, DOI 10.1007/BF02600401; SOX HC, 1990, COMMON DIAGNOSTIC TE; TROEIN M, 1991, FAM PRACT, V8, P223, DOI 10.1093/fampra/8.3.223; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; WACHTEL TJ, 1990, J GEN INTERN MED, V5, P335, DOI 10.1007/BF02600402; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; White L J, 1990, QRB Qual Rev Bull, V16, P50; WILSON MC, 1991, MED DECIS MAKING, V11, P334; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; 1984, SURVEY USE CLIN EFFI; 1992, GUIDELINES CLIN PRAC; 1992, PHYSICIAN PAYMENT RE; 1990, MED PRACTICE GUIDELI; 1990, PRACTICE PARAMETERS, P1	44	376	379	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					956	963		10.7326/0003-4819-120-11-199406010-00008	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172440				2022-12-28	WOS:A1994NN11000008
J	CUMMINGS, P; PSATY, BM				CUMMINGS, P; PSATY, BM			THE ASSOCIATION BETWEEN CHOLESTEROL AND DEATH FROM INJURY	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; EXPANDED CLINICAL-EVALUATION; LOW SERUM-CHOLESTEROL; MIDDLE-AGED MEN; PRIMARY-PREVENTION; BLOOD-LIPIDS; RISK-FACTORS; MODERATE HYPERCHOLESTEROLEMIA; ANTISOCIAL PERSONALITY; MYOCARDIAL-INFARCTION	Purpose: To review the association between low serum cholesterol and death from injury. Data Sources: Relevant English-language papers identified through MEDLINE and Current Contents searches and bibliographies of identified articles. Study Selection: More than 150 articles were reviewed to identify data, meta-analyses, or important reviews of the association between low cholesterol and injuries. Data Extraction: Estimates of the association between cholesterol and death from injury were extracted from published reports. Data Synthesis: Animal studies and descriptive studies have provided little information about serum cholesterol and injuries. The Conference on Low Blood Cholesterol pooled results from 14 cohort studies in men and found a relative risk of 1.4 for death from injury in men whose cholesterol levels were lower than 4.14 mmol/L (160 mg/dL) compared with men whose cholesterol levels were 4.14 to 5.15 mmol/L (P = 0.003). Most cohort studies support this finding. The strongest evidence that cholesterol and death from injury are related comes from a meta-analysis of six randomized cardiac primary prevention trials of cholesterol reduction; the relative risk for death from injury for treated men compared with controls was 1.42 (95% CI, 0.94 to 2.15). Conclusions: In cohort studies, the strength of the association between low serum cholesterol levels and subsequent death from injury is weak and may be caused by confounding factors such as socioeconomic status. The modestly elevated risk ratio found in a meta-analysis of trials of cholesterol reduction in men is of borderline statistical significance. This association may be related to efforts to lower cholesterol rather than to low absolute levels of serum cholesterol. Until more data are available, the hypothesized relation between low cholesterol and injuries remains unsettled.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, CARDIOVASC HLTH RES UNIT, SEATTLE, WA 98101 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; ANNAMETHEE G, 1992, J EPIDEMIOL COMMUNIT, V46, P197; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BAKER LL, 1985, PREV MED, V14, P155, DOI 10.1016/0091-7435(85)90030-1; BAKER SP, 1992, INJURY FACT BOOK, P17; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADFORD RH, 1990, AM J CARDIOL, V66, pB44, DOI 10.1016/0002-9149(90)90440-C; BRADFORD RH, 1993, ANN INTERN MED, V118, P850, DOI 10.7326/0003-4819-118-11-199306010-00004; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1987, CONTROL CLIN TRIALS, V8, pS94; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BURR ML, 1989, LANCET, V2, P757; Bursey R. G., 1992, Occupational Medicine (Oxford), V42, P33, DOI 10.1093/occmed/42.1.33; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1992, BRIT MED J, V304, P1689, DOI 10.1136/bmj.304.6843.1689; COSCINA DV, 1986, LIFE SCI, V38, P1789, DOI 10.1016/0024-3205(86)90130-X; DAYTON S, 1969, CIRCULATION S2, V39, P1; Dean A. G., 1990, EPI INFO VERSION 5 W; DEWAR HA, 1972, BRIT MED J, V1, P506, DOI 10.1136/bmj.1.5798.506-a; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EDDY DM, 1992, FAST PRO SOFTWARE ME; Eddy DM., 1992, META ANAL CONFIDENCE; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GORDON T, 1986, ARCH INTERN MED, V146, P262, DOI 10.1001/archinte.146.2.262; GORDON T, 1983, ARCH INTERN MED, V143, P1366, DOI 10.1001/archinte.143.7.1366; GROSS L, 1973, J AM GERIATR SOC, V21, P552, DOI 10.1111/j.1532-5415.1973.tb01662.x; HARROLD BP, 1969, DIABETES, V18, P285, DOI 10.2337/diab.18.5.285; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HJERMANN I, 1981, LANCET, V2, P1303; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1993, ANNU REV PUBL HEALTH, V14, P95; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; KROMHOUT D, 1992, LANCET, V3, P340; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCAUGHAN D, 1981, ARCH INTERN MED, V141, P1428, DOI 10.1001/archinte.141.11.1428; MIETTINEN M, 1972, LANCET, V2, P835; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-a; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MULDOON MF, 1992, BIOL PSYCHIAT, V31, P739, DOI 10.1016/0006-3223(92)90285-8; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEWMAN WP, 1991, ANN NY ACAD SCI, V623, P16, DOI 10.1111/j.1749-6632.1991.tb43715.x; OGLESBY P, 1992, JAMA-J AM MED ASSOC, V267, P2185, DOI 10.1001/jama.1992.03480160041022; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1961, LANCET, V2, P499; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE G, 1983, EUR HEART J, V4, P141; ROSE G, 1986, LANCET, V1, P869; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHERWITZ LW, 1992, AM J EPIDEMIOL, V136, P136, DOI 10.1093/oxfordjournals.aje.a116480; SCHOCH HK, 1968, ADV EXP MED BIOL, V4, P405; SCHUIT AJ, 1993, LANCET, V341, P827, DOI 10.1016/0140-6736(93)90600-L; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SLEIGHT P, 1992, AUST NZ J MED, V22, P576, DOI 10.1111/j.1445-5994.1992.tb00480.x; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEWART MA, 1981, NEUROPSYCHOBIOLOGY, V7, P9, DOI 10.1159/000117826; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TOBERT JA, 1992, BRIT MED J, V304, P713, DOI 10.1136/bmj.304.6828.713; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; VIRKKUNEN M, 1983, NEUROPSYCHOBIOLOGY, V10, P65, DOI 10.1159/000117987; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; YEHUDA S, 1986, PHARMACOL BIOCHEM BE, V24, P1775; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1971, BRIT MED J, V4, P775	94	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					848	855		10.7326/0003-4819-120-10-199405150-00006	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154645				2022-12-28	WOS:A1994NK45800006
J	PERKINS, TT; SMITH, DE; CHU, S				PERKINS, TT; SMITH, DE; CHU, S			DIRECT OBSERVATION OF TUBE-LIKE MOTION OF A SINGLE POLYMER-CHAIN	SCIENCE			English	Article							INDIVIDUAL DNA-MOLECULES; GEL-ELECTROPHORESIS; DYNAMICS; MODEL; PARTICLES; SYSTEMS; MELT	Tube-like motion of a single, fluorescently labeled molecule of DNA in an entangled solution of unlabeled lambda-phage DNA molecules was observed by fluorescence microscopy. One end of a 16- to 100-micrometer-long DNA was attached to a 1-micrometer bead and moved with optical tweezers. The molecule was stretched into various conformations having bends, kinks, and loops. As the polymer relaxed, it closely followed a path defined by its initial contour. The relaxation time of the disturbance caused by the bead was roughly 1 second, whereas tube-like motion in small loops persisted for longer than 2 minutes. Tube deformation, constraint release, and excess chain segment diffusion were also observed. These observations provide direct evidence for several key assumptions in the reptation model developed by de Gennes, Edwards, and Doi.	STANFORD UNIV, DEPT PHYS, STANFORD, CA 94305 USA	Stanford University			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1980, VISCOELASTIC PROPERT; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; DEGENNES PG, 1983, PHYS TODAY, V36, P33, DOI 10.1063/1.2915700; DIMARZIO EA, 1979, FARADAY DISCUSS, V68, P210, DOI 10.1039/dc9796800210; DOI M, 1978, J CHEM SOC FARAD T 2, V74, P1789, DOI 10.1039/f29787401789; DOI M, 1978, J CHEM SOC FARAD T 2, V74, P1802, DOI 10.1039/f29787401802; Doi M., 1988, THEORY POLYM DYNAMIC; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HIGGINS JS, 1985, J CHEM SOC FARAD T 2, V81, P757, DOI 10.1039/f29858100757; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kron S., 1990, INT C QUANTUM ELECTR, V8, P202; LODGE TP, 1990, ADV CHEM PHYS, V79, P1; MARET G, 1983, BIOPOLYMERS, V22, P2727, DOI 10.1002/bip.360221215; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RICHTER D, 1990, PHYS REV LETT, V64, P1389, DOI 10.1103/PhysRevLett.64.1389; RUSSELL TP, 1993, NATURE, V365, P235, DOI 10.1038/365235a0; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; WENDEL H, 1982, MACROMOLECULES, V15, P1318, DOI 10.1021/ma00233a020	27	427	447	2	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 6	1994	264	5160					819	822		10.1126/science.8171335	http://dx.doi.org/10.1126/science.8171335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171335				2022-12-28	WOS:A1994NJ94900025
J	MILANO, CA; ALLEN, LF; ROCKMAN, HA; DOLBER, PC; MCMINN, TR; CHIEN, KR; JOHNSON, TD; BOND, RA; LEFKOWITZ, RJ				MILANO, CA; ALLEN, LF; ROCKMAN, HA; DOLBER, PC; MCMINN, TR; CHIEN, KR; JOHNSON, TD; BOND, RA; LEFKOWITZ, RJ			ENHANCED MYOCARDIAL-FUNCTION IN TRANSGENIC MICE OVEREXPRESSING THE BETA(2)-ADRENERGIC RECEPTOR	SCIENCE			English	Article							T-ANTIGEN TRANSGENES; SENSITIVITY; EXPRESSION	Transgenic mice were created with cardiac-specific overexpression of the beta(2)-adrenergic receptor. This resulted in increased basal myocardial adenylyl cyclase activity, enhanced atrial contractility, and increased left ventricular function in vivo; these parameters at baseline in the transgenic animals were equal to those observed in control animals maximally stimulated with isoproterenol. These results illustrate a useful approach for studying the effect of gene expression on card iac contractility. Because oh ron ic heart failure in humans is accompanied by a reduction in the number of myocardial beta-adrenergic receptors and in inotropic responsiveness, these results suggest a potential gene therapy approach to this disease state.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,AMER HEART ASSOC,BUGHER FDN CTR MOLEC BIOL,LA JOLLA,CA 92093; BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030; UNIV HOUSTON,DEPT PHARMACOL,HOUSTON,TX 77030	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Baylor College of Medicine; University of Houston System; University of Houston			Lefkowitz, Robert/AAW-2649-2021		NCI NIH HHS [5F32-CA09350] Funding Source: Medline; NHLBI NIH HHS [HL-16037, HL-18468] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018468, R01HL016037, R37HL016037, R01HL018468] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTIN B, 1993, CARDIOVASC RES, V27, P1606, DOI 10.1093/cvr/27.9.1606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; MILANO CA, UNPUB; PAULETTO P, 1985, AM HEART J, V109, P1269, DOI 10.1016/0002-8703(85)90350-3; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	25	622	651	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					582	586		10.1126/science.8160017	http://dx.doi.org/10.1126/science.8160017			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160017				2022-12-28	WOS:A1994NH01000041
J	SIGG, D; STEFANI, E; BEZANILLA, F				SIGG, D; STEFANI, E; BEZANILLA, F			GATING CURRENT NOISE PRODUCED BY ELEMENTARY TRANSITIONS IN SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SODIUM-CHANNELS; CHARGE; FLUCTUATIONS; MOVEMENT	Gating currents provide a direct record of the spatial rearrangement of charges occurring within the protein of voltage-sensitive ion channels. If the elementary charges move as very brief discrete pulses of current, they will produce fluctuations in the macroscopic gating current. The variance of such fluctuations in gating currents was measured in Shaker potassium channels expressed in Xenopus oocytes with a sufficiently high recording bandwidth to estimate the magnitude and time distribution of the elementary transition charge movements. Channel activation occurred in two sequential stages. The first stage consisted of numerous, fast transitions, each moving small amounts of charge that contributed little to the fluctuation in gating current, whereas the second stage, which contributed the bulk of the fluctuation, was represented by a number of discrete, correlated transitions, one or more of which carried a charge of at least 2.4 elementary charges across the membrane field.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine				Sigg, Daniel/0000-0003-4944-2988	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030376, R01GM030376, T32GM008042] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39874] Funding Source: Medline; NIGMS NIH HHS [GM30376, GM08042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BEZANILLA F, 1985, J MEMBRANE BIOL, V88, P97, DOI 10.1007/BF01868424; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; BEZANILLA F, 1982, ABNORMAL NERVES MUSC, P62; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; CROUZY SC, 1993, BIOPHYS J, V64, P68, DOI 10.1016/S0006-3495(93)81341-9; DURRELL SR, 1992, BIOPHYS J, V62, P238; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LEVITT DG, 1989, BIOPHYS J, V55, P489, DOI 10.1016/S0006-3495(89)82842-5; LIEBOVITCH LS, 1987, BIOCHIM BIOPHYS ACTA, V896, P173, DOI 10.1016/0005-2736(87)90177-5; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLHAUSER GL, 1988, P NATL ACAD SCI USA, V85, P1503, DOI 10.1073/pnas.85.5.1503; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; PEROZO E, 1993, NEURON, V11, P1; Rice S. O., 1954, SELECTED PAPERS NOIS; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	22	83	84	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					578	582		10.1126/science.8160016	http://dx.doi.org/10.1126/science.8160016			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160016				2022-12-28	WOS:A1994NH01000040
J	BREO, DL				BREO, DL			IN ANTARCTICA, THE DOCTOR IS HEALER, HANDYMAN AND WIDE-EYED TOURIST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1216	1219		10.1001/jama.271.15.1216	http://dx.doi.org/10.1001/jama.271.15.1216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151883				2022-12-28	WOS:A1994NF20700036
J	TYLER, VE				TYLER, VE			REJUVEX FOR POSTMENOPAUSAL SYMPTOMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											TYLER, VE (corresponding author), PURDUE UNIV,W LAFAYETTE,IN 47907, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1210	1210		10.1001/jama.1994.03510390082038	http://dx.doi.org/10.1001/jama.1994.03510390082038			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151882				2022-12-28	WOS:A1994NF20700035
J	MIKULSKI, BA				MIKULSKI, BA			SCIENCE IN THE NATIONAL INTEREST	SCIENCE			English	Editorial Material											MIKULSKI, BA (corresponding author), US SENATE,WASHINGTON,DC 20510, USA.								0	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					221	222		10.1126/science.8146650	http://dx.doi.org/10.1126/science.8146650			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE410	8146650				2022-12-28	WOS:A1994NE41000024
J	RAJARATHNAM, K; SYKES, BD; KAY, CM; DEWALD, B; GEISER, T; BAGGIOLINI, M; CLARKLEWIS, I				RAJARATHNAM, K; SYKES, BD; KAY, CM; DEWALD, B; GEISER, T; BAGGIOLINI, M; CLARKLEWIS, I			NEUTROPHIL ACTIVATION BY MONOMERIC INTERLEUKIN-8	SCIENCE			English	Article							PEPTIDE-1 INTERLEUKIN-8; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; CYTOKINE; RESIDUES; PROTEINS; FAMILY; DIMER	Interleukin-8 (IL-8), a pro-inflammatory protein, has been shown by nuclear magnetic resonance (NMR) and x-ray techniques to exist as a homodimer. An IL-8 analog was chemically synthesized, with the amide nitrogen of leucine-25 methylated to selectively block formation of hydrogen bonds between monomers.and thereby prevent dimerization. This analog was shown to be a monomer, as assessed by analytical ultracentrifugation and NMR. Nevertheless, it was equivalent to IL-8 in assays of neutrophil activation, which indicates that the monomer is a functional form of IL-8.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,PENCE,VANCOUVER V6T 1Z3,BC,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON T6G 2S2,AB,CANADA	University of British Columbia; University of Alberta; University of Bern; University of British Columbia; University of Alberta								BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; GEISER T, UNPUB; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IDA N, 1992, J IMMUNOL METHODS, V156, P27, DOI 10.1016/0022-1759(92)90007-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; Spatola A.F., 1983, CHEM BIOCHEM AMINO, V7, P267; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC	32	278	289	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					90	92		10.1126/science.8140420	http://dx.doi.org/10.1126/science.8140420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140420				2022-12-28	WOS:A1994ND53600036
J	WESTON, CFM; PENNY, WJ; JULIAN, DG				WESTON, CFM; PENNY, WJ; JULIAN, DG			GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CORONARY-CARE UNIT; THROMBOLYTIC TREATMENT; PREHOSPITAL THROMBOLYSIS; TIME DELAYS; ADMISSION; IMPACT; EMERGENCY; SYSTEM; POLICY	In light of recent publications relating to resuscitation and pre-hospital treatment of patients suffering acute myocardial infarction the British Heart Foundation convened a working group to prepare guidelines outlining the responsibilities of general practitioners, ambulance services, and admitting hospitals. The guidelines emphasise the importance of the rapid provision of basic and advanced life support; adequate analgesia; accurate diagnosis; and, when indicted, thrombolytic treatment. The working group developed a standard whereby patients with acute myocardial infarction should receive thrombolysis, when appropriate, within 90 minutes of alerting the medical or ambulance service -the call to needle time. Depending on local circumstances, achieving this standard may involve direct admissions to coronary care units, ''fast track'' assessments in emergency departments, or pre-hospital thrombolytic treatment started by properly equipped and trained general practitioners.	UNIV WALES COLL MED, DEPT EPIDEMIOL, CARDIFF CF4 4XN, S GLAM, WALES; UNIV HOSP WALES, CARDIFF CF4 4XW, S GLAM, WALES; BRITISH HEART FDN, LONDON W1H 4DH, ENGLAND	Cardiff University; Cardiff University; University of London; University College London	WESTON, CFM (corresponding author), UNIV WALES COLL MED, DEPT CARDIOL, CARDIFF CF4 4XN, S GLAM, WALES.			Weston, Clive/0000-0002-8995-8199				AHMAD RAS, 1992, BRIT J GEN PRACT, V42, P145; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; BASINSKI A, 1991, J CLIN EPIDEMIOL, V44, P1085, DOI 10.1016/0895-4356(91)90011-W; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BURNS JMA, 1989, BRIT HEART J, V61, P322; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COLQUHOUN MC, 1989, BMJ-BRIT MED J, V299, P433, DOI 10.1136/bmj.299.6696.433; COLQUHOUN MC, 1992, LANCET, V339, P1167, DOI 10.1016/0140-6736(92)90765-U; FILLMORE SJ, 1970, AM HEART J, V79, P620, DOI 10.1016/0002-8703(70)90281-4; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GERSH BJ, 1993, CIRCULATION, V88, P296, DOI 10.1161/01.CIR.88.1.296; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GREENBERG H, 1988, LANCET, V2, P1187; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HOLMBERG S, 1993, BRIT MED J, V306, P1587; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LESTER R, 1985, ACUTE CORONARY CARE, P299; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MADIAS JE, 1976, CIRCULATION, V53, P198; MCCALLION WA, 1990, BRIT HEART J, V64, P65; MCLAUCHLAN CAJ, 1992, RESUSCITATION, V24, P7, DOI 10.1016/0300-9572(92)90168-C; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; NORRIS RM, 1993, BRIT HEART J, V69, P492; PARRY G, 1993, J ROY COLL PHYS LOND, V27, P19; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAPAPORT E, 1991, J MYOCARD ISCHEM, V3, P25; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; ROWLEY JM, 1982, BRIT MED J, V284, P1741, DOI 10.1136/bmj.284.6331.1741; STENE JK, 1988, AM J EMERG MED, V6, P634, DOI 10.1016/0735-6757(88)90109-X; STLOUIS P, 1982, AM J PUBLIC HEALTH, V72, P1158, DOI 10.2105/AJPH.72.10.1158; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TUNSTALLPEDOE H, 1991, BMJ-BRIT MED J, V303, P701, DOI 10.1136/bmj.303.6804.701; VINCENT R, 1990, MANAGEMENT ACUTE ISC, P148; WALTERS G, 1989, J ROY COLL PHYS LOND, V23, P107; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON C, 1991, J ROY COLL PHYS LOND, V25, P312; WESTON C, 1991, BRIT J GEN PRACT, V41, P476; WESTON CFM, 1992, J ROY COLL PHYS LOND, V26, P86; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1990, MANAGMEENT ACUTE ISC, P133; ZELIS R, 1974, J CLIN INVEST, V54, P1247, DOI 10.1172/JCI107869; [No title captured]; 1991, HLTH NATION CONSULTA, P59	52	94	95	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					767	771		10.1136/bmj.308.6931.767	http://dx.doi.org/10.1136/bmj.308.6931.767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142834	Green Published			2022-12-28	WOS:A1994NC34800026
J	KAHN, JD; YUN, E; CROTHERS, DM				KAHN, JD; YUN, E; CROTHERS, DM			DETECTION OF LOCALIZED DNA FLEXIBILITY	NATURE			English	Article							ESCHERICHIA-COLI; RING-CLOSURE; GEL-ELECTROPHORESIS; BEND DIRECTION; PROTEIN HU; CYCLIZATION; REPLICATION; SIMULATION; ORIGIN; MODEL	THE bending and flexibility of DNA are important in packaging, recombination and transcription(1-3). Bending decreases electrophoretic mobility in a manner depending on bend position within a fragment (circular permutation(4)) and on the distance between bends (phasing analysis(5,6)). Bending can also affect DNA ring closure (cyclization(7-10)). The lack of a complete theory for the mechanism of gel retardation hampers measurement of bend magnitudes by electrophoresis, whereas cyclization is done entirely in solution and is well understood theoretically(9). Disagreements between bend angles estimated by the two electrophoretic assays have been ascribed to DNA flexibility(11). Here we test this interpretation using an internal loop as a model flexible locus. Whereas the circular permutation and helical phasing experiments are only subtly affected by the loop, DNA cyclization kinetics detects and quantifies substantial increases in torsional and bending flexibility. Furthermore, the results support a functional role for the stress of DNA bending in inducing base-pair opening(12).	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University; Yale University			Kahn, Jason D/B-6361-2009	Kahn, Jason D/0000-0001-5060-4724				Crothers D. M., 1992, TRANSCRIPTIONAL REGU, P501; CROTHERS DM, 1971, BIOPOLYMERS, V10, P1949, DOI 10.1002/bip.360101013; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P1; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; ZIMM BH, 1993, MACROMOLECULES, V26, P226, DOI 10.1021/ma00053a035; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	30	177	177	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					163	166		10.1038/368163a0	http://dx.doi.org/10.1038/368163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139661				2022-12-28	WOS:A1994NA03000071
J	PHILLIPS, AO; SNOWDEN, SA; HILLIS, AN; BEWICK, M				PHILLIPS, AO; SNOWDEN, SA; HILLIS, AN; BEWICK, M			RENAL GRAFTS FROM NON-HEART-BEATING DONORS	BRITISH MEDICAL JOURNAL			English	Article									KINGS COLL HOSP DULWICH,RENAL UNIT,LONDON SE22 8PT,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital								CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; DALY LE, 1991, INTERPRETATION USES, P179; GEERLINGS W, 1991, P EUR DIAL TRANSPLAN, V21, P1; GOMEZ M, 1992, BR J SURG S, V79, pS144; KOZAKI M, 1991, TRANSPLANT P, V5, P2575	5	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					575	576		10.1136/bmj.308.6928.575a	http://dx.doi.org/10.1136/bmj.308.6928.575a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148682	Green Published			2022-12-28	WOS:A1994MY71400023
J	BATH, PMW; PRASAD, A; BROWN, MM; MACGREGOR, GA				BATH, PMW; PRASAD, A; BROWN, MM; MACGREGOR, GA			SURVEY OF USE OF ANTICOAGULATION IN PATIENTS WITH ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DIV CLIN NEUROSCI,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London			Bath, Philip/F-9020-2011	Bath, Philip/0000-0003-2734-5132				BARNABY J, 1993, BRIT MED J, V306, P207, DOI 10.1136/bmj.306.6871.207-b; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; RAMSAY LE, 1993, LANCET, V341, P1376, DOI 10.1016/0140-6736(93)90945-D	4	82	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1045	1045		10.1136/bmj.307.6911.1045	http://dx.doi.org/10.1136/bmj.307.6911.1045			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8166802	Green Published, Bronze			2022-12-28	WOS:A1993MD55600020
J	FABIAN, CJ; MANSFIELD, CM; DAHLBERG, S; JONES, SE; MILLER, TP; VANSLYCK, E; GROZEA, PN; MORRISON, FS; COLTMAN, CA; FISHER, RI				FABIAN, CJ; MANSFIELD, CM; DAHLBERG, S; JONES, SE; MILLER, TP; VANSLYCK, E; GROZEA, PN; MORRISON, FS; COLTMAN, CA; FISHER, RI			LOW-DOSE INVOLVED FIELD RADIATION AFTER CHEMOTHERAPY IN ADVANCED HODGKIN DISEASE - A SOUTHWEST-ONCOLOGY-GROUP RANDOMIZED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							COMBINED MODALITY THERAPY; ALLOGENEIC MARROW TRANSPLANTATION; FOLLOW-UP DATA; COMBINATION CHEMOTHERAPY; MOPP CHEMOTHERAPY; LUNG-CANCER; RADIOTHERAPY; WR-2721; ABVD; RADIOPROTECTION	Objective: To determine if low-dose involved field radiation after complete remission induction with chemotherapy is effective in preventing relapse and improving survival in patients with stage III or IV Hodgkin disease. Design: A randomized controlled trial with a median follow-up time of 8.1 years. Setting: A Southwest Oncology Group multiinstitutional study. Patients were entered from university- and community-based practices. Patients: 278 adults with clinical or pathologic stage III or IV Hodgkin disease, who achieved complete responses after 6 cycles of MOP-BAP (nitrogen mustard, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine) and who agreed to be randomly assigned to either radiation or no further treatment. Intervention: Patients were assigned to either no further treatment or low-dose radiation to all initially involved sites (radiation dose, 2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites). Measurements: Differences in remission duration, relapse-free survival, and survival. Results: Remission duration, relapse-free survival, and overall survival were similar for the two groups (P = 0.09, P > 0.2, and P = 0.14, respectively). Factors that predicted shorter remission duration in a multivariate analysis were nodular sclerosis histology, bulky disease, and receipt of less than 85% of planned chemotherapy. Low-dose radiation improved remission duration in the subgroups of patients with nodular sclerosis and bulky disease. For the 169 patients with nodular sclerosis, the 5-year remission-duration estimate was 82% for the low-dose radiation group and 60% for the no further treatment group (P = 0.002). For all patients with bulky disease, the 5-year remission-duration estimate was 75% for the low-dose radiation group and 57% for the no further treatment group (P = 0.05). No difference in overall survival was noted between low-dose radiation and no further treatment in all patients or major subgroups. The 5-year survival was 86% for all patients who had a complete response as well as for patients in the nodular sclerosis subgroup. Conclusions: Low-dose involved field radiation after MOP-BAP chemotherapy in patients with stage III or IV Hodgkin disease did not prolong remission duration or overall survival in randomized patients. However, remission duration was prolonged in several subgroups of patients, most prominently in those with nodular sclerosis histology.	UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA; SW ONCOL GRP, CTR STAT, SEATTLE, WA USA; UNIV ARIZONA, CTR CANC, TUCSON, AZ USA; HENRY FORD HOSP, DETROIT, MI USA; UNIV OKLAHOMA, HLTH SCI CTR, OKLAHOMA CITY, OK USA; UNIV MISSISSIPPI, MED CTR, JACKSON, MS 39216 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA	University of Kansas; University of Kansas Medical Center; Southwest Oncology Group; University of Arizona; Henry Ford Health System; Henry Ford Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Mississippi; University of Mississippi Medical Center; University of Texas System; University of Texas Health San Antonio; Loyola University Chicago	FABIAN, CJ (corresponding author), SW ONCOL GRP, SWOG 7808, OPERAT OFF, 14980 OMICRON DR, SAN ANTONIO, TX 78229 USA.				NCI NIH HHS [CA-12644, CA-37429, CA-13612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013612, U10CA012644, U10CA037429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1989, RADIAT RES, V118, P581, DOI 10.2307/3577415; APPELBAUM FR, 1985, J CLIN ONCOL, V3, P1490, DOI 10.1200/JCO.1985.3.11.1490; BAKEMEIER RF, 1984, ANN INTERN MED, V101, P447, DOI 10.7326/0003-4819-101-4-447; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BUESA JM, 1984, CANCER TREAT REP, V68, P683; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CANELLOS GP, 1990, SEMIN ONCOL, V17, P2; CANELLOS GP, 1988, SEMIN HEMATOL, V25, P58; CARBONE PP, 1971, CANCER RES, V31, P1860; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; CIONINI L, 1982, EUR J RADIOL, V2, P301; COSSET JM, 1989, P AN M AM SOC CLIN, V8, P253; COX DR, 1972, J R STAT SOC B, V34, P187; DEVI PU, 1990, RADIAT RES, V124, P165, DOI 10.2307/3577861; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; DEVITA VT, 1981, CANCER, V47, P1, DOI 10.1002/1097-0142(19810101)47:1<1::AID-CNCR2820470102>3.0.CO;2-2; DIEHL LF, 1983, CANCER TREAT REP, V67, P827; DURAND RE, 1989, BRIT J CANCER, V60, P517, DOI 10.1038/bjc.1989.305; FABIAN C, 1989, P AN M AM SOC CLIN, V8, P253; FISHER RI, 1979, ANN INTERN MED, V90, P761, DOI 10.7326/0003-4819-90-5-761; FLOERSHEIM GL, 1990, BRIT J RADIOL, V63, P468, DOI 10.1259/0007-1285-63-750-468; FOX KA, 1987, J CLIN ONCOL, V5, P38, DOI 10.1200/JCO.1987.5.1.38; GAREWAL HS, 1990, J CLIN ONCOL, V8, P1715, DOI 10.1200/JCO.1990.8.10.1715; GLICK J, 1984, P AN M AM SOC CLIN, V3, P237; GLICK J, 1988, P AN M AM SOC CLIN, V7, P223; GLICK JH, 1986, ANN INTERN MED, V104, P876, DOI 10.7326/0003-4819-104-6-876; GROZEA PN, 1985, P AN M AM SOC CLIN, V4, P201; HANCOCK SL, 1988, ANN INTERN MED, V109, P183, DOI 10.7326/0003-4819-109-3-183; HARKER WG, 1984, ANN INTERN MED, V101, P440, DOI 10.7326/0003-4819-101-4-440; HONG WK, 1990, P AN M AM SOC CLIN, V9, P171; HOPPE RT, 1980, CANCER, V46, P1240, DOI 10.1002/1097-0142(19800901)46:5<1240::AID-CNCR2820460526>3.0.CO;2-T; JONES SE, 1983, CANCER, V51, P1339, DOI 10.1002/1097-0142(19830415)51:8<1339::AID-CNCR2820510803>3.0.CO;2-8; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN HS, 1966, CANCER RES, V26, P1221; KOLETSKY AJ, 1986, J CLIN ONCOL, V4, P311, DOI 10.1200/JCO.1986.4.3.311; KUENTZ M, 1983, CANCER, V52, P780, DOI 10.1002/1097-0142(19830901)52:5<780::AID-CNCR2820520504>3.0.CO;2-1; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; LONGO DL, 1991, J CLIN ONCOL, V9, P227, DOI 10.1200/JCO.1991.9.2.227; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAUCH P, 1987, J CLIN ONCOL, V5, P544, DOI 10.1200/JCO.1987.5.4.544; OREILLY SE, 1991, ANN ONCOL, V2, P17, DOI 10.1093/annonc/2.suppl_1.17; PATCHEN ML, 1990, INT J RADIAT ONCOL, V18, P1069, DOI 10.1016/0360-3016(90)90442-M; PHILLIPS GL, 1989, J CLIN ONCOL, V7, P1039, DOI 10.1200/JCO.1989.7.8.1039; PROSNITZ LR, 1973, RADIOLOGY, V107, P187, DOI 10.1148/107.1.187; PROSNITZ LR, 1988, J CLIN ONCOL, V6, P603, DOI 10.1200/JCO.1988.6.4.603; PROSNITZ LR, 1982, CANCER TREAT REP, V66, P871; ROACH M, 1987, J CLIN ONCOL, V5, P550, DOI 10.1200/JCO.1987.5.4.550; ROSKOS RR, 1982, CANCER TREAT REP, V66, P961; Schein P S, 1990, Cancer Invest, V8, P265, DOI 10.3109/07357909009017579; STEWART FA, 1989, INT J RADIAT ONCOL, V16, P1195, DOI 10.1016/0360-3016(89)90282-4; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1987, J CLIN ONCOL, V5, P1624, DOI 10.1200/JCO.1987.5.10.1624; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VIVIANI S, 1991, ANN ONCOL, V2, P55, DOI 10.1093/annonc/2.suppl_2.55; YELLE L, 1991, J CLIN ONCOL, V9, P1983, DOI 10.1200/JCO.1991.9.11.1983; YOUNG RC, 1978, CANCER, V42, P1001, DOI 10.1002/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO;2-Z	61	133	139	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					903	912		10.7326/0003-4819-120-11-199406010-00002	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172436				2022-12-28	WOS:A1994NN11000002
J	ZEHENDER, M				ZEHENDER, M			STRUCK BY LIGHTNING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ZEHENDER, M (corresponding author), UNIV FREIBURG KLIN,D-79106 FREIBURG,GERMANY.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1492	1492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164702				2022-12-28	WOS:A1994NM06800005
J	POUPON, RE; POUPON, R; BALKAU, B; HUET, PM; WILLEMS, B; MATHIEUCHANDELIER, C; PARIS, JC; MATHIEXFORTUNET, H; CAPRON, JP; CAPRON, D; DHUMEAUX, D; METREAU, JM; DEUGNIER, Y; OPOLON, P; BOUSQUET, O; PAYEN, JL; BRESSONHADNI, S; MIGUET, JP; DEGOS, F; BEAUGRAND, M; TRINCHET, JC; BLANC, F; CASSAN, P; GINESTON, JL; MORIN, T; PARELON, G; MICHEL, H; ETIENNE, JP; BUFFET, C; COUZIGOU, P; LEVYBRUHL, A; PARIENTE, EA; VALLA, A; VERWAERDE, JC; CHAPUT, JC; POYNARD, T; GAUTHIER, A; LEVY, VG; PAUMGARTNER, G; NIARD, AM; ESCHWEGE, E; ATLAN, P; ATTALI, P				POUPON, RE; POUPON, R; BALKAU, B; HUET, PM; WILLEMS, B; MATHIEUCHANDELIER, C; PARIS, JC; MATHIEXFORTUNET, H; CAPRON, JP; CAPRON, D; DHUMEAUX, D; METREAU, JM; DEUGNIER, Y; OPOLON, P; BOUSQUET, O; PAYEN, JL; BRESSONHADNI, S; MIGUET, JP; DEGOS, F; BEAUGRAND, M; TRINCHET, JC; BLANC, F; CASSAN, P; GINESTON, JL; MORIN, T; PARELON, G; MICHEL, H; ETIENNE, JP; BUFFET, C; COUZIGOU, P; LEVYBRUHL, A; PARIENTE, EA; VALLA, A; VERWAERDE, JC; CHAPUT, JC; POYNARD, T; GAUTHIER, A; LEVY, VG; PAUMGARTNER, G; NIARD, AM; ESCHWEGE, E; ATLAN, P; ATTALI, P			URSODIOL FOR THE LONG-TERM TREATMENT OF PRIMARY BILIARY-CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; D-PENICILLAMINE; URSODEOXYCHOLIC ACID; PROGNOSTIC IMPORTANCE; INTERNATIONAL TRIAL; AZATHIOPRINE; COLCHICINE; THERAPY	Background. Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The benefit of long-term treatment is uncertain. Methods. We randomly assigned 145 patients with biopsy-proved primary biliary cirrhosis to receive ursodiol (13 to 15 mg per kilogram of body weight per day) (72 patients) or placebo (73 patients). After two years of follow-up, because of the benefit from ursodiol, all patients completing the study received ursodiol in an open trial and were monitored for two more years. The end points in the assessment of efficacy were as follows: progression of disease, as defined by the presence of hyperbilirubinemia, variceal bleeding, ascites, or encephalopathy; liver transplantation or a referral for that procedure; and liver transplantation (or a referral) or death. Results. Disease progressed significantly less frequently in the ursodiol group than in the placebo group (P<0.002; relative risk, 0.28; 95 percent confidence interval, 0.12 to 0.63). The probability of liver transplantation or a referral for that procedure and the probability of transplantation or death were significantly lower in the group assigned to ursodiol than in the group assigned to placebo (for transplantation alone, P = 0.003; relative risk, 0.21; 95 percent confidence interval, 0.07 to 0.66; for transplantation or death, P = 0.005; relative risk, 0.32; 95 percent confidence interval, 0.14 to 0.74). High bilirubin levels and, to a lesser extent, signs of cirrhosis at entry into the trial were predictive of disease progression, liver transplantation or a referral, and transplantation or death. Conclusions. Long-term ursodiol therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation.	HOP ST ANTOINE,SERV HEPATOL,PARIS,FRANCE; SYNTHELABO RECH,BAGNEUX,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France	POUPON, RE (corresponding author), INSERM,U21,16 AVE PAUL VAILLANT COUTURIER,F-94807 VILLEJUIF,FRANCE.		Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				BABBS C, 1988, LANCET, V1, P1021; BASSENDINE MF, 1982, GUT, V23, pA909; BATTEZZATI PM, 1993, J HEPATOL, V17, P332, DOI 10.1016/S0168-8278(05)80214-4; BODENHEIMER H, 1988, GASTROENTEROLOGY, V95, P124, DOI 10.1016/0016-5085(88)90300-9; BODENHEIMER HC, 1985, HEPATOLOGY, V5, P1139, DOI 10.1002/hep.1840050613; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; COMBES B, 1991, HEPATOLOGY, V14, pA91; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE J, 1980, GASTROENTEROLOGY, V78, P1005; DICKSON ER, 1985, NEW ENGL J MED, V312, P1011, DOI 10.1056/NEJM198504183121602; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; EPSTEIN O, 1981, LANCET, V1, P1275; GOUDIE BM, 1989, AM J GASTROENTEROL, V84, P1474; GOUDIE BM, 1989, AM J GASTROENTEROL, V84, P713; HADZIYANNIS S, 1988, HEPATOLOGY, V8, P1421; HEATHCOTE EJL, 1992, HEPATOLOGY, V16, pA91; HEATHCOTE J, 1976, GASTROENTEROLOGY, V70, P656; HOOFNAGLE JH, 1986, GASTROENTEROLOGY, V91, P1327, DOI 10.1016/0016-5085(86)90183-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; LEUSCHNER U, 1989, GASTROENTEROLOGY, V97, P1268, DOI 10.1016/0016-5085(89)91698-3; LINDOR KD, 1992, HEPATOLOGY, V16, pA91; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; MARKUS BH, 1989, NEW ENGL J MED, V320, P1709, DOI 10.1056/NEJM198906293202602; MATLOFF DS, 1982, NEW ENGL J MED, V306, P319, DOI 10.1056/NEJM198202113060602; MINUK GY, 1988, GASTROENTEROLOGY, V95, P1356, DOI 10.1016/0016-5085(88)90373-3; MITCHISON HC, 1992, J HEPATOL, V15, P336, DOI 10.1016/0168-8278(92)90065-W; NEUBERGER J, 1985, GUT, V26, P114, DOI 10.1136/gut.26.2.114; OKA H, 1990, Gastroenterologia Japonica, V25, P774; PERDIGOTO R, 1992, GASTROENTEROLOGY, V102, P1389; POUPON R, 1987, LANCET, V1, P834; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; RYDNING A, 1990, SCAND J GASTROENTERO, V25, P119, DOI 10.3109/00365529009107932; TAAL BG, 1983, LIVER, V3, P345; TRIGER DR, 1980, GUT, V21, pA919; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; 1993, J HEPATOL, V17, P227	40	420	427	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1342	1347		10.1056/NEJM199405123301903	http://dx.doi.org/10.1056/NEJM199405123301903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152446				2022-12-28	WOS:A1994NK75300003
J	PARSONNET, J; HANSEN, S; RODRIGUEZ, L; GELB, AB; WARNKE, RA; JELLUM, E; ORENTREICH, N; VOGELMAN, JH; FRIEDMAN, GD				PARSONNET, J; HANSEN, S; RODRIGUEZ, L; GELB, AB; WARNKE, RA; JELLUM, E; ORENTREICH, N; VOGELMAN, JH; FRIEDMAN, GD			HELICOBACTER-PYLORI INFECTION AND GASTRIC LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSOCIATION; BINDING; CANCER	Background, Helicobacter pylori infection is a risk factor for gastric adenocarcinoma. We examined whether this infection is also a risk factor for primary gastric non-Hodgkin's lymphoma. Methods. This nested case-control study involved two large cohorts (230,593 participants). Serum had been collected from cohort members and stored, and all subjects were followed for cancer. Thirty-three patients with gastric non-Hodgkin's lymphoma were identified, and each was matched to four controls according to cohort, age, sex, and date of serum collection. For comparison, 31 patients with nongastric non-Hodgkin's lymphoma from one of the cohorts were evaluated, each of whom had ;been previously matched to 2 controls. Pathological reports and specimens were reviewed to confirm the histologic type of the tumor. Serum samples from all subjects were tested for H. pylori IgG by an enzyme-linked immunosorbent assay. Results. Thirty-three cases of gastric non-Hodgkin's lymphoma occurred a median of 14 years after serum collection. Patients with gastric lymphoma were significantly more likely than matched controls to have evidence of previous H. pylori infection (matched odds ratio, 6.3; 95 percent confidence interval, 2.0 to 19.9). The results were similar in both cohorts. Among the 31 patients with nongastric lymphoma, 8 median of six years had elapsed between serum collection and the development of disease. No association was found between nongastric non-Hodgkin's lymphoma and previous H. pylori infection (matched odds ratio, 1.2; 95 percent confidence interval, 0.5 to 3.0). Conclusions. Non-Hodgkin's lymphoma affecting the stomach, but not other sites, is associated with previous H. pylori infection. A causative role for the organism is plausible, but remains unproved.	STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; NORWEGIAN CANC SOC,JANUS COMM,OSLO,NORWAY; ORENTREICH FDN ADVANCEMENT SCI,COLD SPRING,NY; KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611; CANC REGISTRY NORWAY,OSLO,NORWAY	Stanford University; Stanford University; Kaiser Permanente; University of Oslo	PARSONNET, J (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,HRP BLDG,RM 225,STANFORD,CA 94305, USA.			Parsonnet, Julie/0000-0001-7342-5366	NATIONAL CANCER INSTITUTE [R01CA033119, P01CA034233, R35CA049761] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233, CA33119, R35CA49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, CANCER, V49, P2112; Ben Rejeb A, 1992, Arch Anat Cytol Pathol, V40, P12; BINDL JM, 1986, AM J CLIN PATHOL, V85, P490, DOI 10.1093/ajcp/85.4.490; BROOKS JJ, 1983, CANCER, V51, P701, DOI 10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; Dunn Bruce E., 1993, P191; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLFORD TR, 1992, CANCER RES, V52, pS5443; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1991, B CANCER, V78, P203; ISHIDO T, 1989, ACTA PATHOL JAPON, V39, P229; JELLUM E, IN PRESS ENV HLTH PE; JELLUM E, 1987, BIOCH CLIN, V11, P191; KHOJASTEH A, 1983, NEW ENGL J MED, V308, P1401, DOI 10.1056/NEJM198306093082309; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P159; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P234; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; Lee Jung-Dal, 1993, Journal of Korean Medical Science, V8, P17, DOI 10.1007/BF00973797; MING SC, 1992, PATHOLOGY GASTROINTE, P584; MUELLER N, 1991, INT J CANCER, V49, P387, DOI 10.1002/ijc.2910490313; NEWELL DG, 1989, SERODIAG IMMUN INF D, V3, P1, DOI 10.1016/0888-0786(89)90010-3; PAGANO M, 1993, PRINICPLES BIOSTATIS, P279; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; ROBERT ME, 1993, GASTROENTEROL CLIN N, V22, P59; RUBIN E, 1990, ESSENTIAL PATHOLOGY, P352; SEVERSON RK, 1990, CANCER, V66, P1283, DOI 10.1002/1097-0142(19900915)66:6<1283::AID-CNCR2820660631>3.0.CO;2-4; SPIRO HM, 1983, CLIN GASTROENTEROL, P292; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; VILLAR HV, 1991, AM J SURG, V161, P171, DOI 10.1016/0002-9610(91)90380-V; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; 1980, IARC SCI PUBL, V32, P248	37	1553	1598	0	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1267	1271		10.1056/NEJM199405053301803	http://dx.doi.org/10.1056/NEJM199405053301803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145781				2022-12-28	WOS:A1994NJ51200003
J	HAEFNER, HK				HAEFNER, HK			ITS A BOY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											HAEFNER, HK (corresponding author), UNIV MICHIGAN, MED CTR, DIV GYNECOL, MED PROFESS BLDG D2202-0718, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					806	806		10.7326/0003-4819-120-9-199405010-00013	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147554				2022-12-28	WOS:A1994NH25100013
J	LORENZO, A; RAZZABONI, B; WEIR, GC; YANKNER, BA				LORENZO, A; RAZZABONI, B; WEIR, GC; YANKNER, BA			PANCREATIC-ISLET CELL TOXICITY OF AMYLIN ASSOCIATED WITH TYPE-2 DIABETES-MELLITUS	NATURE			English	Article							AMYLOID POLYPEPTIDE; ALZHEIMERS-DISEASE; SKELETAL-MUSCLE; HORMONE; LANGERHANS; SEQUENCE; PEPTIDE; PROTEIN; DEATH	THE 37-amino-acid polypeptide amylin is the principal constituent of the amyloid deposits that form in the islets of Langerhans in patients with type-2 diabetes menitus(1-5), but its role in the pathogenesis of this disease is unresolved(6-8). In view of the fact that the beta-amyloid protein that forms fibrils in Alzheimer's disease is toxic to neurons(9,10), we have investigated whether amylin fibrils could be toxic to pancreatic islet cells. We show here that human amylin is toxic to insulin-producing beta-cells of the adult pancreas of rats and humans. This toxicity is mediated by the fibrillar form of the amylin peptide and requires direct contact of the fibrils with the cell surface. The mechanism of cell death involves RNA and protein synthesis and is characterized by plasma membrane-blebbing, chromatin condensation and DNA fragmentation, indicating that amylin induces islet cell apoptosis. These findings indicate that amylin fibril formation in the pancreas may cause islet cell dysfunction and death in type-2 diabetes mellitus.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School								BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BETSHOLTZ C, 1989, FEBS LETT, V251, P261, DOI 10.1016/0014-5793(89)81467-X; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; JOHNSON KH, 1989, NEW ENGL J MED, V321, P513; LEFFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127, DOI 10.1073/pnas.86.9.3127; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MALOY AL, 1981, HUM PATHOL, V12, P917, DOI 10.1016/S0046-8177(81)80197-9; MAY PC, 1993, J NEUROCHEM, V61, P2330, DOI 10.1111/j.1471-4159.1993.tb07480.x; NISHI M, 1989, P NATL ACAD SCI USA, V86, P5738, DOI 10.1073/pnas.86.15.5738; OBRIEN TD, 1993, VET PATHOL, V30, P317, DOI 10.1177/030098589303000401; OPIE EL, 1900, J EXP MED, V5, P397; RICORDI C, 1990, SURGERY, V107, P688; SCHUPPIN GT, 1993, IN VITRO CELL DEV-AN, V29A, P339; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; WESTERMARK P, 1987, AM J PATHOL, V127, P414; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1972, UPSALA J MED SCI, V77, P91, DOI 10.1517/03009734000000014; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	29	718	741	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					756	760		10.1038/368756a0	http://dx.doi.org/10.1038/368756a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152488				2022-12-28	WOS:A1994NG55300063
J	GARG, SK; CHASE, HP; MARSHALL, G; HOOPS, SL; HOLMES, DL; JACKSON, WE				GARG, SK; CHASE, HP; MARSHALL, G; HOOPS, SL; HOLMES, DL; JACKSON, WE			ORAL-CONTRACEPTIVES AND RENAL AND RETINAL COMPLICATIONS IN YOUNG-WOMEN WITH INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; RETINOPATHY; RISK; PROGRESSION; PREVALENCE; DIAGNOSIS; INCREASES; ALBUMIN; HEART; AGE	Objective.-To evaluate the effects of oral contraceptives (OCs) as a possible risk factor for early diabetic renal and/or retinal complications. Design.-A retrospective case-control study. Setting.-A university hospital diabetes clinic. Participants.-Forty-three diabetic women who used OCs for 1 year or longer (mean, 3.4 years; range, 1.0 to 7.0 years) were compared with a computer-matched control group of 43 diabetic women who never used OCs. Main Outcome Measures.-Hemoglobin A1c levels, albumin excretion rates, and mean retinopathy scores. Results.-The mean+/-SEM age and duration of diabetes were 22.7+/-0.5 years (range, 17.1 to 30.5 years) and 13.8+/-0.8 years, respectively, for the study group. The mean longitudinal hemoglobin Al, values were similar for study subjects and control subjects. The final mean albumin excretion rates, reflecting diabetic renal damage, and the mean eye grades were not significantly different between the groups. Conclusions.-The use of OCs among young women with insulin-dependent diabetes mellitus does not pose an additional risk for the development of early diabetic retinopathy and/or nephropathy.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOSTAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT OPHTHALMOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GARG, SK (corresponding author), UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR CHILDHOOD DIABET, 4200 E 9TH AVE, BOX B140, DENVER, CO 80262 USA.		Marshall, Guillermo/F-2302-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00069] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; CHASE HP, 1990, OPHTHALMOLOGY, V97, P155; CHASE HP, 1990, ARCH INTERN MED, V150, P639, DOI 10.1001/archinte.150.3.639; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; CHASE HP, 1991, CLIN CHEM, V37, P2048; CHASE HP, 1990, DIABETIC MED, V7, P299, DOI 10.1111/j.1464-5491.1990.tb01393.x; CRUICKSHANKS KJ, 1985, DIABETES CARE, V8, P118, DOI 10.2337/diacare.8.2.118; GARG SK, 1992, DIABETES NUTR METAB, V5, P205; KALKHOFF RK, 1982, AM J OBSTET GYNECOL, V142, P735; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN BEK, 1990, DIABETES CARE, V13, P895, DOI 10.2337/diacare.13.8.895; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; OSBERG I, 1990, CLIN CHEM, V36, P1428; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VOORS AW, 1976, CIRCULATION, V54, P319, DOI 10.1161/01.CIR.54.2.319; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; WILSON ESB, 1984, BRIT J OBSTET GYNAEC, V91, P1254, DOI 10.1111/j.1471-0528.1984.tb04747.x; 1981, INVEST OPHTH VIS SCI, V21, P210; 1987, SAS STAT GUIDE PERSO; 1985, 032741987 HLTH CAR F	26	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1099	1102		10.1001/jama.271.14.1099	http://dx.doi.org/10.1001/jama.271.14.1099			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151852				2022-12-28	WOS:A1994NE22800032
J	BOCHNER, F; MARTIN, ED; BURGESS, NG; SOMOGYI, AA; MISAN, GMH; ANTIC, R; BARKER, C; COBAIN, W; DEVITT, P; ERDT, F; HORVATH, N; LEE, TI; LELEU, L; MAGUIRE, L; WILLIAMS, JAR; YEOH, E				BOCHNER, F; MARTIN, ED; BURGESS, NG; SOMOGYI, AA; MISAN, GMH; ANTIC, R; BARKER, C; COBAIN, W; DEVITT, P; ERDT, F; HORVATH, N; LEE, TI; LELEU, L; MAGUIRE, L; WILLIAMS, JAR; YEOH, E			DRUG RATIONING IN A TEACHING HOSPITAL - A METHOD TO ASSIGN PRIORITIES	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS ANALYSIS; HEALTH-CARE TECHNOLOGY; RESOURCE-ALLOCATION; OREGON; DECISIONS; INEVITABILITY; GUIDELINES; CONFLICT; LESSONS; SOCIETY		UNIV ADELAIDE,DEPT CLIN & EXPTL PHARMACOL,ADELAIDE 5005,AUSTRALIA; UNIV ABERDEEN,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND; UNIV CENT LANCASHIRE,CTR PROFESS ETH,PRESTON PR1 2HE,ENGLAND	University of Adelaide; University of Aberdeen; University of Aberdeen; University of Central Lancashire	BOCHNER, F (corresponding author), ROYAL ADELAIDE HOSP,CLIN PHARMACOL UNIT,ADELAIDE,SA 5000,AUSTRALIA.		Somogyi, Andrew A/A-7742-2008; Misan, Gary/C-8894-2009; Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219; Donaldson, Cam/0000-0003-4670-5340				BECK JR, 1990, JAMA-J AM MED ASSOC, V264, P83, DOI 10.1001/jama.264.1.83; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; CHATURVEDI N, 1993, BRIT MED J, V306, P395, DOI 10.1136/bmj.306.6874.395-b; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P2399, DOI 10.1001/jama.265.18.2399; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P3342, DOI 10.1001/jama.267.24.3342; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HEGINBOTHAM C, 1992, BRIT MED J, V304, P496, DOI 10.1136/bmj.304.6825.496; KLEIN R, 1992, BRIT MED J, V304, P1457, DOI 10.1136/bmj.304.6840.1457; KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1; LAMB D, 1989, J MED ETHICS, V15, P33, DOI 10.1136/jme.15.1.33; LARKINS R, 1989, AUSTR MED, V1, P377; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEAF A, 1984, NEW ENGL J MED, V310, P718, DOI 10.1056/NEJM198403153101111; LEEDER SR, 1987, MED J AUSTRALIA, V147, P68, DOI 10.5694/j.1326-5377.1987.tb133262.x; LEEDER SR, 1989, HOSPITAL HEALTHCARE, V20, P18; LEEDER SR, 1989, HOSPITAL HEALTHCARE, V20, P16; LEEDER SR, 1989, HOSPITAL HEALTHCARE, V20, P30; LEWIS PA, 1989, J MED ETHICS, V15, P28, DOI 10.1136/jme.15.1.28; MISAN GMH, 1990, EUR J CLIN PHARMACOL, V39, P457; NORMAND C, 1991, BRIT MED J, V303, P1572, DOI 10.1136/bmj.303.6817.1572; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; SCHWARTZ WB, 1984, NEW ENGL J MED, V310, P52, DOI 10.1056/NEJM198401053100120; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310	38	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					901	905		10.1136/bmj.308.6933.901	http://dx.doi.org/10.1136/bmj.308.6933.901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173373	Green Published			2022-12-28	WOS:A1994NE60000028
J	CROUCHER, C; AZZOPARDI, D				CROUCHER, C; AZZOPARDI, D			COMPLIANCE WITH RECOMMENDATIONS FOR GIVING VITAMIN-K TO NEWBORN-INFANTS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN CHARLOTTES & CHELSEA HOSP,DEPT PAEDIAT & NEONATAL MED,LONDON W6 0XG,ENGLAND	Imperial College London								EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; PIETERSMADEBRUYN ALJM, 1990, HAEMOSTASIS, V20, P8; 1992, PROPHYLAXIS VITAMIN; 1992, VITAMIN K PROPHYLAXI	5	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					894	895		10.1136/bmj.308.6933.894	http://dx.doi.org/10.1136/bmj.308.6933.894			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173369	Green Published			2022-12-28	WOS:A1994NE60000022
J	WICKMAN, KD; INIGUEZLLUHI, JA; DAVENPORT, PA; TAUSSIG, R; KRAPIVINSKY, GB; LINDER, ME; GILMAN, AG; CLAPHAM, DE				WICKMAN, KD; INIGUEZLLUHI, JA; DAVENPORT, PA; TAUSSIG, R; KRAPIVINSKY, GB; LINDER, ME; GILMAN, AG; CLAPHAM, DE			RECOMBINANT G-PROTEIN BETA-GAMMA-SUBUNITS ACTIVATE THE MUSCARINIC-GATED ATRIAL POTASSIUM CHANNEL	NATURE			English	Article							BINDING REGULATORY PROTEINS; K+ CHANNELS; AFFINITY; PRENYLATION; RECEPTORS; MEMBRANES; CELLS; HEART	ACETYLCHOLINE activates inwardly rectifying potassium channels (I-K.ACh) in the heart(1) through muscarinic receptor binding and activation of pertussis-toxin-sensitive G proteins(2,3). Experiments showing that only the beta gamma-subunit (G beta gamma) activates I-K.ACh (ref. 4) were challenged by reports that only the activated alpha-subunit (G alpha) was effective(5). Here we examine I-K.ACh regulation using purified brain and recombinant G-protein subunits. Six recombinant G beta gamma-subunits activated I-K.ACh with apparent half-maximal activation concentrations of 3-30 nM. Activation of I-K.ACh by recombinant G alpha-GTP gamma S was observed, but this was probably due to release of GTP gamma S from the protein. Importantly, I-K.ACh activity elicited by GTP gamma S was inhibited by purified brain and recombinant G alpha-GDP, suggesting that native G beta gamma plays a major role in this pathway. We conclude that G beta gamma is a primary regulator of I-K.ACh activity.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Mayo Clinic; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Linder, Maurine/AAU-9999-2021; Clapham, David/R-5974-2019	Linder, Maurine/0000-0003-2202-9712; Clapham, David/0000-0002-4459-9428; Wickman, Kevin/0000-0002-5179-9540; Iniguez-Lluhi, Jorge/0000-0001-7010-089X				BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATTERA R, 1989, J BIOL CHEM, V264, P465; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAUSSIG R, 1993, SCIENCE, V268, P9; UEDA N, IN PRESS J BIOL CHEM	17	399	405	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					255	257		10.1038/368255a0	http://dx.doi.org/10.1038/368255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145826				2022-12-28	WOS:A1994NA87000059
J	BRUNO, S; ROSSI, S; PETRONI, ML; VILLA, E; ZUIN, M; PODDA, M				BRUNO, S; ROSSI, S; PETRONI, ML; VILLA, E; ZUIN, M; PODDA, M			NORMAL AMINOTRANSFERASE CONCENTRATIONS IN PATIENTS WITH ANTIBODIES TO HEPATITIS-C VIRUS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MODENA,DEPT GASTROENTEROL,I-41100 MODENA,ITALY	Universita di Modena e Reggio Emilia	BRUNO, S (corresponding author), UNIV MILAN,S PAULO INST BIOMED SCI,DEPT INTERNAL MED,I-20142 MILAN,ITALY.		Petroni, Maria Letizia/AAD-9430-2021; Villa, Erica/A-7576-2012	Petroni, Maria Letizia/0000-0002-7040-6466; Villa, Erica/0000-0001-6388-7022; Zuin, Massimo/0000-0003-3906-4362; Bruno, Savino/0000-0002-3887-864X				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; BRILLANTI S, 1993, LANCET, V341, P464, DOI 10.1016/0140-6736(93)90210-8; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7	3	39	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					697	697		10.1136/bmj.308.6930.697	http://dx.doi.org/10.1136/bmj.308.6930.697			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142795	Green Published			2022-12-28	WOS:A1994NA86900023
J	ZHENG, JQ; FELDER, M; CONNOR, JA; POO, MM				ZHENG, JQ; FELDER, M; CONNOR, JA; POO, MM			TURNING OF NERVE GROWTH CONES INDUCED BY NEUROTRANSMITTERS	NATURE			English	Article							PROTEIN KINASE-II; INTRACELLULAR CALCIUM; NEURITE ELONGATION; ACETYLCHOLINE-RECEPTORS; IDENTIFIED NEURONS; GUIDANCE; MOTILITY; SEROTONIN; CULTURE; AXONS	PATHFINDING by growing nerve processes in the developing nervous system depends on the turning response of the growing tip, the growth cone, to extracellular guidance cues(1-4). There is evidence in vivo and in cell culture that some growth cones exhibit chemotropic behaviour(5-12), but the identity of endogenous chemoattractants remains elusive. Neurotransmitters appear early in the developing embryo and may have morphogenic roles in development(13,14). In cell culture a number of neurotransmitters were found to induce growth inhibition or retraction of neurites(15-19). Here we report positive turning responses of the nerve growth cone in a defined extracellular gradient of the neurotransmitter acetylcholine (ACh). The growth cone response depends on the activation of neuronal nicotinic ACh receptors, requires the presence of extracellular Ca2+, and appears to be mediated by Ca2+-calmodulin-dependent protein kinase II. Fluorescence imaging of cytosolic Ca2+ concentration ([Ca2+](i)) at the growth cone showed a small but significant evaluation of [Ca2+](i) within minutes of the onset of ACh application and before the turning of the growth cone. These findings suggest that neurotransmitters may serve as specific chemoattractants for growth cone guidance and that cytosolic Ca2+ may act as a second messenger in the cytoplasm of the growth cone to initiate the turning response.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Columbia University; Roche Holding								ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BEDLACK RS, 1992, NEURON, V9, P393, DOI 10.1016/0896-6273(92)90178-G; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; BUZNIKOV GA, 1968, J EMBRYOL EXP MORPH, V20, P119; COHAN CS, 1987, J NEUROSCI, V7, P3588; Conner J.A., 1982, Lectures on Mathematics in the Life Sciences, V15, P79; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; EVERS J, 1989, J NEUROSCI, V9, P1523; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JEFFNER CD, 1990, SCIENCE, V247, P217; LANDMESSER L, 1986, TRENDS NEUROSCI, V9, P489, DOI 10.1016/0166-2236(86)90156-6; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P2839, DOI 10.1073/pnas.85.8.2839; LAUDER JM, 1988, PROG BRAIN RES, V73, P365; LETO, 1985, LETOURNEAU P, P269; LETOURNEAU PC, 1978, DEV BIOL, V66, P183, DOI 10.1016/0012-1606(78)90283-X; LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1987, J NEUROSCI, V7, P4034; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; MCCOBB DP, 1988, J NEUROSCI RES, V19, P19, DOI 10.1002/jnr.490190104; MCCRAIG CD, 1986, J PHYSL, V375, P39; Menesini Chen M G, 1978, Arch Ital Biol, V116, P53; PATEL NB, 1984, J NEUROSCI, V4, P2939; Purves, 1985, PRINCIPLES NEURAL DE; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Tabti N., 1991, CULTURING NERVE CELL, P137; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YAGINUMA H, 1991, J NEUROSCI, V11, P2598	40	508	517	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 10	1994	368	6467					140	144		10.1038/368140a0	http://dx.doi.org/10.1038/368140a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139655				2022-12-28	WOS:A1994NA03000064
J	DECOCK, KM; ADJORLOLO, G; EKPINI, E; SIBAILLY, T; KOUADIO, J; MARAN, M; BRATTEGAARD, K; VETTER, KM; DOORLY, R; GAYLE, HD				DECOCK, KM; ADJORLOLO, G; EKPINI, E; SIBAILLY, T; KOUADIO, J; MARAN, M; BRATTEGAARD, K; VETTER, KM; DOORLY, R; GAYLE, HD			EPIDEMIOLOGY AND TRANSMISSION OF HIV-2 - WHY THERE IS NO HIV-2 PANDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; COTE-DIVOIRE; WEST-AFRICA; HOSPITALIZED-PATIENTS; GUINEA-BISSAU; IVORY-COAST; INFECTION; ABIDJAN; WOMEN; AIDS	Although human immunodeficiency virus type 1 (HIV-1) and HIV-2 share modes of transmission, their epidemiologic characteristics differ and international spread of HIV-2 has been very limited. Recently, the prevalence of infection with HIV-1 but not HIV-2 has increased rapidly in different West African countries, where HIV-2 was probably present earlier. Among 19 701 women of reproductive age tested in Abidjan, Ivory Coast, between 1988 and 1992, the prevalence of HIV-1 infection increased from 5.0% to 9.2%, while that of HIV-2 declined from 2.6% to 1.5%. Differences in viral load may be responsible: reported results of virus culture and polymerase chain reaction assays suggest that at high CD4+ T-lymphocyte counts viral load is lower in HIV-2-infected than in HIV-1-infected persons; the efficacy of heterosexual and perinatal transmission of HIV-2 is less efficient than that of HIV-1 at this stage. At low (<0.20 x 10(9)/L [<200/muL]) CD4+ T-lymphocyte counts, virus isolation is equally successful for both viruses, and the efficacy of heterosexual transmission is similar. Differences in HIV-1 and HIV-2 natural history are reflected in differences in viral load, that for HIV-2 being lower until immunodeficiency is severe. Differences in viral load throughout most of the natural history of infection appear to correlate with lower transmissibility of HIV-2 than HIV-1, and are the likeliest explanation for their markedly different global epidemiology.	PROJET RETRO CI, ABIDJAN, COTE IVOIRE; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA 30322 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA USA	Emory University; Centers for Disease Control & Prevention - USA								ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19; DOORLY R, 1991, 7TH INT C AIDS FLOR; EGBOGA A, 1992, AIDS, V6, P1045, DOI 10.1097/00002030-199209000-00025; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; KANKI P, 1990, 5TH INT C AIDS AFR K; KANKI PJ, 1987, AIDS, V1, P141; KAWAMURA M, 1989, LANCET, V1, P385; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KOFFI K, 1992, EUR J CLIN MICROBIOL, V11, P271, DOI 10.1007/BF02098100; KOUROUMA K, 1990, AIDS, V4, P1299, DOI 10.1097/00002030-199012000-00026; LEGUENNO B, 1989, T ROY SOC TROP MED H, V83, P847, DOI 10.1016/0035-9203(89)90350-7; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LEISENRING W, 1992, 8TH INT C AIDS 3RD S; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; LOUSSERTAJAKA I, 1992, 7TH INT C AIDS AFR Y; LUCAS S, 1991, 6TH INT C AIDS AEFR; LUCAS SB, IN PRESS AIDS; MABEY DCW, 1988, BRIT MED J, V296, P83, DOI 10.1136/bmj.296.6615.83; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; NAUCHER A, 1992, 8TH INT C AIDS AFR Y; NAUCLER A, 1991, AIDS, V5, P301, DOI 10.1097/00002030-199103000-00009; NGBICHI JM, 1991, 7TH INT C AIDS FLOR; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PEPIN J, 1991, AIDS, V5, P69, DOI 10.1097/00002030-199101000-00010; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PFLUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SIBAILLY TS, 1992, 8TH INT C AIDS STD W; SIBY T, 1966, 8TH INT C AIDS 3RD S; SIMON F, IN PRESS AIDS; SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480; STUVER SO, 1993, J INFECT DIS, V167, P57, DOI 10.1093/infdis/167.1.57; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TRAOREETTIEGNE V, 1993, 9TH INT C AIDS BERL; WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015	49	194	196	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2083	2086		10.1001/jama.270.17.2083	http://dx.doi.org/10.1001/jama.270.17.2083			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8147962				2022-12-28	WOS:A1993MD88200028
J	ELIAS, S; ANNAS, GJ				ELIAS, S; ANNAS, GJ			GENERIC CONSENT FOR GENETIC SCREENING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CYSTIC-FIBROSIS		BOSTON UNIV,SCH MED,BOSTON,MA 02118; BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118	Boston University; Boston University	ELIAS, S (corresponding author), BAYLOR COLL MED,HOUSTON,TX 77030, USA.			Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1992, MAPPING OUR GENES US, P269; Bernstein T, 1994, RADON RENTAL HOUSING; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BIESECKER L, 1992, AM J HUM GENET, V50, P438; CAPLAN AL, 1993, PRESCRIBING OUR FUTU, P149; ELIAS S, 1987, REPRODUCTIVE GENETIC; FRASER FC, 1974, AM J HUM GENET, V26, P636; Rodwin M, 1993, MED MONEY MORALS, P214; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; WILFOND BS, 1993, JAMA-J AM MED ASSOC, V270, P2948, DOI 10.1001/jama.270.24.2948; 1990, NEW ENGL J MED, V323, P70; 1992, CYSTIC FIBROSIS DNA, P124; 1990, AM J HUM GENET, V46, P393; 1991, CURRENT STATUS CYSTI; 1992, AM J HUM GENET, V51, P1443	16	110	112	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1611	1613		10.1056/NEJM199406023302213	http://dx.doi.org/10.1056/NEJM199406023302213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177253				2022-12-28	WOS:A1994NN21500013
J	ADAL, KA; COCKERELL, CJ; PETRI, WA				ADAL, KA; COCKERELL, CJ; PETRI, WA			CAT-SCRATCH DISEASE, BACILLARY ANGIOMATOSIS, AND OTHER INFECTIONS DUE TO ROCHALIMAEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; AIDS-RELATED COMPLEX; HENSELAE SP-NOV; EPITHELIOID ANGIOMATOSIS; PELIOSIS HEPATIS; HIV-INFECTION; BARTONELLA-BACILLIFORMIS; DIFFERENTIAL-DIAGNOSIS; IMMUNOCOMPROMISED HOST		UNIV VIRGINIA,MED CTR,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV TEXAS,SW MED CTR,DEPT DERMATOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX	University of Virginia; University of Virginia; University of Virginia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Petri, William A./D-3639-2019; Petri, William/AAL-3642-2020	Petri, William/0000-0002-7268-1218	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI07046] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALKAN S, 1991, NEW ENGL J MED, V324, P1513, DOI 10.1056/NEJM199105233242116; ANGRITT P, 1988, LANCET, V1, P996; ANGRITT P, 1988, MIL MED, V153, pM25; ARIASSTELLA J, 1986, AM J SURG PATHOL, V10, P595, DOI 10.1097/00000478-198609000-00002; AXIOTIS CA, 1989, AM J DERMATOPATH, V11, P177, DOI 10.1097/00000372-198911020-00011; BARKA NE, 1993, J INFECT DIS, V167, P1503, DOI 10.1093/infdis/167.6.1503; BARON AL, 1990, RADIOLOGY, V177, P77, DOI 10.1148/radiology.177.1.2399342; BERGER TG, 1989, ARCH DERMATOL, V125, P1543, DOI 10.1001/archderm.125.11.1543; BIRTLES RJ, 1991, NEW ENGL J MED, V325, P1447; BIRTLES RJ, 1991, FEMS MICROBIOL LETT, V83, P187, DOI 10.1111/j.1574-6968.1991.tb04439.x; BLACK JR, 1986, ARCH INTERN MED, V146, P394, DOI 10.1001/archinte.146.2.394; BODOKH I, 1992, PRESSE MED, V21, P1616; BODOKH I, 1992, PRESSE MED, V21, P1623; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P1299, DOI 10.1128/JCM.29.7.1299-1302.1991; BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; CAIRO I, 1991, BRIT J DERMATOL, V125, P393; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; CHAN JKC, 1991, AM J SURG PATHOL, V15, P430, DOI 10.1097/00000478-199105000-00002; Cockerell C J, 1990, Prog AIDS Pathol, V2, P111; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P501, DOI 10.1016/0190-9622(90)70071-O; COCKERELL CJ, 1990, ARCH DERMATOL, V126, P787, DOI 10.1001/archderm.126.6.787; COCKERELL CJ, 1991, J INVEST DERMATOL, V97, P812, DOI 10.1111/1523-1747.ep12487507; COCKERELL CJ, 1987, LANCET, V2, P654; CONRAD SE, 1991, J BONE JOINT SURG AM, V73A, P774, DOI 10.2106/00004623-199173050-00019; DALY JS, 1993, J CLIN MICROBIOL, V31, P872, DOI 10.1128/JCM.31.4.872-881.1993; DEBRE R., 1950, BuL Mem. Soc. Med. Hop., V66, P76; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; DUONG M, 1992, ANN MED INTERNE, V143, P107; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; FOUCHARD N, 1992, ANN DERMATOL VENER, V119, P870; GARCIATSAO G, 1992, GASTROENTEROLOGY, V102, P1065, DOI 10.1016/0016-5085(92)90200-I; Goodman P, 1993, AJR Am J Roentgenol, V160, P207; GUERRA LG, 1993, CLIN INFECT DIS, V17, P264, DOI 10.1093/clinids/17.2.264; HALL AV, 1988, LANCET, V2, P453; HARRIS PJ, 1992, ANN INTERN MED, V117, P795, DOI 10.7326/0003-4819-117-9-795_1; HERTS BR, 1991, AM J ROENTGENOL, V157, P1249, DOI 10.2214/ajr.157.6.1950875; JIMENEZACOSTA F, 1990, J AM ACAD DERMATOL, V22, P525, DOI 10.1016/S0190-9622(08)80400-8; KELLY CS, 1992, 32ND INT C ANT AG CH, P371; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; KINLOCHDELOES S, 1992, SCHWEIZ MED WSCHR, V122, P1168; KIRKPATRICK CE, 1989, MED HYPOTHESES, V28, P145, DOI 10.1016/0306-9877(89)90042-X; KNOBLER EH, 1988, JAMA-J AM MED ASSOC, V260, P524, DOI 10.1001/jama.260.4.524; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KREKORIAN TD, 1990, AM J MED, V89, P820, DOI 10.1016/0002-9343(90)90231-2; LEBOIT PE, 1990, ARCH DERMATOL, V126, P808, DOI 10.1001/archderm.126.6.808; LEBOIT PE, 1989, AM J SURG PATHOL, V13, P909, DOI 10.1097/00000478-198911000-00001; LEBOIT PE, 1988, LANCET, V1, P960; LEBOIT PE, 1989, SEMIN DERMATOL, V8, P298; LEONG SS, 1992, ARCH PATHOL LAB MED, V116, P866; LOPEZELZAURDIA C, 1991, BRIT J DERMATOL, V125, P175, DOI 10.1111/j.1365-2133.1991.tb06067.x; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MARASCO WA, 1989, REV INFECT DIS, V11, P793; MARGILETH AM, 1992, PEDIATR INFECT DIS J, V11, P474, DOI 10.1097/00006454-199206000-00010; MARGILETH AM, 1992, 32 INT C ANT AG CHEM, P413; MARULLO S, 1992, J INFECT DIS, V166, P1462, DOI 10.1093/infdis/166.6.1462-a; MILAM MW, 1990, AM J MED, V88, P180, DOI 10.1016/0002-9343(90)90471-O; MUI BSK, 1990, AM J MED, V89, P229, DOI 10.1016/0002-9343(90)90303-U; NEIRA C, 1992, 32ND INT C ANT AG CH, P376; PATNAIK M, 1992, LANCET, V340, P971, DOI 10.1016/0140-6736(92)92855-A; PATNAIK M, 1993, 9TH INT C AIDS 4TH S, V1, P424; PERKINS BA, 1992, NEW ENGL J MED, V327, P1599, DOI 10.1056/NEJM199211263272215; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; PICKETT DA, 1992, 32ND INT C ANT AG CH; PILON VA, 1989, AM J CLIN PATHOL, V92, P236, DOI 10.1093/ajcp/92.2.236; QUINT L, 1993, PRESSE MED, V22, P532; RADIN DR, 1991, AM J ROENTGENOL, V156, P91, DOI 10.2214/ajr.156.1.1845436; REGNERY R, 1992, LANCET, V340, P557, DOI 10.1016/0140-6736(92)91760-6; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1992, MOL MICROBIOL, V6, P1801, DOI 10.1111/j.1365-2958.1992.tb01352.x; RELMAN DA, 1993, J INFECT DIS, V168, P1; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RILEY LE, 1992, OBSTET GYNECOL, V79, P818; ROBERTKNEBELMANN C, 1992, ANN DERMATOL VENER, V119, P867; RUDIKOFF D, 1989, ARCH DERMATOL, V125, P706, DOI 10.1001/archderm.125.5.706b; SCHINELLA RA, 1990, HUM PATHOL, V21, P567, DOI 10.1016/0046-8177(90)90017-Y; SCHLOSSBERG D, 1990, ARCH INTERN MED, V150, P1116, DOI 10.1001/archinte.1990.00390170140031; SCHLOSSBERG D, 1989, ARCH INTERN MED, V149, P1437, DOI 10.1001/archinte.149.6.1437; SCHWARTZMAN WA, 1990, SCAND J INFECT DIS, V22, P121, DOI 10.3109/00365549009037892; SCHWARTZMAN WA, 1993, 9TH INT C AIDS 4TH S, V1, P315; SEVALL JS, 1993, 9 INT C AIDS 4 STD W, V1, P424; SLATER LN, 1992, CHEST, V102, P972, DOI 10.1378/chest.102.3.972; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; SLATER LN, 1992, J CLIN MICROBIOL, V30, P1722, DOI 10.1128/JCM.30.7.1722-1727.1992; SLATER LN, 1994, ARCH PATHOL LAB MED, V118, P33; SPACH DH, 1992, INT J DERMATOL, V31, P19, DOI 10.1111/j.1365-4362.1992.tb03512.x; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; SPACH DH, 1992, ANN INTERN MED, V116, P740, DOI 10.7326/0003-4819-116-9-740; SPEIGHT PM, 1991, BRIT DENT J, V171, P367, DOI 10.1038/sj.bdj.4807726; STEEPER TA, 1992, AM J CLIN PATHOL, V97, P713, DOI 10.1093/ajcp/97.5.713; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; SZANIAWSKI WK, 1990, J AM ACAD DERMATOL, V23, P41, DOI 10.1016/0190-9622(90)70183-I; TAPPERO J, 1992, 32ND INT C ANT AG CH, P223; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; TSANG WYW, 1992, HISTOL HISTOPATHOL, V7, P143; VANDERWOUW PA, 1989, AIDS, V3, P751, DOI 10.1097/00002030-198911000-00011; WALFORD N, 1990, HISTOPATHOLOGY, V16, P83; WEBSTER GF, 1992, BRIT J DERMATOL, V126, P535; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	106	189	193	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1509	1515		10.1056/NEJM199405263302108	http://dx.doi.org/10.1056/NEJM199405263302108			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164704				2022-12-28	WOS:A1994NM06800008
J	CLEMENT, DG; RETCHIN, SM; BROWN, RS; STEGALL, MBH				CLEMENT, DG; RETCHIN, SM; BROWN, RS; STEGALL, MBH			ACCESS AND OUTCOMES OF ELDERLY PATIENTS ENROLLED IN MANAGED CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE-ORGANIZATIONS	Objective.-To determine differences in access to care and medical outcomes for Medicare patients with an acute or a chronic symptom who were enrolled in health maintenance organizations (HMOs) compared with similar fee-for-service (FFS) nonenrollees. Design.-A 1990 household telephone survey of Medicare beneficiaries who reported joint pain or chest pain during the previous 12 months. Sample.-Stratified random sample of HMO enrollees (n=6476) and comparable sample of FFS Medicare beneficiaries (n=6381). Access and Outcome Measures.-Care-seeking behavior, physician visits, diagnostic procedures performed, therapeutic interventions prescribed, follow-up recommended by a physician, and symptom response to treatment. Results.-After controlling for demographic factors, health and functional status, and health behavior characteristics, HMO enrollees with joint pain (n=2243) were more likely than nonenrollees (n=2009) to have a physician visit (odds ratio [OR], 1.19; 95% confidence interval [Cl], 1.03 to 1.38) and medication prescribed (OR, 1.35; 95% Cl, 1:14 to 1.60). Patients with chest pain who were enrolled in HMOs (n=556) were less likely than nonenrollees (n=524) to have a physician visit (OR, 0.50; 95% Cl, 0.30 to 0.82). For both joint and chest pain, HMO enrollees were less likely to see a specialist for care, have follow-up recommended, or have their progress monitored. There were no differences in complete elimination of symptoms, but HMO enrollees with continued joint pain reported less symptomatic improvement than nonenrollees (OR, 0.72; 95% Cl, 0.59 to 0.86). Conclusions.-Reduced utilization of services for patients with specific ambulatory conditions was observed in HMOs with Medicare risk contracts, with less symptomatic improvement in one of the four outcomes studied.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT INTERNAL MED,RICHMOND,VA 23298; MATHEMAT POLICY RES INC,PRINCETON,NJ; UNIV OSTEOPATH MED & HLTH SCI,HLTHCARE ADM PROGRAM,DES MOINES,IA; VIRGINIA COMMONWEALTH UNIV,DEPT PREVENT MED & COMMUNITY HLTH,RICHMOND,VA	Virginia Commonwealth University; Mathematica; Virginia Commonwealth University	CLEMENT, DG (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT HLTH ADM,BOX 980203,RICHMOND,VA 23298, USA.							BROWN RS, 1993, MEDICARE RISK PROGRA; CLEMENT DG, 1992, EVALUATION ACCESS SA; COOKE TDV, 1986, CLIN RHEUM DIS, V12, P155; GILLICK MR, 1987, ANN INTERN MED, V106, P139, DOI 10.7326/0003-4819-106-1-139; IGLEHART J, 1982, NEW ENGL J MED, V308, P451; LURIE N, 1994, ANN INTERN MED, V120, P506, DOI 10.7326/0003-4819-120-6-199403150-00010; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; ROSSITER LF, 1988, ANAL PATIENT SATISFA; SCOTT B, 1981, CONCEPTUALIZATION ME; VERBRUGGE LM, 1987, HLTH AGING SOCIOLOGI, P17; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1990, SAS STAT USERS GUIDE, P1	14	101	101	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1487	1492		10.1001/jama.271.19.1487	http://dx.doi.org/10.1001/jama.271.19.1487			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK711	8176827				2022-12-28	WOS:A1994NK71100026
J	WHITE, K; GRETHER, ME; ABRAMS, JM; YOUNG, L; FARRELL, K; STELLER, H				WHITE, K; GRETHER, ME; ABRAMS, JM; YOUNG, L; FARRELL, K; STELLER, H			GENETIC-CONTROL OF PROGRAMMED CELL-DEATH IN DROSOPHILA	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; EMBRYONIC-DEVELOPMENT; SEGMENTATION GENE; NEURONAL DEATH; RNA-SYNTHESIS; CHICK-EMBRYO; MELANOGASTER; PROTEIN; LOCUS; SURVIVAL	A gene, reaper (rpr), that appears to play a central control function for the initiation of programmed cell death (apoptosis) in Drosophila was identified. Virtually all programmed cell death that normally occurs during Drosophila embryogenesis was blocked in embryos homozygous for a small deletion that includes the reaper gene. Mutant embryos contained many extra cells and failed to hatch, but many other aspects of development appeared quite normal. Deletions that include reaper also protected embryos from apoptosis caused by x-irradiation and developmental defects. However, high doses of x-rays induced some apoptosis in mutant embryos, and the resulting corpses were phagocytosed by macrophages. These data suggest that the basic cell death program is intact although it was not activated in mutant embryos. The DNA encompassed by the deletion was cloned and the reaper gene was identified on the basis of the ability of cloned DNA to restore apoptosis to cell death defective embryos in germ line transformation experiments. The reaper gene appears to encode a small peptide that shows no homology to known proteins, and reaper messenger RNA is expressed in cells destined to undergo apoptosis.	MIT,HOWARD HUGHES MED INST,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			White, Kristin/D-7936-2013		NINDS NIH HHS [5 F32 NS08536] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008536] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT MK, 1991, GENETICS, V129, P783; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ABRAMS JM, UNPUB; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALDARELLI RM, 1988, DEV BIOL, V125, P85, DOI 10.1016/0012-1606(88)90061-9; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BATE M, 1981, J NEUROSCI, V1, P103, DOI 10.1523/JNEUROSCI.01-01-00103.1981; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVANER R, 1987, NUCLEIC ACIDS RES, V15, P1353; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CMAPOS KF, 1992, DEVELOPMENT, V114, P355; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; Freeman Robert S., 1993, Current Opinion in Neurobiology, V3, P25, DOI 10.1016/0959-4388(93)90031-S; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GARCIABELLIDO A, 1983, MOL GEN GENET, V192, P253, DOI 10.1007/BF00327675; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GRETHER M, UNPUB; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMURA K, 1990, J NEUROSCI, V10, P403; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACKAY WJ, 1989, GENETICS, V122, P643; MAGRASSI L, 1988, DEVELOPMENT, V104, P447; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINEZARIAS A, 1985, J EMBRYOL EXP MORPH, V87, P99; MURPHY C, 1974, DEV BIOL, V39, P23, DOI 10.1016/S0012-1606(74)80005-9; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; POTTEN CS, 1978, CELL TISSUE KINET, V11, P149, DOI 10.1111/j.1365-2184.1978.tb00883.x; PROKOP A, 1991, DEVELOPMENT, V111, P79; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; TRUMAN JW, COMMUNICATION; UMANSKY SR, 1991, APOPTOSIS MOL BASIS; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE K, UNPUB; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOLFF T, 1991, DEVELOPMENT, V113, P825; WURGLER FE, 1976, GENETICS BIOL DROSOP; YUAN J, 1991, DEV BIOL, V138, P33; [No title captured]	62	874	911	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					677	683		10.1126/science.8171319	http://dx.doi.org/10.1126/science.8171319			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171319				2022-12-28	WOS:A1994NH71300025
J	TINKER, RL; WILLIAMS, KP; KASSAVETIS, GA; GEIDUSCHEK, EP				TINKER, RL; WILLIAMS, KP; KASSAVETIS, GA; GEIDUSCHEK, EP			TRANSCRIPTIONAL ACTIVATION BY A DNA-TRACKING PROTEIN - STRUCTURAL CONSEQUENCES OF ENHANCEMENT AT THE T4 LATE PROMOTER	CELL			English	Article							BACTERIOPHAGE-T4 LATE PROMOTER; RNA-POLYMERASE; ESCHERICHIA-COLI; REPLICATION APPARATUS; ACCESSORY PROTEINS; PRIMER-TEMPLATE; GENE; SUBUNIT; COMPLEX; RECOGNITION	Transcriptional initiation at bacteriophage T4 late promoters is activated from enhancer-like distal sites by the T4 gene 44, 62, and 45 DNA polymerase accessory proteins (gp44, gp62, and gp45, respectively). Enhancement is ATP hydrolysis-dependent and requires protein tracking along DNA. The structural analysis of the entranced transcription initiation complex shows gp45 located at the upstream end of this promoter complex in the vicinity of its transcriptional coactivator, the T4 gene 33 protein. The ATP-cleaving gene 44 protein-gene 62 protein complex serves as the assembly factor for gp45, but does not stably associate with the enhanced promoter complex. Transcriptional enhancement quantitatively favors, but does not qualitatively change, DNA strand separation in the transcription bubble. A model of the transcriptional activation that rationalizes its DNA-tracking and activation-polarity properties is presented.			TINKER, RL (corresponding author), UNIV CALIF SAN DIEGO, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA.							BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MALIK S, 1988, J BIOL CHEM, V263, P1174; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20024; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RABUSSAY D, 1983, BACTERIOPHAGE T, V4, P163; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TICHELAAR W, 1990, J STRUCT BIOL, V103, P180, DOI 10.1016/1047-8477(90)90021-4; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WILLIAM SKP, 1994, IN PRESS MOL BIOL T, V4; WILLIAM SKP, 1987, J BIOL CHEM, V262, P12365; WILLIAMS KP, 1989, J BACTERIOL, V171, P3579, DOI 10.1128/jb.171.6.3579-3582.1989; WILLIAMS KP, 1990, THESIS U CALIFORNIA; WINKELMAN JW, 1994, IN PRESS J BACTERIOL	44	58	58	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					225	237		10.1016/0092-8674(94)90315-8	http://dx.doi.org/10.1016/0092-8674(94)90315-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168131				2022-12-28	WOS:A1994NH63400008
J	BORTOLOTTO, ZA; BASHIR, ZI; DAVIES, CH; COLLINGRIDGE, GL				BORTOLOTTO, ZA; BASHIR, ZI; DAVIES, CH; COLLINGRIDGE, GL			A MOLECULAR SWITCH ACTIVATED BY METABOTROPIC GLUTAMATE RECEPTORS REGULATES INDUCTION OF LONG-TERM POTENTIATION	NATURE			English	Article							RAT HIPPOCAMPUS; AREA CA1; STIMULATION; DEPRESSION; NEURONS	PHARMACOLOGICAL studies of long-term potentiation (LTP) in the hippocampus are starting to provide a molecular understanding of synaptic plastic processes which are believed to be important for learning and memory in vertebrates(1). In the CA1 region of the hippocampus, the synaptic activation of glutamate receptors of the N-methyl-D-aspartate (NMDA) subtype is necessary for the induction of LTP under most experimental conditions(2,3). The synaptic activation of metabotropic glutamate receptors (mGluRs) is also needed for the induction of LTP(4,5). We now show that the role of mGluRs in the induction of LTP is fundamentally different from that of NMDA receptors. NMDA receptors initiate a molecular event that needs to be triggered each time a tetanus is delivered to induce LTP. In contrast, mGluRs activate a molecular switch which then negates the need for mGluR stimulation during the induction of LTP. This mGluR-activated switch is input-specific and can be turned off by a train of low-frequency stimulation. The molecular switch is a new feature of LTP which has fundamental consequences for our understanding of synaptic plastic mechanisms.			BORTOLOTTO, ZA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,ENGLAND.		Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; Bashir, Zafar/0000-0003-3650-2136				BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P266; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; BORTOLOTTO ZA, 1993, SOC NEUR ABSTR, V19; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; REYMANN KG, 1990, EUR J NEUROSCI, V2, P481, DOI 10.1111/j.1460-9568.1990.tb00439.x; SERGUEEVA OA, 1993, NEUROPHARMACOLOGY, V32, P933, DOI 10.1016/0028-3908(93)90150-2; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0	18	332	349	3	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					740	743		10.1038/368740a0	http://dx.doi.org/10.1038/368740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152485				2022-12-28	WOS:A1994NG55300058
J	KINGMAN, S				KINGMAN, S			COMMUNITY CARE - THE 1ST YEAR - NEWCASTLE - MAKING STRIDES	BRITISH MEDICAL JOURNAL			English	Article								In the past year those involved in implementing community care in Newcastle have been on a massive learning curve, starting to understand purchasing services, moving towards all kinds of domiciliary services. Provision of services by the independent sector is still developing, leaving the social services department to consolidate its own home care services; voluntary agencies are being contracted to supply others. A new assessment system is evolving. Joint planning is moving forward slowly.											0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					966	969		10.1136/bmj.308.6934.966	http://dx.doi.org/10.1136/bmj.308.6934.966			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173407	Green Published			2022-12-28	WOS:A1994NF48500023
J	DEBYSER, Z; TABOR, S; RICHARDSON, CC				DEBYSER, Z; TABOR, S; RICHARDSON, CC			COORDINATION OF LEADING AND LAGGING-STRAND DNA-SYNTHESIS AT THE REPLICATION FORK OF BACTERIOPHAGE-T7	CELL			English	Article							POLYMERASE-III HOLOENZYME; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; RNA PRIMER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; GENE-4 PROTEIN; HELICASE ACTIVITY; PRIMASE; INVITRO; THIOREDOXIN	We have used the T7 DNA replication system to examine coordination of leading and lagging strand synthesis at a replication fork. The 63 kd gene 4 protein provides both helicase and primase activities; we demonstrate that primer synthesis inhibits helicase activity on a synthetic replication fork. Lagging strand DNA synthesis by a complex of gene 4 protein and T7 DNA polymerase decreases the rate of leading strand synthesis. Both leading and fagging strand synthesis are resistant to dilution of the replication proteins, and to challenge with heparin. Furthermore, dilution does trot increase the average length of Okazaki fragments. We propose that leading and lagging strand synthesis at a T7 replication fork are coupled and that the replication proteins are recycled.			DEBYSER, Z (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.		debyser, zeger/H-1310-2013	debyser, zeger/0000-0002-3982-1565	NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ARAI N, 1981, J BIOL CHEM, V256, P5294; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1988, CANCER CELL, V6, P11; KOLODNER R, 1978, J BIOL CHEM, V253, P574; KORNBERG A, 1991, DNA REPLICATION, P487; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MENDELMAN LV, 1992, J BIOL CHEM, V89, P10638; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SCHERZINGER E, 1979, NUCLEIC ACIDS RES, V4, P4151; SINHA NK, 1980, J BIOL CHEM, V255, P4290; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; WU CA, 1992, J BIOL CHEM, V267, P4064	41	81	81	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					157	166		10.1016/0092-8674(94)90243-7	http://dx.doi.org/10.1016/0092-8674(94)90243-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156591				2022-12-28	WOS:A1994NF21100018
J	KNOBLICH, JA; SAUER, K; JONES, L; RICHARDSON, H; SAINT, R; LEHNER, CF				KNOBLICH, JA; SAUER, K; JONES, L; RICHARDSON, H; SAINT, R; LEHNER, CF			CYCLIN-E CONTROLS S-PHASE PROGRESSION AND ITS DOWN-REGULATION DURING DROSOPHILA EMBRYOGENESIS IS REQUIRED FOR THE ARREST OF CELL-PROLIFERATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CDC2-RELATED KINASE; CATALYTIC SUBUNIT; DNA-REPLICATION; GENETIC-CONTROL; CDC28 MUTATION; CLN FUNCTION	Most cells of the dorsal epidermis exit from the mitotic cycle after division 16 in Drosophila embryogenesis. This exit is dependent on the down-regulation of Drosaphila cyclin E (DmcycE) during the final mitotic cycle. Ectopic expression of DmcycE after the final mitosis induces entry into S phase and reaccumulation of G2 cyclins and results in progression through a complete additional cell cycle. Conversely, analyses in DmcycE mutant embryos indicate that cyclin E is required for progression through S phase of the mitotic cycle. Moreover, endoreplication, which occurs in late wild-type embryos in the same pattern as DmcycE expression, is not observed in the mutant embryos. Therefore, Drosophila cyclin E, which forms a complex with the Dmcdc2c kinase, controls progression through S phase and its down-regulation limits embryonic proliferation.	UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5005, AUSTRALIA	University of Adelaide	KNOBLICH, JA (corresponding author), MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, SPEMANNSTR 37-39, D-72076 TUBINGEN, GERMANY.		Knoblich, Juergen A/C-2974-2015; Richardson, Helena E/A-8080-2013; Saint, Robert/A-4190-2008	Knoblich, Juergen A/0000-0002-6751-3404; Richardson, Helena E/0000-0003-3852-4953; Saint, Robert/0000-0002-7989-6043				ASHBURNER M, 1990, GENETICS, V126, P679; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HARTENSTEIN V, 1990, DEV BIOL, V138, P147, DOI 10.1016/0012-1606(90)90184-K; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KARPEN GH, 1992, GENETICS, V132, P737; KATO J, 1993, GENE DEV, V7, P331; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MALDONADOCODINA G, 1993, J CELL SCI, V105, P711; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MICHIELS F, 1987, CHROMOSOMA, V95, P387, DOI 10.1007/BF00333989; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH AV, 1991, DEVELOPMENT, V112, P997; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STERN B, 1993, DEVELOPMENT, V117, P219; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	75	479	482	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					107	120		10.1016/0092-8674(94)90239-9	http://dx.doi.org/10.1016/0092-8674(94)90239-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156587				2022-12-28	WOS:A1994NF21100014
J	HALL, RR				HALL, RR			CURRENT ISSUES IN CANCER .4. SUPERFICIAL BLADDER-CANCER	BRITISH MEDICAL JOURNAL			English	Article							TRANSITIONAL-CELL-CARCINOMA; GUERIN INTRAVESICAL THERAPY; RESEARCH-COUNCIL SUBGROUP; CALMETTE-GUERIN; WORKING PARTY; IMMUNOTHERAPY; RECURRENCE; SMOKING	Bladder cancer is almost certainly a product of the industrial revolution and the cigarette smoking that has accompanied it. Exposure to a chemical bladder carcinogen such as beta naphthylamine, benzidine, or 4-diphenylaniline2 can be proved in only a small proportion of patients and only a handful obtain industrial diseases benefit after developing ''Prescribed Industrial Disease C23.'' None the less, the continued use of known carcinogenic substances in British industry for many years after their identification, the wide range of industries with a known or suspected increased risk of bladder cancer, and our ignorance of the carcinogenic potential of many materials used in current manufacturing should be a cause for continuing concern.			HALL, RR (corresponding author), FREEMAN RD HOSP,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.							ABEL PD, 1988, BRIT J UROL, V62, P235, DOI 10.1111/j.1464-410X.1988.tb04325.x; BIRCH BRP, 1989, BRIT J UROL, V64, P109, DOI 10.1111/j.1464-410X.1989.tb05967.x; BOUFFIOUX C, 1991, SCAND J UROL NEPHR S, V138, P167; DAVENZO B, 1990, EUR J CANCER, V26, P714; HALL RR, 1994, BRIT MED J, V308, P252; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HERR HW, 1988, J CLIN ONCOL, V6, P1450, DOI 10.1200/JCO.1988.6.9.1450; HUEPER WC, 1969, OCCUPATIONAL ENV CAN; JAKSE G, 1992, EVALUATION CHEMOTHER, P13; JONES HC, 1961, LANCET, V2, P615; JONES PA, 1991, CANCER RES, V51, P3617; Kramer A A, 1991, Epidemiology, V2, P145, DOI 10.1097/00001648-199103000-00010; LAMM DL, 1991, NEW ENGL J MED, V325, P1205, DOI 10.1056/NEJM199110243251703; LAMM DL, 1992, J UROLOGY, V147, P596, DOI 10.1016/S0022-5347(17)37316-0; MORALES A, 1986, WORLD J UROL, V3, P209, DOI 10.1007/BF00632180; MORALES A, 1976, J UROLOGY, V115, P181; MORRISON AS, 1984, J UROLOGY, V131, P650, DOI 10.1016/S0022-5347(17)50559-5; NEWCOMB PA, 1992, MED CLIN N AM, V76, P305, DOI 10.1016/S0025-7125(16)30355-8; Olumi A F, 1990, Semin Urol, V8, P270; OOSTERLINCK W, 1993, J UROLOGY, V149, P749, DOI 10.1016/S0022-5347(17)36198-0; PARMAR MKB, 1989, J UROLOGY, V142, P284, DOI 10.1016/S0022-5347(17)38731-1; ROBINSON MRG, 1984, EORTC GENITOURINARY, V2, P161; SPRUCK CH, 1993, CANCER RES, V53, P1162; TOLLEY DA, 1988, BRIT MED J, V296, P1759, DOI 10.1136/bmj.296.6639.1759; TOLLEY DA, 1983, 49TH P ANN M BRIT AS; VANDERMEIJDEN APM, 1991, J UROLOGY, V146, P444, DOI 10.1016/S0022-5347(17)37821-7; WRIGHT C, 1991, BRIT J CANCER, V63, P967, DOI 10.1038/bjc.1991.211; 1988, REQUIREMENTS APPROVA; 1988, BR J UROL, V61, P183	29	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					910	913		10.1136/bmj.308.6933.910	http://dx.doi.org/10.1136/bmj.308.6933.910			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173377	Green Published			2022-12-28	WOS:A1994NE60000034
J	CHEN, LY; DURLEY, RCE; MATHEWS, FS; DAVIDSON, VL				CHEN, LY; DURLEY, RCE; MATHEWS, FS; DAVIDSON, VL			STRUCTURE OF AN ELECTRON-TRANSFER COMPLEX - METHYLAMINE DEHYDROGENASE, AMICYANIN, AND CYTOCHROME-C(551I)	SCIENCE			English	Article							C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; PLASTOCYANIN; COFACTOR; PROTEIN; RESOLUTION; OXIDATION	The crystal structure of a ternary protein complex has been determined at 2.4 angstrom resolution. The complex is composed of three electron transfer proteins from Paracoccus denitrificans, the quinoprotein methylamine dehydrogenase, the blue copper protein amicyanin, and the cytochrome c551i. The central region of the c551i is folded similarly to several small bacterial c-type cytochromes; there is a 45-residue extension at the amino terminus and a 25-residue extension at the carboxyl terminus. The methylamine dehydrogenase-amicyanin interface is largely hydrophobic, whereas the amicyanin-cytochrome interface is more polar, with several charged groups present on each surface. Analysis of the simplest electron transfer pathways between the redox partners points out the importance of other factors such as energetics in determining the electron transfer rates.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	Washington University (WUSTL); University of Mississippi; University of Mississippi Medical Center				Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS H, UNPUB; BROOKS HB, 1993, BIOCHEM J, V294, P211, DOI 10.1042/bj2940211; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CANTERS CW, 1992, CURR OPIN STRUC BIOL, V2, P859; CHEN L, 1993, PROTEIN SCI, V2, P47; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; CHISTOSERDOV AY, 1992, BIOCHEM BIOPH RES CO, V184, P1181, DOI 10.1016/S0006-291X(05)80007-5; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIDSON VL, 1991, ANAL CHIM ACTA, V249, P235, DOI 10.1016/0003-2670(91)87028-6; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; Denoyelle S., SYNTHESIS SAR STUDY; DURLEY R, 1993, PROTEIN SCI, V2, P739, DOI 10.1002/pro.5560020506; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; GRAY KA, 1986, FEBS LETT, V207, P239, DOI 10.1016/0014-5793(86)81496-X; GUSS JM, 1983, J MOL BIOL, V169, P521; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1986, BIOCHEMISTRY-US, V25, P2431, DOI 10.1021/bi00357a020; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PEEREY LM, 1991, BIOCHEMISTRY-US, V30, P9297, DOI 10.1021/bi00102a023; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; REGAN J, 1993, PATHWAYS, V2; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; VELLIEUX FMD, 1990, ACTA CRYSTALLOGR B, V46, P806, DOI 10.1107/S010876819000636X	35	217	223	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					86	90		10.1126/science.8140419	http://dx.doi.org/10.1126/science.8140419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140419				2022-12-28	WOS:A1994ND53600035
J	DEEN, PMT; VERDIJK, MAJ; KNOERS, NVAM; WIERINGA, B; MONNENS, LAH; VANOS, CH; VANOOST, BA				DEEN, PMT; VERDIJK, MAJ; KNOERS, NVAM; WIERINGA, B; MONNENS, LAH; VANOS, CH; VANOOST, BA			REQUIREMENT OF HUMAN RENAL WATER CHANNEL AQUAPORIN-2 FOR VASOPRESSIN-DEPENDENT CONCENTRATION OF URINE	SCIENCE			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; XENOPUS OOCYTES; IDENTIFICATION; RESPONSES; PROTEIN; RNA	Concentration of urine in mammals is regulated by the antidiuretic hormone vasopressin. Binding of vasopressin to its V2 receptor leads to the insertion of water channels in apical membranes of principal cells in collecting ducts. In nephrogenic diabetes insipidus (NDI), the kidney fails to concentrate urine in response to vasopressin. A male patient with an autosomal recessive form of NDI was found to be a compound heterozygote for two mutations in the gene encoding aquaporin-2, a water channel. Functional expression studies in Xenopus oocytes revealed that each mutation resulted in nonfunctional water channel proteins. Thus, aquaporin-2 is essential for vasopressin-dependent concentration of urine.	CATHOLIC UNIV NIJMEGEN, DEPT CELL PHYSIOL, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, DEPT CELLULAR BIOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT PEDIAT, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen			Monnens, L.A.H./L-4526-2015; Deen, Peter MT/B-9854-2013; Wieringa, Berend/A-5346-2011; Deen, P.M.T./H-8023-2014	Deen, Peter MT/0000-0002-7868-4655; Wieringa, Berend/0000-0001-9192-8020; Deen, P.M.T./0000-0002-7868-4655				BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BROWN D, 1989, AM J PHYSIOL, V256, pF1; Deen P P, UNPUB; DEENPMT, 1994, CYTOGENET CELL GENET, V66, P260; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KNOERS N, 1991, EUR J PEDIATR, V150, P370, DOI 10.1007/BF01955943; KNOERS N, 1990, NEPHRON, V54, P322, DOI 10.1159/000185888; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; REEVES WB, 1989, METABOLIC BASIS INHE, P1985; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VERDIJK MAJ, UNPUB; ZHANG R, 1991, AM J PHYSIOL, V260, pC26	22	711	725	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					92	95		10.1126/science.8140421	http://dx.doi.org/10.1126/science.8140421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140421				2022-12-28	WOS:A1994ND53600037
J	MACLEAN, G; WESSELY, S				MACLEAN, G; WESSELY, S			PROFESSIONAL AND POPULAR VIEWS OF CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							NEED	Objective-To study the coverage of the chronic fatigue syndrome in the popular and professional press. Design-Search of all original research papers on the chronic fatigue syndrome published in British journals from 1980 onwards and of professional trade papers, national newspapers, and women's magazines. Interviews with six medical journalists. Setting-British scientific, medical, and popular press. Results-37 (49%) articles in research journals did not favour organic causes and 23 (31%) favoured organic causes. By contrast 31 (55%) cuticles in the medical trade press and 118 (69%) in national newspapers and women's magazines favoured organic causes. Conclusions-Press coverage of chronic fatigue syndrome has amplified and distorted divisions in the research community concerning the chronic fatigue syndrome. Articles in the press concentrate on a simple medical model of illness reinforcing the stigma of psychological illness and dissatisfaction with traditional medical authority.	KINGS COLL,SCH MED & DENT,ACAD DEPT PSYCHOL MED,LONDON SE5 9RS,ENGLAND	University of London; King's College London			Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				BRODSKY CM, 1991, PRIMARY CARE, V18, P381; COLLEE J, 1991, OBSERVER        0825; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DEMITRACK MA, 1991, BIOL PSYCHIAT, V30, P747, DOI 10.1016/0006-3223(91)90231-A; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; JAUCHEM JR, 1992, J CLIN EPIDEMIOL, V45, P1137, DOI 10.1016/0895-4356(92)90154-F; KLEINMAN A, 1993, CIBA F S, V173; LECHKY O, 1990, CAN MED ASSOC J, V143, P413; Morris D H, 1993, Arch Fam Med, V2, P181, DOI 10.1001/archfami.2.2.181; REEVES WC, 1992, ANN INTERN MED, V117, P343, DOI 10.7326/0003-4819-117-4-343; YEOMANS JDI, 1991, J INFECTION, V23, P263, DOI 10.1016/0163-4453(91)92864-2; 1990, CONSUMER REPORTS OCT	12	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					776	777		10.1136/bmj.308.6931.776	http://dx.doi.org/10.1136/bmj.308.6931.776			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142836	Green Published			2022-12-28	WOS:A1994NC34800029
J	WILSON, A; HICKIE, I; LLOYD, A; HADZIPAVLOVIC, D; BOUGHTON, C; DWYER, J; WAKEFIELD, D				WILSON, A; HICKIE, I; LLOYD, A; HADZIPAVLOVIC, D; BOUGHTON, C; DWYER, J; WAKEFIELD, D			LONGITUDINAL-STUDY OF OUTCOME OF CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							CANCER; BEHAVIOR	Objective-To examine the predictors of long term outcome for patients with the chronic fatigue syndrome. Design-Cohort study. Subjects-139 subjects previously enrolled in two treatment trials; 103 (74%) were reassessed a mean of 3.2 years after start of the trials. Setting-University hospital referral centre. Main outcome measures-Age at onset, duration of illness, psychological and immunological status at initial assessment. Ongoing symptom severity, levels of disability, and immunological function at follow up. Results-65 subjects had improved but only six reported no current symptoms. An alternative medical diagnosis had been made in two and psychiatric illness diagnosed in 20. The assignment of a primary psychiatric diagnosis at follow up and the strength of the belief that a physical disease process explained all symptoms at entry to the trials both predicted poor outcome. Age at onset of illness, duration of illness, neuroticism, premorbid psychiatric diagnoses, and cell mediated immune function did not predict outcome. Conclusion-Though most patients with the chronic fatigue syndrome improve, a substantial proportion remain functionally impaired. Psychological factors such as illness attitudes and coping style seem more important predictors of long term outcome than immunological or demographic variables.	PRINCE HENRY HOSP,DEPT IMMUNOL & INFECT DIS,LITTLE BAY,NSW 2036,AUSTRALIA		WILSON, A (corresponding author), PRINCE HENRY HOSP,DEPT PSYCHIAT,LITTLE BAY,NSW 2036,AUSTRALIA.		Hadzi-Pavlovic, Dusan/ABE-2266-2021; Lloyd, Andrew/E-7334-2017; Lloyd, Andrew/AAF-6071-2022; Hickie, Ian B/K-8975-2015; Lloyd, Andrew/AFJ-8960-2022	Lloyd, Andrew/0000-0001-6277-8887; Hickie, Ian B/0000-0001-8832-9895; Lloyd, Andrew/0000-0001-6277-8887				BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FARAGHER EB, 1990, PSYCHOL MED, V20, P663, DOI 10.1017/S0033291700017189; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P729; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GOLDBERG DP, 1979, MANUAL GENERAL HLTH; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KELLNER R, 1988, J PSYCHOSOM RES, V32, P303, DOI 10.1016/0022-3999(88)90072-4; KNIFER W, 1984, ANN ALLERGY, V52, P75; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LLOYD A, 1990, AM J MED, V89, P554; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; LLOYD AR, 1988, LANCET, V1, P1286; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; Pilowsky I., 1983, MANUAL ILLNESS BEHAV; PILOWSKY I, 1988, HDB SOCIAL PSYCHIATR; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; WATSON M, 1990, PSYCHOL REP, V66, P39, DOI 10.2466/PR0.66.1.39-48; 1987, DIAGNOSTIC STATISTIC	22	208	209	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					756	759		10.1136/bmj.308.6931.756	http://dx.doi.org/10.1136/bmj.308.6931.756			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NC348	8142830	Green Published			2022-12-28	WOS:A1994NC34800019
J	HOSKER, HSR; JONES, GM; HAWKEY, P				HOSKER, HSR; JONES, GM; HAWKEY, P			MANAGEMENT OF COMMUNITY-ACQUIRED LOWER RESPIRATORY-TRACT INFECTION	BRITISH MEDICAL JOURNAL			English	Article							PNEUMONIA; DIAGNOSIS; ETIOLOGY; ANTIGEN		UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; WENLOCK TERRACE SURG,YORK YO1 4DU,N YORKSHIRE,ENGLAND	University of Leeds	HOSKER, HSR (corresponding author), GEN INFIRM,DEPT RESP MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							ANDERSON H, 1993, EPIDEMIOLOGICALLY BA, P6; ANDREW PW, 1993, CURR OPIN INFECT DIS, V6, P146, DOI 10.1097/00001432-199304000-00003; BOURKE SJ, 1993, BRIT MED J, V306, P1219, DOI 10.1136/bmj.306.6887.1219; BOYLE FM, 1991, MED J AUSTRALIA, V154, P592, DOI 10.5694/j.1326-5377.1991.tb121219.x; BURMAN LA, 1991, J INFECT DIS, V163, P1087, DOI 10.1093/infdis/163.5.1087; CARPENTER JL, 1990, REV INFECT DIS, V12, P672; Denny F W, 1987, Pediatr Rev, V9, P135, DOI 10.1542/pir.9-5-135; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149, DOI 10.1093/oxfordjournals.epirev.a036050; HENDERSON FW, 1992, CURR OPIN INFECT DIS, V5, P183, DOI 10.1097/00001432-199204000-00006; KALIN M, 1993, CURR OPIN INFECT DIS, V6, P150, DOI 10.1097/00001432-199304000-00004; KARALUS NC, 1991, THORAX, V46, P413, DOI 10.1136/thx.46.6.413; MANSEL JK, 1989, CHEST, V95, P639, DOI 10.1378/chest.95.3.639; MARRIE TJ, 1993, THORAX, V48, P1, DOI 10.1136/thx.48.1.1; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; READ RC, 1993, CURR OPIN INFECT DIS, V6, P141, DOI 10.1097/00001432-199304000-00002; VENKATESAN P, 1992, THORAX, V47, P329, DOI 10.1136/thx.47.5.329; WOODHEAD M, 1992, BRIT J HOSP MED, V47, P684; WOODHEAD M, 1992, CURR OPIN INFECT DIS, V5, P164, DOI 10.1097/00001432-199204000-00003; WOODHEAD MA, 1992, RESP MED, V86, P459, DOI 10.1016/S0954-6111(96)80003-5; WOODHEAD MA, 1987, LANCET, V1, P671; 1974, BRIT MED J, V3, P1; 1987, Q J MED, V62, P195	23	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					701	705		10.1136/bmj.308.6930.701	http://dx.doi.org/10.1136/bmj.308.6930.701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142797	Green Published			2022-12-28	WOS:A1994NA86900025
J	SCHUNKERT, H; HENSE, HW; HOLMER, SR; STENDER, M; PERZ, S; KEIL, U; LORELL, BH; RIEGGER, GAJ				SCHUNKERT, H; HENSE, HW; HOLMER, SR; STENDER, M; PERZ, S; KEIL, U; LORELL, BH; RIEGGER, GAJ			ASSOCIATION BETWEEN A DELETION POLYMORPHISM OF THE ANGIOTENSIN-CONVERTING-ENZYME GENE AND LEFT-VENTRICULAR HYPERTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-HYPERTROPHY; BLOOD-PRESSURE; MASS; RAT; HYPERTENSION; RISK; CARDIOMYOPATHY; TWINS; SIZE	Background. Epidemiologic studies have shown that left ventricular hypertrophy is often found in the absence of an elevated cardiac workload. To investigate whether such hypertrophy is determined in part by genetic factors, we studied the association between this condition, as assessed by electrocardiographic criteria, and a deletion (D)-insertion (I) polymorphism of the angiotensin-converting-enzyme (ACE) gene. Methods. A population-based random sample of 711 women and 717 men 45 to 59 years of age was studied cross-sectionally in Augsburg, Germany. Electrocardiographic indexes, including the Sokolow-Lyon index, Minnesota Code 3.1, and the Rautaharju equations, were used to detect left ventricular hypertrophy. The status of the ACE gene with respect to the deletion-insertion allele was determined by the polymerase chain reaction in all subjects with left ventricular hypertrophy and an identical number of control subjects without the condition who were matched for age, sex, and blood-pressure status. Results. We identified 141 women and 149 men with evidence of left ventricular hypertrophy. Among these subjects, an excess were homozygous for the D allele of the ACE gene (odds ratio, 1.76; 95 percent confidence interval, 1.22 to 2.53; P = 0.003). The association of the DD genotype with left ventricular hypertrophy was stronger in men (odds ratio, 2.63; 95 percent confidence interval, 1.50 to 4.64; P<0.001) than in women and was most prominent when blood-pressure measurements were normal (odds ratio, 4.05; 95 percent confidence interval, 1.76 to 9.28; P = 0.001). This association was evident for each of the scores recorded in the electrocardiographic testing for left ventricular hypertrophy. Conclusions. The findings suggest that left ventricular hypertrophy is partially determined by genetic disposition. They identify the DD genotype of ACE as a potential genetic marker associated with an elevated risk of left ventricular hypertrophy in middle-aged men.	UNIV REGENSBURG, MED KLIN 2, REGENSBURG, GERMANY; GESELL STRAHLEN & UMWELTFORSCH MBH, FORSCHUNGSZENTRUM, INST EPIDEMIOL, MUNICH, GERMANY; GESELL STRAHLEN & UMWELTFORSCH MBH, FORSCHUNGSZENTRUM, MEDIS INST, MUNICH, GERMANY; UNIV MUNSTER, INST EPIDEMIOL & SOZIALMED, MUNSTER, GERMANY; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, HARVARD THORNDIKE LAB, DEPT INTERNAL MED, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; University of Munster; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								ADAMS TD, 1985, CIRCULATION, V71, P39, DOI 10.1161/01.CIR.71.1.39; BOTHIG S, 1989, INT J EPIDEMIOL, V18, pS29; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DAHLOF B, 1992, CLIN EXP HYPERTENS A, V14, P173, DOI 10.3109/10641969209036180; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KEIL U, 1988, ACTA MED SCAND, P119; KHAIRALLAH PA, 1983, PERSPECTIVE CARDIOVA, V8, P337; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LEADON SA, 1982, ANAL BIOCHEM, V120, P282, DOI 10.1016/0003-2697(82)90349-9; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINDPAINTNER K, 1985, CIRC RES, V57, P610, DOI 10.1161/01.RES.57.4.610; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; Prineas R., 1982, MINNESOTA CODE MANUA; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SCHUNKERT H, 1993, CIRCULATION, V87, P1328, DOI 10.1161/01.CIR.87.4.1328; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STUDER R, 1992, CIRCULATION, V86, P119; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; VERHAAREN HA, 1991, AM J CARDIOL, V68, P661, DOI 10.1016/0002-9149(91)90361-N	40	680	692	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1634	1638		10.1056/NEJM199406093302302	http://dx.doi.org/10.1056/NEJM199406093302302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177269				2022-12-28	WOS:A1994NP22000002
J	GIBBONS, GH; DZAU, VJ				GIBBONS, GH; DZAU, VJ			THE EMERGING CONCEPT OF VASCULAR REMODELING	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOOTH-MUSCLE CELLS; TRANSFORMING GROWTH FACTOR-BETA-1; AORTIC ENDOTHELIAL-CELLS; CORONARY-ARTERY DISEASE; LAMB DUCTUS-ARTERIOSUS; FLUID SHEAR-STRESS; RAT CAROTID-ARTERY; PLASMINOGEN-ACTIVATOR; INTACT ENDOTHELIUM; GENE-EXPRESSION		STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042663, R01HL035252, R37HL035610, R01HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35252, HL-35610, HL-42663] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO J, 1987, MICROVASC RES, V33, P62, DOI 10.1016/0026-2862(87)90007-0; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V172, P1081, DOI 10.1016/0006-291X(90)91557-9; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMBACH GL, 1989, HYPERTENSION, V13, P968, DOI 10.1161/01.HYP.13.6.968; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; BOTNEY MD, 1992, J CLIN INVEST, V89, P1629, DOI 10.1172/JCI115759; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CALIFF RM, 1991, J AM COLL CARDIOL, V17, pB2; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; COCEANI F, 1991, CAN J PHYSIOL PHARM, V69, P218, DOI 10.1139/y91-033; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; CUNNINGHAM LD, 1992, J CLIN INVEST, V89, P878, DOI 10.1172/JCI115667; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; FALK E, 1992, CIRCULATION, V86, P30; FAULKNER SL, 1975, CIRCULATION, V52, P163; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GIBBONS GH, 1992, J HEART LUNG TRANSPL, V11, pS22; GITTENBERGERDEGROOT AC, 1980, J PEDIATR-US, V96, P88, DOI 10.1016/S0022-3476(80)80337-4; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GOLDEN MA, 1990, J VASC SURG, V11, P580, DOI 10.1067/mva.1990.17625; GREENE AS, 1989, AM J PHYSIOL, V256, pH126, DOI 10.1152/ajpheart.1989.256.1.H126; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; IBA T, 1991, J SURG RES, V50, P457, DOI 10.1016/0022-4804(91)90024-G; ILKIW R, 1989, CIRC RES, V64, P814, DOI 10.1161/01.RES.64.4.814; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; IWATSUKI K, 1977, SCIENCE, V198, P403, DOI 10.1126/science.198877; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; JAMES TW, 1993, J CELL PHYSIOL, V157, P426, DOI 10.1002/jcp.1041570227; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; KOCKX MM, 1992, VIRCHOWS ARCH A, V420, P155, DOI 10.1007/BF02358807; Kovach Julie A., 1993, Journal of the American College of Cardiology, V21, p484A; KRAISS LW, 1991, ARTERIOSCLER THROMB, V11, P1844, DOI 10.1161/01.ATV.11.6.1844; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LEHMANN KH, 1989, THORAC CARDIOV SURG, V37, P187, DOI 10.1055/s-2007-1020315; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOGERFO FW, 1983, CIRCULATION, V68, P117; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; LUSCHER TF, 1987, HYPERTENSION, V9, P193, DOI 10.1161/01.HYP.9.6_Pt_2.III193; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; MORISHITA R, 1992, HYPERTENSION, V19, P62; MULVANY MJ, 1987, J HYPERTENS, V5, P129, DOI 10.1097/00004872-198704000-00001; NAKACHE M, 1988, P NATL ACAD SCI USA, V85, P1841, DOI 10.1073/pnas.85.6.1841; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ODONOHOE MK, 1991, ANN SURG, V214, P727, DOI 10.1097/00000658-199112000-00014; OHNO M, IN PRESS J CLIN INVE; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PATY PSK, 1990, J VASC SURG, V11, P171, DOI 10.1067/mva.1990.17030; RAKUGI H, 1992, Journal of the American College of Cardiology, V19, p329A; RAUGI GJ, 1990, AM J PATHOL, V137, P179; REID LM, 1989, AM REV RESPIR DIS, V140, P1490, DOI 10.1164/ajrccm/140.5.1490; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P7908, DOI 10.1073/pnas.90.16.7908-d; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RYAN US, 1989, J MOL CELL CARDIOL, V21, P85, DOI 10.1016/0022-2828(89)90841-9; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SARZANI R, 1989, J CLIN INVEST, V83, P1404, DOI 10.1172/JCI114029; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHROEDER JS, 1993, NEW ENGL J MED, V328, P164, DOI 10.1056/NEJM199301213280303; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; TOZZI CA, 1989, J CLIN INVEST, V84, P1005, DOI 10.1172/JCI114221; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; YAMADA E, 1986, EXP MOL PATHOL, V44, P147, DOI 10.1016/0014-4800(86)90065-1; ZHU L, 1993, LAB INVEST, V68, P321	91	1239	1351	1	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1431	1438						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159199				2022-12-28	WOS:A1994NK97200008
J	TOPAZIAN, M; BINDER, HJ				TOPAZIAN, M; BINDER, HJ			FACTITIOUS DIARRHEA DETECTED BY MEASUREMENT OF STOOL OSMOLALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							LAXATIVE ABUSE; OSMOTIC GAP; ELECTROLYTE; DIAGNOSIS; MAGNESIUM; INGESTION; ORIGIN		YALE UNIV, SCH MED, GEN CLIN RES CTR, NEW HAVEN, CT 06510 USA	Yale University	TOPAZIAN, M (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,DIGEST DIS SECT, 1080 LMP, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00125] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; ASHER R, 1951, LANCET, V260, P339; BINDER HJ, 1992, GASTROENTEROLOGY, V103, P702, DOI 10.1016/0016-5085(92)90870-5; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; DUNCAN A, 1991, ANN CLIN BIOCHEM, V28, P568, DOI 10.1177/000456329102800605; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1993, GASTROINTESTINAL DIS, V2, P1043; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; KREJS GJ, 1977, AM J DIG DIS, V22, P280, DOI 10.1007/BF01072184; LADEFOGED K, 1987, SCAND J GASTROENTERO, V22, P813, DOI 10.3109/00365528708991920; OSTER JR, 1980, AM J GASTROENTEROL, V74, P451; POWELL DW, 1992, TXB INTERNAL MED, P620; READ NW, 1980, GASTROENTEROLOGY, V78, P264; READ NW, 1982, DIGEST DIS SCI, V27, P193, DOI 10.1007/BF01296914; SHIAU YF, 1985, ANN INTERN MED, V102, P773, DOI 10.7326/0003-4819-102-6-773; THOMPSON J, 1981, BRIT J SURG, V68, P441, DOI 10.1002/bjs.1800680627	17	21	21	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1418	1419		10.1056/NEJM199405193302004	http://dx.doi.org/10.1056/NEJM199405193302004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159195				2022-12-28	WOS:A1994NK97200004
J	GROS, F; TOCCHINIVALENTINI, GP				GROS, F; TOCCHINIVALENTINI, GP			IN SEARCH OF EUROPEAN EXCELLENCE	NATURE			English	Editorial Material									CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)	GROS, F (corresponding author), INST PASTEUR,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.								0	6	6	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					11	12		10.1038/369011a0	http://dx.doi.org/10.1038/369011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164728	Bronze			2022-12-28	WOS:A1994NJ86000023
J	HORN, DL; HEWLETT, D; ALFALLA, C; PETERSON, S; OPAL, SM				HORN, DL; HEWLETT, D; ALFALLA, C; PETERSON, S; OPAL, SM			LIMITED TOLERANCE OF OFLOXACIN AND PYRAZINAMIDE PROPHYLAXIS AGAINST TUBERCULOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									BROWN UNIV,SCH MED,PROVIDENCE,RI 02918	Brown University	HORN, DL (corresponding author), LINCOLN MED & MENTAL HLTH CTR,BRONX,NY 10451, USA.							1992, MORB MORTAL WKLY REP, V41, P61; 1993, MMWR MORB MORTAL WKL, V42, P433	2	60	62	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1241	1241		10.1056/NEJM199404283301718	http://dx.doi.org/10.1056/NEJM199404283301718			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139647				2022-12-28	WOS:A1994NG58600031
J	BERKELMAN, RL; BRYAN, RT; OSTERHOLM, MT; LEDUC, JW; HUGHES, JM				BERKELMAN, RL; BRYAN, RT; OSTERHOLM, MT; LEDUC, JW; HUGHES, JM			INFECTIOUS-DISEASE SURVEILLANCE - A CRUMBLING FOUNDATION	SCIENCE			English	Editorial Material									MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55440; WHO,DIV COMMUNICABLE DIS,MICROBIOL & IMMUNOL SUPPORT SERV,CH-1211 GENEVA 27,SWITZERLAND	Minnesota Department of Health (MHD); World Health Organization	BERKELMAN, RL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30333, USA.							BELL B, 1993, 33RD INT C ANT AG CH; BERKELMAN RL, 1993, ANN INTERN MED, V119, P426, DOI 10.7326/0003-4819-119-5-199309010-00014; BROWN RE, 1993, ESTIMATE IDENTIFIABL; BRYAN RT, IN PRESS DISEASE EVO; BUEHLER JW, 1989, JAMA-J AM MED ASSOC, V262, P2896; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CIESLAK P, COMMUNICATION; DAVIS JE, UNPUB; DOWDLE WR, 1993, ANNU REV PUBL HEALTH, V14, P649; HEDBERG CW, IN PRESS CLIN INFECT; LEDUC J, UNPUB; NEAL JJ, 1993, 8TH INT S VIR HEP LI; OSTERHOLM MT, UNPUB; OSTERHOLM MT, IN PRESS PRINCIPLES; SLATER PE, 1989, INT J EPIDEMIOL, V18, P693, DOI 10.1093/ije/18.3.693; 1992, EMERGING INFECTIONS; 1993, 1993 WORLD BANK REP; 1993, MORB MORTAL WKLY REP, V42, P258	18	142	146	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					368	370		10.1126/science.8153621	http://dx.doi.org/10.1126/science.8153621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153621				2022-12-28	WOS:A1994NG19400024
J	LAUNER, LJ; HARRIS, T; RUMPEL, C; MADANS, J				LAUNER, LJ; HARRIS, T; RUMPEL, C; MADANS, J			BODY-MASS INDEX, WEIGHT CHANGE, AND RISK OF MOBILITY DISABILITY IN MIDDLE-AGED AND OLDER WOMEN - THE EPIDEMIOLOGIC FOLLOW-UP-STUDY OF NHANES-I	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; MUSCLE LOSS; OVERWEIGHT; POPULATION; STRATEGIES; ARTHRITIS; MORTALITY; STRENGTH; OBESITY; ADULTS	Objective.-As disability is highly prevalent among older women, is costly, and affects the quality of life, preventable causes of disability must be identified. In this study, we investigated the relationship between the body mass index (BMI), weight change, and the onset of disability in older women. Design.-Prospective cohort study. Setting.-The nationally representative US epidemiologic follow-up study of the National Health and Nutrition Examination Survey (NHANES) I (1971 through 1987). Patients.-White women classified as young-old (mean age 60 years at baseline, mean age 65 years at follow-up) and old-old (mean age 76 years at baseline, mean age 80 years at follow-up). Main Outcome Measures.-The relative odds for the onset of mobility disability associated with tertiles of past BMI (measured 8 to 16 years prior to disability ascertainment) and current BMI (measured 2 to 5 years prior to disability ascertainment) and with weight change between the two weight measurements. Results.-In both cohorts, women in the high past BMI group (>27 in the young-old and >28.1 in the old-old cohort) had a twofold increase in the risk for disability compared with women in the low past BMI group. High current BMI was as strongly related as past-BMI to risk of disability in the young-old women; it was not as strong a predictor in old-old women. In the old-old group only, women who experienced a weight loss of more than 5% had a twofold increase in risk of disability compared with weight-stable women. These results were adjusted for age, smoking, education, and study time and were not importantly modified with the addition into the models of single or multiple health conditions. Conclusions.-These prospective data suggest that high BMI is a strong predictor of long-term risk for mobility disability in older women and that this risk persists even to very old age. However, the paradoxical increase in risk associated with weight loss in the old-old women requires further study. Programs to prevent over weight may have potential for decreasing disability in women.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Erasmus University Rotterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	LAUNER, LJ (corresponding author), FREE UNIV AMSTERDAM,DEPT PSYCHIAT,1007 MC AMSTERDAM,NETHERLANDS.							ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; Buchner D M, 1992, Clin Geriatr Med, V8, P1; COOK NR, 1989, AM J EPIDEMIOL, V130, P66, DOI 10.1093/oxfordjournals.aje.a115324; CRIMMINS EM, 1993, J ING HLTH, V0005; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; Grunfeld C, 1992, AIDS Clin Rev, P191; GURALNIK JM, 1993, AM J EPIDEMIL, V137, P858; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HELLERSTEIN MK, 1990, SEMIN ONCOL, V17, P17; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KALLMAN DA, 1990, J GERONTOL, V45, pM82, DOI 10.1093/geronj/45.3.M82; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KUCZMARSKI RJ, 1989, AM J CLIN NUTR, V50, P1150, DOI 10.1093/ajcn/50.5.1150; Lawrence RC, 1990, HLTH STATUS WELL BEI, P136; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; PINSKY JL, 1985, AM J EPIDEMIOL, V122, P644, DOI 10.1093/oxfordjournals.aje.a114144; POPE AM, 1991, DISABILITY AM, P41; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; REED RL, 1991, J AM GERIATR SOC, V39, P555, DOI 10.1111/j.1532-5415.1991.tb03592.x; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROUBENOFF R, 1991, NUTR REV, V49, P163, DOI 10.1111/j.1753-4887.1991.tb03013.x; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223; VERBRUGGE LM, 1991, J CLIN EPIDEMIOL, V44, P167, DOI 10.1016/0895-4356(91)90264-A; WADDEN TA, 1992, MAR METH VOL WEIGHT; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; 1992, VITAL HLTH STAT 1, V27; 1987, VITAL HLTH STAT 1, V25; 1977, VITAL HLTH STAT 1 B, V10; 1987, VITAL HLTH STAT 1, V22	33	360	369	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1093	1098		10.1001/jama.271.14.1093	http://dx.doi.org/10.1001/jama.271.14.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151851				2022-12-28	WOS:A1994NE22800031
J	HILLMAN, JG				HILLMAN, JG			AUDIT OF ELDERLY PEOPLES EYE PROBLEMS AND NON-ATTENDANCE AT HOSPITAL EYE SERVICE	BRITISH MEDICAL JOURNAL			English	Article								Because eye disease is common in elderly people' and the number of people aged greater-than-or-equal-to 80 in Britain is increasing, 2 outpatient referrals to the hospital eye service will probably rise. Many studies have discussed the reasons why people do not keep their outpatient appointments and ways in which non-attendance could be reduced. Few have given details of the morbidity that arises in patients who have not kept appointments.3 Could general practitioners have an important influence on non-attendance?			HILLMAN, JG (corresponding author), MED CTR BRIDLINGTON,BRIDLINGTON Y016 4LZ,ENGLAND.							GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P192; JONES RB, 1988, PUBLIC HEALTH, V102, P385, DOI 10.1016/S0033-3506(88)80110-0; 1991, GLOBAL POPULATION ES, P364	3	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					953	953		10.1136/bmj.308.6934.953	http://dx.doi.org/10.1136/bmj.308.6934.953			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173403	Green Published			2022-12-28	WOS:A1994NF48500018
J	GONZALEZCRESPO, S; LEVINE, M				GONZALEZCRESPO, S; LEVINE, M			RELATED TARGET ENHANCERS FOR DORSAL AND NF-KAPPA-B SIGNALING PATHWAYS	SCIENCE			English	Article							ACHAETE-SCUTE COMPLEX; DNA-BINDING PROTEIN; DROSOPHILA EMBRYO; DORSOVENTRAL PATTERN; SEX DETERMINATION; REL ONCOGENE; GENE-COMPLEX; EXPRESSION; SEQUENCE; MORPHOGEN	Drosophila dorsoventral (DV) patterning and mammalian hematopoiesis are regulated by related signaling pathways (Toll, interleukin-1) and transcription factors (dorsal, nuclear factor-kappaB). These factors interact with related enhancers, such as the rhomboid NEE and kappa light chain enhancer, that contain similar arrangements of activator and repressor binding sites. It is shown that the kappa enhancer can generate lateral stripes of gene expression in transgenic Drosophila embryos in a pattern similar to that directed by the rhomboid NEE. Drosophila DV determinants direct these stripes through the corresponding mammalian cis regulatory elements in the kappa enhancer, including the kappaB site and kappaE boxes. These results suggest that enhancers can couple conserved signaling pathways to divergent gene functions.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM 46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1993, MECH DEVELOP, V42, P159, DOI 10.1016/0925-4773(93)90005-I; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GONZALEZCRESPO S, UNPUB; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NIETO MA, 1992, DEVELOPMENT, V116, P227; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DE, 1992, DEVELOPMENT, V116, P1033; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P	48	29	31	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					255	258		10.1126/science.8146656	http://dx.doi.org/10.1126/science.8146656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146656				2022-12-28	WOS:A1994NE41000035
J	ROBINSON, R				ROBINSON, R			COMMUNITY CARE - THE FIRST YEAR - GWENT - A GOOD START AND BETTER PROSPECTS .2.	BRITISH MEDICAL JOURNAL			English	Article																		ROBINSON R, 1993, BRIT MED J, V306, P44, DOI 10.1136/bmj.306.6869.44; 1993, COMMUNITY CARE GWENT; 1990, NATIONAL HLTH SERVIC; 1992, ALL WALES MENTAL HAN; 1985, MANAGING SOCIAL SERV; 1989, MENTAL ILLNESS SERVI	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					778	780		10.1136/bmj.308.6931.778	http://dx.doi.org/10.1136/bmj.308.6931.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NC348	8142837	Green Published			2022-12-28	WOS:A1994NC34800031
J	IRVING, WL; NEAL, KR; UNDERWOOD, JCE; SIMMONDS, PN; JONES, DA; NUTTALL, P; DAY, S; BENNETT, D; EGLIN, RP; FINCH, RG; READ, R; MCKENDRICK, M; TRIGER, RD; WILLIAMS, D; SCOTT, BB; NICHOLSON, KG; WISELKA, M; FREEMAN, J; ROSE, K				IRVING, WL; NEAL, KR; UNDERWOOD, JCE; SIMMONDS, PN; JONES, DA; NUTTALL, P; DAY, S; BENNETT, D; EGLIN, RP; FINCH, RG; READ, R; MCKENDRICK, M; TRIGER, RD; WILLIAMS, D; SCOTT, BB; NICHOLSON, KG; WISELKA, M; FREEMAN, J; ROSE, K			CHRONIC HEPATITIS IN UNITED-KINGDOM BLOOD-DONORS INFECTED WITH HEPATITIS-C VIRUS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; UNIV EDINBURGH,SCH MED,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; TRENT REG BLOOD TRANSFUS CTR,SHEFFIELD S5 7JN,S YORKSHIRE,ENGLAND; LEEDS PUBL HLTH LAB,LEEDS,W YORKSHIRE,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; LINCOLN CTY HOSP,LINCOLN,ENGLAND; LEICESTER ROYAL INFIRM,LEICESTER,ENGLAND; DERBYSHIRE ROYAL INFIRM,DERBY DE1 2QY,ENGLAND; UNIV EDINBURGH,DEPT MICROBIOL,EDINBURGH,SCOTLAND	University of Sheffield; University of Edinburgh; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Leicester; University of Edinburgh	IRVING, WL (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.			Irving, William/0000-0002-7268-3168; Simmonds, Peter/0000-0002-7964-4700				ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; IRVING WL, 1993, VOX SANG, V65, P38, DOI 10.1111/j.1423-0410.1993.tb04522.x; MAKRIS M, 1991, BLOOD, V78, P1672; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993	5	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					695	696		10.1136/bmj.308.6930.695	http://dx.doi.org/10.1136/bmj.308.6930.695			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142794	Green Submitted, Green Published			2022-12-28	WOS:A1994NA86900021
J	MATSUMURA, Y; HANBURY, D; SMITH, J; TARIN, D				MATSUMURA, Y; HANBURY, D; SMITH, J; TARIN, D			NONINVASIVE DETECTION OF MALIGNANCY BY IDENTIFICATION OF UNUSUAL CD44 GENE ACTIVITY IN EXFOLIATED CANCER-CELLS	BRITISH MEDICAL JOURNAL			English	Article							BLADDER-CANCER; URINE; MUTATIONS; CYTOLOGY; VARIANTS; TUMORS	Objective-To investigate non-invasive detection of cancer by testing for unusual CD44 gene activity in a clinical sample as an indicator of exfoliated tumour cells. Design-Case-control study. Subjects-44 unselected, consecutive patients with bladder cancer and 46 people with no evidence of neoplasia. Main outcome measure-Presence or absence of large CD44 gene products containing exon 6 derivatives in urine samples. Results-Novel abnormalities in the pattern of expression of this gene, seen specifically in tumour tissue, led to cloning of a newly recognised coding region in it (exon 6). This was tested as a probe for detection of exfoliated malignant cells in naturally voided urine. CD44 gene products extracted from the urine and amplified with polymerase chain reaction contained predicted electrophoretic band of 735 base pairs in 40 of the 44 patients with bladder cancer (sensitivity 91%). Products from 38 of the 46 people with no evidence of neoplasia showed no such band (specificity 83%). Conclusions-Unusual activity of the CD44 locus in neoplasia and malignancy is confirmed, and techniques for the analysis of such activity can enable non-invasive investigation of patients for primary or recurrent bladder cancer or for other tumours that shed neoplastic cells into body fluids.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; CHURCHILL HOSP,DEPT UROL,OXFORD OX3 8LJ,ENGLAND	University of Oxford; University of Oxford			Matsumura, Yasuhiro/N-4472-2016					BRITTON JP, 1992, J UROLOGY, V148, P788, DOI 10.1016/S0022-5347(17)36720-4; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FINN L, 1993, LAB INVEST, V68, pA49; HALIASSOS A, 1992, INT J ONCOL, V1, P731; HEDIN A, 1983, P NATL ACAD SCI-BIOL, V80, P3470, DOI 10.1073/pnas.80.11.3470; HEIDER KH, 1993, CANCER RES, V53, P4197; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; Kantoff P W, 1990, Curr Probl Cancer, V14, P233; KERN WH, 1984, CANCER, V53, P1185, DOI 10.1002/1097-0142(19840301)53:5<1185::AID-CNCR2820530526>3.0.CO;2-R; KOSS LG, 1985, ACTA CYTOL, V29, P810; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MATSUMURA Y, 1993, J PATHOL, V171, P249; MATZKIN H, 1992, UROLOGY, V39, P201, DOI 10.1016/0090-4295(92)90288-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TARIN D, 1981, CANCER RES, V41, P3604; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	23	88	96	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					619	624		10.1136/bmj.308.6929.619	http://dx.doi.org/10.1136/bmj.308.6929.619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148709	Green Published			2022-12-28	WOS:A1994MZ69800019
J	HODGKINSON, DW; ODRISCOLL, BR; DRISCOLL, PA; NICHOLSON, DA				HODGKINSON, DW; ODRISCOLL, BR; DRISCOLL, PA; NICHOLSON, DA			ABC OF EMERGENCY RADIOLOGY - CHEST RADIOGRAPHS .2.	BRITISH MEDICAL JOURNAL			English	Article											HODGKINSON, DW (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1273	1277		10.1136/bmj.307.6914.1273	http://dx.doi.org/10.1136/bmj.307.6914.1273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8166807	Green Published, Bronze			2022-12-28	WOS:A1993MH00100033
J	WILLIAMS, RL; CHALMERS, TC; STANGE, KC; CHALMERS, FT; BOWLIN, SJ				WILLIAMS, RL; CHALMERS, TC; STANGE, KC; CHALMERS, FT; BOWLIN, SJ			USE OF ANTIBIOTICS IN PREVENTING RECURRENT ACUTE OTITIS-MEDIA AND IN TREATING OTITIS-MEDIA WITH EFFUSION - A METAANALYTIC ATTEMPT TO RESOLVE THE BROUHAHA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MIDDLE-EAR EFFUSION; DOUBLE-BLIND; CLINICAL-TRIALS; DECONGESTANT-ANTIHISTAMINE; ANTIMICROBIAL THERAPY; RANDOMIZED TRIAL; CO-TRIMOXAZOLE; SEROUS OTITIS; EFFICACY; CHILDREN	Objective.-To determine the efficacy of antibiotics for prophylaxis of recurrent otitis media and treatment of otitis media with effusion (OME) in children. Data Sources.-MEDLINE from 1966 through April 1993, textbooks, Current Contents, and bibliographies of selected articles. Study Selection.-Thirty-three studies initially identified were reviewed by three blinded reviewers assessing study quality and suitability for inclusion. Twenty-seven met inclusion criteria for the meta-analyses. Data Extraction.-We abstracted quantitative data and calculated rate differences (RDs) using tympanometry as the preferred outcome measure. Data Synthesis.-Nine studies of antibiotic prophylaxis of recurrent otitis media with 958 subjects had an RD of 0.11 (95% confidence interval [CI], 0.03 to 0.1 9) favoring antibiotic treatment. Twelve studies of short-term patient outcomes of OME with 1697 subjects had an RD favoring antibiotics of 0.16 (95% CI, 0.03 to 0.29), while eight studies using the ear as the outcome measure with 2052 ears studied had an RD of 0.25 (95% CI, 0.10 to 0.40). No significant difference was shown between placebo and antibiotics (RD, 0.06; 95% CI, -0.03 to 0.14) in the eight studies of longer-term outcome of OME. Subgroup analyses by antibiotic grouping, duration of treatment, and duration of disease did not show significant differences. Conclusions.-Antibiotics appear to have beneficial but limited effect on recurrent otitis media and short-term resolution of OME. Longer-term benefit for OME has not been shown. The findings are limited by the failure of most studies to consider potential confounders and by inability to identify groups of patients most likely to benefit.	SKAGIT PEDIAT, MT VERNON, WA USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT FAMILY MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Case Western Reserve University; Case Western Reserve University; Harvard University; Harvard T.H. Chan School of Public Health	WILLIAMS, RL (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, METROL HLTH CLEMENT CTR, CLEVELAND, OH 44106 USA.				AHRQ HHS [HS05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUESTONE CD, 1989, PEDIATR CLIN N AM, V36, P1371; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; CORWIN M J, 1982, Pediatric Research, V16, p238A; CORWIN MJ, 1986, INT J PEDIATR OTORHI, V11, P109, DOI 10.1016/S0165-5876(86)80005-2; DALY K, 1988, 4TH P INT S REC ADV, P247; DECASTRO FJ, 1982, MO MED, V79, P629; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DONALDSON JD, 1990, J OTOLARYNGOL, V19, P175; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ERNSTSON S, 1985, ACTA OTO-LARYNGOL, P17; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GASKINS JD, 1982, DRUG INTEL CLIN PHAR, V16, P387, DOI 10.1177/106002808201600505; Giebink GC, 1988, 4TH P INT S REC ADV, P240; GIEBINK GS, 1990, PEDIATR INFECT DIS J, V9, P33, DOI 10.1097/00006454-199001000-00008; GONZALEZ C, 1986, LARYNGOSCOPE, V96, P1330; HEALY GB, 1984, INT J PEDIATR OTORHI, V8, P13, DOI 10.1016/S0165-5876(84)80021-X; HEAREY C, 1990, AM J DIS CHILD, V144, P420; LISTON TE, 1983, PEDIATRICS, V71, P524; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MANDEL EM, 1991, PEDIATR INFECT DIS J, V10, P899, DOI 10.1097/00006454-199112000-00004; MANDEL EM, 1993, JAMA-J AM MED ASSOC, V269, P516, DOI 10.1001/jama.269.4.516; MARKS NJ, 1983, J LARYNGOL OTOL, V97, P213, DOI 10.1017/S0022215100094020; MARKS NJ, 1981, J LARYNGOL OTOL, V95, P1003, DOI 10.1017/S0022215100091751; MAYNARD JE, 1972, J AMER MED ASSOC, V219, P597, DOI 10.1001/jama.219.5.597; MOLLER P, 1990, J LARYNGOL OTOL, V104, P200, DOI 10.1017/S0022215100112277; OTTEN FWA, 1990, LARYNGOSCOPE, V100, P627; PARADISE JL, 1981, ANN OTO RHINOL LARYN, V90, P53, DOI 10.1177/00034894810903S213; PERRIN JM, 1974, NEW ENGL J MED, V291, P664, DOI 10.1056/NEJM197409262911307; PERSICO M, 1985, INT J PEDIATR OTORHI, V10, P37, DOI 10.1016/S0165-5876(85)80055-0; PODOSHIN L, 1990, ARCH OTOLARYNGOL, V116, P1404; PRINCIPI N, 1989, AM J DIS CHILD, V143, P1414, DOI 10.1001/archpedi.1989.02150240036013; REITMAN D, 1987, CONTROL CLIN TRIALS, V8, P282; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P3333, DOI 10.1001/jama.266.23.3333; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SCHLOSSMD, 1988, 4TH P INT S REC ADV, P261; SCHULLER DE, 1983, PEDIATR INFECT DIS J, V2, P280, DOI 10.1097/00006454-198307000-00004; SCHWARTZ RH, 1982, PEDIATR INFECT DIS J, V1, P333, DOI 10.1097/00006454-198209000-00010; SCHWARTZ RH, 1982, ARCH DIS CHILD, V57, P590, DOI 10.1136/adc.57.8.590; SMITH IM, 1991, CLIN OTOLARYNGOL, V16, P266, DOI 10.1111/j.1365-2273.1991.tb00927.x; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; THOMSEN J, 1989, ARCH OTOLARYNGOL, V115, P447; THOMSEN J, 1988, 4TH P INT S REC ADV, P244; VARSANO I, 1985, AM J DIS CHILD, V139, P632, DOI 10.1001/archpedi.1985.02140080102044	49	178	181	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1344	1351		10.1001/jama.270.11.1344	http://dx.doi.org/10.1001/jama.270.11.1344			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8141875				2022-12-28	WOS:A1993LW34500033
J	KINDIG, DA				KINDIG, DA			COUNTING GENERALIST PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE		UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	KINDIG, DA (corresponding author), UNIV WISCONSIN,SCH MED,PROGRAMS HLTH MANAGEMENT,2ND FLOOR BRADLEY MEM,1300 UNIV AVE,MADISON,WI 53706, USA.							AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KINDIG DA, 1987, INQUIRY-J HEALTH CAR, V24, P136; KINDIG DA, 1989, HLTH AFF, V81, P61; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; WEINER J, 1993, ASSESSING IMPACT MAN; 1993, ANN REPORT C, P55; 1992, IMPROVING ACCESS HLT; 1980, HRA81656 US DEP HLTH, P6; 1993, SOCIOECONOMIC ENV ST; 1993, PHYSICIAN CHARACTERI, V116, P583; 1989, REVISION BHPR PHYSIC	18	38	38	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	1994	271	19					1505	1507		10.1001/jama.271.19.1505	http://dx.doi.org/10.1001/jama.271.19.1505			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK711	8176830				2022-12-28	WOS:A1994NK71100029
J	NIENABER, CA				NIENABER, CA			DISSECTION OF THE ASCENDING THORACIC AORTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NIENABER, CA (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,D-20246 HAMBURG,GERMANY.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1361	1361						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152448				2022-12-28	WOS:A1994NK75300006
J	FELDMAN, S; ANDREW, M; GILBERT, J; BRACKEN, B; THOMPSON, FE				FELDMAN, S; ANDREW, M; GILBERT, J; BRACKEN, B; THOMPSON, FE			MEASLES IMMUNIZATION OF 2-YEAR-OLDS IN A RURAL SOUTHERN STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HERD-IMMUNITY	Objective.-To assess the measles vaccine coverage of 2-year-old children livin Design.-Survey of 2-year-olds randomly selected from the 1987 birth cohort. The status of measles-mumps-rubella (MMR) vaccination was determined by medical record reviews and family contacts. Setting.-A predominantly rural state in the southeastern United States with a large black minority population (35%) and; a low per capita income ($9827 to $12 899). Approximately 80% of MMR immunizations are given by public health service nurses working in nine health districts. Subjects.-A total of 2450 preschool-aged children representing 6% of the 1987 birth cohort (n=41 279). Three hundred forty-one children were considered ineligible, leaving 2109 in the final sample. Main Outcome M easures.-Confirmed vaccination by the age of 2 years. Rates of immunization were calculated for the entire state, its health districts, and subgroups based on population density, per capita income, type of clin ic visited, and race. Results.-The statewide immunization rate was 87% (95% confidence interval, 86% to 88%). Among the nine health districts, rates varied from 79% to 97% (median, 88%). They were similar for white and black children in each health district and within the state as a whole. The lever of vaccine coverage was significantly higher in districts with lower population densities (89% vs 85%, P=.02) and in those with higher per capita incomes (89% vs 86%, P=.03). There were four minor outbreaks of measles during 1989 and 1990; half of the cases occurred in unimmunized children too young to receive the MMR Vaccine. Conclusion.-A high rate of measles immunization is attainable among 2-year-olds living in a rural state with a large black minority population and limited economic resources.	UNIV MISSISSIPPI, MED CTR, DEPT PREVENT MED, JACKSON, MS 39216 USA; MISSISSIPPI DEPT HLTH, JACKSON, MS USA	University of Mississippi; University of Mississippi Medical Center	FELDMAN, S (corresponding author), UNIV MISSISSIPPI, MED CTR, DEPT PEDIAT, 2500 N STATE ST, JACKSON, MS 39216 USA.							[Anonymous], 2017, RE DANIEL; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; FARIZO KM, 1992, PEDIATRICS, V89, P589; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; FREED GL, 1993, NEW ENGL J MED, V329, P1957, DOI 10.1056/NEJM199312233292611; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; GUENTHER W, 1973, CONCEPTS STATISTICAL, P517; JONES VF, 1992, CLIN RES, V40, pA809; KATZ SL, 1991, REP PEDIAT INFECT DI, V1, P1; LANGBEIN LI, 1978, ECOLOGICAL INFERENCE, P9; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; WOJCIECHOWSKI B, 1992, CLIN RES, V40, pA809; YOUNG SA, 1980, AM J PUBLIC HEALTH, V70, P422, DOI 10.2105/AJPH.70.4.422; 1991, MMWR MORB MORTAL WKL, V40, P369; 1991, RANKINGS STATES 1991, P54; 1994, MMWR MORB MORTAL WKL, V42, P985; 1992, REPORT BUREAU EC ANA, P8; 1991, MMWR MORB MORTAL WKL, V40, P36; 1992, 1991 MISS STAT DEP H, P43; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, STATE HLTH AGENCY OR; 1992, STATISTICAL ABSTRACT, P22	22	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1417	1420						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176803				2022-12-28	WOS:A1994NJ69300029
J	BERTINA, RM; KOELEMAN, BPC; KOSTER, T; ROSENDAAL, FR; DIRVEN, RJ; DERONDE, H; VANDERVELDEN, PA; REITSMA, PH				BERTINA, RM; KOELEMAN, BPC; KOSTER, T; ROSENDAAL, FR; DIRVEN, RJ; DERONDE, H; VANDERVELDEN, PA; REITSMA, PH			MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C	NATURE			English	Article							FACTOR-XA; COMPLETE CDNA; FACTOR-VIII; CERULOPLASMIN; DEFICIENCY; INHIBITION; SEQUENCE; THROMBIN; CLONING; HEPARIN	ACTIVATED protein C (APC) is a serine protease with potent anticoagulant properties, which is formed in blood on the endothelium from an inactive precursor(1). During normal haemostasis, APC limits clot formation by proteolytic inactivation of factors Va and VIIIa (ref. 2). To do this efficiently the enzyme needs a nonenzymatic cofactor, protein S (ref. 3). Recently it was found that the anticoagulant response to APC (APC resistance)(4) was very weak in the plasma of 21% of unselected consecutive patients with thrombosis(5) and about 50% of selected patients with a personal or family history of thrombosis(6,7); moreover, 5% of healthy individuals show APC resistance, which is associated with a sevenfold increase in the risk for deep vein thrombosis(5). Here we demonstrate that the phenotype of APC resistance is associated with heterozygosity or homozygosity for a single point mutation in the factor V gene (at nucleotide position 1,691, G --> A substitution) which predicts the synthesis of a factor V molecule (FV Q506, or FV Leiden) that is not properly inactivated by APC. The allelic frequency of the mutation in the Dutch population is similar to 2% and is at least tenfold higher than that of all other known genetic risk factors for thrombosis (protein C (ref. 8), protein S (ref. 9), antithrombin(10) deficiency) together.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	BERTINA, RM (corresponding author), UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,BLDG 1-C2R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Bertina, Rogier/AGQ-5246-2022	Rosendaal, Frits/0000-0003-2558-7496; Dirven, Richard/0000-0001-9626-9925; van der Velden, Pieter/0000-0002-5710-9256				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; GRIFFIN JH, 1993, BLOOD, V82, P1989; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HIRSH J, 1989, AM J MED S3B, V87, P345; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PIETERS J, 1988, BLOOD, V72, P2048; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; SHEN NLL, 1993, J IMMUNOL, V150, P2992; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VERDUYN W, 1993, HUM IMMUNOL, V37, P59, DOI 10.1016/0198-8859(93)90143-O; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1990, J BIOL CHEM, V265, P1834; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Wang H, 1988, GENOMICS, V2, P324, DOI 10.1016/0888-7543(88)90021-3; YANG XJ, 1990, BIOCHEM J, V272, P399, DOI 10.1042/bj2720399	30	3609	3741	2	143	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					64	67		10.1038/369064a0	http://dx.doi.org/10.1038/369064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164741				2022-12-28	WOS:A1994NJ86000054
J	READING, R; COLVER, A; OPENSHAW, S; JARVIS, S				READING, R; COLVER, A; OPENSHAW, S; JARVIS, S			DO INTERVENTIONS THAT IMPROVE IMMUNIZATION UPTAKE ALSO REDUCE SOCIAL INEQUALITIES IN UPTAKE	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; IMMUNIZATION; CHILDREN; FICTION; RATES; FACT	Objective-To investigate whether an intervention designed to improve overall immunisation uptake affected social inequalities in uptake. Design-Cross-sectional small area analyses measuring immunisation uptake in cohorts of children before and after intervention. Small areas classified into five groups, from most deprived to most affluent, with Townsend deprivation score of census enumeration districts. Setting-County of Northumberland. Subjects-All children born in county in four birth cohorts (1981-2, 1985-6, 1987-8, and 1990-1) and still resident at time of analysis. Main outcome measures-Overall uptake in each cohort of pertussis, diphtheria, and measles immunisation, difference in uptake between most deprived and most affluent areas, and odds ratio of uptake between deprived and affluent areas. Results-Coverage for pertussis immunisation rose from 53.4% in first cohort to 91.1% in final cohort. Coverage in the most deprived areas was lower than in the most affluent areas by 4.7%, 8.7%, 10.2%, and 7.0% respectively in successive cohorts, corresponding to an increase in odds ratio of uptake between deprived and affluent areas from 1.2 to 1.6 to 1.9 to 2.3. Coverage for diphtheria immunisation rose from 70.0% to 93.8%; differences between deprived and affluent areas changed from 8.6% to 8.3% to 9.0% to 5.5%, corresponding to odds ratios of 1.5, 2.0, 2.5, and 2.6. Coverage for measles immunisation rose from 52.5% to 91.4%; differences between deprived and affluent areas changed from 9.1% to 5.7% to 8.2% to 3.6%, corresponding to odds ratios of 1.4, 1.4, 1.7, and 1.5. Conclusion-Despite substantial increase in immunisation uptake, inequalities between deprived and affluent areas persisted or became wider. Any reduction in inequality occurred only after uptake in affluent areas approached 95%. Interventions that improve overall uptake of preventive measures are unlikely to reduce social inequalities in uptake.	BEACONHILL CHILDRENS CTR,CRAMLINGTON NE23 8EH,ENGLAND; UNIV LEEDS,SCH GEOG,LEEDS LS2 9LT,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND	University of Leeds; Newcastle University - UK	READING, R (corresponding author), NORFOLK & NORWICH HOSP,JENNY LIND DEPT,NORWICH NR1 3SR,NORFOLK,ENGLAND.							ALWASH R, 1988, ARCH DIS CHILD, V63, P635, DOI 10.1136/adc.63.6.635; COLVER A, 1989, LANCET, V1, P906; COLVER AF, 1990, BRIT MED J, V300, P1246, DOI 10.1136/bmj.300.6734.1246; Culyer A. J., 1988, ACCEPTABLE INEQUALIT, P31; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; JEFFERIES S, 1991, J PUBLIC HEALTH MED, V13, P312; Le Grand J., 1982, STRATEGY EQUALITY; Macintyre S., 1989, HLTH INEQUALITIES EU, P317; MARSH GN, 1988, BRIT MED J, V296, P173, DOI 10.1136/bmj.296.6616.173; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; READING R, 1993, J EPIDEMIOL COMMUN H, V47, P238, DOI 10.1136/jech.47.3.238; READING R, 1993, ARCH DIS CHILD, V68, P686, DOI 10.1136/adc.68.5.686; SCOTT EA, 1990, PUBLIC HEALTH, V104, P275, DOI 10.1016/S0033-3506(05)80477-9; SENTURIA YD, 1987, CHILDREN SOC, V3, P198; Townsend PP., 1988, HLTH DEPRIVATION INE; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; WHITEHEAD M, 1991, LANCET, V338, P1059, DOI 10.1016/0140-6736(91)91911-D; 1983, KEY POPULATION VI VS, P10	18	52	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1142	1144		10.1136/bmj.308.6937.1142	http://dx.doi.org/10.1136/bmj.308.6937.1142			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK182	8173457	Green Published			2022-12-28	WOS:A1994NK18200021
J	GELLERT, GA; HIGGINS, KV; LOWERY, RM; MAXWELL, RM				GELLERT, GA; HIGGINS, KV; LOWERY, RM; MAXWELL, RM			A NATIONAL SURVEY OF PUBLIC-HEALTH OFFICERS INTERACTIONS WITH THE MEDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MASS-MEDIA; DISEASE	Objectives.-To assess the perceptions, practices, and needs of state and local health officers with respect to professional interactions with the media. Design.-A survey of 759 public health officers (56 state and 703 local) on jurisdiction demographics, frequency of media interactions, agency process for media contacts, provision and need for media training, and character of media relations. Participants.-Fifty-two state health officers and 568 US local health officers responded, for a survey response rate of 82%. Results.-Media reporting was perceived as accurate 52% to 73% of the time, although reporters were seen as needing improved technical and scientific knowledge. Media were used frequently as a component of health education. State health jurisdictions were more likely than local jurisdictions to have a media protocol and designated media contact, to internally review media releases, to interact regularly with media, and to provide staff training on media relations. Media interaction time comprised print media (63%), television (19%), and radio (17%). One third of the health officers found media relations adversarial, but most held a positive overall view of the media. Favorable evaluation of the media was associated with high frequency of media contact, high perceived accuracy of reporting, and presence of an institutional media protocol. Conclusions.-While health officers evaluated media favorably, problem areas were identified where mutual education could improve the accuracy and value of media reporting on health issues. Training capacity for both professions should be developed to increase the effectiveness of public health in media relations.	ORANGE CTY HLTH CARE AGCY,SANTA ANA,CA		GELLERT, GA (corresponding author), PROJECT HOPE,MILLWOOD,VA 22646, USA.							[Anonymous], 1988, FUTURE PUBLIC HLTH; ARKIN EB, 1990, PUBLIC HEALTH REP, V105, P219; Atkin CK., 1990, MASS COMMUNICATION P; BELLICHA T, 1990, PUBLIC HEALTH REP, V105, P245; ERICKSON AC, 1990, PUBLIC HEALTH REP, V105, P239; HARRIS L, 1993, SIPISCOPE, V20, P2; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; JASON L A, 1989, Journal of Primary Prevention, V9, P233, DOI 10.1007/BF01326545; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; LAU R, 1980, HLTH ED Q, V1, P56; LIANG AP, 1993, PUBLIC HEALTH REP, V108, P116; LICHTER SR, 1993, SCI OPINION VS MEDIA; OTTEN AL, 1992, HEALTH AFFAIR, V11, P111, DOI 10.1377/hlthaff.11.4.111; PHILEN RM, 1992, JAMA-J AM MED ASSOC, V268, P1008, DOI 10.1001/jama.268.8.1008; PHILLIPS DP, 1991, NEW ENGL J MED, V325, P1180, DOI 10.1056/NEJM199110173251620; RAINEY DY, 1992, AM J PUBLIC HEALTH, V82, P745, DOI 10.2105/AJPH.82.5.745; ROPER WL, 1993, PUBLIC HEALTH REP, V108, P179; SAFER DJ, 1992, JAMA-J AM MED ASSOC, V268, P1004, DOI 10.1001/jama.268.8.1004; Schwitzer G, 1992, JAMA, V267, P1969, DOI 10.1001/jama.267.14.1969; WILKES MS, 1992, JAMA-J AM MED ASSOC, V268, P999, DOI 10.1001/jama.268.8.999; WINETT RA, 1986, INFORMATION BEHAVIOR; 1990, NATIONAL PROFILE LOC; 1991, MMWR MORB MORTAL WKL, V40, P543	23	19	19	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1285	1289		10.1001/jama.271.16.1285	http://dx.doi.org/10.1001/jama.271.16.1285			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NG362	8151905				2022-12-28	WOS:A1994NG36200032
J	TRAVERS, AA; NER, SS; CHURCHILL, MEA				TRAVERS, AA; NER, SS; CHURCHILL, MEA			DNA CHAPERONES - A SOLUTION TO A PERSISTENCE PROBLEM	CELL			English	Review							PROTEIN; NUCLEOSOME; BINDING; HMG1; HU		UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	TRAVERS, AA (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.		Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X				BLANCHI ME, 1992, EMBO J, V11, P1055; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; KOHLSTAEDT LA, 1987, J BIOL CHEM, V262, P524; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; NER SS, 1994, IN PRESS EMBO J, V13; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	19	112	113	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					167	169		10.1016/0092-8674(94)90306-9	http://dx.doi.org/10.1016/0092-8674(94)90306-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168125				2022-12-28	WOS:A1994NH63400001
J	FISHER, PJ; PRENDERGAST, FG; EHRHARDT, MR; URBAUER, JL; WAND, AJ; SEDAROUS, SS; MCCORMICK, DJ; BUCKLEY, PJ				FISHER, PJ; PRENDERGAST, FG; EHRHARDT, MR; URBAUER, JL; WAND, AJ; SEDAROUS, SS; MCCORMICK, DJ; BUCKLEY, PJ			CALMODULIN INTERACTS WITH AMPHIPHILIC PEPTIDES COMPOSED OF ALL D-AMINO ACIDS	NATURE			English	Article							LIGHT-CHAIN KINASE; MULTIDIMENSIONAL NMR; COMPLEX-FORMATION; BINDING DOMAIN; PROTEINS; MELITTIN; RECOGNITION; SEQUENCE; SPECTRA; ENZYME	CALMODULIN binds to amphiphilic, helical peptides of a variety of amino-acid sequences1-8. These peptides are usually positively charged, although there is spectroscopic evidence that at least one neutral peptide binds5. The complex between calmodulin and one of its natural target peptides, the binding site for calmodulin on smooth muscle myosin light-chain kinase (RS20)9, has been investigated by crystallography10 and NMR11-13 which have characterized the interactions between the ligand and the protein. From these data, it appears that the calmodulin-binding surface is sterically malleable and van der Waals forces probably dominate the binding. To explore further this apparently permissive binding, we investigated the chiral selectivity of calmodulin using synthesized analogues of melittin and RS20 that consisted of only D-amino acids. Fluorescence and NMR measurements show that D-melittin and D-RS20 both bind avidly to calmodulin, probably in the same general binding site as that for peptides having all L-amino acids. The calmodulin-peptide binding surface is therefore remarkably tolerant sterically. Our results suggest a potentially useful approach to the design of non-hydrolysable or slowly hydrolysable intracellular inhibitors of calmodulin.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801	Mayo Clinic; Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign								BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; CORIGLIANOMURPHY MA, 1985, INT J PEPT PROT RES, V25, P225; COX JA, 1985, J BIOL CHEM, V260, P2527; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1433; Seeholzer S.H., 1987, CALCIUM BINDING PROT, P360; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TOMITA U, 1991, BIOCHEM BIOPH RES CO, V178, P400, DOI 10.1016/0006-291X(91)91827-Y; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761	28	59	62	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					651	653		10.1038/368651a0	http://dx.doi.org/10.1038/368651a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145853				2022-12-28	WOS:A1994NF39200065
J	NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK				NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK			STRUCTURE OF RESTRICTION-ENDONUCLEASE BAMHI AND ITS RELATIONSHIP TO ECORI	NATURE			English	Article								TYPE II restriction endonucleases are characterized by the remarkable specificity with which they cleave specific DNA sequences. Surprisingly, their protein sequences are in most cases unrelated, and no recurring structural motif has yet been identified1,2. We have determined the structure of restriction endonuclease BamHI at 1.95 angstrom resolution. BamHI shows striking resemblance to the structure of endonuclease EcoRI (refs 3, 4), despite the lack of sequence similarity between them. We also observe some curious differences between the two structures, and propose an evolutionary scheme that may explain them. The active site of BamHI is structurally similar to the active sites of EcoRI and EcoRV (ref. 5), but the mechanism by which BamHI activates a water molecule for nucleophilic attack may be different.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University								ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; Creighton T. E., 1993, PROTEINS STRUCTURES; DORNER LF, 1994, NUCLEIC ACIDS RES, V22, P1068, DOI 10.1093/nar/22.6.1068; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; HELTMAN J, 1993, GENETIC ENG, P57; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; ROBERTS RJ, 1993, NUCLEASES; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XU SY, 1991, J BIOL CHEM, V266, P4425	18	164	166	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					660	664		10.1038/368660a0	http://dx.doi.org/10.1038/368660a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145855				2022-12-28	WOS:A1994NF39200068
J	HENDLEY, JO; ABBOTT, RD; BEASLEY, PP; GWALTNEY, JM				HENDLEY, JO; ABBOTT, RD; BEASLEY, PP; GWALTNEY, JM			EFFECT OF INHALATION OF HOT HUMIDIFIED AIR ON EXPERIMENTAL RHINOVIRUS INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COMMON COLD; SYMPTOMS	Objective.-Nasal inhalation of steam has been proposed as treatment of viral colds on the assumption that increased intranasal temperature will inhibit replication of rhinovirus (RV). The effect of steam inhalation on RV shedding by infected volunteers was examined in this study. Design.-Randomized controlled trial. Volunteers experimentally infected with RV were treated with machine-generated humidified air, which was either hot (active) or at room temperature (placebo). Viral shedding was assessed over the 4 days following treatment. Setting.-Local hotel. Participants.-Twenty volunteers from the university community who were susceptible to the challenge virus. Intervention.-Two 30-minute intranasal treatments, the first at 24 hours after inoculation and the second at 48 hours. The temperature of active vapor was 42-degrees-C to 44-degrees-C and of placebo vapor was 22-degrees-C. Main Outcome Measures.-Viral titers in nasal washings on each of 5 days following inoculation. Results.-Mean viral titers prior to the first treatment were 10(1.7) tissue culture infectious doses50 per milliliter in the active group and 10(1.5) in the placebo group. Mean titers for the next 4 days were 10(1.7), 10(1.7), 10(1.2), and 10(0.9)/mL in the active group and 10(1.8), 10(1.9), 10(1.6, and 10(0.7)/mL in the placebo group (no significant difference). The proportion of volunteers who shed virus on each day was also similar in the two groups. Conclusion.-Two nasal inhalation treatments with steam had no effect on viral shedding in volunteers with experimental RV colds.	UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	University of Virginia	HENDLEY, JO (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,BOX 386,CHARLOTTESVILLE,VA 22908, USA.							HAMRE D, 1968, MONNOGR VIROL, V1, P17; MACKNIN ML, 1990, JAMA-J AM MED ASSOC, V264, P989; OPHIR D, 1987, AM J OTOLARYNG, V8, P149, DOI 10.1016/S0196-0709(87)80037-6; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SPERBER SJ, 1992, ANN INTERN MED, V117, P37, DOI 10.7326/0003-4819-117-1-37; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; YERUSHALMI A, 1980, CR ACAD SCI D NAT, V291, P957	7	35	35	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1112	1113		10.1001/jama.271.14.1112	http://dx.doi.org/10.1001/jama.271.14.1112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151855				2022-12-28	WOS:A1994NE22800035
J	MCCANCE, DR; PETTITT, DJ; HANSON, RL; JACOBSSON, LTH; KNOWLER, WC; BENNETT, PH				MCCANCE, DR; PETTITT, DJ; HANSON, RL; JACOBSSON, LTH; KNOWLER, WC; BENNETT, PH			BIRTH-WEIGHT AND NON-INSULIN-DEPENDENT DIABETES - THRIFTY GENOTYPE, THRIFTY PHENOTYPE, OR SURVIVING SMALL BABY GENOTYPE	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA INDIAN WOMEN; MELLITUS; PREGNANCY; GROWTH; FETAL	Objective-To determine the prevalence of diabetes in relation to birth weight in Pima Indians. Design-Follow up study of infants born during 1940-72 who had undergone a glucose tolerance test at ages 20-39 years. Setting-Gila River Indian community, Arizona. Subjects-1179 American Indians. Main outcome measure-Prevalence of non-insulin dependent diabetes mellitus (plasma glucose concentration greater-than-or-equal-to 11.1 mmol/l two hours after ingestion of carbohydrate). Results-The prevalence was greatest in those with the lowest and highest birth weights. The age adjusted prevalences for birth weights <2500 g, 2500-4499 g, and greater-than-or-equal-to 4500 g were 30%, 17%, and 32%, respectively. When age, sex, body mass index, maternal diabetes during pregnancy, and birth year were controlled for, subjects with birth weights < 2500 g had a higher rate than those with weights 2500-4499 g (odds ratio 3.81; 95% confidence interval 1.70 to 8.52). The risk for subsequent diabetes among higher birthweight infants (greater-than-or-equal-to 4500 g) was associated with maternal diabetes during pregnancy. Most diabetes, however, occurred in subjects with intermediate birth weights (2500-4500 g). Conclusions-The relation of the prevalence of diabetes to birth weight in the Pima Indians is U shaped and is related to parental diabetes. Low birth weight is associated with non-insulin dependent diabetes. Given the high mortality of low birthweight infants selective survival in infancy of those genetically predisposed to insulin resistance and diabetes provides an explanation for the observed relation between low birth weight and diabetes and the high prevalence of diabetes in many populations.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,DIABET & ARTHRIT EPIDEMIOL SECT,PHOENIX,AZ 85014	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Bennett, Peter/AAH-9605-2021; Hanson, Robert L/O-3238-2015	Hanson, Robert L/0000-0002-4252-7068				[Anonymous], 1989, LANCET, V2, P839; ATHENS M, 1993, DIABETES, V42, pA61; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BENNETT PH, 1971, LANCET, V2, P125; COMESS LJ, 1969, DIABETES, V18, P471, DOI 10.2337/diab.18.7.471; FRIENKEL N, 1980, DIABETES, V29, P1023; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001; NEEL JV, 1962, AM J HUM GENET, V14, P353; NEEL JV, 1982, P SERONO S, P283; PETITT DJ, 1980, DIABETES CARE, V4, P458; PETTITT DJ, 1991, DIABETES, V40, P126, DOI 10.2337/diab.40.2.S126; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SAVAGE PJ, 1979, DIABETES, V28, P939; SWEENE I, 1981, DIABETES, V29, P686; SWEENE I, 1987, DIABETES, V36, P454; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44; WILKIN TJ, 1993, BRIT MED J, V306, P283, DOI 10.1136/bmj.306.6873.283; 1985, WHO TECH REP SER, V727, P9	28	534	542	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					942	945		10.1136/bmj.308.6934.942	http://dx.doi.org/10.1136/bmj.308.6934.942			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173400	Green Published			2022-12-28	WOS:A1994NF48500015
J	ZHONG, Z; WEN, ZL; DARNELL, JE				ZHONG, Z; WEN, ZL; DARNELL, JE			STAT3 - A STAT FAMILY MEMBER ACTIVATED BY TYROSINE PHOSPHORYLATION IN RESPONSE TO EPIDERMAL GROWTH-FACTOR AND INTERLEUKIN-6	SCIENCE			English	Article							INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; PROMOTER; ISGF-3; GAMMA	The STAT family of proteins carries out a dual function: signal transduction and activation of transcription. A new family member, Stat3, becomes activated through phosphorylation on tyrosine as a DNA binding protein in response to epidermal growth factor (EGF) and interleukin-6 (IL-6) but not interferon gamma (IFN-gamma). It is likely that this phosphoprotein forms homodimers as well as heterodimers with the first described member of the STAT family, Stat91 (renamed Stat1alpha), which is activated by the IFNs and EGF. Differential activation of different STAT proteins in response to different ligands should help to explain specificity in nuclear signaling from the cell surface.			ZHONG, Z (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISONS, 1993, SCIENCE, V261, P1733; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, IN PRESS CELL; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMOTO K, UNPUB; ZHONG Z, IN PRESS P NATL ACAD	23	1752	1817	3	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					95	98		10.1126/science.8140422	http://dx.doi.org/10.1126/science.8140422			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140422				2022-12-28	WOS:A1994ND53600038
J	WEBB, PM; KNIGHT, T; GREAVES, S; WILSON, A; NEWELL, DG; ELDER, J; FORMAN, D				WEBB, PM; KNIGHT, T; GREAVES, S; WILSON, A; NEWELL, DG; ELDER, J; FORMAN, D			RELATION BETWEEN INFECTION WITH HELICOBACTER-PYLORI AND LIVING-CONDITIONS IN CHILDHOOD - EVIDENCE FOR PERSON-TO-PERSON TRANSMISSION IN EARLY-LIFE	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; SEROPREVALENCE; EPIDEMIOLOGY; FAMILIES	Objectives-To relate the prevalence of infection with Helicobacter pylori in adults to their living conditions in childhood to identify risk factors for infection. Design-Prevalence study of IgG antibodies to H pylori (> 10 mu g IgG/ml, determined by enzyme linked immunosorbent assay (ELISA)) and reported living conditions and other socioeconomic factors in childhood. Setting-Three factories in Stoke on Trent. Subjects-471 male volunteers aged 18 to 65 years. Main outcome measures-Seroprevalence and variables in childhood. Results-Seroprevalence of H pylori increased with age (22/74 (29.7%) at < 30 years v 29/46 (63%) at 55-65 years; P < 0.001 for trend) and was related to manual occupation (14/65 (21.5%) for non-manual v 162/406 (39.9%) for manual; P = 0.003). After data were adjusted for age and occupation subjects from large families, whose childhood homes were crowded or who regularly shared a bed in childhood, were significantly more likely to be seropositive (adjusted odds ratio (95% confidence interval) 2.15 (1.41 to 3.30) for crowding and 2.13 (1.38 to 3.30) for sharing a bed), but there was no relation with possession of a bathroom, inside toilet, refrigerator, or household pets in childhood. Conclusions-Close person to person contact in childhood is an important determinant of seroprevalence of H pylori in adulthood, suggesting that the infection is transmitted directly from one person to another and may be commonly acquired in early life.	UNIV KEELE,DEPT SURG,STOKE ON TRENT,STAFFS,ENGLAND; CENT VET LABS,APPL & MOLEC IMMUNOL UNIT,WEYBRIDGE KT15 4NB,SURREY,ENGLAND	Keele University	WEBB, PM (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,OXON,ENGLAND.		Webb, Penelope/D-5736-2013	Webb, Penelope/0000-0003-0733-5930				[Anonymous], 1980, CLASSIFICATION OCCUP; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; BERKOWICZ J, 1987, LANCET, V2, P680; DIXON MF, 1992, HELICOBACTER PYLORI, P124; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FORMAN D, 1992, EUR J GASTROEN HEPAT, V4, pS31; GALPIN OP, 1992, LANCET, V339, P619, DOI 10.1016/0140-6736(92)90907-K; HAMMERMEISTER I, 1992, EUR J CLIN MICROBIOL, V11, P9, DOI 10.1007/BF01971264; KRAJDEN S, 1989, J CLIN MICROBIOL, V27, P1397, DOI 10.1128/JCM.27.6.1397-1398.1989; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MEGRAUD F, 1992, HELICOBACTER PYLORI, P107; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; PEREZPEREZ GI, 1991, J CLIN MICROBIOL, V29, P642, DOI 10.1128/JCM.29.3.642-644.1991; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SOBALA GM, 1992, HELICOBACTER PYLORI, P150; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685; WYATT JI, 1992, HELICOBACTER PYLORI, P140; 1986, BRITAINS HOUSEHOLDS, V4	24	298	307	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					750	753		10.1136/bmj.308.6931.750	http://dx.doi.org/10.1136/bmj.308.6931.750			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142828	Green Published			2022-12-28	WOS:A1994NC34800017
J	LAKKA, TA; VENALAINEN, JM; RAURAMAA, R; SALONEN, R; TUOMILEHTO, J; SALONEN, JT				LAKKA, TA; VENALAINEN, JM; RAURAMAA, R; SALONEN, R; TUOMILEHTO, J; SALONEN, JT			RELATION OF LEISURE-TIME PHYSICAL-ACTIVITY AND CARDIORESPIRATORY FITNESS TO THE RISK OF ACUTE MYOCARDIAL-INFARCTION IN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; EASTERN FINNISH MEN; UNITED-STATES RAILROAD; ALL-CAUSE MORTALITY; PROSPECTIVE POPULATION; PLASMA-FIBRINOGEN; COLLEGE ALUMNI; FOLLOW-UP; ASSOCIATION; PREDICTOR	Background. Previous studies have suggested that higher levels of regular physical activity and cardiorespiratory fitness are associated with a reduced risk of coronary heart disease. We investigated the independent associations of physical activity during leisure time and maximal oxygen uptake (a measure of cardiorespiratory fitness) with the risk of acute myocardial infarction. Methods. During the period 1984 to 1989, we performed base-line examinations in 1453 men 42 to 60 years old who did not report having cardiovascular disease or cancer. Physical activity was assessed quantitatively with a detailed questionnaire, and maximal oxygen uptake was measured directly by exercise testing. During an average follow-up of 4.9 years, 42 of the 1166 men with normal electrocardiograms at base line had a first acute myocardial infarction. Results. After adjustment for age and the year of examination, the relative hazard (risk) of myocardial infarction in the third of subjects with the highest level of physical activity (> 2.2 hours per week) was 0.31 (95 percent confidence interval, 0.12 to 0.85; P = 0.02), as compared with the third with the lowest level (P = 0.04 for linear trend over all three groups). The relative hazard in the third with the highest maximal oxygen uptake (> 2.7 liters per minute) was 0.26 (95 percent confidence interval, 0.10 to 0.68; P = 0.006) (P = 0.006 for linear trend), after adjustment for age, the year and season when the examination was performed, weight, height, and the type of respiratory-gas analyzer used. After up to 17 confounding variables were controlled for, the relative hazards for the third of subjects with the highest level of physical activity (0.34; 95 percent confidence interval, 0.12 to 0.94; P = 0.04) and maximal oxygen uptake (0.35; 95 percent confidence interval, 0.13 to 0.92; P = 0.03), as compared with the values in the lowest third, were significantly (P < 0.05) less than 1.0. Conclusions. Higher levels of both leisure-time physical activity and cardiorespiratory fitness had a strong, graded, inverse association with the risk of acute myocardial infarction, supporting the idea that lower levels of physical activity-and cardiorespiratory fitness are independent risk factors for coronary heart disease in men.	UNIV KUOPIO, PUBL HLTH RES INST, SF-70211 KUOPIO, FINLAND; KUOPIO RES INST EXERCISE MED, KUOPIO, FINLAND; NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	University of Eastern Finland; Finland National Institute for Health & Welfare				Lakka, Timo/0000-0002-9199-2871				BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COX DR, 1972, J R STAT SOC B, V34, P187; DEBACKER G, 1981, CARDIOLOGY, V67, P110, DOI 10.1159/000173235; DIXON WJ, 1988, BMDP STATISTICAL SOF; Durnin J., 1967, ENERGY WORK LEISURE; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; Fox S M 3rd, 1972, Mod Concepts Cardiovasc Dis, V41, P25; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; HASKELL WL, 1992, MED SCI SPORT EXER, V24, pS201, DOI 10.1249/00005768-199206001-00004; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; JACOBS DR, 1993, MED SCI SPORT EXER, V25, P81, DOI 10.1249/00005768-199301000-00012; KARVONEN MJ, 1982, ANN CLIN RES, V14, P118; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LAKKA TA, 1992, INT J EPIDEMIOL, V21, P467, DOI 10.1093/ije/21.3.467; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LAKKA TA, 1993, J CLIN EPIDEMIOL, V46, P1119, DOI 10.1016/0895-4356(93)90111-D; LAKKA TA, IN PRESS AM J EPIDEM; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MALKIA E, 1988, SUOMALAISTEN AIKUIST; MORRIS JN, 1980, LANCET, V2, P1207; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SALONEN JT, 1991, AM J EPIDEMIOL, V134, P268, DOI 10.1093/oxfordjournals.aje.a116080; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, AM J EPIDEMIOL, V127, P87, DOI 10.1093/oxfordjournals.aje.a114794; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHAPER AG, 1992, BRIT HEART J, V67, P209; SHAPER AG, 1991, BRIT HEART J, V66, P384; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; TUOMILEHTO J, 1992, EUR HEART J, V13, P1153, DOI 10.1093/oxfordjournals.eurheartj.a060329; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676	42	611	619	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1549	1554		10.1056/NEJM199406023302201	http://dx.doi.org/10.1056/NEJM199406023302201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177243				2022-12-28	WOS:A1994NN21500001
J	ALLAIRE, M; CHERNAIA, MM; MALCOLM, BA; JAMES, MNG				ALLAIRE, M; CHERNAIA, MM; MALCOLM, BA; JAMES, MNG			PICORNAVIRAL 3C CYSTEINE PROTEINASES HAVE A FOLD SIMILAR TO CHYMOTRYPSIN-LIKE SERINE PROTEINASES	NATURE			English	Article							HEPATITIS-A VIRUS; MACROMOLECULAR STRUCTURES; WEISSENBERG CAMERA; DIFFRACTION DATA; CRYSTALLOGRAPHY; MUTAGENESIS; REFINEMENT; PROTEASES; PROGRAM	THE picornavirus family includes several pathogens such as poliovirus, rhinovirus (the major cause of the common cold), hepatitis A virus and the foot-and-mouth disease virus. Picornaviral proteins are expressed by direct translation of the genomic RNA into a single, large polyprotein precursor(1,2). Proteolysis of the viral polyprotein into the mature proteins is assured by the viral 3C enzymes, which are cysteine proteinases(3-6). Here we report the Xray crystal structure at 2.3 Angstrom resolution of the 3C proteinase from hepatitis A virus (HAV-3C). The overall architecture of HAV-3C reveals a fold resembling that of the chymotrypsin family of serine proteinases, which is consistent with earlier predictions(7,8). Catalytic residues include Cys 172 as nucleophile and His 44 as general base. The 3C cleavage specificity for glutamine residues is defined primarily by His 191. The overall structure suggests that an intermolecular (trans) cleavage releases 3C and that there is an active proteinase in the polyprotein.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,AB,CANADA	University of Alberta; University of Alberta; University of Alberta								ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHERNAIA MM, 1993, J MOL BIOL, V234, P890, DOI 10.1006/jmbi.1993.1636; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; FUJINAGA M, 1985, J MOL BIOL, V183, P479; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; JEWELL DA, 1992, BIOCHEMISTRY-US, V31, P7862, DOI 10.1021/bi00149a017; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KEAN KM, 1991, VIROLOGY, V181, P609, DOI 10.1016/0042-6822(91)90894-H; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1971, COLD SPRING HARB SYM, V36, P117, DOI 10.1101/SQB.1972.036.01.017; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	30	258	275	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					72	76		10.1038/369072a0	http://dx.doi.org/10.1038/369072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164744				2022-12-28	WOS:A1994NJ86000056
J	WEEKS, WB; WALLACE, AE; WALLACE, MM; WELCH, HG				WEEKS, WB; WALLACE, AE; WALLACE, MM; WELCH, HG			A COMPARISON OF THE EDUCATIONAL COSTS AND INCOMES OF PHYSICIANS AND OTHER PROFESSIONALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Efforts at physician-payment reform in the United States have focused largely on the relative incomes of primary care physicians and specialists, who more often have procedure-based practices. Comparisons of the incomes of physicians and other professional groups have received less attention. Methods. We used standard financial techniques to determine the return on educational investment over a working lifetime for five groups of professionals: primary care physicians, specialist physicians, dentists, attorneys, and graduates of business schools. Results. In current dollars, the difference in the average future hourly income between a given professional and a high-school graduate of the same age, after educational expenses are subtracted (average hours-adjusted net present value of the educational investment) was greatest for specialist physicians and attorneys; dentists and businesspeople had intermediate values; and primary care physicians had the lowest value. The annual yield on the educational investment over a working life (hours-adjusted internal rate of return) was 15.9 percent for primary care physicians, as compared with 29.0 percent for businesspeople, 25.4 percent for attorneys, 20.9 percent for specialist physicians, and 20.7 percent for dentists. A sensitivity analysis showed that primary care physicians did less well in terms of the return on investment than the other groups even when we varied the assumptions in our model widely and that specialist physicians did less well than attorneys working in law firms and dental specialists. Conclusions. Students can expect a poorer financial return on their educational investment when they choose a career in primary care medicine than when they choose a procedure-based medical or surgical specialty, business, the law, or dentistry.	DARTMOUTH COLL,SCH MED,DEPT PSYCHIAT,HANOVER,NH; DARTMOUTH COLL,SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH	Dartmouth College; Dartmouth College	WEEKS, WB (corresponding author), VET AFFAIRS MED CTR,VET AFFAIRS OUTCOMES GRP,111B,WHITE RIVER JCT,VT 05009, USA.		Weeks, WB/G-7436-2014					Becker Gary S., 1975, HUMAN CAPITAL; BOBROW J, 1991, BARRONS ED SERIES; BURSTEIN PL, 1985, J HEALTH ECON, V4, P63, DOI 10.1016/0167-6296(85)90024-4; BYRNE JA, 1990, BUSINESS WEEK   1029, P52; CURRAN B, 1988, US LEGAL PROFESSION; ECKHOLM E, 1993, NY TIMES        1107, P26; Eckholm E., 1993, NY TIMES        0328, P1; GONZALEZ ML, 1991, SOCIOECONOMIC CHARAC; HILTS PJ, 1993, NY TIMES        0401, pB9; HSIAO WC, 1992, MED CARE, V30, pNS1, DOI 10.1097/00005650-199211001-00001; HSIAO WC, 1992, MED CARE, V30, pNS61, DOI 10.1097/00005650-199211001-00006; HSIAO WC, 1988, NATIONAL STUDY RESOU; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; KROE PE, 1992, BASIC STUDENT CHARGE; LANGER S, 1992, COMPENSATION LEGAL R; LEVY JM, 1992, MED CARE, V30, pNS80, DOI 10.1097/00005650-199211001-00007; MILLER E, 1992, BARRONS ED SERIES; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SLOAN FA, 1970, IND LABOR RELAT REV, V24, P47, DOI 10.2307/2521285; WELCH HG, 1992, NEW ENGL J MED, V327, P1312, DOI 10.1056/NEJM199210293271813; 1991, DENTAL SCH TUITION S, V3; 1992, 1992 GREEN BOOK OVER, P1379; 1992, PHYSICIAN MARKETPLAC; 1991, 1991 SURVEY DENTAL P; 1991, CURRENT POPULATION P, V60; 1992, TUITION FEE MEMORAND; 1992, REAS AUTHORIATIVE GU; 1991, COUNCIL TEACHING HOS; 1992, DHHS PHS921232 NAT C; 1992, MED SCH ADMISSION RE; 1992, REAS AUTHORITATIVE G; 1991, 1991 SURVEY LAW FIRM	33	77	77	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1280	1286		10.1056/NEJM199405053301807	http://dx.doi.org/10.1056/NEJM199405053301807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	8145784				2022-12-28	WOS:A1994NJ51200007
J	DEBUSK, RF; MILLER, NH; SUPERKO, HR; DENNIS, CA; THOMAS, RJ; LEW, HT; BERGER, WE; HELLER, RS; ROMPF, J; GEE, D; KRAEMER, HC; BANDURA, A; GHANDOUR, G; CLARK, M; SHAH, RV; FISHER, L; TAYLOR, CB				DEBUSK, RF; MILLER, NH; SUPERKO, HR; DENNIS, CA; THOMAS, RJ; LEW, HT; BERGER, WE; HELLER, RS; ROMPF, J; GEE, D; KRAEMER, HC; BANDURA, A; GHANDOUR, G; CLARK, M; SHAH, RV; FISHER, L; TAYLOR, CB			A CASE-MANAGEMENT SYSTEM FOR CORONARY RISK FACTOR MODIFICATION AFTER ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; RISK FACTORS; SMOKING CESSATION; HYPERLIPIDEMIA; EXERCISE THERAPY	ARTERY DISEASE; HEART-DISEASE; FOLLOW-UP; CHOLESTEROL; EXERCISE; THERAPY; INTERVENTION; MEN; HYPERCHOLESTEROLEMIA; PROGRESSION	Objective: To evaluate the efficacy of a physician-directed, nurse-managed, home-based case-management system for coronary risk factor modification. Design: Randomized clinical trial in which patients received a special intervention (n = 293) or usual medical Care (n = 292) during the first year after acute myocardial infarction. n Setting: 5 Kaiser Permanents Medical Centers in the San Francisco Bay area. Patients: 585 men and women aged 70 years or younger who were hospitalized for acute myocardial infarction. Intervention: In the hospital, specially trained nurses initiated interventions for smoking cessation, exercise training, and diet-drug therapy for hyperlipidemia. Intervention after discharge was implemented primarily by telephone and mail contact with patients in their homes. All medically eligible patients received exercise training; all smokers received the smoking cessation intervention; and all patients received dietary counseling and, if needed, lipid-lowering drug therapy. Outcome: Smoking prevalence and plasma low-density lipoprotein cholesterol (LDL) concentrations were measured 2 months alter infarction, and functional capacity was measured 6 months after infarction. Results: In the special intervention and usual care groups, the cotinine-confirmed smoking cessation rates were 70% and 53% (P = 0.03), plasma LDL cholesterol levels were 2.77 +/- 0.69 mmol/L and 3.41 +/- 0.90 mmol/L (107 +/- 30 mg/dL and 132 +/- 30 mg/dL) (P = 0.001), and functional capacities were 9.3 +/- 2.4 METS and 8.4 +/- 2.5 METS (P = 0.001), respectively. Conclusion: In a large health maintenance organization, a case-management system was considerably more effective than usual medical care for modification of coronary risk factors after myocardial infarction.	STANFORD UNIV, SCH MED, STANFORD, CA USA; KAISER PERMANENTE MED CARE PROGRAM, SANTA CLARA, CA USA; KAISER PERMANENTE MED CARE PROGRAM, REDWOOD CITY, CA USA; KAISER PERMANENTE MED CARE PROGRAM, HAYWARD, CA USA; KAISER PERMANENTE MED CARE PROGRAM, SAN JOSE, CA USA; KAISER PERMANENTE MED CARE PROGRAM, WALNUT CREEK, CA USA; DEBORAH HEART & LUNG INST, BROWNS MILLS, NJ USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA; LAWRENCE BERKELEY LAB, BERKELEY, CA USA	Stanford University; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory				Superko, H. Robert/0000-0002-3542-0393; Thomas, Randal/0000-0003-1448-7182; Taylor, C. Barr/0000-0002-4564-6548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL038874, R01HL038874] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38874] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNVE S, 1989, J INTERN MED, V226, P297, DOI 10.1111/j.1365-2796.1989.tb01399.x; ALDERMAN EL, 1991, CIRCULATION S2, V84, P560; BANDURA A, 1986, SOCIAL FDN THOUGHT A, P393; Bandura A., 1991, SELF EFFICACY MECH P, P229, DOI DOI 10.4135/9781412952576.N182; BLAIR TP, 1988, ARCH INTERN MED, V148, P1046, DOI 10.1001/archinte.148.5.1046; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BRESLOW L, 1990, HEALTH AFFAIR, V9, P6, DOI 10.1377/hlthaff.9.2.6; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BURNS D, 1992, TOBACCO USE CALIFORN, P1; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COHEN MV, 1991, CIRCULATION, V83, P1294, DOI 10.1161/01.CIR.83.4.1294; CONNOR SL, 1989, J AM DIET ASSOC, V89, P807; DEBUSK RF, 1979, AM J CARDIOL, V44, P1223, DOI 10.1016/0002-9149(79)90433-8; DEBUSK RF, 1983, CIRCULATION, V68, P245, DOI 10.1161/01.CIR.68.2.245; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HODIS HN, 1992, MANAGEMENT ATHEROSCL, V3, P67; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; MARTIN MJ, 1986, LANCET, V2, P933; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RUSSELL ML, 1985, AM J MED, V78, P277, DOI 10.1016/0002-9343(85)90438-3; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SUPERKO HR, 1988, AM HEART J, V116, P849, DOI 10.1016/0002-8703(88)90347-X; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TAYLOR CB, 1988, AM COLLEGE SPORTS ME, P329; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; 1989, PHS DHHS898411 US DE, P11	34	557	561	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					721	729		10.7326/0003-4819-120-9-199405010-00001	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147544				2022-12-28	WOS:A1994NH25100001
J	FISHBEIN, DB; DAWSON, JE; ROBINSON, LE				FISHBEIN, DB; DAWSON, JE; ROBINSON, LE			HUMAN EHRLICHIOSIS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article						EHRLICHIOSIS; EHRLICHIA; CHLORAMPHENICOL; TETRACYCLINE; AGE FACTORS	TROPICAL CANINE PANCYTOPENIA; MOUNTAIN SPOTTED-FEVER; HUMAN INFECTION; RICKETTSIA; FEATURES; TICKS; TEXAS	Objective: To describe the epidemiology, clinical features, laboratory manifestations, response to therapy, and factors related to morbidity and mortality in a large group of patients with ehrlichiosis. Design: Case-series. Setting: Laboratory-based surveillance in the United States. Patients: 237 patients whose serum had a fourfold increase or decrease in antibodies to Ehrlichia canis or E. chaffeensis. Measurements: Epidemiologic, clinical, laboratory data, hospitalization, duration of illness, complications, and treatment response. Results: From 1985 through 1990, 237 case-patients were identified in 21 states; rates exceeded 1 per 100 000 per year in only 5 counties. Incidence rates increased with age and were higher among men. Most case-patients had nonspecific illness and were not suspected of having a rickettsial infection. Many patients (60.8%) were hospitalized. Leukocyte and platelet counts typically decreased and liver function tests typically increased through day 7. Three (6.1%) of 49 outpatients treated only with tetracycline were hospitalized compared with 35 (92%) of 38 outpatients treated only with antibiotics other than tetracycline or chloramphenicol (P < 0.001). Among hospitalized patients, recovery was faster for those initially treated with tetracycline (median, 16 days) or chloramphenicol (median, 12 days) than for those initially treated with other antibiotics (median, 27 days; P = 0.03 for both comparisons). In a logistic regression analysis, severe illness or death was more probable among case-patients 60 years or older (odds ratio [OR], 4.60; 95% Cl, 1.87 to 11.2) and among those who did not receive tetracycline or chloramphenicol until 8 or more days after symptom onset (OR, 4.38; Cl, 1.36 to 14.0). Conclusions: The findings of this!study are primarily representative of more seriously ill patients with human ehrlichiosis. Although rates are low, ehrlichiosis is found in many areas of the United States. Patients with a history of tick exposure, acute febrile illness, decreasing leukocyte counts, and decreasing platelet counts may have ehrlichiosis. Prompt treatment with tetracycline or chloramphenicol markedly decreases the morbidity.	NATL CTR INFECT DIS, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	FISHBEIN, DB (corresponding author), CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA.							ABBOTT KC, 1991, AM J HEMATOL, V38, P230, DOI 10.1002/ajh.2830380315; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BROUQUI P, 1992, 32ND INT C ANT AG CH, P394; BUHLES WC, 1974, J INFECT DIS, V130, P357, DOI 10.1093/infdis/130.4.357; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DORAN TI, 1989, J PEDIATR-US, V114, P809, DOI 10.1016/S0022-3476(89)80143-X; DUMLER JS, 1991, JAMA-J AM MED ASSOC, V266, P1365, DOI 10.1001/jama.266.10.1365; ELLISON RT, 1987, JAMA-J AM MED ASSOC, V258, P1731, DOI 10.1001/jama.258.13.1731; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; FISHBEIN DB, 1991, MANUAL CLIN MICROBIO, P1054; GOODPASTURE HC, 1978, ANN INTERN MED, V88, P303, DOI 10.7326/0003-4819-88-3-303; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; HATTWICK MAW, 1978, JAMA-J AM MED ASSOC, V240, P1499; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; HUXSOLL DL, 1976, VET PARASITOL, V2, P49, DOI 10.1016/0304-4017(76)90052-2; Kaplowitz LG., 1981, CURR CLIN TOP INFECT, V2, P108; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MCDADE JE, 1986, ANNU REV MICROBIOL, V40, P287, DOI 10.1146/annurev.mi.40.100186.001443; PEARCE CJ, 1988, AM J HEMATOL, V28, P53, DOI 10.1002/ajh.2830280111; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; ROHRBACH BW, 1990, AM J PUBLIC HEALTH, V80, P442, DOI 10.2105/AJPH.80.4.442; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; Strausbaugh L J, 1987, Hematol Oncol Clin North Am, V1, P185; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; WOODWARD TE, 1984, J INFECT DIS, V150, P465, DOI 10.1093/infdis/150.4.465; YEVICH SJ, 1991, 25TH P INT C ANT AG, P999; 1988, MMWR MORB MORTAL WKL, V37, P270; 1988, MMWR MORB MORTAL WKL, V37, P275; 1990, MMWR MORB MORTAL WKL, V39, P281	32	250	256	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					736	743		10.7326/0003-4819-120-9-199405010-00003	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147546				2022-12-28	WOS:A1994NH25100003
J	SCHULTZ, S				SCHULTZ, S			A FATHERS EYES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1146	1146						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151859				2022-12-28	WOS:A1994NF20700002
J	AFAR, DEH; GOGA, A; MCLAUGHLIN, J; WITTE, ON; SAWYERS, CL				AFAR, DEH; GOGA, A; MCLAUGHLIN, J; WITTE, ON; SAWYERS, CL			DIFFERENTIAL COMPLEMENTATION OF BCR-ABL POINT MUTANTS WITH C-MYC	SCIENCE			English	Article							V-SRC; TYROSINE KINASES; SH2; TRANSFORMATION; DOMAIN; ONCOGENE; RAS; LEUKEMIA; PROTEINS; MUTATION	A complementation strategy was developed to define the signaling pathways activated by the Bcr-Abl tyrosine kinase. Transformation inactive point mutants of Bcr-Abl were tested for complementation with c-Myc. Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Hyperexpression of c-Myc efficiently restored transformation activity only to the Bcr-Abl SH2 mutant. These data support a model in which Bcr-Abl activates at least two independent pathways for transformation. This strategy may be useful for discerning signaling pathways activated by other oncogenes.	UNIV CALIF LOS ANGELES,INST MICROBIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Sawyers, Charles/G-5327-2016		NCI NIH HHS [CA 01551, CA 53867] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001551, R35CA053867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, IN PRESS; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAWYERS C, UNPUB; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	34	185	188	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					424	426		10.1126/science.8153630	http://dx.doi.org/10.1126/science.8153630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153630				2022-12-28	WOS:A1994NG19400040
J	COLLAZO, A; FRASER, SE; MABEE, PM				COLLAZO, A; FRASER, SE; MABEE, PM			A DUAL EMBRYONIC ORIGIN FOR VERTEBRATE MECHANORECEPTORS	SCIENCE			English	Article							LATERAL-LINE SYSTEM; CARDIAC NEURAL CREST; CELLS; ZEBRAFISH; TELEOSTEI; PLACODES; XENOPUS; ABSENCE; HEART	Neuromasts, the mechanoreceptors of the lateral line system of fishes and aquatic amphibians, have previously been thought to develop exclusively from embryonic epidermal placodes. Use of fate mapping techniques shows that neuromasts of the head and body of zebrafish, Siamese fighting fish, and Xenopus are also derived from neural crest. Neural crest migrates away from the neural tube in developing vertebrates to form much of the peripheral nervous system, pigment cells, and skeletal elements of the head. The data presented here demonstrate that neuromasts are derived from both neural crest and epidermal placodes.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; CALTECH,BECKMAN INST 13974,DIV BIOL,PASADENA,CA 91125	California State University System; San Diego State University; California Institute of Technology			Fraser, Scott/Y-3406-2019; Collazo, Andres/AAW-5952-2020	Fraser, Scott/0000-0002-5377-0223; Mabee, Paula/0000-0002-8455-3213	NICHD NIH HHS [HD25138, HD26864] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025138] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atema J., 1988, SENSORY BIOL AQUATIC; Bailey SW, 1937, J EXP ZOOL, V76, P187, DOI 10.1002/jez.1400760203; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; COLLAZO A, 1993, DEVELOPMENT, V118, P363; COULY GF, 1985, DEV BIOL, V110, P422, DOI 10.1016/0012-1606(85)90101-0; FOREY P, 1993, NATURE, V361, P129, DOI 10.1038/361129a0; Hall B. K., 1988, NEURAL CREST; Harrison RG, 1904, ARCH MIKRO ANAT ENTW, V63, P35; Holtfreter Johannes, 1933, Wilhelm Roux Arch Entwickl Mech Org, V127, P619, DOI 10.1007/BF01380476; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JONES JE, 1993, J NEUROSCI, V13, P1022; KIRBY ML, 1988, CELL TISSUE RES, V252, P17; KIRBY ML, 1988, J NEUROSCI, V8, P1089; LAMERS CHJ, 1981, J EMBRYOL EXP MORPH, V62, P309; Landacre FL, 1910, J COMP NEUROL PSYCHO, V20, P309, DOI 10.1002/cne.920200404; LANDACRE FL, 1913, J COMP NEUROL, V23, P576; Le Douarin N.M., 1982, NEURAL CREST; LEKANDER BERTIL, 1949, ACTA ZOOL [STOCKHOLM], V30, P1; MABEE PM, UNPUB; METCALFE WK, 1985, J COMP NEUROL, V238, P218, DOI 10.1002/cne.902380208; METCALFE WK, 1985, J COMP NEUROL, V233, P377, DOI 10.1002/cne.902330307; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Noden D. M., 1987, DEV EVOLUTIONARY ASP, P89; NODEN DM, 1991, BRAIN BEHAV EVOLUT, V38, P190, DOI 10.1159/000114388; NODEN DM, 1988, DEVELOPMENT, V103, P121; NORTHCUTT RG, 1983, Q REV BIOL, V58, P1, DOI 10.1086/413055; NORTHCUTT RG, 1992, EVOLUTIONARY BIOLOGY OF HEARING, P21; Stone LS, 1922, J EXP ZOOL, V35, P421; Stone LS, 1937, J COMP NEUROL, V68, P83, DOI 10.1002/cne.900680105; Stone LS, 1933, J COMP NEUROL, V57, P507, DOI 10.1002/cne.900570307; STONE LS, 1931, ANAT REC, V48, P64; VISCHER HA, 1989, BRAIN BEHAV EVOLUT, V33, P205, DOI 10.1159/000115929; Westerfield M, 1993, ZEBRAFISH BOOK; WILSON HV, 1897, ANAT ANZ, V13; Wilson HVP, 1891, B US FISH COMM, V9, P209; WINKLBAUER R, 1989, PROG NEUROBIOL, V32, P181, DOI 10.1016/0301-0082(89)90016-6; WINKLBAUER R, 1985, J EMBRYOL EXP MORPH, V88, P193	37	122	125	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					426	430		10.1126/science.8153631	http://dx.doi.org/10.1126/science.8153631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153631				2022-12-28	WOS:A1994NG19400041
J	SOONPAA, MH; KOH, GY; KLUG, MG; FIELD, LJ				SOONPAA, MH; KOH, GY; KLUG, MG; FIELD, LJ			FORMATION OF NASCENT INTERCALATED DISKS BETWEEN GRAFTED FETAL CARDIOMYOCYTES AND HOST MYOCARDIUM	SCIENCE			English	Article							TRANSGENIC MICE; T-ANTIGEN; EXPRESSION; HYPERTROPHY; MYOCYTES; NEURONS; INVIVO; CELLS; GENES	Fetal cardiomyocytes isolated from transgenic mice carrying a fusion gene of the alpha-cardiac myosin heavy chain promoter with a beta-galactosidase reporter were examined for their ability to form stable intracardiac grafts. Embryonic day 15 transgenic cardiomyocytes delivered directly into the myocardium of syngeneic hosts formed stable graft, as identified by nuclear beta-galactosidase activity. Grafted cardiomyocytes were observed as long as 2 months after implantation, the latest date assayed. Intracardiac graft formation did not induce overtly negative effects on the host myocardium and was not associated with chronic immune rejection. Electron microscopy revealed the presence of nascent intercalated disks connecting the engrafted fetal cardiomyocytes and the host myocardium. These results suggest that intracardiac grafting might provide a useful approach for myocardial repair, provided that the grafted cells can contribute to myocardial function.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,1111 W 10TH ST,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis			Koh, Gou Young/C-1615-2011		NHLBI NIH HHS [HL45453] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRODSKY WY, 1980, CELL TISSUE RES, V210, P133; BULLOCK GR, 1983, TECHNIQUES IMMUNOCYT, V1, P188; CLUBB FJ, 1984, LAB INVEST, V50, P571; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GULICK J, 1991, J BIOL CHEM, V266, P9180; HOGAN B, 1986, MANIPULATING MOUSE E; KOH GY, 1993, AM J PHYSIOL, V264, pH1727, DOI 10.1152/ajpheart.1993.264.5.H1727; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; LANSON NA, 1992, CIRCULATION, V85, P1835, DOI 10.1161/01.CIR.85.5.1835; LOEWY AD, 1991, BRAIN RES, V555, P346, DOI 10.1016/0006-8993(91)90364-2; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MIKAWA T, 1992, DEV DYNAM, V195, P133, DOI 10.1002/aja.1001950208; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; RUMYANTSEV PP, 1991, GROWTH HYPERPLASIA C, P3; SOONPAA MH, UNPUB; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; UBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613	23	461	553	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					98	101		10.1126/science.8140423	http://dx.doi.org/10.1126/science.8140423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140423				2022-12-28	WOS:A1994ND53600039
J	TENDIJKE, P; YAMASHITA, H; ICHIJO, H; FRANZEN, P; LAIHO, M; MIYAZONO, K; HELDIN, CH				TENDIJKE, P; YAMASHITA, H; ICHIJO, H; FRANZEN, P; LAIHO, M; MIYAZONO, K; HELDIN, CH			CHARACTERIZATION OF TYPE-I RECEPTORS FOR TRANSFORMING GROWTH-FACTOR-BETA AND ACTIVIN	SCIENCE			English	Article							SERINE THREONINE KINASE; EXPRESSION CLONING; PROTEIN; SEQUENCE; COMPLEX; SITES	Transforming growth factor-beta (TGF-beta) and activin exert their effects by binding to heteromeric complexes of type I and type II receptors. The type II receptors for TGF-beta and activin are transmembrane serine-threonine kinases; a series of related receptors, denoted activin receptor-like kinase (ALK) 1 to 5, have recently been identified, and ALK-6 is described here. ALK-5 has been shown to be a functional TGF-beta type I receptor. A systematic analysis revealed that most ALKs formed heteromeric complexes with the type II receptors for TGF-beta and activin after overexpression in COS cells; however, among the six ALKs, only ALK-5 was a functional TGF-beta type I receptor for activation of plasminogen activator inhibitor-1, and only ALK-2 and ALK-4 bound activin with high affinity.	LUDWIG INST CANC RES,BOX 595 BIOMED CTR,S-75124 UPPSALA,SWEDEN; UNIV HELSINKI,DEPT VIROL,SF-00014 HELSINKI,FINLAND	Ludwig Institute for Cancer Research; University of Helsinki			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; RANZEN P, 1993, CELL, V75, P681; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TENDIJKE P, UNPUB; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	29	520	597	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					101	104		10.1126/science.8140412	http://dx.doi.org/10.1126/science.8140412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140412				2022-12-28	WOS:A1994ND53600040
J	HARRISON, G; MASON, P; GLAZEBROOK, C; MEDLEY, I; CROUDACE, T; DOCHERTY, S				HARRISON, G; MASON, P; GLAZEBROOK, C; MEDLEY, I; CROUDACE, T; DOCHERTY, S			RESIDENCE OF INCIDENT COHORT OF PSYCHOTIC-PATIENTS AFTER 13 YEARS OF FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM; SCHIZOPHRENIA	Objective-To establish the residential history of an incident cohort of psychotic patients 13 years after their first contact with the psychiatric services. Design-Tracing of all patients admitted to the WHO study on determinants of outcome of severe mental disorders in Nottingham between 1978 and 1980. Patients were assessed using standardised and comparable instruments, and extra information was obtained from key informants and medical records. Setting-Catchment area of Nottingham psychiatric services. Main outcome measures-Main place of residence over the previous two years and residential history over 13 years in terms of homelessness, imprisonment, and use of high dependency psychiatric facilities. Results-95 patients were traced. At the point of follow up no patients were in long stay psychiatric wards, two were in supervised residence, none was homeless, and none was in prison or a high security hospital. 85 patients were living either independently alone or with their family or friends in the community. Of these, 44 had had no contact with the psychiatric services at the point of follow up. Conclusions-Although many patients experienced a difficult early course of illness, the longer term outcome of the disorder was associated with remarkably low periods of homelessness and imprisonment and low use of intensive care facilities. These findings offer some reassurance, given the concerns about the effectiveness of community oriented care for this potentially most vulnerable group of psychiatric patients.	UNIV NOTTINGHAM,DEPT PSYCHOL,NOTTINGHAM NG7 2RD,ENGLAND; ROYAL LIVERPOOL HOSP,DEPT PSYCHIAT,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND; MANDALA CTR,NOTTINGHAM,ENGLAND	University of Nottingham; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	HARRISON, G (corresponding author), UNIV NOTTINGHAM HOSP,DEPT PSYCHIAT,NOTTINGHAM NG7 2UH,ENGLAND.		Croudace, Tim/ABC-9681-2021	Croudace, Tim/0000-0001-8346-7463; Glazebrook, Cristine/0000-0002-7459-9445				BLEULER E, 1950, DEMENTIA PAECOX GROU; Bleuler M., 1978, SCHIZOPHRENIC DISORD; CIOMPI L, 1980, SCHIZOPHRENIA BULL, V6, P606, DOI 10.1093/schbul/6.4.606; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; HARDING CM, 1987, AM J PSYCHIAT, V144, P727; HARRISON G, 1993, BRIT J PSYCHIAT, V163, P535, DOI 10.1192/bjp.163.4.535; Jablensky A, 1992, PSYCHOL MED S20; KRAEPELIN E, 1913, PSYCHIATRIE EIN LEHR; LAMB HR, 1990, HOSP COMMUNITY PSYCH, V41, P301; SUNDQVISTSTENSMAN UB, 1987, ACTA PSYCHIAT SCAND, V76, P15, DOI 10.1111/j.1600-0447.1987.tb02856.x; TSUANG MT, 1978, ARCH GEN PSYCHIAT, V35, P153; TYRER P, 1989, BRIT MED J, V299, P298, DOI 10.1136/bmj.299.6694.298; WELLER M, 1989, LANCET, V2, P1509; ZUBIN J, 1983, PSYCHOL MED, V13, P551, DOI 10.1017/S003329170004798X; 1992, LIFE CHART SCHEDULE	16	22	22	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					813	816		10.1136/bmj.308.6932.813	http://dx.doi.org/10.1136/bmj.308.6932.813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND243	8167487	Green Published			2022-12-28	WOS:A1994ND24300018
J	DIXON, J				DIXON, J			CAN THERE BE FAIR FUNDING FOR FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Most regional health authorities set budgets for fundholding practices according to the amount of care used by the practice population. This article explains why this funding method can only lead to an inequitable allocation of resources between fundholding and non-fundholding practices. Using the experience of North West Thames region, the efforts made to make funding fairer are discussed. The steps that health authorities could take to investigate and reduce the problem are also outlined. In the absence of a capitation formula for funding fundholding practices, the paper suggests that health authorities should do much more to investigate the amount of money they spend on non-fundholding practices. Regions could develop and use other methods to set budgets rather than rely on activity recorded by practices. Regions and the Department of Health should resolve urgently if and how far the budgets for fundholders should be compensated for increases in provider prices.			DIXON, J (corresponding author), LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; GLEN, 1992, 12 KINGS FUND I RES; MCAVOY BR, 1993, BRIT MED J, V306, P694, DOI 10.1136/bmj.306.6879.694; MIHIL C, 1993, GUARDIAN        1010, P5; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; Reeves C, 1993, Health Serv J, V103, P28; 1991, NHSME EL9136; 1993, HLTH SERVICES J, V103, P3; 1993, NHSME EL9283; 1989, WORKING PATIENTS; 1993, REPORT ACCOUNTS	12	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					772	775		10.1136/bmj.308.6931.772	http://dx.doi.org/10.1136/bmj.308.6931.772			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142835	Green Published			2022-12-28	WOS:A1994NC34800027
J	BASLER, K; STRUHL, G				BASLER, K; STRUHL, G			COMPARTMENT BOUNDARIES AND THE CONTROL OF DROSOPHILA LIMB PATTERN BY HEDGEHOG PROTEIN	NATURE			English	Article							SEGMENT-POLARITY GENE; CELL-CELL COMMUNICATION; FACTOR-BETA FAMILY; ENGRAILED EXPRESSION; IMAGINAL DISKS; POSTERIOR COMPARTMENTS; DECAPENTAPLEGIC GENE; GERM LAYERS; MELANOGASTER; WINGLESS	Drosophila limbs are subdivided into anterior and posterior compartments which derive from adjacent cell populations founded early in development. Evidence is now provided that posterior cells organize growth and cell patterning in both compartments by secreting hedgehog protein and that hedgehog protein acts indirectly by inducing neighbouring anterior cells to secrete decapentaplegic or wingless protein.	COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	BASLER, K (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529				ANDERSON R, 1993, DEVELOPMENT, V117, P1421; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; CABRERA CV, 1987, CELL, V50, P569; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1975, GENETIC CONTROL WING; GOLIC K, 1981, SCIENCE, V252, P958; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOAZED D, 1992, DEVELOPMENT, V116, P805; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1981, DEV BIOL, V84, P372, DOI 10.1016/0012-1606(81)90406-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VOGEL A, 1993, DEVELOPMENT, V119, P199; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	72	762	784	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 17	1994	368	6468					208	214		10.1038/368208a0	http://dx.doi.org/10.1038/368208a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145818				2022-12-28	WOS:A1994NA87000045
J	GROVES, T				GROVES, T			COMMUNITY CARE - THE FIRST YEAR - COMMUNITY CARE IN BASSETLAW .1.	BRITISH MEDICAL JOURNAL			English	Article								Last April the United Kingdom's system for providing community care-practical and social care for ill and disabled people who need help with daily life-was changed in an effort to make it better and more efficient.(1) The BMJ ran a series of articles about the changes that included descriptions of community care in four places: Gwent in Wales, Bassetlaw in Nottinghamshire, Northern Ireland, and Newcastle in north east England.(2-5) In this and the next three articles we look at what has happened to community care over the past year in these places.					Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				GROVES T, 1993, BRIT MED J, V306, P132, DOI 10.1136/bmj.306.6870.132; ROBINSON R, 1993, BRIT MED J, V306, P44, DOI 10.1136/bmj.306.6869.44; SMITH J, 1993, BRIT MED J, V306, P566, DOI 10.1136/bmj.306.6877.566; THORNICROFT G, 1993, BRIT MED J, V306, P768, DOI 10.1136/bmj.306.6880.768; TONKS A, 1993, BRIT MED J, V306, P262, DOI 10.1136/bmj.306.6872.262; 1990, GC9023LASSL9011 DEP	6	3	3	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					708	711		10.1136/bmj.308.6930.708	http://dx.doi.org/10.1136/bmj.308.6930.708			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142799	Green Published			2022-12-28	WOS:A1994NA86900027
J	HALL, WA; LUCIANO, MG; DOPPMAN, JL; PATRONAS, NJ; OLDFIELD, EH				HALL, WA; LUCIANO, MG; DOPPMAN, JL; PATRONAS, NJ; OLDFIELD, EH			PITUITARY MAGNETIC-RESONANCE-IMAGING IN NORMAL HUMAN VOLUNTEERS - OCCULT ADENOMAS IN THE GENERAL-POPULATION	ANNALS OF INTERNAL MEDICINE			English	Article						ADENOMA; PITUITARY NEOPLASMS; MAGNETIC RESONANCE IMAGING; GADOLINIUM; CUSHINGS SYNDROME	SECRETING MICROADENOMAS; CUSHING DISEASE; GLAND; APPEARANCE; EXPERIENCE; 1.5-T; AGE	Objective: To determine the prevalence of focal lesions of the pituitary gland that suggest the presence of a pituitary adenoma in asymptomatic persons. Design: 100 normal volunteers (70 women, 30 men; age range, 18 to 60 years old) were studied by high-resolution magnetic resonance imaging (MRI) of the pituitary gland before and after administration of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA). Setting: Occult pituitary adenomas are identified at autopsy in 3% to 27% of unselected asymptomatic patients. The frequency of incidental pituitary adenomas detected by MRI in normal persons is unknown. Measurements: The MRI scans from volunteers were randomly mixed with scans of 57 patients with Cushing disease and interpreted independently by three blinded reviewers. Results: Seven women (10%) and three men (10%) had focal areas of decreased signal intensity in the pituitary gland after administration of Gd-DTPA. The lesions ranged from 3 to 6 mm in greatest diameter and were diagnosed as pituitary adenomas by at least two of the three reviewers. When similar lesions were detected on MRI scans in patients with Cushing disease, the positive predictive value for identification of an adenoma at that site was 86%. Conclusions: About 10% of the normal adult population have pituitary abnormalities on MRI scans that are compatible with the diagnosis of asymptomatic pituitary adenomas. Most pituitary adenomas remain asymptomatic and do not require treatment.	NIH, CTR CLIN, SURG NEUROL BRANCH, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT DIAGNOST RADIOL, BETHESDA, MD 20892 USA; NINCDS, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								AHMADI H, 1990, RADIOLOGY, V177, P389, DOI 10.1148/radiology.177.2.2217774; BROWN SB, 1983, NEURORADIOLOGY, V24, P259, DOI 10.1007/BF00333177; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; CHAMBERS EF, 1982, RADIOLOGY, V144, P109, DOI 10.1148/radiology.144.1.7089241; Costello RT, 1936, AM J PATHOL, V12, P205; DAVIS PC, 1985, AM J NEURORADIOL, V6, P711; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; ELSTER AD, 1990, RADIOLOGY, V174, P681, DOI 10.1148/radiology.174.3.2305049; FINDLING JW, 1991, J CLIN ENDOCR METAB, V73, P408, DOI 10.1210/jcem-73-2-408; GOLD EB, 1981, EPIDEMIOL REV, V3, P163, DOI 10.1093/oxfordjournals.epirev.a036232; HEMMINGHYTT S, 1983, RADIOLOGY, V146, P65, DOI 10.1148/radiology.146.1.6294733; KAUFMAN B, 1987, J LAB CLIN MED, V109, P308; KULKARNI MV, 1988, AM J NEURORADIOL, V9, P5; LURIE SN, 1990, J CLIN ENDOCR METAB, V71, P505, DOI 10.1210/jcem-71-2-505; MUHR C, 1981, NEURORADIOLOGY, V21, P55, DOI 10.1007/BF00342982; NEWTON DR, 1989, AM J NEURORADIOL, V10, P949; PARENT AD, 1981, J NEUROSURG, V54, P228, DOI 10.3171/jns.1981.54.2.0228; PECK WW, 1989, AM J ROENTGENOL, V152, P145, DOI 10.2214/ajr.152.1.145; PEYSTER RG, 1983, AM J NEURORADIOL, V4, P411; SARIS SC, 1987, RADIOLOGY, V162, P775, DOI 10.1148/radiology.162.3.3809493; SWANSON HA, 1975, BRIT J RADIOL, V48, P366, DOI 10.1259/0007-1285-48-569-366; SWARTZ JD, 1983, RADIOLOGY, V147, P115, DOI 10.1148/radiology.147.1.6828714; WILSON CB, 1984, J NEUROSURG, V61, P814, DOI 10.3171/jns.1984.61.5.0814; WOLPERT SM, 1984, AM J ROENTGENOL, V143, P377, DOI 10.2214/ajr.143.2.377	26	406	425	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					817	820		10.7326/0003-4819-120-10-199405150-00001	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154641				2022-12-28	WOS:A1994NK45800001
J	BISSET, AF; RUSSELL, D				BISSET, AF; RUSSELL, D			GROMMETS, TONSILLECTOMIES, AND DEPRIVATION IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							GLUE EAR; SURGERY	Objective-To see whether there is a relation between grommet insertion operation and tonsillectomy rates, otolaryngology services, and deprivation scores in Scotland. Design-Analysis of routine 1990 NHS data on grommet insertions and tonsillectomies in Scottish children aged 0-15 years compared with data on general practitioner and otolaryngology services and Carstairs deprivation scores. Setting-All 15 Scottish health boards. Subjects-All children aged 0-15 (1 021 933). Results-Tonsillectomy was more common than grommet insertion operations in Scotland (6182:4850). Health boards with high grommet insertion rates were more likely to have low tonsillectomy rates (Spearman's rank correlation -0.59; 95% confidence interval -0.87 to -0.03). Grommet insertion rates varied fourfold (from 2.4/1000 to 9.2/1000) and tonsillectomy rates twofold (from 3.6/1000 to 8.0/1000) across Scottish health boards. Variation between health boards had changed over the 15 years 1975-90. Variation in grommet insertion rates did not reflect variation in the supply of otolaryngology consultants (Spearman's rank correlation -0.25). There was a non-significant tendency for high general practitioner referral rates to be associated with high grommet insertion rates, low tonsillectomy rates, and less deprived areas (Spearman's rank correlation coefficients 0.50, -0.53, and -0.43). Deprivation (measured by Carstairs scoring for each health board) was associated with higher tonsillectomy rates (Spearman's rank correlation 0.41; 95% confidence interval -0.22 to 0.80) and significantly lower grommet insertion rates (-0.73; -0.92 to -0.28). Conclusion-Social factors as well as differences in disease prevalence and medical practice need to be considered when studying variation in childhood grommet insertion and tonsillectomy rates.	UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN,SCOTLAND	University of Aberdeen	BISSET, AF (corresponding author), GRAMPIAN AREA HLTH BOARD,DEPT PUBL HLTH MED,SUMMERFIELD HOUSE,2 EDAY RD,ABERDEEN AB9 1RE,SCOTLAND.							BAIN DJG, 1981, BRIT MED J, V283, P585, DOI 10.1136/bmj.283.6291.585; BISSET AF, 1993, BRIT MED J, V306, P454, DOI 10.1136/bmj.306.6875.454-c; BISSET AF, 1993, LANCET, V341, P57; BISSET AF, 1993, CLIN OTOLARYNGOL, V18, P430, DOI 10.1111/j.1365-2273.1993.tb00608.x; BLACK N, 1984, LANCET, V1, P835; BLACK N, 1985, INT J EPIDEMIOL, V14, P594, DOI 10.1093/ije/14.4.594; BLAXTER M, 1981, MOTHERS DAUGHTERS; BLOOR M, 1976, SOCIOLOGY, V10, P43, DOI 10.1177/003803857601000103; BLOOR MJ, 1978, 2 U AB I MED SOC OCC; Carstairs V., 1991, DEPRIVATION HLTH SCO; COULTER A, 1985, BRIT MED J, V291, P183, DOI 10.1136/bmj.291.6489.183; CURRIE E, 1992, 5 HLTH EC CONS OCC P; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; GARDNER MJ, 1989, STATISTICS CONFIDENC; SCHILDER AGM, 1992, EUR ARCH OTO-RHINO-L, V249, P370, DOI 10.1007/BF00192256; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; SMITH IM, 1991, CLIN OTOLARYNGOL, V16, P266, DOI 10.1111/j.1365-2273.1991.tb00927.x; VENTERS GA, 1974, BRIT J PREV SOC MED, V28, P1; WENNBERG JE, 1982, SCI AM, V246, P100; 1990, SPSS PC PLUS; 1992, U LEEDS B, V4; 1990, LANCET, V336, P23; 1992, LANCET, V340, P1324	23	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1129	1132		10.1136/bmj.308.6937.1129	http://dx.doi.org/10.1136/bmj.308.6937.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173453	Green Published			2022-12-28	WOS:A1994NK18200017
J	LONBERG, N; TAYLOR, LD; HARDING, FA; TROUNSTINE, M; HIGGINS, KM; SCHRAMM, SR; KUO, CC; MASHAYEKH, R; WYMORE, K; MCCABE, JG; MUNOZOREGAN, D; ODONNELL, SL; LAPACHET, ESG; BENGOECHEA, T; FISHWILD, DM; CARMACK, CE; KAY, RM; HUSZAR, D				LONBERG, N; TAYLOR, LD; HARDING, FA; TROUNSTINE, M; HIGGINS, KM; SCHRAMM, SR; KUO, CC; MASHAYEKH, R; WYMORE, K; MCCABE, JG; MUNOZOREGAN, D; ODONNELL, SL; LAPACHET, ESG; BENGOECHEA, T; FISHWILD, DM; CARMACK, CE; KAY, RM; HUSZAR, D			ANTIGEN-SPECIFIC HUMAN-ANTIBODIES FROM MICE COMPRISING 4 DISTINCT GENETIC MODIFICATIONS	NATURE			English	Article							CELL-SPECIFIC ENHANCER; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN; RECOMBINATION; REJECTION; LOCUS	HUMAN sequence monoclonal antibodies, which in theory combine high specificity with low immunogenicity, represent a class of potential therapeutic agents. But nearly 20 years after Kohler and Milstein first developed methods for obtaining mouse antibodies(1), no comparable technology exists for reliably obtaining high-affinity human antibodies directed against selected targets. Thus, rodent antibodies(2), and in vitro modified derivatives of rodent antibodies(3-5), are still being used and tested in the clinic. The rodent system has certain clear advantages; mice are easy to immunize, are not tolerant to most human antigens, and their B cells form stable hybridoma cell lines. To exploit these advantages, we have developed transgenic mice that express human IgM, IgG and Ig kappa in the absence of mouse IgM or Ig kappa. We report here that these mice contain human sequence transgenes that undergo V(D)J joining, heavy-chain class switching, and somatic mutation to generate a repertoire of human sequence immunoglobulins. They are also homozygous for targeted mutations that disrupt V(D)J rearrangement at the endogenous heavy- and kappa light-chain loci. We have immunized the mice with human proteins and isolated hybridomas secreting human IgG kappa antigen-specific antibodies.	GENPHARM INT,MT VIEW,CA 94043									CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; HOGAN B, 1986, METHODS MANIPULATING; HYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MOREL P, 1992, CLIN IMMUNOL IMMUNOP, V64, P248, DOI 10.1016/0090-1229(92)90207-5; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PIEPER FR, 1992, NUCLEIC ACIDS RES, V20, P1259, DOI 10.1093/nar/20.6.1259; QUEEN C, 1991, NATURE, V351, P501; TAYLOR LD, 1994, INT IMMUNOL, V6, P579, DOI 10.1093/intimm/6.4.579; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; WALDMANN TA, 1992, ANNU REV IMMUNOL, V10, P675, DOI 10.1146/annurev.immunol.10.1.675; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	18	268	1264	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					856	859		10.1038/368856a0	http://dx.doi.org/10.1038/368856a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159246				2022-12-28	WOS:A1994NH71700072
J	BENGTSON, A; HERLITZ, J; KARLSSON, T; BRANDRUPWOGNSEN, G; HJALMARSON, A				BENGTSON, A; HERLITZ, J; KARLSSON, T; BRANDRUPWOGNSEN, G; HJALMARSON, A			THE APPROPRIATENESS OF PERFORMING CORONARY ANGIOGRAPHY AND CORONARY-ARTERY REVASCULARIZATION IN A SWEDISH POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS-SURGERY; FOLLOW-UP; SURVIVAL	Objective.-To evaluate the appropriateness of performing coronary angiography and revascularization in a Swedish population. Design.-Prospective population study of questionnaires and medical records. Setting.-All the hospitals in southwestern Sweden that perform coronary angiography and revascularization. Patients.-Random sample of 831 patients (with chronic stable angina) on the waiting list for coronary angiography or revascularization in southwestern Sweden in September 1990. Main Outcome Measure.-Percentage of patients referred for coronary angiography or revascularization for appropriate, uncertain, or inappropriate indications. Results.-Of the patients referred for angiography, 89% were classified as appropriate, 9% as uncertain, and 2% as inappropriate. The percentages are similar for patients referred for coronary artery bypass graft surgery and for angioplasty (91% and 86%, respectively, classified as appropriate). The majority of patients had chest pain rated as Canadian Cardiovascular Society classes II through IV (93%), despite maximum anti-ischemic therapy in 90% of these patients.	GOTHENBURG UNIV,DEPT HEART & LUNG DIS,WALLENBERG LAB,DIV CARDIOL,GOTHENBURG,SWEDEN; UNIV GOTHENBURG,GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; [Anonymous], 1982, LANCET, V2, P1173; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BROOK RH, 1988, LANCET, V1, P750; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1983, CIRCULATION, V68, P939; 1991, VITAL HLTH STAT 108, P13; 1984, NEW ENGL J MED, V311, P1333	13	43	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1260	1265		10.1001/jama.271.16.1260	http://dx.doi.org/10.1001/jama.271.16.1260			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	8151901				2022-12-28	WOS:A1994NG36200026
J	EVANS, TC; CRITTENDEN, SL; KODOYIANNI, V; KIMBLE, J				EVANS, TC; CRITTENDEN, SL; KODOYIANNI, V; KIMBLE, J			TRANSLATIONAL CONTROL OF MATERNAL GLP-1 MESSENGER-RNA ESTABLISHES AN ASYMMETRY IN THE C-ELEGANS EMBRYO	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYO; CELL-INTERACTIONS; CYTOPLASMIC LOCALIZATION; PATTERN-FORMATION; BODY PATTERN; GERM-LINE; NOTCH; PROTEIN	In C. elegans, the glp-1 gene encodes a membrane receptor that is required for anterior cell fates in the early embryo. We report that GLP-1 protein is focalized to anterior blastomeres in 2- to 28-cell embryos. By contrast, glp-1 mRNA is present in all blastomeres until the 8-cell stage. Furthermore, the glp-1 3' untranslated region can restrict translation of a reporter mRNA to anterior blastomeres. Therefore, the translation of maternal glp-1 mRNA is temporally and spatially regulated in the C. elegans embryo. The regulation of maternal glp-1 mRNA has striking parallels to the regulation of maternal hunchback mRNA in the Drosophila embryo. Thus, the establishment of embryonic asymmetry in diverse organisms may involve conserved mechanisms of maternal mRNA regulation.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	EVANS, TC (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA.							AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evans T.C., 1992, Seminars in Developmental Biology, V3, P381; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; MACLEOD AR, 1977, J MOL BIOL, V114, P133, DOI 10.1016/0022-2836(77)90287-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MORTON DG, 1992, GENETICS, V130, P771; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; ROUSSELL DL, 1993, P NATL ACAD SCI USA, V90, P9300, DOI 10.1073/pnas.90.20.9300; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	58	198	201	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					183	194		10.1016/0092-8674(94)90311-5	http://dx.doi.org/10.1016/0092-8674(94)90311-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168128				2022-12-28	WOS:A1994NH63400004
J	HEMMATIBRIVANLOU, A; MELTON, DA				HEMMATIBRIVANLOU, A; MELTON, DA			INHIBITION OF ACTIVIN RECEPTOR SIGNALING PROMOTES NEURALIZATION IN XENOPUS	CELL			English	Article							NEURAL DIFFERENTIATION; NERVOUS-SYSTEM; MESSENGER-RNA; HOMEO PROTEIN; VEGETAL POLE; BODY AXIS; EMBRYOS; LAEVIS; EXPRESSION; INDUCTION	Expression of a truncated activin type II receptor, which blocks signaling by activin, neuralizes explants of embryonic cells that would otherwise become epidermal cells. This neuralization is direct and does not require the presence of mesoderm. The induced neural tissue expresses general molecular markers of the central nervous system as well as an array of neural markers along the anteroposterior axis. In the context of the whole embryo, expression of this truncated activin receptor diverts prospective ectoderm and endoderm to a neural fate. We propose that inhibition of the activin type II receptor signaling causes the cells of Xenopus embryos to adopt a neural fate. These results, along with previous experiments performed in Drosophila, suggest that the formation of the nervous system in vertebrates and invertebrates occurs by a common strategy.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; FERREIRO B, 1993, MECH DEVELOP, V40, P25, DOI 10.1016/0925-4773(93)90085-C; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GRUNZ H, 1990, CELL DIFFER DEV, V32, P117, DOI 10.1016/0922-3371(90)90105-6; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, IN PRESS ENDOCRINE R; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MALACINSKI G, 1975, DEV BIOL, V56, P24; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1990, ANAT EMBRYOL, V182, P347, DOI 10.1007/BF02433495; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAHA MS, 1993, MOL BRAIN RES, V17, P307, DOI 10.1016/0169-328X(93)90016-I; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	54	373	382	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					273	281		10.1016/0092-8674(94)90319-0	http://dx.doi.org/10.1016/0092-8674(94)90319-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168134				2022-12-28	WOS:A1994NH63400012
J	MAGNUSON, R; SOLOMON, J; GROSSMAN, AD				MAGNUSON, R; SOLOMON, J; GROSSMAN, AD			BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF A COMPETENCE PHEROMONE FROM BACILLUS-SUBTILIS	CELL			English	Article							SIGNAL TRANSDUCTION SYSTEM; BACILLUS-SUBTILIS; MYXOCOCCUS-XANTHUS; REGULATORY GENE; OLIGOPEPTIDE PERMEASE; SURFACTIN PRODUCTION; NUCLEOTIDE-SEQUENCE; SPORULATION; COMA; PROTEIN	We have purified and characterized a modified peptide pheromone that accumulates in culture medium as B. subtilis grows to high density. This pheromone is required for the development of genetic competence. When added to cells at low density, the pheromone induces the premature development of competence. The peptide moiety of the pheromone matches nine of the last ten amino acids predicted from a 55 codon open reading frame, comX. comX and comQ, the gene immediately upstream of comX, are required for production of the pheromone. Response to the pheromone requires the comP-comA two-component regulatory system and the oligopeptide permease encoded by spoOK. SpoOK could transport the pheromone into the cell, or function as a receptor, binding the pheromone and sending a transmembrane signal, leading to activation of the ComA transcription factor and induction of competence development.			MAGNUSON, R (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCRR NIH HHS [RR00317] Funding Source: Medline; NIGMS NIH HHS [GM41934] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKRIGG A, 1970, BIOCHEM J, V117, P397, DOI 10.1042/bj1170397; AKRIGG A, 1967, BIOCHEM BIOPH RES CO, V28, P1062, DOI 10.1016/0006-291X(67)90090-3; ALBANO M, 1989, J BACTERIOL, V171, P5386, DOI 10.1128/jb.171.10.5386-5404.1989; ALBANO M, 1989, J BACTERIOL, V171, P5376, DOI 10.1128/jb.171.10.5376-5385.1989; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CLEWELL DB, 1993, CELL, V73, P9, DOI 10.1016/0092-8674(93)90153-H; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; COX GB, 1989, J BACTERIOL, V171, P1531, DOI 10.1128/jb.171.3.1531-1534.1989; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; Davis R., 1980, ADV BACTERIAL GENETI; DSOUZA C, 1993, J BACTERIOL, V175, P3502, DOI 10.1128/jb.175.11.3502-3510.1993; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; DUBNAU D, 1991, SEMIN DEV BIOL, V2, P3; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; GROSSMAN AD, 1988, P NATL ACAD SCI USA, V85, P4369, DOI 10.1073/pnas.85.12.4369; GROSSMAN AD, 1991, SEMIN DEV BIOL, V2, P31; HAHN J, 1991, J BACTERIOL, V173, P7275, DOI 10.1128/jb.173.22.7275-7282.1991; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HUI FM, 1991, J BACTERIOL, V173, P372, DOI 10.1128/jb.173.1.372-381.1991; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; ITAYA M, 1989, NUCLEIC ACIDS RES, V17, P4410, DOI 10.1093/nar/17.11.4410; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; JOENJE H, 1972, BIOCHIM BIOPHYS ACTA, V262, P189, DOI 10.1016/0005-2787(72)90232-8; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KAPLAN HB, 1991, J BACTERIOL, V173, P1460, DOI 10.1128/jb.173.4.1460-1470.1991; KIM SK, 1992, ANNU REV MICROBIOL, V46, P117, DOI 10.1146/annurev.mi.46.100192.001001; KIM SK, 1990, P NATL ACAD SCI USA, V87, P3635, DOI 10.1073/pnas.87.10.3635; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; KUSPA A, 1992, J BACTERIOL, V174, P3319, DOI 10.1128/jb.174.10.3319-3326.1992; LACKS S, 1973, J BACTERIOL, V114, P152; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Miller J.H., 1972, EXPT MOL GENETICS; MITANI T, 1977, BIOCHEM BIOPH RES CO, V77, P1118, DOI 10.1016/S0006-291X(77)80094-6; MSADEK T, 1991, J BACTERIOL, V173, P2366, DOI 10.1128/JB.173.7.2366-2377.1991; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P1770, DOI 10.1128/jb.173.5.1770-1778.1991; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; NAKANO MM, 1991, J BACTERIOL, V173, P7269, DOI 10.1128/jb.173.22.7269-7274.1991; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; RHIE HG, 1989, J BACTERIOL, V171, P3268, DOI 10.1128/jb.171.6.3268-3276.1989; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; ROGGIANI M, 1990, J BACTERIOL, V172, P4056, DOI 10.1128/jb.172.7.4056-4063.1990; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; RUHFEL RE, 1993, J BACTERIOL, V175, P5253, DOI 10.1128/JB.175.16.5253-5259.1993; SADAIE Y, 1983, J BACTERIOL, V153, P813, DOI 10.1128/JB.153.2.813-821.1983; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SHIMKETS LJ, 1990, J BACTERIOL, V172, P5299, DOI 10.1128/jb.172.9.5299-5306.1990; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEED PM, 1993, J BACTERIOL, V175, P6797, DOI 10.1128/jb.175.21.6797-6809.1993; TANIMOTO K, 1993, J BACTERIOL, V175, P5260, DOI 10.1128/JB.175.16.5260-5264.1993; TOMASZ A, 1966, P NATL ACAD SCI USA, V55, P58, DOI 10.1073/pnas.55.1.58; TOMASZ A, 1964, P NATL ACAD SCI USA, V51, P480, DOI 10.1073/pnas.51.3.480; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; VANSINDEREN D, 1990, MOL GEN GENET, V224, P396, DOI 10.1007/BF00262434; VANSINDEREN D, 1993, MOL MICROBIOL, V8, P833; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; WALDBURGER C, 1993, J BACTERIOL, V175, P6321, DOI 10.1128/JB.175.19.6321-6327.1993; WEINRAUCH Y, 1989, J BACTERIOL, V171, P5362, DOI 10.1128/jb.171.10.5362-5375.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; WEINRAUCH Y, 1991, J BACTERIOL, V173, P5685, DOI 10.1128/jb.173.18.5685-5693.1991; YANG M, 1986, J BACTERIOL, V166, P133; YOUNGMAN P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P65	73	369	382	1	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					207	216		10.1016/0092-8674(94)90313-1	http://dx.doi.org/10.1016/0092-8674(94)90313-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168130				2022-12-28	WOS:A1994NH63400006
J	ABBOTT, A				ABBOTT, A			BASF OPENS BIOTECH LABORATORY IN THE US	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					679	679		10.1038/368679b0	http://dx.doi.org/10.1038/368679b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152473	Bronze			2022-12-28	WOS:A1994NG55300013
J	NIKAIDO, H				NIKAIDO, H			PREVENTION OF DRUG ACCESS TO BACTERIAL TARGETS - PERMEABILITY BARRIERS AND ACTIVE EFFLUX	SCIENCE			English	Article							BETA-LACTAM ANTIBIOTICS; ESCHERICHIA-COLI K-12; OUTER-MEMBRANE PERMEABILITY; ENERGY-DEPENDENT EFFLUX; NONENZYMATIC CHLORAMPHENICOL RESISTANCE; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; TETRACYCLINE RESISTANCE; CELL-WALL; ANTIMICROBIAL RESISTANCE	Some species of bacteria have low-permeability membrane barriers and are thereby ''intrinsically'' resistant to many antibiotics; they are selected out in the multitude of antibiotics present in the hospital environment and thus cause many hospital-acquired infections. Some strains of originally antibiotic-susceptible species may also acquire resistance through decreases in the permeability of membrane barriers. Another mechanism for preventing access of drugs to targets is the membrane-associated energy-driven efflux, which plays a major role in drug resistance, especially in combination with the permeation barrier. Recent results indicate the existence of bacterial efflux-systems of extremely broad substrate specificity, in many ways reminiscent of the multidrug resistance pump of mammalian cells. One such system seems to play a major role in the intrinsic resistance of Pseudomonas aeruginosa, a common opportunistic pathogen. As the pharmaceutical industry succeeds in producing agents that can overcome specific mechanisms of bacterial resistance, less specific resistance mechanisms such as permeability barriers and multidrug active efflux may become increasingly significant in the clinical setting.			NIKAIDO, H (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.				NIAID NIH HHS [AI-09644, AI-33702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R01AI033702, R37AI009644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIZA RR, 1994, J BACTERIOL, V176, P143, DOI 10.1128/JB.176.1.143-148.1994; BELLIDO F, 1992, J BACTERIOL, V174, P5196, DOI 10.1128/JB.174.16.5196-5203.1992; BISSONNETTE L, 1991, J BACTERIOL, V173, P4493, DOI 10.1128/JB.173.14.4493-4502.1991; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRYAN LE, 1977, ANTIMICROB AGENTS CH, V12, P163, DOI 10.1128/AAC.12.2.163; BURNS JL, 1986, ANTIMICROB AGENTS CH, V29, P445, DOI 10.1128/AAC.29.3.445; BURNS JL, 1985, ANTIMICROB AGENTS CH, V27, P46, DOI 10.1128/AAC.27.1.46; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; COHEN SP, 1988, ANTIMICROB AGENTS CH, V32, P1187, DOI 10.1128/AAC.32.8.1187; COHEN SP, 1989, ANTIMICROB AGENTS CH, V33, P1318, DOI 10.1128/AAC.33.8.1318; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, pCH2; CURTIS NAC, 1985, J ANTIMICROB CHEMOTH, V15, P642, DOI 10.1093/jac/15.5.642; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; EDSALL JT, 1958, BIOPHYS CHEM, V1, pCH9; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FURET YX, 1992, ANTIMICROB AGENTS CH, V36, P2506, DOI 10.1128/AAC.36.11.2506; GEORGE AM, 1983, J BACTERIOL, V155, P541, DOI 10.1128/JB.155.2.541-548.1983; GEORGE AM, 1983, J BACTERIOL, V155, P531, DOI 10.1128/JB.155.2.531-540.1983; GILLESPIE MT, 1986, MICROBIOL SCI, V3, P53; GOLDMAN RC, 1990, ANTIMICROB AGENTS CH, V34, P1973, DOI 10.1128/AAC.34.10.1973; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HANCOCK REW, 1990, MOL MICROBIOL, V4, P1069, DOI 10.1111/j.1365-2958.1990.tb00680.x; IYER R, 1978, FEBS LETT, V85, P127, DOI 10.1016/0014-5793(78)81263-0; JAFFE A, 1983, ANTIMICROB AGENTS CH, V23, P622, DOI 10.1128/AAC.23.4.622; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEWIS K, IN PRESS TRENDS BIOC; Li X., UNPUB; LIVERMORE DM, 1991, ANTIMICROB AGENTS CH, V35, P916, DOI 10.1128/AAC.35.5.916; LIVERMORE DM, 1987, J INFECT DIS, V155, P775, DOI 10.1093/infdis/155.4.775; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MA ZY, COMMUNICATION; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MCMURRY LM, 1983, ANTIMICROB AGENTS CH, V24, P544, DOI 10.1128/AAC.24.4.544; MCMURRY LM, 1987, ANTIMICROB AGENTS CH, V31, P1648, DOI 10.1128/AAC.31.10.1648; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; NAKAE T, 1975, J BIOL CHEM, V250, P7359; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; NIKAIDO H, 1990, J BACTERIOL, V172, P1361, DOI 10.1128/jb.172.3.1361-1367.1990; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1991, RES MICROBIOL, V142, P437, DOI 10.1016/0923-2508(91)90117-S; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NIKAIDO H, 1987, MOL MICROBIOL, V1, P29, DOI 10.1111/j.1365-2958.1987.tb00523.x; NIKAIDO H, 1993, ANTIMICROB AGENTS CH, V37, P1393, DOI 10.1128/AAC.37.7.1393; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; NIKAIDO H, 1990, MEMBRANE TRANSPORT I, pCH7; OHNUKI T, 1985, J BACTERIOL, V161, P1010, DOI 10.1128/JB.161.3.1010-1016.1985; PLESIAT P, 1992, MOL MICROBIOL, V6, P1323, DOI 10.1111/j.1365-2958.1992.tb00853.x; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; PUGSLEY AP, 1978, J BACTERIOL, V133, P1181, DOI 10.1128/JB.133.3.1181-1189.1978; PUREWAL AS, 1991, FEMS MICROBIOL LETT, V82, P229, DOI 10.1111/j.1574-6968.1991.tb04870.x; QUINN JP, 1986, J INFECT DIS, V154, P289, DOI 10.1093/infdis/154.2.289; ROSNER JL, 1985, P NATL ACAD SCI USA, V82, P8771, DOI 10.1073/pnas.82.24.8771; ROSS JI, 1990, MOL MICROBIOL, V4, P1207, DOI 10.1111/j.1365-2958.1990.tb00696.x; SAIER MH, IN PRESS MOL MICROBI; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; SEYDEL U, 1993, IMMUNOBIOLOGY, V187, P191, DOI 10.1016/S0171-2985(11)80339-6; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; TORO CS, 1990, ANTIMICROB AGENTS CH, V34, P1715, DOI 10.1128/AAC.34.9.1715; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TSURUOKA T, 1975, J ANTIBIOT, V28, P906, DOI 10.7164/antibiotics.28.906; TYNECKA Z, 1981, J BACTERIOL, V147, P313, DOI 10.1128/JB.147.2.313-319.1981; VAARA M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P152, DOI 10.1016/0005-2736(90)90218-D; WANDERSMAN C, 1992, TRENDS GENET, V8, P317, DOI 10.1016/0168-9525(92)90264-5; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WATANABE NA, 1987, ANTIMICROB AGENTS CH, V31, P497, DOI 10.1128/AAC.31.4.497; XU J, 1993, 93RD P ANN M AM SOC; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990; YOSHIMURA F, 1985, ANTIMICROB AGENTS CH, V27, P84, DOI 10.1128/AAC.27.1.84	95	1159	1215	4	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					382	388		10.1126/science.8153625	http://dx.doi.org/10.1126/science.8153625			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153625				2022-12-28	WOS:A1994NG19400028
J	GU, W; BHATIA, K; MAGRATH, IT; DANG, CV; DALLAFAVERA, R				GU, W; BHATIA, K; MAGRATH, IT; DANG, CV; DALLAFAVERA, R			BINDING AND SUPPRESSION OF THE MYC TRANSCRIPTIONAL ACTIVATION DOMAIN BY P107	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; HELIX ZIPPER PROTEIN; LARGE T-ANTIGEN; C-MYC; CYCLIN-A; MAX; E2F; EXPRESSION; IDENTIFICATION; SEQUENCE	An amino-terminal transactivation domain is required for Myc to function as a transcription factor controlling cell proliferation, differentiation, and apoptosis. A complementary DNA expression library was screened with a Myc fusion protein to identify proteins interacting with this domain, and a clone encoding the Rb-related p107 protein was isolated. The p107 protein was shown to associate with Myc in vivo and to suppress the activity of the Myc transactivation domain. However, mutant forms of Myc from Burkitt lymphoma cells, which contain sequence alterations in the transactivation domain, were resistant to p107-mediated suppression. Thus, disruption of a regulatory interaction between Myc and p107 may be important in tumorigenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NCI,PEDIAT ONCOL BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA 51497, CA 37165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037165, R37CA051497, R01CA051497, R29CA051497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BHATIA K, 1993, NATURE GENET, V56; BHATIA K, UNPUB; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CZIEPLUCH C, 1993, ONCOGENE, V8, P2833; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Gu W.Q., UNPUB; HATEBOER J, 1993, P NATL ACAD SCI USA, V90, P8489; HERCHBACH BM, 1993, ANN REV CELL BIOL, V9, P479; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LOMBARDI L, 1987, CELL, V49, P101; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MURPHY JW, UNPUB; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SET A, 1993, MOL CELL BIOL, V13, P4125; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YANO T, 1993, ONCOGENE, V8, P2741; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZMANANIAN M, 1992, EMBO J, V11, P2603	41	212	216	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					251	254		10.1126/science.8146655	http://dx.doi.org/10.1126/science.8146655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146655				2022-12-28	WOS:A1994NE41000034
J	CUSHNAGHAN, J; MCCARTHY, C; DIEPPE, P				CUSHNAGHAN, J; MCCARTHY, C; DIEPPE, P			TAPING THE PATELLA MEDIALLY - A NEW TREATMENT FOR OSTEOARTHRITIS OF THE KNEE-JOINT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To test the hypothesis that medial taping of the patella reduces the symptoms of osteoarthritis of the knee when the patellofemoral joint is affected. Design-Randomised, single blind, crossover trial of three different forms of taping of the knee joint. Each tape (medial, lateral, or neutral) was applied for four days, with three days of no treatment between tape positions. Subjects-14 patients with established, symptomatic osteoarthritis of the knee and both clinical and radiographic evidence of patellofemoral compartment disease. Main outcome measures-Daily visual analogue scale ratings for pain; patients' rating of change with each treatment; and tape preference. Results-Medial taping of the patella was significantly better than the neutral or lateral taping for pain scores, symptom change, and patient preference. The medial tape resulted in a 25% reduction in knee pain. Conclusion-Patella taping is a simple, safe, cheap way of providing short term pain relief in patients with osteoarthritis of the patellofemoral joint.			CUSHNAGHAN, J (corresponding author), UNIV BRISTOL,BRISTO ROYAL INFIRM,RHEUMATOL UNIT,BRISTOL BS2 8HW,ENGLAND.							ALTMAN RD, 1991, J RHEUMATOL, V18, P10; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; Dieppe P, 1993, Curr Opin Rheumatol, V5, P487; DIEPPE P, 1991, OSTEOARTHRITIS CURRE; DIEPPE PA, 1993, LANCET, V341, P353, DOI 10.1016/0140-6736(93)90147-9; DOUCETTE SA, 1992, AM J SPORT MED, V20, P434, DOI 10.1177/036354659202000412; IWANO T, 1990, CLIN ORTHOPAEDICS, V252, P190; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P520, DOI 10.1136/ard.52.7.520; MARKS R, 1993, PHYSIOTHERAPY, V79, P13; MCALINDON TE, 1992, BRIT J RHEUMATOL, V31, P189; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; McCONNELL J, 1986, Aust J Physiother, V32, P215, DOI 10.1016/S0004-9514(14)60654-1; MCCONNELL JS, 1987, 10TH P INT C WCPT SY; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; SENN S, 1993, CROSSOVER TRIALS CLI, P137; SPECTOR JD, 1992, ANN RHEUM DIS, V51, P1105; SPECTOR TD, 1992, RADIOGRAPHIC ATLAS; 1986, SERIES MBS, V1	18	88	91	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					753	755		10.1136/bmj.308.6931.753	http://dx.doi.org/10.1136/bmj.308.6931.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142829	Green Published			2022-12-28	WOS:A1994NC34800018
J	DEARNALEY, DP				DEARNALEY, DP			CURRENT ISSUES IN CANCER - CANCER OF THE PROSTATE .2.	BRITISH MEDICAL JOURNAL			English	Article							RADICAL PROSTATECTOMY; RADIOTHERAPY; CARCINOMA; ADENOCARCINOMA; RADIATION; ANTIGEN; THERAPY; TRIAL	Prostate cancer presents a growing health problem in Western societies as longevity increases. It is characteristically a disease of elderly men associated with the development of osteoblastic bone metastases and initial hormone responsiveness to androgen deprivation. Previously regarded as a Cinderella of cancers, there is currently more controversy concerning the detection and management of both localised and metastatic disease than for any other common malignancy. A balance needs to be drawn between the potential gains of more aggressive management and the disadvantages in terms of increased treatment side effects and cost, taking into account both the natural course of the disease and the life expectancy of patients.	ROYAL MARSDEN HOSP, DEPT RADIOTHERAPY & ONCOL, SUTTON SM2 5PT, SURREY, ENGLAND	Royal Marsden NHS Foundation Trust	DEARNALEY, DP (corresponding author), INST CANC RES, SUTTON SM2 5PT, SURREY, ENGLAND.		Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806				BELT E, 1972, J UROLOGY, V107, P91, DOI 10.1016/S0022-5347(17)60956-X; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; Cannon L., 1982, CANCER SURV, V1, P47; CHADWICK DJ, 1991, LANCET, V338, P613; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COLEMAN MP, 1993, IARC SCI PUBL, V121; CRAWFORD ED, 1990, CANCER-AM CANCER SOC, V66, P1039; Dearnaley D P, 1992, Clin Oncol (R Coll Radiol), V4, P101, DOI 10.1016/S0936-6555(05)80975-6; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; FELLOWS GJ, 1992, BRIT J UROL, V70, P304, DOI 10.1111/j.1464-410X.1992.tb15736.x; GEORGE NJR, 1988, LANCET, V1, P494; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GOFFINET DR, 1990, PROG CLIN BIOL RES, V359, P209; GUESS HA, 1993, EUR J CANCER, V29A, P1055, DOI 10.1016/S0959-8049(05)80223-0; HANKS GE, 1987, INT J RADIAT ONCOL, V13, P499, DOI 10.1016/0360-3016(87)90063-0; HANKS GE, 1988, INT J RADIAT ONCOL, V14, P1053, DOI 10.1016/0360-3016(88)90033-8; HILL PB, 1979, CANCER LETT, V7, P273, DOI 10.1016/S0304-3835(79)80054-3; HUGGINS C, 1941, CANCER RES, V1, P292; LICHTER A, 1992, SEMINARS RAD ONCOLOG; LOWE BA, 1988, J UROLOGY, V140, P1430; MEIKLE AW, 1990, UROL CLIN N AM, V17, P709; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; ONEAL AJ, IN PRESS CLIN ONCOLO; PANTELIDES ML, 1992, BRIT J UROL, V70, P299, DOI 10.1111/j.1464-410X.1992.tb15735.x; PAULSON DF, 1982, J UROLOGY, V128, P502, DOI 10.1016/S0022-5347(17)53016-5; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PEREZ CA, 1989, RADIOTHER ONCOL, V16, P1, DOI 10.1016/0167-8140(89)90066-2; PILEPICH MV, 1993, INT J RADIAT ONCOL, V27, P246, DOI 10.1016/0360-3016(93)90822-D; PLOWMAN PN, 1987, BR J UROL, V59, P225; PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360-3016(93)90309-J; PRICE A, 1993, LANCET, V342, P901; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; RIFKIN MD, 1990, NEW ENGL J MED, V323, P621, DOI 10.1056/NEJM199009063231001; SCHRODER FH, 1993, BRIT MED J, V306, P407, DOI 10.1136/bmj.306.6875.407; SHEARER RJ, 1992, BRIT J UROL, V69, P521, DOI 10.1111/j.1464-410X.1992.tb15601.x; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; WALSH PC, 1983, PROSTATE, V4, P473, DOI 10.1002/pros.2990040506; YATANI R, 1982, INT J CANCER, V29, P611, DOI 10.1002/ijc.2910290602; ZAGARS GK, 1987, CANCER, V60, P1489, DOI 10.1002/1097-0142(19871001)60:7<1489::AID-CNCR2820600715>3.0.CO;2-9; 1989, NCI NIH892789 DEP HL	43	53	54	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					780	784		10.1136/bmj.308.6931.780	http://dx.doi.org/10.1136/bmj.308.6931.780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142838	Green Published			2022-12-28	WOS:A1994NC34800032
J	MORRISON, NA; QI, JC; TOKITA, A; KELLY, PJ; CROFTS, L; NGUYEN, TV; SAMBROOK, PN; EISMAN, JA				MORRISON, NA; QI, JC; TOKITA, A; KELLY, PJ; CROFTS, L; NGUYEN, TV; SAMBROOK, PN; EISMAN, JA			PREDICTION OF BONE-DENSITY FROM VITAMIN-D RECEPTOR ALLELES	NATURE			English	Article							OSTEOCALCIN GENE; PHYSICAL-FITNESS; MINERAL DENSITY; FEMORAL-NECK; MASS; TWIN; OSTEOPOROSIS; DETERMINANTS; SPINE; WOMEN	BONE density achieved in early adulthood is the major determinant of risk of osteoporotic fracture. Up to 60% of women1,2 suffer osteoporotic fractures as a result of low bone density2, which is under strong genetic control-3-6 acting through effects on bone turnover 7, 8. Here we show that common allelic variants in the gene encoding the vitamin D receptor9 can be used to predict differences in bone density, accounting for up to 75% of the total genetic effect on bone density in healthy individuals. The genotype associated with lower bone density was overrepresented in postmenopausal women with bone densities more than 2 standard deviations below values in young normal women. The molecular mechanisms by which bone density is regulated by the vitamin D receptor gene are not certain, although allelic differences in the 3' untranslated region may alter messenger RNA levels. These findings could open new avenues to the development and targeting of prophylactic interventions. It follows that other pathophysiological processes considered to be subject to complex multifactorial genetic regulation may also be modulated by a single gene with pleiotropic transcriptional actions.			MORRISON, NA (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL RES,DARLINGHURST,NSW 2010,AUSTRALIA.							ARVEILER B, 1988, NUCLEIC ACIDS RES, V16, P6252, DOI 10.1093/nar/16.13.6252; BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367; KELLY PJ, 1991, J CLIN ENDOCR METAB, V72, P808, DOI 10.1210/jcem-72-4-808; KELLY PJ, 1990, OSTEOPOROSIS INT, V1, P1; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; MOLLER M, 1978, CALC TISS RES, V25, P197, DOI 10.1007/BF02010768; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; POCOCK N, 1989, J BONE MINER RES, V4, P441; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; POCOCK NA, 1987, MED J AUSTRALIA, V146, P293, DOI 10.5694/j.1326-5377.1987.tb120264.x; POCOCK NA, 1988, J BONE MINER RES, V3, P601; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476	21	1646	1815	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					284	287		10.1038/367284a0	http://dx.doi.org/10.1038/367284a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8161378				2022-12-28	WOS:A1994MR49400060
J	CANNISTRA, SA				CANNISTRA, SA			MEDICAL PROGRESS - CANCER OF THE OVARY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GYNECOLOGIC-ONCOLOGY-GROUP; COLONY-STIMULATING FACTOR; PHASE-II TRIAL; CISPLATIN-BASED CHEMOTHERAPY; WHOLE-ABDOMINAL IRRADIATION; BONE-MARROW TRANSPLANTATION; HIGH-DOSE CARBOPLATIN; BLOOD PROGENITOR CELLS; NON-HODGKINS LYMPHOMA; 2ND-LOOK LAPAROTOMY		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CANNISTRA, SA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.							AHLGREN JD, 1993, P ASCO, V12, P258; ALBERTS DS, 1992, J CLIN ONCOL, V10, P706, DOI 10.1200/JCO.1992.10.5.706; ALBERTS DS, 1992, J CLIN ONCOL, V10, P1505; ALLAN SG, 1984, BRIT MED J, V288, P1714, DOI 10.1136/bmj.288.6432.1714; BAST RC, 1992, J NATL CANCER I, V84, P556, DOI 10.1093/jnci/84.8.556; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BERCHUCK A, 1990, CANCER RES, V50, P4087; BEREK JS, 1986, OBSTET GYNECOL, V67, P685, DOI 10.1097/00006250-198605000-00016; BEREK JS, 1983, OBSTET GYNECOL, V61, P189; BEREK JS, 1984, OBSTET GYNECOL, V64, P207; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; BRENNER DE, 1985, OBSTET GYNECOL, V65, P715; BURGHARDT E, 1991, GYNECOL ONCOL, V40, P103, DOI 10.1016/0090-8258(91)90099-Q; CANNISTRA SA, 1991, J CLIN ONCOL, V9, P368, DOI 10.1200/JCO.1991.9.3.368; COLOMBO N, 1993, P AN M AM SOC CLIN, V12, P255; COPELAND LJ, 1985, CANCER, V55, P472, DOI 10.1002/1097-0142(19850115)55:2<472::AID-CNCR2820550231>3.0.CO;2-A; DAUPLAT J, 1989, GYNECOL ONCOL, V34, P294, DOI 10.1016/0090-8258(89)90161-3; EIFEL PJ, 1991, INT J RADIAT ONCOL, V21, P1013, DOI 10.1016/0360-3016(91)90743-N; EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187; ELIAS AD, 1992, BLOOD, V79, P3036; FENNELLY D, 1993, P AM SOC CLIN ONCOL, V12, P260; FRANCIS P, 1993, P AN M AM SOC CLIN, V12, P257; FUKS Z, 1988, J CLIN ONCOL, V6, P509, DOI 10.1200/JCO.1988.6.3.509; GIANNI AM, 1989, LANCET, V2, P580; GOODMAN HM, 1992, GYNECOL ONCOL, V46, P367, DOI 10.1016/0090-8258(92)90234-A; GREENLEE JE, 1983, ANN NEUROL, V14, P609, DOI 10.1002/ana.410140603; HACKER NF, 1983, OBSTET GYNECOL, V61, P413; HAINSWORTH JD, 1990, J CLIN ONCOL, V8, P502, DOI 10.1200/JCO.1990.8.3.502; HAINSWORTH JD, 1988, ANN INTERN MED, V108, P165, DOI 10.7326/0003-4819-108-2-165; HAKES TB, 1992, GYNECOL ONCOL, V245, P284; HAMILTON T, 1990, P AN M AM SOC CLIN, V9, P73; HILLCOAT BL, 1985, GYNECOL ONCOL, V22, P162, DOI 10.1016/0090-8258(85)90022-8; HOLGUIN T, 1986, GYNECOL ONCOL, V25, P128, DOI 10.1016/0090-8258(86)90074-0; HOLTZ F, 1982, CANCER, V50, P2438, DOI 10.1002/1097-0142(19821201)50:11<2438::AID-CNCR2820501132>3.0.CO;2-X; HOSKINS WJ, 1989, GYNECOL ONCOL, V34, P365, DOI 10.1016/0090-8258(89)90175-3; HOWELL SB, 1987, J CLIN ONCOL, V5, P1607, DOI 10.1200/JCO.1987.5.10.1607; HUININK WWT, 1992, P AM SOC CLIN ONCOL, V11, P230; HUNTER RW, 1992, AM J OBSTET GYNECOL, V166, P504; IZQUIERDO MA, 1992, GYNECOL ONCOL, V45, P206, DOI 10.1016/0090-8258(92)90287-S; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1992, OVARIAN CANCER, V2, P265; JODRELL DI, 1992, J CLIN ONCOL, V10, P520, DOI 10.1200/JCO.1992.10.4.520; KAYE SB, 1992, LANCET, V340, P329, DOI 10.1016/0140-6736(92)91404-V; KIRMANI S, 1991, J CLIN ONCOL, V9, P649, DOI 10.1200/JCO.1991.9.4.649; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; LAVIN PT, 1987, OBSTET GYNECOL, V69, P223; LEVIN L, 1987, J CLIN ONCOL, V5, P756, DOI 10.1200/JCO.1987.5.5.756; LOUIE KG, 1985, CANCER RES, V45, P2110; LOUIE KG, 1986, J CLIN ONCOL, V4, P1579, DOI 10.1200/JCO.1986.4.11.1579; LUND B, 1989, J CLIN ONCOL, V7, P1469, DOI 10.1200/JCO.1989.7.10.1469; LUND B, 1990, J CLIN ONCOL, V8, P1226, DOI 10.1200/JCO.1990.8.7.1226; LYNCH HT, 1992, HEMATOL ONCOL CLIN N, V6, P783; MALKASIAN GD, 1988, AM J OBSTET GYNECOL, V159, P341, DOI 10.1016/S0002-9378(88)80081-4; MANETTA A, 1990, GYNECOL ONCOL, V36, P93, DOI 10.1016/0090-8258(90)90115-2; MARKMAN M, 1991, J CLIN ONCOL, V9, P1801, DOI 10.1200/JCO.1991.9.10.1801; MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389; MARKMAN M, 1992, GYNECOL ONCOL, V45, P3, DOI 10.1016/0090-8258(92)90482-X; MCGONIGLE KF, 1992, GYNECOL ONCOL, V45, P225, DOI 10.1016/0090-8258(92)90291-P; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MCGUIRE WP, 1993, P AN M AM SOC CLIN, V12, P255; MIYAZAKI T, 1988, GYNECOL ONCOL, V30, P329, DOI 10.1016/0090-8258(88)90247-8; MULDER POM, 1989, EUR J CANCER CLIN ON, V25, P645, DOI 10.1016/0277-5379(89)90199-5; NAROD SA, 1991, LANCET, V338, P82; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; NILOFF JM, 1986, AM J OBSTET GYNECOL, V155, P56, DOI 10.1016/0002-9378(86)90077-3; NILOFF JM, 1985, AM J OBSTET GYNECOL, V151, P981, DOI 10.1016/0002-9378(85)90678-7; NUSSBAUM SR, 1990, NEW ENGL J MED, V323, P1324, DOI 10.1056/NEJM199011083231907; ODWYER PJ, 1992, J CLIN ONCOL, V10, P1352, DOI 10.1200/JCO.1992.10.8.1352; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; OZOLS RF, 1987, J CLIN ONCOL, V5, P197, DOI 10.1200/JCO.1987.5.2.197; PAI LH, 1991, J CLIN ONCOL, V9, P2095, DOI 10.1200/JCO.1991.9.12.2095; PETERS WA, 1986, CANCER, V58, P880, DOI 10.1002/1097-0142(19860815)58:4<880::AID-CNCR2820580413>3.0.CO;2-Z; PETRU E, 1992, GYNECOL ONCOL, V44, P83, DOI 10.1016/0090-8258(92)90017-D; PEYLANRAMU N, 1992, P AM SOC CLIN ONCOL, V11, P124; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PIVER MS, 1988, J CLIN ONCOL, V6, P983, DOI 10.1200/JCO.1988.6.6.983; PIVER MS, 1988, J CLIN ONCOL, V6, P1679, DOI 10.1200/JCO.1988.6.11.1679; PIVR MS, 1992, GYNECOL ONCOL, V46, P357; REICHMAN B, 1989, J CLIN ONCOL, V7, P1327, DOI 10.1200/JCO.1989.7.9.1327; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; ROTHENBERG ML, 1992, J CLIN ONCOL, V10, P727, DOI 10.1200/JCO.1992.10.5.727; SAROSY G, 1992, J CLIN ONCOL, V10, P1165, DOI 10.1200/JCO.1992.10.7.1165; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SCHRAY MF, 1988, J CLIN ONCOL, V6, P1433, DOI 10.1200/JCO.1988.6.9.1433; SCHWARTZ PE, 1991, YALE J BIOL MED, V64, P573; SCHWARTZ PE, 1980, AM J OBSTET GYNECOL, V138, P1124, DOI 10.1016/S0002-9378(16)32778-8; SHEA TC, 1989, J CLIN ONCOL, V7, P651, DOI 10.1200/JCO.1989.7.5.651; SHEA TC, 1992, J CLIN ONCOL, V10, P464, DOI 10.1200/JCO.1992.10.3.464; SHEA TC, 1989, J CLIN ONCOL, V7, P1177; SHPALL EJ, 1990, GYNECOL ONCOL, V38, P386, DOI 10.1016/0090-8258(90)90079-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEHMAN FB, 1988, GYNECOL ONCOL, V29, P37, DOI 10.1016/0090-8258(88)90144-8; STEWART JA, 1990, CANCER RES, V50, P6302; STEWART JSW, 1990, J CLIN ONCOL, V8, P1941, DOI 10.1200/JCO.1990.8.12.1941; SUTTON GP, 1989, J CLIN ONCOL, V7, P1672, DOI 10.1200/JCO.1989.7.11.1672; SWENERTON K, 1992, J CLIN ONCOL, V10, P718, DOI 10.1200/JCO.1992.10.5.718; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; TEPLER I, 1993, J CLIN ONCOL, V11, P1583, DOI 10.1200/JCO.1993.11.8.1583; THIGPEN T, 1990, P AN M AM SOC CLIN, V9, P156; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; VIENS P, 1990, BONE MARROW TRANSPL, V5, P227; VRIESENDORP R, 1984, GYNECOL ONCOL, V17, P271, DOI 10.1016/0090-8258(84)90210-5; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; WHARTON JT, 1981, CANCER-AM CANCER SOC, V48, P582, DOI 10.1002/1097-0142(19810715)48:1+<582::AID-CNCR2820481323>3.0.CO;2-C; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; 1991, BMJ, V303, P884; 1989, NEW ENGL J MED, V321, P524; 1987, LANCET, V2, P353	113	365	373	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1550	1559		10.1056/NEJM199311183292108	http://dx.doi.org/10.1056/NEJM199311183292108			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8155119				2022-12-28	WOS:A1993MG18800008
